0000914475-21-000020.txt : 20210205 0000914475-21-000020.hdr.sgml : 20210205 20210205161949 ACCESSION NUMBER: 0000914475-21-000020 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 82 CONFORMED PERIOD OF REPORT: 20201231 FILED AS OF DATE: 20210205 DATE AS OF CHANGE: 20210205 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NEUROCRINE BIOSCIENCES INC CENTRAL INDEX KEY: 0000914475 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 330525145 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-22705 FILM NUMBER: 21595641 BUSINESS ADDRESS: STREET 1: 12780 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: (858) 617-7600 MAIL ADDRESS: STREET 1: 12780 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 10-K 1 nbix-20201231.htm 10-K nbix-20201231
false2020FY0000914475us-gaap:AccountingStandardsUpdate201602MemberP3YP3Yoneone0.00131711P3YP4Yus-gaap:OtherLiabilitiesCurrent00009144752020-01-012020-12-31iso4217:USD00009144752020-06-30xbrli:shares00009144752021-01-2900009144752020-12-3100009144752019-12-310000914475us-gaap:ShortTermInvestmentsMember2020-12-310000914475us-gaap:ShortTermInvestmentsMember2019-12-310000914475nbix:LongTermInvestmentsMember2020-12-310000914475nbix:LongTermInvestmentsMember2019-12-31iso4217:USDxbrli:shares0000914475us-gaap:ProductMember2020-01-012020-12-310000914475us-gaap:ProductMember2019-01-012019-12-310000914475us-gaap:ProductMember2018-01-012018-12-310000914475nbix:CollaborationRevenueMember2020-01-012020-12-310000914475nbix:CollaborationRevenueMember2019-01-012019-12-310000914475nbix:CollaborationRevenueMember2018-01-012018-12-3100009144752019-01-012019-12-3100009144752018-01-012018-12-310000914475us-gaap:CommonStockMember2017-12-310000914475us-gaap:AdditionalPaidInCapitalMember2017-12-310000914475us-gaap:AccumulatedOtherComprehensiveIncomeMember2017-12-310000914475us-gaap:RetainedEarningsMember2017-12-3100009144752017-12-310000914475us-gaap:RetainedEarningsMember2018-01-012018-12-310000914475us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-01-012018-12-310000914475us-gaap:AdditionalPaidInCapitalMember2018-01-012018-12-310000914475us-gaap:CommonStockMember2018-01-012018-12-310000914475us-gaap:CommonStockMember2018-12-310000914475us-gaap:AdditionalPaidInCapitalMember2018-12-310000914475us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-12-310000914475us-gaap:RetainedEarningsMember2018-12-3100009144752018-12-310000914475us-gaap:RetainedEarningsMember2019-01-012019-12-310000914475us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-01-012019-12-310000914475us-gaap:AdditionalPaidInCapitalMember2019-01-012019-12-310000914475us-gaap:RetainedEarningsMembersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2018-12-310000914475srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2018-12-310000914475us-gaap:CommonStockMember2019-01-012019-12-310000914475us-gaap:CommonStockMember2019-12-310000914475us-gaap:AdditionalPaidInCapitalMember2019-12-310000914475us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310000914475us-gaap:RetainedEarningsMember2019-12-310000914475us-gaap:RetainedEarningsMember2020-01-012020-12-310000914475us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-12-310000914475us-gaap:AdditionalPaidInCapitalMember2020-01-012020-12-310000914475us-gaap:CommonStockMember2020-01-012020-12-310000914475us-gaap:CommonStockMember2020-12-310000914475us-gaap:AdditionalPaidInCapitalMember2020-12-310000914475us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310000914475us-gaap:RetainedEarningsMember2020-12-31nbix:subsidiary0000914475srt:MinimumMember2020-01-012020-12-310000914475srt:MaximumMember2020-01-012020-12-31xbrli:pure0000914475us-gaap:CustomerConcentrationRiskMembernbix:LargestTwoCustomersMemberus-gaap:SalesRevenueProductLineMember2019-01-012019-12-310000914475us-gaap:CustomerConcentrationRiskMembernbix:LargestTwoCustomersMemberus-gaap:SalesRevenueProductLineMember2020-01-012020-12-310000914475nbix:LargestThreeCustomersMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueProductLineMember2018-01-012018-12-310000914475us-gaap:EmployeeStockMember2020-01-012020-12-310000914475nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember2020-12-012020-12-310000914475nbix:PerformanceBasedRestrictedStockUnitMember2020-12-31nbix:segment0000914475nbix:TakedaPharmaceuticalCompanyLimitedMemberus-gaap:CollaborativeArrangementMember2020-07-310000914475nbix:TakedaPharmaceuticalCompanyLimitedMemberus-gaap:CollaborativeArrangementMember2020-12-310000914475us-gaap:CollaborativeArrangementMembernbix:IdorsiaPharmaceuticalsLtdMember2020-05-310000914475us-gaap:CollaborativeArrangementMembernbix:IdorsiaPharmaceuticalsLtdMember2020-05-012020-05-310000914475nbix:NBI827104Memberus-gaap:CollaborativeArrangementMembernbix:IdorsiaPharmaceuticalsLtdMember2020-12-310000914475us-gaap:CollaborativeArrangementMembernbix:IdorsiaPharmaceuticalsLtdMembernbix:DevelopmentProductCandidatesMember2020-12-310000914475us-gaap:CollaborativeArrangementMembernbix:IdorsiaPharmaceuticalsLtdMember2020-12-310000914475us-gaap:CollaborativeArrangementMembernbix:XenonPharmaceuticalsIncMember2019-12-310000914475us-gaap:CommonStockMemberus-gaap:CollaborativeArrangementMembernbix:XenonPharmaceuticalsIncMember2019-12-310000914475us-gaap:CollaborativeArrangementMembernbix:XenonPharmaceuticalsIncMember2020-12-310000914475us-gaap:CollaborativeArrangementMembernbix:XenonPharmaceuticalsIncMember2019-10-012019-12-310000914475nbix:VoyagerTherapeuticsMemberus-gaap:CollaborativeArrangementMember2019-03-310000914475nbix:VoyagerTherapeuticsMemberus-gaap:CommonStockMemberus-gaap:CollaborativeArrangementMember2019-03-310000914475nbix:VoyagerTherapeuticsMemberus-gaap:CollaborativeArrangementMember2020-12-310000914475nbix:VoyagerTherapeuticsMemberus-gaap:CollaborativeArrangementMember2019-01-012019-03-310000914475nbix:VoyagerTherapeuticsMemberus-gaap:CollaborativeArrangementMember2019-04-012019-06-300000914475nbix:BIALMemberus-gaap:CollaborativeArrangementMember2020-04-300000914475nbix:BIALMemberus-gaap:CollaborativeArrangementMember2019-12-310000914475nbix:BIALMemberus-gaap:CollaborativeArrangementMember2018-12-310000914475nbix:BIALMemberus-gaap:CollaborativeArrangementMember2020-12-310000914475nbix:MitsubishiTanabePharmaCorporationMemberus-gaap:CollaborativeArrangementMember2015-03-012017-06-300000914475nbix:MitsubishiTanabePharmaCorporationMemberus-gaap:CollaborativeArrangementMember2017-07-012020-12-310000914475nbix:MitsubishiTanabePharmaCorporationMemberus-gaap:CollaborativeArrangementMember2020-01-012020-12-310000914475nbix:MitsubishiTanabePharmaCorporationMemberus-gaap:CollaborativeArrangementMember2019-01-012019-12-310000914475nbix:MitsubishiTanabePharmaCorporationMemberus-gaap:CollaborativeArrangementMember2020-12-310000914475nbix:MitsubishiTanabePharmaCorporationMemberus-gaap:CollaborativeArrangementMember2015-03-012015-03-310000914475nbix:MitsubishiTanabePharmaCorporationMembersrt:MinimumMemberus-gaap:PatentsMemberus-gaap:CollaborativeArrangementMember2015-03-012015-03-310000914475nbix:AbbvieIncMemberus-gaap:RoyaltyMember2020-01-012020-12-310000914475nbix:AbbvieIncMemberus-gaap:RoyaltyMember2019-01-012019-12-310000914475nbix:AbbvieIncMemberus-gaap:RoyaltyMember2018-01-012018-12-310000914475nbix:AbbvieIncMemberus-gaap:CollaborativeArrangementMember2020-04-012020-06-300000914475nbix:AbbvieIncMemberus-gaap:CollaborativeArrangementMember2019-01-012019-12-310000914475nbix:AbbvieIncMemberus-gaap:CollaborativeArrangementMember2018-01-012018-12-310000914475nbix:AbbvieIncMemberus-gaap:CollaborativeArrangementMember2010-06-012010-06-300000914475nbix:AbbvieIncMemberus-gaap:CollaborativeArrangementMember2010-07-012020-12-310000914475nbix:AbbvieIncMemberus-gaap:CollaborativeArrangementMember2020-12-310000914475nbix:AbbvieIncMembersrt:MinimumMemberus-gaap:PatentsMemberus-gaap:CollaborativeArrangementMember2010-06-012010-06-300000914475us-gaap:ShortTermInvestmentsMemberus-gaap:CommercialPaperMember2020-12-310000914475us-gaap:CorporateDebtSecuritiesMemberus-gaap:ShortTermInvestmentsMember2020-12-310000914475us-gaap:ShortTermInvestmentsMemberus-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember2020-12-310000914475nbix:LongTermInvestmentsMemberus-gaap:CorporateDebtSecuritiesMember2020-12-310000914475nbix:LongTermInvestmentsMemberus-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember2020-12-310000914475us-gaap:ShortTermInvestmentsMemberus-gaap:CommercialPaperMember2019-12-310000914475us-gaap:CorporateDebtSecuritiesMemberus-gaap:ShortTermInvestmentsMember2019-12-310000914475us-gaap:ShortTermInvestmentsMemberus-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember2019-12-310000914475nbix:LongTermInvestmentsMemberus-gaap:CorporateDebtSecuritiesMember2019-12-310000914475nbix:LongTermInvestmentsMemberus-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember2019-12-310000914475us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember2020-12-31nbix:security0000914475us-gaap:CorporateDebtSecuritiesMember2019-12-310000914475nbix:CashAndMoneyMarketFundMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000914475nbix:CashAndMoneyMarketFundMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000914475nbix:CashAndMoneyMarketFundMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2020-12-310000914475nbix:CashAndMoneyMarketFundMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000914475us-gaap:CashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000914475us-gaap:FairValueInputsLevel1Memberus-gaap:CashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000914475us-gaap:CashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2020-12-310000914475us-gaap:FairValueInputsLevel3Memberus-gaap:CashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000914475us-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000914475us-gaap:FairValueInputsLevel1Memberus-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000914475us-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2020-12-310000914475us-gaap:FairValueInputsLevel3Memberus-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000914475nbix:RestrictedCashMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000914475us-gaap:FairValueInputsLevel1Membernbix:RestrictedCashMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000914475nbix:RestrictedCashMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2020-12-310000914475us-gaap:FairValueInputsLevel3Membernbix:RestrictedCashMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000914475us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000914475us-gaap:FairValueInputsLevel1Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000914475us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2020-12-310000914475us-gaap:FairValueInputsLevel3Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000914475us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000914475us-gaap:FairValueInputsLevel1Memberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000914475us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2020-12-310000914475us-gaap:FairValueInputsLevel3Memberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000914475us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000914475us-gaap:FairValueInputsLevel1Memberus-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000914475us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2020-12-310000914475us-gaap:FairValueInputsLevel3Memberus-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000914475us-gaap:AvailableforsaleSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000914475us-gaap:FairValueInputsLevel1Memberus-gaap:AvailableforsaleSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000914475us-gaap:AvailableforsaleSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2020-12-310000914475us-gaap:FairValueInputsLevel3Memberus-gaap:AvailableforsaleSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000914475us-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000914475us-gaap:FairValueInputsLevel1Memberus-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000914475us-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2020-12-310000914475us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000914475us-gaap:FairValueMeasurementsRecurringMembernbix:TotalEquitySecuritiesMember2020-12-310000914475us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMembernbix:TotalEquitySecuritiesMember2020-12-310000914475us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Membernbix:TotalEquitySecuritiesMember2020-12-310000914475us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMembernbix:TotalEquitySecuritiesMember2020-12-310000914475us-gaap:FairValueMeasurementsRecurringMember2020-12-310000914475us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000914475us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2020-12-310000914475us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000914475nbix:CashAndMoneyMarketFundMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000914475nbix:CashAndMoneyMarketFundMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000914475nbix:CashAndMoneyMarketFundMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2019-12-310000914475nbix:CashAndMoneyMarketFundMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000914475us-gaap:CashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000914475us-gaap:FairValueInputsLevel1Memberus-gaap:CashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000914475us-gaap:CashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2019-12-310000914475us-gaap:FairValueInputsLevel3Memberus-gaap:CashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000914475us-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000914475us-gaap:FairValueInputsLevel1Memberus-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000914475us-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2019-12-310000914475us-gaap:FairValueInputsLevel3Memberus-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000914475nbix:RestrictedCashMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000914475us-gaap:FairValueInputsLevel1Membernbix:RestrictedCashMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000914475nbix:RestrictedCashMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2019-12-310000914475us-gaap:FairValueInputsLevel3Membernbix:RestrictedCashMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000914475us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000914475us-gaap:FairValueInputsLevel1Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000914475us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2019-12-310000914475us-gaap:FairValueInputsLevel3Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000914475us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000914475us-gaap:FairValueInputsLevel1Memberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000914475us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2019-12-310000914475us-gaap:FairValueInputsLevel3Memberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000914475us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000914475us-gaap:FairValueInputsLevel1Memberus-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000914475us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2019-12-310000914475us-gaap:FairValueInputsLevel3Memberus-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000914475us-gaap:AvailableforsaleSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000914475us-gaap:FairValueInputsLevel1Memberus-gaap:AvailableforsaleSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000914475us-gaap:AvailableforsaleSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2019-12-310000914475us-gaap:FairValueInputsLevel3Memberus-gaap:AvailableforsaleSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000914475us-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000914475us-gaap:FairValueInputsLevel1Memberus-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000914475us-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2019-12-310000914475us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000914475us-gaap:FairValueMeasurementsRecurringMembernbix:TotalEquitySecuritiesMember2019-12-310000914475us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMembernbix:TotalEquitySecuritiesMember2019-12-310000914475us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Membernbix:TotalEquitySecuritiesMember2019-12-310000914475us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMembernbix:TotalEquitySecuritiesMember2019-12-310000914475us-gaap:FairValueMeasurementsRecurringMember2019-12-310000914475us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000914475us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2019-12-310000914475us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000914475us-gaap:FairValueInputsLevel3Memberus-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000914475us-gaap:FairValueInputsLevel3Memberus-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2018-12-310000914475us-gaap:FairValueInputsLevel3Memberus-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2017-12-310000914475us-gaap:FairValueInputsLevel3Memberus-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2020-01-012020-12-310000914475us-gaap:FairValueInputsLevel3Memberus-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2019-01-012019-12-310000914475us-gaap:FairValueInputsLevel3Memberus-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2018-01-012018-12-310000914475us-gaap:FairValueInputsLevel3Memberus-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000914475srt:MinimumMemberus-gaap:MeasurementInputDiscountForLackOfMarketabilityMember2020-12-310000914475srt:MaximumMemberus-gaap:MeasurementInputDiscountForLackOfMarketabilityMember2020-12-310000914475srt:WeightedAverageMemberus-gaap:MeasurementInputDiscountForLackOfMarketabilityMember2020-12-310000914475nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember2017-05-020000914475nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember2017-05-022017-05-02utr:D0000914475nbix:ConversionPeriodOneMembernbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember2017-05-022017-05-020000914475nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMembernbix:ConversionPeriodTwoMember2017-05-022017-05-020000914475nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMembernbix:ConversionPeriodTwoMember2017-05-020000914475nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember2020-01-012020-12-310000914475nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember2020-11-300000914475nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember2020-11-012020-11-300000914475us-gaap:MeasurementInputDiscountRateMembernbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember2020-11-300000914475nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember2020-12-310000914475nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember2019-12-310000914475us-gaap:LeaseholdImprovementsMember2020-12-310000914475us-gaap:LeaseholdImprovementsMember2019-12-310000914475nbix:ScientificEquipmentMember2020-12-310000914475nbix:ScientificEquipmentMember2019-12-310000914475us-gaap:ComputerEquipmentMember2020-12-310000914475us-gaap:ComputerEquipmentMember2019-12-310000914475us-gaap:FurnitureAndFixturesMember2020-12-310000914475us-gaap:FurnitureAndFixturesMember2019-12-310000914475us-gaap:EmployeeStockOptionMember2020-01-012020-12-310000914475us-gaap:EmployeeStockOptionMember2019-01-012019-12-310000914475us-gaap:EmployeeStockOptionMember2018-01-012018-12-310000914475us-gaap:RestrictedStockMember2020-01-012020-12-310000914475us-gaap:RestrictedStockMember2019-01-012019-12-310000914475us-gaap:RestrictedStockMember2018-01-012018-12-310000914475nbix:A225ConvertibleSeniorNotesMember2020-01-012020-12-310000914475nbix:A225ConvertibleSeniorNotesMember2019-01-012019-12-310000914475nbix:A225ConvertibleSeniorNotesMember2018-01-012018-12-310000914475nbix:StockOptionsRestrictedStockAndConvertibleSeniorNotesMember2020-01-012020-12-310000914475nbix:StockOptionsRestrictedStockAndConvertibleSeniorNotesMember2019-01-012019-12-310000914475nbix:StockOptionsRestrictedStockAndConvertibleSeniorNotesMember2018-01-012018-12-310000914475nbix:TwoThousandAndElevenPlanMember2011-05-310000914475nbix:TwoThousandAndElevenPlanMember2020-12-310000914475us-gaap:EmployeeStockMember2018-05-310000914475us-gaap:EmployeeStockMember2020-12-310000914475nbix:A2020EquityIncentivePlanMember2020-05-310000914475nbix:A2020EquityIncentivePlanMember2020-12-310000914475us-gaap:SellingGeneralAndAdministrativeExpensesMember2020-01-012020-12-310000914475us-gaap:SellingGeneralAndAdministrativeExpensesMember2019-01-012019-12-310000914475us-gaap:SellingGeneralAndAdministrativeExpensesMember2018-01-012018-12-310000914475us-gaap:ResearchAndDevelopmentExpenseMember2020-01-012020-12-310000914475us-gaap:ResearchAndDevelopmentExpenseMember2019-01-012019-12-310000914475us-gaap:ResearchAndDevelopmentExpenseMember2018-01-012018-12-310000914475us-gaap:EmployeeStockOptionMember2020-01-012020-12-310000914475us-gaap:EmployeeStockOptionMember2019-01-012019-12-310000914475us-gaap:EmployeeStockOptionMember2018-01-012018-12-310000914475us-gaap:RestrictedStockUnitsRSUMember2020-01-012020-12-310000914475us-gaap:RestrictedStockUnitsRSUMember2019-01-012019-12-310000914475us-gaap:RestrictedStockUnitsRSUMember2018-01-012018-12-310000914475nbix:PerformanceBasedRestrictedStockUnitMember2020-01-012020-12-310000914475nbix:PerformanceBasedRestrictedStockUnitMember2019-01-012019-12-310000914475nbix:PerformanceBasedRestrictedStockUnitMember2018-01-012018-12-310000914475us-gaap:EmployeeStockMember2020-01-012020-12-310000914475us-gaap:EmployeeStockMember2019-01-012019-12-310000914475us-gaap:EmployeeStockMember2018-01-012018-12-310000914475us-gaap:EmployeeStockOptionMember2020-12-310000914475us-gaap:RestrictedStockUnitsRSUMember2020-12-310000914475srt:MinimumMemberus-gaap:EmployeeStockOptionMember2020-01-012020-12-310000914475srt:MaximumMemberus-gaap:EmployeeStockOptionMember2020-01-012020-12-310000914475us-gaap:RestrictedStockUnitsRSUMember2019-12-310000914475nbix:PerformanceBasedRestrictedStockUnitMembersrt:MinimumMember2020-01-012020-12-310000914475nbix:PerformanceBasedRestrictedStockUnitMembersrt:MaximumMember2020-01-012020-12-310000914475nbix:PerformanceBasedRestrictedStockUnitMember2019-12-310000914475srt:MaximumMemberus-gaap:EmployeeStockMember2020-01-012020-12-310000914475us-gaap:InternalRevenueServiceIRSMember2020-12-310000914475us-gaap:StateAndLocalJurisdictionMember2020-12-31nbix:renewalOption0000914475us-gaap:LetterOfCreditMember2020-12-3100009144752020-01-012020-03-3100009144752020-04-012020-06-3000009144752020-07-012020-09-3000009144752020-10-012020-12-3100009144752019-01-012019-03-3100009144752019-04-012019-06-3000009144752019-07-012019-09-3000009144752019-10-012019-12-310000914475us-gaap:CollaborativeArrangementMembernbix:IdorsiaPharmaceuticalsLtdMember2020-04-012020-06-300000914475nbix:TakedaPharmaceuticalCompanyLimitedMemberus-gaap:CollaborativeArrangementMember2020-07-012020-09-30

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K
☑ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2020
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from __________to__________
Commission file number 0-22705
NEUROCRINE BIOSCIENCES, INC.
(Exact name of registrant as specified in its charter)
Delaware33-0525145
(State or other jurisdiction of
incorporation or organization)		(I.R.S. Employer
Identification No.)
12780 El Camino Real,San Diego,California92130
(Address of principal executive offices)(Zip Code)
(858) 617-7600
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Common Stock, $0.001 par valueNBIXNasdaq Global Select Market
(Title of each class)(Trading Symbol)(Name of each exchange on which registered)
Securities registered pursuant to Section 12(g) of the Act:
None
(Title of class)
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes  ☑    No  ☐ 
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes  ☐     No  ☑ 
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  ☑     No  ☐ 
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes  ☑     No  ☐ 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer
☑
 Accelerated filer☐ Non-accelerated filer☐ Smaller reporting company☐ Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐ 
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. Yes  ☑    No  ☐ 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes  ☐     No  ☑ 
The aggregate market value of registrant’s common stock held by non-affiliates of the registrant, computed by reference to the closing price as of the last business day of the registrant’s most recently completed second fiscal quarter, June 30, 2020, was approximately $11,231,617,436.
As of January 29, 2021, 93,943,645 shares of the registrant’s common stock were outstanding.
DOCUMENTS INCORPORATED BY REFERENCE
Portions of the registrant’s definitive proxy statement relating to the registrant’s annual meeting of stockholders to be filed pursuant to Regulation 14A within 120 days following the end of the registrant’s fiscal year ended December 31, 2020 are incorporated by reference into Part III of this Form 10-K.


TABLE OF CONTENTS
  Page
 
   
Item 1.
Item 1A.
Item 1B.
Item 2.
Item 3.
Item 4.
   
 
   
Item 5.
Item 6.
Selected Financial Data
34
Item 7.
Item 7A.
Item 8.
Item 9.
Item 9A.
Item 9B.
   
 
   
Item 10.
Item 11.
Item 12.
Item 13.
Item 14.
   
 
   
Item 15.
INGREZZA® and ONGENTYS® are registered trademarks of Neurocrine Biosciences, Inc. Any other brand names or trademarks appearing in this Annual Report that are not the property of Neurocrine Biosciences, Inc. are the property of their respective holders.
2

PART I
Forward-Looking Statements
This Annual Report on Form 10-K and the information incorporated herein by reference contain forward-looking statements that involve a number of risks and uncertainties. Although our forward-looking statements reflect the good faith judgment of our management, these statements can only be based on facts and factors currently known by us. Consequently, these forward-looking statements are inherently subject to risks and uncertainties, and actual results and outcomes may differ materially from results and outcomes discussed in the forward-looking statements.
Forward-looking statements can be identified by the use of forward-looking words such as “believes,” “expects,” “hopes,” “may,” “will,” “plan,” “intends,” “estimates,” “could,” “should,” “would,” “continue,” “seeks,” “pro forma,” or “anticipates,” or other similar words (including their use in the negative), or by discussions of future matters such as the development of new products, technology enhancements, possible changes in legislation and other statements that are not historical. These statements include but are not limited to statements under the captions “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Business,” as well as other sections in this report. You should be aware that the occurrence of any of the events discussed under the heading in Part I titled “Item 1A. Risk Factors” and elsewhere in this report could substantially harm our business, results of operations and financial condition and that if any of these events occurs, the trading price of our common stock could decline and you could lose all or a part of the value of your shares of our common stock.
The cautionary statements made in this report are intended to be applicable to all related forward-looking statements wherever they may appear in this report. We urge you not to place undue reliance on these forward-looking statements, which speak only as of the date of this report. Except as required by law, we assume no obligation to update our forward-looking statements, even if new information becomes available in the future.

3

Item 1. Business
Overview
We are a neuroscience-focused, biopharmaceutical company dedicated to discovering, developing and delivering life-changing treatments for people with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. Our diverse portfolio includes United States Food and Drug Administration, or FDA, approved treatments for tardive dyskinesia, Parkinson’s disease, endometriosis*, uterine fibroids* and clinical programs in multiple therapeutic areas. For nearly three decades, we have specialized in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems. (*in collaboration with AbbVie Inc.)
Product Pipeline
Exclusive and Partnered Commercial Products
The following table summarizes our exclusive and partnered commercial products and is followed by detailed descriptions of each product:
nbix-20201231_g1.jpg
INGREZZA (valbenazine)
We launched INGREZZA in the U.S. in May 2017, after receiving FDA approval for INGREZZA as the first FDA-approved drug for the treatment of tardive dyskinesia in April 2017. INGREZZA provides a once-daily dosing treatment option for tardive dyskinesia and has two dosing options (40 mg and 80 mg capsules), with 40 mg taken for the first seven days of treatment and an option to take 40 mg or 80 mg thereafter, depending on the patient’s dosing needs.
In February 2021, Mitsubishi Tanabe Pharmaceutical Company, or MTPC, reported positive top-line results from the J-KINECT Phase III study, designed to evaluate the efficacy and safety of valbenazine in tardive dyskinesia. Detailed results from this trial will be presented at a future medical conference. With positive data in hand, a marketing authorization with the Ministry of Health and Welfare is planned for 2021 in Japan. In addition, MTPC submitted filings for marketing authorizations in South Korea, Thailand, Singapore, Indonesia, and Malaysia in 2020.
Tardive dyskinesia is defined by hyperkinetic involuntary movements which arise after months or years of treatment with dopamine receptor blocking agents, such as antipsychotics used for treating schizophrenia, bipolar disorder and depression, and certain treatments for nausea, vomiting and gastric emptying in patients with gastroparesis. While the prevalence rates of tardive dyskinesia can vary greatly in accordance with the population being studied, it is estimated that over 500 thousand individuals are affected by tardive dyskinesia in the U.S. alone (Kantar Health).
4

INGREZZA net product sales totaled $993.1 million, $752.9 million and $409.6 million for 2020, 2019 and 2018, respectively, and represented the significant majority of our total net product sales for 2020 and all of our net product sales for 2019 and 2018.
ONGENTYS (opicapone)
We launched ONGENTYS in the U.S. in September 2020, after receiving FDA approval for ONGENTYS as an adjunctive therapy to levodopa/DOPA decarboxylase inhibitors in adult Parkinson's disease patients in April 2020. We acquired the U.S. and Canada rights to ONGENTYS from BIAL – Portela & Ca, S.A., or BIAL, in the first quarter of 2017.
ONGENTYS is a novel, once-daily, peripherally acting, highly selective Catechol-O-methyltransferase, or COMT, inhibitor utilized as an adjunct therapy to levodopa/carbidopa in patients with Parkinson’s disease experiencing motor fluctuations. COMT inhibitors are utilized to prolong the duration of effect of levodopa, the primary treatment option for Parkinson’s disease patients, during periods of the day where the effects of levodopa wear off and motor symptoms worsen, also referred to as “off-time.” Parkinson’s disease is a chronic and progressive movement disorder that affects approximately 1 million individuals in the U.S. alone.
ORILISSA (elagolix)
AbbVie Inc., or AbbVie, launched ORILISSA in the U.S. and Canada in August and November 2018, respectively, after receiving FDA and Health Canada approval for ORILISSA for the management of moderate to severe endometriosis pain in women in July and October 2018, respectively. Discovered and developed through Phase II clinical studies by us, we out-licensed the global rights to elagolix to AbbVie in 2010.
The World Endometriosis Research Foundation estimates that there are over 170 million women worldwide who suffer from endometriosis, including approximately 7.5 million women in the U.S. alone.
ORIAHNN (elagolix, estradiol, and norethindrone acetate; elagolix)
AbbVie launched ORIAHNN in the U.S. in June 2020, after receiving FDA approval for ORIAHNN as the first FDA-approved non-surgical, oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women in May 2020. We out-licensed the global rights to elagolix to AbbVie in 2010.
Uterine fibroids are benign hormonally responsive tumors that form in the wall of the uterus with a prevalence rate of at least 25% (American College of Obstetricians and Gynecologists) and are a leading indication for hysterectomy in the U.S., with approximately 250,000 hysterectomies performed each year related to uterine fibroids (Whiteman et al AJOG 2008, 198, e1).
5

Clinical Development Pipeline
The following table summarizes our clinical development pipeline and is followed by detailed descriptions of each program:
nbix-20201231_g2.jpg
Neurology
valbenazine – VMAT2 Inhibitor
VMAT2 is a protein concentrated in the human brain that is essential for the transmission of nerve impulses between neurons. VMAT2 is primarily responsible for packaging and transporting monoamines (dopamine, norepinephrine, serotonin and histamine) in neurons. Specifically, dopamine enables neurotransmission among nerve cells that are involved in voluntary and involuntary motor control. Disease states such as tardive dyskinesia, Tourette syndrome, Huntington’s chorea, schizophrenia, and tardive dystonia are characterized in part by a hyperdopaminergic state in the brain, and modulation of neuronal dopamine levels may provide symptomatic benefits for patients with these conditions, among others.
We are currently conducting the KINECT-HD study, a Phase III, randomized, placebo-controlled, double-blind, multi-center Phase III clinical study to evaluate the efficacy, safety and tolerability of valbenazine for the treatment of chorea in 120 patients with Huntington’s disease, or HD, with Phase III top-line data expected in the fourth quarter of 2021.
HD is a hereditary progressive neurodegenerative disorder, in which neurons within the brain break down, resulting in motor, cognitive and psychiatric symptoms. Symptoms generally appear between the ages of 30 to 50 and worsen over a 10 to 25-year period. Many patients with HD experience chorea, a troublesome involuntary movement disorder, in which patients develop abnormal, abrupt or irregular movements. Chorea can affect various body parts, and interfere with speech, swallowing, posture and gait. HD is estimated to affect approximately 30,000 adults in the U.S., with more than 200,000 at risk of inheriting the disease (NORD).
NBI-921352 (XEN901) – Nav1.6 Sodium Channel Inhibitor
NBI-921352 is a potent, highly selective Nav1.6 sodium channel inhibitor being developed to treat pediatric patients with SCN8A-DEE and other potential indications, including adult focal epilepsy.
The safety, tolerability and pharmacokinetics of NBI-921352 have been evaluated in a randomized, double-blind, placebo-controlled Phase I study using a powder-in-capsule formulation of NBI-921352 in healthy adult subjects.
6

Xenon has developed a pediatric-specific, granule formulation of NBI-921352, and completed juvenile toxicology studies to support pediatric development activities.
In October 2020, the FDA requested additional non-clinical data to support the IND we submitted in August 2020 in support of a Phase II clinical study for NBI-921352 in patients with SCN8A-DEE. Based on feedback received in January 2021, we plan to initiate a Phase II clinical study in adolescent patients (aged 12 years and older) with SCN8A-DEE in the third quarter of 2021, and the study protocol will be amended to include younger pediatric patients (aged 2-11 years) with SCN8A-DEE as soon as the FDA has reviewed and approved additional non-clinical information. We are also advancing clinical plans to initiate a Phase II clinical study of NBI-921352 for the treatment of adult focal epilepsy in 2021. In addition, in October 2020, we announced the FDA granted us Rare Pediatric Disease Designation for NBI-921352 for the treatment of SCN8A-DEE.
SCN8A-DEE is a rare, extremely severe, single-gene epilepsy caused by mutations in the SCN8A gene that activates Nav1.6, the most highly expressed sodium channel in the excitatory pathways of the central nervous system, or CNS. Children born with SCN8A-DEE typically start experiencing seizures between birth and 18 months of age, and most have multiple seizures per day. Other symptoms include learning difficulties, muscle spasms, low or high muscle tone, poor coordination, developmental delay, and features similar to autism. An estimated 10% of people with SCN8A are reported to have experienced sudden unexpected death in epilepsy. The prevalence of SCN8A-DEE is estimated to be 1% of all developmental and epileptic encephalopathies (Larsen et al, Neurology 2015, 84, 480). As SCN8A mutations were discovered only recently (i.e., in 2012), the number of SCN8A-DEE cases is expected to increase as awareness of and access to genetic surveillance increases. SCN8A-DEE is generally refractory to anti-epilepsy treatments.
We are developing NBI-921352 with Xenon Pharmaceuticals Inc., or Xenon, as part of a strategic collaboration announced in December 2019.
NBI-827104 (ACT-709478) – T-type Calcium Channel Blocker
We acquired the global rights to NBI-827104 from Idorsia Pharmaceuticals Ltd., or Idorsia, in May 2020. NBI-827104 is a potent, selective, orally active and brain penetrating T-type calcium channel blocker, being developed for the treatment of a rare pediatric epilepsy and other potential indications, including essential tremor.
In November 2020, we initiated a Phase II clinical study for NBI-827104 in a rare pediatric epileptic encephalopathy known as Continuous Spike and Wave During Sleep, or CSWS. CSWS typically impacts children initially between the ages of two and four years old and manifests itself via a variety of seizure types, including atypical absence seizures, generalized tonic-clonic seizures and focal seizures that usually occur during sleep. In addition, children with CSWS often present with cognitive, behavioral and developmental regression or delay. Due to the differentiated mechanism of action of this molecule, when compared to non-selective calcium channel inhibitors, treatment with NBI-827104 could lead to an enhanced benefit risk profile for patients with this rare pediatric form of epilepsy. In parallel we are advancing clinical plans to initiate a Proof of Concept clinical study of NBI-827104 for the treatment of essential tremor in 2021.
Endocrinology
crinecerfont (NBI-74788) – CRF1 Antagonist
Crinecerfont is a potent, selective, orally active, corticotropin-releasing factor1, or CRF1, receptor antagonist as demonstrated in a range of in vitro and in vivo assays. CRF1, is a hypothalamic hormone released directly into the hypophyseal portal vasculature which acts on the CRF1 receptor, a G protein-coupled receptor, or GPCR, in the anterior pituitary to stimulate the release of adrenocorticotropin hormone, or ACTH. The primary role of ACTH is the stimulation of the synthesis and release of adrenal steroids, including cortisol. Cortisol from the adrenals have a negative feedback role at the level of the hypothalamus that decreases CRF1 release as well as at the level of the pituitary to inhibit the release of ACTH. This tight control loop is known as the hypothalamic-pituitary-adrenal axis. Blockade of CRF1 receptors at the pituitary has been shown to decrease the release of ACTH, which in turn decreases the production of adrenal steroids including androgens, and potentially the symptoms associated with classic CAH. Lower ACTH levels would also reduce the amount of exogenous corticosteroid necessary for classic CAH patients to thrive avoiding the side-effects currently associated with excessive steroid therapy.
7

Classic CAH is a group of autosomal recessive genetic disorders that affects approximately 30 thousand people in the U.S. and approximately 50 thousand people in the EU, and results in an enzyme deficiency altering the production of adrenal steroids. Because of this deficiency, the adrenal glands have little to no cortisol biosynthesis resulting in a potentially life-threatening condition. If left untreated, classic CAH can result in salt wasting, dehydration, and eventually death. Even with cortisol replacement, persistent elevation of ACTH from the pituitary gland results in excessive androgen levels leading to virilization of females including precocious puberty, menstrual irregularity, short stature, hirsutism, acne and fertility problems.
Corticosteroids are the current standard of care for classic CAH and are used chronically to both correct the endogenous cortisol deficiency and to reduce the excessive ACTH levels and androgen excess. However, the dose and duration of steroid use required to suppress ACTH is well above the normal physiological level of cortisol; resulting in metabolic syndrome, bone loss, growth impairment, and Cushing’s syndrome as common and serious side effects. We have been granted orphan drug designation for crinecerfont in the treatment of classic CAH in the U.S. and the EU.
In June 2020, positive data from a completed Phase II, open-label, pharmacokinetic/pharmacodynamic clinical study of crinecerfont in adult patients with classic CAH, which assessed key pharmacodynamic biomarkers including ACTH, 17-hydroxyprogesterone (17-OHP), androgen and cortisol levels collected the morning following bedtime dosing on Day 1 and Day 14, demonstrated meaningful reductions in elevated ACTH and 17-hydroxyprogesterone (17-OHP) levels (by 54% to 75%) at all doses studied, together with a dose-related decrease in androstenedione (A4) levels, ranging from 21% to 64%. At the highest dose of crinecerfont (100 mg twice daily), 75% of patients showed a response of at least 50% reduction from baseline for each of the three hormone markers at day 14. Treatment with crinecerfont was well tolerated with a favorable safety profile with no related serious adverse events reported. Adverse events reported in two or more participants included headache, upper respiratory tract infection, fatigue, contusion, insomnia and nausea.
In July 2020, we initiated the CAHtalyst study, a global registrational Phase III, randomized, double-blind, placebo-controlled clinical study to evaluate the safety and efficacy of crinecerfont in 165 adult patients with classic CAH, followed by an open-label treatment period.
In July 2019, we initiated a Phase IIa proof-of-concept, pharmacokinetic/pharmacodynamic clinical study to evaluate the safety and tolerability of crinecerfont in pediatric patients with classic CAH. We plan to initiate a single global registrational Phase III clinical study for crinecerfont in pediatric patients with CAH in 2021.
elagolix – GnRH Antagonist
The gonadotropin-releasing hormone, or GnRH, is the endogenous peptide that binds to the GnRH receptor and stimulates the secretion of the pituitary hormones that are responsible for sex steroid production and normal reproductive function. Researchers have found that chronic administration of GnRH agonists, after initial stimulation, reversibly shuts down this transmitter pathway and is clinically useful in treating hormone-dependent diseases such as Polycystic Ovary Syndrome, or PCOS.
AbbVie initiated a Phase II clinical study of elagolix in patients with PCOS in mid-2019. The study is designed to evaluate whether there is a potential impact on disordered hormonal dynamics in women with PCOS. We out-licensed the global rights to elagolix to AbbVie in 2010.
PCOS is one of the most common hormonal disorders among women of reproductive age, affecting approximately 3.5 million women in the U.S. PCOS occurs when the ovaries or adrenal glands produce more male hormones (androgens) than normal. Women with PCOS experience irregular menstrual periods, infertility, pelvic pain, weight gain, acne and excess hair growth on the face, chest, stomach and thighs. There is no cure for PCOS, and treatment options are limited. If left untreated, PCOS can lead to certain cancers, diabetes and coronary artery disease.
8

Psychiatry
We acquired the global rights to develop and commercialize NBI-1065844 (TAK-831), NBI-1065845 (TAK-653) and NBI-1065846 (TAK-041) from Takeda Pharmaceutical Company Limited, or Takeda, in June 2020.
NBI-1065844 (TAK-831) – DAAO Inhibitor
NBI-1065844 is a potential first-in-class D-Amino Acid Oxidase, or DAAO, inhibitor that has completed multiple Phase I clinical studies and is currently in on-going Phase II clinical studies, including the Phase II INTERACT proof-of-concept clinical study in negative symptoms of schizophrenia, with Phase II top-line data expected in the first quarter of 2021.
According to the World Health Organization, or WHO, 20 million people across the globe are affected by schizophrenia. In the U.S., the prevalence of schizophrenia is estimated to be approximately 0.6% of the population. The negative symptoms associated with schizophrenia describe a lessening or absence of behaviors and functions related to motivation and interest, or verbal and emotional expression. There are currently no approved treatment options in the U.S. for patients with predominant negative symptoms of schizophrenia.
NBI-1065844 is currently designated as a royalty-bearing product for Takeda. Takeda retains a one-time opt-in right for a 50:50 profit share arrangement upon achievement of a certain development event.
NBI-1065845 (TAK-653) – AMPA Potentiator
NBI-1065845 is a potential first-in-class Alpha-Amino-3-Hydroxy-5-Methyl-4-Isoxazole Propionic Acid, or AMPA, potentiator with the potential to be developed for treatment-resistant depression. NBI-1065845 has completed multiple Phase I clinical studies. We plan to initiate a Phase II clinical study of NBI-1065845 in treatment-resistant depression in 2021.
According to the WHO, major depressive disorder, or MDD, is one of the leading causes of disability. While there are a number of marketed treatments for MDD, approximately 1/3 of patients do not benefit from them. There is a significant need to develop new therapies with improved, faster onset of efficacy that are well tolerated.
NBI-1065845 is currently designated as a 50:50 profit share product with Takeda. Takeda retains a one-time opt-out right to convert the designation to a royalty-bearing product dependent on a certain development event.
NBI-1065846 (TAK-041) – G Protein-Coupled Receptor 139 Agonist
NBI-1065846 is a potential first-in-class G Protein-Coupled Receptor 139, or GPR139, agonist with the potential to be developed for the treatment of anhedonia in depression. NBI-1065846 has completed multiple Phase I clinical studies. We plan to initiate a Phase II clinical study of NBI-1065846 in anhedonia in 2021.
Anhedonia is a psychological condition characterized by the inability to experience pleasure. In patients with depression, anhedonia often does not improve with current treatments and predicts lack of functional improvement.
NBI-1065846 is currently designated as a 50:50 profit share product with Takeda. Takeda retains a one-time opt-out right to convert the designation to a royalty-bearing product dependent on a certain development event.
Research Programs
We invest in research and development in order to address diseases and disorders of the central nervous and endocrine systems, which include therapeutic categories ranging from hypothalamic-pituitary-adrenal disorders to stress-related disorders and neurological/neuropsychiatric diseases. CNS and endocrinology drug therapies are among the largest therapeutic categories, accounting for over $110 billion in drug sales in the U.S. alone according to IQVIA (2018).
9

Business Strategy
Our mission is to improve the lives of patients living with serious and under-addressed neurological, neuro-endocrinology and psychiatry related diseases and disorders. The following are the key elements of our business strategy:
Commercializing Our Product Portfolio. In April 2017, we received approval from the FDA for INGREZZA for the treatment of tardive dyskinesia. In April 2020, we received FDA approval for ONGENTYS as an adjunctive therapy to levodopa/DOPA decarboxylase inhibitors in adult Parkinson's disease patients. We market INGREZZA and ONGENTYS in the U.S. The commercial launch of INGREZZA occurred in May 2017 and ONGENTYS occurred in September 2020. We have built a specialty sales force in the U.S. of approximately 250 experienced sales professionals. This specialty sales force focuses on promotion to physicians, primarily psychiatrists and neurologists. Our commercial team is comprised of experienced professionals in marketing, access and reimbursement, managed markets, market research, commercial operations, and sales force planning and management. In addition, our commercial infrastructure includes capabilities in manufacturing, medical affairs, quality control and compliance. We intend to retain commercial rights to certain products, including INGREZZA, that we can effectively and efficiently develop, secure regulatory approval and commercialize, which includes products with a concentrated prescriber base and well-defined patient population that can be accessed with an efficient patient and prescriber outreach program.
Advancing Life-Changing Discoveries in Neurology, Neuro-Endocrinology and Psychiatry. We believe that by continuing to advance and extend our product pipeline, we can mitigate some of the clinical development risks associated with drug development. We currently have multiple programs in various stages of research and development, including symptomatic disease modifying and curative treatments. We take a portfolio approach to managing our pipeline that balances the size of the market opportunities with clear and defined clinical and regulatory paths to approval. By doing so, we focus our internal development resources on innovative therapies with improved probabilities of technical and commercial success.
Discovering Novel Medicines to Address Unmet Patient Needs. We seek to identify and validate new medicines on novel targets for internal development or collaboration. We believe the creativity and productivity of our discovery research group will continue to be a critical component for our ongoing success.
Acquiring Rights to Commercial Products, Drug Development Candidates and Technologies. We plan to continue to selectively acquire rights to programs at all stages of development and commercial products to take advantage of our drug development and commercial capabilities.
Corporate Collaborations and Strategic Alliances
One of our business strategies is to utilize strategic alliances to enhance our development and commercialization capabilities. The following is a summary of our significant collaborations/alliances:
Takeda. In June 2020, we entered into an exclusive license agreement with Takeda, which became effective in July 2020, to develop and commercialize certain compounds in Takeda’s early to mid-stage psychiatry pipeline. Specifically, Takeda granted us an exclusive license to the following seven assets: (i) NBI-1065844 (TAK-831) for schizophrenia, (ii) NBI-1065845 (TAK-653) for treatment-resistant depression, (iii) NBI-1065846 (TAK-041) for anhedonia (which together with the NBI-1065845 are referred to as the Phase II Ready Assets), and (iv) four non-clinical stage assets, or the Non-Clinical Assets.
NBI-1065844 is deemed a royalty-bearing product under the license agreement pursuant to which we will be responsible for all costs and expenses associated with the development, manufacture, and commercialization of such asset, subject to certain exceptions, and Takeda will be eligible to receive development and commercial milestones and royalties with respect to such asset, or a Royalty-Bearing Product, and Takeda will retain the right to opt-in to a profit sharing arrangement pursuant to which we and Takeda will equally share in the operating profits and losses related to such asset, subject to certain exceptions, in lieu of receiving milestones and royalties, or a Profit-Share Product. Subject to specified conditions, Takeda may elect to exercise such opt-in right for NBI-1065844 before we initiate a Phase III clinical trial. Each of the Phase II Ready Assets is deemed a Profit-Share Product and Takeda will retain the right to opt-out of the profit-sharing arrangement for such asset pursuant to which such asset would become a Royalty-Bearing Product. Takeda may elect to exercise such opt-out rights with respect to a Phase II
10

Ready Asset immediately following the completion of the second Phase II clinical trial for such Phase II Ready Asset. In addition, under certain circumstances related to the development and commercialization activities to be performed by us, Takeda may elect to opt-out of the profit-sharing arrangement for a Profit-Share Product before the initiation of a Phase III clinical trial for such product.
Each of the Non-Clinical Assets will be Royalty-Bearing Products pursuant to which we will be responsible for all costs and expenses associated with the development, manufacture, and commercialization of such assets, subject to certain exceptions.
Unless earlier terminated, the license agreement will continue on a licensed product-by-licensed product and country-by-country basis until the date on which, (i) for any Royalty-Bearing Product, the royalty term has expired in such country; and (ii) for any Profit-Share Product, for so long as we continue to develop, manufacture, or commercialize such licensed product. We may terminate the license agreement for convenience in its entirety or in one or more (but not all) of the United States, Japan, the European Union, and the United Kingdom, or the Major Markets, on 6 months’ written notice to Takeda (i) with respect to all licensed products prior to the first commercial sale of the first licensed product for which first commercial sale occurs, or (ii) with respect to all licensed products in one or more given target classes, as defined in the agreement, prior to the first commercial sale of the first licensed product in such target class(es) for which first commercial sale occurs. We may terminate the license agreement for convenience in its entirety or in one or more (but not all) of the Major Markets on 12 months’ written notice to Takeda (i) with respect to all licensed products following the first commercial sale of the first licensed product for which first commercial sale occurs, or (ii) with respect to all licensed products in one or more given target classes following the first commercial sale of the first licensed product in such target class(es) for which first commercial sale. Takeda may terminate the license agreement, subject to specified conditions, (i) if we challenge the validity or enforceability of certain Takeda intellectual property rights or (ii) on a target class-by-target class basis, in the event that we do not conduct any material development or commercialization activities with respect to any licensed product within such target class for a specified continuous period. Subject to a cure period, either party may terminate the license agreement in the event of any material breach, solely with respect to the target class of a licensed product to which such material breach relates, or in its entirety in the event of any material breach that relates to all licensed products.
Idorsia. We acquired the global rights to NBI-827104 from Idorsia in May 2020. NBI-827104 is a potent, selective, orally active and brain penetrating T-type calcium channel blocker, being developed for the treatment of a rare pediatric epilepsy and other potential indications, including essential tremor. The agreement also included a research collaboration to discover and identify additional novel T-type calcium channel blockers as development candidates. Under the terms of the agreement, we are responsible for all manufacturing, development and commercialization costs of any collaboration product. We may terminate the collaboration and licensing agreement, in its entirety or with respect to a particular compound or development candidate, by providing 90 days’ written notice to Idorsia. Further, in the event a party commits a material breach and fails to cure such material breach within 90 days after receiving written notice thereof, the non-breaching party may terminate the agreement in its entirety immediately upon written notice to the breaching party.
Xenon. In December 2019, we entered into a license and collaboration agreement with Xenon to identify, research, and develop sodium channel inhibitors, including clinical candidate NBI-921352 and three preclinical candidates, which compounds we will have the exclusive right to further develop and commercialize under the terms and conditions set forth in the agreement.
We will be solely responsible, at our sole cost and expense, for all development and manufacturing of the compounds and any pharmaceutical product that contains a compound, subject to Xenon’s right to elect to co-fund the development of one product in a major indication and thus receive a mid-single digit percentage increase in royalties owed on the net sales of such product in the U.S. If Xenon exercises such option, the parties will share equally all reasonable and documented costs and expenses incurred in connection with the development of such product in the applicable indication, except costs and expenses that are solely related to the development of such product for regulatory approval outside the U.S.
Unless earlier terminated, the term of the license and collaboration agreement will continue on a product-by-product and country-by-country basis until the expiration of the royalty term for such product in such country. Upon the expiration of the royalty term for a particular product and country, the exclusive license granted by Xenon to us with
11

respect to such product and country will become fully paid, royalty free, perpetual, and irrevocable. We may terminate the license and collaboration agreement by providing at least 90 days’ written notice, provided that such unilateral termination will not be effective for certain products until we have used commercially reasonable efforts to complete certain specified clinical studies. Either party may terminate the agreement in the event of a material breach in whole or in part, subject to specified conditions.
Voyager. We entered into a collaboration and license agreement with Voyager, a clinical-stage gene therapy company, which became effective in March 2019. The agreement is focused on the development and commercialization of four programs using Voyager’s proprietary gene therapy platform. The four programs consist of the following: NBIb-1817 for Parkinson’s disease, the Friedreich’s ataxia program and two undisclosed programs.
Pursuant to development plans agreed to by us and Voyager, unless Voyager exercises its co-development and co-commercialization rights as provided for in the agreement, we will be responsible for all development costs. Further, upon the occurrence of a specified event for each program, we will assume responsibility for the development, manufacturing, and commercialization activities of such program.
On February 2, 2021, we notified Voyager of our termination of the NBIb-1817 for Parkinson’s disease program. The effective date of this termination will be August 2, 2021. The termination does not apply to any other development program other than NBIb-1817 for Parkinson’s disease, and our collaboration and license agreement with Voyager will otherwise continue in effect. With respect to the other programs, we may terminate the collaboration and license agreement with Voyager upon 180 days written notice to Voyager prior to the first commercial sale of any collaboration product or upon 1 year after the date of notice if such notice is provided after the first commercial sale of any collaboration product. Unless terminated earlier, the agreement will continue in effect until the expiration of the last to expire royalty term with respect to any collaboration product or the last expiration or termination of any exercised co-development and co-commercialization rights by Voyager as provided for in the agreement.
BIAL. We acquired the U.S. and Canada rights to ONGENTYS from BIAL in the first quarter of 2017. We launched ONGENTYS in the U.S. in September 2020, after receiving FDA approval for ONGENTYS as an adjunctive therapy to levodopa/DOPA decarboxylase inhibitors in adult Parkinson's disease patients in April 2020.
Under the terms of the agreement, we are responsible for the commercialization of ONGENTYS in the U.S. and Canada. Further, we rely on BIAL for the commercial supply of ONGENTYS. Upon our written request prior to the estimated expiration of the term of a licensed product, the parties shall negotiate a good faith continuation of BIAL’s supply of such licensed product after the term. After the term, and if BIAL is not supplying a certain licensed product, we shall pay BIAL a trademark royalty based on the net sales of such licensed product.
Upon commercialization of ONGENTYS, we determined certain annual sales forecasts. In the event we fail to meet the minimum sales requirements for a particular year, we would be obligated to pay BIAL an amount equal to the difference between the actual net sales and minimum sales requirements for such year.
Unless earlier terminated, the agreement will continue on a licensed product-by-product and country-by-country basis until a generic product in respect of such licensed product under the agreement is sold in a country and sales of such generic product are greater than a specified percentage of total sales of such licensed product in such country.
Either party may terminate the agreement if the other party materially breaches the agreement and does not cure the breach within a specified notice period, or upon the other party’s insolvency. BIAL may terminate the agreement if we fail to use commercially reasonable efforts to submit a new drug application, or NDA, for a licensed product by a specified date, in the event we fail to meet the minimum sales requirements for any two years, or under certain circumstances involving a change of control of Neurocrine Biosciences. Under certain circumstances where BIAL elects to terminate the agreement in connection with a change of control of Neurocrine Biosciences, BIAL would be obligated to pay us a termination fee. We may terminate the agreement at any time for any reason upon nine months’ written notice to BIAL.
MTPC. In March 2015, we entered into a collaboration and license agreement with MTPC for the development and commercialization of INGREZZA for movement disorders in Japan and other select Asian markets. Under the terms of the agreement, MTPC is responsible for all development, marketing and commercialization costs in Japan and other select Asian markets, with the exception of a single Huntington’s chorea study to be performed by us. We will
12

be entitled to a percentage of sales of INGREZZA in Japan and other select Asian markets for the longer of ten years or the life of the related patent rights. MTPC may terminate the agreement at its discretion upon 180 days’ written notice to us. In such event, all INGREZZA product rights for Japan and other select Asian markets would revert to us.
AbbVie. In June 2010, we entered into an exclusive worldwide collaboration with AbbVie to develop and commercialize elagolix and all next-generation GnRH antagonists, or collectively the GnRH Compounds, for women’s and men’s health.
AbbVie received approval of ORILISSA for the management of moderate to severe endometriosis pain in women from the FDA in July 2018 and Health Canada in October 2018. In May 2020, AbbVie received approval from the FDA for ORIAHNN for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women.
Under the terms of the agreement, AbbVie is responsible for all third-party development, marketing, and commercialization costs. We are entitled to a percentage of worldwide sales of GnRH Compounds for the longer of ten years or the life of the related patent rights. AbbVie may terminate the collaboration at its discretion upon 180 days’ written notice to us.
Intellectual Property
We actively seek to protect our products and product candidates and related inventions and improvements that we consider important to our business. We own a portfolio of U.S and non-U.S. patents and patent applications and have licensed rights to a number of U.S. and non-U.S. patents and patent applications. Our owned and licensed patents and patent applications cover or relate to our products and product candidates, including certain formulations, used to treat particular conditions and methods of administration, drug delivery technologies and delivery profiles and methods of manufacturing.
We own or have licensed rights to the following U.S. patents relating to INGREZZA and our other products and product candidates in our pipeline (in addition to non-U.S. patents and certain patents covering our early-stage product candidates):
•INGREZZA, our highly selective VMAT2 inhibitor for the treatment of tardive dyskinesia, is covered by eight issued U.S. patents that are listed in the FDA’s Orange Book and are set to expire between 2027 and 2037. There is also a potential patent term extension of up to an additional two years for U.S. Patent No. 8,039,627, which is currently set to expire in 2029 and is the earliest patent covering valbenazine, the active pharmaceutical ingredient contained in INGREZZA. In Japan and certain other East Asian markets, we are actively pursuing most of the patents corresponding to those listed in the FDA’s Orange Book entry for INGREZZA.
•ONGENTYS, a highly selective COMT inhibitor for Parkinson’s disease, is covered by nine issued U.S. patents that are listed in the FDA’s Orange Book and set to expire between 2026 to 2035 (not including a potential patent term extension of up to an additional four years for one of these patents).
•ORILISSA, our small molecule GnRH antagonist for the treatment of endometriosis pain, is covered by eight issued U.S. patents that are listed in the FDA’s Orange Book and are set to expire between 2021 to 2036 (not including a potential patent term extension of up to an additional five years for one of the patents currently set to expire either in 2021 or 2024).
•ORIAHNN, containing our small molecule GnRH antagonist for the treatment of menstrual bleeding associated with uterine fibroids, is covered by six issued U.S. patents that are listed in the FDA’s Orange Book and are set to expire between 2021 to 2024 (not including a potential patent term extension of up to an additional five years for one of the patents).
•Valbenazine, our highly selective VMAT2 inhibitor under further clinical development for the treatment of chorea in Huntington’s disease, is covered by at least six of the issued U.S. patents that are listed in the FDA’s Orange Book entry for INGREZZA and are set to expire between 2027 and 2036 . There is also a potential patent term extension of up to an additional two years for U.S. Patent No. 8,039,627, which is currently set to expire in 2029.
13

•Crinecerfont, our CRF1 antagonist for the treatment of CAH, is covered by U.S. Patent No. 10,905,690, which expires in 2035 (not including a potential patent term extension of up to an additional five years).
•NBI-1065844, a DAAO inhibitor for the treatment of negative symptoms of schizophrenia, is covered by U.S. Patent No. 9,290,456, among others, which expires in 2032 (not including a potential patent term extension of up to an additional five years).
•NBI-827104, an inhibitor of T-type calcium channels for the treatment of CSWS epilepsy, is covered by U.S. Patent No. US 9,932,314, among others, which expires in 2035 (not including a potential patent term extension of up to an additional five years).
•NBI-921352, an inhibitor of the Nav1.6 voltage-gated sodium channel for the treatment of SCN8A-DEE epilepsy, is covered by U.S. Patent No. US 10,246,453, among others, which expires in 2037 (not including a potential patent term extension of up to an additional five years).
•Elagolix, our small molecule GnRH antagonist under further development for the treatment of polycystic ovary syndrome, is covered by six of the issued U.S. patents that are listed in the FDA’s Orange Book entry for ORILISSA and are set to expire between 2021 to 2024 (not including a potential patent term extension of up to an additional five years for one of the patents).
•NBI-1065845, a positive allosteric modulator of AMPA for the treatment of treatment-resistant depression is covered by U.S. Patent No. 8,778,934, among others, which expires in 2031 (not including a potential patent term extension of up to an additional five years).
•NBI-1065846, a GPR139 agonist for the treatment of anhedonia in depression, is covered by U.S. Patent No. 9,556,130, among others, which expires in 2035 (not including a potential patent term extension of up to an additional five years).
In addition to the potential patent term extensions referenced above, the products and product candidates in our pipeline may be subject to additional terms of exclusivity that we might obtain by future patent issuances.
Separately, the U.S., the European Union, or EU, and Japan all provide data and marketing exclusivity for new medicinal compounds. If this protection is available, no competitor may use the original applicant’s data as the basis of a generic marketing application during the period of data and marketing exclusivity, which is measured from the date of marketing approval by the FDA or corresponding foreign regulatory authority. This period of exclusivity is generally five years in the U.S., six years in Japan and ten years in the EU, except that for biologics, this period of exclusivity in the U.S. is twelve years under the Biologics Price Competition and Innovation Act. In addition, if granted orphan drug designation, certain of our product candidates, including crinecerfont, may also be eligible for market exclusivity in the U.S. and EU for seven years and ten years, respectively.
Manufacturing and Supply
We currently rely on, and intend to continue to rely on, third-party manufacturers for the production of INGREZZA and our product candidates. Raw materials, active pharmaceutical ingredients, or API, and other supplies required for the production of INGREZZA and our product candidates are procured from various third-party manufacturers and suppliers in quantities adequate to meet our needs. Continuing adequate supply of such raw materials and API is assured through our long-term commercial supply and manufacturing agreements with multiple manufacturers and our continued focus on the expansion and diversification of our third-party manufacturing relationships. In addition, under the terms of our agreement with BIAL, we rely on BIAL and its suppliers to supply all drug product for the commercialization of ONGENTYS.
We believe our outsource manufacturing strategy enables us to direct our financial resources to the maximization of our opportunities with INGREZZA and ONGENTYS, investment in our internal R&D programs and expansion of our clinical pipeline through business development opportunities.
Our third-party manufacturers, suppliers and service providers may be subject to routine current Good Manufacturing Practice, or cGMP, inspections by the FDA or comparable agencies in other jurisdictions. We depend on our third-party partners for continued compliance with cGMP requirements and applicable foreign standards.
14

Marketing, Sales and Distribution
Our sales force in the U.S. consists of approximately 250 experienced sales professionals focused on educating health care professionals, including psychiatrists and neurologists, who treat patients with tardive dyskinesia and Parkinson’s disease.
For INGREZZA, our customers in the U.S. consist of a limited network of specialty pharmacy providers that deliver INGREZZA to patients by mail and a specialty distributor that distributes INGREZZA primarily to closed-door pharmacies and government facilities. For ONGENTYS, our customers in the U.S. consist primarily of wholesale distributors. We rely on third-party service providers to perform a variety of functions related to the packaging, storage and distribution of INGREZZA and ONGENTYS.
Government Regulation
Our business activities are subject to extensive regulation by the U.S. and other countries. Regulation by government authorities in the U.S. and foreign countries is a significant factor in the development, manufacture, distribution, tracking, marketing and sale of our proposed products and in our ongoing research and product development activities. All of our products in development will require regulatory approval by government agencies prior to commercialization. The process of obtaining these approvals and the subsequent compliance with appropriate federal and state statutes and regulations require the expenditure of substantial time and financial resources.
In addition, federal and state healthcare laws restrict business practices in the pharmaceutical industry. These laws include, without limitation, federal and state fraud and abuse laws, false claims laws, data privacy and security laws, as well as transparency laws regarding payments or other items of value provided to healthcare providers. We have a comprehensive compliance program designed to ensure our business practices remain compliant.
The federal Anti-Kickback Statute makes it illegal for any person or entity to knowingly and willfully, directly or indirectly, solicit, receive, offer, or pay any remuneration that is intended to induce the referral of business, including the purchase, order, lease of any good, facility, item or service for which payment may be made under a federal healthcare program, such as Medicare or Medicaid.
Federal civil and criminal false claims laws and the federal civil monetary penalties law, which prohibit among other things, any person or entity from knowingly presenting, or causing to be presented, for payment to, or approval by, federal programs, including Medicare and Medicaid, claims for items or services, including drugs, that are false or fraudulent or not provided as claimed and knowingly making, or causing to be made, a false record or to avoid or decrease an obligation to pay money to the federal government.
The Health Insurance Portability and Accountability Act of 1996, or HIPAA, created additional federal criminal statutes that prohibit among other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payors and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services.
In addition, we may be subject to HIPPA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their privacy and security regulations, which impose certain obligations, including the adoption of administrative, physical and technical safeguards to protect individually identifiable health information on covered entities subject to HIPPA (i.e., health plans, healthcare clearinghouses and certain healthcare providers) and their business associates that perform certain services for or on their behalf involving the use or disclosure of individually identifiable health information as we as their covered subcontractors.
The federal Physician Payments Sunshine Act requires certain manufacturers of drugs, devices, biologics and medical supplies to report annually to the Centers for Medicare and Medicaid Services, or CMS, information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, and applicable entities to report ownership and investment interests held by the physicians and their immediate family members. Beginning in 2022, such obligations will include payments and other transfers of value provided in the previous year to certain other healthcare professionals, including physician assistants, nurse practitioners, clinical nurse specialists, anesthesiologist assistants, certified nurse anesthetists, and certified nurse-midwives.
15

Also, many states have similar healthcare statutes or regulations that may be broader in scope and may apply regardless of payor. Additionally, to the extent that our product is sold in a foreign country, we may be subject to similar foreign laws.
Failure to comply with these laws, where applicable, can result in significant penalties, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgement, imprisonment, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, and additional reporting requirements and regulatory oversight, any of which could adversely affect our ability to operate our business and our results of operations.
Development and Marketing Approval for Products
Preclinical studies generally are conducted in laboratory animals to evaluate the potential safety and efficacy of a product. Drug developers submit the results of preclinical studies to the FDA as a part of an investigational new drug, or IND, application before clinical trials can begin in humans. Typically, clinical evaluation involves a time consuming and costly three-phase process.
Phase IClinical trials are conducted with a small number of subjects to determine the early safety profile, maximum tolerated dose and pharmacokinetic properties of the product in human volunteers and for certain products, such as gene therapies, in patients with the target disease.
Phase IIClinical trials are conducted with groups of patients afflicted with a specific disease in order to determine preliminary efficacy, optimal dosages and expanded evidence of safety.
Phase IIILarger, multi-center, comparative clinical trials are conducted with patients afflicted with a specific disease in order to determine safety and efficacy as primary support for regulatory approval by the FDA to market a product candidate for a specific disease.
The FDA closely monitors the progress of each of the three phases of clinical trials that are conducted in the U.S. and may, at its discretion, re-evaluate, alter, suspend or terminate the testing based upon the data accumulated to that point and the FDA’s assessment of the risk/benefit ratio to the patient. Institutional Review Boards, Institutional Ethics Committees, and Data Safety Monitoring Boards also closely monitor the conduct of our trials and may also place holds on our clinical trials or recommend that we voluntarily do so. Clinical trials conducted in foreign countries are also subject to oversight by regulatory authorities in those countries.
Once Phase III trials are completed, drug developers submit the results of preclinical studies and clinical trials to the FDA in the form of an NDA or a biologics license application, or BLA, for approval to commence commercial sales. In most cases, the submission of an NDA or BLA is subject to a substantial application user fee. Under the Prescription Drug User Fee Act, or PDUFA, the FDA has a goal of ten months from the date of filing of a standard NDA for a new molecular entity to review and act on the submission. The FDA generally has a six-month review goal of priority NDAs.
In addition, under the Pediatric Research Equity Act of 2003 as amended and reauthorized, certain applications or supplements to an application must contain data that are adequate to assess the safety and effectiveness of the drug for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults or full or partial waivers from the pediatric data requirements.
The FDA also may require submission of a risk evaluation and mitigation strategy to ensure that the benefits of the drug outweigh its risks. The risk evaluation and mitigation strategy could include medication guides, physician communication plans, assessment plans, and/or additional elements to assure safe use, such as restricted distribution methods, patient registries, or other risk minimization tools.
The FDA conducts a preliminary review of all NDAs and BLAs within the first 60 days after submission, before accepting them for filing, to determine whether they are sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an application for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review. The FDA reviews an NDA or BLA to determine, among other things, whether the drug is safe and effective for its intended use and whether the facility in which it is
16

manufactured, processed, packaged or held meets standards designed to assure the product’s continued safety, quality and purity.
The FDA may refer an application for a novel drug to an advisory committee. An advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.
Before approving an NDA or BLA, the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with current Good Manufacturing Practice requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA or BLA, the FDA may inspect one or more clinical trial sites to assure compliance with Good Clinical Practice requirements.
After evaluating the NDA or BLA and all related information, including the advisory committee recommendation, if any, and inspection reports regarding the manufacturing facilities and clinical trial sites, the FDA may issue an approval letter, or, in some cases, a complete response letter. A complete response letter generally contains a statement of specific conditions that must be met in order to secure final approval of the application and may require additional clinical or preclinical testing in order for FDA to reconsider the application. Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. If and when those conditions have been met to the FDA’s satisfaction, the FDA will typically issue an approval letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications.
Even if the FDA approves a product, it may limit the approved indications for use of the product, require that contraindications, warnings or precautions be included in the product labeling, require that post-approval studies, including Phase IV clinical trials, be conducted to further assess a drug’s safety after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution and use restrictions or other risk management mechanisms under a risk evaluation and mitigation strategy, which can materially affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post-marketing studies or surveillance programs. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes, and additional labeling claims, are subject to further testing requirements and FDA review and approval.
We will also have to complete an approval process similar to that in the U.S. in order to commercialize our product candidates in each foreign country. The approval procedure and the time required for approval vary from country to country and may involve additional testing. Foreign approvals may not be granted on a timely basis, or at all. In addition, regulatory approval of prices is required in most countries other than the U.S. The resulting prices may not be sufficient to generate an acceptable return to us or our corporate collaborators.
In the EU, there are currently two potential tracks for seeking marketing approval for a product not authorized in any EU member state: a decentralized procedure and a centralized procedure. In the decentralized procedure, identical applications for marketing authorization are submitted simultaneously to the national regulatory agencies. Regulatory review is led by one member state (the reference-member state), and its assessment—based on safety, quality and efficacy—is reviewed and approved (assuming there are no concerns that the product poses a serious risk to public health) by the other member states from which the applicant is seeking approval (the concerned-member states). The decentralized procedure leads to a series of single national approvals in all relevant countries. In the centralized procedure, which is required of all products derived from biotechnology, a company submits a single marketing authorization application to the European Medicines Agency, or EMA, which conducts an evaluation of the dossier, drawing upon its scientific resources across Europe. If the drug product is proven to fulfill the requirements for quality, safety and efficacy, the EMA’s Committee for Medicinal Products of Human Use, or CHMP, adopts a positive opinion, which is transmitted to the European Commission for final decision on grant of the marketing authorization. While the EC generally follows the CHMP’s opinion, it is not bound to do so. Subsequent commercialization is enabled by country-by-country reimbursement approval.
17

Orphan Drug Designation
Under the Orphan Drug Act, the FDA may grant orphan drug designation to a drug intended to treat a rare disease or condition, which is a disease or condition that affects fewer than 200,000 individuals in the U.S., or if it affects more than 200,000, there is no reasonable expectation that sales of the drug in the U.S. will be sufficient to offset the costs of developing and making the drug available in the U.S. Orphan drug designation must be requested before submitting an NDA or BLA. Orphan drug designation does not convey any advantage in or shorten the duration of the regulatory review and approval process.
If the FDA approves a sponsor’s marketing application for a designated orphan drug for use in the rare disease or condition for which it was designated, the sponsor is eligible for a seven-year period of marketing exclusivity, during which the FDA may not approve another sponsor’s marketing application for a drug with the same active moiety and intended for the same use or indication as the approved orphan drug, except in limited circumstances, such as if a subsequent sponsor demonstrates its product is clinically superior. During a sponsor’s orphan drug exclusivity period, competitors, however, may receive approval for drugs with different active moieties for the same indication as the approved orphan drug, or for drugs with the same active moiety as the approved orphan drug, but for different indications. Orphan drug exclusivity could block the approval of one of our products for seven years if a competitor obtains approval for a drug with the same active moiety intended for the same indication before we do, unless we are able to demonstrate that grounds for withdrawal of the orphan drug exclusivity exist, or that our product is clinically superior. Further, if a designated orphan drug receives marketing approval for an indication broader than the rare disease or condition for which it received orphan drug designation, it may not be entitled to exclusivity.
Legislation similar to the Orphan Drug Act has been enacted in other countries outside of the United States, including the EU. The orphan legislation in the EU is available for therapies addressing conditions that affect five or fewer out of 10,000 persons, are life‑threatening or chronically debilitating conditions and for which no satisfactory treatment is authorized. The market exclusivity period is for ten years, although that period can be reduced to six years if, at the end of the fifth year, available evidence establishes that the product does not justify maintenance of market exclusivity.
Post-Approval Requirements
Drugs manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion and reporting of adverse experiences with the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims are subject to prior FDA review and approval. There also are continuing, annual program user fee requirements for any marketed products, as well as new application fees for supplemental applications with clinical data.
The FDA may impose a number of post-approval requirements as a condition of approval of an NDA or BLA. For example, the FDA may require post-marketing testing, including Phase IV clinical trials, and surveillance to further assess and monitor the product’s safety and effectiveness after commercialization.
In addition, drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and state agencies and are subject to periodic unannounced inspections by the FDA and these state agencies for compliance with current Good Manufacturing Practices, or cGMP, requirements. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP requirements and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance.
Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in mandatory revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess
18

new safety risks; or imposition of distribution or other restrictions under a risk evaluation and mitigation strategy program. Other potential consequences include, among other things:
•restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;
•fines, warning letters or holds on post-approval clinical trials;
•refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product approvals;
•product seizure or detention, or refusal to permit the import or export of products; or
•injunctions or the imposition of civil or criminal penalties.
The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs may be promoted only for the approved indications and in accordance with the provisions of the approved label. However, companies may share truthful and not misleading information that is otherwise consistent with a product’s FDA approved labeling. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability. Physicians may prescribe legally available products for uses that are not described in the product’s labeling and that differ from those tested by us and approved by the FDA. The FDA does not regulate behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer’s communications on the subject of off-label use of their products.
Additional Regulation for Gene Therapy Products
In addition to the regulations discussed above, there are a number of standards that apply to gene therapy. FDA has issued various guidance documents regarding gene therapies, which outline factors that FDA will consider at each of the stages of development and relate to, among other things: the proper preclinical assessment of gene therapies; the chemistry, manufacturing and controls information that should be included in an IND application; the proper design of tests to measure product potency in support of an IND or BLA; and measures to observe delayed adverse effects in subjects who have been exposed to investigational gene therapies when the risk of such effects is high. For instance, FDA usually recommends that sponsors observe all surviving subjects who receive treatment using gene therapies that are based on adeno-associated virus vectors in clinical trials for potential gene therapy-related delayed adverse events for a minimum five-year period, followed by 10 years of annual queries, either in person or by questionnaire. FDA does not require the long-term tracking to be complete prior to its review of the BLA.
In addition to FDA oversight and oversight by institutional review boards, gene therapy clinical trials are also subject to review and oversight by an institutional biosafety committee, or IBC, a local institutional committee that reviews and oversees research utilizing recombinant or synthetic nucleic acid molecules at that institution. The IBC assesses the safety of the research and identifies any potential risk to public health or the environment.
Reimbursement
Significant uncertainty exists as to the coverage and reimbursement status of any product candidates for which we obtain regulatory approval. In the U.S. and markets in other countries, sales of any products for which we receive regulatory approval will depend, in part, on the extent to which third-party payors provide coverage and establish adequate reimbursement levels for such drug products.
In the U.S., third-party payors include federal and state healthcare programs, government authorities, private managed care providers, private health insurers and other organizations. No uniform policy for coverage and reimbursement exists in the United States, and coverage and reimbursement can differ significantly from payor to payor. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement rates, but also have their own methods and approval process apart from Medicare determinations. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our drug products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance.
19

Third-party payors are increasingly challenging the price, examining the medical necessity and reviewing the cost-effectiveness of medical drug products and medical services, in addition to questioning their safety and efficacy. Such payors may limit coverage to specific drug products on an approved list, also known as a formulary, which might not include all of the FDA-approved drugs for a particular indication. We may need to conduct expensive pharmaco-economic studies in order to demonstrate the medical necessity and cost-effectiveness of our products, in addition to the costs required to obtain the FDA approvals. Nonetheless, our products or product candidates, including INGREZZA, may not be considered medically necessary or cost-effective.
Moreover, the process for determining whether a third-party payor will provide coverage for a drug product may be separate from the process for setting the price of a drug product or for establishing the reimbursement rate that such a payor will pay for the drug product. A payor’s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Further, one payor’s determination to provide coverage for a drug product does not assure that other payors will also provide coverage for the drug product. Adequate third-party payor reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development.
The marketability of any product or product candidates for which we or our collaborators receive regulatory approval for commercial sale may suffer if third-party payors fail to provide coverage and adequate reimbursement. In addition, emphasis on managed care in the U.S. has increased and we expect will continue to increase the pressure on pharmaceutical pricing. Coverage policies and third-party payor reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.
Healthcare Reform
The U.S. and some foreign jurisdictions are considering or have enacted a number of legislative and regulatory proposals to change the healthcare system in ways that could affect our ability to sell our products profitably. Among policy makers and payors in the U.S. and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality or expanding access. In the U.S., the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives.
By way of example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, collectively the ACA, was signed into law, which intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add transparency requirements for the healthcare and health insurance industries, impose taxes and fees on the health industry and impose additional health policy reforms.
We expect that the ACA, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and lower reimbursement, and in additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government-funded programs may result in a similar reduction in payments from private third-party payor.
There remain legal and political challenges to certain aspects of the ACA. Since January 2017, the Trump administration signed several executive orders and other directives designed to delay, circumvent, or loosen certain requirements mandated by the ACA. Concurrently, Congress considered legislation that would repeal or repeal and replace all or part of the ACA. Legislation enacted in 2017, informally titled the Tax Cuts and Jobs Act, includes a provision that repealed, effective January 1, 2019, the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the “individual mandate”. In addition, the 2020 federal spending package permanently eliminated, effective January 1, 2020, the ACA-mandated “Cadillac” tax on high-cost employer-sponsored health coverage and medical device tax and, effective January 1, 2021, also eliminated the health insurer tax. On December 14, 2018, a Texas U.S. District Court Judge ruled that the ACA is unconstitutional in its entirety because the “individual mandate” was repealed by Congress as part of the Tax Cuts and Jobs Act. Additionally, on December 18, 2019, the U.S. Court of Appeals for the 5th Circuit ruled that the individual mandate was unconstitutional and remanded the case back to the District Court to determine whether the remaining provisions of the ACA are invalid as well. The
20

U.S. Supreme Court is currently reviewing this case, although it is unclear when a decision will be made. It is also unclear how such litigation will impact the ACA.
Other legislative changes have been proposed and adopted since the ACA was enacted. These changes include, among others, aggregate reductions to Medicare payments to providers of up to 2% per fiscal year pursuant to the Budget Control Act of 2011, which began in 2013 and will remain in effect through 2030, except for a temporary suspension from May 1, 2020 through May 31, 2021 due to the COVID-19 pandemic, unless additional Congressional action is taken.
Also, there has been heightened governmental scrutiny recently over pharmaceutical pricing practices in light of the rising cost of prescription drugs and biologics. Such scrutiny has resulted in several Congressional hearings and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. Both the U.S. House of Representatives and the Senate Finance Committee passed legislation in 2019 to reform pharmaceutical pricing in a variety of meaningful ways, and we expect legislative efforts to reform drug pricing to continue in 2021.
At the federal level, the Trump administration’s budget proposal for fiscal year 2021 included a $135 billion allowance to support legislative proposals seeking to reduce drug prices, increase competition, lower out-of-pocket drug costs for patients, and increase patient access to lower-cost generic and biosimilar drugs. On March 10, 2020, the Trump administration sent “principles” for drug pricing to Congress, calling for legislation that would, among other things, cap Medicare Part D beneficiary monthly out-of-pocket expenses, and place limits on pharmaceutical price increases. Additionally, the Trump administration previously released a “Blueprint” to lower drug prices and reduce out-of-pocket costs of drugs. On July 24, 2020 and September 13, 2020, the Trump administration announced several executive orders related to drug pricing that sought to implement several of the administration’s proposals. As a result, the FDA released a final rule on September 24, 2020, effective November 30, 2020, providing guidance for states to build and submit importation plans for drugs from Canada. This rule is undergoing legal challenge.
Further, on November 20, 2020, HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers. This rule has been stayed until 2023 while pending litigation is heard in the courts.
On November 20, 2020, CMS issued an interim final rule implementing President Trump’s Most Favored Nation executive order, which would tie Medicare Part B payments for certain physician-administered drugs to the lowest price paid in other economically advanced countries, effective January 1, 2021. On December 28, 2020, the United States District Court in Northern California issued a nationwide preliminary injunction against implementation of the interim final rule. Two additional lawsuits in other jurisdictions are challenging the legality of this rule.
At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Further, it is possible that additional governmental action is taken in response to the COVID-19 pandemic.
Competition
The biotechnology and pharmaceutical industries are subject to rapid and intense technological change. We face, and will continue to face, competition in the development and marketing of our products and product candidates from academic institutions, government agencies, research institutions and biotechnology and pharmaceutical companies. Many of our competitors have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approval and marketing than we do.
Competition may also arise from, among other things, new drug development technologies, new or improved treatment options for preventing or reducing the incidence of disease in diseases our products treat and new small
21

molecule or other classes of therapeutic agents. Such developments by competitors could reduce or eliminate the use of our products or may limit the utility and application of ongoing clinical trials for our product candidates.
Additional information about the competition that our marketed products face is set forth below.
Tardive Dyskinesia. INGREZZA competes with AUSTEDO (deutetrabenazine), which was approved by the FDA for the treatment of tardive dyskinesia in adults in August 2017 and is marketed by Teva Pharmaceutical Industries, and several clinical development-stage programs targeting tardive dyskinesia and related movement disorders. Additionally, there are a number of commercially available medicines used to treat tardive dyskinesia off-label, such as Xenazine® (tetrabenazine) and generic equivalents, and various antipsychotic medications (e.g., clozapine), anticholinergics, benzodiazepines (off-label), and botulinum toxin.
Parkinson’s Disease. ONGENTYS competes with two other FDA-approved COMT inhibitors and their generic equivalents. Additionally, there are a number of alternative adjunctive treatment options (FDA-approved and in clinical development) for Parkinson’s patients which compete with ONGENTYS, including various L-dopa preparations, dopamine agonists, MAO-B inhibitors and others. In terms of potential future competition, there are several programs in late-stage clinical development.
Endometriosis and Uterine Fibroids. ORILISSA and ORIAHNN each compete with several FDA-approved products for the treatment of endometriosis, uterine fibroids, infertility, and central precocious puberty. Additionally, there is also competition from surgical intervention, including hysterectomies and ablations. Separate from these options, there are many programs in clinical development which serve as potential future competition. Lastly, there are numerous medicines used to treat the symptoms of disease (vs. endometriosis or uterine fibroids directly) which may also serve as competition: oral contraceptives, NSAIDs and other pain medications including opioids.
Congenital Adrenal Hyperplasia. For CAH, high doses of corticosteroids are the current standard of care to both correct the endogenous cortisol deficiency as well as reduce the excessive ACTH levels. In the U.S. alone, there are more than two dozen companies manufacturing steroid-based products. In addition, there are several clinical development-stage programs targeting CAH and several companies developing medicinal treatments for CAH.
Epilepsy. Our investigational treatments for potential use in epilepsy may in the future compete with numerous approved anti-seizure medications, or ASMs, and development-stage programs being pursued by several other companies. Commonly used ASMs, among others, include phenytoin, levetiracetam, brivaracetam, cenobamate, carbamazepine, clobazam, lamotrigine, valproate, oxcarbazepine, topiramate, lacosamide, perampanel and cannabidiol. There are currently no FDA-approved treatments specifically indicated for the early infantile epileptic encephalopathies SCN8A-DEE and EE-CSWS; however, a number of different ASMs are currently used in these patient populations.
Schizophrenia. The investigational treatment NBI-1065844 for the negative symptoms of schizophrenia may in the future compete with off-label antipsychotic and antidepressant medicines, including cariprazine, clozapine, fluoxetine, citalopram, sertraline, and amisulpride. In addition, there are several development-stage programs being pursued by other companies, including pimavanserin, roluperidone, RO6889450 and sodium benzoate. Currently, there are no-FDA approved treatments specifically indicated for the negative symptoms of schizophrenia.
Other. Our investigational treatments for potential use in endocrinology, neurology, and psychiatry, as well as our investigational gene therapies, may in the future compete with numerous approved products and development-stage programs being pursued by several other companies.
Human Capital
Our Employees. We have grown to a team of over 845 employees as of December 31, 2020, all of whom were employed in the U.S. Our highly qualified and experienced team which includes scientists, physicians and professionals across sales, marketing, manufacturing, regulatory, finance and other important functions are critical to our success. We also leverage temporary workers to provide flexibility for our business needs. During 2020, we added 191 new employees to our team.
We expect to continue to add additional employees in 2021 with a focus on expanding our expertise and bandwidth in clinical and preclinical research and development. We continually evaluate our business needs and opportunities
22

and balance in house expertise and capacity with external expertise and capacity. Currently, we rely on third-party contract manufacturers.
Our Culture. The success of our human capital management investments is evidenced by our low employee turnover, a number which is regularly reviewed by our Board of Directors as part of their oversight of our human capital strategy. In recognition of our efforts, in 2020, we were named to the Fortune Best Small and Medium Workplaces 2020 list ranking Number 8 across the country. We were also named a Great Place to Work Certified company and were recognized on Great Place to Work’s Best Workplace for Parents 2020 list.
Employee Engagement, Talent Development & Benefits. We believe that our future success largely depends upon our continued ability to attract and retain highly skilled employees. We provide our employees with competitive salaries and bonuses, opportunities for equity ownership, development programs that enable continued learning and growth and a robust employment package that promotes well-being across all aspects of their lives, including health care, retirement planning and paid time off. As part of our promotion and retention efforts, we also invest in ongoing leadership development through programs as well as offer tuition reimbursement. In addition, we regularly conduct an employee survey to gauge employee engagement and identify areas of focus.
Diversity & Inclusion. Much of our success is rooted in the diversity of our teams and our commitment to inclusion. We value diversity at all levels and continue to focus on extending our diversity and inclusion initiatives across our entire workforce. We believe that our business benefits from the different perspectives a diverse workforce brings, and we pride ourselves on having a strong, inclusive and positive culture based on our shared mission and values.
Corporate Information
We were originally incorporated in California in January 1992 and reincorporated in Delaware in May 1996. Our principal executive offices are located at 12780 El Camino Real, San Diego, California 92130. Our telephone number is (858) 617-7600.
Our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to reports filed pursuant to Sections 13(a) and 15(d) of the Securities Exchange Act of 1934, as amended, are available free of charge on our website at www.neurocrine.com, as soon as reasonably practicable after such reports are available on the Securities and Exchange Commission, or SEC, website at www.sec.gov. Additionally, copies of our Annual Report will be made available, free of charge, upon written request. Information found on, or accessible through, our website is not a part of, and is not incorporated into, this Annual Report on Form 10-K.
Item 1A. Risk Factors
The following information sets forth risk factors that could cause our actual results to differ materially from those contained in forward-looking statements we have made in this Annual Report on Form 10-K and those we may make from time to time. If any of the following risks actually occur, our business, operating results, prospects or financial condition could be harmed. Additional risks not presently known to us, or that we currently deem immaterial, may also affect our business operations.
Summary Risk Factors
We face risks and uncertainties related to our business, many of which are beyond our control. In particular, risks associated with our business include:
•We may not be able to successfully commercialize INGREZZA, ONGENTYS, or any of our product candidates if they are approved in the future.
•If physicians and patients do not continue to accept INGREZZA or do not accept ONGENTYS, or our sales and marketing efforts are not effective, we may not generate sufficient revenue.
•Governmental and third-party payors may impose sales and pharmaceutical pricing controls on our products or limit coverage and/or reimbursement for our products that could limit our product revenues and delay sustained profitability.
23

•Our business could be adversely affected by the effects of health pandemics or epidemics, including the COVID-19 pandemic, in regions where we or third parties on which we rely have significant sales and marketing efforts or manufacturing facilities, concentrations of clinical trial sites or other business operations, or materially affect our operations, and at our clinical trial sites, as well as the business or operations of our manufacturers, CROs or other third parties with whom we conduct business.
•Because the development of our product candidates is subject to a substantial degree of technological uncertainty, we may not succeed in developing any of our product candidates.
•Our clinical studies may be delayed for safety or other reasons, or fail to demonstrate the safety and efficacy of our product candidates, which could prevent or significantly delay their regulatory approval. For example, the FDA has placed a clinical hold on the RESTORE-1 study, a Phase II, randomized, placebo-surgery controlled, double-blind, multi-center clinical study of NBIb-1817 in Parkinson’s disease patients, following our submission of an IND safety report related to the observation of MRI abnormalities in some study participants. The clinical implications of this observation are currently unknown and are being evaluated. On February 2, 2021, we notified Voyager of our termination of the NBIb-1817 for Parkinson’s disease program. The effective date of the termination will be August 2, 2021.
•We depend on our current collaborators for the development and commercialization of several of our products and product candidates and may need to enter into future collaborations to develop and commercialize certain of our product candidates.
•Use of our approved products or those of our collaborators could be associated with side effects or adverse events.
•We face intense competition, and if we are unable to compete effectively, the demand for our products may be reduced.
•We currently have no manufacturing capabilities. If third-party manufacturers of INGREZZA, ONGENTYS or any of our product candidates fail to devote sufficient time and resources to our concerns, or if their performance is substandard, our clinical trials and product introductions may be delayed, and our costs may rise.
•We currently depend on a limited number of third-party suppliers. The loss of these suppliers, or delays or problems in the supply of INGREZZA or ONGENTYS, could materially and adversely affect our ability to successfully commercialize INGREZZA or ONGENTYS.
•If we are unable to retain and recruit qualified scientists or if any of our key senior executives discontinues his or her employment with us, it may delay our development efforts or impact our commercialization of INGREZZA, ONGENTYS or any product candidate approved by the FDA.
•We license some of our core technologies and drug candidates from third parties. If we default on any of our obligations under those licenses, or violate the terms of these licenses, we could lose our rights to those technologies and drug candidates or be forced to pay damages.
•Our indebtedness and liabilities could limit the cash flow available for our operations, expose us to risks that could adversely affect our business, financial condition and results of operations.
•We have a history of losses and expect to increase our expenses for the foreseeable future, and we may not be able to sustain profitability.
•We have recently increased the size of our organization and will need to continue to increase the size of our organization. We may encounter difficulties with managing our growth, which could adversely affect our results of operations.
•Our customers are concentrated and therefore the loss of a significant customer may harm our business.
•If we cannot raise additional funding, we may be unable to complete development of our product candidates or establish commercial and manufacturing capabilities in the future.
•Health care reform measures and other recent legislative initiatives could adversely affect our business.
24

•If we are unable to protect our intellectual property, our competitors could develop and market products based on our discoveries, which may reduce demand for our products.
Risks Related to Our Company
We may not be able to continue to successfully commercialize INGREZZA, ONGENTYS, or any of our product candidates if they are approved in the future.
Our ability to produce INGREZZA revenues consistent with expectations ultimately depends on our ability to successfully commercialize INGREZZA and secure adequate third-party reimbursement. Our experience in marketing and selling pharmaceutical products began with INGREZZA’s approval in 2017, when we hired our sales force and established our distribution and reimbursement capabilities, all of which are necessary to successfully commercialize our current and future products. We have continued to invest in our commercial infrastructure and distribution capabilities in the past four years, including our sales force expansion in late 2018. While our team members and consultants have experience marketing and selling pharmaceutical products, we may face difficulties related to managing the rapid growth of our personnel and infrastructure, and there can be no guarantee that we will be able to maintain the personnel, systems, arrangements and capabilities necessary to continue to successfully commercialize INGREZZA, or to successfully commercialize ONGENTYS or any product candidate approved by the FDA in the future.
In addition, our business has been and may continue to be adversely affected by the effects of health pandemics or epidemics, including the ongoing COVID-19 pandemic. Most hospitals, community mental health facilities, and other healthcare facilities have implemented policies that limit access of our sales representatives, medical affairs personnel, and patients to such facilities. Due to these closures and our work from home decisions, our field force is currently functioning utilizing digital and telephonic engagement tools and tactics, which may be less effective than our ordinary sales and marketing and medical education programs. The ultimate impact of the COVID-19 pandemic, including any lasting effects on the way we conduct our business, is highly uncertain and subject to change. If we fail to maintain successful marketing, sales and reimbursement capabilities, our product revenues may suffer.
If physicians and patients do not continue to accept INGREZZA or do not accept ONGENTYS or our sales and marketing efforts are not effective, we may not generate sufficient revenue.
The commercial success of INGREZZA or ONGENTYS will depend upon the acceptance of those products as safe and effective by the medical community and patients.
The market acceptance of INGREZZA or ONGENTYS could be affected by a number of factors, including:
•the timing of receipt of marketing approvals for indications;
•the safety and efficacy of the products;
•the pricing of our products;
•the availability of healthcare payor coverage and adequate reimbursement for the products;
•public perception regarding any products we may develop;
•the success of existing competitor products addressing our target markets or the emergence of equivalent or superior products; and
•the cost-effectiveness of the products.
If the medical community and patients do not continue to accept our products as being safe, effective, superior and/or cost-effective, we may not generate sufficient revenue.
Governmental and third-party payors may impose sales and pharmaceutical pricing controls on our products or limit coverage and/or reimbursement for our products that could limit our product revenues and delay sustained profitability.
Our ability to continue to commercialize INGREZZA successfully or to commercialize ONGENTYS, will depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available. The continuing efforts of government and third-party payors to contain or reduce the costs of health care
25

and the price of prescription drugs through various means may reduce our potential revenues. These payors’ efforts could decrease the price that we receive for any products we may develop and sell in the future.
Assuming we obtain coverage for a given product by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high. Patients who are prescribed medications for the treatment of their conditions, and their prescribing physicians, generally rely on third-party payors to reimburse all or part of the costs associated with their prescription drugs. Patients are unlikely to use our products unless coverage is provided and reimbursement is adequate to cover all or a significant portion of the cost of our products. Coverage decisions may depend upon clinical and economic standards that disfavor new drug products when more established or lower cost therapeutic alternatives are already available or subsequently become available regardless of whether they are approved by the FDA for that particular use.
Government authorities and other third-party payors are developing increasingly sophisticated methods of controlling healthcare costs, such as by limiting coverage and the amount of reimbursement for particular medications. Further, no uniform policy requirement for coverage and reimbursement for drug products exists among third-party payors in the U.S. Therefore, coverage and reimbursement for drug products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. In addition, communications from government officials regarding health care costs and pharmaceutical pricing could have a negative impact on our stock price, even if such communications do not ultimately impact coverage or reimbursement decisions for our products.
There may also be significant delays in obtaining coverage and reimbursement for newly approved drugs, and coverage may be more limited than the purposes for which the drug is approved by the FDA or comparable foreign regulatory authorities. Moreover, eligibility for coverage and reimbursement does not imply that a drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future. In addition, gene therapy treatments, which we are developing pursuant to our collaboration and license agreement with Voyager, face additional uncertainty related to pricing and reimbursement. As an example, there are a limited number of gene therapy products currently approved for coverage and reimbursement by the Centers for Medicare & Medicaid Services, or CMS.
If coverage and reimbursement are not available or reimbursement is available only to limited levels, we may not successfully commercialize INGREZZA, ONGENTYS or any other product candidate for which we obtain marketing approval. Our inability to promptly obtain coverage and profitable reimbursement rates from both government-funded and private payors for any approved products that we develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition.
Our business could be adversely affected by the effects of health pandemics or epidemics, including the COVID-19 pandemic, in regions where we or third parties on which we rely have significant sales and marketing efforts or manufacturing facilities, concentrations of clinical trial sites or other business operations, or materially affect our operations, and at our clinical trial sites, as well as the business or operations of our manufacturers, CROs or other third parties with whom we conduct business.
Our business could be adversely affected by the effects of health pandemics or epidemics in regions where we have concentrations of clinical trial sites or other business operations, and could cause significant disruption in the operations of third-party manufacturers and CROs upon whom we rely. As a result of the ongoing COVID-19 pandemic, we may experience disruptions that could severely impact our supply chain, ongoing and future clinical trials and commercialization of INGREZZA and ONGENTYS. For example, the COVID-19 pandemic has resulted in increased travel restrictions and the shutdown or delay of business activities in various regions, including San Diego, California, where our headquarters are located. In response to state and local restrictions, we implemented work-from-home policies for all employees except certain key essential members involved in business-critical activities. The effects of the stay at home order and our work-from-home policies may negatively impact productivity, disrupt our business and delay our clinical programs and timelines, the magnitude of which will
26

depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course. In addition, we may face several challenges or disruptions upon a return back to the workplace if and when the COVID-19 pandemic subsides, including re-integration challenges by our employees and distractions to management related to such transition. These and similar, and perhaps more severe, disruptions in our operations due to the COVID-19 pandemic could negatively impact our business, operating results and financial condition.
Quarantines, stay at home orders and other state and local restrictions, or the perception that such orders, shutdowns or other restrictions on the conduct of business operations could occur, related to COVID-19 or other infectious diseases, could impact personnel at third-party manufacturing facilities in the United States and other countries, or the availability or cost of materials, which would disrupt our supply chain.
In addition, clinical site initiation and patient enrollment may be delayed due to concerns for patient safety and prioritization of healthcare resources toward the COVID-19 pandemic. Some patients may not be able to comply with clinical trial protocols if quarantines impede patient movement or interrupt healthcare services. Similarly, our ability to recruit and retain patients, principal investigators and site staff (who as healthcare providers may have heightened exposure to COVID-19) may be hindered, which would adversely impact our clinical trial operations. For example, due to the impact of the COVID-19 pandemic, we initially paused enrollment of new patients in several of our clinical trials. Since then, we have begun enrolling patients again in the Phase III study of valbenazine for chorea in HD and the Phase IIa pediatric study of crinecerfont in CAH. However, increases in COVID-19 cases or hospitalizations in the future could cause us to again limit or suspend our patient enrollment and screening activities.
The spread of COVID-19, which has caused a broad impact globally, may materially affect us economically. While the potential economic impact brought by, and the duration of, the COVID-19 pandemic may be difficult to assess or predict, the pandemic is currently resulting in disruption of global financial markets. This disruption, if sustained or recurrent, could make it more difficult for us to access capital, which could in the future negatively affect our liquidity. In addition, a recession or market correction resulting from the spread of COVID-19 could materially affect our business and the value of our common stock.
The global COVID-19 pandemic continues to rapidly evolve. The ultimate impact of the COVID-19 pandemic or a similar health pandemic or epidemic is highly uncertain and subject to change. We do not yet know the full extent of potential delays or impacts on our business, our clinical trials, healthcare systems or the global economy as a whole. These effects could have a material impact on our operations.
Because the development of our product candidates is subject to a substantial degree of technological uncertainty, we may not succeed in developing any of our product candidates.
All of our product candidates are currently in research or clinical development with the exceptions of INGREZZA, which has been approved by the FDA for tardive dyskinesia, ONGENTYS, which has been approved by the FDA for Parkinson’s disease, ORILISSA (partnered with AbbVie), which has been approved by the FDA for the management of moderate to severe endometriosis pain in women, and ORIAHNN (partnered with AbbVie), which has been approved by the FDA for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Only a small number of research and development programs ultimately result in commercially successful drugs. In addition, to date the FDA has granted regulatory approval for only a very limited number of gene therapy products and the clinical development of a gene therapy product may result in unforeseen adverse events. For example, the FDA has placed a clinical hold on the RESTORE-1 study, a Phase II, randomized, placebo-surgery controlled, double-blind, multi-center clinical study of NBIb-1817 in Parkinson’s disease patients, following our submission of an IND safety report related to the observation of MRI abnormalities in some study participants. The clinical implications of this observation are currently unknown and are being evaluated. On February 2, 2021, we notified Voyager of our termination of the NBIb-1817 for Parkinson’s disease program. The effective date of the termination will be August 2, 2021.
Potential products that appear to be promising at early stages of development may not reach the market for a number of reasons. These reasons include the possibilities that the potential products may:
•be found ineffective or cause harmful side effects during preclinical studies or clinical trials;
27

•fail to receive necessary regulatory approvals on a timely basis or at all;
•be precluded from commercialization by proprietary rights of third parties;
•be difficult to manufacture on a large scale; or
•be uneconomical to commercialize or fail to achieve market acceptance.
If any of our product candidates encounters any of these potential problems, we may never successfully market that product candidate.
Our clinical trials may be delayed or fail to demonstrate the safety and efficacy of our product candidates, which could prevent or significantly delay their regulatory approval.
Before obtaining regulatory approval for the sale of any of our potential products, we must subject these product candidates to extensive preclinical and clinical testing to demonstrate their safety and efficacy for humans. Clinical trials are expensive, time-consuming and may take years to complete and the outcomes are uncertain.
In connection with the clinical trials of our product candidates, we face the risks that:
•the FDA or similar foreign regulatory authority may not allow an IND application or foreign equivalent filings required to initiate human clinical studies for our drug candidates or the FDA may require additional preclinical studies as a condition of the initiation of Phase I clinical studies, or additional clinical studies for progression from Phase I to Phase II, or Phase II to Phase III, or for NDA approval;
•the product candidate may not prove to be effective or as effective as other competing product candidates;
•we may discover that a product candidate may cause harmful side effects or results of required toxicology or other studies may not be acceptable to the FDA;
•the results may not replicate the results of earlier, smaller trials;
•the FDA or similar foreign regulatory authorities may require use of new or experimental endpoints that may prove insensitive to treatment effects;
•we or the FDA or similar foreign regulatory authorities may suspend the trials;
•the results may not be statistically significant;
•patient recruitment and enrollment may be slower or more difficult than expected;
•the FDA may not accept the data from any trial or trial site outside of the US;
•patients may drop out of the trials;
•unforeseen disruptions or delays may occur, caused by man-made or natural disasters or public health pandemics or epidemics or other business interruptions, including, for example, the COVID-19 pandemic; and
•regulatory requirements may change.
These risks and uncertainties impact all of our clinical programs and any of the clinical, regulatory or operational events described above could change our planned clinical and regulatory activities. For example, due to the impact of the COVID-19 pandemic, we paused enrollment of new patients in several of our clinical trials, and increases in COVID-19 cases or hospitalizations in the future could cause us to further limit or suspend our patient enrollment and screening activities. Additionally, any of these events described above could result in suspension of a program and/or obviate any filings for necessary regulatory approvals.
In addition, late-stage clinical trials are often conducted with patients having the most advanced stages of disease. During the course of treatment, these patients can die or suffer other adverse medical effects for reasons that may not be related to the pharmaceutical agent being tested but which can nevertheless adversely affect clinical trial results. Any failure or substantial delay in completing clinical trials for our product candidates may severely harm our business.
28

Even if the clinical trials are successfully completed, we cannot guarantee that the FDA or foreign regulatory authorities will interpret the results as we do, and more trials could be required before we submit our product candidates for approval. To the extent that the results of the trials are not satisfactory to the FDA or foreign regulatory authorities for support of a marketing application, approval of our product candidates may be significantly delayed, or we may be required to expend significant additional resources, which may not be available to us, to conduct additional trials in support of potential approval of our product candidates.
We depend on our current collaborators for the development and commercialization of several of our products and product candidates and may need to enter into future collaborations to develop and commercialize certain of our product candidates.
We depend on our current collaborators for the development and commercialization of several of our products and product candidates and may need to enter into future collaborations to develop and commercialize certain of our product candidates. For example, we collaborate with AbbVie for the manufacture and commercialization of two of our commercial products, ORILISSA and ORIAHNN, and for the continued development of elagolix. We collaborate with MTPC for the development and commercialization of INGREZZA for movement disorders in Japan and other select Asian markets. We also rely on BIAL for the commercial supply of ONGENTYS. In addition, we collaborate with Xenon for the development of NBI-921352, Idorsia for the development of NBI-827104 and Takeda for the development of NBI-1065844.
Our current and future collaborations and licenses could subject us to a number of risks, including:
•we may be required to undertake the expenditure of substantial operational, financial and management resources;
•we may be required to assume substantial actual or contingent liabilities;
•we may not be able to control the amount and timing of resources that our strategic collaborators devote to the development or commercialization of our products or product candidates;
•we may not be able to influence our strategic collaborator’s decisions regarding the development and collaboration of our partnered product and product candidates, and as a result, our collaboration partners may not pursue or prioritize the development and commercialization of those partnered products and product candidates in a manner that is in our best interest;
•strategic collaborators may select indications or design clinical trials in a way that may be less successful than if we were doing so;
•strategic collaborators may not conduct collaborative activities in a timely manner, provide insufficient funding, terminate a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new version of a product candidate for clinical testing;
•strategic collaborators may not pursue further development and commercialization of products resulting from the strategic collaboration arrangement or may elect to discontinue research and development programs;
•disagreements or disputes may arise between us and our strategic collaborators that result in delays or in costly litigation or arbitration that diverts management’s attention and consumes resources;
•strategic collaborators may experience financial difficulties;
•strategic collaborators may not properly maintain, enforce or defend our intellectual property rights or may use our proprietary information in a manner that could jeopardize or invalidate our proprietary information or expose us to potential litigation;
•strategic collaborators could terminate the arrangement or allow it to expire, which would delay the development and commercialization and may increase the cost of developing and commercializing our products or product candidates; and
•strategic collaborators could develop, either alone or with others, products or product candidates that may compete with ours.
29

If any of these issues arise, it may delay and/or negatively impact the development and commercialization of drug candidates and, ultimately, our generation of product revenues.
We may not be able to successfully commercialize ONGENTYS.
In April 2020, we received FDA approval for ONGENTYS as an adjunctive therapy to levodopa/DOPA decarboxylase inhibitors in adult Parkinson’s disease patients, and in September 2020, we launched the commercial sale of ONGENTYS with our existing INGREZZA infrastructure. The successful commercialization of ONGENTYS is subject to many risks, and there are numerous examples of unsuccessful product launches and failures, including by pharmaceutical companies with more experience and resources than us. If we are unable to effectively train our employees and equip them with effective materials, including medical and sales literature to help them inform and educate health care practitioners about the benefits of ONGENTYS and its proper administration, our commercialization of ONGENTYS may not be successful. Even if we are successful in effectively training and equipping our sales force, there are many factors that could cause the commercialization of ONGENTYS to be unsuccessful, including a number of factors that are outside our control. Health care practitioners may not prescribe ONGENTYS and patients may be unwilling to use ONGENTYS if insurance coverage is not provided or reimbursement is inadequate. In addition, our ability to train our employees and effectively communicate with potential prescribers could be adversely affected by the effects of health pandemics or epidemics, including the ongoing COVID-19 pandemic.
Use of our approved products or those of our collaborators could be associated with side effects or adverse events.
As with most pharmaceutical products, use of our approved products or those of our collaborators could be associated with side effects or adverse events which can vary in severity (from minor adverse reactions to death) and frequency (infrequent or prevalent). Side effects or adverse events associated with the use of our products or those of our collaborators may be observed at any time, including after a product is commercialized, and reports of any such side effects or adverse events may negatively impact demand for our or our collaborators’ products or affect our or our collaborators’ ability to maintain regulatory approval for such products. Side effects or other safety issues associated with the use of our approved products or those of our collaborators could require us or our collaborators to modify or halt commercialization of these products or expose us to product liability lawsuits which will harm our business. We or our collaborators may be required by regulatory agencies to conduct additional studies regarding the safety and efficacy of our products which we have not planned or anticipated. Furthermore, there can be no assurance that we or our collaborators will resolve any issues related to any product related adverse events to the satisfaction of the FDA or any regulatory agency in a timely manner or ever, which could harm our business, prospects and financial condition.
Gene therapy treatments, which we are developing pursuant to our collaboration and license agreement with Voyager, may be perceived as unsafe or may result in unforeseen adverse events. Negative public opinion and increased regulatory scrutiny of gene therapy may adversely affect our ability to initiate or continue clinical development or obtain regulatory approvals for gene therapy product candidates or the commercialization of gene therapy products.
Gene therapy remains a novel technology, with few gene therapy products approved to date in the US. Public perception may be influenced by claims that gene therapy is unsafe, and gene therapy may not gain the acceptance of the public or the medical community. Even if we are able to successfully complete clinical development of a gene therapy product and obtain commercial approval, the success of our collaboration with Voyager will depend upon physicians who specialize in the treatment of genetic diseases targeted by gene therapy product candidates, prescribing treatments that involve the use of our product candidates in lieu of, or in addition to, existing treatments with which they are familiar and for which greater clinical data may be available. More restrictive government regulations, negative public opinion related to gene therapy products, or safety issues identified in our clinical trials may delay or impair the development and commercialization of our gene therapy product candidates or demand for any gene therapy products we develop.
30

The limited precedent for gene therapy approvals makes it difficult to determine how long it will take or how much it will cost to obtain regulatory approvals for the product candidates we are developing through our collaboration with Voyager.
The FDA has limited experience in the review and approval of gene therapy products. The limited precedent for gene therapy approvals makes it difficult to determine how long it will take or how much it will cost to obtain regulatory approvals for the product candidates we are developing through our collaboration with Voyager.
Regulatory requirements governing gene therapy products have changed frequently and may continue to change in the future. As a result, the regulatory review process may take longer or cost more than we anticipate, including requirements for additional preclinical studies or clinical trials, and delay or prevent approval and commercialization of our gene therapy product candidates we are developing through our collaboration with Voyager. While the FDA has issued draft guidance for the development of gene therapies and proposed rules that would streamline certain requirements to which gene therapies are currently subject, it remains to be seen as to whether such initiatives will ultimately increase the speed of drug development in gene therapies such as the product candidates we are developing through our collaboration with Voyager.
Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary to bring a potential product to market could decrease our ability to generate sufficient product revenue, and our business, financial condition, results of operations and prospects would be harmed. If our gene therapy products are approved but fail to achieve market acceptance among physicians, patients, hospitals, third-party payors or others in the medical community, we will not be able to generate significant revenue.
We face intense competition, and if we are unable to compete effectively, the demand for our products may be reduced.
The biotechnology and pharmaceutical industries are subject to rapid and intense technological change. We face, and will continue to face, competition in the development and marketing of our products and product candidates from academic institutions, government agencies, research institutions and biotechnology and pharmaceutical companies.
Competition may also arise from, among other things:
•other drug development technologies;
•methods of preventing or reducing the incidence of disease, including vaccines; and
•new small molecule or other classes of therapeutic agents.
Developments by others may render our product candidates or technologies obsolete or noncompetitive.
We are commercializing and performing research on or developing products for the treatment of several disorders including endometriosis, tardive dyskinesia, uterine fibroids, essential tremor, classic congenital adrenal hyperplasia, pain, Parkinson’s disease, Friedreich’s ataxia, and other neurological and endocrine-related diseases and disorders, and there are a number of competitors to our products and product candidates. If one or more of our competitors’ products or programs are successful, the market for our products may be reduced or eliminated.
•With respect to INGREZZA for tardive dyskinesia, we compete with Teva Pharmaceutical Industries, which received FDA approval for AUSTEDO to treat tardive dyskinesia in August 2017, and several clinical development-stage programs targeting tardive dyskinesia and related movement disorders. Additionally, there are a number of commercially available medicines used to treat tardive dyskinesia off-label, such as Xenazine (tetrabenazine) and generic equivalents, and various antipsychotic medications (e.g., clozapine), anticholinergics, benzodiazepines (off-label), and botulinum toxin.
•In endometriosis, ORILISSA and ORIAHNN each compete with several FDA-approved products for the treatment of endometriosis, uterine fibroids, infertility, and central precocious puberty. Additionally, there is also competition from surgical intervention, including hysterectomies and ablations. Separate from these options, there are many programs in clinical development which serve as potential future competition. Lastly, there are numerous medicines used to treat the symptoms of disease (vs. endometriosis or uterine fibroids directly) which may also serve as competition: oral contraceptives, NSAIDs and other pain medications including opioids.
31

•With respect to ONGENTYS for Parkinson’s disease, there are currently two other FDA-approved COMT inhibitors. ONGENTYS competes directly with these two drugs and their generic equivalents. Additionally, there are a number of alternative adjunctive treatment options (FDA-approved and in clinical development) for Parkinson’s patients which compete with ONGENTYS, including various L-dopa preparations, dopamine agonists, MAO-B inhibitors and others. In terms of potential future competition, there are several programs in late-stage clinical development.
•As for CAH, high doses of corticosteroids are the current standard of care to both correct the endogenous cortisol deficiency as well as reduce the excessive ACTH levels. In the U.S. alone, there are more than two dozen companies manufacturing steroid-based products. Additionally, there are several clinical development-stage programs targeting CAH and several companies developing medicinal treatments for CAH.
•Our investigational treatments for potential use in epilepsy may in the future compete with numerous approved anti-seizure medications, or ASMs, and development-stage programs being pursued by several other companies. Commonly used ASMs, among others, include phenytoin, levetiracetam, brivaracetam, cenobamate, carbamazepine, clobazam, lamotrigine, valproate, oxcarbazepine, topiramate, lacosamide, perampanel and cannabidiol. There are currently no FDA-approved treatments specifically indicated for the early infantile epileptic encephalopathies SCN8A-DEE and EE-CSWS; however, a number of different ASMs are currently used in these patient populations.
•The investigational treatment NBI-1065844 for the negative symptoms of schizophrenia may in the future compete with off-label antipsychotic and antidepressant medicines, including ciraprazine, clozapine, fluoxetine, citalopram, sertraline, and amisulpride. In addition, there are several development-stage programs being pursued by other companies, including pimavanserin, roluperidone, RO6889450 and sodium benzoate. Currently, there are no-FDA approved treatments specifically indicated for the negative symptoms of schizophrenia.
•Our investigational treatments for potential use in endocrinology, neurology, and psychiatry, as well as our investigational gene therapies, may in the future compete with numerous approved products and development-stage programs being pursued by several other companies.
Compared to us, many of our competitors and potential competitors have substantially greater:
•capital resources;
•research and development resources, including personnel and technology;
•regulatory experience;
•preclinical study and clinical testing experience;
•manufacturing, marketing and distribution experience; and
•production facilities.
Moreover, increased competition in certain disorders or therapies may make it more difficult for us to recruit or enroll patients in our clinical trials for similar disorders or therapies.
We currently have no manufacturing capabilities. If third-party manufacturers of INGREZZA, ONGENTYS or any of our product candidates fail to devote sufficient time and resources to our concerns, or if their performance is substandard, our clinical trials and product introductions may be delayed, and our costs may rise.
We have in the past utilized, and intend to continue to utilize, third-party manufacturers to produce the drug compounds we use in our clinical trials and for the commercialization of our products. We have limited experience in manufacturing products for commercial purposes and do not currently have any manufacturing facilities. Establishing internal commercial manufacturing capabilities would require significant time and resources, and we may not be able to timely or successfully establish such capabilities. Consequently, we depend on, and will continue to depend on, several contract manufacturers for all production of products for development and commercial purposes, including INGREZZA and ONGENTYS. If we are unable to obtain or retain third-party manufacturers, we will not be able to develop or commercialize our products, including INGREZZA and ONGENTYS. The
32

manufacture of our products for clinical trials and commercial purposes is subject to specific FDA regulations, including current Good Manufacturing Practice regulations. Our third-party manufacturers, including BIAL and its suppliers, might not comply with FDA regulations relating to manufacturing our products for clinical trials and commercial purposes or other regulatory requirements now or in the future. In addition, the manufacture of gene therapy products, which will be necessary under our collaboration and license agreement with Voyager, is technically complex and necessitates substantial expertise and capital investment. Our reliance on contract manufacturers also exposes us to the following risks:
•contract manufacturers may encounter difficulties in achieving volume production, quality control or quality assurance, and also may experience shortages in qualified personnel. As a result, our contract manufacturers might not be able to meet our clinical schedules or adequately manufacture our products in commercial quantities when required;
•switching manufacturers may be difficult because the number of potential manufacturers is limited. It may be difficult or impossible for us to find a replacement manufacturer quickly on acceptable terms, or at all;
•our contract manufacturers may not perform as agreed or may not remain in the contract manufacturing business for the time required to successfully produce, store or distribute our products; and
•drug manufacturers are subject to ongoing periodic unannounced inspection by the FDA, the U.S. Drug Enforcement Administration, and other agencies to ensure strict compliance with cGMP and other government regulations and corresponding foreign standards. We do not have control over third-party manufacturers’ compliance with these regulations and standards.
Our current dependence upon third parties for the manufacture of our products may reduce our profit margin, if any, on the sale of INGREZZA, ONGENTYS, or our future products and our ability to develop and deliver products on a timely and competitive basis.
We currently depend on a limited number of third-party suppliers. The loss of these suppliers, or delays or problems in the supply of INGREZZA or ONGENTYS, could materially and adversely affect our ability to successfully commercialize INGREZZA or ONGENTYS.
The manufacture of pharmaceutical products requires significant expertise and capital investment, including the development of process controls required to consistently produce the active pharmaceutical ingredients, or API, and the finished product in sufficient quantities while meeting detailed product specifications on a repeated basis. Manufacturers of pharmaceutical products may encounter difficulties in production, such as difficulties with production costs and yields, process controls, quality control and quality assurance, including testing of stability, impurities and impurity levels and other product specifications by validated test methods, compliance with strictly enforced U.S., state, and non-U.S. regulations, and disruptions caused by man-made or natural disasters or public health pandemics or epidemics or other business interruptions, including, for example, the COVID-19 pandemic. We depend on a limited number of suppliers for the production of INGREZZA and its API. If our third-party suppliers for INGREZZA encounter these or any other manufacturing, quality or compliance difficulties, we may be unable to meet commercial demand for INGREZZA, which could materially and adversely affect our ability to successfully commercialize INGREZZA. In addition, under the terms of our agreement with BIAL, although we are responsible for the management of all ONGENTYS commercialization activities, we rely on BIAL and its suppliers to supply all drug product for the commercialization of ONGENTYS. BIAL relies on third-party contract manufacturers to produce ONGENTYS. These contract manufacturers may encounter difficulties in achieving volume production, quality control, or quality assurance. As a result, these contract manufacturers may not be able to adequately produce ONGENTYS in commercial quantities when required, which may impact our ability to deliver ONGENTYS on a timely basis.
In addition, if our suppliers fail or refuse to supply us with INGREZZA or its API for any reason, it would take a significant amount of time and expense to qualify a new supplier. The FDA and similar international regulatory bodies must approve manufacturers of the active and inactive pharmaceutical ingredients and certain packaging materials used in pharmaceutical products. The loss of a supplier could require us to obtain regulatory clearance and to incur validation and other costs associated with the transfer of the API or product manufacturing processes. If there are delays in qualifying new suppliers or facilities or a new supplier is unable to meet FDA or a similar international regulatory body’s requirements for approval, there could be a shortage of INGREZZA, which could
33

materially and adversely affect our ability to successfully commercialize INGREZZA. If BIAL is unable or refuses to supply us with ONGENTYS drug product for any reason, or does not meet FDA or international regulators’ requirements for approval, we have limited opportunity to qualify a new supplier. This could materially and adversely affect our ability to successfully commercialize ONGENTYS.
The independent clinical investigators and contract research organizations that we rely upon to conduct our clinical trials may not be diligent, careful or timely, and may make mistakes, in the conduct of our trials.
We depend on independent clinical investigators and contract research organizations, or CROs, to conduct our clinical trials under their agreements with us. The investigators are not our employees, and we cannot control the amount or timing of resources that they devote to our programs. If our independent investigators fail to devote sufficient time and resources to our drug development programs, or if their performance is substandard, or not in compliance with Good Clinical Practices, it may delay or prevent the approval of our FDA applications and our introduction of new drugs. The CROs we contract with for execution of our clinical trials play a significant role in the conduct of the trials and the subsequent collection and analysis of data. Failure of the CROs to meet their obligations could adversely affect clinical development of our products. Moreover, these independent investigators and CROs may also have relationships with other commercial entities, some of which may compete with us. If independent investigators and CROs assist our competitors at our expense, it could harm our competitive position.
We do not and will not have access to all information regarding the products and product candidates we licensed to AbbVie.
We do not and will not have access to all information regarding elagolix, including potentially material information about commercialization plans, medical information strategies, clinical trial design and execution, safety reports from clinical trials, safety reports, regulatory affairs, process development, manufacturing and other areas known by AbbVie. In addition, we have confidentiality obligations under our agreement with AbbVie. Thus, our ability to keep our shareholders informed about the status of elagolix will be limited by the degree to which AbbVie keeps us informed and allows us to disclose such information to the public. If AbbVie fails to keep us informed about commercialization efforts related to elagolix, or the status of the clinical development or regulatory approval pathway of other product candidates licensed to it, we may make operational and/or investment decisions that we would not have made had we been fully informed, which may materially and adversely affect our business and operations.
We are subject to ongoing obligations and continued regulatory review for INGREZZA. Additionally, our other product candidates, if approved, could be subject to labeling and other post-marketing requirements and restrictions.
Regulatory approvals for any of our product candidates may be subject to limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase IV clinical trials, and surveillance to monitor the safety and efficacy of the product candidate. For example, with respect to the FDA’s approval of INGREZZA for tardive dyskinesia in April 2017, we are subject to certain post-marketing requirements and commitments. In addition, with respect to INGREZZA, and any product candidate that the FDA or a comparable foreign regulatory authority approves, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion and recordkeeping for the product will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with current Good Manufacturing Practices for any clinical trials that we conduct post-approval. Failure to comply with these ongoing regulatory requirements, or later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, may result in, among other things:
•restrictions on the marketing or manufacturing of the product, changes in the product’s label, withdrawal of the product from the market, or voluntary or mandatory product recalls;
•fines, warning letters or holds on clinical trials;
•refusal by the FDA to approve pending applications or supplements to approved applications filed by us, or suspension or revocation of product license approvals;
34

•product seizure or detention, or refusal to permit the import or export of products; and
•product injunctions or the imposition of civil or criminal penalties.
The occurrence of any of these events may adversely affect our business, prospects and ability to achieve or sustain profitability on a sustained basis.
If we are unable to retain and recruit qualified scientists or if any of our key senior executives discontinues his or her employment with us, it may delay our development efforts or impact our commercialization of INGREZZA, ONGENTYS or any product candidate approved by the FDA.
We are highly dependent on the principal members of our management and scientific staff. The loss of any of these people could impede the achievement of our objectives, including the successful commercialization of INGREZZA, ONGENTYS or any product candidate approved by the FDA. Furthermore, recruiting and retaining qualified scientific personnel to perform research and development work in the future, along with personnel with experience marketing and selling pharmaceutical products, is critical to our success. We may be unable to attract and retain personnel on acceptable terms given the competition among biotechnology, pharmaceutical and health care companies, universities and non-profit research institutions for experienced scientists and individuals with experience marketing and selling pharmaceutical products. We may face particular retention challenges in light of the recent rapid growth in our personnel and infrastructure and the perceived impact of those changes upon our corporate culture. In addition, we rely on a significant number of consultants to assist us in formulating our research and development strategy and our commercialization strategy. Our consultants may have commitments to, or advisory or consulting agreements with, other entities that may limit their availability to us.
If the market opportunities for our products and product candidates are smaller than we believe they are, our revenues may be adversely affected, and our business may suffer.
Certain of the diseases that INGREZZA, ONGENTYS and our other product candidates are being developed to address are in underserved and underdiagnosed populations. Our projections of both the number of people who have these diseases, as well as the subset of people with these diseases who will seek treatment utilizing our products or product candidates, may not be accurate. If our estimates of the prevalence or number of patients potentially on therapy prove to be inaccurate, the market opportunities for INGREZZA, ONGENTYS and our other product candidates may be smaller than we believe they are, our prospects for generating expected revenue may be adversely affected and our business may suffer.
We license some of our core technologies and drug candidates from third parties. If we default on any of our obligations under those licenses, or violate the terms of these licenses, we could lose our rights to those technologies and drug candidates or be forced to pay damages.
We are dependent on licenses from third parties for some of our key technologies. These licenses typically subject us to various commercialization, reporting and other obligations. If we fail to comply with these obligations, we could lose important rights. If we were to default on our obligations under any of our licenses, we could lose some or all of our rights to develop, market and sell products covered by these licenses. For example, BIAL may terminate our license agreement, pursuant to which we have rights to commercialize ONGENTYS, if we fail to use commercially reasonable efforts to comply with specified obligations under the license agreement, or if we otherwise breach the license agreement. In addition, several of our collaboration and license agreements allow our licensors to terminate such agreements if we challenge the validity or enforceability of certain intellectual property rights or if we commit a material breach in whole or in part of the agreement and do not cure such breach within the agreed upon cure period. In addition, if we were to violate any of the terms of our licenses, we could become subject to damages. Likewise, if we were to lose our rights under a license to use proprietary research tools, it could adversely affect our existing collaborations or adversely affect our ability to form new collaborations. We also face the risk that our licensors could, for a number of reasons, lose patent protection or lose their rights to the technologies we have licensed, thereby impairing or extinguishing our rights under our licenses with them.
Our indebtedness and liabilities could limit the cash flow available for our operations, expose us to risks that could adversely affect our business, financial condition and results of operations.
In May 2017, we sold $517.5 million aggregate principal amount of 2.25% convertible senior notes due May 15, 2024, or the 2024 Notes. In November 2020, we entered into separate, privately negotiated transactions with certain
35

holders of the 2024 Notes to repurchase $136.2 million aggregate principal amount of the 2024 Notes for an aggregate repurchase price of $186.9 million in cash. At December 31, 2020, $381.3 million aggregate principal amount of the 2024 Notes remained outstanding. We may also incur additional indebtedness to meet future financing needs. Our indebtedness could have significant negative consequences for our security holders and our business, results of operations and financial condition by, among other things:
•increasing our vulnerability to adverse economic and industry conditions;
•limiting our ability to obtain additional financing;
•requiring the dedication of a substantial portion of our cash flow from operations to service our indebtedness, which will reduce the amount of cash available for other purposes;
•limiting our flexibility to plan for, or react to, changes in our business;
•diluting the interests of our existing stockholders as a result of issuing shares of our common stock upon conversion of the 2024 Notes; and
•placing us at a possible competitive disadvantage with competitors that are less leveraged than us or have better access to capital.
Our business may not generate sufficient funds, and we may otherwise be unable to maintain sufficient cash reserves, to pay amounts due under the 2024 Notes and any additional indebtedness that we may incur. In addition, our cash needs may increase in the future. In addition, any future indebtedness that we may incur may contain financial and other restrictive covenants that limit our ability to operate our business, raise capital or make payments under our other indebtedness. If we fail to comply with these covenants or to make payments under our indebtedness when due, then we would be in default under that indebtedness, which could, in turn, result in that and our other indebtedness becoming immediately payable in full.
We have a history of losses and expect to increase our expenses for the foreseeable future, and we may not be able to sustain profitability.
Since our inception, we have incurred significant net losses and negative cash flow from operations. At December 31, 2020, we had an accumulated deficit of $0.7 billion as a result of historical operating losses.
We received FDA approval for INGREZZA for tardive dyskinesia in April 2017 and for ONGENTYS for Parkinson’s disease in April 2020. Our partner AbbVie received FDA approval for ORILISSA for endometriosis in July 2018 and for ORIAHNN for uterine fibroids in May 2020. However, we have not yet obtained regulatory approvals for any other product candidates. Even if we continue to succeed in commercializing INGREZZA, or if we successfully commercialize ONGENTYS or are successful in developing and commercializing any of our other product candidates, we may not be able to sustain profitability. We also expect to continue to incur significant operating and capital expenditures as we:
•commercialize INGREZZA for tardive dyskinesia;
•commercialize ONGENTYS for Parkinson’s disease;
•seek regulatory approvals for our product candidates;
•develop, formulate, manufacture and commercialize our product candidates;
•in-license or acquire new product development opportunities;
•implement additional internal systems and infrastructure; and
•hire additional clinical, scientific, sales and marketing personnel.
We expect to increase our expenses and other investments in the coming years as we fund our operations, in-licensing or acquisition opportunities, and capital expenditures. While we were profitable for the year ended December 31, 2020, our future operating results and profitability may fluctuate from period to period due to the factors described above, and we will need to generate significant revenues to achieve and maintain profitability and positive cash flow on a sustained basis. We may not be able to generate these revenues, and we may never achieve
36

profitability on a sustained basis in the future. Our failure to maintain or increase profitability on a sustained basis could negatively impact the market price of our common stock.
We have recently increased the size of our organization and will need to continue to increase the size of our organization. We may encounter difficulties with managing our growth, which could adversely affect our results of operations.
At December 31, 2020, we had approximately 845 full-time employees. Although we have substantially increased the size of our organization, we may need to add additional qualified personnel and resources, especially now that we have a commercial sales force. Our current infrastructure may be inadequate to support our development and commercialization efforts and expected growth. Future growth will impose significant added responsibilities on members of management, including the need to identify, recruit, maintain and integrate additional employees, and may take time away from running other aspects of our business, including development and commercialization of our product candidates.
Our future financial performance and our ability to commercialize INGREZZA, ONGENTYS and any other product candidates that receive regulatory approval will depend, in part, on our ability to manage any future growth effectively. In particular, as we commercialize INGREZZA and ONGENTYS, we will need to support the training and ongoing activities of our sales force and will likely need to continue to expand the size of our employee base for managerial, operational, financial and other resources. To that end, we must be able to successfully:
•manage our development efforts effectively;
•integrate additional management, administrative and manufacturing personnel;
•further develop our marketing and sales organization; and
•maintain sufficient administrative, accounting and management information systems and controls.
We may not be able to accomplish these tasks or successfully manage our operations and, accordingly, may not achieve our research, development, and commercialization goals. Our failure to accomplish any of these goals could harm our financial results and prospects.
We may be subject to claims that we or our employees have wrongfully used or disclosed alleged trade secrets of their former employers.
As is commonplace in the biotechnology industry, we employ individuals who were previously employed at other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although no claims against us are currently pending, we may be subject to claims that these employees or we have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management.
Because our operating results may vary significantly in future periods, our stock price may decline.
Our quarterly revenues, expenses and operating results have fluctuated in the past and are likely to fluctuate significantly in the future. Our financial results are unpredictable and may fluctuate, for among other reasons, due to seasonality and timing of customer purchases and commercial sales of INGREZZA, impact of the commercial launch of ONGENTYS and ORIAHNN, royalties from out-licensed products, the impact of Medicare Part D coverage, our achievement of product development objectives and milestones, clinical trial enrollment and expenses, research and development expenses and the timing and nature of contract manufacturing, contract research payments, fluctuations in our effective tax rate, and disruptions caused by man-made or natural disasters or public health pandemics or epidemics or other business interruptions, including, for example, the COVID-19 pandemic. A high portion of our costs are predetermined on an annual basis, due in part to our significant research and development costs. Thus, small declines in revenue could disproportionately affect financial results in a quarter. While we were profitable for the year ended December 31, 2020, our future operating results and profitability may fluctuate from period to period, and even if we become profitable on a quarterly or annual basis, we may not be able to sustain or increase our profitability. Moreover, as our company and our market capitalization have grown, our financial performance has become increasingly subject to quarterly and annual comparisons with the expectations of
37

securities analysts or investors. The failure of our financial results to meet these expectations, either in a single quarterly or annual period over a sustained period time, could cause our stock price to decline.
Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business, cash flows, financial condition or results of operations.
New income, sales, use or other tax laws, statutes, rules, regulations or ordinances could be enacted at any time, which could adversely affect our business and financial condition. Further, existing tax laws, statutes, rules, regulations or ordinances could be interpreted, changed, modified or applied adversely to us. For example, legislation enacted in 2017, informally titled the Tax Cuts and Jobs Act, or the Tax Act, enacted many significant changes to the US tax laws. Future guidance from the Internal Revenue Service and other tax authorities with respect to the Tax Act may affect us, and certain aspects of the Tax Act repealed or modified in future legislation. For example, the Coronavirus Aid, Relief, and Economic Security Act, or the CARES Act, modified certain provisions of the Tax Act. In addition, it is uncertain if and to what extent various states will conform to the Tax Act or any newly enacted federal tax legislation. Changes in corporate tax rates, the realization of net deferred tax assets relating to our operations, the taxation of foreign earnings, and the deductibility of expenses under the Tax Act or future reform legislation could have a material impact on the value of our deferred tax assets, could result in significant one-time charges, and could increase our future US tax expense.
Our ability to use net operating loss carryforwards and certain other tax attributes may be limited.
Our net operating loss, or NOL, carryforwards generated in tax years ending on or prior to December 31, 2017, are only permitted to be carried forward for 20 years under applicable US tax law. Under the Tax Cut and Jobs Act, as modified by the CARES Act, our federal NOLs generated in tax years beginning after December 31, 2017, may be carried forward indefinitely, but the deductibility of such federal NOLs in tax years beginning after December 31, 2020, is limited to 80% of taxable income. It is uncertain if and to what extent various states will conform to the Tax Cut and Jobs Act or the CARES Act. In addition, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, and corresponding provisions of state law, if a corporation undergoes an “ownership change,” which is generally defined as a greater than 50% change, by value, in its equity ownership over a three-year period, the corporation’s ability to use its pre-change NOL carryforwards and other pre-change tax attributes to offset its post-change income or taxes may be limited. We do not believe we have experienced any previous ownership changes, but the determination is complex and there can be no assurance we are correct. Furthermore, we may experience ownership changes in the future as a result of subsequent shifts in our stock ownership, some of which may be outside of our control.
As a result, our pre-2018 NOL carryforwards may expire prior to being used and our NOL carryforwards generated in tax years beginning after December 31, 2020, will be subject to a percentage limitation and, if we undergo an ownership change (or if we previously underwent such an ownership change), our ability to use all of our pre-change NOLs and other pre-change tax attributes (such as research tax credits) to offset our post-change income or taxes may be limited. Similar provisions of state tax law may also apply to limit our use of accumulated state tax attributes. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. For example, California passed legislation imposing limits on the usability of California state NOLs and certain tax credits in tax years beginning after 2019 and before 2023. As a result, we may be unable to use all or a material portion of our NOLs and other tax attributes, which could adversely affect our future cash flows.
Our effective tax rate may fluctuate, and we may incur obligations in tax jurisdictions in excess of accrued amounts.
Our effective tax rate is derived from a combination of applicable tax rates in the various places that we operate. In preparing our financial statements, we estimate the amount of tax that will become payable in each of such places. Nevertheless, our effective tax rate may be different than experienced in the past due to numerous factors, including changes in the mix of our profitability from state to state, the results of examinations and audits of our tax filings, our inability to secure or sustain acceptable agreements with tax authorities, changes in accounting for income taxes and changes in tax laws. Any of these factors could cause us to experience an effective tax rate significantly different from previous periods or our current expectations and may result in tax obligations in excess of amounts accrued in our financial statements.
38

In addition, on December 31, 2020, we determined, based on our facts and circumstances, that it was more likely than not that a substantial portion of our deferred tax assets would be realized and, as a result, substantially all of our valuation allowance against our deferred tax assets was released. Therefore, beginning in 2021, we expect to commence recording income tax expense at an estimated tax rate that will likely approximate statutory tax rates, which would result in a significant reduction in our net income and net income per share.
The price of our common stock is volatile.
The market prices for securities of biotechnology and pharmaceutical companies historically have been highly volatile, and the market for these securities has from time to time experienced significant price and volume fluctuations that are unrelated to the operating performance of particular companies. The COVID-19 pandemic, for example, has negatively affected the stock market and investor sentiment and has resulted in significant volatility. Furthermore, especially as we and our market capitalization have grown, the price of our common stock has been increasingly affected by quarterly and annual comparisons with the valuations and recommendations of the analysts who cover our business. If our results do not meet these analysts’ forecasts, the expectations of our investors or the financial guidance we provide to investors in any period, which is based on assumptions that may be incorrect or that may change from quarter to quarter, the market price of our common stock could decline. Over the course of the last twelve months, the price of our common stock has ranged from approximately $72 per share to approximately $136 per share. The market price of our common stock may fluctuate in response to many factors, including:
•sales of INGREZZA and ORILISSA;
•impact of the commercial launch of ONGENTYS and ORIAHNN;
•the status and cost of our post-marketing commitments for INGREZZA and ONGENTYS;
•the results of our clinical trials;
•reports of safety issues related to INGREZZA, ONGENTYS, ORILISSA, or ORIAHNN;
•developments concerning new and existing collaboration agreements;
•announcements of technological innovations or new therapeutic products by us or others;
•general economic and market conditions, including economic and market conditions affecting the biotechnology industry;
•developments in patent or other proprietary rights;
•developments related to the FDA;
•future sales of our common stock by us or our stockholders;
•comments by securities analysts;
•additions or departures of key personnel;
•fluctuations in our operating results;
•potential litigation matters;
•government regulation;
•government and third-party payor coverage and reimbursement;
•failure of any of our product candidates, if approved, to achieve commercial success;
•disruptions caused by man-made or natural disasters or public health pandemics or epidemics or other business interruptions, including, for example, the COVID-19 pandemic; and
•public concern as to the safety of our drugs.
Our customers are concentrated and therefore the loss of a significant customer may harm our business.
We have entered into agreements for the distribution of INGREZZA with a limited number of specialty pharmacy providers and a specialty distributor, and all of our product sales are to these customers. Two of these customers
39

represented approximately 86% of our product revenue for the year ended December 31, 2020 and a significant majority of our accounts receivable balance at December 31, 2020. If any of these significant customers becomes subject to bankruptcy, is unable to pay us for our products or is acquired by a company that wants to terminate the relationship with us, or if we otherwise lose any of these significant customers, our revenue, results of operations and cash flows would be adversely affected. Even if we replace the loss of a significant customer, we cannot predict with certainty that such transition would not result in a decline in our revenue, results of operations and cash flows.
If we cannot raise additional funding, we may be unable to complete development of our product candidates or establish commercial and manufacturing capabilities in the future.
We may require additional funding to continue our research and development programs, to conduct preclinical studies and clinical trials, for operating expenses, to pursue regulatory approvals for our product candidates, for the costs involved in filing and prosecuting patent applications and enforcing or defending patent claims, if any, and the cost of product in-licensing and any possible acquisitions. In addition, we may require additional funding to establish manufacturing and marketing capabilities in the future. We believe that our existing capital resources, together with investment income, and future payments due under our strategic alliances, will be sufficient to satisfy our current and projected funding requirements for at least the next twelve months. However, these resources might be insufficient to conduct research and development programs, the cost of product in-taking and possible acquisitions, fully commercialize products and operate the company to the full extent currently planned. If we cannot obtain adequate funds, we may be required to curtail significantly our commercial plans or one or more of our research and development programs or obtain funds through additional arrangements with corporate collaborators or others that may require us to relinquish rights to some of our technologies or product candidates.
Our future capital requirements will depend on many factors, including:
•the commercial success of INGREZZA, ONGENTYS, ORILISSA, and/or ORIAHNN;
•debt service obligations on the 2024 Notes;
•continued scientific progress in our R&D and clinical development programs;
•the magnitude and complexity of our research and development programs;
•progress with preclinical testing and clinical trials;
•the time and costs involved in obtaining regulatory approvals;
•the costs involved in filing and pursuing patent applications, enforcing patent claims, or engaging in interference proceedings or other patent litigation;
•competing technological and market developments;
•the establishment of additional strategic alliances;
•developments related to any future litigation;
•the cost of commercialization activities and arrangements, including manufacturing of our product candidates; and
•the cost of product in-licensing and any possible acquisitions.
We intend to seek additional funding through strategic alliances and may seek additional funding through public or private sales of our securities, including equity securities. In addition, during the second quarter of 2017, we issued the 2024 Notes and we have previously financed capital purchases and may continue to pursue opportunities to obtain additional debt financing in the future. In November 2020, we entered into separate, privately negotiated transactions with certain holders of the 2024 Notes to repurchase $136.2 million aggregate principal amount of the 2024 Notes for an aggregate repurchase price of $186.9 million in cash. At December 31, 2020, $381.3 million aggregate principal amount of the 2024 Notes remained outstanding. Additional equity or debt financing might not be available on reasonable terms, if at all. In addition, disruptions due to the COVID-19 pandemic could make it more difficult for us to access capital. Any additional equity financings will be dilutive to our stockholders and any additional debt financings may involve operating covenants that restrict our business.
40

Compliance with changing regulation of corporate governance and public disclosure may result in additional expenses.
Changing laws, regulations and standards relating to corporate governance and public disclosure, including the Dodd-Frank Wall Street Reform and Consumer Protection Act, new SEC regulations and Nasdaq rules, are creating uncertainty for companies such as ours. These laws, regulations and standards are subject to varying interpretations in some cases due to their lack of specificity, and as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies, which could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. We are committed to maintaining high standards of corporate governance and public disclosure. As a result, our efforts to comply with evolving laws, regulations and standards have resulted in, and are likely to continue to result in, increased selling, general and administrative expenses and management time related to compliance activities. If we fail to comply with these laws, regulations and standards, our reputation may be harmed, and we might be subject to sanctions or investigation by regulatory authorities, such as the SEC. Any such action could adversely affect our financial results and the market price of our common stock.
Increasing use of social media could give rise to liability and result in harm to our business.
Our employees are increasingly utilizing social media tools and our website as a means of communication. Despite our efforts to monitor social media communications, there is risk that the unauthorized use of social media by our employees to communicate about our products or business, or any inadvertent disclosure of material, nonpublic information through these means, may result in violations of applicable laws and regulations, which may give rise to liability and result in harm to our business. In addition, there is also risk of inappropriate disclosure of sensitive information, which could result in significant legal and financial exposure and reputational damages that could potentially have a material adverse impact on our business, financial condition and results of operations. Furthermore, negative posts or comments about us or our products on social media could seriously damage our reputation, brand image and goodwill.
Risks Related to Our Industry
Health care reform measures and other recent legislative initiatives could adversely affect our business.
The business and financial condition of pharmaceutical and biotechnology companies are affected by the efforts of governmental and third-party payors to contain or reduce the costs of health care and to lower drug prices. In the U.S., comprehensive health care reform legislation was enacted by the Federal government and we expect that there will continue to be a number of federal and state proposals to implement government control over the pricing of prescription pharmaceuticals. In addition, increasing emphasis on reducing the cost of health care in the U.S. will continue to put pressure on the rate of adoption and pricing of prescription pharmaceuticals. Moreover, in some foreign jurisdictions, pricing of prescription pharmaceuticals is already subject to government control. Additionally, other federal and state legislation impose obligations on manufacturers of pharmaceutical products, among others, related to product tracking and tracing. Among the requirements of this new legislation, manufacturers are required to provide certain information regarding the drug product provided to individuals and entities to which product ownership is transferred, label drug product with a product identifier, and keep certain records regarding distribution of the drug product. Further, under this new legislation, manufacturers will have drug product investigation, quarantine, disposition, notification and purchaser license verification responsibilities related to counterfeit, diverted, stolen, and intentionally adulterated products, as well as products that are the subject of fraudulent transactions or which are otherwise unfit for distribution such that they would be reasonably likely to result in serious health consequences or death.
Additionally, in March 2010, Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively the ACA, was signed into law, which was intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add transparency requirements for the healthcare and health insurance industries, impose taxes and fees
41

on the health industry and impose additional health policy reforms. Among the provisions of the ACA of importance to our potential drug candidates are:
•an annual, nondeductible fee on any entity that manufactures, or imports, specified branded prescription drugs and biologic agents, apportioned among these entities according to their market share in certain government healthcare programs;
•an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program to 23.1% and 13.0% of the average manufacturer price for branded and generic drugs, respectively;
•a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected;
•extension of a manufacturer’s Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations;
•expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to certain individuals with income at or below 133% of the federal poverty level, thereby potentially increasing a manufacturer’s Medicaid rebate liability;
•a new Medicare Part D coverage gap discount program, in which manufacturers must now agree to offer 70% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for a manufacturer’s outpatient drugs to be covered under Medicare Part D;
•expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program; and
•a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research.
There remain legal and political challenges to certain aspects of the ACA. Since January 2017, several executive orders and other directives designed to delay, circumvent, or loosen certain requirements mandated by the ACA have been put into place. Concurrently, Congress has considered legislation that would repeal or repeal and replace all or part of the ACA. Legislation enacted in 2017, informally titled the Tax Cuts and Jobs Act includes a provision that repealed, effective January 1, 2019, the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the “individual mandate”. In addition, the 2020 federal spending package permanently eliminated, effective January 1, 2020, the ACA-mandated “Cadillac” tax on high-cost employer-sponsored health coverage and medical device tax and, effective January 1, 2021, also eliminated the health insurer tax. On December 14, 2018, a U.S. District Court Judge in Texas ruled that the ACA is unconstitutional in its entirety because the “individual mandate” was repealed by Congress as part of the Tax Cuts and Jobs Act. Additionally, on December 18, 2019, the U.S. Court of Appeals for the 5th Circuit ruled that the individual mandate was unconstitutional and remanded the case back to the District Court to determine whether the remaining provisions of the ACA are invalid as well. On March 2, 2020, the United States Supreme Court is currently reviewing this case, although it is unclear when a decision will be made. It is also unclear how such litigation will impact the ACA and our business.
Other legislative changes have been proposed and adopted since the ACA was enacted. These changes include aggregate reductions to Medicare payments to providers of up to 2% per fiscal year pursuant to the Budget Control Act of 2011, which began in 2013 and, due to subsequent legislative amendments to the statute, including the Bipartisan Budget Act of 2018, will remain in effect through 2030, except for a temporary suspension from May 1, 2020 through May 31, 2021 due to the COVID-19 pandemic, unless additional Congressional action is taken. The American Taxpayer Relief Act of 2012, among other things, further reduced Medicare payments to several providers, including hospitals and cancer treatment centers, increased the statute of limitations period for the government to recover overpayments to providers from three to five years.
Additional changes that may affect our business include the expansion of new programs such as Medicare payment for performance initiatives for physicians under the Medicare Access and CHIP Reauthorization Act of 2015, which
42

ended the use of the statutory formula, also referred to as the Sustainable Growth Rate, for clinician payment and established a quality payment incentive program, also referred to as the Quality Payment Program. This program provides clinicians with two ways to participate, including through the Advanced Alternative Payment Models, or APMs, and the Merit-based Incentive Payment System, or MIPS. In November 2019, CMS issued a final rule finalizing the changes to the Quality Payment Program. At this time, it remains unclear how the introduction of the Quality Payment Program will impact overall physician reimbursement.
Also, there has been heightened governmental scrutiny recently over pharmaceutical pricing practices in light of the rising cost of prescription drugs and biologics. Such scrutiny has resulted in several recent Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. At the federal level, the Trump administration’s budget proposal for the 2021 fiscal year includes a $135 billion allowance to support legislative proposals seeking to reduce drug prices, increase competition, lower out-of-pocket drug costs for patients, and increase patient access to lower-cost generic and biosimilar drugs. On March 10, 2020, the Trump administration sent “principles” for drug pricing to Congress, calling for legislation that would, among other things, cap Medicare Part D beneficiary out-of-pocket pharmacy expenses, provide an option to cap Medicare Part D beneficiary monthly out-of-pocket expenses, and place limits on pharmaceutical price increases. Further, the Trump administration released a “Blueprint” to lower drug prices and reduce out of pocket costs of drugs that contains additional proposals to increase manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products and reduce the out of pocket costs of drug products paid by consumers. On July 24, 2020 and September 13, 2020, the Trump administration announced several executive orders related to prescription drug pricing that attempt to implement several of the administration’s proposals. As a result, the FDA released a final rule on September 24, 2020, effective November 30, 2020, providing guidance for states to build and submit importation plans for drugs from Canada. Further, on November 20, 2020, the U.S. Department of Health and Human Services, or HHS, finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers. On November 20, 2020, CMS issued an interim final rule implementing President Trump’s Most Favored Nation executive order, which would tie Medicare Part B payments for certain physician-administered drugs to the lowest price paid in other economically advanced countries, effective January 1, 2021. On December 28, 2020, the U.S. District Court in Northern California issued a nationwide preliminary injunction against implementation of the interim final rule. It is unclear whether the Biden administration will work to reverse these measures or pursue similar policy initiatives. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.
We expect that the ACA, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and lower reimbursement, and in additional downward pressure on the price that we receive for any approved product. In particular, it is possible that additional governmental action is taken in response to the COVID-19 pandemic. Any reduction in reimbursement from Medicare or other government-funded programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain sustained profitability or commercialize our drugs.
We are currently unable to predict what additional legislation or regulation, if any, relating to the health care industry may be enacted in the future or what effect recently enacted federal legislation or any such additional legislation or regulation would have on our business. The pendency or approval of such proposals or reforms could result in a decrease in our stock price or limit our ability to raise capital or to enter into collaboration agreements for the further development and commercialization of our programs and products.
43

Any relationships with healthcare professionals, principal investigators, consultants, customers (actual and potential) and third-party payors in connection with our current and future business activities are and will continue to be subject, directly or indirectly, to federal and state healthcare laws. If we are unable to comply, or have not fully complied, with such laws, we could face penalties, contractual damages, reputational harm, diminished profits and future earnings and curtailment or restructuring of our operations.
Our business operations and activities may be directly, or indirectly, subject to various federal and state healthcare laws, including without limitation, fraud and abuse laws, false claims laws, data privacy and security laws, as well as transparency laws regarding payments or other items of value provided to healthcare providers. These laws may restrict or prohibit a wide range of business activities, including, but not limited to, research, manufacturing, distribution, pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. These laws may impact, among other things, our current activities with principal investigators and research subjects, as well as current and future sales, marketing, patient co-payment assistance and education programs.
Such laws include:
•the federal Anti-Kickback Statute which prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under a federal healthcare program such as Medicare and Medicaid;
•the federal civil and criminal false claims laws, including the federal civil False Claims Act, and civil monetary penalties laws, which impose criminal and civil penalties against individuals or entities for, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;
•HIPAA, which imposes criminal and civil liability for, among other things, executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;
•HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, and its implementing regulations, which also imposes obligations, including mandatory contractual terms, on covered entities, including certain healthcare providers, health plans, and healthcare clearinghouses, as well as their business associates and their covered subcontractors, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;
•the federal Physician Payments Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children’s Health Insurance Program, with specific exceptions, to report annually to CMS information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists, and chiropractors) and teaching hospitals, and applicable manufacturers and applicable group purchasing organizations to report annually to CMS ownership and investment interests held by physicians and their immediate family members. Beginning in 2022, applicable manufacturers also will be required to report such information regarding its relationships with physician assistants, nurse practitioners, clinical nurse specialists, anesthesiologist assistants, certified registered nurse anesthetists and certified nurse midwives during the previous year; and
•analogous state, local, and foreign laws and regulations, such as state anti-kickback and false claims laws, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third party payors, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry’s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government; state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures or drug pricing; state laws that require disclosure of price increases above certain identified thresholds as well as of new commercial launches in the state; state and local laws that require the registration of pharmaceutical sales representatives; state and local “drug take
44

back” laws and regulations; and state and foreign laws governing the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.
Efforts to ensure that our business arrangements will comply with applicable healthcare laws may involve substantial costs. While our interactions with healthcare professionals, including our speaker programs and other arrangements, such as our contributions to patient assistance programs, have been structured to comply with these laws and related guidance, it is possible that governmental and enforcement authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws. If our operations or activities are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to, without limitation, significant civil, criminal and administrative penalties, damages, monetary fines, disgorgement, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, contractual damages, reputational harm, diminished profits and future earnings and curtailment or restructuring of our operations, any of which could adversely affect our ability to operate.
In addition, any sales of our product once commercialized outside the U.S. will also likely subject us to foreign equivalents of the healthcare laws mentioned above, among other foreign laws.
We could face liability if a regulatory authority determines that we are promoting INGREZZA, ONGENTYS or any of our product candidates that receives regulatory approval, for “off-label” uses.
A company may not promote “off-label” uses for its drug products. An off-label use is the use of a product for an indication that is not described in the product’s FDA-approved label in the U.S. or for uses in other jurisdictions that differ from those approved by the applicable regulatory agencies. Physicians, on the other hand, may prescribe products for off-label uses. Although the FDA and other regulatory agencies do not regulate a physician’s choice of drug treatment made in the physician’s independent medical judgment, they do restrict promotional communications from companies or their sales force with respect to off-label uses of products for which marketing clearance has not been issued. However, companies may share truthful and not misleading information that is otherwise consistent with a product’s FDA approved labeling. A company that is found to have promoted off-label use of its product may be subject to significant liability, including civil and criminal sanctions. We intend to comply with the requirements and restrictions of the FDA and other regulatory agencies with respect to our promotion of our products, including INGREZZA and ONGENTYS, but we cannot be sure that the FDA or other regulatory agencies will agree that we have not violated their restrictions. As a result, we may be subject to criminal and civil liability. In addition, our management’s attention could be diverted to handle any such alleged violations. If the FDA or any other governmental agency initiates an enforcement action against us, or if we are the subject of a qui tam suit brought by a private plaintiff on behalf of the government, and it is determined that we violated prohibitions relating to the promotion of products for unapproved uses, we could be subject to substantial civil or criminal fines or damage awards and other sanctions such as consent decrees and corporate integrity agreements pursuant to which our activities would be subject to ongoing scrutiny and monitoring to ensure compliance with applicable laws and regulations. Any such fines, awards or other sanctions would have an adverse effect on our revenue, business, financial prospects, and reputation.
If we are unable to protect our intellectual property, our competitors could develop and market products based on our discoveries, which may reduce demand for our products.
Our success will depend on our ability to, among other things:
•obtain patent protection for our products;
•preserve our trade secrets;
•prevent third parties from infringing upon our proprietary rights; and
•operate without infringing upon the proprietary rights of others, both in the U.S. and internationally.
Because of the substantial length of time and expense associated with bringing new products through the development and regulatory approval processes in order to reach the marketplace, the pharmaceutical industry places
45

considerable importance on obtaining patent and trade secret protection for new technologies, products and processes. Accordingly, we intend to seek patent protection for our proprietary technology and compounds. However, we face the risk that we may not obtain any of these patents and that the breadth of claims we obtain, if any, may not provide adequate protection of our proprietary technology or compounds.
We also rely upon unpatented trade secrets and improvements, unpatented know-how and continuing technological innovation to develop and maintain our competitive position, which we seek to protect, in part, through confidentiality agreements with our commercial collaborators, employees and consultants. We also have invention or patent assignment agreements with our employees and some, but not all, of our commercial collaborators and consultants. However, if our employees, commercial collaborators or consultants breach these agreements, we may not have adequate remedies for any such breach, and our trade secrets may otherwise become known or independently discovered by our competitors.
In addition, although we own a number of patents, the issuance of a patent is not conclusive as to its validity or enforceability, and third parties may challenge the validity or enforceability of our patents. We cannot assure you how much protection, if any, will be given to our patents if we attempt to enforce them and they are challenged in court or in other proceedings. It is possible that a competitor may successfully challenge our patents or that challenges will result in limitations of their coverage. Moreover, competitors may infringe our patents or successfully avoid them through design innovation. To prevent infringement or unauthorized use, we may need to file infringement claims, which are expensive and time-consuming. In addition, in an infringement proceeding a court may decide that a patent of ours is not valid or is unenforceable or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover its technology. Interference proceedings declared by the U.S. Patent and Trademark Office may be necessary to determine the priority of inventions with respect to our patent applications or those of our licensors. Litigation or interference proceedings may fail and, even if successful, may result in substantial costs and be a distraction to management. We cannot assure you that we will be able to prevent misappropriation of our proprietary rights, particularly in countries where the laws may not protect such rights as fully as in the U.S.
If we fail to obtain or maintain orphan drug designation or other regulatory exclusivity for some of our product candidates, our competitive position would be harmed.
A product candidate that receives orphan drug designation can benefit from a streamlined regulatory process as well as potential commercial benefits following approval. Currently, this designation provides market exclusivity in the U.S. and the EU for seven years and ten years, respectively, if a product is the first such product approved for such orphan indication. This market exclusivity does not, however, pertain to indications other than those for which the drug was specifically designated in the approval, nor does it prevent other types of drugs from receiving orphan designations or approvals in these same indications. Further, even after an orphan drug is approved, the FDA can subsequently approve the same drug for the same condition if the FDA concludes that the new drug is clinically superior to the orphan product or a market shortage occurs.
In the EU, orphan exclusivity may be reduced to six years if the drug no longer satisfies the original designation criteria or can be lost altogether if the marketing authorization holder consents to a second orphan drug application or cannot supply enough drug, or when a second applicant demonstrates its drug is “clinically superior” to the original orphan drug. We may not be successful obtaining orphan drug designations for any indications and, even if we succeed, such orphan drug designations may fail to result in or maintain orphan drug exclusivity upon approval, which would harm our competitive position.
The technologies we use in our research as well as the drug targets we select may infringe the patents or violate the proprietary rights of third parties.
We cannot assure you that third parties will not assert patent or other intellectual property infringement claims against us or our collaborators with respect to technologies used in potential products. If a patent infringement suit were brought against us or our collaborators, we or our collaborators could be forced to stop or delay developing, manufacturing or selling potential products that are claimed to infringe a third party’s intellectual property unless that party grants us or our collaborators rights to use its intellectual property. In such cases, we could be required to obtain licenses to patents or proprietary rights of others in order to continue to commercialize our products. However, we may not be able to obtain any licenses required under any patents or proprietary rights of third parties
46

on acceptable terms, or at all. Even if our collaborators or we were able to obtain rights to the third party’s intellectual property, these rights may be non-exclusive, thereby giving our competitors access to the same intellectual property. Ultimately, we may be unable to commercialize some of our potential products or may have to cease some of our business operations as a result of patent infringement claims, which could severely harm our business.
Our employees, independent contractors, principal investigators, consultants, commercial partners and vendors may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements.
We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees and independent contractors, such as principal investigators, consultants, commercial partners and vendors, or by employees of our commercial partners could include failures to comply with FDA regulations, to provide accurate information to the FDA, to comply with manufacturing standards we have established, to comply with federal and state healthcare fraud and abuse laws, to report financial information or data accurately, to maintain the confidentiality of our trade secrets or the trade secrets of our commercial partners, or to disclose unauthorized activities to us. In particular, sales, marketing and other business arrangements in the healthcare industry are subject to extensive laws intended to prevent fraud, kickbacks, self-dealing and other abusive practices. Employee and independent contractor misconduct could also involve the improper use of individually identifiable information, including, without limitation, information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. Any action against our employees, independent contractors, principal investigators, consultants, commercial partners or vendors for violations of these laws could result in significant civil, criminal, and administrative penalties, fines, and imprisonment.
We face potential product liability exposure far in excess of our insurance coverage.
The use of any of our potential products in clinical trials, and the sale of any approved products, including INGREZZA and ONGENTYS, may expose us to liability claims. These claims might be made directly by consumers, health care providers, pharmaceutical companies or others selling our products. We have product liability insurance coverage for our clinical trials in the amount of $45.0 million per occurrence and $45.0 million in the aggregate. In addition, we have product liability insurance related to the sale of INGREZZA and ONGENTYS in the amount of $45.0 million per occurrence and $45.0 million in the aggregate. However, our insurance may not reimburse us or may not be sufficient to reimburse us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive, and we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability from any current or future clinical trials or approved products. A successful product liability claim, or series of claims, brought against us would decrease our cash reserves and could cause our stock price to fall. Furthermore, regardless of the eventual outcome of a product liability claim, any product liability claim against us may decrease demand for our approved products, including INGREZZA and ONGENTYS, damage our reputation, result in regulatory investigations that could require costly recalls or product modifications, cause clinical trial participants to withdrawal, result in costs to defend the related litigation, decrease our revenue, and divert management’s attention from managing our business.
Our activities involve hazardous materials, and we may be liable for any resulting contamination or injuries.
Our research activities involve the controlled use of hazardous materials. We cannot eliminate the risk of accidental contamination or injury from these materials. If an accident occurs, a court may hold us liable for any resulting damages, which may harm our results of operations and cause us to use a substantial portion of our cash reserves, which would force us to seek additional financing.
Cyber security breaches and other disruptions could compromise our information, including the theft of our intellectual property, and could expose us to liability, which would cause our business and reputation to suffer.
We are increasingly dependent on information technology systems and infrastructure, including mobile technologies, to operate our business. In the ordinary course of our business, we collect and store confidential and sensitive electronic information on our networks and in our data centers. This information includes, among other things, our intellectual property and proprietary information, the confidential information of our collaborators and licensees, and the personally identifiable information of our employees. It is important to our operations and business strategy that this electronic information remains secure and is perceived to be secure. The size and
47

complexity of our information technology systems, and those of third-party vendors with whom we contract, and the volume of data we retain, make such systems potentially vulnerable to breakdown, malicious intrusion, security breaches and other cyber-attacks. Additionally, natural disasters, public health pandemics or epidemics (including, for example, the COVID-19 pandemic), terrorism, war and telecommunication and electrical failures may result in damage to or the interruption or impairment of key business processes, or the loss or corruption of confidential information, including intellectual property, proprietary business information and personal information. Information security risks have significantly increased in recent years in part due to the proliferation of new technologies and the increased sophistication and activities of organized crime, hackers, terrorists and other external parties, including foreign private parties and state actors. A security breach or privacy violation that leads to disclosure or modification of or prevents access to personally identifiable information or other protected information could harm our reputation, compel us to comply with federal and/or state breach notification laws and foreign law equivalents, subject us to mandatory corrective action, require us to verify the correctness of database contents and otherwise subject us to liability under laws and regulations that protect personal data, resulting in increased costs or loss of revenue. Similarly, the loss of clinical trial data from completed or ongoing or planned clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Additionally, theft of our intellectual property or proprietary business information could require substantial expenditures to remedy. If we are unable to prevent such security breaches or privacy violations or implement satisfactory remedial measures, our operations could be disrupted, and we may suffer loss of reputation, financial loss and other regulatory penalties because of lost or misappropriated information. In addition, these breaches and other inappropriate access can be difficult to detect, and any delay in identifying them may lead to increased harm of the type described above. Moreover, the prevalent use of mobile devices that access confidential information increases the risk of data security breaches, which could lead to the loss of confidential information, trade secrets or other intellectual property. As cyber threats continue to evolve, we may be required to expend significant additional resources to continue to modify or enhance our protective measures or to investigate and remediate any information security vulnerabilities. While we have implemented security measures to protect our data security and information technology systems, such measures may not prevent such events. Significant disruptions of our information technology systems or breaches of data security could have a material adverse effect on our business, financial condition and results of operations.
Compliance with evolving U.S. and global privacy and data security requirements could result in additional costs and liabilities to us or inhibit our ability to collect and process data globally, and the failure to comply with such requirements could have a material adverse effect on our business, financial condition or results of operations.
The regulatory framework for the collection, use, safeguarding, sharing, transfer and other processing of information worldwide is rapidly evolving and is likely to remain uncertain for the foreseeable future. For example, the EU’s General Data Protection Regulation, or GDPR, imposes strict obligations on the processing of personal data, including personal health data, and the free movement of such data. The GDPR applies to any company established in the EU as well as any company outside the EU that processes personal data in connection with the offering of goods or services to individuals in the EU or the monitoring of their behavior. The GDPR enhances data protection obligations for processors and controllers of personal data, including, for example, obligations relating to: processing health and other sensitive data; obtaining consent of individuals; providing notice to individuals regarding data processing activities; responding to data subject requests; taking certain measures when engaging third-party processors; notifying data subjects and regulators of data breaches; implementing safeguards to protect the security and confidentiality of personal data; and transferring personal data to countries outside the EU, including the U.S. The GDPR imposes substantial fines for breaches of data protection requirements, which can be up to four percent of global revenue or 20 million euros, whichever is greater, and it also confers a private right of action on data subjects for breaches of data protection requirements. The GDPR and other changes in laws or regulations associated with the enhanced protection of certain types of sensitive data, such as EU regulations governing clinical trial data and other healthcare data, could require us to change our business practices or lead to government enforcement actions, private litigation or significant penalties against us and could have a material adverse effect on our business, financial condition or results of operations.
Additionally, the California Consumer Privacy Act, or CCPA, which went into effect in 2020, created new individual privacy rights for California consumers (as that word is broadly defined in the law) and places increased privacy and security obligations on entities handling personal data of consumers or households. For example, the
48

CCPA requires covered companies to provide additional disclosures to California consumers, and provides such consumers with new rights, such as the ability to opt out of certain disclosures of personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. The CCPA may increase our compliance costs and potential liability. Some observers have noted that the CCPA could mark the beginning of a trend toward more stringent privacy legislation in the U.S., which could increase our potential liability and adversely affect our business.
Item 1B. Unresolved Staff Comments
None.
Item 2. Properties
We lease our corporate headquarters, which are located in San Diego, California, and consist of 141 thousand square feet of laboratory and office space located at 12780 El Camino Real, 88 thousand square feet of office space located at 12790 El Camino Real, 46 thousand square feet of laboratory space located at 10420 Wateridge Circle, and 45 thousand square feet of office space located at 12777 High Bluff Drive.
We believe that our property and equipment are generally well maintained, in good operating condition, and suitable for the conduct of our business.
Item 3. Legal Proceedings
From time to time in the normal course of business, we may be subject to various legal matters such as threatened or pending claims or proceedings. We are not currently a party to any material legal proceedings or claims, nor are we aware of any pending or threatened litigation or claims that could have a material adverse effect on our business, operating results, cash flows or financial condition should such litigation or claim be resolved unfavorably.
Item 4. Mine Safety Disclosures
None.
49

PART II
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
Our common stock is traded on the Nasdaq Global Select Market under the symbol “NBIX”.
At January 29, 2021, there were approximately 47 stockholders of record of our common stock. We have not paid any cash dividends on our common stock since inception and do not anticipate paying cash dividends in the foreseeable future.
Information about our equity compensation plans is incorporated herein by reference to Item 12 of Part III of this Annual Report on Form 10-K.
Recent Sales of Unregistered Securities and Issuer Purchases of Equity Securities
There were no unregistered sales of our equity securities during 2020. In addition, we did not repurchase any of our equity securities during 2020.
Stock Performance Graph and Cumulative Total Return*
The graph below shows the cumulative total stockholder return assuming the investment of $100 on December 31, 2015 (and the reinvestment of dividends thereafter) in each of (i) Neurocrine Biosciences, Inc.’s common stock, (ii) the Nasdaq Composite Index and (iii) the Nasdaq Biotechnology Index. The comparisons in the graph below are based upon historical data and are not indicative of, or intended to forecast, future performance of our common stock or Indexes.
nbix-20201231_g3.jpg
* The material in this section is not “soliciting material”, is not deemed “filed” with the Securities and Exchange Commission, or SEC, and is not to be incorporated by reference into any of our SEC filings whether made before or after the date hereof and irrespective of any general incorporation language in any such SEC filing except to the extent we specifically incorporate this section by reference.
50

Item 6. Selected Financial Data
The following selected financial data have been derived from our audited financial statements. The information set forth below is not necessarily indicative of our results of future operations and should be read in conjunction with “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and the financial statements and notes thereto appearing elsewhere in this Annual Report on Form 10-K.
(in millions, except per share data)20202019201820172016
Consolidated Statements of Operations Data
Revenues:     
Product sales, net$994.1 $752.9 $409.6 $116.6 $— 
Collaboration revenue51.8 35.2 41.6 45.0 15.0 
Total revenues1,045.9 788.1 451.2 161.6 15.0 
Operating expenses: 
Cost of sales10.1 7.4 4.9 1.3 — 
Research and development275.0 200.0 155.8 91.8 94.3 
Acquired in-process research and development164.5 154.3 4.8 30.0 — 
Selling, general and administrative433.3 354.1 248.9 169.9 68.1 
Total operating expenses882.9 715.8 414.4 293.0 162.4 
Operating income (loss)163.0 72.3 36.8 (131.4)(147.4)
Other (expense) income: 
Interest expense(32.8)(32.0)(30.5)(19.5)— 
Unrealized loss on restricted equity securities(17.7)(13.0)— — — 
Loss on extinguishment of convertible senior notes(18.4)— — — — 
Investment income and other, net12.6 19.2 15.5 8.3 6.3 
Total other (expense) income, net(56.3)(25.8)(15.0)(11.2)6.3 
Income (loss) before (benefit from) provision for income taxes106.7 46.5 21.8 (142.5)(141.1)
(Benefit from) provision for income taxes(300.6)9.5 0.7 — — 
Net income (loss)$407.3 $37.0 $21.1 $(142.5)$(141.1)
Net income (loss) per share, basic$4.38 $0.40 $0.23 $(1.62)$(1.63)
Net income (loss) per share, diluted$4.16 $0.39 $0.22 $(1.62)$(1.63)
Weighted average common shares outstanding:
Basic93.1 91.6 90.2 88.1 86.7 
Diluted97.8 95.7 95.4 88.1 86.7 
 
Consolidated Balance Sheets Data 
Cash, cash equivalents and debt securities available-for-sale$1,028.1 $970.2 $866.9 $763.3 $350.8 
Working capital
$829.7 $265.7 $649.5 $500.5 $280.0 
Total assets$1,734.7 $1,306.0 $993.2 $817.6 $365.1 
Convertible senior notes$317.9 $408.8 $388.5 $369.6 $— 
Accumulated deficit$(725.4)$(1,132.7)$(1,177.8)$(1,198.9)$(1,056.3)
Total stockholders’ equity$1,126.2 $636.9 $480.8 $372.1 $314.9 
51

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following Management’s Discussion and Analysis of Financial Condition and Results of Operations section contains forward-looking statements pertaining to, among other things, the commercialization of our product and product candidates, the expected continuation of our collaborative agreements, the receipt of research and development payments thereunder, the future achievement of various milestones in product development and the receipt of payments related thereto, the potential receipt of royalty payments, preclinical testing and clinical trials of potential products, the period of time that our existing capital resources will meet our funding requirements, and our financial results of operations. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various risks and uncertainties, including those set forth in this Annual Report on Form 10-K under the heading “Item 1A. Risk Factors.” See “Forward-Looking Statements” in Part I of this Annual Report on Form 10-K.
Overview
We are a neuroscience-focused, biopharmaceutical company dedicated to discovering, developing and delivering life-changing treatments for people with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. Our diverse portfolio includes United States Food and Drug Administration, or FDA, approved treatments for tardive dyskinesia, Parkinson’s disease, endometriosis*, uterine fibroids* and clinical programs in multiple therapeutic areas. For nearly three decades, we have specialized in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems. (*in collaboration with AbbVie Inc.)
We launched INGREZZA® (valbenazine) in the U.S. with our specialty sales force in May 2017, after receiving FDA approval for INGREZZA as the first FDA-approved drug for the treatment of tardive dyskinesia in April 2017. In September 2020, we launched ONGENTYS® (opicapone) in the U.S. leveraging our existing INGREZZA commercial infrastructure after receiving FDA approval for ONGENTYS for Parkinson's disease in April 2020. INGREZZA net product sales represent the significant majority of our total net product sales.
Our partner AbbVie Inc., or AbbVie, launched ORILISSA® (elagolix) in the U.S. and Canada in August and November 2018, respectively, after receiving FDA and Health Canada approval for ORILISSA for endometriosis in July and October 2018, respectively. In June 2020, AbbVie launched ORIAHNNTM (elagolix, estradiol, and norethindrone acetate; elagolix) in the U.S. after receiving FDA approval for ORIAHNN for uterine fibroids in May 2020. We receive royalties at tiered percentage rates on any net sales of ORILISSA and ORIAHNN.
In addition, we have a rapidly expanding pipeline of potential treatments and gene therapies for diseases such as Huntington’s disease, or HD, Parkinson’s disease, epilepsy, congenital adrenal hyperplasia, or CAH, schizophrenia and depression. Refer to Part I, Item 1, “Business” for more information about our exclusive and partnered commercial products, clinical development pipeline and research programs.
Highlights:
•INGREZZA net product sales for 2020 increased $240.2 million, or 31.9%, to $993.1 million, primarily reflecting strong refill and persistency rates for existing INGREZZA patients.
•We launched ONGENTYS in the U.S. in September 2020, after receiving FDA approval for ONGENTYS as an adjunctive therapy to levodopa/DOPA decarboxylase inhibitors in adult Parkinson's disease patients in April 2020.
•AbbVie launched ORIAHNN in the U.S. in June 2020, after receiving FDA approval for ORIAHNN as the first FDA-approved non-surgical, oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women in May 2020. We recognized a $30.0 million event-based milestone as revenue in the second quarter of 2020.
•Completed strategic partnerships with Idorsia Pharmaceuticals Ltd, or Idorsia, and Takeda Pharmaceutical Company Limited, or Takeda, to expand clinical pipeline for epilepsy and psychiatry disorders. Recognized
52

in-process research and development, or IPR&D, expense for 2020 of $164.5 million, related to upfront payments.
•Total debt outstanding decreased by $136.2 million to $381.3 million after repurchase of approximately 26% of our debt outstanding in December 2020. The total aggregate repurchase price of $186.9 million was paid in cash and resulted in an $18.4 million loss.
•At December 31, 2020, in part because we achieved three years of cumulative pretax income, management determined that there is sufficient positive evidence to conclude that it is more likely than not that deferred tax assets of $319.4 million are realizable. We therefore reduced the valuation allowance accordingly.
Pipeline Highlights:
•Crinecerfont (NBI-74788): In July 2020, we initiated the CAHtalyst study, a global registrational Phase III, randomized, double-blind, placebo-controlled clinical study to evaluate the safety and efficacy of crinecerfont in 165 adult patients with classic CAH, followed by an open-label treatment period.
•NBI-827104 (ACT-709478): In November 2020, we initiated a Phase II clinical study for NBI-827104 in a rare pediatric epileptic encephalopathy known as Continuous Spike and Wave During Sleep.
•INGREZZA: In February 2021, Mitsubishi Tanabe Pharmaceutical Company, or MTPC, reported positive top-line results from the J-KINECT Phase III study, designed to evaluate the efficacy and safety of valbenazine in tardive dyskinesia. Detailed results from this trial will be presented at a future medical conference. With positive data in hand, a marketing authorization with the Ministry of Health and Welfare is planned for 2021 in Japan. In addition, MTPC submitted filings for marketing authorizations in South Korea, Thailand, Singapore, Indonesia, and Malaysia in 2020.
•NBIb-1817 (VY-AADC): On February 2, 2021, we notified Voyager Therapeutics, Inc., or Voyager, of our termination of the NBIb-1817 for Parkinson’s disease program. The effective date of this termination will be August 2, 2021. The termination does not apply to any other development program other than NBIb-1817 for Parkinson’s disease, and our collaboration and license agreement with Voyager will otherwise continue in effect.
COVID-19
The global COVID-19 pandemic has dramatically changed the ways in which we live and interact with one another. While we adapt to this new shared reality, our mission remains unchanged: to discover and develop life-changing treatments for people with serious, challenging and under-addressed disorders.
While we are unable to reliably estimate the duration or extent of any potential business disruption or financial impact during this time, including any impacts on INGREZZA product sales or R&D expense, we remain committed to (1) prioritizing the safety, health and well-being of patients, their caregivers, healthcare providers and our employees; (2) ensuring patients with tardive dyskinesia are well supported and have continued uninterrupted access to INGREZZA, for which we currently do not expect any supply disruption; and (3) advancing ongoing clinical studies. As part of this commitment, we implemented a “Work from Home Policy” in early March 2020 for employees not involved in business-critical activities. For employees involved in business-critical activities, we implemented safety measures designed to comply with federal, state and local guidelines.
Due to the impact of COVID-19, we initially paused enrollment of new patients in several of our clinical trials. Beginning in the third quarter of 2020, we began enrolling patients in our HD and CAH studies. To date, we have not experienced any interruption of our supply of drug products needed to support our ongoing clinical studies, but we expect that completion and data readouts for several of our ongoing and planned studies will be delayed.
We continue to believe that existing funds, cash generated from operations, and existing sources of and access to financing are adequate to satisfy our needs for working capital, capital expenditures, debt service requirements and other business development initiatives that we plan to strategically pursue. However, should the COVID-19 pandemic and any associated recession or depression continue for a prolonged period, our results of operations, financial condition, liquidity and cash flows could be materially impacted by lower revenues and profitability and a lower likelihood of effectively and efficiently developing new medicines.
53

Results of Operations
Revenues
The following table presents revenues by category.
 Year Ended December 31,
(in millions)202020192018
INGREZZA product sales, net$993.1 $752.9 $409.6 
ONGENTYS product sales, net1.0 — — 
Collaboration revenues51.8 35.2 41.6 
Total revenues$1,045.9 $788.1 $451.2 
Product Sales, net. Net product sales were $994.1 million for 2020, $752.9 million for 2019 and $409.6 million for 2018.
Collaboration Revenues. Collaboration revenues reflect the achievement of certain event-based milestones, royalties earned at tiered percentage rates on any net sales of ORILISSA and ORIAHNN and license fees earned under our collaboration agreements with AbbVie and MTPC.
In the second quarter of 2020, we recognized a $30.0 million event-based milestone as revenue upon FDA-approval of AbbVie’s ORIAHNN for uterine fibroids. In the third quarter of 2019, we recognized a $20.0 million event-based milestone as revenue upon the FDA’s acceptance of AbbVie’s new drug application, or NDA, submission of elagolix for uterine fibroids. In the third quarter of 2018, we recognized a $40.0 million event-based milestone as revenue upon FDA-approval of AbbVie’s ORILISSA for the treatment of moderate to severe pain associated with endometriosis.
For ORILISSA and ORIAHNN, we recognized royalty revenue of $19.2 million for 2020, $14.3 million for 2019 and $1.6 million for 2018.
Operating Expenses
Cost of Sales. Cost of sales was $10.1 million for 2020, $7.4 million for 2019 and $4.9 million for 2018, primarily reflecting a higher annual volume of INGREZZA product sales since commercial launch in April 2017.
Research and Development. We support our drug discovery and development efforts through the commitment of significant resources to discovery, R&D programs and business development opportunities.
Costs are reflected in the applicable development stage based upon the program status when incurred. Therefore, the same program could be reflected in different development stages in the same reporting period. For several of our programs, the R&D activities are part of our collaborative and other relationships.
Late stage consists of costs incurred related to product candidates in Phase II registrational studies and onwards. Early stage consists of costs incurred related to product candidates in post-investigational new drug application, or IND, through Phase II non-registrational studies. Research and discovery consists of pre-IND costs. Milestone expenses reflect payments made in connection with our collaborative and other relationships. Payroll and benefits consists of costs incurred for salaries and wages, payroll taxes, benefits and share-based compensation associated with employees involved in ongoing R&D activities. Share-based compensation may fluctuate from period to period based on factors that are not within our control, such as our stock price on the dates share-based grants are issued. Facilities and other consists of indirect costs incurred in support of overall R&D activities and non-specific programs, including activities that benefit multiple programs, such as management costs, as well as depreciation, information technology and facility-based expenses. These costs are not allocated to a specific program or stage.
54

The following table presents R&D expense by category:
 Year Ended December 31,
(in millions)202020192018
Late stage$55.1 $43.7 $14.2 
Early stage30.2 25.3 41.7 
Research and discovery43.3 24.6 17.0 
Milestone payments20.0 10.0 10.0 
Payroll and benefits95.4 71.3 62.0 
Facilities and other31.0 25.1 10.9 
Total R&D expense$275.0 $200.0 $155.8 
R&D expense was $275.0 million for 2020, $200.0 million for 2019 and $155.8 million for 2018. The increase in R&D expense was primarily the result of increased investment to support advancing our expanded clinical portfolio and increased personnel expenses on higher headcount.
Acquired In-Process Research and Development. IPR&D expense was $164.5 million for 2020, $154.3 million for 2019 and $4.8 million for 2018. For 2020, we recorded IPR&D expense of $46.0 million and $118.5 million in connection with the payments of the upfront fees pursuant to our collaborations with Idorsia and Takeda, respectively. For 2019, we recorded IPR&D expense of $118.1 million and $36.2 million in connection with the payments of the upfront fees pursuant to our collaborations with Voyager and Xenon Pharmaceuticals, Inc., or Xenon. For 2018, we recorded IPR&D expense of $4.8 million in connection with payment of the upfront fee to Jnana to obtain access to Jnana’s proprietary drug discovery platform.
Selling, General and Administrative. Selling, general and administrative, or SG&A, expense was $433.3 million for 2020, $354.1 million for 2019 and $248.9 million for 2018. The increase in SG&A expense from 2019 to 2020 was primarily due to increased personnel expenses on higher headcount and continued investment in INGREZZA marketing. The increase in SG&A expense from 2018 to 2019 was primarily due to the sales force expansion completed in the third quarter of 2018, the national launch of a patient-focused disease state awareness campaign, Talk About TD, and an increase in the Branded Pharmaceutical Drug Fee expense.
Other Expense
Other expense, net, was $56.3 million for 2020, $25.8 million for 2019 and $15.0 million for 2018. Periodic fluctuations in other expense, net, primarily reflect unrealized losses recognized to adjust our equity investments in Voyager and Xenon Pharmaceuticals Inc. to fair value. For 2020, other expense, net, also reflects an $18.4 million loss on debt extinguishment recognized for the partial repurchase of the 2024 Notes in November 2020.
(Benefit from) Provision for Income Taxes
Our benefit from income taxes was $300.6 million for 2020, compared to a provision for income taxes of $9.5 million for 2019 and $0.7 million for 2018. The benefit from income taxes for 2020 included a $296.3 million benefit related to the release of substantially all of our valuation allowance against our deferred tax assets on December 31, 2020. The decision to release the valuation allowance was made after we determined that it was more likely than not the deferred tax assets, including net operating losses and tax credits, would be realized, and was based on the evaluation and weighting of both positive and negative evidence, such as our achievement of a cumulative three-year income position at December 31, 2020, as well as our consideration of forecasts of future operating results and utilization of net operating losses and tax credits prior to their expiration. The provision for income taxes for 2019 and 2018 reflected estimated current state income taxes for both periods. At December 31, 2019 and 2018, we had full valuation allowances against our net deferred tax assets as realization was uncertain. Our tax expense for 2020, 2019 and 2018 varied from the statutory tax rate primarily due to changes in our valuation allowances, net of other permanent book/tax differences, tax credits generated and impacts of changes in tax laws.
Net Income
Net income was $407.3 million, or $4.16 diluted earnings per share, for 2020, $37.0 million, or $0.39 diluted earnings per share, for 2019 and $21.1 million, or $0.22 diluted earnings per share, for 2018. The change from 2019
55

to 2020 was primarily the result of increased INGREZZA net product sales and a non-cash tax benefit of $296.3 million related to the release of substantially all of our valuation allowance against our deferred tax assets on December 31, 2020, offset by $164.5 million of IPR&D in connection with our collaborations with Idorsia and Takeda, ongoing support for the commercial launch of INGREZZA for tardive dyskinesia and progression of our clinical pipeline. The change from 2018 to 2019 was primarily the result of increased INGREZZA net product sales, offset by $154.3 million of IPR&D in connection with our collaborations with Voyager and Xenon, ongoing support for the commercial launch of INGREZZA for tardive dyskinesia and progression of our clinical pipeline.
Liquidity and Capital Resources
Cash, cash equivalents and debt securities available-for-sale totaled $1.0 billion and $970.2 million at December 31, 2020 and 2019, respectively.
Net cash provided by operating activities was $228.5 million for 2020, $147.0 million for 2019 and $101.4 million for 2018. The increase in positive cash flow from 2019 to 2020 was primarily due to increased INGREZZA net product sales partially offset by incremental INGREZZA investment and progression of our clinical pipeline. The increase in positive cash flow from 2018 to 2019 was primarily due to increased INGREZZA net product sales, partially offset by incremental INGREZZA investment and upfront payments of $154.3 million in connection with our collaborations with Voyager and Xenon.
Net cash provided by investing activities was $4.1 million for 2020, compared with net cash used in investing activities of $211.1 million for 2019 and $242.9 million for 2018. Periodic fluctuations in cash flows from investing activities primarily reflect timing differences in purchases, sales and maturities of debt securities available-for-sale and changes in our portfolio-mix. Net cash used in investing activities for 2019 also reflects equity investments of $54.7 million in Voyager and $14.2 million in Xenon.
Net cash used in financing activities was $157.8 million for 2020, primarily reflecting our repurchase of $136.2 million aggregate principal amount of the 2024 Notes for an aggregate repurchase price of $186.9 million in cash in November 2020, compared to net cash provided by financing activities of $32.4 million for 2019 and $29.5 million in 2018. For 2019 and 2018, periodic fluctuations in cash flows from financing activities reflect proceeds from issuances of our common stock.
Shelf Registration Statement. In February 2017, we filed an automatic shelf registration statement which immediately became effective by rule of the Securities and Exchange Commission, or SEC. We sold no securities under this shelf registration statement in 2020, 2019 or 2018.
Convertible Senior Notes. In May 2017, we completed a private placement of $517.5 million in aggregate principal amount of 2.25% convertible senior notes scheduled to mature on May 15, 2024, unless earlier converted, redeemed, or repurchased. We may not redeem the 2024 Notes prior to May 15, 2021. On or after this date, at our election, we may redeem all, or any portion, of the 2024 Notes under certain circumstances. The 2024 Notes do not contain any financial or operating covenants or any restrictions on the payment of dividends, the issuance of other indebtedness or the issuance or repurchase of securities by us. There are customary events of default with respect to the 2024 Notes, including that upon certain events of default, 100% of the principal and accrued and unpaid interest on the 2024 Notes will automatically become due and payable. Amounts for the 2024 Notes and related interest in the table above assume that the 2024 Notes will be held until maturity. In November 2020, we entered into separate, privately negotiated transactions with certain holders of the 2024 Notes to repurchase $136.2 million aggregate principal amount of the 2024 Notes for an aggregate repurchase price of $186.9 million in cash. At December 31, 2020, $381.3 million aggregate principal amount of the 2024 Notes remained outstanding.
Critical Accounting Policies and Estimates
Our discussion and analysis of our financial condition and results of operations is based upon financial statements that we have prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP. The preparation of these financial statements requires management to make estimates and judgments that affect the reported amounts of assets, liabilities and expenses, and related disclosures. On an on-going basis, we evaluate these estimates, including those related to revenue recognition and share-based compensation. Estimates are based on historical experience, information received from third parties and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about
56

the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. Historically, revisions to our estimates have not resulted in a material change to the financial statements. The items in our financial statements requiring significant estimates and judgments are as follows:
Product Sales, Net. Revenues from product sales are recorded net of reserves established for applicable discounts and allowances that are offered within contracts with our customers, payors and other third parties. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which could have an effect on earnings in the period of adjustment.
Government Rebates. We are obligated to pay rebates for mandated discounts under the Medicaid Drug Rebate Program. The liability for such rebates consists of invoices received for claims from prior quarters that remain unpaid, or for which an invoice has not been received, and estimated rebates for the current applicable reporting period, which are primarily based on actual historical rebates, estimated payor mix, state and federal regulations and related contractual terms. Estimated rebates are recorded as a reduction of revenue in the period the related sale is recognized. To date, actual government rebates have not differed materially from our estimates.
Share-Based Compensation. For purposes of calculating share-based compensation, we estimate the fair value of share-based compensation awards using a Black-Scholes option-pricing model. The determination of the fair value of share-based compensation awards utilizing the Black-Scholes model is affected by our stock price and a number of assumptions, including but not limited to expected stock price volatility over the term of the awards and the expected term of stock options. Our stock options have characteristics significantly different from those of traded options, and changes in the assumptions can materially affect the fair value estimates. For example, an increase in the underlying stock price results in a significant increase in the Black-Scholes option-pricing. The fair value of performance-based restricted stock units, or PRSUs, is estimated based on the closing sale price of our common stock on the date of grant. Expense recognition for PRSUs commences when attainment of the associated performance-based criteria is determined to be probable.
If factors change and we employ different assumptions, share-based compensation expense may differ significantly from what we have recorded in the past. If there is a difference between the assumptions used in determining share-based compensation expense and the actual factors which become known over time, we may change the input factors used in determining share-based compensation expense for future grants. These changes, if any, may materially impact our results of operations in the period such changes are made. For actual forfeitures, we recognize the adjustment to compensation expense in the period the forfeitures occur.
Income Taxes. Our income tax benefit (provision) is computed under the asset and liability method. Significant estimates are required in determining our income tax benefit (provision). Some of these estimates are based on interpretations of existing tax laws or regulations. We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (temporary differences) at enacted tax rates in effect for the years in which the differences are expected to reverse. A valuation allowance is established for deferred tax assets for which it is more likely than not that some portion or all of the deferred tax assets, including net operating losses and tax credits, will not be realized. We periodically re-assess the need for a valuation allowance against our deferred tax assets based on various factors including our historical earnings experience by taxing jurisdiction, and forecasts of future operating results and utilization of net operating losses and tax credits prior to their expiration. Significant judgment is required in making this assessment and, to the extent that a reversal of any portion of our valuation allowance against our deferred tax assets is deemed appropriate, a tax benefit will be recognized against our income tax provision in the period of such reversal. Prior to 2020, we recorded a valuation allowance that fully offset our deferred tax assets. On December 31, 2020, based on our evaluation of various factors, such as our achievement of a cumulative three-year income position as of December 31, 2020, as well as our consideration of forecasts of future operating results and utilization of net operating losses and tax credits prior to their expiration, we released substantially all of our valuation allowance against our deferred tax assets and recorded
57

a corresponding income tax benefit. We continue to maintain a valuation allowance against our California state deferred tax assets.
Additional Information
Refer to Note 1 to the consolidated financial statements for information on accounting pronouncements that have impacted or are expected to materially impact our consolidated financial condition, results of operations, or cash flows.
Factors That May Affect Future Financial Condition and Liquidity
The funding necessary to execute our business strategies is subject to numerous uncertainties, which may adversely affect our liquidity and capital resources. Marketing of approved pharmaceuticals and completion of clinical trials may take several years or more, but the length of time generally varies substantially according to the type, complexity, novelty and intended use of a product candidate. It is also important to note that if a clinical candidate is identified, the further development of that candidate can be halted or abandoned at any time due to a number of factors. These factors include, but are not limited to, funding constraints, safety or a change in market demand.
The nature and efforts required to develop our product candidates into commercially viable products include research to identify a clinical candidate, preclinical development, clinical testing, FDA approval and commercialization. In the pharmaceutical industry, total R&D spend for a drug candidate that successfully completes all stages of R&D and is commercialized may exceed $2 billion. Further, it can take in excess of ten years to complete all stages of R&D for a drug candidate.
We test our potential product candidates in numerous preclinical studies to identify disease indications for which our product candidates may show efficacy. We may conduct multiple clinical trials to cover a variety of indications for each product candidate. As we obtain results from trials, we may elect to discontinue clinical trials for certain product candidates or for certain indications in order to focus our resources on more promising product candidates or indications. The duration and the cost of clinical trials may vary significantly over the life of a project as a result of differences arising during the clinical trial protocol, including, among others, the following:
•we or the FDA or similar foreign regulatory authorities may suspend the trials;
•we may discover that a product candidate may cause harmful side effects;
•patient recruitment and enrollment may be slower or more difficult than expected; and
•patients may drop out of the trials.
For each of our programs, we periodically assess the scientific progress and merits of the programs to determine if continued R&D is economically viable. Certain of our programs have been terminated due to the lack of scientific progress and lack of prospects for ultimate commercialization. Because of the uncertainties associated with R&D of these programs, we may not be successful in achieving commercialization. As such, the ultimate timeline and costs to commercialize a product cannot be accurately estimated.
Our in-license, research and clinical development agreements are generally cancellable with written notice within 180 days or less. We may be required to pay up to $8.5 billion in milestone payments, plus sales royalties, in the event that all scientific research, development and commercialization milestones under these agreements are achieved.
Other than INGREZZA, which has been FDA-approved for the treatment of tardive dyskinesia; ONGENTYS, which has been FDA-approved as an adjunctive therapy to levodopa/DOPA decarboxylase inhibitors in adult Parkinson’s disease patients; ORILISSA (partnered with AbbVie), which has been FDA-approved for the management of moderate to severe endometriosis pain in women; and ORIAHNN (partnered with AbbVie), which has been FDA-approved for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women, our product candidates have not yet achieved FDA regulatory approval, which is required before we can market them as therapeutic products in the U.S. In order to proceed to subsequent clinical trial stages and to ultimately achieve regulatory approval, the FDA must conclude that our clinical data establish safety and efficacy. We must satisfy the requirements of similar regulatory authorities in foreign countries in order to market products in those countries. The results from preclinical testing and early clinical trials may not be predictive of results in later
58

clinical trials. It is possible for a candidate to show promising results in clinical trials, but subsequently fail to establish sufficient safety and efficacy data necessary to obtain regulatory approvals.
As a result of the uncertainties discussed above, among others, the duration and completion costs of our R&D projects, clinical trials, and post-marketing studies are difficult to estimate and are subject to considerable variation. Our inability to complete our R&D projects in a timely manner or our failure to enter into collaborative agreements, when appropriate, could significantly increase our capital requirements and could adversely impact our liquidity. These uncertainties could force us to seek additional, external sources of financing from time to time in order to continue with our business strategy. Our inability to raise additional capital, or to do so on terms reasonably acceptable to us, would jeopardize the future success of our business.
We currently have limited experience in marketing and selling pharmaceutical products. If we fail to maintain successful marketing, sales, and reimbursement capabilities, or fail to enter into successful arrangements with third parties, our product revenues may suffer. We also may be required to make further substantial expenditures if unforeseen difficulties arise in other areas of our business. In particular, our future capital requirements will depend on many factors, including:
•the commercial success of INGREZZA, ONGENTYS, ORILISSA, and/or ORIAHNN;
•debt service obligations on the 2024 Notes;
•continued scientific progress in our R&D and clinical development programs;
•the magnitude and complexity of our research and development programs;
•progress with preclinical testing and clinical trials;
•the time and costs involved in obtaining regulatory approvals;
•the costs involved in filing and pursuing patent applications, enforcing patent claims, or engaging in interference proceedings or other patent litigation;
•competing technological and market developments;
•the establishment of additional strategic alliances;
•developments related to any future litigation;
•the impact of the COVID-19 pandemic on our business;
•the cost of commercialization activities and arrangements, including manufacturing of our product candidates; and
•the cost of product in-licensing and any possible acquisitions.
We believe that our existing capital resources, funds generated by anticipated INGREZZA net product sales and investment income will be sufficient to satisfy our current and projected funding requirements for at least the next twelve months. However, we cannot guarantee that our existing capital resources and anticipated revenues will be sufficient to conduct and complete all of our research and development programs or commercialization activities as planned.
The spread of COVID-19, which has caused a broad impact globally, may materially affect us economically. While the potential economic impact brought by, and the duration of, the COVID-19 pandemic may be difficult to assess or predict, the pandemic is currently resulting in disruption of global financial markets. This disruption, if sustained or recurrent, could make it more difficult for us to access capital, which could in the future negatively affect our liquidity. In addition, a recession or market correction resulting from the spread of COVID-19 could materially affect our business and the value of our common stock.
We may require additional funding to continue our research and product development programs, to conduct preclinical studies and clinical trials, for operating expenses, to pursue regulatory approvals for our product candidates, for the costs involved in filing and prosecuting patent applications and enforcing or defending patent claims, if any, the cost of product in-licensing and any possible acquisitions, and we may require additional funding to establish manufacturing and marketing capabilities in the future. We may seek to access the public or private
59

equity markets whenever conditions are favorable. For example, we have an effective shelf registration statement on file with the SEC which allows us to issue an unlimited number of shares of our securities from time to time. In addition, we issued $517.5 million of convertible debt in May 2017 and we have previously financed capital purchases and may continue to pursue opportunities to obtain additional debt financing in the future. In November 2020, we entered into separate, privately negotiated transactions with certain holders of the 2024 Notes to repurchase $136.2 million aggregate principal amount of the 2024 Notes for an aggregate repurchase price of $186.9 million in cash. At December 31, 2020, $381.3 million aggregate principal amount of the 2024 Notes remained outstanding. We may also seek additional funding through strategic alliances or other financing mechanisms. We cannot assure you that adequate funding will be available on terms acceptable to us, if at all. In addition, COVID-19 pandemic is currently resulting in disruption of global financial markets. This disruption, if sustained or recurrent, could make it more difficult for us to access capital, which could in the future negatively affect our liquidity. Any additional equity financings will be dilutive to our stockholders and any additional debt may involve operating covenants that may restrict our business. If adequate funds are not available through these means, we may be required to curtail significantly one or more of our research or development programs or obtain funds through arrangements with collaborators or others. This may require us to relinquish rights to certain of our technologies, products or product candidates. To the extent that we are unable to obtain third-party funding for such expenses, we expect that increased expenses will result in increased cash flow losses from operations. We cannot assure you that we will successfully develop our products under development or that our approved products will generate revenues sufficient to enable us to earn a profit.
Contractual Obligations
The following table presents our contractual obligations at December 31, 2020.
(in millions)Total20212022202320242025 and
Thereafter
2024 Notes and related interest (1)
$411.5 $8.7 $8.6 $8.6 $385.6 $— 
Operating leases (2)
159.6 12.3 14.9 15.5 16.0 100.9 
Total contractual obligations$571.1 $21.0 $23.5 $24.1 $401.6 $100.9 
(1) In May 2017, we completed a private placement of $517.5 million in aggregate principal amount of 2.25% convertible senior notes scheduled to mature on May 15, 2024, unless earlier converted, redeemed, or repurchased. We may not redeem the 2024 Notes prior to May 15, 2021. On or after this date, at our election, we may redeem all, or any portion, of the 2024 Notes under certain circumstances. The 2024 Notes do not contain any financial or operating covenants or any restrictions on the payment of dividends, the issuance of other indebtedness or the issuance or repurchase of securities by us. There are customary events of default with respect to the 2024 Notes, including that upon certain events of default, 100% of the principal and accrued and unpaid interest on the 2024 Notes will automatically become due and payable. Amounts for the 2024 Notes and related interest in the table above assume that the 2024 Notes will be held until maturity. In November 2020, we entered into separate, privately negotiated transactions with certain holders of the 2024 Notes to repurchase $136.2 million aggregate principal amount of the 2024 Notes for an aggregate repurchase price of $186.9 million in cash. At December 31, 2020, $381.3 million aggregate principal amount of the 2024 Notes remained outstanding.
(2) We lease our corporate headquarters, which consist of laboratory and office space located San Diego, California, under various operating lease agreements. In addition to minimum rental commitments, these operating leases may require us to pay additional amounts for taxes, insurance, maintenance and other operating expenses. The non-cancelable lease terms for these operating leases expire at various dates between 2025 and 2031 and do not include renewal options. Amounts for operating leases presented in the table above reflect future minimum rental commitments under non-cancelable operating leases as of December 31 for each of the periods presented.

60

Item 7A. Quantitative and Qualitative Disclosures About Market Risk
Interest Rate Risk
We are exposed to interest rate risk on our short-term investments. The primary objective of our investment activities is to preserve principal while at the same time maximizing yields without significantly increasing risk. To achieve this objective, we invest in highly liquid and high-quality government and other debt securities. To minimize our exposure due to adverse shifts in interest rates, we invest in short-term securities and ensure that the maximum average maturity of our investments does not exceed twelve months. If a 1% change in interest rates were to have occurred on December 31, 2020, this change would not have had a material effect on the fair value of our investment portfolio as of that date. Due to the short holding period of our investments, we have concluded that we do not have a material financial market risk exposure.
61

Item 8. Financial Statements and Supplementary Data
NEUROCRINE BIOSCIENCES, INC.
INDEX TO THE CONSOLIDATED FINANCIAL STATEMENTS

62

Report of Independent Registered Public Accounting Firm
To the Shareholders and the Board of Directors of Neurocrine Biosciences, Inc.
Opinion on the Financial Statements
We have audited the accompanying consolidated balance sheets of Neurocrine Biosciences, Inc. (the “Company”) as of December 31, 2020 and 2019, the related consolidated statements of income and comprehensive income, stockholders’ equity, and cash flows for each of the three years in the period ended December 31, 2020, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2020 and 2019, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2020, in conformity with U.S. generally accepted accounting principles.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company’s internal control over financial reporting as of December 31, 2020, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework), and our report dated February 5, 2021 expressed an unqualified opinion thereon.
Adoption of New Accounting Standard
ASU No. 2016-02
As discussed in Note 1 to the consolidated financial statements, the Company changed its method of accounting for leases effective January 1, 2019, due to the adoption of Accounting Standards Update (ASU) No. 2016-02, Leases (Topic 842), and the related amendments.
Basis for Opinion
These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.
Critical Audit Matters
The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below providing a separate opinion on the critical audit matter or on the account or disclosure to which it relates.
63

Reserves for government rebates related to product sales
Description of the Matter
The Company sells drugs to specialty pharmacies and specialty distributors in the U.S. (collectively, “customers”). As described in Note 1 to the consolidated financial statements, the Company recognizes revenues for sales of INGREZZA to its customers after deducting management’s estimates of reserves, including drug coverage gap rebates, it will provide under government rebate programs (“government rebates”). Estimated government rebates are presented within accounts payable and accrued liabilities on the consolidated balance sheets.
Auditing the estimates of government rebates was complex and judgmental due to the level of uncertainty involved in management’s assumptions used in the measurement process. In particular, management was required to estimate, for product that remains in the distribution channel at December 31, 2020, the portion of product that is expected to be subject to a government rebate and the applicable contractual government rebate percentage by forecasting the revenue, the payor type underlying the revenue and the applicable rebate amount for the payor type.
How We Addressed the Matter in Our Audit
We tested the Company’s internal controls over management’s process for estimating the portion of product that is expected to be subject to a government rebate for product that remains in the distribution channel at December 31, 2020, including controls over management’s forecast of revenue and the accuracy of data used in the calculation.
To test management’s estimate of government rebate reserves our audit procedures included, among others, evaluating the methodologies used, testing the significant assumptions discussed above and testing the completeness and accuracy of the underlying data used by the Company in its analyses. Specifically, we compared the significant assumptions to third-party reports used by the Company to estimate product remaining in the distribution channel at December 31, 2020. In addition, we compared the underlying government rebate percentages used in the Company’s analyses to those published by the applicable government entity. We assessed the historical accuracy of management’s rebate estimates, tested payments of rebates and performed a sensitivity analysis of significant assumptions to evaluate the changes in the rebate allowance that would result from changes in the assumptions.
/s/ Ernst & Young LLP
We have served as the Company’s auditor since 1992.
San Diego, California
February 5, 2021
64

NEUROCRINE BIOSCIENCES, INC.
CONSOLIDATED BALANCE SHEETS
 December 31,
(in millions, except per share data)20202019
Assets
Current assets:
Cash and cash equivalents$187.1 $112.3 
Debt securities available-for-sale (amortized cost $612.4 million at December 31, 2020 and $557.3 million at December 31, 2019)
613.9 558.2 
Accounts receivable157.1 126.6 
Inventories28.0 17.3 
Other current assets30.1 16.6 
Total current assets1,016.2 831.0 
Debt securities available-for-sale (amortized cost $226.7 million at December 31, 2020 and $299.3 million at December 31, 2019)
227.1 299.7 
Right-of-use assets82.8 74.3 
Equity securities38.2 55.9 
Property and equipment, net44.6 41.9 
Deferred tax assets319.4 — 
Restricted cash3.2 3.2 
Other long-term assets3.2 — 
Total assets$1,734.7 $1,306.0 
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable and accrued liabilities$168.7 $141.3 
Convertible senior notes— 408.8 
Other current liabilities17.8 15.2 
Total current liabilities186.5 565.3 
Convertible senior notes317.9 — 
Noncurrent operating lease liabilities94.4 86.7 
Other long-term liabilities9.7 17.1 
Total liabilities608.5 669.1 
Stockholders’ equity:
Preferred stock, $0.001 par value; 5.0 shares authorized; no shares issued and outstanding at December 31, 2020 and 2019
— — 
Common stock, $0.001 par value; 220.0 shares authorized; issued and outstanding shares were 93.5 million and 92.3 million at December 31, 2020 and 2019, respectively
0.1 0.1 
Additional paid-in capital1,849.7 1,768.1 
Accumulated other comprehensive income1.8 1.4 
Accumulated deficit(725.4)(1,132.7)
Total stockholders’ equity1,126.2 636.9 
Total liabilities and stockholders’ equity$1,734.7 $1,306.0 
See accompanying notes to consolidated financial statements.
65

NEUROCRINE BIOSCIENCES, INC.
CONSOLIDATED STATEMENTS INCOME
AND COMPREHENSIVE INCOME
Year Ended December 31,
(in millions, except per share data)202020192018
Revenues:
Product sales, net$994.1 $752.9 $409.6 
Collaboration revenue51.8 35.2 41.6 
Total revenues1,045.9 788.1 451.2 
Operating expenses:
Cost of sales10.1 7.4 4.9 
Research and development275.0 200.0 155.8 
Acquired in-process research and development164.5 154.3 4.8 
Selling, general and administrative433.3 354.1 248.9 
Total operating expenses882.9 715.8 414.4 
Operating income163.0 72.3 36.8 
Other (expense) income:
Interest expense(32.8)(32.0)(30.5)
Unrealized loss on restricted equity securities(17.7)(13.0)— 
Loss on extinguishment of convertible senior notes(18.4)— — 
Investment income and other, net12.6 19.2 15.5 
Total other expense, net(56.3)(25.8)(15.0)
Income before (benefit from) provision for income taxes106.7 46.5 21.8 
(Benefit from) provision for income taxes(300.6)9.5 0.7 
Net income407.3 37.0 21.1 
Unrealized gain (loss) on debt securities available-for-sale0.4 3.4 (0.1)
Comprehensive income$407.7 $40.4 $21.0 
Net income per share, basic$4.38 $0.40 $0.23 
Net income per share, diluted$4.16 $0.39 $0.22 
Weighted average common shares outstanding, basic93.1 91.6 90.2 
Weighted average common shares outstanding, diluted97.8 95.7 95.4 
See accompanying notes to consolidated financial statements.
66

NEUROCRINE BIOSCIENCES, INC.
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
Common StockAdditional
Paid-In Capital		Accumulated
Other
Comprehensive Income (Loss) 		Accumulated DeficitTotal Stockholders’ Equity
(in millions)Shares$
Balances at December 31, 201788.8 $0.1 $1,572.8 $(1.9)$(1,198.8)$372.2 
Net income— — — — 21.1 21.1 
Unrealized loss on debt securities available-for-sale— — — (0.1)—(0.1)
Share-based compensation expense— — 58.1 — —58.1 
Issuance of common stock for vested restricted stock units0.4 — — — —— 
Issuance of common stock for stock option exercises1.6 — 29.5 — —29.5 
Balances at December 31, 201890.8 $0.1 $1,660.4 $(2.0)$(1,177.7)$480.8 
Net income— — — — 37.0 37.0 
Unrealized gain on debt securities available-for sale— — — 3.4 — 3.4 
Share-based compensation expense— — 75.3 — — 75.3 
Cumulative-effect adjustment to equity due to adoption of ASU 2016-02— — — — 8.0 8.0 
Issuance of common stock for vested restricted stock units0.4 — — — — — 
Issuance of common stock for stock option exercises1.0 — 27.3 — — 27.3 
Issuance of common stock for employee stock purchase plan0.1 — 5.1 — — 5.1 
Balances at December 31, 201992.3 $0.1 $1,768.1 $1.4 $(1,132.7)$636.9 
Net income— — — — 407.3 407.3 
Unrealized gain on debt securities available-for-sale, net of tax— — — 0.4 — 0.4 
Share-based compensation expense— — 100.0 — — 100.0 
Equity component of repurchased convertible senior notes, net— — (47.5)— — (47.5)
Issuance of common stock for vested restricted stock units0.5 — — — — — 
Issuance of common stock for stock option exercises0.6 — 23.5 — — 23.5 
Issuance of common stock for employee stock purchase plan0.1 — 5.6 — — 5.6 
Balances at December 31, 202093.5 $0.1 $1,849.7 $1.8 $(725.4)$1,126.2 
See accompanying notes to consolidated financial statements.
67

NEUROCRINE BIOSCIENCES, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
Year Ended December 31,
(in millions)202020192018
Cash Flows from Operating Activities:
Net income$407.3 $37.0 $21.1 
Reconciliation of net income to net cash provided by operating activities:
Share-based compensation expense100.0 75.3 58.1 
Depreciation8.6 7.4 4.0 
Amortization of debt discount20.0 18.9 17.6 
Amortization of debt issuance costs1.4 1.4 1.3 
Change in fair value of equity securities17.7 13.0 — 
Deferred income taxes (including benefit from valuation allowance release)
(310.7)— — 
Loss on extinguishment of convertible senior notes18.4 — — 
Other3.7 (1.2)1.0 
Changes in operating assets and liabilities:
Accounts receivable(30.5)(69.2)(25.1)
Inventories(10.7)(6.4)(3.5)
Accounts payable and accrued liabilities26.9 54.0 24.2 
Other assets and liabilities, net(23.6)16.8 2.7 
Net cash provided by operating activities228.5 147.0 101.4 
Cash Flows from Investing Activities:
Purchases of debt securities available-for-sale(735.5)(797.2)(545.9)
Sales and maturities of debt securities available-for-sale750.5 669.7 327.8 
Purchases of equity securities— (68.9)— 
Purchases of property and equipment(10.9)(14.7)(24.8)
Net cash provided by (used in) investing activities4.1 (211.1)(242.9)
Cash Flows from Financing Activities:
Issuances of common stock under benefit plans29.1 32.4 29.5 
Partial repurchase of convertible senior notes(186.9)— — 
Net cash (used in) provided by financing activities(157.8)32.4 29.5 
Change in cash and cash equivalents and restricted cash74.8 (31.7)(112.0)
Cash and cash equivalents and restricted cash at beginning of period115.5 147.2 259.2 
Cash and cash equivalents and restricted cash at end of period$190.3 $115.5 $147.2 
Supplemental Disclosure:
Non-cash capital expenditures$1.4 $1.0 $2.3 
Right-of-use assets acquired through operating leases$12.8 $77.1 $— 
Cash paid for interest $11.6 $11.6 $11.6 
Cash paid for income taxes$15.3 $0.5 $— 
See accompanying notes to consolidated financial statements.
68

NEUROCRINE BIOSCIENCES, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
1. Organization and Summary of Significant Accounting Policies
Business Activities. Neurocrine Biosciences, Inc., or Neurocrine, the Company, we, our or us, was incorporated in California in 1992 and reincorporated in Delaware in 1996. Neurocrine Continental, Inc., is a Delaware corporation and a wholly owned subsidiary of Neurocrine. We also have two wholly-owned Irish subsidiaries, Neurocrine Therapeutics, Ltd. and Neurocrine Europe, Ltd. both of which were formed in December 2014 and are inactive.
We are a neuroscience-focused biopharmaceutical company dedicated to discovering, developing and delivering life-changing treatments for patients with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. Our diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson’s disease, endometriosis*, uterine fibroids* and clinical programs in multiple therapeutic areas. For nearly three decades, we specialize in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems. (*in collaboration with AbbVie Inc.)
Principles of Consolidation. The consolidated financial statements include the accounts of Neurocrine as well as our wholly owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.
Use of Estimates. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America, or GAAP, requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. Actual results could differ from those estimates.
Industry Segment and Geographic Information. We operate in a single industry segment – the discovery, development and marketing of pharmaceuticals for the treatment of neurological, endocrine and psychiatric-based diseases and disorders. We had no foreign-based operations during any of the years presented.
Reclassifications. Certain amounts in prior year periods have been reclassified to conform with the presentation adopted in the current year.
Cash Equivalents. We consider all highly liquid investments that are readily convertible into cash and have an original maturity of three months or less at the time of purchase to be cash equivalents.
Accounts Receivable. Accounts receivable are recorded net of customer allowances for prompt payment discounts, chargebacks and any allowance for doubtful accounts. We estimate the allowance for doubtful accounts based on existing contractual payment terms, actual payment patterns of our customers and individual customer circumstances. To date, an allowance for doubtful accounts has not been material.
Debt Securities. Debt securities consist of investments in certificates of deposit, corporate debt securities, and securities of government-sponsored entities. We classify debt securities as available-for-sale. Debt securities available-for-sale are recorded at fair value, with unrealized gains and losses included in other comprehensive income or loss, net of tax. We exclude accrued interest from both the fair value and amortized cost basis of debt securities. A debt security is placed on nonaccrual status at the time any principal or interest payments become 90 days delinquent. Interest accrued but not received for a debt security placed on nonaccrual status is reversed against interest income.
Interest income includes amortization of purchase premium or discount. Premiums and discounts on debt securities are amortized using the effective interest rate method. Gains and losses on sales of debt securities are recorded on the trade date in investment income and other, net, and determined using the specific identification method.
Allowance for Credit Losses. For debt securities available-for-sale in an unrealized loss position, we first assess whether we intend to sell, or it is more likely than not that we will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security’s amortized cost basis is written down to fair value through earnings. For debt securities available-for-sale that do not meet the aforementioned criteria, we evaluate whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, we consider the extent to which fair value is less than amortized cost, any changes in interest rates, and any changes to the rating of the security by a rating agency, among other factors. If this
69

assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security is compared to the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded, limited by the amount that the fair value is less than the amortized cost basis. Any impairment that has not been recorded through an allowance for credit losses is recognized in other comprehensive income or loss, as applicable.
Accrued interest receivables on debt securities available-for-sale totaled $3.7 million at December 31, 2020. We do not measure an allowance for credit losses for accrued interest receivables. For the purposes of identifying and measuring an impairment, accrued interest is excluded from both the fair value and amortized cost basis of the debt security. Uncollectible accrued interest receivables associated with an impaired debt security are reversed against interest income upon identification of the impairment. No accrued interest receivables were written off during 2020, 2019 or 2018.
Fair Value of Financial Instruments. We record cash equivalents, debt securities available-for-sale and equity securities at fair value based on a fair value hierarchy that distinguishes between assumptions based on market data (observable inputs) and our own assumptions (unobservable inputs). The fair value hierarchy consists of the following three levels:
Level 1 – Quoted prices (unadjusted) in active markets for identical assets or liabilities.
Level 2 – Quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability.
Level 3 – Unobservable inputs that reflect our own assumptions about the assumptions that market participants would use in pricing the asset or liability when there is little, if any, market activity for the asset or liability at the measurement date.
Investments in debt securities available-for-sale are classified as Level 2 and carried at fair value. We estimate the fair value of debt securities available-for-sale by utilizing third-party pricing services. These pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. Such inputs include market pricing based on real-time trade data for similar instruments, issuer credit spreads, benchmark yields, broker/dealer quotes and other observable inputs. We validate valuations obtained from third-party pricing services by understanding the models used, obtaining market values from other pricing sources, and analyzing data in certain instances.
Investments in equity securities of certain companies that are subject to holding period restrictions longer than one year are classified as Level 3 and carried at fair value using an option pricing valuation model. The most significant assumptions within the option pricing valuation model are the stock price volatility, which is based on the historical volatility of similar companies, and the discount for lack of marketability related to the term of the restrictions.
The carrying amounts of accounts receivable and accounts payable and accrued liabilities approximate their fair values due to their short-term maturities.
There were no transfers between levels in the fair value hierarchy during 2020 or 2019.
Inventory. Inventory is valued at the lower of cost or net realizable value. We determine the cost of inventory using the standard-cost method, which approximates actual cost based on the first-in, first-out method. We assess the valuation of our inventory on a quarterly basis and adjust the value for excess and obsolete inventory to the extent management determines that the cost cannot be recovered based on estimates about future demand. Inventory costs resulting from these adjustments are recognized as cost of sales in the period in which they are incurred. When future commercialization is considered probable and the future economic benefit is expected to be realized, based on management’s judgment, we capitalize pre-launch inventory costs prior to regulatory approval.
Property and Equipment. Property and equipment are stated at cost and depreciated over the estimated useful lives of the assets using the straight-line method. Equipment is depreciated over an average estimated useful life of three to seven years. Leasehold improvements are depreciated over the shorter of their estimated useful lives or the remaining lease term. Depreciation expense was $8.6 million for 2020, $7.4 million for 2019 and $4.0 million for 2018.
70

Impairment of Long-Lived Assets. We review long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. If indicators of impairment exist, we assess the recoverability of the affected long-lived assets by determining whether the carrying value of such assets can be recovered through undiscounted future operating cash flows. If the carrying amount is not recoverable, we measure the amount of any impairment by comparing the carrying value of the asset to the present value of the expected future cash flows associated with the use of the asset.
Revenue Recognition. We recognize revenue when the customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. Revenue is recognized using a five-step model: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenues when (or as) we satisfy the performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer.
Product Sales, Net. In the U.S., our product sales, net consist of sales of INGREZZA, primarily to specialty pharmacy providers and a specialty distributor, and sales of ONGENTYS, primarily to wholesale distributors. We recognize product sales, net when the customer obtains control of our product, which occurs at a point in time, typically upon delivery of our product to the customer.
Revenues from product sales are recorded net of reserves established for applicable discounts and allowances that are offered within contracts with our customers, payors and other third parties. Such estimates are based on information received from external sources (such as written or oral information obtained from our customers with respect to their period-end inventory levels and sales to end-users during the reporting period), as supplemented by management’s judgement. Our process for estimating reserves established for these variable consideration components does not differ materially from historical practices. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which could have an effect on earnings in the period of adjustment.
Our significant categories of sales discounts and allowances are as follows:
Product Discounts. Product discounts are based on payment terms extended to our customers at the time of sale, which include incentives offered for prompt payment. We maintain a reserve for product discounts based on our historical experience, including the timing of customer payments. To date, actual product discounts have not differed materially from our estimates.
Government Rebates. We are obligated to pay rebates for mandated discounts under the Medicaid Drug Rebate Program. The liability for such rebates consists of invoices received for claims from prior quarters that remain unpaid, or for which an invoice has not been received, and estimated rebates for the current applicable reporting period. Such estimates are based on actual historical rebates by state, estimated payor mix, state and federal regulations and relevant contractual terms, as supplemented by management’s judgement. Our rebate accrual calculations require us to project the magnitude of our sales, by state, that will be subject to these rebates. There is a significant time-lag in our receiving rebate notices from each state (generally, several months or longer after a sale is recognized). Estimated rebates are recorded as a reduction of revenue in the period the related sale is recognized. To date, actual government rebates have not differed materially from our estimates.
Chargebacks. The difference between the list price, or the price at which we sell our products to our customers, and the contracted price, or the price at which our customers sell our products to qualified healthcare professionals, is charged back to us by our customers. In addition to actual chargebacks received, we maintain a reserve for chargebacks based on estimated contractual discounts on product inventory levels on-hand in our distribution channel. To date, actual chargebacks have not differed materially from our estimates.
Payor and Pharmacy Rebates. We are obligated to pay rebates as a percentage of sales under payor and pharmacy contracts. We estimate these rebates based on actual historical rebates, contractual rebate percentages, sales made through the payor channel and purchases made by pharmacies. To date, actual payor and pharmacy rebates have not differed materially from our estimates.
71

Co-payment Assistance. We offer financial assistance to qualified patients with prescription drug co-payments required by insurance. We accrue for copay assistance based on estimated claims and the cost per claim we expect to receive associated with inventory that remains in the distribution channel at period end. To date, actual copay assistance has not differed materially from our estimates.
Distributor and Other Fees. In connection with the sales of our products, we pay distributor and other fees to certain customers that provide us with inventory management, data and distribution services, which are generally recorded as a reduction of revenue. To the extent we can demonstrate a separable benefit and fair value for these services, we classify the associated costs in selling, general and administrative expenses. These costs are typically known at the time of sale, resulting in minimal adjustments subsequent to the period of sale.
Product Returns. For INGREZZA, we offer our customers product return rights primarily limited to errors in shipment and damaged product. We do not permit returns of INGREZZA for expiring or expired product. Accordingly, we have limited return risk resulting from INGREZZA product sales and therefore do not record an associated returns allowance. For ONGENTYS, we offer our customers product return rights primarily limited to errors in shipment, damaged product, and expiring or expired product, provided it is within a specified period around the product expiration date, as set forth in the associated distribution agreement. Once product is returned, it is destroyed. Where actual returns history is not available, we estimate the associated returns allowance based on benchmarking data for similar products and industry experience. We record this estimate as a reduction of revenue in the period the related sale is recognized. To date, actual product returns have not differed materially from our estimates.
Collaboration Revenues. We have entered into collaboration and licensing agreements under which we license certain rights to our product candidates to third parties. The terms of these arrangements typically include payment to us of one or more of the following: non-refundable, up-front license fees; development, regulatory, and/or commercial milestone payments; and royalties on net sales of licensed products.
Licenses of Intellectual Property. If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, we use judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.
Milestone Payments. At the inception of each arrangement that includes developmental, regulatory or commercial milestone payments, we evaluate whether achieving the milestones is considered probable and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the value of the associated milestone is included in the transaction price. Milestone payments that are not within our control, such as approvals from regulators or where attainment of the specified event is dependent on the development activities of a third party, are not considered probable of being achieved until those approvals are received or the specified event occurs. Revenue is recognized from the satisfaction of performance obligations in the amount billable to the customer.
Royalty Revenues. For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Each quarterly period, sales-based royalties are recorded based on estimated quarterly net sales of the associated collaboration products. Differences between actual results and estimated amounts are adjusted for in the period in which they become known, which typically follows the quarterly period in which the estimate was made. To date, actual royalties received have not differed materially from our estimates.
Concentration of Credit Risk. Financial instruments that potentially subject us to concentration of credit risk consist primarily of cash, cash equivalents and marketable securities. We have established guidelines to limit our exposure to credit risk by diversifying our investment portfolio and by placing investments with high credit quality financial
72

institutions and maturities that maintain safety and liquidity. To date, we have not experienced any credit losses and do not believe we are exposed to any significant credit risk in relation to these financial instruments.
We are also subject to credit risk from our accounts receivable related to our product sales. Our two largest customers represented approximately 86% of our product revenues for both 2020 and 2019, and the significant majority of our accounts receivable balances at December 31, 2020 and 2019. For 2018, our three largest customers represented approximately 93% of our product revenue and substantially all of our accounts receivable balance at December 31, 2018. To date, we have not experienced any significant losses with respect to the collection of these accounts receivable.
Cost of Sales. Cost of sales includes third-party manufacturing, transportation, freight and indirect overhead costs associated with the manufacture and distribution of INGREZZA and ONGENTYS, royalty fees on net sales of ORILISSA and ORIAHNN, and adjustments for excess and obsolete inventory to the extent management determines that the cost cannot be recovered based on estimates about future demand.
Research and Development Expenses. R&D expenses consist primarily of salaries, payroll taxes, employee benefits and share-based compensation charges for those individuals involved in ongoing R&D efforts; as well as scientific consulting fees, preclinical and clinical trial costs, R&D facilities costs, laboratory supply costs and depreciation of scientific equipment. All such costs are charged to R&D expense as incurred. These expenses result from our independent R&D efforts, as well as efforts associated with collaborations, in-licenses and third-party funded research arrangements, including event based milestones.
Asset Acquisitions. We account for acquisitions of an asset or group of assets that do not meet the definition of a business using the cost accumulation method, whereby the cost of the acquisition, including certain transaction costs, is allocated to the assets acquired on the basis of their relative fair values. No goodwill is recognized in an asset acquisition. Intangible assets that are acquired in an asset acquisition for use in R&D activities which have no alternative future use are expensed as in-process research and development, or IPR&D, on the acquisition date. Future costs to develop these assets are recorded to R&D expense as they are incurred.
Advertising Expense. Advertising costs are expensed when services are performed, or goods are delivered. We incurred advertising costs related to INGREZZA and ONGENTYS of $64.8 million for 2020, $40.6 million for 2019 and $20.5 million for 2018.
Share-Based Compensation. We grant stock options to purchase our common stock to eligible employees and directors and also grant certain employees restricted stock units, or RSUs, and performance-based restricted stock units, or PRSUs. Additionally, we allow employees to participate in an employee stock purchase plan, or ESPP.
We estimate the fair value of stock options and shares to be issued under the ESPP using the Black-Scholes option-pricing model on the date of grant. Restricted stock units are valued based on the closing price of our common stock on the date of grant. The fair value of equity instruments expected to vest are recognized and amortized on a straight-line basis over the requisite service period of the award, which is generally three to four years; however, certain provisions in our equity compensation plans provide for shorter vesting periods under certain circumstances. The fair value of shares to be issued under the ESPP are recognized and amortized on a straight-line basis over the purchase period, which is generally six months. Additionally, we granted certain PRSUs that vest upon the achievement of certain predefined company-specific performance-based criteria. Expense related to these PRSUs is generally recognized ratably over the expected performance period once the predefined performance-based criteria for vesting becomes probable.
Income Taxes. Our income tax benefit (provision) is computed under the asset and liability method. Significant estimates are required in determining our income tax benefit (provision). Some of these estimates are based on interpretations of existing tax laws or regulations. We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (temporary differences) at enacted tax rates in effect for the years in which the differences are expected to reverse. A valuation allowance is established for deferred tax assets for which it is more likely than not that some portion or all of the deferred tax assets, including net operating losses and tax credits, will not be realized. We periodically re-assess the need for a valuation allowance against our deferred tax assets based on various factors including our historical earnings experience by
73

taxing jurisdiction, and forecasts of future operating results and utilization of net operating losses and tax credits prior to their expiration. Significant judgment is required in making this assessment and, to the extent that a reversal of any portion of our valuation allowance against our deferred tax assets is deemed appropriate, a tax benefit will be recognized against our income tax provision in the period of such reversal. Prior to 2020, we recorded a valuation allowance that fully offset our deferred tax assets. On December 31, 2020, based on our evaluation of various factors, such as our achievement of a cumulative three-year income position as of December 31, 2020, as well as our consideration of forecasts of future operating results and utilization of net operating losses and tax credits prior to their expiration, we released substantially all of our valuation allowance against our deferred tax assets and recorded a corresponding income tax benefit. Refer to Note 9 to the consolidated financial statements for more information.
We recognize tax benefits from uncertain tax positions only if it is more likely than not that the tax position will be sustained upon examination by the tax authorities based on the technical merits of the position. An adverse resolution of one or more of these uncertain tax positions in any period could have a material impact on the results of operations for that period.
Net Income Per Share. Basic net income per share is computed using the weighted average number of common shares outstanding during the period. Diluted net income per share is computed using the weighted average number of common and potentially dilutive shares outstanding during the period, including the potentially dilutive shares resulting from the conversion of the 2024 Notes and excluding the effect of stock options and restricted stock outstanding for periods when their effect is anti-dilutive, using the treasury stock method.
Convertible debt instruments that may be settled entirely or partly in cash (such as the 2024 Notes) may, in certain circumstances where the borrower has the ability and intent to settle in cash, be accounted for under the treasury stock method. We issued the 2024 Notes with a combination settlement feature, which we have the ability and intent to use upon conversion of the 2024 Notes, to settle the principal amount of debt for cash and the excess of the principal portion in shares of our common stock. As a result, of the approximately 5.0 million shares underlying the 2024 Notes at December 31, 2020, only the shares required to settle the excess of the principal portion would be considered dilutive under the treasury stock method. Further, approximately 0.2 million PRSUs were excluded from the calculation of diluted net income per share as the performance condition has not been achieved. In loss periods, basic net loss per share and diluted net loss per share are identical because the otherwise dilutive potential common shares become anti-dilutive and are therefore excluded.
Recently Adopted Accounting Pronouncements.
ASU 2016-13. On January 1, 2020, we adopted Accounting Standards Update, or ASU, 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, using the modified retrospective transition method. For debt securities available-for-sale, the standard requires an investor to determine whether a decline in the fair value below the amortized cost basis of the investment is due to credit-related factors. Credit-related impairment is recognized as an allowance for credit loss on the balance sheet with a corresponding adjustment to earnings. Credit losses are limited to the amount by which the investment’s amortized cost basis exceeds its fair value and may be subsequently reversed if conditions change. Any impairment that is not credit related is recognized in other comprehensive income or loss, as applicable, net of applicable taxes.
The adoption of ASU 2016-13 did not result in a cumulative-effect adjustment to retained earnings. The comparative prior period information continues to be reported under the accounting standards in effect during those periods.
Recently Issued Accounting Pronouncements.
ASU 2019-12. In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and amends existing guidance to improve consistent application of Topic 740. ASU 2019-12 is effective for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years, with early adoption permitted in any interim period for which financial statements have not yet been made available for issuance. We are currently evaluating the effect ASU 2019-12 will have on our condensed consolidated financial statements and related disclosures.
ASU 2020-06. In August 2020, the FASB issued ASU 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity's Own Equity (Subtopic 815-40): Accounting
74

for Convertible Instruments and Contracts in an Entity's Own Equity, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments, and amends existing earnings-per-share, or EPS, guidance by requiring that an entity use the if-converted method when calculating diluted EPS for convertible instruments. ASU 2020-06 is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years, with early adoption permitted for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. We plan to adopt ASU 2020-06 effective January 1, 2022 and are currently evaluating the effect ASU 2020-06 will have on our consolidated financial statements and related disclosures.
2. License and Collaboration Agreements
Under the terms of the following license and collaboration agreements, we may be required to make milestone payments upon achievement of certain development and regulatory activities of up to $8.5 billion and pay royalties on future sales, if any, of commercial products resulting from these agreements.
Takeda Pharmaceutical Company Limited. We entered into an exclusive license agreement with Takeda Pharmaceutical Company Limited, or Takeda, which became effective in July 2020, to develop and commercialize certain compounds in Takeda’s early to mid-stage psychiatry pipeline. Specifically, Takeda granted us an exclusive license to the following seven assets: (i) NBI-1065844 (TAK-831) for schizophrenia, (ii) NBI-1065845 (TAK-653) for treatment-resistant depression, (iii) NBI-1065846 (TAK-041) for anhedonia (which together with the NBI-1065845 are referred to as the Phase II Ready Assets), and (iv) four non-clinical stage assets, or the Non-Clinical Assets.
NBI-1065844 is deemed a royalty-bearing product under the license agreement pursuant to which we will be responsible for all costs and expenses associated with the development, manufacture, and commercialization of such asset, subject to certain exceptions, and Takeda will be eligible to receive development and commercial milestones and royalties with respect to such asset, or a Royalty-Bearing Product, and Takeda will retain the right to opt-in to a profit sharing arrangement pursuant to which we and Takeda will equally share in the operating profits and losses related to such asset, subject to certain exceptions, in lieu of receiving milestones and royalties, or a Profit-Share Product. Subject to specified conditions, Takeda may elect to exercise such opt-in right for NBI-1065844 before we initiate a Phase III clinical trial. Each of the Phase II Ready Assets is deemed a Profit-Share Product and Takeda will retain the right to opt-out of the profit-sharing arrangement for such asset pursuant to which such asset would become a Royalty-Bearing Product. Takeda may elect to exercise such opt-out rights with respect to a Phase II Ready Asset immediately following the completion of the second Phase II clinical trial for such Phase II Ready Asset. In addition, under certain circumstances related to the development and commercialization activities to be performed by us, Takeda may elect to opt-out of the profit-sharing arrangement for a Profit-Share Product before the initiation of a Phase III clinical trial for such product.
Each of the Non-Clinical Assets will be Royalty-Bearing Products pursuant to which we will be responsible for all costs and expenses associated with the development, manufacture, and commercialization of such assets, subject to certain exceptions.
In connection with the agreement, we paid Takeda $120.0 million upfront, which, including certain transaction related costs, was expensed as in-process research and development, or IPR&D, in the third quarter of 2020. Pursuant to the terms of the agreement, Takeda may also be entitled to receive additional payments of up to $1.9 billion upon the achievement of certain event-based milestones associated with Royalty-Bearing Products, as well as receive royalties on the future net sales of Royalty-Bearing Products. On a country-by-country and product-by-product basis, royalty payments would commence on the first commercial sale of a Royalty-Bearing Product and terminate on the later of (i) the expiration of the last patent covering such Royalty-Bearing Product in such country, (ii) a number of years from the first commercial sale of such Royalty-Bearing Product in such country and (iii) the expiration of regulatory exclusivity for Royalty-Bearing Product in such country.
Idorsia Pharmaceuticals Ltd. In May 2020, we entered a collaboration and licensing agreement with Idorsia Pharmaceuticals Ltd, or Idorsia, to license the global rights to NBI-827104 (ACT-709478), a potent, selective, orally active and brain penetrating T-type calcium channel blocker, in clinical development for the treatment of a rare pediatric epilepsy. The agreement also includes a research collaboration to discover and identify additional novel T-type calcium channel blockers as development candidates.
75

In connection with the exercise of the option, we paid Idorsia $45.0 million upfront, which we expensed as IPR&D in the second quarter of 2020. Further, as part of the research collaboration, we provided Idorsia with an incremental $7.2 million in funding, which we recorded as a prepaid asset and is being expensed over the two-year research collaboration term.
Pursuant to the terms of the agreement, upon the achievement of certain development and regulatory milestones, Idorsia may be entitled to receive additional payments of up to $365.0 million with respect to NBI-827104 and $620.0 million with respect to the development candidates. Idorsia may also be entitled to receive additional payments of up to $750.0 million upon the achievement of certain commercial milestones, as well as receive royalties on the future net sales of any collaboration product. Further, we will be responsible for all manufacturing, development and commercialization costs of any collaboration product.
Xenon Pharmaceuticals, Inc. In December 2019, we entered into a license and collaboration agreement with Xenon Pharmaceuticals Inc., or Xenon, to identify, research, and develop sodium channel inhibitors, including clinical candidate NBI-921352 (XEN901) and three preclinical candidates, which compounds we will have the exclusive right to further develop and commercialize under the terms and conditions set forth in the agreement.
We will be solely responsible, at our sole cost and expense, for all development and manufacturing of the compounds and any pharmaceutical product that contains a compound, subject to Xenon’s right to elect to co-fund the development of one product in a major indication and thus receive a mid-single digit percentage increase in royalties owed on the net sales of such product in the U.S. If Xenon exercises such option, the parties will share equally all reasonable and documented costs and expenses incurred in connection with the development of such product in the applicable indication, except costs and expenses that are solely related to the development of such product for regulatory approval outside the U.S.
In connection with the agreement, we paid Xenon $30.0 million upfront and purchased $20.0 million of Xenon’s common stock at $14.196 per share, representing approximately 1.4 million shares. Pursuant to the terms of the agreement, Xenon may also be entitled to receive additional payments of up to $1.7 billion upon the achievement of certain event-based milestones, as well as receive royalties on the future net sales of any collaboration product.
We accounted for the transaction as an asset acquisition as the set of acquired assets did not constitute a business. Our equity investment in Xenon was recorded at a fair value of $14.1 million after considering Xenon’s stock price on the date of closing and certain lock-up and voting provisions applicable to the acquired shares. The remaining $36.2 million of the purchase price, which includes the applicable transaction costs, was expensed as IPR&D in the fourth quarter of 2019.
Voyager Therapeutics, Inc. We entered into a collaboration and license agreement with Voyager Therapeutics, Inc., or Voyager, which became effective in March 2019, to develop and commercialize four programs using Voyager’s proprietary gene therapy platform. The four programs consist of the NBIb-1817 (VY-AADC) program for Parkinson’s disease, the Friedreich’s ataxia program and the rights to two undisclosed programs.
In connection with the agreement, we paid Voyager $115.0 million upfront and purchased $50.0 million of Voyager’s common stock at $11.9625 per share, representing approximately 4.2 million shares. Pursuant to the terms of the agreement, Voyager may also be entitled to receive additional payments of up to $1.7 billion upon the achievement of certain event-based milestones, as well as receive royalties on the future net sales of any collaboration product.
Pursuant to development plans agreed to by us and Voyager, unless Voyager exercises its co-development and co-commercialization rights as provided for in the agreement, we will be responsible for all development costs. Further, upon the occurrence of a specified event for each program, we will assume responsibility for the development, manufacturing, and commercialization activities of such program.
We accounted for the transaction as an asset acquisition as the set of acquired assets did not constitute a business. Our equity investment in Voyager was recorded at a fair value of $54.7 million after considering Voyager’s stock price on the date of closing and certain lock-up and voting provisions applicable to the acquired shares. The remaining $113.1 million of the purchase price, which includes the applicable transaction costs, was expensed as in-process research and development, or IPR&D, in the first quarter of 2019.
76

In June 2019, we entered into an amendment to the collaboration and license agreement with Voyager. Under the terms of the amendment, we paid Voyager $5.0 million upfront to obtain rights outside the U.S. to the Friedreich’s ataxia program in connection with the early return of those rights to Voyager pursuant to a restructuring of Voyager’s gene therapy relationship with Sanofi Genzyme. The upfront payment was expensed as IPR&D in the second quarter of 2019.
On February 2, 2021, we notified Voyager of our termination of the NBIb-1817 for Parkinson’s disease program. The effective date of this termination will be August 2, 2021. The termination does not apply to any other development program other than NBIb-1817 for Parkinson’s disease, and our collaboration and license agreement with Voyager will otherwise continue in effect.
BIAL – Portela & Ca, S.A. We acquired the U.S. and Canada rights to ONGENTYS® from BIAL in the first quarter of 2017. We launched ONGENTYS in the U.S. in September 2020, after receiving FDA approval for ONGENTYS as an adjunctive therapy to levodopa/DOPA decarboxylase inhibitors in adult Parkinson's disease patients in April 2020. FDA approval for ONGENTYS for Parkinson’s disease resulted in a $20.0 million event-based payment to BIAL, which we expensed as R&D in the second quarter of 2020. We further recognized R&D expense of $10.0 million in each 2019 and 2018 in connection with BIAL’s achievement of certain regulatory event-based milestones related to then ongoing development of ONGENTYS. Pursuant to the terms of the agreement, BIAL may also be entitled to receive additional payments of up to $75.0 million upon the achievement of certain event-based milestones.
Under the terms of the agreement, we are responsible for the commercialization of ONGENTYS in the U.S. and Canada. Further, we rely on BIAL for the commercial supply of ONGENTYS. Upon our written request prior to the estimated expiration of the term of a licensed product, the parties shall negotiate a good faith continuation of BIAL’s supply of such licensed product after the term. After the term, and if BIAL is not supplying a certain licensed product, we shall pay BIAL a trademark royalty based on the net sales of such licensed product.
Upon commercialization of ONGENTYS, we determined certain annual sales forecasts. In the event we fail to meet the minimum sales requirements for a particular year, we would be obligated to pay BIAL an amount equal to the difference between the actual net sales and minimum sales requirements for such year.
Mitsubishi Tanabe Pharma Corporation. In March 2015, we entered into a collaboration and license agreement with Mitsubishi Tanabe Pharma Corporation, or MTPC, for the development and commercialization of INGREZZA for movement disorders in Japan and other select Asian markets.
Since inception of the agreement, we have recognized revenue of $19.8 million associated with the delivery of a technology license and existing know-how and $15.0 million associated with the achievement of a certain event-based milestone. We further recognized revenue of $2.7 million in 2020 and $0.9 million in 2019 in connection with the ongoing KINECT-HD study, a placebo-controlled Phase III study of valbenazine in adult Huntington’s disease patients with chorea. In accordance with our continuing performance obligations, $6.7 million of the $30.0 million upfront payment received from MTPC is being deferred and will be recognized as revenue over the ongoing study period using an input method according to costs incurred to-date relative to estimated total costs associated with the study.
Pursuant to the terms of the agreement, we may also be entitled to receive additional payments of up to $70.0 million upon the achievement of certain event-based milestones, receive payments for the manufacture of certain pharmaceutical products, as well as receive royalties on the future net sales of any collaboration product in select territories in Asia.
Under the terms of the agreement, MTPC is responsible for all third-party development, marketing, and commercialization costs in Japan and other select Asian markets and we would be entitled to a percentage of sales of INGREZZA in Japan and other select Asian markets for the longer of ten years or the life of the related patent rights. Further, the collaboration effort between the parties to advance INGREZZA towards commercialization in Japan and other select Asian markets is governed by joint steering and development committees with representatives from both parties.
77

AbbVie Inc. In June 2010, we entered into an exclusive worldwide collaboration with AbbVie Inc., or AbbVie, to develop and commercialize elagolix and all next-generation gonadotropin-releasing factor, or GnRH, antagonists and collectively, GnRH Compounds, for women’s and men’s health.
AbbVie received approval for ORILISSA for the management of moderate to severe endometriosis pain in women from the FDA in July 2018 and Health Canada in October 2018. In May 2020, AbbVie received FDA approval for ORIAHNN for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. We recognized sales-based royalties on AbbVie net sales of ORILISSA and ORIAHNN of $19.2 million in 2020, $14.3 million in 2019 and $1.6 million in 2018.
FDA approval for ORIAHNN for uterine fibroids resulted in the achievement of a $30.0 million event-based milestone, which we recognized as collaboration revenue in the second quarter of 2020. In 2019, we recognized collaboration revenue of $20.0 million in connection with the FDA’s acceptance of AbbVie’s NDA submission for the approval of ORIAHNN for uterine fibroids. In 2018, we recognized collaboration revenue of $40.0 million in connection with the FDA’s approval for ORILISSA for endometriosis.
Since inception of the agreement, we have recognized revenue of $75.0 million associated with the delivery of a technology license and existing know-how and $165.0 million associated with the achievement of certain event-based milestones. Pursuant to the terms of the agreement, we may also be entitled to receive additional payments of up to $366.0 million upon the achievement of certain event-based milestones.
Under the terms of the agreement, AbbVie is responsible for all third-party development, marketing, and commercialization costs. We are entitled to a percentage of worldwide sales of GnRH Compounds for the longer of ten years or the life of the related patent rights.
3. Debt Securities
The following table summarizes the amortized cost, unrealized gain and loss recognized in accumulated other comprehensive income (loss), allowance for credit losses, and fair value of debt securities available-for-sale at December 31, 2020, aggregated by major security type and contractual maturity:
(in millions)Contractual
Maturity		Amortized
Cost		Unrealized
Gain		Unrealized
Loss		Allowance for Credit LossesFair
Value
Commercial paperWithin 1 year$82.2 $— $— $— $82.2 
Corporate debt securitiesWithin 1 year299.3 1.4 — — 300.7 
Securities of government-sponsored entities
Within 1 year230.9 0.1 — — 231.0 
$612.4 $1.5 $— $— $613.9 
Corporate debt securities1 to 2 years$144.8 $0.4 $— $— $145.2 
Securities of government-sponsored entities
1 to 2 years81.9 0.1 (0.1)— 81.9 
$226.7 $0.5 $(0.1)$— $227.1 
The following table summarizes the amortized cost, unrealized gain and loss recognized in accumulated other comprehensive income, and fair value of debt securities available-for-sale at December 31, 2019, aggregated by major security type and contractual maturity:
(in millions)Contractual
Maturity		Amortized
Cost		Unrealized
Gain		Unrealized
Loss		Fair
Value
Commercial paperWithin 1 year$144.5 $— $— $144.5 
Corporate debt securitiesWithin 1 year270.5 0.5 — 271.0 
Securities of government-sponsored entitiesWithin 1 year142.3 0.4 — 142.7 
$557.3 $0.9 $— $558.2 
Corporate debt securities1 to 2 years$250.5 $0.5 $(0.1)$250.9 
Securities of government-sponsored entities1 to 2 years48.8 — — 48.8 
$299.3 $0.5 $(0.1)$299.7 
78

The following table summarizes debt securities available-for-sale in an unrealized loss position for which an allowance for credit losses has not been recorded at December 31, 2020, aggregated by major security type and length of time in a continuous unrealized loss position:
Less Than 12 Months12 Months or LongerTotal
(in millions)Fair
Value		Unrealized
Loss		Fair
Value		Unrealized
Loss		Fair
Value		Unrealized
Loss
Securities of government-sponsored entities$95.0 $(0.1)$— $— $95.0 $(0.1)
At December 31, 2020, our security portfolio consisted of 148 securities related to investments in debt securities available-for-sale, of which 30 securities were in an unrealized loss position.
Our investments in corporate debt securities in an unrealized loss position at December 31, 2020 are of high credit quality (rated A or higher). Unrealized losses on these investments were primarily due to changes in interest rates. We do not intend to sell these investments and it is not more likely than not that we will be required to sell these investments before recovery of their amortized cost basis.
The following table summarizes debt securities available-for-sale in an unrealized loss position at December 31, 2019, aggregated by major security type and length of time in a continuous unrealized loss position:
Less Than 12 Months12 Months or LongerTotal
(in millions)Fair
Value		Unrealized
Loss		Fair
Value		Unrealized
Loss		Fair
Value		Unrealized
Loss
Corporate debt securities$186.1 $(0.1)$— $— $186.1 $(0.1)
4. Fair Value Measurements
Investments at December 31, 2020, which were measured at fair value on a recurring basis, consisted of the following:
Fair Value Measurements Using
(in millions)Fair ValueLevel 1Level 2Level 3
Cash and cash equivalents:
Cash and money market funds$187.1 $187.1 $— $— 
Total cash and cash equivalents187.1 187.1 — — 
Restricted cash:
Certificates of deposit3.2 3.2 — — 
Total restricted cash3.2 3.2 — — 
Debt securities available-for-sale:
Commercial paper82.2 — 82.2 — 
Corporate debt securities445.9 — 445.9 — 
Securities of government-sponsored entities312.9 — 312.9 — 
Total debt securities available-for-sale841.0 — 841.0 — 
Equity securities:
Equity securities–biotechnology industry38.2 — — 38.2 
Total equity securities38.2 — — 38.2 
Total recurring fair value measurements$1,069.5 $190.3 $841.0 $38.2 
79

Investments at December 31, 2019, which were measured at fair value on a recurring basis, consisted of the following:
Fair Value Measurements Using
(in millions)Fair ValueLevel 1Level 2Level 3
Cash and cash equivalents:
Cash and money market funds$112.3 $112.3 $— $— 
Total cash and cash equivalents112.3 112.3 — — 
Restricted cash:
Certificates of deposit3.2 3.2 ——
Total restricted cash3.2 3.2 ——
Debt securities available-for-sale:
Commercial paper144.5 —144.5 —
Corporate debt securities521.9 —521.9 —
Securities of government-sponsored entities191.5 —191.5 —
Total debt securities available-for-sale857.9 —857.9 —
Equity securities:
Equity securities–biotechnology industry55.9 ——55.9 
Total equity securities55.9 ——55.9 
Total recurring fair value measurements$1,029.3 $115.5 $857.9 $55.9 
The following table presents a reconciliation of equity securities, which were measured at fair value on a recurring basis using significant unobservable inputs (Level 3):
Year Ended December 31,
(in millions)202020192018
Beginning balance$55.9 $— $— 
Purchases— 68.9 — 
Unrealized loss included in earnings(17.7)(13.0)— 
Ending balance$38.2 $55.9 $— 
At December 31, 2020, the discount for lack of marketability used in the valuation analysis of equity securities ranged from 15.0% to 34.0% (weighted average of 24.8%). The discount for lack of marketability was weighted by the relative fair value of the instruments. A significant increase (decrease) in the discount for lack of marketability in isolation would result in a significantly lower (higher) fair value measurement. Unrealized gains and losses on equity securities are included in other income (expense), net.
5. Convertible Senior Notes
On May 2, 2017, we completed a private placement of $517.5 million in aggregate principal amount of 2.25% convertible senior notes due 2024, or the 2024 Notes, and entered into an indenture agreement, or the 2024 Indenture, with respect to the 2024 Notes. The 2024 Notes accrue interest at a fixed rate of 2.25% per year, payable semiannually in arrears on May 15 and November 15 of each year, beginning on November 15, 2017. The 2024 Notes mature on May 15, 2024. The net proceeds from the issuance of the 2024 Notes were approximately $502.8 million, after deducting commissions and the offering expenses payable by us.
Holders of the 2024 Notes may convert the 2024 Notes at any time prior to the close of business on the business day immediately preceding May 15, 2024, only under the following circumstances:
(i)during any calendar quarter (and only during such calendar quarter), if the last reported sale price of our common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than 130% of the conversion price on each applicable trading day;
(ii)during the 5 business-day period immediately after any 5 consecutive trading-day period (the measurement period) in which the trading price (as defined in the 2024 Indenture) per $1,000 principal amount of the
80

2024 Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of our common stock and the conversion rate on each such trading day;
(iii)upon the occurrence of specified corporate events, including a merger or a sale of all or substantially all of our assets; or
(iv)if we call the 2024 Notes for redemption, until the close of business on the business day immediately preceding the redemption date.
On or after January 15, 2024, until the close of business on the scheduled trading day immediately preceding May 15, 2024, holders may convert their 2024 Notes at any time.
Upon conversion, holders will receive the principal amount of their 2024 Notes and any excess conversion value, calculated based on the per share volume-weighted average price for each of the 30 consecutive trading days during the observation period (as more fully described in the 2024 Indenture). For both the principal and excess conversion value, holders may receive cash, shares of our common stock or a combination of cash and shares of our common stock, at our option.
It is our intent and policy to settle conversions through combination settlement, which essentially involves repayment of an amount of cash equal to the “principal portion” and delivery of the “share amount” in excess of the principal portion in shares of common stock or cash. In general, for each $1,000 in principal, the “principal portion” of cash upon settlement is defined as the lesser of $1,000, and the conversion value during the 25-day observation period as described in the notes. The conversion value is the sum of the daily conversion value which is the product of the effective conversion rate divided by 25 days and the daily volume-weighted average price, or VWAP, of our common stock. The “share amount” is the cumulative “daily share amount” during the observation period, which is calculated by dividing the daily VWAP into the difference between the daily conversion value (i.e., conversion rate x daily VWAP) and $1,000.
The initial conversion rate for the 2024 Notes is 13.1711 shares of common stock per $1,000 principal amount, which is equivalent to an initial conversion price of approximately $75.92 per share of our common stock. At the initial conversion rate, settlement of the 2024 Notes for shares of our common stock would approximate 5.0 million shares. The conversion rate will be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. The initial conversion price of the 2024 Notes represented a premium of approximately 42.5% to the closing sale price of $53.28 per share of our common stock on the Nasdaq Global Select Market on April 26, 2017, the date that we priced the private offering of the 2024 Notes.
In the event of conversion, holders would forgo all future interest payments, any unpaid accrued interest and the possibility of further stock price appreciation. Upon the receipt of conversion requests, the settlement of the 2024 Notes will be paid pursuant to the terms of the 2024 Indenture. In the event that all of the 2024 Notes are converted, we would be required to repay the outstanding principal value and any conversion premium in any combination of cash and shares of its common stock (at our option).
We may not redeem the 2024 Notes prior to May 15, 2021. On or after May 15, 2021, we may redeem for cash all or part of the 2024 Notes if the last reported sale price (as defined in the 2024 Indenture) of our common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading-day period ending on, and including, the trading day immediately before the date which we provide notice of redemption. The redemption price will equal the sum of (i) 100% of the principal amount of the 2024 Notes being redeemed, plus (ii) accrued and unpaid interest, including additional interest, if any, to, but excluding, the redemption date. No sinking fund is provided for the 2024 Notes.
If we undergo a fundamental change, as defined in the 2024 Indenture, subject to certain conditions, holders of the 2024 Notes may require us to repurchase for cash all or part of their 2024 Notes at a repurchase price equal to 100% of the principal amount of the 2024 Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. In addition, if a ‘‘make-whole fundamental change’’ (as defined in the 2024 Indenture) occurs prior to January 15, 2024, we will, in certain circumstances, increase the conversion rate for a holder who elects to convert their notes in connection with the make-whole fundamental change.
81

The 2024 Notes are our general unsecured obligations that rank senior in right of payment to all of our indebtedness that is expressly subordinated in right of payment to the 2024 Notes, and equal in right of payment to our unsecured indebtedness.
We are required to separately account for the liability and equity components of the 2024 Notes, as they may be settled entirely or partially in cash upon conversion in a manner that reflects our economic interest cost. The liability component of the instrument was valued in a manner that reflects the market interest rate for a similar nonconvertible instrument at the date of issuance. The initial carrying value of the liability component of $368.3 million was calculated using a 7.5% assumed borrowing rate. The equity component of $149.2 million, representing the conversion option, was determined by deducting the fair value of the liability component from the par value of the 2024 Notes and was recorded in additional paid-in capital on the consolidated balance sheet at the issuance date. That equity component is treated as a discount on the liability component of the 2024 Notes, which is amortized over the seven-year term of the 2024 Notes using the effective interest rate method. The equity component is not re-measured as long as it continues to meet the conditions for equity classification. At December 31, 2020, the remaining period over which the discount on the liability component will be amortized was approximately 3.4 years.
We allocated the total transaction costs of approximately $14.7 million related to the issuance of the 2024 Notes to the liability and equity components of the 2024 Notes based on their relative values. Transaction costs attributable to the liability component are amortized to interest expense over the seven-year term of the 2024 Notes, and transaction costs attributable to the equity component are netted with the equity component in stockholders’ equity.
The 2024 Notes do not contain any financial or operating covenants or any restrictions on the payment of dividends, the issuance of other indebtedness or the issuance or repurchase of securities by us. The 2024 Indenture contains customary events of default with respect to the 2024 Notes, including that upon certain events of default, 100% of the principal and accrued and unpaid interest on the 2024 Notes will automatically become due and payable.
In November 2020, we entered into separate, privately negotiated transactions with certain holders of the 2024 Notes to repurchase $136.2 million aggregate principal amount of the 2024 Notes for an aggregate repurchase price of $186.9 million in cash. We accounted for the partial repurchase of the 2024 Notes as a debt extinguishment. As a result, we attributed $130.7 million of the aggregate repurchase price to the liability component based on the fair value of the liability component immediately before extinguishment. The fair value of the liability component was calculated at settlement using a discounted cash flow analysis with a discount rate of 3.37%, which was the market rate for similar notes that have no conversion rights. The difference of $56.3 million between the fair value of the aggregate consideration remitted to certain holders of the 2024 Notes and the fair value of the liability component was attributed to the reacquisition of the equity component and recognized as a reduction to additional paid-in capital. The carrying amount of the liability of $112.4 million at settlement was recognized as a reduction to convertible senior notes and resulted in an $18.4 million loss on extinguishment.
The 2024 Notes, net of discounts and deferred financing costs, consisted of the following:
 December 31,
(in millions)20202019
Principal$381.3 $517.5 
Deferred financing costs(4.0)(6.9)
Debt discount, net(59.4)(101.8)
Net carrying amount$317.9 $408.8 
The 2024 Notes were recorded at the estimated value of a similar non-convertible instrument on the date of issuance and accretes to the face value of the 2024 Notes over their seven-year term. The fair value of the 2024 Notes, which was estimated utilizing market quotations from an over-the-counter trading market (Level 2), was $514.3 million and $596.8 million at December 31, 2020 and 2019, respectively.
82

6. Other Balance Sheet Details
Inventories consisted of the following:
December 31,
(in millions)20202019
Raw materials$16.6 $14.1 
Work in process2.4 1.5 
Finished goods9.0 1.7 
Total inventories$28.0 $17.3 
Property and equipment, net, consisted of the following:
December 31,
(in millions)20202019
Tenant improvements$29.5 $26.3 
Scientific equipment39.2 33.5 
Computer equipment13.9 12.5 
Furniture and fixtures3.7 3.2 
86.3 75.5 
Less accumulated depreciation(41.7)(33.6)
Total property and equipment, net$44.6 $41.9 
Accounts payable and accrued liabilities consisted of the following:
December 31,
(in millions)20202019
Accrued employee related costs $38.2 $38.9 
Revenue-related reserves for discounts and allowances34.6 30.6 
Accrued development costs32.9 25.5 
Accrued Branded Prescription Drug Fee23.6 4.9 
Accounts payable and other accrued liabilities39.4 41.4 
Total accounts payable and accrued liabilities$168.7 $141.3 
The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows.
December 31,
(in millions)20202019
Cash and cash equivalents$187.1 $112.3 
Restricted cash3.2 3.2 
Total cash, cash equivalents and restricted cash$190.3 $115.5 
83

7. Net Income Per Share
Net income per share was calculated as follows:
Year Ended December 31,
(in millions, except per share data)202020192018
Net income - basic and diluted$407.3 $37.0 $21.1 
Weighted-average common shares outstanding:
Basic93.1 91.6 90.2 
Effect of dilutive securities:
Stock options2.4 2.6 3.2 
Restricted stock units0.5 0.4 0.6 
2024 Notes1.8 1.1 1.3 
Diluted97.8 95.7 95.4 
Net income per share:
Basic$4.38 $0.40 $0.23 
Diluted$4.16 $0.39 $0.22 
Shares which have been excluded from diluted per share amounts because their effect would have been anti-dilutive were 2.5 million, 2.1 million and 0.9 million for 2020, 2019 and 2018, respectively.
Note 8. Share-Based Compensation
In May 2011, we adopted the 2011 Equity Incentive Plan, as amended, or the 2011 Plan. The 2011 Plan authorized 21 million shares of common stock for issuance and allowed for the grant of stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, or RSUs, performance stock awards, performance-based restricted stock units, or PRSUs, and certain other awards. During 2020, the 2011 Plan was merged into the 2020 Plan (defined below). As a result, there were no shares of common stock remaining available for future grant under the 2011 Plan.
In May 2018, we adopted the 2018 Employee Stock Purchase Plan, or ESPP, pursuant to which 0.3 million shares of common stock are authorized for issuance. At December 31, 2020, 0.2 million shares of common stock remain available for future grant under the 2018 ESPP.
In May 2020, we adopted the 2020 Equity Incentive Plan, or the 2020 Plan. The 2020 Plan authorized 3.3 million shares of common stock for issuance and allows for the grant of stock options, stock appreciation rights, restricted stock awards, RSUs, performance stock awards, PRSUs and certain other awards. The 2011 Plan was merged into the 2020 Plan and, as a result, all remaining shares in the 2011 Plan were transferred into the 2020 Plan. At December 31, 2020, 8.2 million shares of common stock remain available for future grant under the 2020 Plan.
Share-Based Compensation Expense. The effect of share-based compensation expense on our consolidated statements of income and comprehensive income by line-item follows:
Year Ended December 31,
(in millions)202020192018
Selling, general and administrative expense$66.3 $49.5 $31.9 
Research and development expense33.7 25.8 26.2 
Total share-based compensation expense$100.0 $75.3 $58.1 
Share-based compensation expense by award-type follows:
Year Ended December 31,
(in millions)202020192018
Stock options$47.5 $36.5 $35.4 
RSUs44.2 30.5 21.9 
PRSUs5.3 5.6 — 
ESPP3.0 2.7 0.8 
Total share-based compensation expense$100.0 $75.3 $58.1 
84

At December 31, 2020, unrecognized share-based compensation expense by award-type and the weighted-average period over which such expense is expected to be recognized, as applicable, were as follows:
(dollars in millions)Unrecognized ExpenseWeighted-Average Recognition Period
Stock options$86.2 2.3 years
RSUs$99.5 2.3 years
Stock Options. Typically, stock options have a ten-year term and vest over a three to four-year period. The exercise price of stock options granted is equal to the closing price of our common stock on the date of grant. We estimate the fair value of stock options using the Black-Scholes option-pricing model on the date of grant. The Black-Scholes option-pricing model incorporates various and highly sensitive assumptions including expected volatility, term and interest rates. The weighted-average grant-date fair values of stock options granted were $45.67, $41.74 and $43.42 for 2020, 2019 and 2018, respectively.
The fair value of each stock option granted was estimated on the date of grant using the Black-Scholes option-pricing valuation model with the following weighted-average assumptions:
Year Ended December 31,
202020192018
Risk-free interest rate1.4 %2.4 %2.5 %
Expected volatility of common stock48.5 %54.8 %59.5 %
Dividend yield0.0 %0.0 %0.0 %
Expected option term5.3 years5.4 years4.7 years
The weighted-average valuation assumptions were determined as follows:
•The expected volatility of common stock is estimated based on the historical volatility of our common stock over the most recent period commensurate with the estimated expected term of our stock options.
•The expected option term is estimated based on historical experience as well as the status of the employee. For example, directors and officers have a longer expected option term than all other employees.
•The risk-free interest rate for periods within the contractual life of a stock option is based upon observed interest rates appropriate for the expected term of our employee stock options.
•We have not historically declared or paid dividends and do not intend to do so in the foreseeable future.
A summary of activity related to stock options follows:
(in millions, except weighted average data)Number of
Stock Options		Weighted
Average
Exercise Price		Weighted-Average Remaining Contractual TermAggregate Intrinsic Value
Outstanding at December 31, 20196.1 $52.62 
Granted1.3 $103.44 
Exercised(0.6)$43.90 
Canceled— $— 
Outstanding at December 31, 20206.8 $62.98 6.4 years$235.4 
Exercisable at December 31, 20204.7 $49.80 5.5 years$218.2 
The total intrinsic value of stock options exercised during 2020, 2019 and 2018 was $40.2 million, $64.3 million and $117.0 million, respectively. Cash received from stock option exercises during 2020, 2019 and 2018 was $23.5 million, $27.3 million and $29.5 million, respectively.
Restricted Stock Units. Typically, RSUs vest over a four-year period. The fair value of RSUs is based on the closing sale price of our common stock on the date of issuance. RSUs may be subject to a deferred delivery arrangement at the election of eligible employees.
85

A summary of activity related to RSUs follows:
(in millions, except weighted average data)Number of
RSUs		Weighted-Average Grant Date
Fair Value		Weighted-Average Remaining Contractual TermAggregate Intrinsic Value
Unvested at December 31, 20191.4 $74.77 
Granted0.7 $102.92 
Released(0.5)$67.86 
Canceled(0.1)$84.95 
Unvested at December 31, 20201.5 $89.60 1.3 years$147.5 
The total fair value of RSUs that vested during 2020, 2019 and 2018 was $49.7 million, $36.1 million and $35.5 million, respectively.
Performance-Based Restricted Stock Units. PRSUs vest based on the achievement of certain predefined Company-specific performance criteria and expire four to five years from the grant date. The fair value of PRSUs is estimated based on the closing sale price of our common stock on the date of grant. Expense recognition for PRSUs commences when attainment of the performance-based criteria is determined to be probable.
A summary of activity related to PRSUs follows:
(in millions, except weighted average data)Number of
PRSUs		Weighted-Average Grant Date
Fair Value		Weighted-Average Remaining Contractual TermAggregate Intrinsic Value
Unvested at December 31, 20190.3 $59.62 
Granted0.2 $102.90 
Released(0.1)$82.04 
Canceled(0.2)$45.67 
Unvested at December 31, 20200.2 $102.90 2.2 years$15.8 
At December 31, 2020, unrecognized share-based compensation expense for PRSUs was $17.0 million. The total fair value of PRSUs that vested during 2020 was $13.5 million. No PRSUs vested during 2019 or 2018.
Employee Stock Purchase Plan. Under the ESPP, eligible employees may purchase shares of our common stock at a discount semi-annually based on a percentage of their annual compensation. The discounted purchase price is equal to the lower of 85% of (i) the market value per share of the common stock on the first day of the offering period or (ii) the market value per share of common stock on the purchase date.
Note 9. Income Taxes
Components of income tax expense for continuing operations were as follows:
Year Ended December 31,
(in millions)202020192018
Current:
Federal$— $— $(0.1)
State10.1 9.5 0.8 
Total current taxes10.1 9.5 0.7 
Deferred:
Federal(287.5)— — 
State(23.2)— — 
Total deferred taxes(310.7)— — 
(Benefit from) provision for income taxes$(300.6)$9.5 $0.7 
86

The provision for income taxes on earnings subject to income taxes differs from the statutory federal rate due to the following:
Year Ended December 31,
(in millions)202020192018
Federal income taxes at 21% for 2020, 2019, 2018
$22.4 $9.8 $4.6 
State income tax, net of federal benefit5.5 4.0 0.4 
Non-deductible expenses0.6 0.8 0.4 
Branded prescription drug fee4.9 3.7 — 
Share-based compensation expense(6.7)(12.8)(9.8)
Officer compensation3.7 3.1 0.9 
Change in tax rate3.3 (4.1)(0.2)
Expired tax attributes1.1 1.2 13.9 
Research credits(39.0)(10.4)(13.5)
Change in valuation allowance(296.3)13.9 4.3 
Other(0.1)0.3 (0.3)
(Benefit from) provision for income taxes$(300.6)$9.5 $0.7 
Significant components of our deferred tax assets as of December 31, 2020 and 2019 are listed below.
 December 31,
(in millions)20202019
Deferred tax assets:
Net operating losses$111.4 $181.3 
Research and development credits109.6 71.9 
Capitalized research and development24.7 28.0 
Share-based compensation expense29.8 22.9 
Operating lease assets25.2 23.3 
Intangible assets86.7 49.3 
Other23.9 18.5 
Total deferred tax assets411.3 395.2 
Deferred tax liabilities:
Convertible senior notes(13.8)(24.1)
Operating lease liabilities(19.9)(18.2)
Other(8.4)(6.9)
Total deferred tax liabilities(42.1)(49.2)
Net of deferred tax assets and liabilities369.2 346.0 
Valuation allowance(49.8)(346.0)
Net deferred tax assets$319.4 $— 
At December 31, 2020, our deferred tax assets were primarily the result of federal net operating loss carry forwards, capitalized research costs, acquired intangible assets and tax credit carryforwards. At December 31, 2020 and 2019, we recorded a valuation allowance of $49.8 million and $346.0 million, respectively, against our gross deferred tax asset balance.
At each reporting date, management considers new evidence, both positive and negative, that could affect its assessment of the future realizability of our deferred tax assets. At December 31, 2020, in part because we achieved three years of cumulative pretax income, management determined there is sufficient positive evidence to conclude that it is more likely than not deferred tax assets of $319.4 million are realizable. Accordingly, we recorded a net valuation release of $296.3 million on the basis of management’s assessment. The remaining valuation allowance of $49.8 million consists primarily of state net operating loss and credit carryforwards for which management cannot conclude it is more likely than not to be realized. The release of the valuation allowance is reported under continuing operations as a benefit to income tax expense.
87

At December 31, 2020, we had federal and state income tax net operating loss carryforwards of $518.2 million and $340.8 million, respectively. The federal net operating losses will begin to expire in 2028, unless previously utilized.
California net operating losses will begin to expire in 2028 unless previously utilized and the net operating losses related to other states will begin to expire in 2026.
In addition, we have federal and California R&D tax credit carryforwards of $92.1 million and $56.4 million, respectively. A portion of the federal R&D tax credit carryforwards expired in 2020. The remaining federal R&D tax credits will continue to expire beginning in 2021, unless previously utilized. The California R&D tax credits carry forward indefinitely.
Additionally, the future utilization of our net operating loss and R&D tax credit carryforwards to offset future taxable income may be subject to an annual limitation, pursuant to Internal Revenue Code Sections 382 and 383, as a result of ownership changes that could occur in the future. No ownership changes have occurred through December 31, 2020.
The impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained.
Our policy is to recognize interest or penalties related to income tax matters in income tax expense. Interest and penalties related to income tax matters were not material for 2020, 2019 or 2018.
We are subject to taxation in the U.S. and various state jurisdictions. Our tax years for 2001 (federal) and 2008 (California) and forward are subject to examination by federal and state tax authorities due to the carryforward of unutilized net operating losses and R&D tax credits.
A summary of activity related to unrecognized tax benefits follows:
Year Ended December 31,
(in millions)202020192018
Balance at January 1$63.9 $54.8 $37.4 
(Decrease) increase related to prior year tax positions(5.7)0.3 6.1 
Increase related to current year tax positions3.9 9.5 11.7 
Settlements related to prior year tax positions(0.2)— — 
Expiration of the statute of limitations for the assessment of taxes(1.1)(0.7)(0.4)
Balance at December 31$60.8 $63.9 $54.8 
We excluded those deferred tax assets that are not more-likely-than-not to be sustained under the technical merits of the tax position. Such unrecognized tax benefits total $3.9 million for current year tax positions, as reflected in the table above.
At December 31, 2020, we had $53.9 million of unrecognized tax benefits that, if recognized and realized, would affect the effective tax rate, subject to the valuation allowance. We do not expect a significant change in our unrecognized tax benefits in the next twelve months.
Note 10. Leases
We have operating leases for our office and laboratory facilities, including our corporate headquarters, with terms that expire from 2025 through 2031. We have two options to extend the term of the operating lease for our corporate headquarters for a period of ten years each. However, as we were not reasonably certain to exercise either of those options at lease commencement, neither option was recognized as part of the associated operating lease right-of-use, or ROU, asset or liability. In connection with our operating leases, in lieu of cash security deposits, Wells Fargo Bank, N.A., issued letters of credit on our behalf, which are secured by deposits totaling $3.2 million.
Our operating lease cost was $10.1 million for 2020 and $8.1 million for 2019. Cash paid for amounts included in the measurement of lease liabilities was $8.6 million for 2020 and $7.7 million for 2019.
88

Our operating leases had a weighted-average remaining lease term of approximately 10.3 years and 11.2 years at December 31, 2020 and 2019, respectively, and a weighted-average discount rate of 5.6% and 5.8% at December 31, 2020 and 2019, respectively.
Approximate future minimum lease payments under operating leases were as follows:
(in millions)December 31,
2020
Year ending December 31, 2021
$10.7 
Year ending December 31, 2022
12.4 
Year ending December 31, 2023
12.7 
Year ending December 31, 2024
13.1 
Year ending December 31, 2025
13.5 
Thereafter77.5 
Total operating lease payments139.9 
Less accreted interest35.2 
Total operating lease liabilities104.7 
Less current operating lease liabilities10.3 
Noncurrent operating lease liabilities$94.4 
Note 1: Amounts presented in the table above exclude $19.7 million of non-cancelable future minimum lease payments for operating leases that have not yet commenced.
Note 2: Current operating lease liabilities are included in other current liabilities on the consolidated balance sheets.
Note 11. Retirement Plan
We have a 401(k) defined contribution savings plan, or the 401(k) Plan. The 401(k) Plan is for the benefit of all qualifying employees and permits voluntary contributions by employees up to 60% of base salary limited by the IRS-imposed maximum. Employer contributions were $6.7 million, $4.9 million, and $1.8 million for 2020, 2019 and 2018, respectively.

89

Note 12. Selected Quarterly Financial Data (Unaudited)
A summary of our quarterly results follows:
(in millions, except per share data)First
Quarter		Second
Quarter		Third
Quarter		Fourth
Quarter
Year Ended December 31, 2020:    
Total revenues$237.1 $302.4 $258.5 $247.9 
Total operating expenses (1)
$178.2 $225.8 $302.8 $176.1 
Net income (loss) (1)
$37.4 $79.6 $(57.6)$347.9 
Net income (loss) per share, basic (1)
$0.40 $0.86 $(0.62)$3.72 
Net income (loss) per share, diluted (1)
$0.39 $0.81 $(0.62)$3.58 
Weighted average common shares outstanding, basic92.6 93.0 93.3 93.5 
Weighted average common shares outstanding, diluted97.0 98.2 93.3 97.2 
Year Ended December 31, 2019:
Total revenues$138.4 $183.5 $222.1 $244.1 
Total operating expenses (2)
$239.4 $149.1 $132.0 $195.3 
Net (loss) income (2)
$(102.1)$51.3 $53.8 $34.0 
Net (loss) income per share, basic (2)
$(1.12)$0.56 $0.59 $0.37 
Net (loss) income per share, diluted (2)
$(1.12)$0.54 $0.56 $0.35 
Weighted average common shares outstanding, basic91.1 91.4 91.9 92.2 
Weighted average common shares outstanding, diluted91.1 94.8 96.1 97.2 
(1) In connection with the payment of the upfront fee pursuant to our collaboration and license agreement with Idorsia, we recorded a charge of $46.0 million, accounted for as IPR&D, in the second quarter of 2020. In connection with the payment of the upfront fee pursuant to our collaboration with Takeda, we recorded a charge of $118.5 million, accounted for as IPR&D, in the third quarter of 2020.
(2) In connection with the payment of the upfront fee pursuant to our collaboration and license agreement with Voyager, we recorded a charge of $113.1 million, accounted for as IPR&D, in the first quarter of 2019. In the second quarter of 2019, we entered into an amendment to the collaboration and license agreement with Voyager, pursuant to which we paid Voyager $5.0 million upfront, accounted for as IPR&D, to obtain outside the U.S. rights to the Friedreich’s ataxia program. In connection with the payment of the upfront fee pursuant to our collaboration with Xenon, we recorded a charge of $36.2 million, accounted for as IPR&D, in the fourth quarter of 2019.
90

Item 9. Changes and Disagreements with Accountants on Accounting and Financial Disclosure
Not applicable.
Item 9A. Controls and Procedures
We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the timelines specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can only provide reasonable assurance of achieving the desired control objectives, and in reaching a reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.
As required by SEC Rule 13a-15(b), we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the year covered by this report. Based on the foregoing, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level.
91

Management’s Report on Internal Control Over Financial Reporting
Internal control over financial reporting refers to the process designed by, or under the supervision of, our Chief Executive Officer and Chief Financial Officer, and effected by our board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles, and includes those policies and procedures that:
(1)    Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets;
(2)    Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorization of our management and directors; and
(3)    Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements.
Internal control over financial reporting cannot provide absolute assurance of achieving financial reporting objectives because of its inherent limitations. Internal control over financial reporting is a process that involves human diligence and compliance and is subject to lapses in judgment and breakdowns resulting from human failures. Internal control over financial reporting also can be circumvented by collusion or improper management override. Because of such limitations, there is a risk that material misstatements may not be prevented or detected on a timely basis by internal control over financial reporting. However, these inherent limitations are known features of the financial reporting process. Therefore, it is possible to design into the process safeguards to reduce, though not eliminate, this risk. Management is responsible for establishing and maintaining adequate internal control over financial reporting for the company.
Management has used the framework set forth in the report entitled Internal Control-Integrated Framework (2013 framework) published by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework), known as COSO, to evaluate the effectiveness of our internal control over financial reporting. Based on this assessment, management has concluded that our internal control over financial reporting was effective as of December 31, 2020. Ernst & Young, LLP, our independent registered public accounting firm, has issued an attestation report on our internal control over financial reporting as of December 31, 2020, which is included herein.
There has been no change in our internal control over financial reporting during our most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
92

Report of Independent Registered Public Accounting Firm
To the Shareholders and the Board of Directors of Neurocrine Biosciences, Inc.
Opinion on Internal Control over Financial Reporting
We have audited Neurocrine Biosciences, Inc.’s internal control over financial reporting as of December 31, 2020, based on criteria established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework), (the COSO criteria). In our opinion, Neurocrine Biosciences, Inc. (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2020, based on the COSO criteria.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2020 and 2019, the related consolidated statements of income and comprehensive income, stockholders‘ equity, and cash flows, for each of the three years in the period ended December 31, 2020, and the related notes and our report dated February 5, 2021 expressed an unqualified opinion thereon.
Basis for Opinion
The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management’s Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.
Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.
Definition and Limitations of Internal Control Over Financial Reporting
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
/s/ Ernst & Young LLP
San Diego, California
February 5, 2021
93

Item 9B. Other Information
None.
94

PART III
Item 10. Directors, Executive Officers and Corporate Governance
Information required by this item will be contained in our Definitive Proxy Statement for our 2021 Annual Meeting of Stockholders, to be filed pursuant to Regulation 14A with the Securities and Exchange Commission within 120 days of December 31, 2020. Such information is incorporated herein by reference.
We have adopted a code of ethics that applies to our Chief Executive Officer, Chief Financial Officer, and to all of our other officers, directors, employees and agents. The code of ethics is available at the Corporate Governance section of the Investors page on our website at www.neurocrine.com. We intend to disclose future amendments to, or waivers from, certain provisions of our code of ethics on the above website within four business days following the date of such amendment or waiver. Information found on, or accessible through, our website is not part of, and is not incorporated into, this Annual Report on Form 10-K.
Item 11. Executive Compensation
Information required by this item will be contained in our Definitive Proxy Statement for our 2021 Annual Meeting of Stockholders, to be filed pursuant to Regulation 14A with the Securities and Exchange Commission within 120 days of December 31, 2020. Such information is incorporated herein by reference.
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
Information required by this item will be contained in our Definitive Proxy Statement for our 2021 Annual Meeting of Stockholders, to be filed pursuant to Regulation 14A with the Securities and Exchange Commission within 120 days of December 31, 2020. Such information is incorporated herein by reference.
Item 13. Certain Relationships and Related Transactions, and Director Independence
Information required by this item will be contained in our Definitive Proxy Statement for our 2021 Annual Meeting of Stockholders, to be filed pursuant to Regulation 14A with the Securities and Exchange Commission within 120 days of December 31, 2020. Such information is incorporated herein by reference.
Item 14. Principal Accounting Fees and Services
Information required by this item will be contained in our Definitive Proxy Statement for our 2021 Annual Meeting of Stockholders, to be filed pursuant to Regulation 14A with the Securities and Exchange Commission within 120 days of December 31, 2020. Such information is incorporated herein by reference.
95

PART IV
Item 15. Exhibits, Financial Statement Schedules
(a) Documents filed as part of this report.
1. List of Financial Statements. The following are included in Item 8 of this report:
Report of Independent Registered Public Accounting Firm
Consolidated Balance Sheets as of December 31, 2020 and 2019
Consolidated Statements of Income and Comprehensive Income for the years ended December 31, 2020, 2019 and 2018
Consolidated Statements of Stockholders’ Equity for the years ended December 31, 2020, 2019 and 2018
Consolidated Statements of Cash Flows for the years ended December 31, 2020, 2019 and 2018
Notes to the Consolidated Financial Statements (includes unaudited Selected Quarterly Financial Data)
2. List of all Financial Statement schedules. All schedules are omitted because they are not applicable, or the required information is shown in the Financial Statements or notes thereto.
3. List of Exhibits required by Item 601 of Regulation S-K. See part (b) below.
(b) Exhibits. The following exhibits are filed as part of, or incorporated by reference into, this report:
Exhibit  
   
3.1Description:
 Reference:Incorporated by reference to Exhibit 3.1 of the Company’s Quarterly Report on Form 10-Q filed on November 5, 2018
3.2Description:
Reference:Incorporated by reference to Exhibit 3.2 of the Company’s Quarterly Report on Form 10-Q filed on November 5, 2018
   
3.3Description:
Reference:Incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K filed on February 4, 2020
3.4Description:
 Reference:Incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K filed on August 28, 2020
   
4.1Description:
 Reference:Incorporated by reference to the Company’s Registration Statement on Form S-1 (Registration No. 333-03172)
   
4.2Description:
 Reference:Incorporated by reference to Exhibit 4.1 of the Company’s Current Report on Form 8-K filed on May 2, 2017
   
4.3Description:
 Reference:Incorporated by reference to Exhibit 99.1 of the Company’s Current Report on Form 8-K filed on May 2, 2017
4.4Description:
Reference:Incorporated by reference to Exhibit 4.4 of the Company’s Annual Report on Form 10-K filed on February 7, 2020
   
21.1Description:
   
23.1Description:
   
96

31.1Description:
   
31.2Description:
   
32***Description:
   
101.INSDescription:Inline XBRL Instance Document. – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
   
101.SCHDescription:Inline XBRL Taxonomy Extension Schema Document.
   
101.CALDescription:Inline XBRL Taxonomy Extension Calculation Linkbase Document.
   
101.DEFDescription:Inline XBRL Taxonomy Extension Definition Linkbase Document.
   
101.LABDescription:Inline XBRL Taxonomy Extension Label Linkbase Document.
   
101.PREDescription:Inline XBRL Taxonomy Extension Presentation Linkbase Document.
   
104Description:Cover Page Interactive Data File (formatted as Inline XBRL with applicable taxonomy extension information contained in Exhibit 101)
Collaboration and License Agreements:
  
10.1*Description:
 Reference:Incorporated by reference to Exhibit 10.2 of the Company’s Quarterly Report on Form 10-Q filed on July 29, 2010
   
10.2*Description:
 Reference:Incorporated by reference to Exhibit 10.2 of the Company’s Quarterly Report on Form 10-Q filed on October 31, 2011
   
10.3*Description:
 Reference:Incorporated by reference to Exhibit 10.1 of the Company’s Quarterly Report on Form 10-Q filed on April 30, 2015
   
10.4*Description:
 Reference:Incorporated by reference to Exhibit 99.4 of the Company’s Current Report on Form 8-K filed on April 25, 2017
   
10.5*Description:
 Reference:Incorporated by reference to Exhibit 10.5 of the Company’s Annual Report on Form 10-K filed on February 7, 2019
   
10.6Description:
 Reference:Incorporated by reference to Exhibit 10.6 of the Company’s Annual Report on Form 10-K filed on February 7, 2019
   
10.7Description:
 Reference:Incorporated by reference to Exhibit 10.7 of the Company’s Annual Report on Form 10-K filed on February 7, 2019
   
10.8Description:
 Reference:Incorporated by reference to Exhibit 10.1 of the Company’s Quarterly Report on Form 10-Q filed on July 29, 2019
10.9**Description:
Reference:Incorporated by reference to Exhibit 10.3 of the Company’s Quarterly Report on Form 10-Q filed on August 3, 2020
97

   
Equity Plans and Related Agreements:
   
10.10+
Description:
 Reference:Incorporated by reference to Exhibit 99.1 of the Company’s Current Report on Form 8-K filed on May 30, 2018
   
10.11+
Description:
 Reference:Incorporated by reference to Exhibit 99.1 of the Company’s Current Report on Form 8-K filed on June 1, 2015
   
10.12+
Description:
 Reference:Incorporated by reference to Exhibit 10.17 of the Company’s Annual Report on Form 10-K filed on February 13, 2018
   
10.13+
Description:
 Reference:Incorporated by reference to Exhibit 10.1 of the Company’s Quarterly Report on Form 10-Q filed on July 29, 2015
   
10.14+
Description:
 Reference:Incorporated by reference to Exhibit 99.2 of the Company’s Current Report on Form 8-K filed on May 30, 2018
10.15+
Description:
Reference:Incorporated by reference to Exhibit 10.1 of the Company’s Quarterly Report on Form 10-Q filed on August 3, 2020
10.16+
Description:
Reference:Incorporated by reference to Exhibit 10.2 of the Company’s Quarterly Report on Form 10-Q filed on August 3, 2020
   
Agreements with Officers and Directors:
   
10.17+
Description:
 Reference:Incorporated by reference to Exhibit 10.3 of the Company’s Quarterly Report on Form 10-Q filed on August 3, 2007
   
10.18+
Description:
 Reference:Incorporated by reference to Exhibit 10.32 of the Company’s Annual Report on Form 10-K filed on February 11, 2008
   
10.19+
Description:
Incorporated by reference to Exhibit 10.16 of the Company’s Annual Report on Form 10-K filed on February 6, 2020
   
10.20+
Description:
 Reference:Incorporated by reference to Exhibit 10.3 of the Company’s Annual Report on Form 10-K filed on February 14, 2017
   
10.21+
Description:
 Reference:Incorporated by reference to Exhibit 10.26 of the Company’s Annual Report on Form 10-K filed on February 13, 2018
   
10.22+
Description:
 Reference:Incorporated by reference to Exhibit 10.1 of the Company’s Quarterly Report on Form 10-Q filed on November 1, 2017
   
98

10.23+
Description:
 Reference:Incorporated by reference to Exhibit 10.2 of the Company’s Quarterly Report on Form 10-Q filed on July 29, 2019
Agreements Related to Real Property:
   
10.24Description:
 Reference:Incorporated by reference to Exhibit 99.2 of the Company’s Current Report on Form 8-K filed on January 18, 2012
   
10.25Description:
 Reference:Incorporated by reference to Exhibit 10.1 of the Company’s Quarterly Report on Form 10-Q filed on August 3, 2017
   
10.26Description:
 Reference:Incorporated by reference to Exhibit 10.3 of the Company’s Quarterly Report on Form 10-Q filed on November 1, 2017
   
10.27Description:
 Reference:Incorporated by reference to Exhibit 10.3 of the Company’s Current Report on Form 8-K filed on December 10, 2007; Exhibit 10.5 of the Company’s Annual Report on Form 10-K filed on February 9, 2015; and Exhibit 10.2 of the Company’s Quarterly Report on Form 10-Q filed on August 3, 2017
   
10.28Description:
 Reference:Incorporated by reference to Exhibit 10.1 of the Company’s Quarterly Report on Form 10-Q filed on November 4, 2019
+Management contract or compensatory plan or arrangement.
*Confidential treatment has been granted with respect to certain portions of the exhibit.
**Certain portions of the exhibit have been omitted because the omitted information is not material and would likely cause competitive harm if publicly disclosed.
***These certifications are being furnished solely to accompany this annual report pursuant to 18 U.S.C. Section 1350 and are not being filed for purposes of Section 18 of the Securities Exchange Act of 1934 and are not to be incorporated by reference into any filing of Neurocrine Biosciences, Inc., whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Except as specifically noted above, the Company’s Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K have a Commission File Number of 000-22705.
(c) Financial Statement Schedules. See Item 15(a)(2) above.
99

SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
NEUROCRINE BIOSCIENCES, INC.
(Registrant)
By:
/s/ Kevin C. Gorman
Kevin C. Gorman
Chief Executive Officer
Date:February 5, 2021
By:
/s/ Matthew C. Abernethy
 Matthew C. Abernethy
 Chief Financial Officer
Date:February 5, 2021
100

POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Kevin C. Gorman and Matthew C. Abernethy, and each of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution for him or her, and in his or her name in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power of authority to do and perform each and every act and thing requisite and necessary to be done therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, and any of them, his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of the Registrant and in the capacities indicated as of February 5, 2021:
SignatureTitle
/s/ Kevin C. Gorman
Chief Executive Officer and Director
Kevin C. Gorman, Ph.D.(Principal Executive Officer)
/s/ Matthew C. Abernethy
Chief Financial Officer
Matthew C. Abernethy(Principal Financial and Accounting Officer)
/s/ William H. Rastetter
Chairman of the Board of Directors
William H. Rastetter, Ph.D. 
/s/ Gary A. Lyons
Director
Gary A. Lyons 
/s/ George J. Morrow
Director
George J. Morrow 
/s/ Leslie V. Norwalk
Director
Leslie V. Norwalk 
/s/ Richard F. Pops
Director
Richard F. Pops 
/s/ Stephen A. Sherwin
Director
Stephen A. Sherwin, M.D. 
/s/ Shalini Sharp
Director
Shalini Sharp 
101
 EX-21.1 2 nbix-20201231exhibit211.htm EX-21.1 Document
Exhibit 21.1
NEUROCRINE BIOSCIENCES INC. SUBSIDIARIES
Name of SubsidiaryJurisdiction
Neurocrine Continental, Inc.Delaware, USA
Neurocrine Europe, Ltd.Ireland
Neurocrine Therapeutics, Ltd.Ireland

 EX-23.1 3 nbix-20201231exhibit231.htm EX-23.1 Document
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the following Registration Statements:

(1) Registration Statements (Form S-8 Nos. 333-175889, 333-190178, 333-197916, and 333-212871) pertaining to the 2011 Equity Incentive Plan of Neurocrine Biosciences, Inc.,

(2) Registration Statements (Form S-8 Nos. 333-199837, and 333-216067) pertaining to the Inducement Plan of Neurocrine Biosciences, Inc.,

(3) Registration Statements (Form S-8 Nos. 333-205933 and 333-223020) pertaining to the 2011 Equity Incentive Plan and Inducement Plan of Neurocrine Biosciences, Inc.,

(4) Registration Statements (Form S-8 No. 333-226971) pertaining to the 2011 Equity Incentive Plan and 2018 Employee Stock Purchase Plan of Neurocrine Biosciences, Inc., and

(5) Registration Statements (Form S-8 No. 333-234501) pertaining to the 2011 Equity Incentive Plan

(6) Registration Statements (Form S-8 No. 333-240301) pertaining to the 2020 Equity Incentive Plan

of our reports dated February 5, 2021 with respect to the consolidated financial statements of Neurocrine Biosciences, Inc., and the effectiveness of internal control over financial reporting of Neurocrine Biosciences, Inc., included in this Annual Report (Form 10-K) of Neurocrine Biosciences, Inc. for the year ended December 31, 2020.
/s/ Ernst & Young LLP
San Diego, California
February 5, 2021

 EX-31.1 4 nbix-20201231exhibit311.htm EX-31.1 Document
Exhibit 31.1
CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT
TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Kevin C. Gorman, Chief Executive Officer of Neurocrine Biosciences, Inc., certify that:
1.I have reviewed this annual report on Form 10-K of Neurocrine Biosciences, Inc.;
2.Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this annual report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this annual report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this annual report based on such evaluation; and
d)Disclosed in this annual report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of the internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent function):
a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting.
Dated: February 5, 2021
/s/ Kevin C. Gorman
Kevin C. Gorman
Chief Executive Officer

 EX-31.2 5 nbix-20201231exhibit312.htm EX-31.2 Document
Exhibit 31.2
CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT
TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Matthew C. Abernethy, Chief Financial Officer of Neurocrine Biosciences, Inc., certify that:
1.I have reviewed this annual report on Form 10-K of Neurocrine Biosciences, Inc.;
2.Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this annual report;
3.Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this annual report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this annual report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this annual report based on such evaluation; and
d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of the internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent function):
a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting.
Dated: February 5, 2021
/s/ Matthew C. Abernethy
Matthew C. Abernethy
Chief Financial Officer

 EX-32 6 nbix-20201231exhibit32.htm EX-32 Document
Exhibit 32
CERTIFICATIONS OF
CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report on Form 10-K of Neurocrine Biosciences, Inc. (the “Company”) for the year ended December 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Kevin C. Gorman, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:
(1)The Report fully complies with the requirements of Section 13(a) or 15(d), of the Securities Exchange Act of 1934; and
(2)That information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
February 5, 2021
By: 
/s/ Kevin C. Gorman
 Name: Kevin C. Gorman
 Title: Chief Executive Officer
In connection with the Annual Report on Form 10-K of Neurocrine Biosciences, Inc. (the “Company”) for the year ended December 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Matthew C. Abernethy, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:
(1)The Report fully complies with the requirements of Section 13(a) or 15(d), of the Securities Exchange Act of 1934; and
(2)That information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
February 5, 2021
By: 
/s/ Matthew C. Abernethy
 Name: Matthew C. Abernethy
 Title: Chief Financial Officer

 EX-101.SCH 7 nbix-20201231.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 1001002 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1002003 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1003004 - Statement - Consolidated Statements Income and Comprehensive Income link:presentationLink link:calculationLink link:definitionLink 1004005 - Statement - Consolidated Statements of Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 1005006 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 2101101 - Disclosure - Organization and Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2202201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2403401 - Disclosure - Organization and Summary of Significant Accounting Policies - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2104102 - Disclosure - License and Collaboration Agreements link:presentationLink link:calculationLink link:definitionLink 2405402 - Disclosure - License and Collaboration Agreements - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2106103 - Disclosure - Debt Securities link:presentationLink link:calculationLink link:definitionLink 2307301 - Disclosure - Debt Securities (Tables) link:presentationLink link:calculationLink link:definitionLink 2408403 - Disclosure - Debt Securities - Amortized Cost, Gross Unrealized Gain (Loss) Positions and Estimated Fair Value for Available-For-Sale Debt Securities (Details) link:presentationLink link:calculationLink link:definitionLink 2409404 - Disclosure - Debt Securities - Gross Unrealized Losses and Fair Value Available-For-Sale Debt securities in Unrealized Loss Position (Details) link:presentationLink link:calculationLink link:definitionLink 2410405 - Disclosure - Debt Securities - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2111104 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 2312302 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 2413406 - Disclosure - Fair Value Measurements - Assets Measured at Fair Value on Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 2414407 - Disclosure - Fair Value Measurements - Reconciliation of Equity Securities Measured at Fair Value on Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 2415408 - Disclosure - Fair Value Measurements - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2116105 - Disclosure - Convertible Senior Notes link:presentationLink link:calculationLink link:definitionLink 2317303 - Disclosure - Convertible Senior Notes (Tables) link:presentationLink link:calculationLink link:definitionLink 2418409 - Disclosure - Convertible Senior Notes - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2419410 - Disclosure - Convertible Senior Notes, Net of Discounts and Deferred Financing Costs (Details) link:presentationLink link:calculationLink link:definitionLink 2120106 - Disclosure - Other Balance Sheet Details link:presentationLink link:calculationLink link:definitionLink 2321304 - Disclosure - Other Balance Sheet Details (Tables) link:presentationLink link:calculationLink link:definitionLink 2422411 - Disclosure - Other Balance Sheet Details - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 2423412 - Disclosure - Other Balance Sheet Details - Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 2424413 - Disclosure - Other Balance Sheet Details - Accounts Payable and Accrued Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2425414 - Disclosure - Other Balance Sheet Details - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details) link:presentationLink link:calculationLink link:definitionLink 2126107 - Disclosure - Net Income Per Share link:presentationLink link:calculationLink link:definitionLink 2327305 - Disclosure - Net Income Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2428415 - Disclosure - Net Income Per Share - Schedule of Net Income (Loss) Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 2429416 - Disclosure - Net Income Per Share - Schedule of Anti-Dilutive Shares Excluded from Diluted Per Share Amounts (Details) link:presentationLink link:calculationLink link:definitionLink 2130108 - Disclosure - Share-Based Compensation link:presentationLink link:calculationLink link:definitionLink 2331306 - Disclosure - Share-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 2432417 - Disclosure - Share-Based Compensation - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2433418 - Disclosure - Share-Based Compensation - Compensation Cost Related to Share-Based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 2434419 - Disclosure - Share-Based Compensation - Schedule of Share-based Compensation Expense by Award-type (Details) link:presentationLink link:calculationLink link:definitionLink 2435420 - Disclosure - Share-Based Compensation - Schedule of Share-based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 2436421 - Disclosure - Share-Based Compensation - Weighted-Average Assumptions for Stock Option Grants using Black-Scholes Option-Pricing Model (Details) link:presentationLink link:calculationLink link:definitionLink 2437422 - Disclosure - Share-Based Compensation - Summary of Activity Related to Stock Options (Details) link:presentationLink link:calculationLink link:definitionLink 2438423 - Disclosure - Share-Based Compensation - Summary and Changes in Restricted Stock Units Outstanding (Details) link:presentationLink link:calculationLink link:definitionLink 2139109 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2340307 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 2441424 - Disclosure - Income Taxes - Components of Income Tax Expense for Continuing Operations (Details) link:presentationLink link:calculationLink link:definitionLink 2442425 - Disclosure - Income Taxes - Provision for Income Taxes on Earnings Subject to Income Taxes Differs from Statutory Federal Rate (Details) link:presentationLink link:calculationLink link:definitionLink 2443426 - Disclosure - Income Taxes - Components of Deferred Tax Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2444427 - Disclosure - Income Taxes - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2445428 - Disclosure - Income Taxes - Summary of Activity Related to Unrecognized Tax Benefits (Details) link:presentationLink link:calculationLink link:definitionLink 2146110 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 2347308 - Disclosure - Leases (Table) link:presentationLink link:calculationLink link:definitionLink 2448429 - Disclosure - Leases - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2449430 - Disclosure - Leases - Summary of Future Minimum Lease Payments Under Operating Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2449430 - Disclosure - Leases - Summary of Future Minimum Lease Payments Under Operating Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2150111 - Disclosure - Retirement Plan link:presentationLink link:calculationLink link:definitionLink 2451431 - Disclosure - Retirement Plan - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2152112 - Disclosure - Selected Quarterly Financial Data (Unaudited) link:presentationLink link:calculationLink link:definitionLink 2353309 - Disclosure - Selected Quarterly Financial Data (Unaudited) (Tables) link:presentationLink link:calculationLink link:definitionLink 2454432 - Disclosure - Summary of Quarterly Results of Operations (Details) link:presentationLink link:calculationLink link:definitionLink 2455433 - Disclosure - Summary of Quarterly Results of Operations - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 nbix-20201231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 9 nbix-20201231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 10 nbix-20201231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Asset Acquisitions Business Combinations Policy [Policy Text Block] Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Debt Instrument, Conversion [Domain] Debt Instrument, Conversion [Domain] Debt Instrument, Conversion NBI-827104 NBI-827104 [Member] NBI-827104 Document Type Document Type ICFR Auditor Attestation Flag ICFR Auditor Attestation Flag Reconciliation of Cash, Cash Equivalents and Restricted Cash Summary Of Reconciliation Of Cash Cash Equivalents And Restricted Cash [Table Text Block] Summary of reconciliation of cash cash equivalents and restricted cash. Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Related Party Related Party [Axis] Accounts payable and accrued liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Amortization of debt discount Amortization of Debt Discount (Premium) Debt Securities Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Retirement Plan Retirement Benefits [Text Block] Released (in USD per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Level 3 Fair Value, Inputs, Level 3 [Member] Change in tax rate Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount Minimum percentage of common stock price trigger Minimum Percentage Of Trading Price To Last Reported Sale Price The minimum percentage of the product of the common stock trading price multiplied by the conversion rate during the measurement period as compared to the principal note amount that triggers a conversion option on the notes, if it falls below this percentage. Transaction cost related to issuance of convertible senior note Debt Issuance Costs, Gross Purchases of equity securities Purchases Payments to Acquire Restricted Investments Upfront payments made Upfront Payments Made Upfront payments made under a collaboration agreement. Statistical Measurement Statistical Measurement [Domain] Liabilities and Stockholders’ Equity Liabilities and Equity [Abstract] Convertible senior notes Convertible Debt, Current Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Investment income and other, net Investment Income And Other Net Investment income and other net. Security Exchange Name Security Exchange Name Proceeds from issuance Proceeds from Convertible Debt Operating income Operating Income (Loss) Total current liabilities Liabilities, Current Beginning Balance, Unvested (in USD per share) Ending Balance, Unvested (in USD per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value 2024 Notes (in shares) Incremental Common Shares Attributable To Dilutive Effect Of Conversion Of Debt Securities Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the treasury stock method. Defined contribution plan, maximum employee contribution percentage Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent Assets Assets [Abstract] Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Vesting period Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Accounting Policies [Abstract] Accounting Policies [Abstract] Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Five 2011 Plan Two Thousand And Eleven Plan [Member] Two Thousand and Eleven Plan [Member]. Furniture and fixtures Furniture and Fixtures [Member] Entity Address, State or Province Entity Address, State or Province Released (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Payments Operating Lease, Payments Federal income taxes at 21% for 2020, 2019, 2018 Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount Accumulated deficit Retained Earnings (Accumulated Deficit) Right-of-use assets Operating Lease, Right-of-Use Asset Debt discount, net Debt Instrument, Unamortized Discount Loss on extinguishment of convertible senior notes Loss on extinguishment of convertible senior notes Gain (Loss) on Extinguishment of Debt Year ending December 31, 2021 Lessee, Operating Lease, Liability, to be Paid, Year One Reconciliation of equity securities measured at fair value on recurring basis using significant unobservable inputs Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Cash paid for income taxes Income Taxes Paid Beginning Balance, Outstanding (in shares) Ending Balance, Outstanding (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Year ending December 31, 2024 Lessee, Operating Lease, Liability, to be Paid, Year Four Unrecognized expense Unrecognized Expense Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Cash and money market funds Cash And Money Market Fund [Member] Currency on hand as well as demand deposits with banks or financial institutions, and funds that invest in short-term money-market instruments, for example, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities. Customer [Axis] Customer [Axis] State Current State and Local Tax Expense (Benefit) Beginning balance (in shares) Ending balance (in shares) Shares, Outstanding Preferred stock, $0.001 par value; 5.0 shares authorized; no shares issued and outstanding at December 31, 2020 and 2019 Preferred Stock, Value, Issued Equity securities, FV-NI, measurement input Equity Securities, FV-NI, Measurement Input Income Taxes Income Tax, Policy [Policy Text Block] Principal amount on conversion rate Principal Amount On Conversion Rate Principal amount on conversion rate. Total operating expenses Total operating expenses Operating Expenses Common stock, par value (in USD per share) Common Stock, Par or Stated Value Per Share Other long-term liabilities Other Liabilities, Noncurrent Deferred tax assets Deferred Income Tax Assets, Net Debt securities available-for-sale (amortized cost $612.4 million at December 31, 2020 and $557.3 million at December 31, 2019) Marketable Securities, Current Work in process Inventory, Work in Process, Net of Reserves Share-based compensation expense APIC, Share-based Payment Arrangement, Increase for Cost Recognition Number of renewal options Number Of Renewal Options The number of renewal options under the terms of the lease. Inventories Total inventories Inventory, Net Trading days during observation period Trading Days During Observation Period Trading days during observation period. Revenues Total revenues Revenue from Contract with Customer, Excluding Assessed Tax Carrying amount of the liability component upon issuance Carrying Amount Of Liability Component Upon Issuance The carrying amount of the liability component upon issuance. Measurement Frequency Measurement Frequency [Domain] Advertising expense Advertising Expense Share price (in USD per share) Market price of common stock (in USD per share) Share Price Other Balance Sheet Details [Abstract] Other Balance Sheet Details [Abstract] Other balance sheet details. Concentration risk, percentage Concentration Risk, Percentage Contractual term of stock options Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period Conversion ratio Debt Instrument, Convertible, Conversion Ratio Statement [Line Items] Statement [Line Items] Net income per share: Earnings Per Share, Basic and Diluted [Abstract] Computer equipment Computer Equipment [Member] Term Debt Instrument, Term Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Entity Voluntary Filers Entity Voluntary Filers Measurement Input Type [Domain] Measurement Input Type [Domain] Statement [Table] Statement [Table] Share-based compensation expense Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits Statistical Measurement Statistical Measurement [Axis] Credit Facility Credit Facility [Axis] Accrued development costs Accrued Research And Development Expense Current Accrued research and development expense current. Fair value Debt Instrument, Fair Value Disclosure Deferred income taxes (including benefit from valuation allowance release) Deferred Income Taxes and Tax Credits Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Number of wholly owned Irish subsidiaries Number Of Irish Subsidiaries Number Of Irish Subsidiaries 2.25% Convertible Senior Notes 2.25% Convertible Senior Notes [Member] 2.25% Convertible Senior Notes. Convertible senior notes Convertible Debt, Noncurrent Weighted average Weighted Average [Member] Business Combinations [Abstract] Business Combinations [Abstract] Debt Securities Marketable Securities, Policy [Policy Text Block] Entity Small Business Entity Small Business Principles of Consolidation Consolidation, Policy [Policy Text Block] 2020 Plan 2020 Equity Incentive Plan [Member] 2020 Equity Incentive Plan Convertible Senior Notes Debt Disclosure [Text Block] Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Domain] Milestone payments Milestone Payment Payments made for milestones under a collaboration agreement. Collaborative Arrangement Collaborative Arrangement [Member] Issuances of common stock under benefit plans Proceeds from Issuance of Common Stock Selling, general and administrative expense Selling, General and Administrative Expenses [Member] Sales and maturities of debt securities available-for-sale Proceeds from Sale and Maturity of Debt Securities, Available-for-sale Amendment Flag Amendment Flag Schedule of net income (loss) per share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Weighted-average common shares outstanding: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Finite-Lived Intangible Assets, Major Class Name Finite-Lived Intangible Assets, Major Class Name [Domain] Number of common stock authorized for issuance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Research and Development Expenses Research and Development Expense, Policy [Policy Text Block] Deferred tax assets: Deferred Tax Assets, Gross [Abstract] Investments measured at fair value on recurring basis Fair Value, Assets Measured on Recurring Basis [Table Text Block] Largest two customers Largest Two Customers [Member] Largest Two Customers Aggregate repurchase price paid in cash Repayments of Debt Other Balance Sheet Details Supplemental Balance Sheet Disclosures [Text Block] Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Entity Central Index Key Entity Central Index Key Patent term Patent term Term of the patent, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Related Party Related Party [Domain] Measurement Frequency Measurement Frequency [Axis] Financial Instruments Financial Instruments [Domain] Operating lease liabilities Deferred Tax Liabilities Operating Leases Liabilities Deferred tax liabilities operating leases liabilities. Finite-Lived Intangible Assets by Major Class Finite-Lived Intangible Assets by Major Class [Axis] 12 Months or Longer, Fair Value Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer Non-cash capital expenditures Capital Expenditures Incurred but Not yet Paid Subsequent Events Subsequent Events [Text Block] Change in valuation allowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount Carrying amount of the liability component at settlement Carrying Amount Of Liability Component At Settlement Carrying amount of the liability component at settlement. Amortized cost Amortized Cost Debt Securities, Available-for-sale, Amortized Cost Renewal term Lessee, Operating Lease, Renewal Term Unrealized Gain Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax Share based compensation arrangement by share based payment award purchase period Share Based Compensation Arrangement By Share Based Payment Award Purchase Period Share based compensation arrangement by share based payment award, purchase period. Upfront payments received Upfront Payments Received Upfront payments received under a collaboration agreement. Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Property, Plant and Equipment, Type Long-Lived Tangible Asset [Axis] ESPP Employee Stock [Member] Accrued Branded Prescription Drug Fee Accrued Branded Prescription Drug Fee Accrued Branded Prescription Drug Fee Income Statement Location Income Statement Location [Axis] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Income Statement Location Income Statement Location [Domain] Research credits Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount Year ending December 31, 2022 Lessee, Operating Lease, Liability, to be Paid, Year Two State and local jurisdiction State and Local Jurisdiction [Member] Cash Flows from Financing Activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Officer compensation Income Tax Reconciliation Nondeductible Expense Officer Compensation Cost Income tax reconciliation nondeductible expense officer compensation cost. Amortized cost, gross unrealized gain (loss) positions and estimated fair value for available-for-sale debt securities Schedule of Available-for-sale Securities Reconciliation [Table Text Block] Accounts Receivable Receivable [Policy Text Block] Selling, general and administrative Selling, General and Administrative Expense Federal Current Federal Tax Expense (Benefit) B I A L B I A L [Member] Information related to BIAL, an entity with which Neurocrine has a license agreement. Year ending December 31, 2023 Lessee, Operating Lease, Liability, to be Paid, Year Three Organization and Summary of Significant Accounting Policies Business Description and Accounting Policies [Text Block] Other long-term assets Other Assets, Noncurrent Plan Name Plan Name [Axis] Threshold percentage of common stock price trigger Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger Debt securities available-for-sale (amortized cost $226.7 million at December 31, 2020 and $299.3 million at December 31, 2019) Marketable Securities, Noncurrent Total assets Assets Ending Balance, Unvested (in shares) Beginning Balance, Unvested (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Title of 12(b) Security Title of 12(b) Security Shares issued to settle notes at initial conversion rate (in shares) Debt Conversion, Converted Instrument, Shares Issued Weighted-average fair values of stock options granted (in USD per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Unrealized gain (loss) on debt securities available-for-sale OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Antidilutive Securities Antidilutive Securities [Axis] Measurement input, discount for lack of marketability Measurement Input, Discount for Lack of Marketability [Member] Investments, Debt and Equity Securities [Abstract] Investments, Debt and Equity Securities [Abstract] Concentration of Credit Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Interest expense Interest Expense Share-based compensation expense Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount Short-term investments Short-term Investments [Member] Components of income tax expense for continuing operations Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Unrealized loss on restricted equity securities Change in fair value of equity securities Unrealized loss included in earnings Equity Securities, FV-NI, Unrealized Gain (Loss) Product and Service Product and Service [Axis] Total liabilities Liabilities Investment Type Investment Type [Axis] Weighted-Average Recognition Period Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Expected volatility of common stock Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Less accreted interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Weighted-Average Remaining Contractual Term, Outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Total Fair Value Debt Securities, Available-for-sale, Unrealized Loss Position Deferred revenue recognized Contract with Customer, Liability, Revenue Recognized Level 1 Fair Value, Inputs, Level 1 [Member] Weighted-Average Remaining Contractual Term, Exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term Inventories Increase (Decrease) in Inventories 2.25% Convertible senior notes due 2024 Senior Convertible Notes Two Point Two Five Percent Due In May Two Thousand Twenty Four [Member] Information related to the 2.25% Convertible Senior Notes Due in May 2024. Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Restricted cash Restricted Cash and Cash Equivalents, Noncurrent Less Than 12 Months, Fair Value Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months Number of Units Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Raw materials Inventory, Raw Materials, Net of Reserves Deferred tax assets, net valuation release Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Debt Instrument Debt Instrument [Axis] Additional Paid-In Capital Additional Paid-in Capital [Member] Antidilutive Securities, Name Antidilutive Securities, Name [Domain] Summary of Quarterly Results of Operations Quarterly Financial Information [Table Text Block] Takeda Takeda Pharmaceutical Company Limited [Member] Takeda Pharmaceutical Company Limited Other Other Operating Activities, Cash Flow Statement Intangible assets Deferred Tax Assets, Goodwill and Intangible Assets Reconciliation of net income to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Fair Value of Financial Instruments Fair Value of Financial Instruments, Policy [Policy Text Block] Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] State income tax, net of federal benefit Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount Income before (benefit from) provision for income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Cash equivalents Cash Equivalents [Member] Beginning Balance, Outstanding (in USD per share) Ending Balance, Outstanding (in USD per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Royalty Royalty [Member] Reclassifications Reclassification, Comparability Adjustment [Policy Text Block] Common stock, shares authorized (in shares) Common Stock, Shares Authorized Summary and changes in restricted stock units outstanding Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Concentration Risk Type [Axis] Concentration Risk Type [Axis] Cash received from stock option exercises Proceeds from Stock Options Exercised Effect of dilutive securities (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements Property and equipment Property, Plant and Equipment, Gross Federal Deferred Federal Income Tax Expense (Benefit) Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Income Statement [Abstract] Income Statement [Abstract] Accumulated Other Comprehensive Income (Loss) AOCI Attributable to Parent [Member] Share-based compensation arrangement by share-based payment award, award requisite service period Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period Noncurrent operating lease liabilities Operating Lease, Liability, Noncurrent Equity component of repurchased convertible senior notes, net Equity component of repurchased convertible senior notes Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Subsequent Adjustments Use of Estimates Use of Estimates, Policy [Policy Text Block] Current assets: Assets, Current [Abstract] Income Tax Authority Income Tax Authority [Domain] Restricted cash Restricted Cash [Member] Restricted cash. Comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Patents Patents [Member] Preferred stock, par value (in USD per share) Preferred Stock, Par or Stated Value Per Share Securities of government-sponsored entities US Government-sponsored Enterprises Debt Securities [Member] Organization And Summary Of Significant Accounting Policies [Table] Organization And Summary Of Significant Accounting Policies [Table] Organization And Summary Of Significant Accounting Policies [Table] Documents Incorporated by Reference Documents Incorporated by Reference [Text Block] Provision for income taxes on earnings subject to income taxes differs from statutory federal rate Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Collateral Held [Axis] Collateral Held [Axis] Potential milestone payment receipts Potential Milestone Payment Receipts Potential later stage milestone payments and royalties. Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment City Area Code City Area Code Income Tax Authority Income Tax Authority [Axis] Document Period End Date Document Period End Date Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Abstract] Allowance for Credit Losses Debt Securities, Available-for-sale, Allowance for Credit Loss Total Unrealized Losses Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss Operating Lease, Liability, Current, Statement of Financial Position [Extensible List] Operating Lease, Liability, Current, Statement of Financial Position [Extensible List] Impairment of Long-Lived Assets Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Cost of sales Cost Of Sales The amount of costs relating to expenses directly or indirectly attributed to the goods or services sold, which may include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, unallocated production overheads and abnormal amounts of production costs of inventories. Quarterly Financial Information Disclosure [Abstract] Quarterly Financial Information Disclosure [Abstract] Inventories Schedule of Inventory, Current [Table Text Block] Share-based compensation expense Share-based Payment Arrangement, Noncash Expense Conversion premium Debt Instrument Convertible Conversion Premium The percentage of excess of the price paid for the convertible note over the closing stock price on the closing date of the convertible note. Research and development Research And Development Expense Excluding Research And Development Asset Acquired Other Than Through Business Combination Written Off The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding the write-off for research and development assets that were acquired in a transaction other than a business combination during the period. Excludes software research and development, which has a separate concept. Cover [Abstract] Cover [Abstract] Measurement Input Type [Axis] Measurement Input Type [Axis] Selected Quarterly Financial Data (Unaudited) Quarterly Financial Information [Text Block] Non-cancelable future minimum lease payments for operating leases that have not yet commenced Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced Non cancelable future minimum lease payments for operating leases not yet commenced. Current: Current Federal, State and Local, Tax Expense (Benefit) [Abstract] Events of default percentage of principal and accrued and unpaid interest due and payable upon default Events Of Default Percentage Of Principal And Accrued And Unpaid Interest Due And Payable Upon Default Events of default percentage of principal and accrued and unpaid interest due and payable upon default. Debt Instrument, Conversion [Axis] Debt Instrument, Conversion [Axis] Debt Instrument, Conversion Property, plant and equipment, useful life Property, Plant and Equipment, Useful Life Cash and Cash Equivalents Cash and Cash Equivalents [Domain] Remaining discount amortization period Debt Instrument, Convertible, Remaining Discount Amortization Period Leases [Line Items] Lessee, Lease, Description [Line Items] Leases Lessee, Operating Leases [Text Block] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Fair value Investments Total cash, cash equivalents and restricted cash Restricted Cash and Cash Equivalents Net deferred tax assets Deferred Tax Assets, Net Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Fair Value Debt Securities, Available-for-sale Equity Components Equity Components [Axis] Restricted stock units Restricted Stock [Member] Finished goods Inventory, Finished Goods, Net of Reserves Aggregate principal amount repurchased Debt Instrument, Repurchased Face Amount Share-based Payment Arrangement [Abstract] Share-based Payment Arrangement [Abstract] Debt Instrument, Name Debt Instrument, Name [Domain] Total deferred tax assets Deferred Tax Assets, Gross Minimum Minimum [Member] Less current operating lease liabilities Operating Lease, Liability, Current Canceled (in USD per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Weighted-average assumptions for stock option grants using black-scholes option-pricing model Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Entity Interactive Data Current Entity Interactive Data Current Exercised (in USD per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Revenues: Revenues [Abstract] Fair Value Measurements Fair Value Disclosures [Text Block] Cash Flows from Operating Activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Summary and changes in stock options outstanding Share-based Payment Arrangement, Option, Activity [Table Text Block] Gross unrealized losses and fair value available-for-sale investments in unrealized loss position Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table Text Block] Share-Based Compensation Share-based Payment Arrangement [Policy Text Block] Customer [Domain] Customer [Domain] Weighted-Average Remaining Contractual Life and Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract] Cumulative-effect adjustment to equity due to adoption of ASU 2016-02 Cumulative Effect, Period of Adoption, Adjustment [Member] Additional paid-in capital Additional Paid in Capital, Common Stock Entity Registrant Name Entity Registrant Name Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Weighted average discount rate Operating Lease, Weighted Average Discount Rate, Percent Total deferred tax liabilities Deferred Tax Liabilities, Gross Exercisable (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number Advertising Expense Advertising Cost [Policy Text Block] Acquired in-process research and development Research and Development Asset Acquired Other than Through Business Combination, Written-off Deferred financing costs Debt Issuance Costs, Net Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Collaboration revenue Collaboration Revenue [Member] Collaboration revenue. Number of reportable segments Number of Reportable Segments Research and development expense Research and Development Expense [Member] Effect of dilutive securities: Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract] Equity securities–biotechnology industry Equity Securities [Member] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Accounts receivable Accounts Receivable, after Allowance for Credit Loss, Current Total operating lease payments Lessee, Operating Lease, Liability, to be Paid Other Deferred Tax Assets, Other Threshold common stock trading days Debt Instrument, Convertible, Threshold Trading Days Cost of Sales Cost of Goods and Service [Policy Text Block] Unrealized Loss Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax Sale of Stock Sale of Stock [Axis] Revenue, Product and Service Benchmark Revenue, Product and Service Benchmark [Member] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Realizable deferred tax assets Deferred Tax Assets, Net of Valuation Allowance Discounted purchase price percentage of common stock authorized for issuance Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent Fair Value Measurement Inputs and Valuation Techniques [Table] Fair Value Measurement Inputs and Valuation Techniques [Table] Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-sale [Line Items] Document Transition Report Document Transition Report 12 Months or Longer, Unrealized Losses Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss Collaborative Arrangement and Arrangement Other than Collaborative Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Net operating losses Deferred Tax Assets, Operating Loss Carryforwards Other (expense) income: Nonoperating Income (Expense) [Abstract] Principal amount Principal Debt Instrument, Face Amount Level 2 Fair Value, Inputs, Level 2 [Member] Other current assets Other Assets, Current Canceled (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period PRSUs Performance Based Restricted Stock Unit [Member] Restricted stock units which are awarded to employees after certain performance targets are met. Fair value of assets on recurring basis Assets, Fair Value Disclosure Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Equity securities Equity securities fair value amount Equity securities, beginning balance Equity securities, ending balance Equity Securities, FV-NI, Restricted Largest three customers Largest Three Customers [Member] Largest Three Customers Accounting Standards Update [Extensible List] Accounting Standards Update [Extensible List] Granted (in USD per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Cumulative Effect, Period of Adoption [Axis] Cumulative Effect, Period of Adoption [Axis] Customer Concentration Risk Customer Concentration Risk [Member] Credit Facility Credit Facility [Domain] Conversion price (in USD per share) Debt Instrument, Convertible, Conversion Price Weighted average common shares outstanding, diluted (in shares) Diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Letter of Credit Letter of Credit [Member] Net income (loss) per share, basic (in USD per share) Basic (in USD per share) Earnings Per Share, Basic Unrecognized tax benefits that would affect effective tax rate Unrecognized Tax Benefits that Would Impact Effective Tax Rate Expected option term Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Number of operating segments Number of Operating Segments Entity File Number Entity File Number Accounts Payable and Accrued Liabilities Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Canceled (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Debt Disclosure [Abstract] Debt Disclosure [Abstract] Weighted average remaining term Operating Lease, Weighted Average Remaining Lease Term Collateral Held [Domain] Collateral Held [Domain] Net cash (used in) provided by financing activities Net Cash Provided by (Used in) Financing Activities Aggregate Intrinsic Value, Exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value Total share-based compensation expense Share-based Payment Arrangement, Expense Balance at January 1 Balance at December 31 Unrecognized Tax Benefits Issuance of common stock for employee stockpurchase plan Stock Issued During Period, Value, Employee Stock Purchase Plan Common stock, $0.001 par value; 220.0 shares authorized; issued and outstanding shares were 93.5 million and 92.3 million at December 31, 2020 and 2019, respectively Common Stock, Value, Issued Document Fiscal Year Focus Document Fiscal Year Focus Document Annual Report Document Annual Report Commercial paper Commercial Paper [Member] Cash and Cash Equivalents Cash and Cash Equivalents [Axis] Settlements related to prior year tax positions Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities Entity Current Reporting Status Entity Current Reporting Status Total debt securities available-for-sale Available-for-sale Securities [Member] Assumed borrowing rate Debt Instrument, Interest Rate During Period Expired tax attributes Income Tax Reconciliation Expiration Of Tax Credits Income tax reconciliation, expiration of tax credits. Retirement Benefits [Abstract] Retirement Benefits [Abstract] Purchases of debt securities available-for-sale Payments to Acquire Debt Securities, Available-for-sale Net Income Per Share Earnings Per Share, Policy [Policy Text Block] Issuance of common stock for vested restricted stock units (in shares) Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Granted (in USD per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value License and Collaboration Agreements Collaborative Arrangement Disclosure [Text Block] Cash Flows from Investing Activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Common stock, shares issued (in shares) Common Stock, Shares, Issued Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Mitsubishi Tanabe Mitsubishi Tanabe Pharma Corporation [Member] Information related to the Mitsubishi Tanabe Pharma Corporation. Equity securities number of shares (in shares) Investment Owned, Balance, Shares Other Deferred Tax Liabilities, Other Total operating lease liabilities Operating Lease, Liability Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Potential milestone payments Potential Milestone Payments The amount of potential milestone payments to be paid under a license agreement. Redemption rate Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed Accounts receivable Increase (Decrease) in Accounts Receivable Debt Instrument [Line Items] Debt Instrument [Line Items] Total stockholders’ equity Beginning balance Ending balance Stockholders' Equity Attributable to Parent Debt securities available for sale position number of positions Debt Securities Available For Sale Position Number Of Positions Debt securities available for sale position number of positions. Concentration Risk Type Concentration Risk Type [Domain] Total liabilities and stockholders’ equity Liabilities and Equity Conversion observation period Debt Conversion Observation Period The duration of time during which the weighted-average share price is used to calculate the excess conversion value due upon conversion of a convertible note, in the format of PnYnMnD. Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax Income Taxes Income Tax Disclosure [Text Block] Entity Address, City or Town Entity Address, City or Town Accrued employee related costs Employee-related Liabilities, Current Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Axis] RSUs Restricted Stock Units (RSUs) [Member] Cost Operating Lease, Cost Expiration of the statute of limitations for the assessment of taxes Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations Accounts payable and accrued liabilities Total accounts payable and accrued liabilities Accounts Payable and Accrued Liabilities, Current Year ending December 31, 2025 Lessee, Operating Lease, Liability, to be Paid, Year Five Deferred tax liabilities: Deferred Tax Liabilities, Gross [Abstract] Non-deductible expenses Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount Financial Instrument Financial Instrument [Axis] Branded prescription drug fee Income Tax Reconciliation Nondeductible Expense Branded Prescription Drug Fee Income tax reconciliation nondeductible expense branded prescription drug fee. Convertible senior notes Deferred Tax Liabilities Convertible Senior Notes Deferred tax liabilities convertible senior notes. Accrued interest receivables write-off Debt Securities, Available-for-Sale, Accrued Interest Writeoff Anti-dilutive shares excluded from diluted per share amounts (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Total current taxes Current Income Tax Expense (Benefit) Product sales, net Product [Member] Increase related to prior year tax positions Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions Increase related to current year tax positions Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Equity Component Equity Component [Domain] Valuation allowance Deferred tax assets, valuation allowance Deferred Tax Assets, Valuation Allowance Schedule of Available-for-sale Securities [Table] Schedule of Available-for-sale Securities [Table] Property and equipment, net Total property and equipment, net Property, Plant and Equipment, Net Entity Tax Identification Number Entity Tax Identification Number Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Leases [Table] Lessee, Lease, Description [Table] Unrealized gain (loss) on debt securities available-for sale Marketable Securities, Unrealized Gain (Loss) Share-Based Compensation Share-based Payment Arrangement [Text Block] Net income Net income Net income (loss) Net Income (Loss) Attributable to Parent Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Other current liabilities Other Liabilities, Current Carrying amount of the equity component upon issuance Debt Instrument, Convertible, Carrying Amount of Equity Component Long-term investments Long Term Investments [Member] Investments which are intended be sold or mature more than one year from the balance sheet date or operating cycle, if longer. Other assets and liabilities, net Increase (Decrease) in Other Current Assets and Liabilities, Net Leases [Abstract] Leases [Abstract] Capitalized research and development Deferred Tax Assets Capitalized Research And Development Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from research and development costs capitalized. Total current assets Assets, Current Current Fiscal Year End Date Current Fiscal Year End Date Operating expenses: Operating Expenses [Abstract] Operating loss carry forward, net Operating Loss Carryforwards Earnings Per Share [Abstract] Earnings Per Share [Abstract] Components of deferred tax assets Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Stockholders’ equity: Stockholders' Equity Attributable to Parent [Abstract] Number of Stock Options Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Document Fiscal Period Focus Document Fiscal Period Focus Net carrying amount Convertible Debt Subsidiary, Sale of Stock [Line Items] Subsidiary, Sale of Stock [Line Items] Certificates of deposit Certificates of Deposit [Member] Total intrinsic value vested in period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested Supplemental Disclosure: Supplemental Cash Flow Information [Abstract] Issuance of common stock for employee stock purchase plan (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Income Taxes [Table] Income Taxes [Table] Income Taxes [Table] Entity Filer Category Entity Filer Category Compensation cost related to share based compensation Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Common Stock Common Stock [Member] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Product and Service Product and Service [Domain] Property, Plant and Equipment, Type Long-Lived Tangible Asset [Domain] Concentration Risk Type Concentration Risk Benchmark [Domain] Defined contribution plan, employer contribution amount Defined Contribution Plan, Cost Property and Equipment Property, Plant and Equipment [Table Text Block] Discount rate Debt Instrument, Measurement Input Tenant improvements Leasehold Improvements [Member] Stated interest rate percentage Debt Instrument, Interest Rate, Stated Percentage Less Than 12 Months, Unrealized Losses Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss Less accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Voyager Voyager Therapeutics [Member] Voyager therapeutics. Aggregate Intrinsic Value, Outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Research and development credits Research and development tax credit carry forwards Deferred Tax Assets, Tax Credit Carryforwards, Research Issuance of common stock for stock option exercises (in shares) Exercised (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Revenue-related reserves for discounts and allowances Revenue Related Reserves For Discounts And Allowances Revenue-related reserves for discounts and allowances. Accrued interest receivables Interest Receivable, Current Change in cash and cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Accrued interest receivables write-off threshold period Debt Securities, Available-for-Sale, Accrued Interest, Threshold Period, Writeoff Total other expense, net Nonoperating Income (Expense) Partial repurchase of convertible senior notes Repayments of Convertible Debt Conversion Period One Conversion Period One [Member] Conversion Period One Summary of minimum lease payments for operating lease liabilities Lessee, Operating Lease, Liability, Maturity [Table Text Block] Stock options Share-based Payment Arrangement, Option [Member] Other Effective Income Tax Rate Reconciliation, Other Adjustments, Amount Business Activities Business Description Policy [Policy Text Block] Business Description Policy [Text Block] Weighted average common shares outstanding, basic (in shares) Basic (in shares) Weighted Average Number of Shares Outstanding, Basic Risk-free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Canceled (in USD per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Number of debt securities available-for-sale in an unrealized loss position Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions Deferred: Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract] Scientific equipment Scientific Equipment [Member] Scientific equipment. Sale of Stock Sale of Stock [Domain] State Deferred State and Local Income Tax Expense (Benefit) Plan Name Plan Name [Domain] Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activities Total equity securities Total Equity Securities [Member] Total equity securities. Investment in equity securities without readily determinable fair value Equity Securities without Readily Determinable Fair Value, Amount Right-of-use assets acquired through operating leases Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Organization And Summary Of Significant Accounting Policies [Line Items] Organization And Summary Of Significant Accounting Policies [Line Items] Organization and summary of significant accounting policies. Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Inventory Inventory, Policy [Policy Text Block] (Benefit from) provision for income taxes (Benefit from) provision for income taxes Income Tax Expense (Benefit) Income Taxes [Line Items] Income Taxes [Line Items] Income Taxes [Line Items] Cash and cash equivalents and restricted cash at beginning of period Cash and cash equivalents and restricted cash at end of period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Property and Equipment Property, Plant and Equipment, Policy [Policy Text Block] Net income (loss) per share, diluted (in USD per share) Diluted (in USD per share) Earnings Per Share, Diluted Local Phone Number Local Phone Number Idorsia Idorsia Pharmaceuticals Ltd [Member] Idorsia Pharmaceuticals Ltd Activity related to unrecognized tax benefits Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block] Cumulative Effect, Period of Adoption [Domain] Cumulative Effect, Period of Adoption [Domain] Collaborative Arrangement and Arrangement Other than Collaborative Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Stock options exercised in period intrinsic value Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value Development Product Candidates Development Product Candidates [Member] Development Product Candidates Convertible senior notes net of discounts and deferred financing costs Schedule of Long-term Debt Instruments [Table Text Block] Depreciation Depreciation Entity Address, Address Line One Entity Address, Address Line One (Decrease) related to prior year tax positions Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions Contract with customer, liability Contract with Customer, Liability Entity Emerging Growth Company Entity Emerging Growth Company Issuance of common stock for stock option exercises Stock Issued During Period, Value, Stock Options Exercised Threshold consecutive common stock trading days Debt Instrument, Convertible, Threshold Consecutive Trading Days Total deferred taxes Deferred Income Tax Expense (Benefit) Fair value of the liability component immediately before extinguishment Fair Value Of Liability Component Immediately Before Extinguishment Fair value of the liability component immediately before extinguishment. Federal Internal Revenue Service (IRS) [Member] Award Type Award Type [Axis] Weighted-Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Incremental funding provided Prepaid Expense and Other Assets Potential commercial milestone payments Potential Commercial Milestone Payments Potential payments for commercial milestones under a collaboration agreement. Net of deferred tax assets and liabilities Deferred Tax Assets Liabilities Gross Deferred tax assts (liabilities) gross. Total fair value of PRSUs vested Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Maximum Maximum [Member] Allowance for Credit Losses Financing Receivable, Allowance for Credit Losses, Policy for Uncollectible Amounts [Policy Text Block] Amortization of debt issuance costs Amortization of Debt Issuance Costs Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Unvested, aggregate intrinsic value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested Accumulated Deficit Retained Earnings [Member] Xenon Xenon Pharmaceuticals Inc [Member] Xenon Pharmaceuticals Inc Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Conversion Period Two Conversion Period Two [Member] Conversion Period Two Operating lease assets Deferred Tax Assets Operating Leases Assets Deferred tax assets operating leases assets. Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Investing Activities Weighted-Average Remaining Contractual Life and Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Research collaboration term Research Collaboration Term Research Collaboration Term Award Type Award Type [Domain] Investments Investments [Domain] Accounts payable and other accrued liabilities Accounts Payable and Other Accrued Liabilities, Current Corporate debt securities Corporate Debt Securities [Member] Trading Symbol Trading Symbol Exercisable (in USD per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Stock options restricted stock and convertible senior notes Stock Options Restricted Stock And Convertible Senior Notes [Member] Stock options, restricted stock and convertible senior notes. Unvested, weighted average remaining contractual term (in years) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms Net Income Per Share Earnings Per Share [Text Block] Current liabilities: Liabilities, Current [Abstract] Federal income taxes, rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Entity Shell Company Entity Shell Company Fair Value Measurement Inputs and Valuation Techniques [Line Items] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Fair value measurements recurring Fair Value, Recurring [Member] AbbVie Abbvie Inc [Member] Information related to AbbVie Inc., an entity with which Neurocrine has a collaboration agreement. Industry Segment and Geographic Information Segment Reporting, Policy [Policy Text Block] Recently Adopted and Issued Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Entity Public Float Entity Public Float Discount rate Measurement Input, Discount Rate [Member] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] EX-101.PRE 11 nbix-20201231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 12 nbix-20201231_g1.jpg GRAPHIC begin 644 nbix-20201231_g1.jpg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end GRAPHIC 13 nbix-20201231_g2.jpg GRAPHIC begin 644 nbix-20201231_g2.jpg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�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nbix-20201231_g3.jpg GRAPHIC begin 644 nbix-20201231_g3.jpg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end XML 15 nbix-20201231_htm.xml IDEA: XBRL DOCUMENT 0000914475 2020-01-01 2020-12-31 0000914475 2020-06-30 0000914475 2021-01-29 0000914475 2020-12-31 0000914475 2019-12-31 0000914475 us-gaap:ShortTermInvestmentsMember 2020-12-31 0000914475 us-gaap:ShortTermInvestmentsMember 2019-12-31 0000914475 nbix:LongTermInvestmentsMember 2020-12-31 0000914475 nbix:LongTermInvestmentsMember 2019-12-31 0000914475 us-gaap:ProductMember 2020-01-01 2020-12-31 0000914475 us-gaap:ProductMember 2019-01-01 2019-12-31 0000914475 us-gaap:ProductMember 2018-01-01 2018-12-31 0000914475 nbix:CollaborationRevenueMember 2020-01-01 2020-12-31 0000914475 nbix:CollaborationRevenueMember 2019-01-01 2019-12-31 0000914475 nbix:CollaborationRevenueMember 2018-01-01 2018-12-31 0000914475 2019-01-01 2019-12-31 0000914475 2018-01-01 2018-12-31 0000914475 us-gaap:CommonStockMember 2017-12-31 0000914475 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0000914475 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0000914475 us-gaap:RetainedEarningsMember 2017-12-31 0000914475 2017-12-31 0000914475 us-gaap:RetainedEarningsMember 2018-01-01 2018-12-31 0000914475 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-12-31 0000914475 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-12-31 0000914475 us-gaap:CommonStockMember 2018-01-01 2018-12-31 0000914475 us-gaap:CommonStockMember 2018-12-31 0000914475 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000914475 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0000914475 us-gaap:RetainedEarningsMember 2018-12-31 0000914475 2018-12-31 0000914475 us-gaap:RetainedEarningsMember 2019-01-01 2019-12-31 0000914475 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-12-31 0000914475 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-12-31 0000914475 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:RetainedEarningsMember 2018-12-31 0000914475 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2018-12-31 0000914475 us-gaap:CommonStockMember 2019-01-01 2019-12-31 0000914475 us-gaap:CommonStockMember 2019-12-31 0000914475 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000914475 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000914475 us-gaap:RetainedEarningsMember 2019-12-31 0000914475 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0000914475 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-12-31 0000914475 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0000914475 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0000914475 us-gaap:CommonStockMember 2020-12-31 0000914475 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000914475 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0000914475 us-gaap:RetainedEarningsMember 2020-12-31 0000914475 srt:MinimumMember 2020-01-01 2020-12-31 0000914475 srt:MaximumMember 2020-01-01 2020-12-31 0000914475 nbix:LargestTwoCustomersMember us-gaap:SalesRevenueProductLineMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0000914475 nbix:LargestTwoCustomersMember us-gaap:SalesRevenueProductLineMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0000914475 nbix:LargestThreeCustomersMember us-gaap:SalesRevenueProductLineMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-12-31 0000914475 us-gaap:EmployeeStockMember 2020-01-01 2020-12-31 0000914475 nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember 2020-12-01 2020-12-31 0000914475 nbix:PerformanceBasedRestrictedStockUnitMember 2020-12-31 0000914475 nbix:TakedaPharmaceuticalCompanyLimitedMember us-gaap:CollaborativeArrangementMember 2020-07-31 0000914475 nbix:TakedaPharmaceuticalCompanyLimitedMember us-gaap:CollaborativeArrangementMember 2020-12-31 0000914475 nbix:IdorsiaPharmaceuticalsLtdMember us-gaap:CollaborativeArrangementMember 2020-05-31 0000914475 nbix:IdorsiaPharmaceuticalsLtdMember us-gaap:CollaborativeArrangementMember 2020-05-01 2020-05-31 0000914475 nbix:NBI827104Member nbix:IdorsiaPharmaceuticalsLtdMember us-gaap:CollaborativeArrangementMember 2020-12-31 0000914475 nbix:DevelopmentProductCandidatesMember nbix:IdorsiaPharmaceuticalsLtdMember us-gaap:CollaborativeArrangementMember 2020-12-31 0000914475 nbix:IdorsiaPharmaceuticalsLtdMember us-gaap:CollaborativeArrangementMember 2020-12-31 0000914475 nbix:XenonPharmaceuticalsIncMember us-gaap:CollaborativeArrangementMember 2019-12-31 0000914475 nbix:XenonPharmaceuticalsIncMember us-gaap:CommonStockMember us-gaap:CollaborativeArrangementMember 2019-12-31 0000914475 nbix:XenonPharmaceuticalsIncMember us-gaap:CollaborativeArrangementMember 2020-12-31 0000914475 nbix:XenonPharmaceuticalsIncMember us-gaap:CollaborativeArrangementMember 2019-10-01 2019-12-31 0000914475 nbix:VoyagerTherapeuticsMember us-gaap:CollaborativeArrangementMember 2019-03-31 0000914475 nbix:VoyagerTherapeuticsMember us-gaap:CommonStockMember us-gaap:CollaborativeArrangementMember 2019-03-31 0000914475 nbix:VoyagerTherapeuticsMember us-gaap:CollaborativeArrangementMember 2020-12-31 0000914475 nbix:VoyagerTherapeuticsMember us-gaap:CollaborativeArrangementMember 2019-01-01 2019-03-31 0000914475 nbix:VoyagerTherapeuticsMember us-gaap:CollaborativeArrangementMember 2019-04-01 2019-06-30 0000914475 nbix:BIALMember us-gaap:CollaborativeArrangementMember 2020-04-30 0000914475 nbix:BIALMember us-gaap:CollaborativeArrangementMember 2019-12-31 0000914475 nbix:BIALMember us-gaap:CollaborativeArrangementMember 2018-12-31 0000914475 nbix:BIALMember us-gaap:CollaborativeArrangementMember 2020-12-31 0000914475 nbix:MitsubishiTanabePharmaCorporationMember us-gaap:CollaborativeArrangementMember 2015-03-01 2017-06-30 0000914475 nbix:MitsubishiTanabePharmaCorporationMember us-gaap:CollaborativeArrangementMember 2017-07-01 2020-12-31 0000914475 nbix:MitsubishiTanabePharmaCorporationMember us-gaap:CollaborativeArrangementMember 2020-01-01 2020-12-31 0000914475 nbix:MitsubishiTanabePharmaCorporationMember us-gaap:CollaborativeArrangementMember 2019-01-01 2019-12-31 0000914475 nbix:MitsubishiTanabePharmaCorporationMember us-gaap:CollaborativeArrangementMember 2020-12-31 0000914475 nbix:MitsubishiTanabePharmaCorporationMember us-gaap:CollaborativeArrangementMember 2015-03-01 2015-03-31 0000914475 srt:MinimumMember us-gaap:PatentsMember nbix:MitsubishiTanabePharmaCorporationMember us-gaap:CollaborativeArrangementMember 2015-03-01 2015-03-31 0000914475 us-gaap:RoyaltyMember nbix:AbbvieIncMember 2020-01-01 2020-12-31 0000914475 us-gaap:RoyaltyMember nbix:AbbvieIncMember 2019-01-01 2019-12-31 0000914475 us-gaap:RoyaltyMember nbix:AbbvieIncMember 2018-01-01 2018-12-31 0000914475 nbix:AbbvieIncMember us-gaap:CollaborativeArrangementMember 2020-04-01 2020-06-30 0000914475 nbix:AbbvieIncMember us-gaap:CollaborativeArrangementMember 2019-01-01 2019-12-31 0000914475 nbix:AbbvieIncMember us-gaap:CollaborativeArrangementMember 2018-01-01 2018-12-31 0000914475 nbix:AbbvieIncMember us-gaap:CollaborativeArrangementMember 2010-06-01 2010-06-30 0000914475 nbix:AbbvieIncMember us-gaap:CollaborativeArrangementMember 2010-07-01 2020-12-31 0000914475 nbix:AbbvieIncMember us-gaap:CollaborativeArrangementMember 2020-12-31 0000914475 srt:MinimumMember us-gaap:PatentsMember nbix:AbbvieIncMember us-gaap:CollaborativeArrangementMember 2010-06-01 2010-06-30 0000914475 us-gaap:CommercialPaperMember us-gaap:ShortTermInvestmentsMember 2020-12-31 0000914475 us-gaap:CorporateDebtSecuritiesMember us-gaap:ShortTermInvestmentsMember 2020-12-31 0000914475 us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember us-gaap:ShortTermInvestmentsMember 2020-12-31 0000914475 us-gaap:CorporateDebtSecuritiesMember nbix:LongTermInvestmentsMember 2020-12-31 0000914475 us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember nbix:LongTermInvestmentsMember 2020-12-31 0000914475 us-gaap:CommercialPaperMember us-gaap:ShortTermInvestmentsMember 2019-12-31 0000914475 us-gaap:CorporateDebtSecuritiesMember us-gaap:ShortTermInvestmentsMember 2019-12-31 0000914475 us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember us-gaap:ShortTermInvestmentsMember 2019-12-31 0000914475 us-gaap:CorporateDebtSecuritiesMember nbix:LongTermInvestmentsMember 2019-12-31 0000914475 us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember nbix:LongTermInvestmentsMember 2019-12-31 0000914475 us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2020-12-31 0000914475 us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0000914475 nbix:CashAndMoneyMarketFundMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000914475 nbix:CashAndMoneyMarketFundMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000914475 nbix:CashAndMoneyMarketFundMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000914475 nbix:CashAndMoneyMarketFundMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000914475 us-gaap:CashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000914475 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000914475 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000914475 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000914475 us-gaap:CertificatesOfDepositMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000914475 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000914475 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000914475 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000914475 nbix:RestrictedCashMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000914475 nbix:RestrictedCashMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000914475 nbix:RestrictedCashMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000914475 nbix:RestrictedCashMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000914475 us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000914475 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000914475 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000914475 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000914475 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2020-12-31 0000914475 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2020-12-31 0000914475 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2020-12-31 0000914475 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2020-12-31 0000914475 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2020-12-31 0000914475 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2020-12-31 0000914475 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2020-12-31 0000914475 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2020-12-31 0000914475 us-gaap:FairValueMeasurementsRecurringMember us-gaap:AvailableforsaleSecuritiesMember 2020-12-31 0000914475 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AvailableforsaleSecuritiesMember 2020-12-31 0000914475 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AvailableforsaleSecuritiesMember 2020-12-31 0000914475 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AvailableforsaleSecuritiesMember 2020-12-31 0000914475 us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2020-12-31 0000914475 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2020-12-31 0000914475 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2020-12-31 0000914475 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2020-12-31 0000914475 us-gaap:FairValueMeasurementsRecurringMember nbix:TotalEquitySecuritiesMember 2020-12-31 0000914475 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember nbix:TotalEquitySecuritiesMember 2020-12-31 0000914475 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember nbix:TotalEquitySecuritiesMember 2020-12-31 0000914475 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember nbix:TotalEquitySecuritiesMember 2020-12-31 0000914475 us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000914475 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000914475 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000914475 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000914475 nbix:CashAndMoneyMarketFundMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000914475 nbix:CashAndMoneyMarketFundMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000914475 nbix:CashAndMoneyMarketFundMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000914475 nbix:CashAndMoneyMarketFundMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000914475 us-gaap:CashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000914475 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000914475 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000914475 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000914475 us-gaap:CertificatesOfDepositMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000914475 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000914475 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000914475 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000914475 nbix:RestrictedCashMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000914475 nbix:RestrictedCashMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000914475 nbix:RestrictedCashMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000914475 nbix:RestrictedCashMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000914475 us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000914475 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000914475 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000914475 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000914475 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0000914475 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0000914475 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0000914475 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0000914475 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2019-12-31 0000914475 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2019-12-31 0000914475 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2019-12-31 0000914475 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2019-12-31 0000914475 us-gaap:FairValueMeasurementsRecurringMember us-gaap:AvailableforsaleSecuritiesMember 2019-12-31 0000914475 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AvailableforsaleSecuritiesMember 2019-12-31 0000914475 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AvailableforsaleSecuritiesMember 2019-12-31 0000914475 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AvailableforsaleSecuritiesMember 2019-12-31 0000914475 us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2019-12-31 0000914475 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2019-12-31 0000914475 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2019-12-31 0000914475 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2019-12-31 0000914475 us-gaap:FairValueMeasurementsRecurringMember nbix:TotalEquitySecuritiesMember 2019-12-31 0000914475 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember nbix:TotalEquitySecuritiesMember 2019-12-31 0000914475 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember nbix:TotalEquitySecuritiesMember 2019-12-31 0000914475 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember nbix:TotalEquitySecuritiesMember 2019-12-31 0000914475 us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000914475 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000914475 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000914475 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000914475 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000914475 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000914475 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000914475 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-01-01 2020-12-31 0000914475 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-01-01 2019-12-31 0000914475 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-01-01 2018-12-31 0000914475 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000914475 srt:MinimumMember us-gaap:MeasurementInputDiscountForLackOfMarketabilityMember 2020-12-31 0000914475 srt:MaximumMember us-gaap:MeasurementInputDiscountForLackOfMarketabilityMember 2020-12-31 0000914475 srt:WeightedAverageMember us-gaap:MeasurementInputDiscountForLackOfMarketabilityMember 2020-12-31 0000914475 nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember 2017-05-02 0000914475 nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember 2017-05-02 2017-05-02 0000914475 nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember nbix:ConversionPeriodOneMember 2017-05-02 2017-05-02 0000914475 nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember nbix:ConversionPeriodTwoMember 2017-05-02 2017-05-02 0000914475 nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember nbix:ConversionPeriodTwoMember 2017-05-02 0000914475 nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember 2020-01-01 2020-12-31 0000914475 nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember 2020-11-30 0000914475 nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember 2020-11-01 2020-11-30 0000914475 nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember us-gaap:MeasurementInputDiscountRateMember 2020-11-30 0000914475 nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember 2020-12-31 0000914475 nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember 2019-12-31 0000914475 us-gaap:LeaseholdImprovementsMember 2020-12-31 0000914475 us-gaap:LeaseholdImprovementsMember 2019-12-31 0000914475 nbix:ScientificEquipmentMember 2020-12-31 0000914475 nbix:ScientificEquipmentMember 2019-12-31 0000914475 us-gaap:ComputerEquipmentMember 2020-12-31 0000914475 us-gaap:ComputerEquipmentMember 2019-12-31 0000914475 us-gaap:FurnitureAndFixturesMember 2020-12-31 0000914475 us-gaap:FurnitureAndFixturesMember 2019-12-31 0000914475 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0000914475 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 0000914475 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-12-31 0000914475 us-gaap:RestrictedStockMember 2020-01-01 2020-12-31 0000914475 us-gaap:RestrictedStockMember 2019-01-01 2019-12-31 0000914475 us-gaap:RestrictedStockMember 2018-01-01 2018-12-31 0000914475 nbix:A225ConvertibleSeniorNotesMember 2020-01-01 2020-12-31 0000914475 nbix:A225ConvertibleSeniorNotesMember 2019-01-01 2019-12-31 0000914475 nbix:A225ConvertibleSeniorNotesMember 2018-01-01 2018-12-31 0000914475 nbix:StockOptionsRestrictedStockAndConvertibleSeniorNotesMember 2020-01-01 2020-12-31 0000914475 nbix:StockOptionsRestrictedStockAndConvertibleSeniorNotesMember 2019-01-01 2019-12-31 0000914475 nbix:StockOptionsRestrictedStockAndConvertibleSeniorNotesMember 2018-01-01 2018-12-31 0000914475 nbix:TwoThousandAndElevenPlanMember 2011-05-31 0000914475 nbix:TwoThousandAndElevenPlanMember 2020-12-31 0000914475 us-gaap:EmployeeStockMember 2018-05-31 0000914475 us-gaap:EmployeeStockMember 2020-12-31 0000914475 nbix:A2020EquityIncentivePlanMember 2020-05-31 0000914475 nbix:A2020EquityIncentivePlanMember 2020-12-31 0000914475 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-01-01 2020-12-31 0000914475 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-01-01 2019-12-31 0000914475 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-01-01 2018-12-31 0000914475 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-12-31 0000914475 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-12-31 0000914475 us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-12-31 0000914475 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0000914475 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 0000914475 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-12-31 0000914475 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-12-31 0000914475 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-12-31 0000914475 us-gaap:RestrictedStockUnitsRSUMember 2018-01-01 2018-12-31 0000914475 nbix:PerformanceBasedRestrictedStockUnitMember 2020-01-01 2020-12-31 0000914475 nbix:PerformanceBasedRestrictedStockUnitMember 2019-01-01 2019-12-31 0000914475 nbix:PerformanceBasedRestrictedStockUnitMember 2018-01-01 2018-12-31 0000914475 us-gaap:EmployeeStockMember 2020-01-01 2020-12-31 0000914475 us-gaap:EmployeeStockMember 2019-01-01 2019-12-31 0000914475 us-gaap:EmployeeStockMember 2018-01-01 2018-12-31 0000914475 us-gaap:EmployeeStockOptionMember 2020-12-31 0000914475 us-gaap:RestrictedStockUnitsRSUMember 2020-12-31 0000914475 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0000914475 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0000914475 us-gaap:RestrictedStockUnitsRSUMember 2019-12-31 0000914475 srt:MinimumMember nbix:PerformanceBasedRestrictedStockUnitMember 2020-01-01 2020-12-31 0000914475 srt:MaximumMember nbix:PerformanceBasedRestrictedStockUnitMember 2020-01-01 2020-12-31 0000914475 nbix:PerformanceBasedRestrictedStockUnitMember 2019-12-31 0000914475 srt:MaximumMember us-gaap:EmployeeStockMember 2020-01-01 2020-12-31 0000914475 us-gaap:InternalRevenueServiceIRSMember 2020-12-31 0000914475 us-gaap:StateAndLocalJurisdictionMember 2020-12-31 0000914475 us-gaap:LetterOfCreditMember 2020-12-31 0000914475 2020-01-01 2020-03-31 0000914475 2020-04-01 2020-06-30 0000914475 2020-07-01 2020-09-30 0000914475 2020-10-01 2020-12-31 0000914475 2019-01-01 2019-03-31 0000914475 2019-04-01 2019-06-30 0000914475 2019-07-01 2019-09-30 0000914475 2019-10-01 2019-12-31 0000914475 nbix:IdorsiaPharmaceuticalsLtdMember us-gaap:CollaborativeArrangementMember 2020-04-01 2020-06-30 0000914475 nbix:TakedaPharmaceuticalCompanyLimitedMember us-gaap:CollaborativeArrangementMember 2020-07-01 2020-09-30 iso4217:USD shares iso4217:USD shares nbix:subsidiary pure nbix:segment nbix:security utr:D nbix:renewalOption false 2020 FY 0000914475 us-gaap:AccountingStandardsUpdate201602Member P3Y P3Y 1 1 0.00131711 P3Y P4Y us-gaap:OtherLiabilitiesCurrent 10-K true 2020-12-31 --12-31 false 0-22705 NEUROCRINE BIOSCIENCES, INC. DE 33-0525145 12780 El Camino Real, San Diego, CA 92130 858 617-7600 Common Stock, $0.001 par value NBIX NASDAQ Yes No Yes Yes Large Accelerated Filer false false true false 11231617436 93943645 Portions of the registrant’s definitive proxy statement relating to the registrant’s annual meeting of stockholders to be filed pursuant to Regulation 14A within 120 days following the end of the registrant’s fiscal year ended December 31, 2020 are incorporated by reference into Part III of this Form 10-K. 8500000000 187100000 112300000 612400000 557300000 613900000 558200000 157100000 126600000 28000000.0 17300000 30100000 16600000 1016200000 831000000.0 226700000 299300000 227100000 299700000 82800000 74300000 38200000 55900000 44600000 41900000 319400000 0 3200000 3200000 3200000 0 1734700000 1306000000.0 168700000 141300000 0 408800000 17800000 15200000 186500000 565300000 317900000 0 94400000 86700000 9700000 17100000 608500000 669100000 0.001 0.001 5000000.0 5000000.0 0 0 0 0 0 0 0.001 0.001 220000000.0 220000000.0 93500000 93500000 92300000 92300000 100000 100000 1849700000 1768100000 1800000 1400000 -725400000 -1132700000 1126200000 636900000 1734700000 1306000000.0 994100000 752900000 409600000 51800000 35200000 41600000 1045900000 788100000 451200000 10100000 7400000 4900000 275000000.0 200000000.0 155800000 164500000 154300000 4800000 433300000 354100000 248900000 882900000 715800000 414400000 163000000.0 72300000 36800000 32800000 32000000.0 30500000 -17700000 -13000000.0 0 -18400000 0 0 12600000 19200000 15500000 -56300000 -25800000 -15000000.0 106700000 46500000 21800000 -300600000 9500000 700000 407300000 37000000.0 21100000 400000 3400000 -100000 407700000 40400000 21000000.0 4.38 0.40 0.23 4.16 0.39 0.22 93100000 91600000 90200000 97800000 95700000 95400000 88800000 100000 1572800000 -1900000 -1198800000 372200000 21100000 21100000 -100000 -100000 58100000 58100000 400000 1600000 29500000 29500000 90800000 100000 1660400000 -2000000.0 -1177700000 480800000 37000000.0 37000000.0 3400000 3400000 75300000 75300000 8000000.0 8000000.0 400000 1000000.0 27300000 27300000 100000 5100000 5100000 92300000 100000 1768100000 1400000 -1132700000 636900000 407300000 407300000 400000 400000 100000000.0 100000000.0 47500000 47500000 500000 600000 23500000 23500000 100000 5600000 5600000 93500000 100000 1849700000 1800000 -725400000 1126200000 407300000 37000000.0 21100000 100000000.0 75300000 58100000 8600000 7400000 4000000.0 20000000.0 18900000 17600000 1400000 1400000 1300000 -17700000 -13000000.0 0 -310700000 0 0 -18400000 0 0 3700000 -1200000 1000000.0 30500000 69200000 25100000 10700000 6400000 3500000 26900000 54000000.0 24200000 23600000 -16800000 -2700000 228500000 147000000.0 101400000 735500000 797200000 545900000 750500000 669700000 327800000 0 68900000 0 10900000 14700000 24800000 4100000 -211100000 -242900000 29100000 32400000 29500000 186900000 0 0 -157800000 32400000 29500000 74800000 -31700000 -112000000.0 115500000 147200000 259200000 190300000 115500000 147200000 1400000 1000000.0 2300000 12800000 77100000 0 11600000 11600000 11600000 15300000 500000 0 Organization and Summary of Significant Accounting Policies<div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Activities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neurocrine Biosciences, Inc., or Neurocrine, the Company, we, our or us, was incorporated in California in 1992 and reincorporated in Delaware in 1996. Neurocrine Continental, Inc., is a Delaware corporation and a wholly owned subsidiary of Neurocrine. We also have two wholly-owned Irish subsidiaries, Neurocrine Therapeutics, Ltd. and Neurocrine Europe, Ltd. both of which were formed in December 2014 and are inactive.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a neuroscience-focused biopharmaceutical company dedicated to discovering, developing and delivering life-changing treatments for patients with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. Our diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson’s disease, endometriosis*, uterine fibroids* and clinical programs in multiple therapeutic areas. For nearly three decades, we specialize in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(*in collaboration with AbbVie Inc.)</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of Neurocrine as well as our wholly owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America, or GAAP, requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. Actual results could differ from those estimates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Industry Segment and Geographic Information. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in a single industry segment – the discovery, development and marketing of pharmaceuticals for the treatment of neurological, endocrine and psychiatric-based diseases and disorders. We had no foreign-based operations during any of the years presented.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Certain amounts in prior year periods have been reclassified to conform with the presentation adopted in the current year.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Equivalents. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all highly liquid investments that are readily convertible into cash and have an original maturity of three months or less at the time of purchase to be cash equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable are recorded net of customer allowances for prompt payment discounts, chargebacks and any allowance for doubtful accounts. We estimate the allowance for doubtful accounts based on existing contractual payment terms, actual payment patterns of our customers and individual customer circumstances. To date, an allowance for doubtful accounts has not been material.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Securities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt securities consist of investments in certificates of deposit, corporate debt securities, and securities of government-sponsored entities. We classify debt securities as available-for-sale. Debt securities available-for-sale are recorded at fair value, with unrealized gains and losses included in other comprehensive income or loss, net of tax. We exclude accrued interest from both the fair value and amortized cost basis of debt securities. A debt security is placed on nonaccrual status at the time any principal or interest payments become 90 days delinquent. Interest accrued but not received for a debt security placed on nonaccrual status is reversed against interest income.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income includes amortization of purchase premium or discount. Premiums and discounts on debt securities are amortized using the effective interest rate method. Gains and losses on sales of debt securities are recorded on the trade date in investment income and other, net, and determined using the specific identification method.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Allowance for Credit Losses. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For debt securities available-for-sale in an unrealized loss position, we first assess whether we intend to sell, or it is more likely than not that we will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security’s amortized cost basis is written down to fair value through earnings. For debt securities available-for-sale that do not meet the aforementioned criteria, we evaluate whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, we consider the extent to which fair value is less than amortized cost, any changes in interest rates, and any changes to the rating of the security by a rating agency, among other factors. If this </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security is compared to the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded, limited by the amount that the fair value is less than the amortized cost basis. Any impairment that has not been recorded through an allowance for credit losses is recognized in other comprehensive income or loss, as applicable.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued interest receivables on debt securities available-for-sale totaled $3.7 million at December 31, 2020. We do not measure an allowance for credit losses for accrued interest receivables. For the purposes of identifying and measuring an impairment, accrued interest is excluded from both the fair value and amortized cost basis of the debt security. Uncollectible accrued interest receivables associated with an impaired debt security are reversed against interest income upon identification of the impairment. No accrued interest receivables were written off during 2020, 2019 or 2018.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record cash equivalents, debt securities available-for-sale and equity securities at fair value based on a fair value hierarchy that distinguishes between assumptions based on market data (observable inputs) and our own assumptions (unobservable inputs). The fair value hierarchy consists of the following three levels:</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">– Quoted prices (unadjusted) in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">– Quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 3 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">– Unobservable inputs that reflect our own assumptions about the assumptions that market participants would use in pricing the asset or liability when there is little, if any, market activity for the asset or liability at the measurement date.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in debt securities available-for-sale are classified as Level 2 and carried at fair value. We estimate the fair value of debt securities available-for-sale by utilizing third-party pricing services. These pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. Such inputs include market pricing based on real-time trade data for similar instruments, issuer credit spreads, benchmark yields, broker/dealer quotes and other observable inputs. We validate valuations obtained from third-party pricing services by understanding the models used, obtaining market values from other pricing sources, and analyzing data in certain instances.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in equity securities of certain companies that are subject to holding period restrictions longer than one year are classified as Level 3 and carried at fair value using an option pricing valuation model. The most significant assumptions within the option pricing valuation model are the stock price volatility, which is based on the historical volatility of similar companies, and the discount for lack of marketability related to the term of the restrictions.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of accounts receivable and accounts payable and accrued liabilities approximate their fair values due to their short-term maturities.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers between levels in the fair value hierarchy during 2020 or 2019.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory is valued at the lower of cost or net realizable value. We determine the cost of inventory using the standard-cost method, which approximates actual cost based on the first-in, first-out method. We assess the valuation of our inventory on a quarterly basis and adjust the value for excess and obsolete inventory to the extent management determines that the cost cannot be recovered based on estimates about future demand. Inventory costs resulting from these adjustments are recognized as cost of sales in the period in which they are incurred. When future commercialization is considered probable and the future economic benefit is expected to be realized, based on management’s judgment, we capitalize pre-launch inventory costs prior to regulatory approval.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost and depreciated over the estimated useful lives of the assets using the straight-line method. Equipment is depreciated over an average estimated useful life of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzk1MTk_8d0fcf19-f18b-4cc7-a570-ecad81280ef1">three</span> to seven years. Leasehold improvements are depreciated over the shorter of their estimated useful lives or the remaining lease term. Depreciation expense was $8.6 million for 2020, $7.4 million for 2019 and $4.0 million for 2018.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We review long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. If indicators of impairment exist, we assess the recoverability of the affected long-lived assets by determining whether the carrying value of such assets can be recovered through undiscounted future operating cash flows. If the carrying amount is not recoverable, we measure the amount of any impairment by comparing the carrying value of the asset to the present value of the expected future cash flows associated with the use of the asset.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue when the customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. Revenue is recognized using a five-step model: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenues when (or as) we satisfy the performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Sales, Net.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In the U.S., our product sales, net consist of sales of INGREZZA, primarily to specialty pharmacy providers and a specialty distributor, and sales of ONGENTYS, primarily to wholesale distributors. We recognize product sales, net when the customer obtains control of our product, which occurs at a point in time, typically upon delivery of our product to the customer.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from product sales are recorded net of reserves established for applicable discounts and allowances that are offered within contracts with our customers, payors and other third parties. Such estimates are based on information received from external sources (such as written or oral information obtained from our customers with respect to their period-end inventory levels and sales to end-users during the reporting period), as supplemented by management’s judgement. Our process for estimating reserves established for these variable consideration components does not differ materially from historical practices. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which could have an effect on earnings in the period of adjustment.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our significant categories of sales discounts and allowances are as follows:</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Discounts.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Product discounts are based on payment terms extended to our customers at the time of sale, which include incentives offered for prompt payment. We maintain a reserve for product discounts based on our historical experience, including the timing of customer payments. To date, actual product discounts have not differed materially from our estimates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Rebates.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We are obligated to pay rebates for mandated discounts under the Medicaid Drug Rebate Program. The liability for such rebates consists of invoices received for claims from prior quarters that remain unpaid, or for which an invoice has not been received, and estimated rebates for the current applicable reporting period. Such estimates are based on actual historical rebates by state, estimated payor mix, state and federal regulations and relevant contractual terms, as supplemented by management’s judgement. Our rebate accrual calculations require us to project the magnitude of our sales, by state, that will be subject to these rebates. There is a significant time-lag in our receiving rebate notices from each state (generally, several months or longer after a sale is recognized). Estimated rebates are recorded as a reduction of revenue in the period the related sale is recognized. To date, actual government rebates have not differed materially from our estimates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chargebacks.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The difference between the list price, or the price at which we sell our products to our customers, and the contracted price, or the price at which our customers sell our products to qualified healthcare professionals, is charged back to us by our customers. In addition to actual chargebacks received, we maintain a reserve for chargebacks based on estimated contractual discounts on product inventory levels on-hand in our distribution channel. To date, actual chargebacks have not differed materially from our estimates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Payor and Pharmacy Rebates.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We are obligated to pay rebates as a percentage of sales under payor and pharmacy contracts. We estimate these rebates based on actual historical rebates, contractual rebate percentages, sales made through the payor channel and purchases made by pharmacies. To date, actual payor and pharmacy rebates have not differed materially from our estimates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Co-payment Assistance.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We offer financial assistance to qualified patients with prescription drug co-payments required by insurance. We accrue for copay assistance based on estimated claims and the cost per claim we expect to receive associated with inventory that remains in the distribution channel at period end. To date, actual copay assistance has not differed materially from our estimates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distributor and Other Fees.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In connection with the sales of our products, we pay distributor and other fees to certain customers that provide us with inventory management, data and distribution services, which are generally recorded as a reduction of revenue. To the extent we can demonstrate a separable benefit and fair value for these services, we classify the associated costs in selling, general and administrative expenses. These costs are typically known at the time of sale, resulting in minimal adjustments subsequent to the period of sale.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Returns.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For INGREZZA, we offer our customers product return rights primarily limited to errors in shipment and damaged product. We do not permit returns of INGREZZA for expiring or expired product. Accordingly, we have limited return risk resulting from INGREZZA product sales and therefore do not record an associated returns allowance. For ONGENTYS, we offer our customers product return rights primarily limited to errors in shipment, damaged product, and expiring or expired product, provided it is within a specified period around the product expiration date, as set forth in the associated distribution agreement. Once product is returned, it is destroyed. Where actual returns history is not available, we estimate the associated returns allowance based on benchmarking data for similar products and industry experience. We record this estimate as a reduction of revenue in the period the related sale is recognized. To date, actual product returns have not differed materially from our estimates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Revenues. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into collaboration and licensing agreements under which we license certain rights to our product candidates to third parties. The terms of these arrangements typically include payment to us of one or more of the following: non-refundable, up-front license fees; development, regulatory, and/or commercial milestone payments; and royalties on net sales of licensed products.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Licenses of Intellectual Property.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, we use judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> At the inception of each arrangement that includes developmental, regulatory or commercial milestone payments, we evaluate whether achieving the milestones is considered probable and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the value of the associated milestone is included in the transaction price. Milestone payments that are not within our control, such as approvals from regulators or where attainment of the specified event is dependent on the development activities of a third party, are not considered probable of being achieved until those approvals are received or the specified event occurs. Revenue is recognized from the satisfaction of performance obligations in the amount billable to the customer.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalty Revenues.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Each quarterly period, sales-based royalties are recorded based on estimated quarterly net sales of the associated collaboration products. Differences between actual results and estimated amounts are adjusted for in the period in which they become known, which typically follows the quarterly period in which the estimate was made. To date, actual royalties received have not differed materially from our estimates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to concentration of credit risk consist primarily of cash, cash equivalents and marketable securities. We have established guidelines to limit our exposure to credit risk by diversifying our investment portfolio and by placing investments with high credit quality financial </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">institutions and maturities that maintain safety and liquidity. To date, we have not experienced any credit losses and do not believe we are exposed to any significant credit risk in relation to these financial instruments.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to credit risk from our accounts receivable related to our product sales. Our two largest customers represented approximately 86% of our product revenues for both 2020 and 2019, and the significant majority of our accounts receivable balances at December 31, 2020 and 2019. For 2018, our three largest customers represented approximately 93% of our product revenue and substantially all of our accounts receivable balance at December 31, 2018. To date, we have not experienced any significant losses with respect to the collection of these accounts receivable.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Sales. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales includes third-party manufacturing, transportation, freight and indirect overhead costs associated with the manufacture and distribution of INGREZZA and ONGENTYS, royalty fees on net sales of ORILISSA and ORIAHNN, and adjustments for excess and obsolete inventory to the extent management determines that the cost cannot be recovered based on estimates about future demand.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expenses consist primarily of salaries, payroll taxes, employee benefits and share-based compensation charges for those individuals involved in ongoing R&amp;D efforts; as well as scientific consulting fees, preclinical and clinical trial costs, R&amp;D facilities costs, laboratory supply costs and depreciation of scientific equipment. All such costs are charged to R&amp;D expense as incurred. These expenses result from our independent R&amp;D efforts, as well as efforts associated with collaborations, in-licenses and third-party funded research arrangements, including event based milestones.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Asset Acquisitions. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for acquisitions of an asset or group of assets that do not meet the definition of a business using the cost accumulation method, whereby the cost of the acquisition, including certain transaction costs, is allocated to the assets acquired on the basis of their relative fair values. No goodwill is recognized in an asset acquisition. Intangible assets that are acquired in an asset acquisition for use in R&amp;D activities which have no alternative future use are expensed as in-process research and development, or IPR&amp;D, on the acquisition date. Future costs to develop these assets are recorded to R&amp;D expense as they are incurred.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advertising Expense. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advertising costs are expensed when services are performed, or goods are delivered. We incurred advertising costs related to INGREZZA and ONGENTYS of $64.8 million for 2020, $40.6 million for 2019 and $20.5 million for 2018.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We grant stock options to purchase our common stock to eligible employees and directors and also grant certain employees restricted stock units, or RSUs, and performance-based restricted stock units, or PRSUs. Additionally, we allow employees to participate in an employee stock purchase plan, or ESPP.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair value of stock options and shares to be issued under the ESPP using the Black-Scholes option-pricing model on the date of grant. Restricted stock units are valued based on the closing price of our common stock on the date of grant. The fair value of equity instruments expected to vest are recognized and amortized on a straight-line basis over the requisite service period of the award, which is generally <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzIzNTk5_9b6b4cf3-899b-4055-94dc-05632180c7d1">three</span> to four years; however, certain provisions in our equity compensation plans provide for shorter vesting periods under certain circumstances. The fair value of shares to be issued under the ESPP are recognized and amortized on a straight-line basis over the purchase period, which is generally six months. Additionally, we granted certain PRSUs that vest upon the achievement of certain predefined company-specific performance-based criteria. Expense related to these PRSUs is generally recognized ratably over the expected performance period once the predefined performance-based criteria for vesting becomes probable.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our income tax benefit (provision) is computed under the asset and liability method. Significant estimates are required in determining our income tax benefit (provision). Some of these estimates are based on interpretations of existing tax laws or regulations. We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (temporary differences) at enacted tax rates in effect for the years in which the differences are expected to reverse. A valuation allowance is established for deferred tax assets for which it is more likely than not that some portion or all of the deferred tax assets, including net operating losses and tax credits, will not be realized. We periodically re-assess the need for a valuation allowance against our deferred tax assets based on various factors including our historical earnings experience by </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">taxing jurisdiction, and forecasts of future operating results and utilization of net operating losses and tax credits prior to their expiration. Significant judgment is required in making this assessment and, to the extent that a reversal of any portion of our valuation allowance against our deferred tax assets is deemed appropriate, a tax benefit will be recognized against our income tax provision in the period of such reversal. Prior to 2020, we recorded a valuation allowance that fully offset our deferred tax assets. On December 31, 2020, based on our evaluation of various factors, such as our achievement of a cumulative three-year income position as of December 31, 2020, as well as our consideration of forecasts of future operating results and utilization of net operating losses and tax credits prior to their expiration, we released substantially all of our valuation allowance against our deferred tax assets and recorded a corresponding income tax benefit. Refer to Note 9 to the consolidated financial statements for more information.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize tax benefits from uncertain tax positions only if it is more likely than not that the tax position will be sustained upon examination by the tax authorities based on the technical merits of the position. An adverse resolution of one or more of these uncertain tax positions in any period could have a material impact on the results of operations for that period.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Income Per Share. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income per share is computed using the weighted average number of common shares outstanding during the period. Diluted net income per share is computed using the weighted average number of common and potentially dilutive shares outstanding during the period, including the potentially dilutive shares resulting from the conversion of the 2024 Notes and excluding the effect of stock options and restricted stock outstanding for periods when their effect is anti-dilutive, using the treasury stock method.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Convertible debt instruments that may be settled entirely or partly in cash (such as the 2024 Notes) may, in certain circumstances where the borrower has the ability and intent to settle in cash, be accounted for under the treasury stock method. We issued the 2024 Notes with a combination settlement feature, which we have the ability and intent to use upon conversion of the 2024 Notes, to settle the principal amount of debt for cash and the excess of the principal portion in shares of our common stock. As a result, of the approximately 5.0 million shares underlying the 2024 Notes at December 31, 2020, only the shares required to settle the excess of the principal portion would be considered dilutive under the treasury stock method. Further, approximately 0.2 million PRSUs were excluded from the calculation of diluted net income per share as the performance condition has not been achieved. In loss periods, basic net loss per share and diluted net loss per share are identical because the otherwise dilutive potential common shares become anti-dilutive and are therefore excluded.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASU 2016-13.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2020, we adopted Accounting Standards Update, or ASU, 2016-13,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">using the modified retrospective transition method. For debt securities available-for-sale, the standard requires an investor to determine whether a decline in the fair value below the amortized cost basis of the investment is due to credit-related factors. Credit-related impairment is recognized as an allowance for credit loss on the balance sheet with a corresponding adjustment to earnings. Credit losses are limited to the amount by which the investment’s amortized cost basis exceeds its fair value and may be subsequently reversed if conditions change. Any impairment that is not credit related is recognized in other comprehensive income or loss, as applicable, net of applicable taxes.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The adoption of ASU 2016-13 did not result in a cumulative-effect adjustment to retained earnings. The comparative prior period information continues to be reported under the accounting standards in effect during those periods.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASU 2019-12.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and amends existing guidance to improve consistent application of Topic 740. ASU 2019-12 is effective for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years, with early adoption permitted in any interim period for which financial statements have not yet been made available for issuance. We are currently evaluating the effect ASU 2019-12 will have on our condensed consolidated financial statements and related disclosures.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASU 2020-06. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU 2020-06,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity's Own Equity (Subtopic 815-40): Accounting </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">for Convertible Instruments and Contracts in an Entity's Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments, and amends existing earnings-per-share, or EPS, guidance by requiring that an entity use the if-converted method when calculating diluted EPS for convertible instruments. ASU 2020-06 is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years, with early adoption permitted for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. We plan to adopt ASU 2020-06 effective January 1, 2022 and are currently evaluating the effect ASU 2020-06 will have on our consolidated financial statements and related disclosures.</span> <div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Activities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neurocrine Biosciences, Inc., or Neurocrine, the Company, we, our or us, was incorporated in California in 1992 and reincorporated in Delaware in 1996. Neurocrine Continental, Inc., is a Delaware corporation and a wholly owned subsidiary of Neurocrine. We also have two wholly-owned Irish subsidiaries, Neurocrine Therapeutics, Ltd. and Neurocrine Europe, Ltd. both of which were formed in December 2014 and are inactive.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a neuroscience-focused biopharmaceutical company dedicated to discovering, developing and delivering life-changing treatments for patients with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. Our diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson’s disease, endometriosis*, uterine fibroids* and clinical programs in multiple therapeutic areas. For nearly three decades, we specialize in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(*in collaboration with AbbVie Inc.)</span></div> 2 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of Neurocrine as well as our wholly owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.</span> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America, or GAAP, requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. Actual results could differ from those estimates.</span> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Industry Segment and Geographic Information. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in a single industry segment – the discovery, development and marketing of pharmaceuticals for the treatment of neurological, endocrine and psychiatric-based diseases and disorders. We had no foreign-based operations during any of the years presented.</span> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Certain amounts in prior year periods have been reclassified to conform with the presentation adopted in the current year.</span> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Equivalents. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all highly liquid investments that are readily convertible into cash and have an original maturity of three months or less at the time of purchase to be cash equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable are recorded net of customer allowances for prompt payment discounts, chargebacks and any allowance for doubtful accounts. We estimate the allowance for doubtful accounts based on existing contractual payment terms, actual payment patterns of our customers and individual customer circumstances. To date, an allowance for doubtful accounts has not been material.</span> <div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Securities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt securities consist of investments in certificates of deposit, corporate debt securities, and securities of government-sponsored entities. We classify debt securities as available-for-sale. Debt securities available-for-sale are recorded at fair value, with unrealized gains and losses included in other comprehensive income or loss, net of tax. We exclude accrued interest from both the fair value and amortized cost basis of debt securities. A debt security is placed on nonaccrual status at the time any principal or interest payments become 90 days delinquent. Interest accrued but not received for a debt security placed on nonaccrual status is reversed against interest income.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income includes amortization of purchase premium or discount. Premiums and discounts on debt securities are amortized using the effective interest rate method. Gains and losses on sales of debt securities are recorded on the trade date in investment income and other, net, and determined using the specific identification method.</span></div> P90D <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Allowance for Credit Losses. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For debt securities available-for-sale in an unrealized loss position, we first assess whether we intend to sell, or it is more likely than not that we will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security’s amortized cost basis is written down to fair value through earnings. For debt securities available-for-sale that do not meet the aforementioned criteria, we evaluate whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, we consider the extent to which fair value is less than amortized cost, any changes in interest rates, and any changes to the rating of the security by a rating agency, among other factors. If this </span><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security is compared to the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded, limited by the amount that the fair value is less than the amortized cost basis. Any impairment that has not been recorded through an allowance for credit losses is recognized in other comprehensive income or loss, as applicable.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued interest receivables on debt securities available-for-sale totaled $3.7 million at December 31, 2020. We do not measure an allowance for credit losses for accrued interest receivables. For the purposes of identifying and measuring an impairment, accrued interest is excluded from both the fair value and amortized cost basis of the debt security. Uncollectible accrued interest receivables associated with an impaired debt security are reversed against interest income upon identification of the impairment. No accrued interest receivables were written off during 2020, 2019 or 2018.</span></div> 3700000 0 0 0 <div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record cash equivalents, debt securities available-for-sale and equity securities at fair value based on a fair value hierarchy that distinguishes between assumptions based on market data (observable inputs) and our own assumptions (unobservable inputs). The fair value hierarchy consists of the following three levels:</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">– Quoted prices (unadjusted) in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">– Quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 3 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">– Unobservable inputs that reflect our own assumptions about the assumptions that market participants would use in pricing the asset or liability when there is little, if any, market activity for the asset or liability at the measurement date.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in debt securities available-for-sale are classified as Level 2 and carried at fair value. We estimate the fair value of debt securities available-for-sale by utilizing third-party pricing services. These pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. Such inputs include market pricing based on real-time trade data for similar instruments, issuer credit spreads, benchmark yields, broker/dealer quotes and other observable inputs. We validate valuations obtained from third-party pricing services by understanding the models used, obtaining market values from other pricing sources, and analyzing data in certain instances.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in equity securities of certain companies that are subject to holding period restrictions longer than one year are classified as Level 3 and carried at fair value using an option pricing valuation model. The most significant assumptions within the option pricing valuation model are the stock price volatility, which is based on the historical volatility of similar companies, and the discount for lack of marketability related to the term of the restrictions.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of accounts receivable and accounts payable and accrued liabilities approximate their fair values due to their short-term maturities.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers between levels in the fair value hierarchy during 2020 or 2019.</span></div> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory is valued at the lower of cost or net realizable value. We determine the cost of inventory using the standard-cost method, which approximates actual cost based on the first-in, first-out method. We assess the valuation of our inventory on a quarterly basis and adjust the value for excess and obsolete inventory to the extent management determines that the cost cannot be recovered based on estimates about future demand. Inventory costs resulting from these adjustments are recognized as cost of sales in the period in which they are incurred. When future commercialization is considered probable and the future economic benefit is expected to be realized, based on management’s judgment, we capitalize pre-launch inventory costs prior to regulatory approval.</span> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost and depreciated over the estimated useful lives of the assets using the straight-line method. Equipment is depreciated over an average estimated useful life of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzk1MTk_8d0fcf19-f18b-4cc7-a570-ecad81280ef1">three</span> to seven years. Leasehold improvements are depreciated over the shorter of their estimated useful lives or the remaining lease term. Depreciation expense was $8.6 million for 2020, $7.4 million for 2019 and $4.0 million for 2018.</span> P7Y 8600000 7400000 4000000.0 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We review long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. If indicators of impairment exist, we assess the recoverability of the affected long-lived assets by determining whether the carrying value of such assets can be recovered through undiscounted future operating cash flows. If the carrying amount is not recoverable, we measure the amount of any impairment by comparing the carrying value of the asset to the present value of the expected future cash flows associated with the use of the asset.</span> <div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue when the customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. Revenue is recognized using a five-step model: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenues when (or as) we satisfy the performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Sales, Net.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In the U.S., our product sales, net consist of sales of INGREZZA, primarily to specialty pharmacy providers and a specialty distributor, and sales of ONGENTYS, primarily to wholesale distributors. We recognize product sales, net when the customer obtains control of our product, which occurs at a point in time, typically upon delivery of our product to the customer.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from product sales are recorded net of reserves established for applicable discounts and allowances that are offered within contracts with our customers, payors and other third parties. Such estimates are based on information received from external sources (such as written or oral information obtained from our customers with respect to their period-end inventory levels and sales to end-users during the reporting period), as supplemented by management’s judgement. Our process for estimating reserves established for these variable consideration components does not differ materially from historical practices. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which could have an effect on earnings in the period of adjustment.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our significant categories of sales discounts and allowances are as follows:</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Discounts.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Product discounts are based on payment terms extended to our customers at the time of sale, which include incentives offered for prompt payment. We maintain a reserve for product discounts based on our historical experience, including the timing of customer payments. To date, actual product discounts have not differed materially from our estimates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Rebates.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We are obligated to pay rebates for mandated discounts under the Medicaid Drug Rebate Program. The liability for such rebates consists of invoices received for claims from prior quarters that remain unpaid, or for which an invoice has not been received, and estimated rebates for the current applicable reporting period. Such estimates are based on actual historical rebates by state, estimated payor mix, state and federal regulations and relevant contractual terms, as supplemented by management’s judgement. Our rebate accrual calculations require us to project the magnitude of our sales, by state, that will be subject to these rebates. There is a significant time-lag in our receiving rebate notices from each state (generally, several months or longer after a sale is recognized). Estimated rebates are recorded as a reduction of revenue in the period the related sale is recognized. To date, actual government rebates have not differed materially from our estimates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chargebacks.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The difference between the list price, or the price at which we sell our products to our customers, and the contracted price, or the price at which our customers sell our products to qualified healthcare professionals, is charged back to us by our customers. In addition to actual chargebacks received, we maintain a reserve for chargebacks based on estimated contractual discounts on product inventory levels on-hand in our distribution channel. To date, actual chargebacks have not differed materially from our estimates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Payor and Pharmacy Rebates.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We are obligated to pay rebates as a percentage of sales under payor and pharmacy contracts. We estimate these rebates based on actual historical rebates, contractual rebate percentages, sales made through the payor channel and purchases made by pharmacies. To date, actual payor and pharmacy rebates have not differed materially from our estimates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Co-payment Assistance.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We offer financial assistance to qualified patients with prescription drug co-payments required by insurance. We accrue for copay assistance based on estimated claims and the cost per claim we expect to receive associated with inventory that remains in the distribution channel at period end. To date, actual copay assistance has not differed materially from our estimates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distributor and Other Fees.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In connection with the sales of our products, we pay distributor and other fees to certain customers that provide us with inventory management, data and distribution services, which are generally recorded as a reduction of revenue. To the extent we can demonstrate a separable benefit and fair value for these services, we classify the associated costs in selling, general and administrative expenses. These costs are typically known at the time of sale, resulting in minimal adjustments subsequent to the period of sale.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Returns.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For INGREZZA, we offer our customers product return rights primarily limited to errors in shipment and damaged product. We do not permit returns of INGREZZA for expiring or expired product. Accordingly, we have limited return risk resulting from INGREZZA product sales and therefore do not record an associated returns allowance. For ONGENTYS, we offer our customers product return rights primarily limited to errors in shipment, damaged product, and expiring or expired product, provided it is within a specified period around the product expiration date, as set forth in the associated distribution agreement. Once product is returned, it is destroyed. Where actual returns history is not available, we estimate the associated returns allowance based on benchmarking data for similar products and industry experience. We record this estimate as a reduction of revenue in the period the related sale is recognized. To date, actual product returns have not differed materially from our estimates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Revenues. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into collaboration and licensing agreements under which we license certain rights to our product candidates to third parties. The terms of these arrangements typically include payment to us of one or more of the following: non-refundable, up-front license fees; development, regulatory, and/or commercial milestone payments; and royalties on net sales of licensed products.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Licenses of Intellectual Property.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, we use judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> At the inception of each arrangement that includes developmental, regulatory or commercial milestone payments, we evaluate whether achieving the milestones is considered probable and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the value of the associated milestone is included in the transaction price. Milestone payments that are not within our control, such as approvals from regulators or where attainment of the specified event is dependent on the development activities of a third party, are not considered probable of being achieved until those approvals are received or the specified event occurs. Revenue is recognized from the satisfaction of performance obligations in the amount billable to the customer.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalty Revenues.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Each quarterly period, sales-based royalties are recorded based on estimated quarterly net sales of the associated collaboration products. Differences between actual results and estimated amounts are adjusted for in the period in which they become known, which typically follows the quarterly period in which the estimate was made. To date, actual royalties received have not differed materially from our estimates.</span></div> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to concentration of credit risk consist primarily of cash, cash equivalents and marketable securities. We have established guidelines to limit our exposure to credit risk by diversifying our investment portfolio and by placing investments with high credit quality financial </span><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">institutions and maturities that maintain safety and liquidity. To date, we have not experienced any credit losses and do not believe we are exposed to any significant credit risk in relation to these financial instruments.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to credit risk from our accounts receivable related to our product sales. Our two largest customers represented approximately 86% of our product revenues for both 2020 and 2019, and the significant majority of our accounts receivable balances at December 31, 2020 and 2019. For 2018, our three largest customers represented approximately 93% of our product revenue and substantially all of our accounts receivable balance at December 31, 2018. To date, we have not experienced any significant losses with respect to the collection of these accounts receivable.</span></div> 0.86 0.86 0.93 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Sales. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales includes third-party manufacturing, transportation, freight and indirect overhead costs associated with the manufacture and distribution of INGREZZA and ONGENTYS, royalty fees on net sales of ORILISSA and ORIAHNN, and adjustments for excess and obsolete inventory to the extent management determines that the cost cannot be recovered based on estimates about future demand.</span> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expenses consist primarily of salaries, payroll taxes, employee benefits and share-based compensation charges for those individuals involved in ongoing R&amp;D efforts; as well as scientific consulting fees, preclinical and clinical trial costs, R&amp;D facilities costs, laboratory supply costs and depreciation of scientific equipment. All such costs are charged to R&amp;D expense as incurred. These expenses result from our independent R&amp;D efforts, as well as efforts associated with collaborations, in-licenses and third-party funded research arrangements, including event based milestones.</span> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Asset Acquisitions. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for acquisitions of an asset or group of assets that do not meet the definition of a business using the cost accumulation method, whereby the cost of the acquisition, including certain transaction costs, is allocated to the assets acquired on the basis of their relative fair values. No goodwill is recognized in an asset acquisition. Intangible assets that are acquired in an asset acquisition for use in R&amp;D activities which have no alternative future use are expensed as in-process research and development, or IPR&amp;D, on the acquisition date. Future costs to develop these assets are recorded to R&amp;D expense as they are incurred.</span> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advertising Expense. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advertising costs are expensed when services are performed, or goods are delivered. We incurred advertising costs related to INGREZZA and ONGENTYS of $64.8 million for 2020, $40.6 million for 2019 and $20.5 million for 2018.</span> 64800000 40600000 20500000 <div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We grant stock options to purchase our common stock to eligible employees and directors and also grant certain employees restricted stock units, or RSUs, and performance-based restricted stock units, or PRSUs. Additionally, we allow employees to participate in an employee stock purchase plan, or ESPP.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair value of stock options and shares to be issued under the ESPP using the Black-Scholes option-pricing model on the date of grant. Restricted stock units are valued based on the closing price of our common stock on the date of grant. The fair value of equity instruments expected to vest are recognized and amortized on a straight-line basis over the requisite service period of the award, which is generally <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzIzNTk5_9b6b4cf3-899b-4055-94dc-05632180c7d1">three</span> to four years; however, certain provisions in our equity compensation plans provide for shorter vesting periods under certain circumstances. The fair value of shares to be issued under the ESPP are recognized and amortized on a straight-line basis over the purchase period, which is generally six months. Additionally, we granted certain PRSUs that vest upon the achievement of certain predefined company-specific performance-based criteria. Expense related to these PRSUs is generally recognized ratably over the expected performance period once the predefined performance-based criteria for vesting becomes probable.</span></div> P4Y P6M <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our income tax benefit (provision) is computed under the asset and liability method. Significant estimates are required in determining our income tax benefit (provision). Some of these estimates are based on interpretations of existing tax laws or regulations. We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (temporary differences) at enacted tax rates in effect for the years in which the differences are expected to reverse. A valuation allowance is established for deferred tax assets for which it is more likely than not that some portion or all of the deferred tax assets, including net operating losses and tax credits, will not be realized. We periodically re-assess the need for a valuation allowance against our deferred tax assets based on various factors including our historical earnings experience by </span><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">taxing jurisdiction, and forecasts of future operating results and utilization of net operating losses and tax credits prior to their expiration. Significant judgment is required in making this assessment and, to the extent that a reversal of any portion of our valuation allowance against our deferred tax assets is deemed appropriate, a tax benefit will be recognized against our income tax provision in the period of such reversal. Prior to 2020, we recorded a valuation allowance that fully offset our deferred tax assets. On December 31, 2020, based on our evaluation of various factors, such as our achievement of a cumulative three-year income position as of December 31, 2020, as well as our consideration of forecasts of future operating results and utilization of net operating losses and tax credits prior to their expiration, we released substantially all of our valuation allowance against our deferred tax assets and recorded a corresponding income tax benefit. Refer to Note 9 to the consolidated financial statements for more information.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize tax benefits from uncertain tax positions only if it is more likely than not that the tax position will be sustained upon examination by the tax authorities based on the technical merits of the position. An adverse resolution of one or more of these uncertain tax positions in any period could have a material impact on the results of operations for that period.</span></div> <div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Income Per Share. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income per share is computed using the weighted average number of common shares outstanding during the period. Diluted net income per share is computed using the weighted average number of common and potentially dilutive shares outstanding during the period, including the potentially dilutive shares resulting from the conversion of the 2024 Notes and excluding the effect of stock options and restricted stock outstanding for periods when their effect is anti-dilutive, using the treasury stock method.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Convertible debt instruments that may be settled entirely or partly in cash (such as the 2024 Notes) may, in certain circumstances where the borrower has the ability and intent to settle in cash, be accounted for under the treasury stock method. We issued the 2024 Notes with a combination settlement feature, which we have the ability and intent to use upon conversion of the 2024 Notes, to settle the principal amount of debt for cash and the excess of the principal portion in shares of our common stock. As a result, of the approximately 5.0 million shares underlying the 2024 Notes at December 31, 2020, only the shares required to settle the excess of the principal portion would be considered dilutive under the treasury stock method. Further, approximately 0.2 million PRSUs were excluded from the calculation of diluted net income per share as the performance condition has not been achieved. In loss periods, basic net loss per share and diluted net loss per share are identical because the otherwise dilutive potential common shares become anti-dilutive and are therefore excluded.</span></div> 5000000.0 200000 <div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASU 2016-13.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2020, we adopted Accounting Standards Update, or ASU, 2016-13,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">using the modified retrospective transition method. For debt securities available-for-sale, the standard requires an investor to determine whether a decline in the fair value below the amortized cost basis of the investment is due to credit-related factors. Credit-related impairment is recognized as an allowance for credit loss on the balance sheet with a corresponding adjustment to earnings. Credit losses are limited to the amount by which the investment’s amortized cost basis exceeds its fair value and may be subsequently reversed if conditions change. Any impairment that is not credit related is recognized in other comprehensive income or loss, as applicable, net of applicable taxes.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The adoption of ASU 2016-13 did not result in a cumulative-effect adjustment to retained earnings. The comparative prior period information continues to be reported under the accounting standards in effect during those periods.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASU 2019-12.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and amends existing guidance to improve consistent application of Topic 740. ASU 2019-12 is effective for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years, with early adoption permitted in any interim period for which financial statements have not yet been made available for issuance. We are currently evaluating the effect ASU 2019-12 will have on our condensed consolidated financial statements and related disclosures.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASU 2020-06. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU 2020-06,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity's Own Equity (Subtopic 815-40): Accounting </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">for Convertible Instruments and Contracts in an Entity's Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments, and amends existing earnings-per-share, or EPS, guidance by requiring that an entity use the if-converted method when calculating diluted EPS for convertible instruments. ASU 2020-06 is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years, with early adoption permitted for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. We plan to adopt ASU 2020-06 effective January 1, 2022 and are currently evaluating the effect ASU 2020-06 will have on our consolidated financial statements and related disclosures.</span> License and Collaboration Agreements<div style="margin-bottom:6pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Takeda Pharmaceutical Company Limited</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We entered into an exclusive license agreement with Takeda Pharmaceutical Company Limited, or Takeda, which became effective in July 2020, to develop and commercialize certain compounds in Takeda’s early to mid-stage psychiatry pipeline. Specifically, Takeda granted us an exclusive license to the following seven assets: (i) NBI-1065844 (TAK-831) for schizophrenia, (ii) NBI-1065845 (TAK-653) for treatment-resistant depression, (iii) NBI-1065846 (TAK-041) for anhedonia (which together with the NBI-1065845 are referred to as the Phase II Ready Assets), and (iv) four non-clinical stage assets, or the Non-Clinical Assets.</span></div><div style="margin-bottom:6pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NBI-1065844 is deemed a royalty-bearing product under the license agreement pursuant to which we will be responsible for all costs and expenses associated with the development, manufacture, and commercialization of such asset, subject to certain exceptions, and Takeda will be eligible to receive development and commercial milestones and royalties with respect to such asset, or a Royalty-Bearing Product, and Takeda will retain the right to opt-in to a profit sharing arrangement pursuant to which we and Takeda will equally share in the operating profits and losses related to such asset, subject to certain exceptions, in lieu of receiving milestones and royalties, or a Profit-Share Product. Subject to specified conditions, Takeda may elect to exercise such opt-in right for NBI-1065844 before we initiate a Phase III clinical trial. Each of the Phase II Ready Assets is deemed a Profit-Share Product and Takeda will retain the right to opt-out of the profit-sharing arrangement for such asset pursuant to which such asset would become a Royalty-Bearing Product. Takeda may elect to exercise such opt-out rights with respect to a Phase II Ready Asset immediately following the completion of the second Phase II clinical trial for such Phase II Ready Asset. In addition, under certain circumstances related to the development and commercialization activities to be performed by us, Takeda may elect to opt-out of the profit-sharing arrangement for a Profit-Share Product before the initiation of a Phase III clinical trial for such product.</span></div><div style="margin-bottom:6pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of the Non-Clinical Assets will be Royalty-Bearing Products pursuant to which we will be responsible for all costs and expenses associated with the development, manufacture, and commercialization of such assets, subject to certain exceptions.</span></div><div style="margin-bottom:6pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the agreement, we paid Takeda $120.0 million upfront</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which, including certain transaction related costs, was expensed as in-process research and development, or IPR&amp;D, in the third quarter of 2020</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the agreement, </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Takeda may also be entitled to receive additional payments of up to $1.9 billion upon the achievement of certain event-based milestones associated with Royalty-Bearing Products, as well as receive royalties on the future net sales of Royalty-Bearing Products. On a country-by-country and product-by-product basis, royalty payments would commence on the first commercial sale of a Royalty-Bearing Product and terminate on the later of (i) the expiration of the last patent covering such Royalty-Bearing Product in such country, (ii) a number of years from the first commercial sale of such Royalty-Bearing Product in such country and (iii) the expiration of regulatory exclusivity for Royalty-Bearing Product in such country.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Idorsia Pharmaceuticals Ltd.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, we entered a collaboration and licensing agreement with Idorsia Pharmaceuticals Ltd, or Idorsia, to license the global rights to NBI-827104 (ACT-709478), a potent, selective, orally active and brain penetrating T-type calcium channel blocker, in clinical development for the treatment of a rare pediatric epilepsy. The agreement also includes a research collaboration to discover and identify additional novel T-type calcium channel blockers as development candidates. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the exercise of the option, we paid Idorsia $45.0 million upfront, which we expensed as IPR&amp;D in the second quarter of 2020. Further, as part of the research collaboration, we provided Idorsia with an incremental $7.2 million in funding, which we recorded as a prepaid asset and is being expensed over the two-year research collaboration term.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the agreement, upon the achievement of certain development and regulatory milestones, Idorsia may be entitled to receive additional payments of up to $365.0 million with respect to NBI-827104 and $620.0 million with respect to the development candidates. Idorsia may also be entitled to receive additional payments of up to $750.0 million upon the achievement of certain commercial milestones, as well as receive royalties on the future net sales of any collaboration product. Further, we will be responsible for all manufacturing, development and commercialization costs of any collaboration product.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Xenon Pharmaceuticals, Inc. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, we entered into a license and collaboration agreement with Xenon Pharmaceuticals Inc., or Xenon, to identify, research, and develop sodium channel inhibitors, including clinical candidate NBI-921352 (XEN901) and three preclinical candidates, which compounds we will have the exclusive right to further develop and commercialize under the terms and conditions set forth in the agreement.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will be solely responsible, at our sole cost and expense, for all development and manufacturing of the compounds and any pharmaceutical product that contains a compound, subject to Xenon’s right to elect to co-fund the development of one product in a major indication and thus receive a mid-single digit percentage increase in royalties owed on the net sales of such product in the U.S. If Xenon exercises such option, the parties will share equally all reasonable and documented costs and expenses incurred in connection with the development of such product in the applicable indication, except costs and expenses that are solely related to the development of such product for regulatory approval outside the U.S.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the agreement, we paid Xenon $30.0 million upfront and purchased $20.0 million of Xenon’s common stock at $14.196 per share, representing approximately 1.4 million shares. Pursuant to the terms of the agreement, Xenon may also be entitled to receive additional payments of up to $1.7 billion upon the achievement of certain event-based milestones, as well as receive royalties on the future net sales of any collaboration product.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accounted for the transaction as an asset acquisition as the set of acquired assets did not constitute a business. Our equity investment in Xenon was recorded at a fair value of $14.1 million after considering Xenon’s stock price on the date of closing and certain lock-up and voting provisions applicable to the acquired shares. The remaining $36.2 million of the purchase price, which includes the applicable transaction costs, was expensed as IPR&amp;D in the fourth quarter of 2019.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Voyager Therapeutics, Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into a collaboration and license agreement with Voyager Therapeutics, Inc., or Voyager, which became effective in March 2019, to develop and commercialize four programs using Voyager’s proprietary gene therapy platform. The four programs consist of the NBIb-1817 (VY-AADC) program for Parkinson’s disease, the Friedreich’s ataxia program and the rights to two undisclosed programs.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the agreement, we paid Voyager $115.0 million upfront and purchased $50.0 million of Voyager’s common stock at $11.9625 per share, representing approximately 4.2 million shares. Pursuant to the terms of the agreement, Voyager may also be entitled to receive additional payments of up to $1.7 billion upon the achievement of certain event-based milestones, as well as receive royalties on the future net sales of any collaboration product.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to development plans agreed to by us and Voyager, unless Voyager exercises its co-development and co-commerci</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">alization rights as provided for in the agreement, we will be responsible for all development costs. Further, upon the occurrence of a specified event for each program, we will assume responsibility for the development, manufacturing, and commercialization activit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ies of such program.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accounted for the transaction as an asset acquisition as the set of acquired assets did not constitute a business. Our equity investment in Voyager was recorded at a fair value of $54.7 million after considering Voyager’s stock price on the date of closing and certain lock-up and voting provisions applicable to the acquired shares. The remaining $113.1 million of the purchase price, which includes the applicable transaction costs, was expensed as in-process research and development, or IPR&amp;D, in the first quarter of 2019.</span></div>In June 2019, we entered into an amendment to the collaboration and license agreement with Voyager. Under the terms of the amendment, we paid Voyager $5.0 million upfront to obtain rights outside the U.S. to the Friedreich’s ataxia program in connection with the early return of those rights to Voyager pursuant to a restructuring of Voyager’s gene therapy relationship with Sanofi Genzyme. The upfront payment was expensed as IPR&amp;D in the second quarter of 2019.<div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BIAL – Portela &amp; Ca, S.A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We acquired the U.S. and Canada rights to ONGENTYS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> from BIAL in the first quarter of 2017. We launched ONGENTYS in the U.S. in September 2020, after receiving FDA approval for ONGENTYS as an adjunctive therapy to levodopa/DOPA decarboxylase inhibitors in adult Parkinson's disease patients in April 2020. FDA approval for ONGENTYS for Parkinson’s disease resulted in a $20.0 million event-based payment to BIAL, which we expensed as R&amp;D in the second quarter of 2020. We further recognized R&amp;D expense of $10.0 million in each 2019 and 2018 in connection with BIAL’s achievement of certain regulatory event-based milestones related to then ongoing development of ONGENTYS. Pursuant to the terms of the agreement, BIAL may also be entitled to receive additional payments of up to $75.0 million upon the achievement of certain event-based milestones.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, we are responsible for the commercialization of ONGENTYS in the U.S. and Canada. Further, we rely on BIAL for the commercial supply of ONGENTYS. Upon our written request prior to the estimated expiration of the term of a licensed product, the parties shall negotiate a good faith continuation of BIAL’s supply of such licensed product after the term. After the term, and if BIAL is not supplying a certain licensed product, we shall pay BIAL a trademark royalty based on the net sales of such licensed product.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon commercialization of ONGENTYS, we determined certain annual sales forecasts. In the event we fail to meet the minimum sales requirements for a particular year, we would be obligated to pay BIAL an amount equal to the difference between the actual net sales and minimum sales requirements for such year.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Mitsubishi Tanabe Pharma Corporation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2015, we entered into a collaboration and license agreement with Mitsubishi Tanabe Pharma Corporation, or MTPC, for the development and commercialization of INGREZZA for movement disorders in Japan and other select Asian markets. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception of the agreement, we have recognized revenue of $19.8 million associated with the delivery of a technology license and existing know-how and $15.0 million associated with the achievement of a certain event-based milestone. We further recognized revenue of $2.7 million in 2020 and $0.9 million in 2019 in connection with the ongoing KINECT-HD study, a placebo-controlled Phase III study of valbenazine in adult Huntington’s disease patients with chorea. In accordance with our continuing performance obligations, $6.7 million of the $30.0 million upfront payment received from MTPC is being deferred and will be recognized as revenue over the ongoing study period using an input method according to costs incurred to-date relative to estimated total costs associated with the study.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the agreement, we may also be entitled to receive additional payments of up to $70.0 million upon the achievement of certain event-based milestones, receive payments for the manufacture of certain pharmaceutical products, as well as receive royalties on the future net sales of any collaboration product in select territories in Asia.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, MTPC is responsible for all third-party development, marketing, and commercialization costs in Japan and other select Asian markets and we would be entitled to a percentage of sales of INGREZZA in Japan and other select Asian markets for the longer of ten years or the life of the related patent rights. Further, the collaboration effort between the parties to advance INGREZZA towards commercialization in Japan and other select Asian markets is governed by joint steering and development committees with representatives from both parties.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">AbbVie Inc. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2010, we entered into an exclusive worldwide collaboration with AbbVie Inc., or AbbVie, to develop and commercialize elagolix and all next-generation gonadotropin-releasing factor, or GnRH, antagonists and collectively, GnRH Compounds, for women’s and men’s health.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AbbVie received approval for ORILISSA for the management of moderate to severe endometriosis pain in women from the FDA in July 2018 and Health Canada in October 2018. In May 2020, AbbVie received FDA approval for ORIAHNN for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. We recognized sales-based royalties on AbbVie net sales of ORILISSA and ORIAHNN of $19.2 million in 2020, $14.3 million in 2019 and $1.6 million in 2018.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDA approval for ORIAHNN for uterine fibroids resulted in the achievement of a $30.0 million event-based milestone, which we recognized as collaboration revenue in the second quarter of 2020. In 2019, we recognized collaboration revenue of $20.0 million in connection with the FDA’s acceptance of AbbVie’s NDA submission for the approval of ORIAHNN for uterine fibroids. In 2018, we recognized collaboration revenue of $40.0 million in connection with the FDA’s approval for ORILISSA for endometriosis.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception of the agreement, we have recognized revenue of $75.0 million associated with the delivery of a technology license and existing know-how and $165.0 million associated with the achievement of certain event-based milestones. Pursuant to the terms of the agreement, we may also be entitled to receive additional payments of up to $366.0 million upon the achievement of certain event-based milestones.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, AbbVie is responsible for all third-party development, marketing, and commercialization costs. We are entitled to a percentage of worldwide sales of GnRH Compounds for the longer of ten years or the life of the related patent rights.</span></div> Under the terms of the following license and collaboration agreements, we may be required to make milestone payments upon achievement of certain development and regulatory activities of up to $8.5 billion and pay royalties on future sales, if any, of commercial products resulting from these agreements. 8500000000 120000000.0 1900000000 45000000.0 7200000 P2Y 365000000.0 620000000.0 750000000.0 30000000.0 20000000.0 14.196 1400000 1700000000 14100000 36200000 115000000.0 50000000.0 11.9625 4200000 1700000000 54700000 113100000 5000000.0 On February 2, 2021, we notified Voyager of our termination of the NBIb-1817 for Parkinson’s disease program. The effective date of this termination will be August 2, 2021. The termination does not apply to any other development program other than NBIb-1817 for Parkinson’s disease, and our collaboration and license agreement with Voyager will otherwise continue in effect. 20000000.0 10000000.0 10000000.0 75000000.0 19800000 15000000.0 2700000 900000 6700000 30000000.0 70000000.0 P10Y 19200000 14300000 1600000 30000000.0 20000000.0 40000000.0 75000000.0 165000000.0 366000000.0 P10Y Debt Securities<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amortized cost, unrealized gain and loss recognized in accumulated other comprehensive income (loss), allowance for credit losses, and fair value of debt securities available-for-sale at December 31, 2020, aggregated by major security type and contractual maturity:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.156%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.560%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.515%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.515%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.515%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.515%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.519%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Gain</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Allowance for Credit Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Within 1 year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Within 1 year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">299.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Within 1 year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">230.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">231.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">612.4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">613.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 to 2 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">145.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 to 2 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">226.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">227.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amortized cost, unrealized gain and loss recognized in accumulated other comprehensive income, and fair value of debt securities available-for-sale at December 31, 2019, aggregated by major security type and contractual maturity:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.560%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.515%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.515%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.515%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.518%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Gain</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Within 1 year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Within 1 year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">270.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">271.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Within 1 year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">142.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">142.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">557.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">558.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 to 2 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">250.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">250.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 to 2 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">299.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">299.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes debt securities available-for-sale in an unrealized loss position for which an allowance for credit losses has not been recorded at December 31, 2020, aggregated by major security type and length of time in a continuous unrealized loss position:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.470%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less Than 12 Months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12 Months or Longer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2020, our security portfolio consisted of 148 securities related to investments in debt securities available-for-sale, of which 30 securities were in an unrealized loss position.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investments in corporate debt securities in an unrealized loss position at December 31, 2020 are of high credit quality (rated A or higher). Unrealized losses on these investments were primarily due to changes in interest rates. We do not intend to sell these investments and it is not more likely than not that we will be required to sell these investments before recovery of their amortized cost basis.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes debt securities available-for-sale in an unrealized loss position at December 31, 2019, aggregated by major security type and length of time in a continuous unrealized loss position:</span></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.470%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less Than 12 Months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12 Months or Longer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">186.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">186.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amortized cost, unrealized gain and loss recognized in accumulated other comprehensive income (loss), allowance for credit losses, and fair value of debt securities available-for-sale at December 31, 2020, aggregated by major security type and contractual maturity:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.156%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.560%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.515%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.515%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.515%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.515%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.519%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Gain</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Allowance for Credit Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Within 1 year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Within 1 year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">299.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Within 1 year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">230.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">231.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">612.4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">613.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 to 2 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">145.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 to 2 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">226.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">227.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amortized cost, unrealized gain and loss recognized in accumulated other comprehensive income, and fair value of debt securities available-for-sale at December 31, 2019, aggregated by major security type and contractual maturity:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.560%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.515%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.515%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.515%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.518%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Gain</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Within 1 year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Within 1 year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">270.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">271.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Within 1 year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">142.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">142.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">557.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">558.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 to 2 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">250.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">250.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 to 2 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">299.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">299.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 82200000 0 0 0 82200000 299300000 1400000 0 0 300700000 230900000 100000 0 0 231000000.0 612400000 1500000 0 0 613900000 144800000 400000 0 0 145200000 81900000 100000 100000 0 81900000 226700000 500000 100000 0 227100000 144500000 0 0 144500000 270500000 500000 0 271000000.0 142300000 400000 0 142700000 557300000 900000 0 558200000 250500000 500000 100000 250900000 48800000 0 0 48800000 299300000 500000 100000 299700000 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes debt securities available-for-sale in an unrealized loss position for which an allowance for credit losses has not been recorded at December 31, 2020, aggregated by major security type and length of time in a continuous unrealized loss position:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.470%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less Than 12 Months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12 Months or Longer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes debt securities available-for-sale in an unrealized loss position at December 31, 2019, aggregated by major security type and length of time in a continuous unrealized loss position:</span></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.470%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less Than 12 Months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12 Months or Longer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">186.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">186.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 95000000.0 100000 0 0 95000000.0 100000 148 30 186100000 100000 0 0 186100000 100000 Fair Value Measurements<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments at December 31, 2020, which were measured at fair value on a recurring basis, consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.701%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">445.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">445.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">312.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">312.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">841.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">841.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities–biotechnology industry</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total equity securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total recurring fair value measurements</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,069.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">190.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">841.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments at December 31, 2019, which were measured at fair value on a recurring basis, consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.701%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">521.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">521.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">191.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">191.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">857.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">857.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities–biotechnology industry</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total equity securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total recurring fair value measurements</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,029.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">857.9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55.9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of equity securities, which were measured at fair value on a recurring basis using significant unobservable inputs (Level 3):</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.361%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized loss included in earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.2 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2020, the discount for lack of marketability used in the valuation analysis of equity securities ranged from 15.0% to 34.0% (weighted average of 24.8%). The discount for lack of marketability was weighted by the relative fair value of the instruments. A significant increase (decrease) in the discount for lack of marketability in isolation would result in a significantly lower (higher) fair value measurement. Unrealized gains and losses on equity securities are included in other income (expense), net.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments at December 31, 2020, which were measured at fair value on a recurring basis, consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.701%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">445.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">445.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">312.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">312.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">841.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">841.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities–biotechnology industry</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total equity securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total recurring fair value measurements</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,069.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">190.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">841.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments at December 31, 2019, which were measured at fair value on a recurring basis, consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.701%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">521.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">521.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">191.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">191.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">857.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">857.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities–biotechnology industry</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total equity securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total recurring fair value measurements</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,029.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">857.9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55.9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 187100000 187100000 0 0 187100000 187100000 0 0 3200000 3200000 0 0 3200000 3200000 0 0 82200000 0 82200000 0 445900000 0 445900000 0 312900000 0 312900000 0 841000000.0 0 841000000.0 0 38200000 0 0 38200000 38200000 0 0 38200000 1069500000 190300000 841000000.0 38200000 112300000 112300000 0 0 112300000 112300000 0 0 3200000 3200000 0 0 3200000 3200000 0 0 144500000 0 144500000 0 521900000 0 521900000 0 191500000 0 191500000 0 857900000 0 857900000 0 55900000 0 0 55900000 55900000 0 0 55900000 1029300000 115500000 857900000 55900000 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of equity securities, which were measured at fair value on a recurring basis using significant unobservable inputs (Level 3):</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.361%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized loss included in earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.2 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 55900000 0 0 0 68900000 0 -17700000 -13000000.0 0 38200000 55900000 0 0.150 0.340 0.248 Convertible Senior Notes<div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 2, 2017, we completed a private placement of $517.5 million in aggregate principal amount of 2.25% convertible senior notes due 2024, or the 2024 Notes, and entered into an indenture agreement, or the 2024 Indenture, with respect to the 2024 Notes. The 2024 Notes accrue interest at a fixed rate of 2.25% per year, payable semiannually in arrears on May 15 and November 15 of each year, beginning on November 15, 2017. The 2024 Notes mature on May 15, 2024. The net proceeds from the issuance of the 2024 Notes were approximately $502.8 million, after deducting commissions and the offering expenses payable by us.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the 2024 Notes may convert the 2024 Notes at any time prior to the close of business on the business day immediately preceding May 15, 2024, only under the following circumstances:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.57pt">during any calendar quarter (and only during such calendar quarter), if the last reported sale price of our common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than 130% of the conversion price on each applicable trading day;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.8pt">during the 5 business-day period immediately after any 5 consecutive trading-day period (the measurement period) in which the trading price (as defined in the 2024 Indenture) per $1,000 principal amount of the </span></div><div style="margin-bottom:3pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024 Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of our common stock and the conversion rate on each such trading day;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:3.03pt">upon the occurrence of specified corporate events, including a merger or a sale of all or substantially all of our assets; or</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:3.57pt">if we call the 2024 Notes for redemption, until the close of business on the business day immediately preceding the redemption date.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On or after January 15, 2024, until the close of business on the scheduled trading day immediately preceding May 15, 2024, holders may convert their 2024 Notes at any time.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon conversion, holders will receive the principal amount of their 2024 Notes and any excess conversion value, calculated based on the per share volume-weighted average price for each of the 30 consecutive trading days during the observation period (as more fully described in the 2024 Indenture). For both the principal and excess conversion value, holders may receive cash, shares of our common stock or a combination of cash and shares of our common stock, at our option.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is our intent and policy to settle conversions through combination settlement, which essentially involves repayment of an amount of cash equal to the “principal portion” and delivery of the “share amount” in excess of the principal portion in shares of common stock or cash. In general, for each $1,000 in principal, the “principal portion” of cash upon settlement is defined as the lesser of $1,000, and the conversion value during the 25-day observation period as described in the notes. The conversion value is the sum of the daily conversion value which is the product of the effective conversion rate divided by 25 days and the daily volume-weighted average price, or VWAP, of our common stock. The “share amount” is the cumulative “daily share amount” during the observation period, which is calculated by dividing the daily VWAP into the difference between the daily conversion value (i.e., conversion rate x daily VWAP) and $1,000. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial conversion rate for the 2024 Notes is 13.1711 shares of common stock per $1,000 principal amount, which is equivalent to an initial conversion price of approximately $75.92 per share of our common stock. At the initial conversion rate, settlement of the 2024 Notes for shares of our common stock would approximate 5.0 million shares. The conversion rate will be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. The initial conversion price of the 2024 Notes represented a premium of approximately 42.5% to the closing sale price of $53.28 per share of our common stock on the Nasdaq Global Select Market on April 26, 2017, the date that we priced the private offering of the 2024 Notes.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event of conversion, holders would forgo all future interest payments, any unpaid accrued interest and the possibility of further stock price appreciation. Upon the receipt of conversion requests, the settlement of the 2024 Notes will be paid pursuant to the terms of the 2024 Indenture. In the event that all of the 2024 Notes are converted, we would be required to repay the outstanding principal value and any conversion premium in any combination of cash and shares of its common stock (at our option).</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not redeem the 2024 Notes prior to May 15, 2021. On or after May 15, 2021, we may redeem for cash all or part of the 2024 Notes if the last reported sale price (as defined in the 2024 Indenture) of our common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading-day period ending on, and including, the trading day immediately before the date which we provide notice of redemption. The redemption price will equal the sum of (i) 100% of the principal amount of the 2024 Notes being redeemed, plus (ii) accrued and unpaid interest, including additional interest, if any, to, but excluding, the redemption date. No sinking fund is provided for the 2024 Notes.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we undergo a fundamental change, as defined in the 2024 Indenture, subject to certain conditions, holders of the 2024 Notes may require us to repurchase for cash all or part of their 2024 Notes at a repurchase price equal to 100% of the principal amount of the 2024 Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. In addition, if a ‘‘make-whole fundamental change’’ (as defined in the 2024 Indenture) occurs prior to January 15, 2024, we will, in certain circumstances, increase the conversion rate for a holder who elects to convert their notes in connection with the make-whole fundamental change.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2024 Notes are our general unsecured obligations that rank senior in right of payment to all of our indebtedness that is expressly subordinated in right of payment to the 2024 Notes, and equal in right of payment to our unsecured indebtedness.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to separately account for the liability and equity components of the 2024 Notes, as they may be settled entirely or partially in cash upon conversion in a manner that reflects our economic interest cost. The liability component of the instrument was valued in a manner that reflects the market interest rate for a similar nonconvertible instrument at the date of issuance. The initial carrying value of the liability component of $368.3 million was calculated using a 7.5% assumed borrowing rate. The equity component of $149.2 million, representing the conversion option, was determined by deducting the fair value of the liability component from the par value of the 2024 Notes and was recorded in additional paid-in capital on the consolidated balance sheet at the issuance date. That equity component is treated as a discount on the liability component of the 2024 Notes, which is amortized over the seven-year term of the 2024 Notes using the effective interest rate method. The equity component is not re-measured as long as it continues to meet the conditions for equity classification. At December 31, 2020, the remaining period over which the discount on the liability component will be amortized was approximately 3.4 years.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocated the total transaction costs of approximately $14.7 million related to the issuance of the 2024 Notes to the liability and equity components of the 2024 Notes based on their relative values. Transaction costs attributable to the liability component are amortized to interest expense over the seven-year term of the 2024 Notes, and transaction costs attributable to the equity component are netted with the equity component in stockholders’ equity.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2024 Notes do not contain any financial or operating covenants or any restrictions on the payment of dividends, the issuance of other indebtedness or the issuance or repurchase of securities by us. The 2024 Indenture contains customary events of default with respect to the 2024 Notes, including that upon certain events of default, 100% of the principal and accrued and unpaid interest on the 2024 Notes will automatically become due and payable.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, we entered into separate, privately negotiated transactions with certain holders of the 2024 Notes to repurchase $136.2 million aggregate principal amount of the 2024 Notes for an aggregate repurchase price of $186.9 million in cash. We accounted for the partial repurchase of the 2024 Notes as a debt extinguishment. As a result, we attributed $130.7 million of the aggregate repurchase price to the liability component based on the fair value of the liability component immediately before extinguishment. The fair value of the liability component was calculated at settlement using a discounted cash flow analysis with a discount rate of 3.37%, which was the market rate for similar notes that have no conversion rights. The difference of $56.3 million between the fair value of the aggregate consideration remitted to certain holders of the 2024 Notes and the fair value of the liability component was attributed to the reacquisition of the equity component and recognized as a reduction to additional paid-in capital. The carrying amount of the liability of $112.4 million at settlement was recognized as a reduction to convertible senior notes and resulted in an $18.4 million loss on extinguishment.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2024 Notes, net of discounts and deferred financing costs, consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.701%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Principal</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">381.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">517.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt discount, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(59.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(101.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net carrying amount</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">317.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">408.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2024 Notes were recorded at the estimated value of a similar non-convertible instrument on the date of issuance and accretes to the face value of the 2024 Notes over their seven-year term. The fair value of the 2024 Notes, which was estimated utilizing market quotations from an over-the-counter trading market (Level 2), was $514.3 million and $596.8 million at December 31, 2020 and 2019, respectively.</span></div> 517500000 0.0225 0.0225 502800000 20 30 1.30 5 5 1000 0.98 P30D 1000 1000 1000 P25D P25D 1000 1000 75.92 5000000.0 0.425 53.28 1.30 20 30 1 1 368300000 0.075 149200000 P7Y P3Y4M24D 14700000 1 136200000 186900000 130700000 0.0337 56300000 112400000 -18400000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2024 Notes, net of discounts and deferred financing costs, consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.701%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Principal</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">381.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">517.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt discount, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(59.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(101.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net carrying amount</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">317.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">408.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 381300000 517500000 4000000.0 6900000 59400000 101800000 317900000 408800000 P7Y 514300000 596800000 Other Balance Sheet Details<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.701%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total inventories</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net, consisted of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.701%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tenant improvements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Scientific equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(41.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(33.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41.9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued liabilities consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.701%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued employee related costs </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue-related reserves for discounts and allowances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued development costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued Branded Prescription Drug Fee</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and other accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total accounts payable and accrued liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">168.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">141.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows.</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.701%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">190.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.701%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total inventories</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 16600000 14100000 2400000 1500000 9000000.0 1700000 28000000.0 17300000 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net, consisted of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.701%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tenant improvements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Scientific equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(41.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(33.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41.9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 29500000 26300000 39200000 33500000 13900000 12500000 3700000 3200000 86300000 75500000 41700000 33600000 44600000 41900000 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued liabilities consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.701%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued employee related costs </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue-related reserves for discounts and allowances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued development costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued Branded Prescription Drug Fee</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and other accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total accounts payable and accrued liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">168.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">141.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 38200000 38900000 34600000 30600000 32900000 25500000 23600000 4900000 39400000 41400000 168700000 141300000 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows.</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.701%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">190.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 187100000 112300000 3200000 3200000 190300000 115500000 Net Income Per Share<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income per share was calculated as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.201%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income - basic and diluted</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">407.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95.7 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95.4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income per share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.38 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.40 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.39 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.22 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares which have been excluded from diluted per share amounts because their effect would have been anti-dilutive were 2.5 million, 2.1 million and 0.9 million for 2020, 2019 and 2018, respectively.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income per share was calculated as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.201%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income - basic and diluted</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">407.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95.7 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95.4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income per share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.38 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.40 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.39 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.22 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 407300000 37000000.0 21100000 93100000 91600000 90200000 2400000 2600000 3200000 500000 400000 600000 1800000 1100000 1300000 97800000 95700000 95400000 4.38 0.40 0.23 4.16 0.39 0.22 2500000 2100000 900000 Share-Based Compensation<div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2011, we adopted the 2011 Equity Incentive Plan, as amended, or the 2011 Plan. The 2011 Plan authorized 21 million shares of common stock for issuance and allowed for the grant of stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, or RSUs, performance stock awards, performance-based restricted stock units, or PRSUs, and certain other awards. During 2020, the 2011 Plan was merged into the 2020 Plan (defined below). As a result, there were no shares of common stock remaining available for future grant under the 2011 Plan.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, we adopted the 2018 Employee Stock Purchase Plan, or ESPP, pursuant to which 0.3 million shares of common stock are authorized for issuance. At December 31, 2020, 0.2 million shares of common stock remain available for future grant under the 2018 ESPP.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, we adopted the 2020 Equity Incentive Plan, or the 2020 Plan. The 2020 Plan authorized 3.3 million shares of common stock for issuance and allows for the grant of stock options, stock appreciation rights, restricted stock awards, RSUs, performance stock awards, PRSUs and certain other awards. The 2011 Plan was merged into the 2020 Plan and, as a result, all remaining shares in the 2011 Plan were transferred into the 2020 Plan. At December 31, 2020, 8.2 million shares of common stock remain available for future grant under the 2020 Plan.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation Expense. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effect of share-based compensation expense on our consolidated statements of income and comprehensive income by line-item follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.201%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation expense by award-type follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.201%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PRSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2020, unrecognized share-based compensation expense by award-type and the weighted-average period over which such expense is expected to be recognized, as applicable, were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.038%"><tr><td style="width:1.0%"/><td style="width:64.110%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.890%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.891%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(dollars in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrecognized Expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Recognition Period</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.3 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">RSUs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">99.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.3 years</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Typically, stock options have a ten-year term and vest over a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90ZXh0cmVnaW9uOjA5OWY1NzA5YmE5ODQ1YTI4MTcxMGI1YmI4MDc2YTgxXzEwOTk1MTE2MzYwODU_f346abaf-45c2-4a93-82f2-7b777236c5aa">three</span> to four-year period. The exercise price of stock options granted is equal to the closing price of our common stock on the date of grant. We estimate the fair value of stock options using the Black-Scholes option-pricing model on the date of grant. The Black-Scholes option-pricing model incorporates various and highly sensitive assumptions including expected volatility, term and interest rates. The weighted-average grant-date fair values of stock options granted were $45.67, $41.74 and $43.42 for 2020, 2019 and 2018, respectively.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each stock option granted was estimated on the date of grant using the Black-Scholes option-pricing valuation model with the following weighted-average assumptions: </span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.201%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.4 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.5 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility of common stock</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48.5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54.8 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59.5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected option term</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.3 years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.4 years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.7 years</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average valuation assumptions were determined as follows:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The expected volatility of common stock is estimated based on the historical volatility of our common stock over the most recent period commensurate with the estimated expected term of our stock options.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The expected option term is estimated based on historical experience as well as the status of the employee. For example, directors and officers have a longer expected option term than all other employees. </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The risk-free interest rate for periods within the contractual life of a stock option is based upon observed interest rates appropriate for the expected term of our employee stock options. </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have not historically declared or paid dividends and do not intend to do so in the foreseeable future. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of activity related to stock options follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.880%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except weighted average data)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of <br/>Stock Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52.62 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103.44 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43.90 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62.98 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.4 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">235.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercisable at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.7 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49.80 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.5 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic value of stock options exercised during 2020, 2019 and 2018 was $40.2 million, $64.3 million and $117.0 million, respectively. Cash received from stock option exercises during 2020, 2019 and 2018 was $23.5 million, $27.3 million and $29.5 million, respectively.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Typically, RSUs vest over a four-year period. The fair value of RSUs is based on the closing sale price of our common stock on the date of issuance. RSUs may be subject to a deferred delivery arrangement at the election of eligible employees.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of activity related to RSUs follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.880%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except weighted average data)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of <br/>RSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Grant Date <br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74.77 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102.92 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67.86 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84.95 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89.60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.3 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total fair value of RSUs that vested during 2020, 2019 and 2018 was $49.7 million, $36.1 million and $35.5 million, respectively.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance-Based Restricted Stock Units. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PRSUs vest based on the achievement of certain predefined Company-specific performance criteria and expire <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90ZXh0cmVnaW9uOjA5OWY1NzA5YmE5ODQ1YTI4MTcxMGI1YmI4MDc2YTgxXzEwOTk1MTE2MzY3ODc_5d15221a-7a45-46b5-9a36-6d279f3cbde9">four</span> to five years from the grant date. The fair value of PRSUs is estimated based on the closing sale price of our common stock on the date of grant. Expense recognition for PRSUs commences when attainment of the performance-based criteria is determined to be probable. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of activity related to PRSUs follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.880%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except weighted average data)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of <br/>PRSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Grant Date <br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59.62 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102.90 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82.04 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45.67 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102.90 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.2 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2020, unrecognized share-based compensation expense for PRSUs was $17.0 million. The total fair value of PRSUs that vested during 2020 was $13.5 million. No PRSUs vested during 2019 or 2018.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the ESPP, eligible employees may purchase shares of our common stock at a discount semi-annually based on a percentage of their annual compensation. The discounted purchase price is equal to the lower of 85% of (i) the market value per share of the common stock on the first day of the offering period or (ii) the market value per share of common stock on the purchase date.</span></div> 21000000 0 300000 200000 3300000 8200000 The effect of share-based compensation expense on our consolidated statements of income and comprehensive income by line-item follows:<div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.201%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation expense by award-type follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.201%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PRSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2020, unrecognized share-based compensation expense by award-type and the weighted-average period over which such expense is expected to be recognized, as applicable, were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.038%"><tr><td style="width:1.0%"/><td style="width:64.110%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.890%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.891%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(dollars in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrecognized Expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Recognition Period</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.3 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">RSUs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">99.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.3 years</span></td></tr></table></div> 66300000 49500000 31900000 33700000 25800000 26200000 100000000.0 75300000 58100000 47500000 36500000 35400000 44200000 30500000 21900000 5300000 5600000 0 3000000.0 2700000 800000 100000000.0 75300000 58100000 86200000 P2Y3M18D 99500000 P2Y3M18D P10Y P4Y 45.67 41.74 43.42 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each stock option granted was estimated on the date of grant using the Black-Scholes option-pricing valuation model with the following weighted-average assumptions: </span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.201%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.4 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.5 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility of common stock</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48.5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54.8 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59.5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected option term</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.3 years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.4 years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.7 years</span></td></tr></table></div> 0.014 0.024 0.025 0.485 0.548 0.595 0.000 0.000 0.000 P5Y3M18D P5Y4M24D P4Y8M12D <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of activity related to stock options follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.880%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except weighted average data)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of <br/>Stock Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52.62 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103.44 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43.90 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62.98 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.4 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">235.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercisable at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.7 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49.80 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.5 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 6100000 52.62 1300000 103.44 600000 43.90 0 0 6800000 62.98 P6Y4M24D 235400000 4700000 49.80 P5Y6M 218200000 40200000 64300000 117000000.0 23500000 27300000 29500000 P4Y <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of activity related to RSUs follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.880%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except weighted average data)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of <br/>RSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Grant Date <br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74.77 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102.92 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67.86 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84.95 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89.60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.3 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of activity related to PRSUs follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.880%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except weighted average data)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of <br/>PRSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Grant Date <br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59.62 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102.90 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82.04 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45.67 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102.90 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.2 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1400000 74.77 700000 102.92 500000 67.86 100000 84.95 1500000 89.60 P1Y3M18D 147500000 49700000 36100000 35500000 P5Y 300000 59.62 200000 102.90 100000 82.04 200000 45.67 200000 102.90 P2Y2M12D 15800000 17000000.0 13500000 0 0 0.85 Income Taxes<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of income tax expense for continuing operations were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.470%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(287.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(310.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Benefit from) provision for income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(300.6)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes on earnings subject to income taxes differs from the statutory federal rate due to the following: </span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.470%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal income taxes at 21% for 2020, 2019, 2018</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State income tax, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-deductible expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Branded prescription drug fee</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Officer compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in tax rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expired tax attributes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(39.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(296.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Benefit from) provision for income taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(300.6)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of our deferred tax assets as of December 31, 2020 and 2019 are listed below. </span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net operating losses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">111.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">181.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capitalized research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">411.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">395.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Convertible senior notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(24.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(42.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(49.2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net of deferred tax assets and liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">369.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">346.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(49.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(346.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">319.4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2020, our deferred tax assets were primarily the result of federal net operating loss carry forwards, capitalized research costs, acquired intangible assets and tax credit carryforwards. At December 31, 2020 and 2019, we recorded a valuation allowance of $49.8 million and $346.0 million, respectively, against our gross deferred tax asset balance.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At each reporting date, management considers new evidence, both positive and negative, that could affect its assessment of the future realizability of our deferred tax assets. At December 31, 2020, in part because we achieved three years of cumulative pretax income, management determined there is sufficient positive evidence to conclude that it is more likely than not deferred tax assets of $319.4 million are realizable. Accordingly, we recorded a net valuation release of $296.3 million on the basis of management’s assessment. The remaining valuation allowance of $49.8 million consists primarily of state net operating loss and credit carryforwards for which management cannot conclude it is more likely than not to be realized. The release of the valuation allowance is reported under continuing operations as a benefit to income tax expense.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2020, we had federal and state income tax net operating loss carryforwards of $518.2 million and $340.8 million, respectively. The federal net operating losses will begin to expire in 2028, unless previously utilized.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">California net operating losses will begin to expire in 2028 unless previously utilized and the net operating losses related to other states will begin to expire in 2026.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we have federal and California R&amp;D tax credit carryforwards of $92.1 million and $56.4 million, respectively. A portion of the federal R&amp;D tax credit carryforwards expired in 2020. The remaining federal R&amp;D tax credits will continue to expire beginning in 2021, unless previously utilized. The California R&amp;D tax credits carry forward indefinitely.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the future utilization of our net operating loss and R&amp;D tax credit carryforwards to offset future taxable income may be subject to an annual limitation, pursuant to Internal Revenue Code Sections 382 and 383, as a result of ownership changes that could occur in the future. No ownership changes have occurred through December 31, 2020.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our policy is to recognize interest or penalties related to income tax matters in income tax expense. Interest and penalties related to income tax matters were not material for 2020, 2019 or 2018.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to taxation in the U.S. and various state jurisdictions. Our tax years for 2001 (federal) and 2008 (California) and forward are subject to examination by federal and state tax authorities due to the carryforward of unutilized net operating losses and R&amp;D tax credits.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of activity related to unrecognized tax benefits follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.470%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at January 1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Decrease) increase related to prior year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increase related to current year tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements related to prior year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expiration of the statute of limitations for the assessment of taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We excluded those deferred tax assets that are not more-likely-than-not to be sustained under the technical merits of the tax position. Such unrecognized tax benefits total $3.9 million for current year tax positions, as reflected in the table above.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2020, we had $53.9 million of unrecognized tax benefits that, if recognized and realized, would affect the effective tax rate, subject to the valuation allowance. We do not expect a significant change in our unrecognized tax benefits in the next twelve months.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of income tax expense for continuing operations were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.470%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(287.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(310.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Benefit from) provision for income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(300.6)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 0 0 -100000 10100000 9500000 800000 10100000 9500000 700000 -287500000 0 0 -23200000 0 0 -310700000 0 0 -300600000 9500000 700000 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes on earnings subject to income taxes differs from the statutory federal rate due to the following: </span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.470%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal income taxes at 21% for 2020, 2019, 2018</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State income tax, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-deductible expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Branded prescription drug fee</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Officer compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in tax rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expired tax attributes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(39.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(296.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Benefit from) provision for income taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(300.6)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 0.21 0.21 0.21 22400000 9800000 4600000 5500000 4000000.0 400000 600000 800000 400000 4900000 3700000 0 -6700000 -12800000 -9800000 3700000 3100000 900000 3300000 -4100000 -200000 1100000 1200000 13900000 39000000.0 10400000 13500000 -296300000 13900000 4300000 -100000 300000 -300000 -300600000 9500000 700000 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of our deferred tax assets as of December 31, 2020 and 2019 are listed below. </span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net operating losses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">111.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">181.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capitalized research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">411.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">395.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Convertible senior notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(24.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(42.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(49.2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net of deferred tax assets and liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">369.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">346.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(49.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(346.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">319.4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 111400000 181300000 109600000 71900000 24700000 28000000.0 29800000 22900000 25200000 23300000 86700000 49300000 23900000 18500000 411300000 395200000 13800000 24100000 19900000 18200000 8400000 6900000 42100000 49200000 369200000 346000000.0 49800000 346000000.0 319400000 0 49800000 346000000.0 319400000 -296300000 49800000 518200000 340800000 92100000 56400000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of activity related to unrecognized tax benefits follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.470%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at January 1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Decrease) increase related to prior year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increase related to current year tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements related to prior year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expiration of the statute of limitations for the assessment of taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 63900000 54800000 37400000 5700000 300000 6100000 3900000 9500000 11700000 200000 0 0 1100000 700000 400000 60800000 63900000 54800000 3900000 53900000 Leases<div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have operating leases for our office and laboratory facilities, including our corporate headquarters, with terms that expire from 2025 through 2031. We have two options to extend the term of the operating lease for our corporate headquarters for a period of ten years each. However, as we were not reasonably certain to exercise either of those options at lease commencement, neither option was recognized as part of the associated operating lease right-of-use, or ROU, asset or liability. In connection with our operating leases, in lieu of cash security deposits, Wells Fargo Bank, N.A., issued letters of credit on our behalf, which are secured by deposits totaling $3.2 million.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating lease cost was $10.1 million for 2020 and $8.1 million for 2019. Cash paid for amounts included in the measurement of lease liabilities was $8.6 million for 2020 and $7.7 million for 2019.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating leases had a weighted-average remaining lease term of approximately 10.3 years and 11.2 years at December 31, 2020 and 2019, respectively, and a weighted-average discount rate of 5.6% and 5.8% at December 31, 2020 and 2019, respectively.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximate future minimum lease payments under operating leases were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.957%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2021</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2024</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2025</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">139.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less accreted interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xODEvZnJhZzpkZjk2OWMxNDIxOGE0NTY4OWQ4Mzg3ZDRhZGJkNDg1Mi90YWJsZTpmMjgyMzhhYWViNDk0NjIzOTRhNzNhZDgwNzA4NTcxYy90YWJsZXJhbmdlOmYyODIzOGFhZWI0OTQ2MjM5NGE3M2FkODA3MDg1NzFjXzExLTAtMS0xLTMxNg_d8b1a23d-ec0a-4994-85b7-72ebf9c2e5ad">Less current operating lease liabilities</span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent operating lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94.4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Note 1: Amounts presented in the table above exclude $19.7 million of non-cancelable future minimum lease payments for operating leases that have not yet commenced.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Note 2: Current operating lease liabilities are included in other current liabilities on the consolidated balance sheets.</span></div> 2 P10Y 3200000 10100000 8100000 8600000 7700000 P10Y3M18D P11Y2M12D 0.056 0.058 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximate future minimum lease payments under operating leases were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.957%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2021</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2024</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2025</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">139.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less accreted interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xODEvZnJhZzpkZjk2OWMxNDIxOGE0NTY4OWQ4Mzg3ZDRhZGJkNDg1Mi90YWJsZTpmMjgyMzhhYWViNDk0NjIzOTRhNzNhZDgwNzA4NTcxYy90YWJsZXJhbmdlOmYyODIzOGFhZWI0OTQ2MjM5NGE3M2FkODA3MDg1NzFjXzExLTAtMS0xLTMxNg_d8b1a23d-ec0a-4994-85b7-72ebf9c2e5ad">Less current operating lease liabilities</span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent operating lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94.4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Note 1: Amounts presented in the table above exclude $19.7 million of non-cancelable future minimum lease payments for operating leases that have not yet commenced.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Note 2: Current operating lease liabilities are included in other current liabilities on the consolidated balance sheets.</span></div> 10700000 12400000 12700000 13100000 13500000 77500000 139900000 35200000 104700000 10300000 94400000 19700000 Retirement PlanWe have a 401(k) defined contribution savings plan, or the 401(k) Plan. The 401(k) Plan is for the benefit of all qualifying employees and permits voluntary contributions by employees up to 60% of base salary limited by the IRS-imposed maximum. Employer contributions were $6.7 million, $4.9 million, and $1.8 million for 2020, 2019 and 2018, respectively. 0.60 6700000 4900000 1800000 Selected Quarterly Financial Data (Unaudited)<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our quarterly results follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.701%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">First<br/>Quarter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Second<br/>Quarter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Third<br/>Quarter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fourth<br/>Quarter</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2020:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">237.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">302.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">258.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">247.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">178.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">225.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">302.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">176.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(57.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">347.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss) per share, basic </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.40 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.86 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.62)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.72 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss) per share, diluted </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.39 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.81 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.62)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.58 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average common shares outstanding, basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average common shares outstanding, diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2019:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">138.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">183.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">222.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">244.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">239.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">149.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">132.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">195.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(102.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income per share, basic </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.56 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.59 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income per share, diluted </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.54 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.56 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.35 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average common shares outstanding, basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average common shares outstanding, diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(1) In connection with the payment of the upfront fee pursuant to our collaboration and license agreement with Idorsia, we recorded a charge of $46.0 million, accounted for as IPR&amp;D, in the second quarter of 2020. In connection with the payment of the upfront fee pursuant to our collaboration with Takeda, we recorded a charge of $118.5 million, accounted for as IPR&amp;D, in the third quarter of 2020.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(2) In connection with the payment of the upfront fee pursuant to our collaboration and license agreement with Voyager, we recorded a charge of $113.1 million, accounted for as IPR&amp;D, in the first quarter of 2019. In the second quarter of 2019, we entered into an amendment to the collaboration and license agreement with Voyager, pursuant to which we paid Voyager $5.0 million upfront, accounted for as IPR&amp;D, to obtain outside the U.S. rights to the Friedreich’s ataxia program. In connection with the payment of the upfront fee pursuant to our collaboration with Xenon, we recorded a charge of $36.2 million, accounted for as IPR&amp;D, in the fourth quarter of 2019.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our quarterly results follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.701%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">First<br/>Quarter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Second<br/>Quarter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Third<br/>Quarter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fourth<br/>Quarter</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2020:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">237.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">302.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">258.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">247.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">178.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">225.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">302.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">176.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(57.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">347.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss) per share, basic </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.40 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.86 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.62)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.72 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss) per share, diluted </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.39 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.81 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.62)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.58 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average common shares outstanding, basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average common shares outstanding, diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2019:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">138.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">183.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">222.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">244.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">239.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">149.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">132.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">195.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(102.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income per share, basic </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.56 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.59 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income per share, diluted </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.54 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.56 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.35 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average common shares outstanding, basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average common shares outstanding, diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(1) In connection with the payment of the upfront fee pursuant to our collaboration and license agreement with Idorsia, we recorded a charge of $46.0 million, accounted for as IPR&amp;D, in the second quarter of 2020. In connection with the payment of the upfront fee pursuant to our collaboration with Takeda, we recorded a charge of $118.5 million, accounted for as IPR&amp;D, in the third quarter of 2020.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(2) In connection with the payment of the upfront fee pursuant to our collaboration and license agreement with Voyager, we recorded a charge of $113.1 million, accounted for as IPR&amp;D, in the first quarter of 2019. In the second quarter of 2019, we entered into an amendment to the collaboration and license agreement with Voyager, pursuant to which we paid Voyager $5.0 million upfront, accounted for as IPR&amp;D, to obtain outside the U.S. rights to the Friedreich’s ataxia program. In connection with the payment of the upfront fee pursuant to our collaboration with Xenon, we recorded a charge of $36.2 million, accounted for as IPR&amp;D, in the fourth quarter of 2019.</span></div> 237100000 302400000 258500000 247900000 178200000 225800000 302800000 176100000 37400000 79600000 -57600000 347900000 0.40 0.86 -0.62 3.72 0.39 0.81 -0.62 3.58 92600000 93000000.0 93300000 93500000 97000000.0 98200000 93300000 97200000 138400000 183500000 222100000 244100000 239400000 149100000 132000000.0 195300000 -102100000 51300000 53800000 34000000.0 -1.12 0.56 0.59 0.37 -1.12 0.54 0.56 0.35 91100000 91400000 91900000 92200000 91100000 94800000 96100000 97200000 46000000.0 118500000 113100000 5000000.0 36200000 XML 16 R1.htm IDEA: XBRL DOCUMENT v3.20.4
Cover Page - USD ($)
 12 Months Ended
Dec. 31, 2020
Jan. 29, 2021
Jun. 30, 2020
Cover [Abstract]      
Document Type 10-K    
Document Annual Report true    
Document Period End Date Dec. 31, 2020    
Current Fiscal Year End Date --12-31    
Document Transition Report false    
Entity File Number 0-22705    
Entity Registrant Name NEUROCRINE BIOSCIENCES, INC.    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 33-0525145    
Entity Address, Address Line One 12780 El Camino Real,    
Entity Address, City or Town San Diego,    
Entity Address, State or Province CA    
Entity Address, Postal Zip Code 92130    
City Area Code 858    
Local Phone Number 617-7600    
Title of 12(b) Security Common Stock, $0.001 par value    
Trading Symbol NBIX    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer Yes    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Large Accelerated Filer    
Entity Small Business false    
Entity Emerging Growth Company false    
ICFR Auditor Attestation Flag true    
Entity Shell Company false    
Entity Public Float     $ 11,231,617,436
Entity Common Stock, Shares Outstanding   93,943,645  
Documents Incorporated by Reference Portions of the registrant’s definitive proxy statement relating to the registrant’s annual meeting of stockholders to be filed pursuant to Regulation 14A within 120 days following the end of the registrant’s fiscal year ended December 31, 2020 are incorporated by reference into Part III of this Form 10-K.    
Amendment Flag false    
Document Fiscal Year Focus 2020    
Document Fiscal Period Focus FY    
Entity Central Index Key 0000914475    

XML 17 R2.htm IDEA: XBRL DOCUMENT v3.20.4
Consolidated Balance Sheets - USD ($)
$ in Millions
Dec. 31, 2020
Dec. 31, 2019
Current assets:    
Cash and cash equivalents $ 187.1 $ 112.3
Debt securities available-for-sale (amortized cost $612.4 million at December 31, 2020 and $557.3 million at December 31, 2019) 613.9 558.2
Accounts receivable 157.1 126.6
Inventories 28.0 17.3
Other current assets 30.1 16.6
Total current assets 1,016.2 831.0
Debt securities available-for-sale (amortized cost $226.7 million at December 31, 2020 and $299.3 million at December 31, 2019) 227.1 299.7
Right-of-use assets 82.8 74.3
Equity securities 38.2 55.9
Property and equipment, net 44.6 41.9
Deferred tax assets 319.4 0.0
Restricted cash 3.2 3.2
Other long-term assets 3.2 0.0
Total assets 1,734.7 1,306.0
Current liabilities:    
Accounts payable and accrued liabilities 168.7 141.3
Convertible senior notes 0.0 408.8
Other current liabilities 17.8 15.2
Total current liabilities 186.5 565.3
Convertible senior notes 317.9 0.0
Noncurrent operating lease liabilities 94.4 86.7
Other long-term liabilities 9.7 17.1
Total liabilities 608.5 669.1
Stockholders’ equity:    
Preferred stock, $0.001 par value; 5.0 shares authorized; no shares issued and outstanding at December 31, 2020 and 2019 0.0 0.0
Common stock, $0.001 par value; 220.0 shares authorized; issued and outstanding shares were 93.5 million and 92.3 million at December 31, 2020 and 2019, respectively 0.1 0.1
Additional paid-in capital 1,849.7 1,768.1
Accumulated other comprehensive income 1.8 1.4
Accumulated deficit (725.4) (1,132.7)
Total stockholders’ equity 1,126.2 636.9
Total liabilities and stockholders’ equity $ 1,734.7 $ 1,306.0
XML 18 R3.htm IDEA: XBRL DOCUMENT v3.20.4
Consolidated Balance Sheets (Parenthetical) - USD ($)
$ in Millions
Dec. 31, 2020
Dec. 31, 2019
Preferred stock, par value (in USD per share) $ 0.001 $ 0.001
Preferred stock, shares authorized (in shares) 5,000,000.0 5,000,000.0
Preferred stock, shares issued (in shares) 0 0
Preferred stock, shares outstanding (in shares) 0 0
Common stock, shares outstanding (in shares) 93,500,000 92,300,000
Common stock, shares issued (in shares) 93,500,000 92,300,000
Common stock, shares authorized (in shares) 220,000,000.0 220,000,000.0
Common stock, par value (in USD per share) $ 0.001 $ 0.001
Short-term investments    
Amortized cost $ 612.4 $ 557.3
Long-term investments    
Amortized cost $ 226.7 $ 299.3
XML 19 R4.htm IDEA: XBRL DOCUMENT v3.20.4
Consolidated Statements Income and Comprehensive Income - USD ($)
shares in Millions, $ in Millions
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Revenues:      
Revenues $ 1,045.9 $ 788.1 $ 451.2
Operating expenses:      
Cost of sales 10.1 7.4 4.9
Research and development 275.0 200.0 155.8
Acquired in-process research and development 164.5 154.3 4.8
Selling, general and administrative 433.3 354.1 248.9
Total operating expenses 882.9 715.8 414.4
Operating income 163.0 72.3 36.8
Other (expense) income:      
Interest expense (32.8) (32.0) (30.5)
Unrealized loss on restricted equity securities (17.7) (13.0) 0.0
Loss on extinguishment of convertible senior notes (18.4) 0.0 0.0
Investment income and other, net 12.6 19.2 15.5
Total other expense, net (56.3) (25.8) (15.0)
Income before (benefit from) provision for income taxes 106.7 46.5 21.8
(Benefit from) provision for income taxes (300.6) 9.5 0.7
Net income 407.3 37.0 21.1
Unrealized gain (loss) on debt securities available-for-sale 0.4 3.4 (0.1)
Comprehensive income $ 407.7 $ 40.4 $ 21.0
Net income (loss) per share, basic (in USD per share) $ 4.38 $ 0.40 $ 0.23
Net income (loss) per share, diluted (in USD per share) $ 4.16 $ 0.39 $ 0.22
Weighted average common shares outstanding, basic (in shares) 93.1 91.6 90.2
Weighted average common shares outstanding, diluted (in shares) 97.8 95.7 95.4
Product sales, net      
Revenues:      
Revenues $ 994.1 $ 752.9 $ 409.6
Collaboration revenue      
Revenues:      
Revenues $ 51.8 $ 35.2 $ 41.6
XML 20 R5.htm IDEA: XBRL DOCUMENT v3.20.4
Consolidated Statements of Stockholders' Equity - USD ($)
$ in Millions
Total
Cumulative-effect adjustment to equity due to adoption of ASU 2016-02
Common Stock
Additional Paid-In Capital
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Accumulated Deficit
Cumulative-effect adjustment to equity due to adoption of ASU 2016-02
Beginning balance (in shares) at Dec. 31, 2017     88,800,000        
Beginning balance at Dec. 31, 2017 $ 372.2   $ 0.1 $ 1,572.8 $ (1.9) $ (1,198.8)  
Net income 21.1         21.1  
Unrealized gain (loss) on debt securities available-for sale (0.1)       (0.1)    
Share-based compensation expense $ 58.1     58.1      
Accounting Standards Update [Extensible List] us-gaap:AccountingStandardsUpdate201602Member            
Issuance of common stock for vested restricted stock units (in shares)     400,000        
Issuance of common stock for stock option exercises (in shares)     1,600,000        
Issuance of common stock for stock option exercises $ 29.5     29.5      
Ending balance (in shares) at Dec. 31, 2018     90,800,000        
Ending balance at Dec. 31, 2018 480.8 $ 8.0 $ 0.1 1,660.4 (2.0) (1,177.7) $ 8.0
Net income 37.0         37.0  
Unrealized gain (loss) on debt securities available-for sale 3.4       3.4    
Share-based compensation expense 75.3     75.3      
Issuance of common stock for vested restricted stock units (in shares)     400,000        
Issuance of common stock for stock option exercises (in shares)     1,000,000.0        
Issuance of common stock for stock option exercises 27.3     27.3      
Issuance of common stock for employee stock purchase plan (in shares)     100,000        
Issuance of common stock for employee stockpurchase plan 5.1     5.1      
Ending balance (in shares) at Dec. 31, 2019     92,300,000        
Ending balance at Dec. 31, 2019 636.9   $ 0.1 1,768.1 1.4 (1,132.7)  
Net income 407.3         407.3  
Unrealized gain (loss) on debt securities available-for sale 0.4       0.4    
Share-based compensation expense 100.0     100.0      
Equity component of repurchased convertible senior notes, net $ (47.5)     (47.5)      
Issuance of common stock for vested restricted stock units (in shares)     500,000        
Issuance of common stock for stock option exercises (in shares) 600,000   600,000        
Issuance of common stock for stock option exercises $ 23.5     23.5      
Issuance of common stock for employee stock purchase plan (in shares)     100,000        
Issuance of common stock for employee stockpurchase plan 5.6     5.6      
Ending balance (in shares) at Dec. 31, 2020     93,500,000        
Ending balance at Dec. 31, 2020 $ 1,126.2   $ 0.1 $ 1,849.7 $ 1.8 $ (725.4)  
XML 21 R6.htm IDEA: XBRL DOCUMENT v3.20.4
Consolidated Statements of Cash Flows - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Cash Flows from Operating Activities:      
Net income $ 407.3 $ 37.0 $ 21.1
Reconciliation of net income to net cash provided by operating activities:      
Share-based compensation expense 100.0 75.3 58.1
Depreciation 8.6 7.4 4.0
Amortization of debt discount 20.0 18.9 17.6
Amortization of debt issuance costs 1.4 1.4 1.3
Change in fair value of equity securities 17.7 13.0 0.0
Deferred income taxes (including benefit from valuation allowance release) (310.7) 0.0 0.0
Loss on extinguishment of convertible senior notes 18.4 0.0 0.0
Other 3.7 (1.2) 1.0
Changes in operating assets and liabilities:      
Accounts receivable (30.5) (69.2) (25.1)
Inventories (10.7) (6.4) (3.5)
Accounts payable and accrued liabilities 26.9 54.0 24.2
Other assets and liabilities, net (23.6) 16.8 2.7
Net cash provided by operating activities 228.5 147.0 101.4
Cash Flows from Investing Activities:      
Purchases of debt securities available-for-sale (735.5) (797.2) (545.9)
Sales and maturities of debt securities available-for-sale 750.5 669.7 327.8
Purchases of equity securities 0.0 (68.9) 0.0
Purchases of property and equipment (10.9) (14.7) (24.8)
Net cash provided by (used in) investing activities 4.1 (211.1) (242.9)
Cash Flows from Financing Activities:      
Issuances of common stock under benefit plans 29.1 32.4 29.5
Partial repurchase of convertible senior notes (186.9) 0.0 0.0
Net cash (used in) provided by financing activities (157.8) 32.4 29.5
Change in cash and cash equivalents and restricted cash 74.8 (31.7) (112.0)
Cash and cash equivalents and restricted cash at beginning of period 115.5 147.2 259.2
Cash and cash equivalents and restricted cash at end of period 190.3 115.5 147.2
Supplemental Disclosure:      
Non-cash capital expenditures 1.4 1.0 2.3
Right-of-use assets acquired through operating leases 12.8 77.1 0.0
Cash paid for interest 11.6 11.6 11.6
Cash paid for income taxes $ 15.3 $ 0.5 $ 0.0
XML 22 R7.htm IDEA: XBRL DOCUMENT v3.20.4
Organization and Summary of Significant Accounting Policies
 12 Months Ended
Dec. 31, 2020
Accounting Policies [Abstract]  
Organization and Summary of Significant Accounting Policies Organization and Summary of Significant Accounting Policies
Business Activities. Neurocrine Biosciences, Inc., or Neurocrine, the Company, we, our or us, was incorporated in California in 1992 and reincorporated in Delaware in 1996. Neurocrine Continental, Inc., is a Delaware corporation and a wholly owned subsidiary of Neurocrine. We also have two wholly-owned Irish subsidiaries, Neurocrine Therapeutics, Ltd. and Neurocrine Europe, Ltd. both of which were formed in December 2014 and are inactive.
We are a neuroscience-focused biopharmaceutical company dedicated to discovering, developing and delivering life-changing treatments for patients with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. Our diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson’s disease, endometriosis*, uterine fibroids* and clinical programs in multiple therapeutic areas. For nearly three decades, we specialize in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems. (*in collaboration with AbbVie Inc.)
Principles of Consolidation. The consolidated financial statements include the accounts of Neurocrine as well as our wholly owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.
Use of Estimates. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America, or GAAP, requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. Actual results could differ from those estimates.
Industry Segment and Geographic Information. We operate in a single industry segment – the discovery, development and marketing of pharmaceuticals for the treatment of neurological, endocrine and psychiatric-based diseases and disorders. We had no foreign-based operations during any of the years presented.
Reclassifications. Certain amounts in prior year periods have been reclassified to conform with the presentation adopted in the current year.
Cash Equivalents. We consider all highly liquid investments that are readily convertible into cash and have an original maturity of three months or less at the time of purchase to be cash equivalents.
Accounts Receivable. Accounts receivable are recorded net of customer allowances for prompt payment discounts, chargebacks and any allowance for doubtful accounts. We estimate the allowance for doubtful accounts based on existing contractual payment terms, actual payment patterns of our customers and individual customer circumstances. To date, an allowance for doubtful accounts has not been material.
Debt Securities. Debt securities consist of investments in certificates of deposit, corporate debt securities, and securities of government-sponsored entities. We classify debt securities as available-for-sale. Debt securities available-for-sale are recorded at fair value, with unrealized gains and losses included in other comprehensive income or loss, net of tax. We exclude accrued interest from both the fair value and amortized cost basis of debt securities. A debt security is placed on nonaccrual status at the time any principal or interest payments become 90 days delinquent. Interest accrued but not received for a debt security placed on nonaccrual status is reversed against interest income.
Interest income includes amortization of purchase premium or discount. Premiums and discounts on debt securities are amortized using the effective interest rate method. Gains and losses on sales of debt securities are recorded on the trade date in investment income and other, net, and determined using the specific identification method.
Allowance for Credit Losses. For debt securities available-for-sale in an unrealized loss position, we first assess whether we intend to sell, or it is more likely than not that we will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security’s amortized cost basis is written down to fair value through earnings. For debt securities available-for-sale that do not meet the aforementioned criteria, we evaluate whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, we consider the extent to which fair value is less than amortized cost, any changes in interest rates, and any changes to the rating of the security by a rating agency, among other factors. If this
assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security is compared to the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded, limited by the amount that the fair value is less than the amortized cost basis. Any impairment that has not been recorded through an allowance for credit losses is recognized in other comprehensive income or loss, as applicable.
Accrued interest receivables on debt securities available-for-sale totaled $3.7 million at December 31, 2020. We do not measure an allowance for credit losses for accrued interest receivables. For the purposes of identifying and measuring an impairment, accrued interest is excluded from both the fair value and amortized cost basis of the debt security. Uncollectible accrued interest receivables associated with an impaired debt security are reversed against interest income upon identification of the impairment. No accrued interest receivables were written off during 2020, 2019 or 2018.
Fair Value of Financial Instruments. We record cash equivalents, debt securities available-for-sale and equity securities at fair value based on a fair value hierarchy that distinguishes between assumptions based on market data (observable inputs) and our own assumptions (unobservable inputs). The fair value hierarchy consists of the following three levels:
Level 1 – Quoted prices (unadjusted) in active markets for identical assets or liabilities.
Level 2 – Quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability.
Level 3 – Unobservable inputs that reflect our own assumptions about the assumptions that market participants would use in pricing the asset or liability when there is little, if any, market activity for the asset or liability at the measurement date.
Investments in debt securities available-for-sale are classified as Level 2 and carried at fair value. We estimate the fair value of debt securities available-for-sale by utilizing third-party pricing services. These pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. Such inputs include market pricing based on real-time trade data for similar instruments, issuer credit spreads, benchmark yields, broker/dealer quotes and other observable inputs. We validate valuations obtained from third-party pricing services by understanding the models used, obtaining market values from other pricing sources, and analyzing data in certain instances.
Investments in equity securities of certain companies that are subject to holding period restrictions longer than one year are classified as Level 3 and carried at fair value using an option pricing valuation model. The most significant assumptions within the option pricing valuation model are the stock price volatility, which is based on the historical volatility of similar companies, and the discount for lack of marketability related to the term of the restrictions.
The carrying amounts of accounts receivable and accounts payable and accrued liabilities approximate their fair values due to their short-term maturities.
There were no transfers between levels in the fair value hierarchy during 2020 or 2019.
Inventory. Inventory is valued at the lower of cost or net realizable value. We determine the cost of inventory using the standard-cost method, which approximates actual cost based on the first-in, first-out method. We assess the valuation of our inventory on a quarterly basis and adjust the value for excess and obsolete inventory to the extent management determines that the cost cannot be recovered based on estimates about future demand. Inventory costs resulting from these adjustments are recognized as cost of sales in the period in which they are incurred. When future commercialization is considered probable and the future economic benefit is expected to be realized, based on management’s judgment, we capitalize pre-launch inventory costs prior to regulatory approval.
Property and Equipment. Property and equipment are stated at cost and depreciated over the estimated useful lives of the assets using the straight-line method. Equipment is depreciated over an average estimated useful life of three to seven years. Leasehold improvements are depreciated over the shorter of their estimated useful lives or the remaining lease term. Depreciation expense was $8.6 million for 2020, $7.4 million for 2019 and $4.0 million for 2018.
Impairment of Long-Lived Assets. We review long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. If indicators of impairment exist, we assess the recoverability of the affected long-lived assets by determining whether the carrying value of such assets can be recovered through undiscounted future operating cash flows. If the carrying amount is not recoverable, we measure the amount of any impairment by comparing the carrying value of the asset to the present value of the expected future cash flows associated with the use of the asset.
Revenue Recognition. We recognize revenue when the customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. Revenue is recognized using a five-step model: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenues when (or as) we satisfy the performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer.
Product Sales, Net. In the U.S., our product sales, net consist of sales of INGREZZA, primarily to specialty pharmacy providers and a specialty distributor, and sales of ONGENTYS, primarily to wholesale distributors. We recognize product sales, net when the customer obtains control of our product, which occurs at a point in time, typically upon delivery of our product to the customer.
Revenues from product sales are recorded net of reserves established for applicable discounts and allowances that are offered within contracts with our customers, payors and other third parties. Such estimates are based on information received from external sources (such as written or oral information obtained from our customers with respect to their period-end inventory levels and sales to end-users during the reporting period), as supplemented by management’s judgement. Our process for estimating reserves established for these variable consideration components does not differ materially from historical practices. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which could have an effect on earnings in the period of adjustment.
Our significant categories of sales discounts and allowances are as follows:
Product Discounts. Product discounts are based on payment terms extended to our customers at the time of sale, which include incentives offered for prompt payment. We maintain a reserve for product discounts based on our historical experience, including the timing of customer payments. To date, actual product discounts have not differed materially from our estimates.
Government Rebates. We are obligated to pay rebates for mandated discounts under the Medicaid Drug Rebate Program. The liability for such rebates consists of invoices received for claims from prior quarters that remain unpaid, or for which an invoice has not been received, and estimated rebates for the current applicable reporting period. Such estimates are based on actual historical rebates by state, estimated payor mix, state and federal regulations and relevant contractual terms, as supplemented by management’s judgement. Our rebate accrual calculations require us to project the magnitude of our sales, by state, that will be subject to these rebates. There is a significant time-lag in our receiving rebate notices from each state (generally, several months or longer after a sale is recognized). Estimated rebates are recorded as a reduction of revenue in the period the related sale is recognized. To date, actual government rebates have not differed materially from our estimates.
Chargebacks. The difference between the list price, or the price at which we sell our products to our customers, and the contracted price, or the price at which our customers sell our products to qualified healthcare professionals, is charged back to us by our customers. In addition to actual chargebacks received, we maintain a reserve for chargebacks based on estimated contractual discounts on product inventory levels on-hand in our distribution channel. To date, actual chargebacks have not differed materially from our estimates.
Payor and Pharmacy Rebates. We are obligated to pay rebates as a percentage of sales under payor and pharmacy contracts. We estimate these rebates based on actual historical rebates, contractual rebate percentages, sales made through the payor channel and purchases made by pharmacies. To date, actual payor and pharmacy rebates have not differed materially from our estimates.
Co-payment Assistance. We offer financial assistance to qualified patients with prescription drug co-payments required by insurance. We accrue for copay assistance based on estimated claims and the cost per claim we expect to receive associated with inventory that remains in the distribution channel at period end. To date, actual copay assistance has not differed materially from our estimates.
Distributor and Other Fees. In connection with the sales of our products, we pay distributor and other fees to certain customers that provide us with inventory management, data and distribution services, which are generally recorded as a reduction of revenue. To the extent we can demonstrate a separable benefit and fair value for these services, we classify the associated costs in selling, general and administrative expenses. These costs are typically known at the time of sale, resulting in minimal adjustments subsequent to the period of sale.
Product Returns. For INGREZZA, we offer our customers product return rights primarily limited to errors in shipment and damaged product. We do not permit returns of INGREZZA for expiring or expired product. Accordingly, we have limited return risk resulting from INGREZZA product sales and therefore do not record an associated returns allowance. For ONGENTYS, we offer our customers product return rights primarily limited to errors in shipment, damaged product, and expiring or expired product, provided it is within a specified period around the product expiration date, as set forth in the associated distribution agreement. Once product is returned, it is destroyed. Where actual returns history is not available, we estimate the associated returns allowance based on benchmarking data for similar products and industry experience. We record this estimate as a reduction of revenue in the period the related sale is recognized. To date, actual product returns have not differed materially from our estimates.
Collaboration Revenues. We have entered into collaboration and licensing agreements under which we license certain rights to our product candidates to third parties. The terms of these arrangements typically include payment to us of one or more of the following: non-refundable, up-front license fees; development, regulatory, and/or commercial milestone payments; and royalties on net sales of licensed products.
Licenses of Intellectual Property. If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, we use judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.
Milestone Payments. At the inception of each arrangement that includes developmental, regulatory or commercial milestone payments, we evaluate whether achieving the milestones is considered probable and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the value of the associated milestone is included in the transaction price. Milestone payments that are not within our control, such as approvals from regulators or where attainment of the specified event is dependent on the development activities of a third party, are not considered probable of being achieved until those approvals are received or the specified event occurs. Revenue is recognized from the satisfaction of performance obligations in the amount billable to the customer.
Royalty Revenues. For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Each quarterly period, sales-based royalties are recorded based on estimated quarterly net sales of the associated collaboration products. Differences between actual results and estimated amounts are adjusted for in the period in which they become known, which typically follows the quarterly period in which the estimate was made. To date, actual royalties received have not differed materially from our estimates.
Concentration of Credit Risk. Financial instruments that potentially subject us to concentration of credit risk consist primarily of cash, cash equivalents and marketable securities. We have established guidelines to limit our exposure to credit risk by diversifying our investment portfolio and by placing investments with high credit quality financial
institutions and maturities that maintain safety and liquidity. To date, we have not experienced any credit losses and do not believe we are exposed to any significant credit risk in relation to these financial instruments.
We are also subject to credit risk from our accounts receivable related to our product sales. Our two largest customers represented approximately 86% of our product revenues for both 2020 and 2019, and the significant majority of our accounts receivable balances at December 31, 2020 and 2019. For 2018, our three largest customers represented approximately 93% of our product revenue and substantially all of our accounts receivable balance at December 31, 2018. To date, we have not experienced any significant losses with respect to the collection of these accounts receivable.
Cost of Sales. Cost of sales includes third-party manufacturing, transportation, freight and indirect overhead costs associated with the manufacture and distribution of INGREZZA and ONGENTYS, royalty fees on net sales of ORILISSA and ORIAHNN, and adjustments for excess and obsolete inventory to the extent management determines that the cost cannot be recovered based on estimates about future demand.
Research and Development Expenses. R&D expenses consist primarily of salaries, payroll taxes, employee benefits and share-based compensation charges for those individuals involved in ongoing R&D efforts; as well as scientific consulting fees, preclinical and clinical trial costs, R&D facilities costs, laboratory supply costs and depreciation of scientific equipment. All such costs are charged to R&D expense as incurred. These expenses result from our independent R&D efforts, as well as efforts associated with collaborations, in-licenses and third-party funded research arrangements, including event based milestones.
Asset Acquisitions. We account for acquisitions of an asset or group of assets that do not meet the definition of a business using the cost accumulation method, whereby the cost of the acquisition, including certain transaction costs, is allocated to the assets acquired on the basis of their relative fair values. No goodwill is recognized in an asset acquisition. Intangible assets that are acquired in an asset acquisition for use in R&D activities which have no alternative future use are expensed as in-process research and development, or IPR&D, on the acquisition date. Future costs to develop these assets are recorded to R&D expense as they are incurred.
Advertising Expense. Advertising costs are expensed when services are performed, or goods are delivered. We incurred advertising costs related to INGREZZA and ONGENTYS of $64.8 million for 2020, $40.6 million for 2019 and $20.5 million for 2018.
Share-Based Compensation. We grant stock options to purchase our common stock to eligible employees and directors and also grant certain employees restricted stock units, or RSUs, and performance-based restricted stock units, or PRSUs. Additionally, we allow employees to participate in an employee stock purchase plan, or ESPP.
We estimate the fair value of stock options and shares to be issued under the ESPP using the Black-Scholes option-pricing model on the date of grant. Restricted stock units are valued based on the closing price of our common stock on the date of grant. The fair value of equity instruments expected to vest are recognized and amortized on a straight-line basis over the requisite service period of the award, which is generally three to four years; however, certain provisions in our equity compensation plans provide for shorter vesting periods under certain circumstances. The fair value of shares to be issued under the ESPP are recognized and amortized on a straight-line basis over the purchase period, which is generally six months. Additionally, we granted certain PRSUs that vest upon the achievement of certain predefined company-specific performance-based criteria. Expense related to these PRSUs is generally recognized ratably over the expected performance period once the predefined performance-based criteria for vesting becomes probable.
Income Taxes. Our income tax benefit (provision) is computed under the asset and liability method. Significant estimates are required in determining our income tax benefit (provision). Some of these estimates are based on interpretations of existing tax laws or regulations. We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (temporary differences) at enacted tax rates in effect for the years in which the differences are expected to reverse. A valuation allowance is established for deferred tax assets for which it is more likely than not that some portion or all of the deferred tax assets, including net operating losses and tax credits, will not be realized. We periodically re-assess the need for a valuation allowance against our deferred tax assets based on various factors including our historical earnings experience by
taxing jurisdiction, and forecasts of future operating results and utilization of net operating losses and tax credits prior to their expiration. Significant judgment is required in making this assessment and, to the extent that a reversal of any portion of our valuation allowance against our deferred tax assets is deemed appropriate, a tax benefit will be recognized against our income tax provision in the period of such reversal. Prior to 2020, we recorded a valuation allowance that fully offset our deferred tax assets. On December 31, 2020, based on our evaluation of various factors, such as our achievement of a cumulative three-year income position as of December 31, 2020, as well as our consideration of forecasts of future operating results and utilization of net operating losses and tax credits prior to their expiration, we released substantially all of our valuation allowance against our deferred tax assets and recorded a corresponding income tax benefit. Refer to Note 9 to the consolidated financial statements for more information.
We recognize tax benefits from uncertain tax positions only if it is more likely than not that the tax position will be sustained upon examination by the tax authorities based on the technical merits of the position. An adverse resolution of one or more of these uncertain tax positions in any period could have a material impact on the results of operations for that period.
Net Income Per Share. Basic net income per share is computed using the weighted average number of common shares outstanding during the period. Diluted net income per share is computed using the weighted average number of common and potentially dilutive shares outstanding during the period, including the potentially dilutive shares resulting from the conversion of the 2024 Notes and excluding the effect of stock options and restricted stock outstanding for periods when their effect is anti-dilutive, using the treasury stock method.
Convertible debt instruments that may be settled entirely or partly in cash (such as the 2024 Notes) may, in certain circumstances where the borrower has the ability and intent to settle in cash, be accounted for under the treasury stock method. We issued the 2024 Notes with a combination settlement feature, which we have the ability and intent to use upon conversion of the 2024 Notes, to settle the principal amount of debt for cash and the excess of the principal portion in shares of our common stock. As a result, of the approximately 5.0 million shares underlying the 2024 Notes at December 31, 2020, only the shares required to settle the excess of the principal portion would be considered dilutive under the treasury stock method. Further, approximately 0.2 million PRSUs were excluded from the calculation of diluted net income per share as the performance condition has not been achieved. In loss periods, basic net loss per share and diluted net loss per share are identical because the otherwise dilutive potential common shares become anti-dilutive and are therefore excluded.
Recently Adopted Accounting Pronouncements.
ASU 2016-13. On January 1, 2020, we adopted Accounting Standards Update, or ASU, 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, using the modified retrospective transition method. For debt securities available-for-sale, the standard requires an investor to determine whether a decline in the fair value below the amortized cost basis of the investment is due to credit-related factors. Credit-related impairment is recognized as an allowance for credit loss on the balance sheet with a corresponding adjustment to earnings. Credit losses are limited to the amount by which the investment’s amortized cost basis exceeds its fair value and may be subsequently reversed if conditions change. Any impairment that is not credit related is recognized in other comprehensive income or loss, as applicable, net of applicable taxes.
The adoption of ASU 2016-13 did not result in a cumulative-effect adjustment to retained earnings. The comparative prior period information continues to be reported under the accounting standards in effect during those periods.
Recently Issued Accounting Pronouncements.
ASU 2019-12. In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and amends existing guidance to improve consistent application of Topic 740. ASU 2019-12 is effective for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years, with early adoption permitted in any interim period for which financial statements have not yet been made available for issuance. We are currently evaluating the effect ASU 2019-12 will have on our condensed consolidated financial statements and related disclosures.
ASU 2020-06. In August 2020, the FASB issued ASU 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity's Own Equity (Subtopic 815-40): Accounting
for Convertible Instruments and Contracts in an Entity's Own Equity, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments, and amends existing earnings-per-share, or EPS, guidance by requiring that an entity use the if-converted method when calculating diluted EPS for convertible instruments. ASU 2020-06 is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years, with early adoption permitted for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. We plan to adopt ASU 2020-06 effective January 1, 2022 and are currently evaluating the effect ASU 2020-06 will have on our consolidated financial statements and related disclosures.
XML 23 R8.htm IDEA: XBRL DOCUMENT v3.20.4
License and Collaboration Agreements
 12 Months Ended
Dec. 31, 2020
Business Combinations [Abstract]  
Commitments and Contingencies Under the terms of the following license and collaboration agreements, we may be required to make milestone payments upon achievement of certain development and regulatory activities of up to $8.5 billion and pay royalties on future sales, if any, of commercial products resulting from these agreements.
License and Collaboration Agreements License and Collaboration Agreements
Takeda Pharmaceutical Company Limited. We entered into an exclusive license agreement with Takeda Pharmaceutical Company Limited, or Takeda, which became effective in July 2020, to develop and commercialize certain compounds in Takeda’s early to mid-stage psychiatry pipeline. Specifically, Takeda granted us an exclusive license to the following seven assets: (i) NBI-1065844 (TAK-831) for schizophrenia, (ii) NBI-1065845 (TAK-653) for treatment-resistant depression, (iii) NBI-1065846 (TAK-041) for anhedonia (which together with the NBI-1065845 are referred to as the Phase II Ready Assets), and (iv) four non-clinical stage assets, or the Non-Clinical Assets.
NBI-1065844 is deemed a royalty-bearing product under the license agreement pursuant to which we will be responsible for all costs and expenses associated with the development, manufacture, and commercialization of such asset, subject to certain exceptions, and Takeda will be eligible to receive development and commercial milestones and royalties with respect to such asset, or a Royalty-Bearing Product, and Takeda will retain the right to opt-in to a profit sharing arrangement pursuant to which we and Takeda will equally share in the operating profits and losses related to such asset, subject to certain exceptions, in lieu of receiving milestones and royalties, or a Profit-Share Product. Subject to specified conditions, Takeda may elect to exercise such opt-in right for NBI-1065844 before we initiate a Phase III clinical trial. Each of the Phase II Ready Assets is deemed a Profit-Share Product and Takeda will retain the right to opt-out of the profit-sharing arrangement for such asset pursuant to which such asset would become a Royalty-Bearing Product. Takeda may elect to exercise such opt-out rights with respect to a Phase II Ready Asset immediately following the completion of the second Phase II clinical trial for such Phase II Ready Asset. In addition, under certain circumstances related to the development and commercialization activities to be performed by us, Takeda may elect to opt-out of the profit-sharing arrangement for a Profit-Share Product before the initiation of a Phase III clinical trial for such product.
Each of the Non-Clinical Assets will be Royalty-Bearing Products pursuant to which we will be responsible for all costs and expenses associated with the development, manufacture, and commercialization of such assets, subject to certain exceptions.
In connection with the agreement, we paid Takeda $120.0 million upfront, which, including certain transaction related costs, was expensed as in-process research and development, or IPR&D, in the third quarter of 2020. Pursuant to the terms of the agreement, Takeda may also be entitled to receive additional payments of up to $1.9 billion upon the achievement of certain event-based milestones associated with Royalty-Bearing Products, as well as receive royalties on the future net sales of Royalty-Bearing Products. On a country-by-country and product-by-product basis, royalty payments would commence on the first commercial sale of a Royalty-Bearing Product and terminate on the later of (i) the expiration of the last patent covering such Royalty-Bearing Product in such country, (ii) a number of years from the first commercial sale of such Royalty-Bearing Product in such country and (iii) the expiration of regulatory exclusivity for Royalty-Bearing Product in such country.
Idorsia Pharmaceuticals Ltd. In May 2020, we entered a collaboration and licensing agreement with Idorsia Pharmaceuticals Ltd, or Idorsia, to license the global rights to NBI-827104 (ACT-709478), a potent, selective, orally active and brain penetrating T-type calcium channel blocker, in clinical development for the treatment of a rare pediatric epilepsy. The agreement also includes a research collaboration to discover and identify additional novel T-type calcium channel blockers as development candidates.
In connection with the exercise of the option, we paid Idorsia $45.0 million upfront, which we expensed as IPR&D in the second quarter of 2020. Further, as part of the research collaboration, we provided Idorsia with an incremental $7.2 million in funding, which we recorded as a prepaid asset and is being expensed over the two-year research collaboration term.
Pursuant to the terms of the agreement, upon the achievement of certain development and regulatory milestones, Idorsia may be entitled to receive additional payments of up to $365.0 million with respect to NBI-827104 and $620.0 million with respect to the development candidates. Idorsia may also be entitled to receive additional payments of up to $750.0 million upon the achievement of certain commercial milestones, as well as receive royalties on the future net sales of any collaboration product. Further, we will be responsible for all manufacturing, development and commercialization costs of any collaboration product.
Xenon Pharmaceuticals, Inc. In December 2019, we entered into a license and collaboration agreement with Xenon Pharmaceuticals Inc., or Xenon, to identify, research, and develop sodium channel inhibitors, including clinical candidate NBI-921352 (XEN901) and three preclinical candidates, which compounds we will have the exclusive right to further develop and commercialize under the terms and conditions set forth in the agreement.
We will be solely responsible, at our sole cost and expense, for all development and manufacturing of the compounds and any pharmaceutical product that contains a compound, subject to Xenon’s right to elect to co-fund the development of one product in a major indication and thus receive a mid-single digit percentage increase in royalties owed on the net sales of such product in the U.S. If Xenon exercises such option, the parties will share equally all reasonable and documented costs and expenses incurred in connection with the development of such product in the applicable indication, except costs and expenses that are solely related to the development of such product for regulatory approval outside the U.S.
In connection with the agreement, we paid Xenon $30.0 million upfront and purchased $20.0 million of Xenon’s common stock at $14.196 per share, representing approximately 1.4 million shares. Pursuant to the terms of the agreement, Xenon may also be entitled to receive additional payments of up to $1.7 billion upon the achievement of certain event-based milestones, as well as receive royalties on the future net sales of any collaboration product.
We accounted for the transaction as an asset acquisition as the set of acquired assets did not constitute a business. Our equity investment in Xenon was recorded at a fair value of $14.1 million after considering Xenon’s stock price on the date of closing and certain lock-up and voting provisions applicable to the acquired shares. The remaining $36.2 million of the purchase price, which includes the applicable transaction costs, was expensed as IPR&D in the fourth quarter of 2019.
Voyager Therapeutics, Inc. We entered into a collaboration and license agreement with Voyager Therapeutics, Inc., or Voyager, which became effective in March 2019, to develop and commercialize four programs using Voyager’s proprietary gene therapy platform. The four programs consist of the NBIb-1817 (VY-AADC) program for Parkinson’s disease, the Friedreich’s ataxia program and the rights to two undisclosed programs.
In connection with the agreement, we paid Voyager $115.0 million upfront and purchased $50.0 million of Voyager’s common stock at $11.9625 per share, representing approximately 4.2 million shares. Pursuant to the terms of the agreement, Voyager may also be entitled to receive additional payments of up to $1.7 billion upon the achievement of certain event-based milestones, as well as receive royalties on the future net sales of any collaboration product.
Pursuant to development plans agreed to by us and Voyager, unless Voyager exercises its co-development and co-commercialization rights as provided for in the agreement, we will be responsible for all development costs. Further, upon the occurrence of a specified event for each program, we will assume responsibility for the development, manufacturing, and commercialization activities of such program.
We accounted for the transaction as an asset acquisition as the set of acquired assets did not constitute a business. Our equity investment in Voyager was recorded at a fair value of $54.7 million after considering Voyager’s stock price on the date of closing and certain lock-up and voting provisions applicable to the acquired shares. The remaining $113.1 million of the purchase price, which includes the applicable transaction costs, was expensed as in-process research and development, or IPR&D, in the first quarter of 2019.
In June 2019, we entered into an amendment to the collaboration and license agreement with Voyager. Under the terms of the amendment, we paid Voyager $5.0 million upfront to obtain rights outside the U.S. to the Friedreich’s ataxia program in connection with the early return of those rights to Voyager pursuant to a restructuring of Voyager’s gene therapy relationship with Sanofi Genzyme. The upfront payment was expensed as IPR&D in the second quarter of 2019.
BIAL – Portela & Ca, S.A. We acquired the U.S. and Canada rights to ONGENTYS® from BIAL in the first quarter of 2017. We launched ONGENTYS in the U.S. in September 2020, after receiving FDA approval for ONGENTYS as an adjunctive therapy to levodopa/DOPA decarboxylase inhibitors in adult Parkinson's disease patients in April 2020. FDA approval for ONGENTYS for Parkinson’s disease resulted in a $20.0 million event-based payment to BIAL, which we expensed as R&D in the second quarter of 2020. We further recognized R&D expense of $10.0 million in each 2019 and 2018 in connection with BIAL’s achievement of certain regulatory event-based milestones related to then ongoing development of ONGENTYS. Pursuant to the terms of the agreement, BIAL may also be entitled to receive additional payments of up to $75.0 million upon the achievement of certain event-based milestones.
Under the terms of the agreement, we are responsible for the commercialization of ONGENTYS in the U.S. and Canada. Further, we rely on BIAL for the commercial supply of ONGENTYS. Upon our written request prior to the estimated expiration of the term of a licensed product, the parties shall negotiate a good faith continuation of BIAL’s supply of such licensed product after the term. After the term, and if BIAL is not supplying a certain licensed product, we shall pay BIAL a trademark royalty based on the net sales of such licensed product.
Upon commercialization of ONGENTYS, we determined certain annual sales forecasts. In the event we fail to meet the minimum sales requirements for a particular year, we would be obligated to pay BIAL an amount equal to the difference between the actual net sales and minimum sales requirements for such year.
Mitsubishi Tanabe Pharma Corporation. In March 2015, we entered into a collaboration and license agreement with Mitsubishi Tanabe Pharma Corporation, or MTPC, for the development and commercialization of INGREZZA for movement disorders in Japan and other select Asian markets.
Since inception of the agreement, we have recognized revenue of $19.8 million associated with the delivery of a technology license and existing know-how and $15.0 million associated with the achievement of a certain event-based milestone. We further recognized revenue of $2.7 million in 2020 and $0.9 million in 2019 in connection with the ongoing KINECT-HD study, a placebo-controlled Phase III study of valbenazine in adult Huntington’s disease patients with chorea. In accordance with our continuing performance obligations, $6.7 million of the $30.0 million upfront payment received from MTPC is being deferred and will be recognized as revenue over the ongoing study period using an input method according to costs incurred to-date relative to estimated total costs associated with the study.
Pursuant to the terms of the agreement, we may also be entitled to receive additional payments of up to $70.0 million upon the achievement of certain event-based milestones, receive payments for the manufacture of certain pharmaceutical products, as well as receive royalties on the future net sales of any collaboration product in select territories in Asia.
Under the terms of the agreement, MTPC is responsible for all third-party development, marketing, and commercialization costs in Japan and other select Asian markets and we would be entitled to a percentage of sales of INGREZZA in Japan and other select Asian markets for the longer of ten years or the life of the related patent rights. Further, the collaboration effort between the parties to advance INGREZZA towards commercialization in Japan and other select Asian markets is governed by joint steering and development committees with representatives from both parties.
AbbVie Inc. In June 2010, we entered into an exclusive worldwide collaboration with AbbVie Inc., or AbbVie, to develop and commercialize elagolix and all next-generation gonadotropin-releasing factor, or GnRH, antagonists and collectively, GnRH Compounds, for women’s and men’s health.
AbbVie received approval for ORILISSA for the management of moderate to severe endometriosis pain in women from the FDA in July 2018 and Health Canada in October 2018. In May 2020, AbbVie received FDA approval for ORIAHNN for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. We recognized sales-based royalties on AbbVie net sales of ORILISSA and ORIAHNN of $19.2 million in 2020, $14.3 million in 2019 and $1.6 million in 2018.
FDA approval for ORIAHNN for uterine fibroids resulted in the achievement of a $30.0 million event-based milestone, which we recognized as collaboration revenue in the second quarter of 2020. In 2019, we recognized collaboration revenue of $20.0 million in connection with the FDA’s acceptance of AbbVie’s NDA submission for the approval of ORIAHNN for uterine fibroids. In 2018, we recognized collaboration revenue of $40.0 million in connection with the FDA’s approval for ORILISSA for endometriosis.
Since inception of the agreement, we have recognized revenue of $75.0 million associated with the delivery of a technology license and existing know-how and $165.0 million associated with the achievement of certain event-based milestones. Pursuant to the terms of the agreement, we may also be entitled to receive additional payments of up to $366.0 million upon the achievement of certain event-based milestones.
Under the terms of the agreement, AbbVie is responsible for all third-party development, marketing, and commercialization costs. We are entitled to a percentage of worldwide sales of GnRH Compounds for the longer of ten years or the life of the related patent rights.
Subsequent Events On February 2, 2021, we notified Voyager of our termination of the NBIb-1817 for Parkinson’s disease program. The effective date of this termination will be August 2, 2021. The termination does not apply to any other development program other than NBIb-1817 for Parkinson’s disease, and our collaboration and license agreement with Voyager will otherwise continue in effect.
XML 24 R9.htm IDEA: XBRL DOCUMENT v3.20.4
Debt Securities
 12 Months Ended
Dec. 31, 2020
Investments, Debt and Equity Securities [Abstract]  
Debt Securities Debt Securities
The following table summarizes the amortized cost, unrealized gain and loss recognized in accumulated other comprehensive income (loss), allowance for credit losses, and fair value of debt securities available-for-sale at December 31, 2020, aggregated by major security type and contractual maturity:
(in millions)Contractual
Maturity		Amortized
Cost		Unrealized
Gain		Unrealized
Loss		Allowance for Credit LossesFair
Value
Commercial paperWithin 1 year$82.2 $— $— $— $82.2 
Corporate debt securitiesWithin 1 year299.3 1.4 — — 300.7 
Securities of government-sponsored entities
Within 1 year230.9 0.1 — — 231.0 
$612.4 $1.5 $— $— $613.9 
Corporate debt securities1 to 2 years$144.8 $0.4 $— $— $145.2 
Securities of government-sponsored entities
1 to 2 years81.9 0.1 (0.1)— 81.9 
$226.7 $0.5 $(0.1)$— $227.1 
The following table summarizes the amortized cost, unrealized gain and loss recognized in accumulated other comprehensive income, and fair value of debt securities available-for-sale at December 31, 2019, aggregated by major security type and contractual maturity:
(in millions)Contractual
Maturity		Amortized
Cost		Unrealized
Gain		Unrealized
Loss		Fair
Value
Commercial paperWithin 1 year$144.5 $— $— $144.5 
Corporate debt securitiesWithin 1 year270.5 0.5 — 271.0 
Securities of government-sponsored entitiesWithin 1 year142.3 0.4 — 142.7 
$557.3 $0.9 $— $558.2 
Corporate debt securities1 to 2 years$250.5 $0.5 $(0.1)$250.9 
Securities of government-sponsored entities1 to 2 years48.8 — — 48.8 
$299.3 $0.5 $(0.1)$299.7 
The following table summarizes debt securities available-for-sale in an unrealized loss position for which an allowance for credit losses has not been recorded at December 31, 2020, aggregated by major security type and length of time in a continuous unrealized loss position:
Less Than 12 Months12 Months or LongerTotal
(in millions)Fair
Value		Unrealized
Loss		Fair
Value		Unrealized
Loss		Fair
Value		Unrealized
Loss
Securities of government-sponsored entities$95.0 $(0.1)$— $— $95.0 $(0.1)
At December 31, 2020, our security portfolio consisted of 148 securities related to investments in debt securities available-for-sale, of which 30 securities were in an unrealized loss position.
Our investments in corporate debt securities in an unrealized loss position at December 31, 2020 are of high credit quality (rated A or higher). Unrealized losses on these investments were primarily due to changes in interest rates. We do not intend to sell these investments and it is not more likely than not that we will be required to sell these investments before recovery of their amortized cost basis.
The following table summarizes debt securities available-for-sale in an unrealized loss position at December 31, 2019, aggregated by major security type and length of time in a continuous unrealized loss position:
Less Than 12 Months12 Months or LongerTotal
(in millions)Fair
Value		Unrealized
Loss		Fair
Value		Unrealized
Loss		Fair
Value		Unrealized
Loss
Corporate debt securities$186.1 $(0.1)$— $— $186.1 $(0.1)
XML 25 R10.htm IDEA: XBRL DOCUMENT v3.20.4
Fair Value Measurements
 12 Months Ended
Dec. 31, 2020
Fair Value Disclosures [Abstract]  
Fair Value Measurements Fair Value Measurements
Investments at December 31, 2020, which were measured at fair value on a recurring basis, consisted of the following:
Fair Value Measurements Using
(in millions)Fair ValueLevel 1Level 2Level 3
Cash and cash equivalents:
Cash and money market funds$187.1 $187.1 $— $— 
Total cash and cash equivalents187.1 187.1 — — 
Restricted cash:
Certificates of deposit3.2 3.2 — — 
Total restricted cash3.2 3.2 — — 
Debt securities available-for-sale:
Commercial paper82.2 — 82.2 — 
Corporate debt securities445.9 — 445.9 — 
Securities of government-sponsored entities312.9 — 312.9 — 
Total debt securities available-for-sale841.0 — 841.0 — 
Equity securities:
Equity securities–biotechnology industry38.2 — — 38.2 
Total equity securities38.2 — — 38.2 
Total recurring fair value measurements$1,069.5 $190.3 $841.0 $38.2 
Investments at December 31, 2019, which were measured at fair value on a recurring basis, consisted of the following:
Fair Value Measurements Using
(in millions)Fair ValueLevel 1Level 2Level 3
Cash and cash equivalents:
Cash and money market funds$112.3 $112.3 $— $— 
Total cash and cash equivalents112.3 112.3 — — 
Restricted cash:
Certificates of deposit3.2 3.2 ——
Total restricted cash3.2 3.2 ——
Debt securities available-for-sale:
Commercial paper144.5 —144.5 —
Corporate debt securities521.9 —521.9 —
Securities of government-sponsored entities191.5 —191.5 —
Total debt securities available-for-sale857.9 —857.9 —
Equity securities:
Equity securities–biotechnology industry55.9 ——55.9 
Total equity securities55.9 ——55.9 
Total recurring fair value measurements$1,029.3 $115.5 $857.9 $55.9 
The following table presents a reconciliation of equity securities, which were measured at fair value on a recurring basis using significant unobservable inputs (Level 3):
Year Ended December 31,
(in millions)202020192018
Beginning balance$55.9 $— $— 
Purchases— 68.9 — 
Unrealized loss included in earnings(17.7)(13.0)— 
Ending balance$38.2 $55.9 $— 
At December 31, 2020, the discount for lack of marketability used in the valuation analysis of equity securities ranged from 15.0% to 34.0% (weighted average of 24.8%). The discount for lack of marketability was weighted by the relative fair value of the instruments. A significant increase (decrease) in the discount for lack of marketability in isolation would result in a significantly lower (higher) fair value measurement. Unrealized gains and losses on equity securities are included in other income (expense), net.
XML 26 R11.htm IDEA: XBRL DOCUMENT v3.20.4
Convertible Senior Notes
 12 Months Ended
Dec. 31, 2020
Debt Disclosure [Abstract]  
Convertible Senior Notes Convertible Senior Notes
On May 2, 2017, we completed a private placement of $517.5 million in aggregate principal amount of 2.25% convertible senior notes due 2024, or the 2024 Notes, and entered into an indenture agreement, or the 2024 Indenture, with respect to the 2024 Notes. The 2024 Notes accrue interest at a fixed rate of 2.25% per year, payable semiannually in arrears on May 15 and November 15 of each year, beginning on November 15, 2017. The 2024 Notes mature on May 15, 2024. The net proceeds from the issuance of the 2024 Notes were approximately $502.8 million, after deducting commissions and the offering expenses payable by us.
Holders of the 2024 Notes may convert the 2024 Notes at any time prior to the close of business on the business day immediately preceding May 15, 2024, only under the following circumstances:
(i)during any calendar quarter (and only during such calendar quarter), if the last reported sale price of our common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than 130% of the conversion price on each applicable trading day;
(ii)during the 5 business-day period immediately after any 5 consecutive trading-day period (the measurement period) in which the trading price (as defined in the 2024 Indenture) per $1,000 principal amount of the
2024 Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of our common stock and the conversion rate on each such trading day;
(iii)upon the occurrence of specified corporate events, including a merger or a sale of all or substantially all of our assets; or
(iv)if we call the 2024 Notes for redemption, until the close of business on the business day immediately preceding the redemption date.
On or after January 15, 2024, until the close of business on the scheduled trading day immediately preceding May 15, 2024, holders may convert their 2024 Notes at any time.
Upon conversion, holders will receive the principal amount of their 2024 Notes and any excess conversion value, calculated based on the per share volume-weighted average price for each of the 30 consecutive trading days during the observation period (as more fully described in the 2024 Indenture). For both the principal and excess conversion value, holders may receive cash, shares of our common stock or a combination of cash and shares of our common stock, at our option.
It is our intent and policy to settle conversions through combination settlement, which essentially involves repayment of an amount of cash equal to the “principal portion” and delivery of the “share amount” in excess of the principal portion in shares of common stock or cash. In general, for each $1,000 in principal, the “principal portion” of cash upon settlement is defined as the lesser of $1,000, and the conversion value during the 25-day observation period as described in the notes. The conversion value is the sum of the daily conversion value which is the product of the effective conversion rate divided by 25 days and the daily volume-weighted average price, or VWAP, of our common stock. The “share amount” is the cumulative “daily share amount” during the observation period, which is calculated by dividing the daily VWAP into the difference between the daily conversion value (i.e., conversion rate x daily VWAP) and $1,000.
The initial conversion rate for the 2024 Notes is 13.1711 shares of common stock per $1,000 principal amount, which is equivalent to an initial conversion price of approximately $75.92 per share of our common stock. At the initial conversion rate, settlement of the 2024 Notes for shares of our common stock would approximate 5.0 million shares. The conversion rate will be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. The initial conversion price of the 2024 Notes represented a premium of approximately 42.5% to the closing sale price of $53.28 per share of our common stock on the Nasdaq Global Select Market on April 26, 2017, the date that we priced the private offering of the 2024 Notes.
In the event of conversion, holders would forgo all future interest payments, any unpaid accrued interest and the possibility of further stock price appreciation. Upon the receipt of conversion requests, the settlement of the 2024 Notes will be paid pursuant to the terms of the 2024 Indenture. In the event that all of the 2024 Notes are converted, we would be required to repay the outstanding principal value and any conversion premium in any combination of cash and shares of its common stock (at our option).
We may not redeem the 2024 Notes prior to May 15, 2021. On or after May 15, 2021, we may redeem for cash all or part of the 2024 Notes if the last reported sale price (as defined in the 2024 Indenture) of our common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading-day period ending on, and including, the trading day immediately before the date which we provide notice of redemption. The redemption price will equal the sum of (i) 100% of the principal amount of the 2024 Notes being redeemed, plus (ii) accrued and unpaid interest, including additional interest, if any, to, but excluding, the redemption date. No sinking fund is provided for the 2024 Notes.
If we undergo a fundamental change, as defined in the 2024 Indenture, subject to certain conditions, holders of the 2024 Notes may require us to repurchase for cash all or part of their 2024 Notes at a repurchase price equal to 100% of the principal amount of the 2024 Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. In addition, if a ‘‘make-whole fundamental change’’ (as defined in the 2024 Indenture) occurs prior to January 15, 2024, we will, in certain circumstances, increase the conversion rate for a holder who elects to convert their notes in connection with the make-whole fundamental change.
The 2024 Notes are our general unsecured obligations that rank senior in right of payment to all of our indebtedness that is expressly subordinated in right of payment to the 2024 Notes, and equal in right of payment to our unsecured indebtedness.
We are required to separately account for the liability and equity components of the 2024 Notes, as they may be settled entirely or partially in cash upon conversion in a manner that reflects our economic interest cost. The liability component of the instrument was valued in a manner that reflects the market interest rate for a similar nonconvertible instrument at the date of issuance. The initial carrying value of the liability component of $368.3 million was calculated using a 7.5% assumed borrowing rate. The equity component of $149.2 million, representing the conversion option, was determined by deducting the fair value of the liability component from the par value of the 2024 Notes and was recorded in additional paid-in capital on the consolidated balance sheet at the issuance date. That equity component is treated as a discount on the liability component of the 2024 Notes, which is amortized over the seven-year term of the 2024 Notes using the effective interest rate method. The equity component is not re-measured as long as it continues to meet the conditions for equity classification. At December 31, 2020, the remaining period over which the discount on the liability component will be amortized was approximately 3.4 years.
We allocated the total transaction costs of approximately $14.7 million related to the issuance of the 2024 Notes to the liability and equity components of the 2024 Notes based on their relative values. Transaction costs attributable to the liability component are amortized to interest expense over the seven-year term of the 2024 Notes, and transaction costs attributable to the equity component are netted with the equity component in stockholders’ equity.
The 2024 Notes do not contain any financial or operating covenants or any restrictions on the payment of dividends, the issuance of other indebtedness or the issuance or repurchase of securities by us. The 2024 Indenture contains customary events of default with respect to the 2024 Notes, including that upon certain events of default, 100% of the principal and accrued and unpaid interest on the 2024 Notes will automatically become due and payable.
In November 2020, we entered into separate, privately negotiated transactions with certain holders of the 2024 Notes to repurchase $136.2 million aggregate principal amount of the 2024 Notes for an aggregate repurchase price of $186.9 million in cash. We accounted for the partial repurchase of the 2024 Notes as a debt extinguishment. As a result, we attributed $130.7 million of the aggregate repurchase price to the liability component based on the fair value of the liability component immediately before extinguishment. The fair value of the liability component was calculated at settlement using a discounted cash flow analysis with a discount rate of 3.37%, which was the market rate for similar notes that have no conversion rights. The difference of $56.3 million between the fair value of the aggregate consideration remitted to certain holders of the 2024 Notes and the fair value of the liability component was attributed to the reacquisition of the equity component and recognized as a reduction to additional paid-in capital. The carrying amount of the liability of $112.4 million at settlement was recognized as a reduction to convertible senior notes and resulted in an $18.4 million loss on extinguishment.
The 2024 Notes, net of discounts and deferred financing costs, consisted of the following:
 December 31,
(in millions)20202019
Principal$381.3 $517.5 
Deferred financing costs(4.0)(6.9)
Debt discount, net(59.4)(101.8)
Net carrying amount$317.9 $408.8 
The 2024 Notes were recorded at the estimated value of a similar non-convertible instrument on the date of issuance and accretes to the face value of the 2024 Notes over their seven-year term. The fair value of the 2024 Notes, which was estimated utilizing market quotations from an over-the-counter trading market (Level 2), was $514.3 million and $596.8 million at December 31, 2020 and 2019, respectively.
XML 27 R12.htm IDEA: XBRL DOCUMENT v3.20.4
Other Balance Sheet Details
 12 Months Ended
Dec. 31, 2020
Other Balance Sheet Details [Abstract]  
Other Balance Sheet Details Other Balance Sheet Details
Inventories consisted of the following:
December 31,
(in millions)20202019
Raw materials$16.6 $14.1 
Work in process2.4 1.5 
Finished goods9.0 1.7 
Total inventories$28.0 $17.3 
Property and equipment, net, consisted of the following:
December 31,
(in millions)20202019
Tenant improvements$29.5 $26.3 
Scientific equipment39.2 33.5 
Computer equipment13.9 12.5 
Furniture and fixtures3.7 3.2 
86.3 75.5 
Less accumulated depreciation(41.7)(33.6)
Total property and equipment, net$44.6 $41.9 
Accounts payable and accrued liabilities consisted of the following:
December 31,
(in millions)20202019
Accrued employee related costs $38.2 $38.9 
Revenue-related reserves for discounts and allowances34.6 30.6 
Accrued development costs32.9 25.5 
Accrued Branded Prescription Drug Fee23.6 4.9 
Accounts payable and other accrued liabilities39.4 41.4 
Total accounts payable and accrued liabilities$168.7 $141.3 
The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows.
December 31,
(in millions)20202019
Cash and cash equivalents$187.1 $112.3 
Restricted cash3.2 3.2 
Total cash, cash equivalents and restricted cash$190.3 $115.5 
XML 28 R13.htm IDEA: XBRL DOCUMENT v3.20.4
Net Income Per Share
 12 Months Ended
Dec. 31, 2020
Earnings Per Share [Abstract]  
Net Income Per Share Net Income Per Share
Net income per share was calculated as follows:
Year Ended December 31,
(in millions, except per share data)202020192018
Net income - basic and diluted$407.3 $37.0 $21.1 
Weighted-average common shares outstanding:
Basic93.1 91.6 90.2 
Effect of dilutive securities:
Stock options2.4 2.6 3.2 
Restricted stock units0.5 0.4 0.6 
2024 Notes1.8 1.1 1.3 
Diluted97.8 95.7 95.4 
Net income per share:
Basic$4.38 $0.40 $0.23 
Diluted$4.16 $0.39 $0.22 
Shares which have been excluded from diluted per share amounts because their effect would have been anti-dilutive were 2.5 million, 2.1 million and 0.9 million for 2020, 2019 and 2018, respectively.
XML 29 R14.htm IDEA: XBRL DOCUMENT v3.20.4
Share-Based Compensation
 12 Months Ended
Dec. 31, 2020
Share-based Payment Arrangement [Abstract]  
Share-Based Compensation Share-Based Compensation
In May 2011, we adopted the 2011 Equity Incentive Plan, as amended, or the 2011 Plan. The 2011 Plan authorized 21 million shares of common stock for issuance and allowed for the grant of stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, or RSUs, performance stock awards, performance-based restricted stock units, or PRSUs, and certain other awards. During 2020, the 2011 Plan was merged into the 2020 Plan (defined below). As a result, there were no shares of common stock remaining available for future grant under the 2011 Plan.
In May 2018, we adopted the 2018 Employee Stock Purchase Plan, or ESPP, pursuant to which 0.3 million shares of common stock are authorized for issuance. At December 31, 2020, 0.2 million shares of common stock remain available for future grant under the 2018 ESPP.
In May 2020, we adopted the 2020 Equity Incentive Plan, or the 2020 Plan. The 2020 Plan authorized 3.3 million shares of common stock for issuance and allows for the grant of stock options, stock appreciation rights, restricted stock awards, RSUs, performance stock awards, PRSUs and certain other awards. The 2011 Plan was merged into the 2020 Plan and, as a result, all remaining shares in the 2011 Plan were transferred into the 2020 Plan. At December 31, 2020, 8.2 million shares of common stock remain available for future grant under the 2020 Plan.
Share-Based Compensation Expense. The effect of share-based compensation expense on our consolidated statements of income and comprehensive income by line-item follows:
Year Ended December 31,
(in millions)202020192018
Selling, general and administrative expense$66.3 $49.5 $31.9 
Research and development expense33.7 25.8 26.2 
Total share-based compensation expense$100.0 $75.3 $58.1 
Share-based compensation expense by award-type follows:
Year Ended December 31,
(in millions)202020192018
Stock options$47.5 $36.5 $35.4 
RSUs44.2 30.5 21.9 
PRSUs5.3 5.6 — 
ESPP3.0 2.7 0.8 
Total share-based compensation expense$100.0 $75.3 $58.1 
At December 31, 2020, unrecognized share-based compensation expense by award-type and the weighted-average period over which such expense is expected to be recognized, as applicable, were as follows:
(dollars in millions)Unrecognized ExpenseWeighted-Average Recognition Period
Stock options$86.2 2.3 years
RSUs$99.5 2.3 years
Stock Options. Typically, stock options have a ten-year term and vest over a three to four-year period. The exercise price of stock options granted is equal to the closing price of our common stock on the date of grant. We estimate the fair value of stock options using the Black-Scholes option-pricing model on the date of grant. The Black-Scholes option-pricing model incorporates various and highly sensitive assumptions including expected volatility, term and interest rates. The weighted-average grant-date fair values of stock options granted were $45.67, $41.74 and $43.42 for 2020, 2019 and 2018, respectively.
The fair value of each stock option granted was estimated on the date of grant using the Black-Scholes option-pricing valuation model with the following weighted-average assumptions:
Year Ended December 31,
202020192018
Risk-free interest rate1.4 %2.4 %2.5 %
Expected volatility of common stock48.5 %54.8 %59.5 %
Dividend yield0.0 %0.0 %0.0 %
Expected option term5.3 years5.4 years4.7 years
The weighted-average valuation assumptions were determined as follows:
•The expected volatility of common stock is estimated based on the historical volatility of our common stock over the most recent period commensurate with the estimated expected term of our stock options.
•The expected option term is estimated based on historical experience as well as the status of the employee. For example, directors and officers have a longer expected option term than all other employees.
•The risk-free interest rate for periods within the contractual life of a stock option is based upon observed interest rates appropriate for the expected term of our employee stock options.
•We have not historically declared or paid dividends and do not intend to do so in the foreseeable future.
A summary of activity related to stock options follows:
(in millions, except weighted average data)Number of
Stock Options		Weighted
Average
Exercise Price		Weighted-Average Remaining Contractual TermAggregate Intrinsic Value
Outstanding at December 31, 20196.1 $52.62 
Granted1.3 $103.44 
Exercised(0.6)$43.90 
Canceled— $— 
Outstanding at December 31, 20206.8 $62.98 6.4 years$235.4 
Exercisable at December 31, 20204.7 $49.80 5.5 years$218.2 
The total intrinsic value of stock options exercised during 2020, 2019 and 2018 was $40.2 million, $64.3 million and $117.0 million, respectively. Cash received from stock option exercises during 2020, 2019 and 2018 was $23.5 million, $27.3 million and $29.5 million, respectively.
Restricted Stock Units. Typically, RSUs vest over a four-year period. The fair value of RSUs is based on the closing sale price of our common stock on the date of issuance. RSUs may be subject to a deferred delivery arrangement at the election of eligible employees.
A summary of activity related to RSUs follows:
(in millions, except weighted average data)Number of
RSUs		Weighted-Average Grant Date
Fair Value		Weighted-Average Remaining Contractual TermAggregate Intrinsic Value
Unvested at December 31, 20191.4 $74.77 
Granted0.7 $102.92 
Released(0.5)$67.86 
Canceled(0.1)$84.95 
Unvested at December 31, 20201.5 $89.60 1.3 years$147.5 
The total fair value of RSUs that vested during 2020, 2019 and 2018 was $49.7 million, $36.1 million and $35.5 million, respectively.
Performance-Based Restricted Stock Units. PRSUs vest based on the achievement of certain predefined Company-specific performance criteria and expire four to five years from the grant date. The fair value of PRSUs is estimated based on the closing sale price of our common stock on the date of grant. Expense recognition for PRSUs commences when attainment of the performance-based criteria is determined to be probable.
A summary of activity related to PRSUs follows:
(in millions, except weighted average data)Number of
PRSUs		Weighted-Average Grant Date
Fair Value		Weighted-Average Remaining Contractual TermAggregate Intrinsic Value
Unvested at December 31, 20190.3 $59.62 
Granted0.2 $102.90 
Released(0.1)$82.04 
Canceled(0.2)$45.67 
Unvested at December 31, 20200.2 $102.90 2.2 years$15.8 
At December 31, 2020, unrecognized share-based compensation expense for PRSUs was $17.0 million. The total fair value of PRSUs that vested during 2020 was $13.5 million. No PRSUs vested during 2019 or 2018.
Employee Stock Purchase Plan. Under the ESPP, eligible employees may purchase shares of our common stock at a discount semi-annually based on a percentage of their annual compensation. The discounted purchase price is equal to the lower of 85% of (i) the market value per share of the common stock on the first day of the offering period or (ii) the market value per share of common stock on the purchase date.
XML 30 R15.htm IDEA: XBRL DOCUMENT v3.20.4
Income Taxes
 12 Months Ended
Dec. 31, 2020
Income Tax Disclosure [Abstract]  
Income Taxes Income Taxes
Components of income tax expense for continuing operations were as follows:
Year Ended December 31,
(in millions)202020192018
Current:
Federal$— $— $(0.1)
State10.1 9.5 0.8 
Total current taxes10.1 9.5 0.7 
Deferred:
Federal(287.5)— — 
State(23.2)— — 
Total deferred taxes(310.7)— — 
(Benefit from) provision for income taxes$(300.6)$9.5 $0.7 
The provision for income taxes on earnings subject to income taxes differs from the statutory federal rate due to the following:
Year Ended December 31,
(in millions)202020192018
Federal income taxes at 21% for 2020, 2019, 2018
$22.4 $9.8 $4.6 
State income tax, net of federal benefit5.5 4.0 0.4 
Non-deductible expenses0.6 0.8 0.4 
Branded prescription drug fee4.9 3.7 — 
Share-based compensation expense(6.7)(12.8)(9.8)
Officer compensation3.7 3.1 0.9 
Change in tax rate3.3 (4.1)(0.2)
Expired tax attributes1.1 1.2 13.9 
Research credits(39.0)(10.4)(13.5)
Change in valuation allowance(296.3)13.9 4.3 
Other(0.1)0.3 (0.3)
(Benefit from) provision for income taxes$(300.6)$9.5 $0.7 
Significant components of our deferred tax assets as of December 31, 2020 and 2019 are listed below.
 December 31,
(in millions)20202019
Deferred tax assets:
Net operating losses$111.4 $181.3 
Research and development credits109.6 71.9 
Capitalized research and development24.7 28.0 
Share-based compensation expense29.8 22.9 
Operating lease assets25.2 23.3 
Intangible assets86.7 49.3 
Other23.9 18.5 
Total deferred tax assets411.3 395.2 
Deferred tax liabilities:
Convertible senior notes(13.8)(24.1)
Operating lease liabilities(19.9)(18.2)
Other(8.4)(6.9)
Total deferred tax liabilities(42.1)(49.2)
Net of deferred tax assets and liabilities369.2 346.0 
Valuation allowance(49.8)(346.0)
Net deferred tax assets$319.4 $— 
At December 31, 2020, our deferred tax assets were primarily the result of federal net operating loss carry forwards, capitalized research costs, acquired intangible assets and tax credit carryforwards. At December 31, 2020 and 2019, we recorded a valuation allowance of $49.8 million and $346.0 million, respectively, against our gross deferred tax asset balance.
At each reporting date, management considers new evidence, both positive and negative, that could affect its assessment of the future realizability of our deferred tax assets. At December 31, 2020, in part because we achieved three years of cumulative pretax income, management determined there is sufficient positive evidence to conclude that it is more likely than not deferred tax assets of $319.4 million are realizable. Accordingly, we recorded a net valuation release of $296.3 million on the basis of management’s assessment. The remaining valuation allowance of $49.8 million consists primarily of state net operating loss and credit carryforwards for which management cannot conclude it is more likely than not to be realized. The release of the valuation allowance is reported under continuing operations as a benefit to income tax expense.
At December 31, 2020, we had federal and state income tax net operating loss carryforwards of $518.2 million and $340.8 million, respectively. The federal net operating losses will begin to expire in 2028, unless previously utilized.
California net operating losses will begin to expire in 2028 unless previously utilized and the net operating losses related to other states will begin to expire in 2026.
In addition, we have federal and California R&D tax credit carryforwards of $92.1 million and $56.4 million, respectively. A portion of the federal R&D tax credit carryforwards expired in 2020. The remaining federal R&D tax credits will continue to expire beginning in 2021, unless previously utilized. The California R&D tax credits carry forward indefinitely.
Additionally, the future utilization of our net operating loss and R&D tax credit carryforwards to offset future taxable income may be subject to an annual limitation, pursuant to Internal Revenue Code Sections 382 and 383, as a result of ownership changes that could occur in the future. No ownership changes have occurred through December 31, 2020.
The impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained.
Our policy is to recognize interest or penalties related to income tax matters in income tax expense. Interest and penalties related to income tax matters were not material for 2020, 2019 or 2018.
We are subject to taxation in the U.S. and various state jurisdictions. Our tax years for 2001 (federal) and 2008 (California) and forward are subject to examination by federal and state tax authorities due to the carryforward of unutilized net operating losses and R&D tax credits.
A summary of activity related to unrecognized tax benefits follows:
Year Ended December 31,
(in millions)202020192018
Balance at January 1$63.9 $54.8 $37.4 
(Decrease) increase related to prior year tax positions(5.7)0.3 6.1 
Increase related to current year tax positions3.9 9.5 11.7 
Settlements related to prior year tax positions(0.2)— — 
Expiration of the statute of limitations for the assessment of taxes(1.1)(0.7)(0.4)
Balance at December 31$60.8 $63.9 $54.8 
We excluded those deferred tax assets that are not more-likely-than-not to be sustained under the technical merits of the tax position. Such unrecognized tax benefits total $3.9 million for current year tax positions, as reflected in the table above.
At December 31, 2020, we had $53.9 million of unrecognized tax benefits that, if recognized and realized, would affect the effective tax rate, subject to the valuation allowance. We do not expect a significant change in our unrecognized tax benefits in the next twelve months.
XML 31 R16.htm IDEA: XBRL DOCUMENT v3.20.4
Leases
 12 Months Ended
Dec. 31, 2020
Leases [Abstract]  
Leases Leases
We have operating leases for our office and laboratory facilities, including our corporate headquarters, with terms that expire from 2025 through 2031. We have two options to extend the term of the operating lease for our corporate headquarters for a period of ten years each. However, as we were not reasonably certain to exercise either of those options at lease commencement, neither option was recognized as part of the associated operating lease right-of-use, or ROU, asset or liability. In connection with our operating leases, in lieu of cash security deposits, Wells Fargo Bank, N.A., issued letters of credit on our behalf, which are secured by deposits totaling $3.2 million.
Our operating lease cost was $10.1 million for 2020 and $8.1 million for 2019. Cash paid for amounts included in the measurement of lease liabilities was $8.6 million for 2020 and $7.7 million for 2019.
Our operating leases had a weighted-average remaining lease term of approximately 10.3 years and 11.2 years at December 31, 2020 and 2019, respectively, and a weighted-average discount rate of 5.6% and 5.8% at December 31, 2020 and 2019, respectively.
Approximate future minimum lease payments under operating leases were as follows:
(in millions)December 31,
2020
Year ending December 31, 2021
$10.7 
Year ending December 31, 2022
12.4 
Year ending December 31, 2023
12.7 
Year ending December 31, 2024
13.1 
Year ending December 31, 2025
13.5 
Thereafter77.5 
Total operating lease payments139.9 
Less accreted interest35.2 
Total operating lease liabilities104.7 
Less current operating lease liabilities10.3 
Noncurrent operating lease liabilities$94.4 
Note 1: Amounts presented in the table above exclude $19.7 million of non-cancelable future minimum lease payments for operating leases that have not yet commenced.
Note 2: Current operating lease liabilities are included in other current liabilities on the consolidated balance sheets.
XML 32 R17.htm IDEA: XBRL DOCUMENT v3.20.4
Retirement Plan
 12 Months Ended
Dec. 31, 2020
Retirement Benefits [Abstract]  
Retirement Plan Retirement PlanWe have a 401(k) defined contribution savings plan, or the 401(k) Plan. The 401(k) Plan is for the benefit of all qualifying employees and permits voluntary contributions by employees up to 60% of base salary limited by the IRS-imposed maximum. Employer contributions were $6.7 million, $4.9 million, and $1.8 million for 2020, 2019 and 2018, respectively.
XML 33 R18.htm IDEA: XBRL DOCUMENT v3.20.4
Selected Quarterly Financial Data (Unaudited)
 12 Months Ended
Dec. 31, 2020
Quarterly Financial Information Disclosure [Abstract]  
Selected Quarterly Financial Data (Unaudited) Selected Quarterly Financial Data (Unaudited)
A summary of our quarterly results follows:
(in millions, except per share data)First
Quarter		Second
Quarter		Third
Quarter		Fourth
Quarter
Year Ended December 31, 2020:    
Total revenues$237.1 $302.4 $258.5 $247.9 
Total operating expenses (1)
$178.2 $225.8 $302.8 $176.1 
Net income (loss) (1)
$37.4 $79.6 $(57.6)$347.9 
Net income (loss) per share, basic (1)
$0.40 $0.86 $(0.62)$3.72 
Net income (loss) per share, diluted (1)
$0.39 $0.81 $(0.62)$3.58 
Weighted average common shares outstanding, basic92.6 93.0 93.3 93.5 
Weighted average common shares outstanding, diluted97.0 98.2 93.3 97.2 
Year Ended December 31, 2019:
Total revenues$138.4 $183.5 $222.1 $244.1 
Total operating expenses (2)
$239.4 $149.1 $132.0 $195.3 
Net (loss) income (2)
$(102.1)$51.3 $53.8 $34.0 
Net (loss) income per share, basic (2)
$(1.12)$0.56 $0.59 $0.37 
Net (loss) income per share, diluted (2)
$(1.12)$0.54 $0.56 $0.35 
Weighted average common shares outstanding, basic91.1 91.4 91.9 92.2 
Weighted average common shares outstanding, diluted91.1 94.8 96.1 97.2 
(1) In connection with the payment of the upfront fee pursuant to our collaboration and license agreement with Idorsia, we recorded a charge of $46.0 million, accounted for as IPR&D, in the second quarter of 2020. In connection with the payment of the upfront fee pursuant to our collaboration with Takeda, we recorded a charge of $118.5 million, accounted for as IPR&D, in the third quarter of 2020.
(2) In connection with the payment of the upfront fee pursuant to our collaboration and license agreement with Voyager, we recorded a charge of $113.1 million, accounted for as IPR&D, in the first quarter of 2019. In the second quarter of 2019, we entered into an amendment to the collaboration and license agreement with Voyager, pursuant to which we paid Voyager $5.0 million upfront, accounted for as IPR&D, to obtain outside the U.S. rights to the Friedreich’s ataxia program. In connection with the payment of the upfront fee pursuant to our collaboration with Xenon, we recorded a charge of $36.2 million, accounted for as IPR&D, in the fourth quarter of 2019.
XML 34 R19.htm IDEA: XBRL DOCUMENT v3.20.4
Organization and Summary of Significant Accounting Policies (Policies)
 12 Months Ended
Dec. 31, 2020
Accounting Policies [Abstract]  
Business Activities
Business Activities. Neurocrine Biosciences, Inc., or Neurocrine, the Company, we, our or us, was incorporated in California in 1992 and reincorporated in Delaware in 1996. Neurocrine Continental, Inc., is a Delaware corporation and a wholly owned subsidiary of Neurocrine. We also have two wholly-owned Irish subsidiaries, Neurocrine Therapeutics, Ltd. and Neurocrine Europe, Ltd. both of which were formed in December 2014 and are inactive.
We are a neuroscience-focused biopharmaceutical company dedicated to discovering, developing and delivering life-changing treatments for patients with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. Our diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson’s disease, endometriosis*, uterine fibroids* and clinical programs in multiple therapeutic areas. For nearly three decades, we specialize in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems. (*in collaboration with AbbVie Inc.)
Principles of Consolidation Principles of Consolidation. The consolidated financial statements include the accounts of Neurocrine as well as our wholly owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.
Use of Estimates Use of Estimates. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America, or GAAP, requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. Actual results could differ from those estimates.
Industry Segment and Geographic Information Industry Segment and Geographic Information. We operate in a single industry segment – the discovery, development and marketing of pharmaceuticals for the treatment of neurological, endocrine and psychiatric-based diseases and disorders. We had no foreign-based operations during any of the years presented.
Reclassifications Reclassifications. Certain amounts in prior year periods have been reclassified to conform with the presentation adopted in the current year.
Cash Equivalents Cash Equivalents. We consider all highly liquid investments that are readily convertible into cash and have an original maturity of three months or less at the time of purchase to be cash equivalents.
Accounts Receivable Accounts Receivable. Accounts receivable are recorded net of customer allowances for prompt payment discounts, chargebacks and any allowance for doubtful accounts. We estimate the allowance for doubtful accounts based on existing contractual payment terms, actual payment patterns of our customers and individual customer circumstances. To date, an allowance for doubtful accounts has not been material.
Debt Securities
Debt Securities. Debt securities consist of investments in certificates of deposit, corporate debt securities, and securities of government-sponsored entities. We classify debt securities as available-for-sale. Debt securities available-for-sale are recorded at fair value, with unrealized gains and losses included in other comprehensive income or loss, net of tax. We exclude accrued interest from both the fair value and amortized cost basis of debt securities. A debt security is placed on nonaccrual status at the time any principal or interest payments become 90 days delinquent. Interest accrued but not received for a debt security placed on nonaccrual status is reversed against interest income.
Interest income includes amortization of purchase premium or discount. Premiums and discounts on debt securities are amortized using the effective interest rate method. Gains and losses on sales of debt securities are recorded on the trade date in investment income and other, net, and determined using the specific identification method.
Allowance for Credit Losses Allowance for Credit Losses. For debt securities available-for-sale in an unrealized loss position, we first assess whether we intend to sell, or it is more likely than not that we will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security’s amortized cost basis is written down to fair value through earnings. For debt securities available-for-sale that do not meet the aforementioned criteria, we evaluate whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, we consider the extent to which fair value is less than amortized cost, any changes in interest rates, and any changes to the rating of the security by a rating agency, among other factors. If this
assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security is compared to the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded, limited by the amount that the fair value is less than the amortized cost basis. Any impairment that has not been recorded through an allowance for credit losses is recognized in other comprehensive income or loss, as applicable.
Accrued interest receivables on debt securities available-for-sale totaled $3.7 million at December 31, 2020. We do not measure an allowance for credit losses for accrued interest receivables. For the purposes of identifying and measuring an impairment, accrued interest is excluded from both the fair value and amortized cost basis of the debt security. Uncollectible accrued interest receivables associated with an impaired debt security are reversed against interest income upon identification of the impairment. No accrued interest receivables were written off during 2020, 2019 or 2018.
Fair Value of Financial Instruments
Fair Value of Financial Instruments. We record cash equivalents, debt securities available-for-sale and equity securities at fair value based on a fair value hierarchy that distinguishes between assumptions based on market data (observable inputs) and our own assumptions (unobservable inputs). The fair value hierarchy consists of the following three levels:
Level 1 – Quoted prices (unadjusted) in active markets for identical assets or liabilities.
Level 2 – Quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability.
Level 3 – Unobservable inputs that reflect our own assumptions about the assumptions that market participants would use in pricing the asset or liability when there is little, if any, market activity for the asset or liability at the measurement date.
Investments in debt securities available-for-sale are classified as Level 2 and carried at fair value. We estimate the fair value of debt securities available-for-sale by utilizing third-party pricing services. These pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. Such inputs include market pricing based on real-time trade data for similar instruments, issuer credit spreads, benchmark yields, broker/dealer quotes and other observable inputs. We validate valuations obtained from third-party pricing services by understanding the models used, obtaining market values from other pricing sources, and analyzing data in certain instances.
Investments in equity securities of certain companies that are subject to holding period restrictions longer than one year are classified as Level 3 and carried at fair value using an option pricing valuation model. The most significant assumptions within the option pricing valuation model are the stock price volatility, which is based on the historical volatility of similar companies, and the discount for lack of marketability related to the term of the restrictions.
The carrying amounts of accounts receivable and accounts payable and accrued liabilities approximate their fair values due to their short-term maturities.
There were no transfers between levels in the fair value hierarchy during 2020 or 2019.
Inventory Inventory. Inventory is valued at the lower of cost or net realizable value. We determine the cost of inventory using the standard-cost method, which approximates actual cost based on the first-in, first-out method. We assess the valuation of our inventory on a quarterly basis and adjust the value for excess and obsolete inventory to the extent management determines that the cost cannot be recovered based on estimates about future demand. Inventory costs resulting from these adjustments are recognized as cost of sales in the period in which they are incurred. When future commercialization is considered probable and the future economic benefit is expected to be realized, based on management’s judgment, we capitalize pre-launch inventory costs prior to regulatory approval.
Property and Equipment Property and Equipment. Property and equipment are stated at cost and depreciated over the estimated useful lives of the assets using the straight-line method. Equipment is depreciated over an average estimated useful life of three to seven years. Leasehold improvements are depreciated over the shorter of their estimated useful lives or the remaining lease term. Depreciation expense was $8.6 million for 2020, $7.4 million for 2019 and $4.0 million for 2018.
Impairment of Long-Lived Assets Impairment of Long-Lived Assets. We review long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. If indicators of impairment exist, we assess the recoverability of the affected long-lived assets by determining whether the carrying value of such assets can be recovered through undiscounted future operating cash flows. If the carrying amount is not recoverable, we measure the amount of any impairment by comparing the carrying value of the asset to the present value of the expected future cash flows associated with the use of the asset.
Revenue Recognition
Revenue Recognition. We recognize revenue when the customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. Revenue is recognized using a five-step model: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenues when (or as) we satisfy the performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer.
Product Sales, Net. In the U.S., our product sales, net consist of sales of INGREZZA, primarily to specialty pharmacy providers and a specialty distributor, and sales of ONGENTYS, primarily to wholesale distributors. We recognize product sales, net when the customer obtains control of our product, which occurs at a point in time, typically upon delivery of our product to the customer.
Revenues from product sales are recorded net of reserves established for applicable discounts and allowances that are offered within contracts with our customers, payors and other third parties. Such estimates are based on information received from external sources (such as written or oral information obtained from our customers with respect to their period-end inventory levels and sales to end-users during the reporting period), as supplemented by management’s judgement. Our process for estimating reserves established for these variable consideration components does not differ materially from historical practices. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which could have an effect on earnings in the period of adjustment.
Our significant categories of sales discounts and allowances are as follows:
Product Discounts. Product discounts are based on payment terms extended to our customers at the time of sale, which include incentives offered for prompt payment. We maintain a reserve for product discounts based on our historical experience, including the timing of customer payments. To date, actual product discounts have not differed materially from our estimates.
Government Rebates. We are obligated to pay rebates for mandated discounts under the Medicaid Drug Rebate Program. The liability for such rebates consists of invoices received for claims from prior quarters that remain unpaid, or for which an invoice has not been received, and estimated rebates for the current applicable reporting period. Such estimates are based on actual historical rebates by state, estimated payor mix, state and federal regulations and relevant contractual terms, as supplemented by management’s judgement. Our rebate accrual calculations require us to project the magnitude of our sales, by state, that will be subject to these rebates. There is a significant time-lag in our receiving rebate notices from each state (generally, several months or longer after a sale is recognized). Estimated rebates are recorded as a reduction of revenue in the period the related sale is recognized. To date, actual government rebates have not differed materially from our estimates.
Chargebacks. The difference between the list price, or the price at which we sell our products to our customers, and the contracted price, or the price at which our customers sell our products to qualified healthcare professionals, is charged back to us by our customers. In addition to actual chargebacks received, we maintain a reserve for chargebacks based on estimated contractual discounts on product inventory levels on-hand in our distribution channel. To date, actual chargebacks have not differed materially from our estimates.
Payor and Pharmacy Rebates. We are obligated to pay rebates as a percentage of sales under payor and pharmacy contracts. We estimate these rebates based on actual historical rebates, contractual rebate percentages, sales made through the payor channel and purchases made by pharmacies. To date, actual payor and pharmacy rebates have not differed materially from our estimates.
Co-payment Assistance. We offer financial assistance to qualified patients with prescription drug co-payments required by insurance. We accrue for copay assistance based on estimated claims and the cost per claim we expect to receive associated with inventory that remains in the distribution channel at period end. To date, actual copay assistance has not differed materially from our estimates.
Distributor and Other Fees. In connection with the sales of our products, we pay distributor and other fees to certain customers that provide us with inventory management, data and distribution services, which are generally recorded as a reduction of revenue. To the extent we can demonstrate a separable benefit and fair value for these services, we classify the associated costs in selling, general and administrative expenses. These costs are typically known at the time of sale, resulting in minimal adjustments subsequent to the period of sale.
Product Returns. For INGREZZA, we offer our customers product return rights primarily limited to errors in shipment and damaged product. We do not permit returns of INGREZZA for expiring or expired product. Accordingly, we have limited return risk resulting from INGREZZA product sales and therefore do not record an associated returns allowance. For ONGENTYS, we offer our customers product return rights primarily limited to errors in shipment, damaged product, and expiring or expired product, provided it is within a specified period around the product expiration date, as set forth in the associated distribution agreement. Once product is returned, it is destroyed. Where actual returns history is not available, we estimate the associated returns allowance based on benchmarking data for similar products and industry experience. We record this estimate as a reduction of revenue in the period the related sale is recognized. To date, actual product returns have not differed materially from our estimates.
Collaboration Revenues. We have entered into collaboration and licensing agreements under which we license certain rights to our product candidates to third parties. The terms of these arrangements typically include payment to us of one or more of the following: non-refundable, up-front license fees; development, regulatory, and/or commercial milestone payments; and royalties on net sales of licensed products.
Licenses of Intellectual Property. If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, we use judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.
Milestone Payments. At the inception of each arrangement that includes developmental, regulatory or commercial milestone payments, we evaluate whether achieving the milestones is considered probable and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the value of the associated milestone is included in the transaction price. Milestone payments that are not within our control, such as approvals from regulators or where attainment of the specified event is dependent on the development activities of a third party, are not considered probable of being achieved until those approvals are received or the specified event occurs. Revenue is recognized from the satisfaction of performance obligations in the amount billable to the customer.
Royalty Revenues. For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Each quarterly period, sales-based royalties are recorded based on estimated quarterly net sales of the associated collaboration products. Differences between actual results and estimated amounts are adjusted for in the period in which they become known, which typically follows the quarterly period in which the estimate was made. To date, actual royalties received have not differed materially from our estimates.
Concentration of Credit Risk Concentration of Credit Risk. Financial instruments that potentially subject us to concentration of credit risk consist primarily of cash, cash equivalents and marketable securities. We have established guidelines to limit our exposure to credit risk by diversifying our investment portfolio and by placing investments with high credit quality financial
institutions and maturities that maintain safety and liquidity. To date, we have not experienced any credit losses and do not believe we are exposed to any significant credit risk in relation to these financial instruments.
We are also subject to credit risk from our accounts receivable related to our product sales. Our two largest customers represented approximately 86% of our product revenues for both 2020 and 2019, and the significant majority of our accounts receivable balances at December 31, 2020 and 2019. For 2018, our three largest customers represented approximately 93% of our product revenue and substantially all of our accounts receivable balance at December 31, 2018. To date, we have not experienced any significant losses with respect to the collection of these accounts receivable.
Cost of Sales Cost of Sales. Cost of sales includes third-party manufacturing, transportation, freight and indirect overhead costs associated with the manufacture and distribution of INGREZZA and ONGENTYS, royalty fees on net sales of ORILISSA and ORIAHNN, and adjustments for excess and obsolete inventory to the extent management determines that the cost cannot be recovered based on estimates about future demand.
Research and Development Expenses Research and Development Expenses. R&D expenses consist primarily of salaries, payroll taxes, employee benefits and share-based compensation charges for those individuals involved in ongoing R&D efforts; as well as scientific consulting fees, preclinical and clinical trial costs, R&D facilities costs, laboratory supply costs and depreciation of scientific equipment. All such costs are charged to R&D expense as incurred. These expenses result from our independent R&D efforts, as well as efforts associated with collaborations, in-licenses and third-party funded research arrangements, including event based milestones.
Asset Acquisitions Asset Acquisitions. We account for acquisitions of an asset or group of assets that do not meet the definition of a business using the cost accumulation method, whereby the cost of the acquisition, including certain transaction costs, is allocated to the assets acquired on the basis of their relative fair values. No goodwill is recognized in an asset acquisition. Intangible assets that are acquired in an asset acquisition for use in R&D activities which have no alternative future use are expensed as in-process research and development, or IPR&D, on the acquisition date. Future costs to develop these assets are recorded to R&D expense as they are incurred.
Advertising Expense Advertising Expense. Advertising costs are expensed when services are performed, or goods are delivered. We incurred advertising costs related to INGREZZA and ONGENTYS of $64.8 million for 2020, $40.6 million for 2019 and $20.5 million for 2018.
Share-Based Compensation
Share-Based Compensation. We grant stock options to purchase our common stock to eligible employees and directors and also grant certain employees restricted stock units, or RSUs, and performance-based restricted stock units, or PRSUs. Additionally, we allow employees to participate in an employee stock purchase plan, or ESPP.
We estimate the fair value of stock options and shares to be issued under the ESPP using the Black-Scholes option-pricing model on the date of grant. Restricted stock units are valued based on the closing price of our common stock on the date of grant. The fair value of equity instruments expected to vest are recognized and amortized on a straight-line basis over the requisite service period of the award, which is generally three to four years; however, certain provisions in our equity compensation plans provide for shorter vesting periods under certain circumstances. The fair value of shares to be issued under the ESPP are recognized and amortized on a straight-line basis over the purchase period, which is generally six months. Additionally, we granted certain PRSUs that vest upon the achievement of certain predefined company-specific performance-based criteria. Expense related to these PRSUs is generally recognized ratably over the expected performance period once the predefined performance-based criteria for vesting becomes probable.
Income Taxes Income Taxes. Our income tax benefit (provision) is computed under the asset and liability method. Significant estimates are required in determining our income tax benefit (provision). Some of these estimates are based on interpretations of existing tax laws or regulations. We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (temporary differences) at enacted tax rates in effect for the years in which the differences are expected to reverse. A valuation allowance is established for deferred tax assets for which it is more likely than not that some portion or all of the deferred tax assets, including net operating losses and tax credits, will not be realized. We periodically re-assess the need for a valuation allowance against our deferred tax assets based on various factors including our historical earnings experience by
taxing jurisdiction, and forecasts of future operating results and utilization of net operating losses and tax credits prior to their expiration. Significant judgment is required in making this assessment and, to the extent that a reversal of any portion of our valuation allowance against our deferred tax assets is deemed appropriate, a tax benefit will be recognized against our income tax provision in the period of such reversal. Prior to 2020, we recorded a valuation allowance that fully offset our deferred tax assets. On December 31, 2020, based on our evaluation of various factors, such as our achievement of a cumulative three-year income position as of December 31, 2020, as well as our consideration of forecasts of future operating results and utilization of net operating losses and tax credits prior to their expiration, we released substantially all of our valuation allowance against our deferred tax assets and recorded a corresponding income tax benefit. Refer to Note 9 to the consolidated financial statements for more information.
We recognize tax benefits from uncertain tax positions only if it is more likely than not that the tax position will be sustained upon examination by the tax authorities based on the technical merits of the position. An adverse resolution of one or more of these uncertain tax positions in any period could have a material impact on the results of operations for that period.
Net Income Per Share
Net Income Per Share. Basic net income per share is computed using the weighted average number of common shares outstanding during the period. Diluted net income per share is computed using the weighted average number of common and potentially dilutive shares outstanding during the period, including the potentially dilutive shares resulting from the conversion of the 2024 Notes and excluding the effect of stock options and restricted stock outstanding for periods when their effect is anti-dilutive, using the treasury stock method.
Convertible debt instruments that may be settled entirely or partly in cash (such as the 2024 Notes) may, in certain circumstances where the borrower has the ability and intent to settle in cash, be accounted for under the treasury stock method. We issued the 2024 Notes with a combination settlement feature, which we have the ability and intent to use upon conversion of the 2024 Notes, to settle the principal amount of debt for cash and the excess of the principal portion in shares of our common stock. As a result, of the approximately 5.0 million shares underlying the 2024 Notes at December 31, 2020, only the shares required to settle the excess of the principal portion would be considered dilutive under the treasury stock method. Further, approximately 0.2 million PRSUs were excluded from the calculation of diluted net income per share as the performance condition has not been achieved. In loss periods, basic net loss per share and diluted net loss per share are identical because the otherwise dilutive potential common shares become anti-dilutive and are therefore excluded.
Recently Adopted and Issued Accounting Pronouncements
Recently Adopted Accounting Pronouncements.
ASU 2016-13. On January 1, 2020, we adopted Accounting Standards Update, or ASU, 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, using the modified retrospective transition method. For debt securities available-for-sale, the standard requires an investor to determine whether a decline in the fair value below the amortized cost basis of the investment is due to credit-related factors. Credit-related impairment is recognized as an allowance for credit loss on the balance sheet with a corresponding adjustment to earnings. Credit losses are limited to the amount by which the investment’s amortized cost basis exceeds its fair value and may be subsequently reversed if conditions change. Any impairment that is not credit related is recognized in other comprehensive income or loss, as applicable, net of applicable taxes.
The adoption of ASU 2016-13 did not result in a cumulative-effect adjustment to retained earnings. The comparative prior period information continues to be reported under the accounting standards in effect during those periods.
Recently Issued Accounting Pronouncements.
ASU 2019-12. In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and amends existing guidance to improve consistent application of Topic 740. ASU 2019-12 is effective for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years, with early adoption permitted in any interim period for which financial statements have not yet been made available for issuance. We are currently evaluating the effect ASU 2019-12 will have on our condensed consolidated financial statements and related disclosures.
ASU 2020-06. In August 2020, the FASB issued ASU 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity's Own Equity (Subtopic 815-40): Accounting
for Convertible Instruments and Contracts in an Entity's Own Equity, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments, and amends existing earnings-per-share, or EPS, guidance by requiring that an entity use the if-converted method when calculating diluted EPS for convertible instruments. ASU 2020-06 is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years, with early adoption permitted for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. We plan to adopt ASU 2020-06 effective January 1, 2022 and are currently evaluating the effect ASU 2020-06 will have on our consolidated financial statements and related disclosures.
XML 35 R20.htm IDEA: XBRL DOCUMENT v3.20.4
Debt Securities (Tables)
 12 Months Ended
Dec. 31, 2020
Investments, Debt and Equity Securities [Abstract]  
Amortized cost, gross unrealized gain (loss) positions and estimated fair value for available-for-sale debt securities
The following table summarizes the amortized cost, unrealized gain and loss recognized in accumulated other comprehensive income (loss), allowance for credit losses, and fair value of debt securities available-for-sale at December 31, 2020, aggregated by major security type and contractual maturity:
(in millions)Contractual
Maturity		Amortized
Cost		Unrealized
Gain		Unrealized
Loss		Allowance for Credit LossesFair
Value
Commercial paperWithin 1 year$82.2 $— $— $— $82.2 
Corporate debt securitiesWithin 1 year299.3 1.4 — — 300.7 
Securities of government-sponsored entities
Within 1 year230.9 0.1 — — 231.0 
$612.4 $1.5 $— $— $613.9 
Corporate debt securities1 to 2 years$144.8 $0.4 $— $— $145.2 
Securities of government-sponsored entities
1 to 2 years81.9 0.1 (0.1)— 81.9 
$226.7 $0.5 $(0.1)$— $227.1 
The following table summarizes the amortized cost, unrealized gain and loss recognized in accumulated other comprehensive income, and fair value of debt securities available-for-sale at December 31, 2019, aggregated by major security type and contractual maturity:
(in millions)Contractual
Maturity		Amortized
Cost		Unrealized
Gain		Unrealized
Loss		Fair
Value
Commercial paperWithin 1 year$144.5 $— $— $144.5 
Corporate debt securitiesWithin 1 year270.5 0.5 — 271.0 
Securities of government-sponsored entitiesWithin 1 year142.3 0.4 — 142.7 
$557.3 $0.9 $— $558.2 
Corporate debt securities1 to 2 years$250.5 $0.5 $(0.1)$250.9 
Securities of government-sponsored entities1 to 2 years48.8 — — 48.8 
$299.3 $0.5 $(0.1)$299.7 
Gross unrealized losses and fair value available-for-sale investments in unrealized loss position
The following table summarizes debt securities available-for-sale in an unrealized loss position for which an allowance for credit losses has not been recorded at December 31, 2020, aggregated by major security type and length of time in a continuous unrealized loss position:
Less Than 12 Months12 Months or LongerTotal
(in millions)Fair
Value		Unrealized
Loss		Fair
Value		Unrealized
Loss		Fair
Value		Unrealized
Loss
Securities of government-sponsored entities$95.0 $(0.1)$— $— $95.0 $(0.1)
The following table summarizes debt securities available-for-sale in an unrealized loss position at December 31, 2019, aggregated by major security type and length of time in a continuous unrealized loss position:
Less Than 12 Months12 Months or LongerTotal
(in millions)Fair
Value		Unrealized
Loss		Fair
Value		Unrealized
Loss		Fair
Value		Unrealized
Loss
Corporate debt securities$186.1 $(0.1)$— $— $186.1 $(0.1)
XML 36 R21.htm IDEA: XBRL DOCUMENT v3.20.4
Fair Value Measurements (Tables)
 12 Months Ended
Dec. 31, 2020
Fair Value Disclosures [Abstract]  
Investments measured at fair value on recurring basis
Investments at December 31, 2020, which were measured at fair value on a recurring basis, consisted of the following:
Fair Value Measurements Using
(in millions)Fair ValueLevel 1Level 2Level 3
Cash and cash equivalents:
Cash and money market funds$187.1 $187.1 $— $— 
Total cash and cash equivalents187.1 187.1 — — 
Restricted cash:
Certificates of deposit3.2 3.2 — — 
Total restricted cash3.2 3.2 — — 
Debt securities available-for-sale:
Commercial paper82.2 — 82.2 — 
Corporate debt securities445.9 — 445.9 — 
Securities of government-sponsored entities312.9 — 312.9 — 
Total debt securities available-for-sale841.0 — 841.0 — 
Equity securities:
Equity securities–biotechnology industry38.2 — — 38.2 
Total equity securities38.2 — — 38.2 
Total recurring fair value measurements$1,069.5 $190.3 $841.0 $38.2 
Investments at December 31, 2019, which were measured at fair value on a recurring basis, consisted of the following:
Fair Value Measurements Using
(in millions)Fair ValueLevel 1Level 2Level 3
Cash and cash equivalents:
Cash and money market funds$112.3 $112.3 $— $— 
Total cash and cash equivalents112.3 112.3 — — 
Restricted cash:
Certificates of deposit3.2 3.2 ——
Total restricted cash3.2 3.2 ——
Debt securities available-for-sale:
Commercial paper144.5 —144.5 —
Corporate debt securities521.9 —521.9 —
Securities of government-sponsored entities191.5 —191.5 —
Total debt securities available-for-sale857.9 —857.9 —
Equity securities:
Equity securities–biotechnology industry55.9 ——55.9 
Total equity securities55.9 ——55.9 
Total recurring fair value measurements$1,029.3 $115.5 $857.9 $55.9 
Reconciliation of equity securities measured at fair value on recurring basis using significant unobservable inputs
The following table presents a reconciliation of equity securities, which were measured at fair value on a recurring basis using significant unobservable inputs (Level 3):
Year Ended December 31,
(in millions)202020192018
Beginning balance$55.9 $— $— 
Purchases— 68.9 — 
Unrealized loss included in earnings(17.7)(13.0)— 
Ending balance$38.2 $55.9 $— 
XML 37 R22.htm IDEA: XBRL DOCUMENT v3.20.4
Convertible Senior Notes (Tables)
 12 Months Ended
Dec. 31, 2020
Debt Disclosure [Abstract]  
Convertible senior notes net of discounts and deferred financing costs
The 2024 Notes, net of discounts and deferred financing costs, consisted of the following:
 December 31,
(in millions)20202019
Principal$381.3 $517.5 
Deferred financing costs(4.0)(6.9)
Debt discount, net(59.4)(101.8)
Net carrying amount$317.9 $408.8 
XML 38 R23.htm IDEA: XBRL DOCUMENT v3.20.4
Other Balance Sheet Details (Tables)
 12 Months Ended
Dec. 31, 2020
Other Balance Sheet Details [Abstract]  
Inventories
Inventories consisted of the following:
December 31,
(in millions)20202019
Raw materials$16.6 $14.1 
Work in process2.4 1.5 
Finished goods9.0 1.7 
Total inventories$28.0 $17.3 
Property and Equipment
Property and equipment, net, consisted of the following:
December 31,
(in millions)20202019
Tenant improvements$29.5 $26.3 
Scientific equipment39.2 33.5 
Computer equipment13.9 12.5 
Furniture and fixtures3.7 3.2 
86.3 75.5 
Less accumulated depreciation(41.7)(33.6)
Total property and equipment, net$44.6 $41.9 
Accounts Payable and Accrued Liabilities
Accounts payable and accrued liabilities consisted of the following:
December 31,
(in millions)20202019
Accrued employee related costs $38.2 $38.9 
Revenue-related reserves for discounts and allowances34.6 30.6 
Accrued development costs32.9 25.5 
Accrued Branded Prescription Drug Fee23.6 4.9 
Accounts payable and other accrued liabilities39.4 41.4 
Total accounts payable and accrued liabilities$168.7 $141.3 
Reconciliation of Cash, Cash Equivalents and Restricted Cash
The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows.
December 31,
(in millions)20202019
Cash and cash equivalents$187.1 $112.3 
Restricted cash3.2 3.2 
Total cash, cash equivalents and restricted cash$190.3 $115.5 
XML 39 R24.htm IDEA: XBRL DOCUMENT v3.20.4
Net Income Per Share (Tables)
 12 Months Ended
Dec. 31, 2020
Earnings Per Share [Abstract]  
Schedule of net income (loss) per share
Net income per share was calculated as follows:
Year Ended December 31,
(in millions, except per share data)202020192018
Net income - basic and diluted$407.3 $37.0 $21.1 
Weighted-average common shares outstanding:
Basic93.1 91.6 90.2 
Effect of dilutive securities:
Stock options2.4 2.6 3.2 
Restricted stock units0.5 0.4 0.6 
2024 Notes1.8 1.1 1.3 
Diluted97.8 95.7 95.4 
Net income per share:
Basic$4.38 $0.40 $0.23 
Diluted$4.16 $0.39 $0.22 
XML 40 R25.htm IDEA: XBRL DOCUMENT v3.20.4
Share-Based Compensation (Tables)
 12 Months Ended
Dec. 31, 2020
Share-based Payment Arrangement [Abstract]  
Compensation cost related to share based compensation The effect of share-based compensation expense on our consolidated statements of income and comprehensive income by line-item follows:
Year Ended December 31,
(in millions)202020192018
Selling, general and administrative expense$66.3 $49.5 $31.9 
Research and development expense33.7 25.8 26.2 
Total share-based compensation expense$100.0 $75.3 $58.1 
Share-based compensation expense by award-type follows:
Year Ended December 31,
(in millions)202020192018
Stock options$47.5 $36.5 $35.4 
RSUs44.2 30.5 21.9 
PRSUs5.3 5.6 — 
ESPP3.0 2.7 0.8 
Total share-based compensation expense$100.0 $75.3 $58.1 
At December 31, 2020, unrecognized share-based compensation expense by award-type and the weighted-average period over which such expense is expected to be recognized, as applicable, were as follows:
(dollars in millions)Unrecognized ExpenseWeighted-Average Recognition Period
Stock options$86.2 2.3 years
RSUs$99.5 2.3 years
Weighted-average assumptions for stock option grants using black-scholes option-pricing model
The fair value of each stock option granted was estimated on the date of grant using the Black-Scholes option-pricing valuation model with the following weighted-average assumptions:
Year Ended December 31,
202020192018
Risk-free interest rate1.4 %2.4 %2.5 %
Expected volatility of common stock48.5 %54.8 %59.5 %
Dividend yield0.0 %0.0 %0.0 %
Expected option term5.3 years5.4 years4.7 years
Summary and changes in stock options outstanding
A summary of activity related to stock options follows:
(in millions, except weighted average data)Number of
Stock Options		Weighted
Average
Exercise Price		Weighted-Average Remaining Contractual TermAggregate Intrinsic Value
Outstanding at December 31, 20196.1 $52.62 
Granted1.3 $103.44 
Exercised(0.6)$43.90 
Canceled— $— 
Outstanding at December 31, 20206.8 $62.98 6.4 years$235.4 
Exercisable at December 31, 20204.7 $49.80 5.5 years$218.2 
Summary and changes in restricted stock units outstanding
A summary of activity related to RSUs follows:
(in millions, except weighted average data)Number of
RSUs		Weighted-Average Grant Date
Fair Value		Weighted-Average Remaining Contractual TermAggregate Intrinsic Value
Unvested at December 31, 20191.4 $74.77 
Granted0.7 $102.92 
Released(0.5)$67.86 
Canceled(0.1)$84.95 
Unvested at December 31, 20201.5 $89.60 1.3 years$147.5 
A summary of activity related to PRSUs follows:
(in millions, except weighted average data)Number of
PRSUs		Weighted-Average Grant Date
Fair Value		Weighted-Average Remaining Contractual TermAggregate Intrinsic Value
Unvested at December 31, 20190.3 $59.62 
Granted0.2 $102.90 
Released(0.1)$82.04 
Canceled(0.2)$45.67 
Unvested at December 31, 20200.2 $102.90 2.2 years$15.8 
XML 41 R26.htm IDEA: XBRL DOCUMENT v3.20.4
Income Taxes (Tables)
 12 Months Ended
Dec. 31, 2020
Income Tax Disclosure [Abstract]  
Components of income tax expense for continuing operations
Components of income tax expense for continuing operations were as follows:
Year Ended December 31,
(in millions)202020192018
Current:
Federal$— $— $(0.1)
State10.1 9.5 0.8 
Total current taxes10.1 9.5 0.7 
Deferred:
Federal(287.5)— — 
State(23.2)— — 
Total deferred taxes(310.7)— — 
(Benefit from) provision for income taxes$(300.6)$9.5 $0.7 
Provision for income taxes on earnings subject to income taxes differs from statutory federal rate
The provision for income taxes on earnings subject to income taxes differs from the statutory federal rate due to the following:
Year Ended December 31,
(in millions)202020192018
Federal income taxes at 21% for 2020, 2019, 2018
$22.4 $9.8 $4.6 
State income tax, net of federal benefit5.5 4.0 0.4 
Non-deductible expenses0.6 0.8 0.4 
Branded prescription drug fee4.9 3.7 — 
Share-based compensation expense(6.7)(12.8)(9.8)
Officer compensation3.7 3.1 0.9 
Change in tax rate3.3 (4.1)(0.2)
Expired tax attributes1.1 1.2 13.9 
Research credits(39.0)(10.4)(13.5)
Change in valuation allowance(296.3)13.9 4.3 
Other(0.1)0.3 (0.3)
(Benefit from) provision for income taxes$(300.6)$9.5 $0.7 
Components of deferred tax assets
Significant components of our deferred tax assets as of December 31, 2020 and 2019 are listed below.
 December 31,
(in millions)20202019
Deferred tax assets:
Net operating losses$111.4 $181.3 
Research and development credits109.6 71.9 
Capitalized research and development24.7 28.0 
Share-based compensation expense29.8 22.9 
Operating lease assets25.2 23.3 
Intangible assets86.7 49.3 
Other23.9 18.5 
Total deferred tax assets411.3 395.2 
Deferred tax liabilities:
Convertible senior notes(13.8)(24.1)
Operating lease liabilities(19.9)(18.2)
Other(8.4)(6.9)
Total deferred tax liabilities(42.1)(49.2)
Net of deferred tax assets and liabilities369.2 346.0 
Valuation allowance(49.8)(346.0)
Net deferred tax assets$319.4 $— 
Activity related to unrecognized tax benefits
A summary of activity related to unrecognized tax benefits follows:
Year Ended December 31,
(in millions)202020192018
Balance at January 1$63.9 $54.8 $37.4 
(Decrease) increase related to prior year tax positions(5.7)0.3 6.1 
Increase related to current year tax positions3.9 9.5 11.7 
Settlements related to prior year tax positions(0.2)— — 
Expiration of the statute of limitations for the assessment of taxes(1.1)(0.7)(0.4)
Balance at December 31$60.8 $63.9 $54.8 
XML 42 R27.htm IDEA: XBRL DOCUMENT v3.20.4
Leases (Table)
 12 Months Ended
Dec. 31, 2020
Leases [Abstract]  
Summary of minimum lease payments for operating lease liabilities
Approximate future minimum lease payments under operating leases were as follows:
(in millions)December 31,
2020
Year ending December 31, 2021
$10.7 
Year ending December 31, 2022
12.4 
Year ending December 31, 2023
12.7 
Year ending December 31, 2024
13.1 
Year ending December 31, 2025
13.5 
Thereafter77.5 
Total operating lease payments139.9 
Less accreted interest35.2 
Total operating lease liabilities104.7 
Less current operating lease liabilities10.3 
Noncurrent operating lease liabilities$94.4 
Note 1: Amounts presented in the table above exclude $19.7 million of non-cancelable future minimum lease payments for operating leases that have not yet commenced.
Note 2: Current operating lease liabilities are included in other current liabilities on the consolidated balance sheets.
XML 43 R28.htm IDEA: XBRL DOCUMENT v3.20.4
Selected Quarterly Financial Data (Unaudited) (Tables)
 12 Months Ended
Dec. 31, 2020
Quarterly Financial Information Disclosure [Abstract]  
Summary of Quarterly Results of Operations
A summary of our quarterly results follows:
(in millions, except per share data)First
Quarter		Second
Quarter		Third
Quarter		Fourth
Quarter
Year Ended December 31, 2020:    
Total revenues$237.1 $302.4 $258.5 $247.9 
Total operating expenses (1)
$178.2 $225.8 $302.8 $176.1 
Net income (loss) (1)
$37.4 $79.6 $(57.6)$347.9 
Net income (loss) per share, basic (1)
$0.40 $0.86 $(0.62)$3.72 
Net income (loss) per share, diluted (1)
$0.39 $0.81 $(0.62)$3.58 
Weighted average common shares outstanding, basic92.6 93.0 93.3 93.5 
Weighted average common shares outstanding, diluted97.0 98.2 93.3 97.2 
Year Ended December 31, 2019:
Total revenues$138.4 $183.5 $222.1 $244.1 
Total operating expenses (2)
$239.4 $149.1 $132.0 $195.3 
Net (loss) income (2)
$(102.1)$51.3 $53.8 $34.0 
Net (loss) income per share, basic (2)
$(1.12)$0.56 $0.59 $0.37 
Net (loss) income per share, diluted (2)
$(1.12)$0.54 $0.56 $0.35 
Weighted average common shares outstanding, basic91.1 91.4 91.9 92.2 
Weighted average common shares outstanding, diluted91.1 94.8 96.1 97.2 
(1) In connection with the payment of the upfront fee pursuant to our collaboration and license agreement with Idorsia, we recorded a charge of $46.0 million, accounted for as IPR&D, in the second quarter of 2020. In connection with the payment of the upfront fee pursuant to our collaboration with Takeda, we recorded a charge of $118.5 million, accounted for as IPR&D, in the third quarter of 2020.
(2) In connection with the payment of the upfront fee pursuant to our collaboration and license agreement with Voyager, we recorded a charge of $113.1 million, accounted for as IPR&D, in the first quarter of 2019. In the second quarter of 2019, we entered into an amendment to the collaboration and license agreement with Voyager, pursuant to which we paid Voyager $5.0 million upfront, accounted for as IPR&D, to obtain outside the U.S. rights to the Friedreich’s ataxia program. In connection with the payment of the upfront fee pursuant to our collaboration with Xenon, we recorded a charge of $36.2 million, accounted for as IPR&D, in the fourth quarter of 2019.
XML 44 R29.htm IDEA: XBRL DOCUMENT v3.20.4
Organization and Summary of Significant Accounting Policies - Additional Information (Details)
shares in Millions
 1 Months Ended 12 Months Ended
Dec. 31, 2020
USD ($)
shares
Dec. 31, 2020
USD ($)
segment
subsidiary
shares
Dec. 31, 2019
USD ($)
shares
Dec. 31, 2018
USD ($)
Organization And Summary Of Significant Accounting Policies [Line Items]        
Number of wholly owned Irish subsidiaries | subsidiary   2    
Number of operating segments | segment   1    
Number of reportable segments | segment   1    
Accrued interest receivables write-off threshold period 90 days 90 days    
Accrued interest receivables $ 3,700,000 $ 3,700,000    
Accrued interest receivables write-off   0 $ 0 $ 0
Depreciation   8,600,000 7,400,000 4,000,000.0
Advertising expense   $ 64,800,000 $ 40,600,000 $ 20,500,000
PRSUs        
Organization And Summary Of Significant Accounting Policies [Line Items]        
Ending Balance, Unvested (in shares) | shares 0.2 0.2 0.3  
2.25% Convertible senior notes due 2024        
Organization And Summary Of Significant Accounting Policies [Line Items]        
Shares issued to settle notes at initial conversion rate (in shares) | shares 5.0      
ESPP        
Organization And Summary Of Significant Accounting Policies [Line Items]        
Share based compensation arrangement by share based payment award purchase period   6 months    
Revenue, Product and Service Benchmark | Customer Concentration Risk | Largest two customers        
Organization And Summary Of Significant Accounting Policies [Line Items]        
Concentration risk, percentage   86.00% 86.00%  
Revenue, Product and Service Benchmark | Customer Concentration Risk | Largest three customers        
Organization And Summary Of Significant Accounting Policies [Line Items]        
Concentration risk, percentage       93.00%
Minimum        
Organization And Summary Of Significant Accounting Policies [Line Items]        
Property, plant and equipment, useful life   3 years    
Share-based compensation arrangement by share-based payment award, award requisite service period   3 years    
Maximum        
Organization And Summary Of Significant Accounting Policies [Line Items]        
Property, plant and equipment, useful life   7 years    
Share-based compensation arrangement by share-based payment award, award requisite service period   4 years    
XML 45 R30.htm IDEA: XBRL DOCUMENT v3.20.4
License and Collaboration Agreements - Additional Information (Details) - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
 1 Months Ended 3 Months Ended 12 Months Ended 28 Months Ended 42 Months Ended 126 Months Ended
May 31, 2020
Mar. 31, 2015
Jun. 30, 2010
Dec. 31, 2020
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Jun. 30, 2017
Dec. 31, 2020
Dec. 31, 2020
Jul. 31, 2020
Apr. 30, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                      
Potential milestone payments       $ 8,500.0               $ 8,500.0       $ 8,500.0 $ 8,500.0    
Equity securities fair value amount       38.2       $ 55.9       38.2 $ 55.9     38.2 38.2    
Acquired in-process research and development                       164.5 154.3 $ 4.8          
Revenues       247.9 $ 258.5 $ 302.4 $ 237.1 244.1 $ 222.1 $ 183.5 $ 138.4 1,045.9 788.1 451.2          
Takeda | Collaborative Arrangement                                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                      
Potential milestone payments       1,900.0               1,900.0       1,900.0 1,900.0    
Upfront payments made                                   $ 120.0  
Acquired in-process research and development         $ 118.5                            
Idorsia | Collaborative Arrangement                                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                      
Upfront payments made $ 45.0                                    
Incremental funding provided $ 7.2                                    
Research collaboration term 2 years                                    
Potential commercial milestone payments       750.0               750.0       750.0 750.0    
Acquired in-process research and development           46.0                          
Idorsia | Collaborative Arrangement | NBI-827104                                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                      
Potential milestone payments       365.0               365.0       365.0 365.0    
Idorsia | Collaborative Arrangement | Development Product Candidates                                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                      
Potential milestone payments       620.0               620.0       620.0 620.0    
Xenon | Collaborative Arrangement                                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                      
Potential milestone payments       1,700.0               1,700.0       1,700.0 1,700.0    
Upfront payments made               30.0         30.0            
Investment in equity securities without readily determinable fair value               $ 20.0         $ 20.0            
Share price (in USD per share)               $ 14.196         $ 14.196            
Equity securities fair value amount               $ 14.1         $ 14.1            
Acquired in-process research and development               $ 36.2                      
Xenon | Collaborative Arrangement | Common Stock                                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                      
Equity securities number of shares (in shares)               1.4         1.4            
Voyager | Collaborative Arrangement                                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                      
Potential milestone payments       1,700.0               1,700.0       1,700.0 1,700.0    
Upfront payments made                     115.0                
Investment in equity securities without readily determinable fair value                     $ 50.0                
Share price (in USD per share)                     $ 11.9625                
Equity securities fair value amount                     $ 54.7                
Acquired in-process research and development                   $ 5.0 $ 113.1                
Voyager | Collaborative Arrangement | Common Stock                                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                      
Equity securities number of shares (in shares)                     4.2                
B I A L | Collaborative Arrangement                                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                      
Potential milestone payments       75.0               75.0       75.0 75.0    
Milestone payments               $ 10.0         $ 10.0 10.0         $ 20.0
Mitsubishi Tanabe | Collaborative Arrangement                                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                      
Revenues                             $ 19.8 15.0      
Deferred revenue recognized                       2.7 0.9            
Contract with customer, liability       6.7               6.7       6.7 6.7    
Upfront payments received   $ 30.0                                  
Potential milestone payment receipts       70.0               70.0       70.0 70.0    
Mitsubishi Tanabe | Collaborative Arrangement | Patents | Minimum                                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                      
Patent term   10 years                                  
AbbVie | Royalty                                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                      
Revenues                       19.2 14.3 1.6          
AbbVie | Collaborative Arrangement                                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                      
Revenues     $ 75.0     $ 30.0             $ 20.0 $ 40.0     165.0    
Potential milestone payment receipts       $ 366.0               $ 366.0       $ 366.0 $ 366.0    
AbbVie | Collaborative Arrangement | Patents | Minimum                                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                      
Patent term     10 years                                
XML 46 R31.htm IDEA: XBRL DOCUMENT v3.20.4
Debt Securities - Amortized Cost, Gross Unrealized Gain (Loss) Positions and Estimated Fair Value for Available-For-Sale Debt Securities (Details) - USD ($)
$ in Millions
Dec. 31, 2020
Dec. 31, 2019
Short-term investments    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost $ 612.4 $ 557.3
Unrealized Gain 1.5 0.9
Unrealized Loss 0.0 0.0
Allowance for Credit Losses 0.0  
Fair Value 613.9 558.2
Short-term investments | Corporate debt securities    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost 299.3 270.5
Unrealized Gain 1.4 0.5
Unrealized Loss 0.0 0.0
Allowance for Credit Losses 0.0  
Fair Value 300.7 271.0
Short-term investments | Securities of government-sponsored entities    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost 230.9 142.3
Unrealized Gain 0.1 0.4
Unrealized Loss 0.0 0.0
Allowance for Credit Losses 0.0  
Fair Value 231.0 142.7
Short-term investments | Commercial paper    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost 82.2 144.5
Unrealized Gain 0.0 0.0
Unrealized Loss 0.0 0.0
Allowance for Credit Losses 0.0  
Fair Value 82.2 144.5
Long-term investments    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost 226.7 299.3
Unrealized Gain 0.5 0.5
Unrealized Loss (0.1) (0.1)
Allowance for Credit Losses 0.0  
Fair Value 227.1 299.7
Long-term investments | Corporate debt securities    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost 144.8 250.5
Unrealized Gain 0.4 0.5
Unrealized Loss 0.0 (0.1)
Allowance for Credit Losses 0.0  
Fair Value 145.2 250.9
Long-term investments | Securities of government-sponsored entities    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost 81.9 48.8
Unrealized Gain 0.1 0.0
Unrealized Loss (0.1) 0.0
Allowance for Credit Losses 0.0  
Fair Value $ 81.9 $ 48.8
XML 47 R32.htm IDEA: XBRL DOCUMENT v3.20.4
Debt Securities - Gross Unrealized Losses and Fair Value Available-For-Sale Debt securities in Unrealized Loss Position (Details) - USD ($)
$ in Millions
Dec. 31, 2020
Dec. 31, 2019
Securities of government-sponsored entities    
Debt Securities, Available-for-sale [Line Items]    
Less Than 12 Months, Fair Value $ 95.0  
Less Than 12 Months, Unrealized Losses (0.1)  
12 Months or Longer, Fair Value 0.0  
12 Months or Longer, Unrealized Losses 0.0  
Total Fair Value 95.0  
Total Unrealized Losses $ (0.1)  
Corporate debt securities    
Debt Securities, Available-for-sale [Line Items]    
Less Than 12 Months, Fair Value   $ 186.1
Less Than 12 Months, Unrealized Losses   (0.1)
12 Months or Longer, Fair Value   0.0
12 Months or Longer, Unrealized Losses   0.0
Total Fair Value   186.1
Total Unrealized Losses   $ (0.1)
XML 48 R33.htm IDEA: XBRL DOCUMENT v3.20.4
Debt Securities - Additional Information (Details)
Dec. 31, 2020
security
Investments, Debt and Equity Securities [Abstract]  
Debt securities available for sale position number of positions 148
Number of debt securities available-for-sale in an unrealized loss position 30
XML 49 R34.htm IDEA: XBRL DOCUMENT v3.20.4
Fair Value Measurements - Assets Measured at Fair Value on Recurring Basis (Details) - Fair value measurements recurring - USD ($)
$ in Millions
Dec. 31, 2020
Dec. 31, 2019
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value $ 1,069.5 $ 1,029.3
Cash and money market funds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value 187.1 112.3
Cash equivalents    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value 187.1 112.3
Certificates of deposit    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value 3.2 3.2
Restricted cash    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value 3.2 3.2
Commercial paper    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value 82.2 144.5
Corporate debt securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value 445.9 521.9
Securities of government-sponsored entities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value 312.9 191.5
Total debt securities available-for-sale    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value 841.0 857.9
Equity securities–biotechnology industry    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value 38.2 55.9
Total equity securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value 38.2 55.9
Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of assets on recurring basis 190.3 115.5
Level 1 | Cash and money market funds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of assets on recurring basis 187.1 112.3
Level 1 | Cash equivalents    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of assets on recurring basis 187.1 112.3
Level 1 | Certificates of deposit    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of assets on recurring basis 3.2 3.2
Level 1 | Restricted cash    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of assets on recurring basis 3.2 3.2
Level 1 | Commercial paper    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of assets on recurring basis 0.0 0.0
Level 1 | Corporate debt securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of assets on recurring basis 0.0 0.0
Level 1 | Securities of government-sponsored entities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of assets on recurring basis 0.0 0.0
Level 1 | Total debt securities available-for-sale    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of assets on recurring basis 0.0 0.0
Level 1 | Equity securities–biotechnology industry    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of assets on recurring basis 0.0 0.0
Level 1 | Total equity securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of assets on recurring basis 0.0 0.0
Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of assets on recurring basis 841.0 857.9
Level 2 | Cash and money market funds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of assets on recurring basis 0.0 0.0
Level 2 | Cash equivalents    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of assets on recurring basis 0.0 0.0
Level 2 | Certificates of deposit    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of assets on recurring basis 0.0 0.0
Level 2 | Restricted cash    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of assets on recurring basis 0.0 0.0
Level 2 | Commercial paper    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of assets on recurring basis 82.2 144.5
Level 2 | Corporate debt securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of assets on recurring basis 445.9 521.9
Level 2 | Securities of government-sponsored entities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of assets on recurring basis 312.9 191.5
Level 2 | Total debt securities available-for-sale    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of assets on recurring basis 841.0 857.9
Level 2 | Equity securities–biotechnology industry    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of assets on recurring basis 0.0 0.0
Level 2 | Total equity securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of assets on recurring basis 0.0 0.0
Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of assets on recurring basis 38.2 55.9
Level 3 | Cash and money market funds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of assets on recurring basis 0.0 0.0
Level 3 | Cash equivalents    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of assets on recurring basis 0.0 0.0
Level 3 | Certificates of deposit    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of assets on recurring basis 0.0 0.0
Level 3 | Restricted cash    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of assets on recurring basis 0.0 0.0
Level 3 | Commercial paper    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of assets on recurring basis 0.0 0.0
Level 3 | Corporate debt securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of assets on recurring basis 0.0 0.0
Level 3 | Securities of government-sponsored entities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of assets on recurring basis 0.0 0.0
Level 3 | Total debt securities available-for-sale    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of assets on recurring basis 0.0 0.0
Level 3 | Equity securities–biotechnology industry    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of assets on recurring basis 38.2 55.9
Level 3 | Total equity securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of assets on recurring basis $ 38.2 $ 55.9
XML 50 R35.htm IDEA: XBRL DOCUMENT v3.20.4
Fair Value Measurements - Reconciliation of Equity Securities Measured at Fair Value on Recurring Basis (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Equity securities, beginning balance $ 55.9    
Purchases 0.0 $ 68.9 $ 0.0
Unrealized loss included in earnings (17.7) (13.0) 0.0
Equity securities, ending balance 38.2 55.9  
Fair value measurements recurring | Equity securities–biotechnology industry | Level 3      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Equity securities, beginning balance 55.9 0.0 0.0
Purchases 0.0 68.9 0.0
Unrealized loss included in earnings (17.7) (13.0) 0.0
Equity securities, ending balance $ 38.2 $ 55.9 $ 0.0
XML 51 R36.htm IDEA: XBRL DOCUMENT v3.20.4
Fair Value Measurements - Additional Information (Details) - Measurement input, discount for lack of marketability
Dec. 31, 2020
Minimum  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Equity securities, FV-NI, measurement input 0.150
Maximum  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Equity securities, FV-NI, measurement input 0.340
Weighted average  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Equity securities, FV-NI, measurement input 0.248
XML 52 R37.htm IDEA: XBRL DOCUMENT v3.20.4
Convertible Senior Notes - Additional Information (Details)
$ / shares in Units, shares in Millions
 1 Months Ended 12 Months Ended
May 02, 2017
USD ($)
d
$ / shares
Dec. 31, 2020
USD ($)
shares
Nov. 30, 2020
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Debt Instrument [Line Items]            
Principal amount   $ 381,300,000   $ 381,300,000 $ 517,500,000  
Equity component of repurchased convertible senior notes       47,500,000    
Loss on extinguishment of convertible senior notes       $ 18,400,000 0 $ 0
2.25% Convertible senior notes due 2024            
Debt Instrument [Line Items]            
Principal amount $ 517,500,000          
Stated interest rate percentage 2.25%          
Proceeds from issuance $ 502,800,000          
Threshold common stock trading days | d 20          
Threshold consecutive common stock trading days | d 30          
Threshold percentage of common stock price trigger 130.00%          
Principal amount on conversion rate $ 1,000          
Trading days during observation period 30 days          
Conversion observation period 25 days          
Conversion ratio 0.00131711          
Conversion price (in USD per share) | $ / shares $ 75.92          
Shares issued to settle notes at initial conversion rate (in shares) | shares   5.0        
Conversion premium 42.50%          
Market price of common stock (in USD per share) | $ / shares $ 53.28          
Redemption rate 100.00%          
Carrying amount of the liability component upon issuance $ 368,300,000          
Assumed borrowing rate 7.50%          
Carrying amount of the equity component upon issuance $ 149,200,000          
Term 7 years          
Remaining discount amortization period       3 years 4 months 24 days    
Transaction cost related to issuance of convertible senior note $ 14,700,000          
Events of default percentage of principal and accrued and unpaid interest due and payable upon default 100.00%          
Aggregate principal amount repurchased     $ 136,200,000      
Aggregate repurchase price paid in cash     186,900,000      
Fair value of the liability component immediately before extinguishment     130,700,000      
Equity component of repurchased convertible senior notes     56,300,000      
Carrying amount of the liability component at settlement     112,400,000      
Loss on extinguishment of convertible senior notes     $ 18,400,000      
Fair value   $ 514,300,000   $ 514,300,000 $ 596,800,000  
2.25% Convertible senior notes due 2024 | Conversion Period One            
Debt Instrument [Line Items]            
Threshold common stock trading days | d 20          
Threshold consecutive common stock trading days | d 30          
Threshold percentage of common stock price trigger 130.00%          
2.25% Convertible senior notes due 2024 | Conversion Period Two            
Debt Instrument [Line Items]            
Threshold common stock trading days | d 5          
Threshold consecutive common stock trading days | d 5          
Principal amount on conversion rate $ 1,000          
Minimum percentage of common stock price trigger 98.00%          
2.25% Convertible senior notes due 2024 | Discount rate            
Debt Instrument [Line Items]            
Discount rate     0.0337      
XML 53 R38.htm IDEA: XBRL DOCUMENT v3.20.4
Convertible Senior Notes, Net of Discounts and Deferred Financing Costs (Details) - USD ($)
$ in Millions
Dec. 31, 2020
Dec. 31, 2019
Debt Disclosure [Abstract]    
Principal $ 381.3 $ 517.5
Deferred financing costs (4.0) (6.9)
Debt discount, net (59.4) (101.8)
Net carrying amount $ 317.9 $ 408.8
XML 54 R39.htm IDEA: XBRL DOCUMENT v3.20.4
Other Balance Sheet Details - Inventories (Details) - USD ($)
$ in Millions
Dec. 31, 2020
Dec. 31, 2019
Other Balance Sheet Details [Abstract]    
Raw materials $ 16.6 $ 14.1
Work in process 2.4 1.5
Finished goods 9.0 1.7
Total inventories $ 28.0 $ 17.3
XML 55 R40.htm IDEA: XBRL DOCUMENT v3.20.4
Other Balance Sheet Details - Property and Equipment (Details) - USD ($)
$ in Millions
Dec. 31, 2020
Dec. 31, 2019
Property, Plant and Equipment [Line Items]    
Property and equipment $ 86.3 $ 75.5
Less accumulated depreciation (41.7) (33.6)
Total property and equipment, net 44.6 41.9
Tenant improvements    
Property, Plant and Equipment [Line Items]    
Property and equipment 29.5 26.3
Scientific equipment    
Property, Plant and Equipment [Line Items]    
Property and equipment 39.2 33.5
Computer equipment    
Property, Plant and Equipment [Line Items]    
Property and equipment 13.9 12.5
Furniture and fixtures    
Property, Plant and Equipment [Line Items]    
Property and equipment $ 3.7 $ 3.2
XML 56 R41.htm IDEA: XBRL DOCUMENT v3.20.4
Other Balance Sheet Details - Accounts Payable and Accrued Liabilities (Details) - USD ($)
$ in Millions
Dec. 31, 2020
Dec. 31, 2019
Other Balance Sheet Details [Abstract]    
Accrued employee related costs $ 38.2 $ 38.9
Revenue-related reserves for discounts and allowances 34.6 30.6
Accrued development costs 32.9 25.5
Accrued Branded Prescription Drug Fee 23.6 4.9
Accounts payable and other accrued liabilities 39.4 41.4
Total accounts payable and accrued liabilities $ 168.7 $ 141.3
XML 57 R42.htm IDEA: XBRL DOCUMENT v3.20.4
Other Balance Sheet Details - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($)
$ in Millions
Dec. 31, 2020
Dec. 31, 2019
Other Balance Sheet Details [Abstract]    
Cash and cash equivalents $ 187.1 $ 112.3
Restricted cash 3.2 3.2
Total cash, cash equivalents and restricted cash $ 190.3 $ 115.5
XML 58 R43.htm IDEA: XBRL DOCUMENT v3.20.4
Net Income Per Share - Schedule of Net Income (Loss) Per Share (Details) - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
 3 Months Ended 12 Months Ended
Dec. 31, 2020
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Subsidiary, Sale of Stock [Line Items]                      
Net income (loss) $ 347.9 $ (57.6) $ 79.6 $ 37.4 $ 34.0 $ 53.8 $ 51.3 $ (102.1) $ 407.3 $ 37.0 $ 21.1
Weighted-average common shares outstanding:                      
Basic (in shares) 93.5 93.3 93.0 92.6 92.2 91.9 91.4 91.1 93.1 91.6 90.2
Effect of dilutive securities:                      
Diluted (in shares) 97.2 93.3 98.2 97.0 97.2 96.1 94.8 91.1 97.8 95.7 95.4
Net income per share:                      
Basic (in USD per share) $ 3.72 $ (0.62) $ 0.86 $ 0.40 $ 0.37 $ 0.59 $ 0.56 $ (1.12) $ 4.38 $ 0.40 $ 0.23
Diluted (in USD per share) $ 3.58 $ (0.62) $ 0.81 $ 0.39 $ 0.35 $ 0.56 $ 0.54 $ (1.12) $ 4.16 $ 0.39 $ 0.22
2.25% Convertible Senior Notes                      
Effect of dilutive securities:                      
2024 Notes (in shares)                 1.8 1.1 1.3
Stock options                      
Effect of dilutive securities:                      
Effect of dilutive securities (in shares)                 2.4 2.6 3.2
Restricted stock units                      
Effect of dilutive securities:                      
Effect of dilutive securities (in shares)                 0.5 0.4 0.6
XML 59 R44.htm IDEA: XBRL DOCUMENT v3.20.4
Net Income Per Share - Schedule of Anti-Dilutive Shares Excluded from Diluted Per Share Amounts (Details) - shares
shares in Millions
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Stock options restricted stock and convertible senior notes      
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
Anti-dilutive shares excluded from diluted per share amounts (in shares) 2.5 2.1 0.9
XML 60 R45.htm IDEA: XBRL DOCUMENT v3.20.4
Share-Based Compensation - Additional Information (Details) - USD ($)
$ / shares in Units, $ in Millions
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
May 31, 2020
May 31, 2018
May 31, 2011
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Weighted-average fair values of stock options granted (in USD per share) $ 45.67 $ 41.74 $ 43.42      
Stock options exercised in period intrinsic value $ 40.2 $ 64.3 $ 117.0      
Cash received from stock option exercises $ 23.5 27.3 29.5      
ESPP            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Number of common stock authorized for issuance (in shares) 200,000       300,000  
ESPP | Maximum            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Discounted purchase price percentage of common stock authorized for issuance 85.00%          
Stock options            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Contractual term of stock options 10 years          
Unrecognized expense $ 86.2          
Stock options | Minimum            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Vesting period 3 years          
Stock options | Maximum            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Vesting period 4 years          
RSUs            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Vesting period 4 years          
Total intrinsic value vested in period $ 49.7 $ 36.1 $ 35.5      
Unrecognized expense 99.5          
PRSUs            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Unrecognized expense 17.0          
Total fair value of PRSUs vested $ 13.5          
PRSUs | Minimum            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Vesting period 4 years          
PRSUs | Maximum            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Vesting period 5 years          
2011 Plan            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Number of common stock authorized for issuance (in shares) 0         21,000,000
2020 Plan            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Number of common stock authorized for issuance (in shares) 8,200,000     3,300,000    
XML 61 R46.htm IDEA: XBRL DOCUMENT v3.20.4
Share-Based Compensation - Compensation Cost Related to Share-Based Compensation (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]      
Total share-based compensation expense $ 100.0 $ 75.3 $ 58.1
Selling, general and administrative expense      
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]      
Total share-based compensation expense 66.3 49.5 31.9
Research and development expense      
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]      
Total share-based compensation expense $ 33.7 $ 25.8 $ 26.2
XML 62 R47.htm IDEA: XBRL DOCUMENT v3.20.4
Share-Based Compensation - Schedule of Share-based Compensation Expense by Award-type (Details) - USD ($)
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]      
Total share-based compensation expense $ 100,000,000.0 $ 75,300,000 $ 58,100,000
Stock options      
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]      
Total share-based compensation expense 47,500,000 36,500,000 35,400,000
RSUs      
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]      
Total share-based compensation expense 44,200,000 30,500,000 21,900,000
PRSUs      
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]      
Total share-based compensation expense 5,300,000 5,600,000 0
ESPP      
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]      
Total share-based compensation expense $ 3,000,000.0 $ 2,700,000 $ 800,000
XML 63 R48.htm IDEA: XBRL DOCUMENT v3.20.4
Share-Based Compensation - Schedule of Share-based Compensation Expense (Details)
$ in Millions
 12 Months Ended
Dec. 31, 2020
USD ($)
Stock options  
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]  
Unrecognized Expense $ 86.2
Weighted-Average Recognition Period 2 years 3 months 18 days
RSUs  
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]  
Unrecognized Expense $ 99.5
Weighted-Average Recognition Period 2 years 3 months 18 days
XML 64 R49.htm IDEA: XBRL DOCUMENT v3.20.4
Share-Based Compensation - Weighted-Average Assumptions for Stock Option Grants using Black-Scholes Option-Pricing Model (Details) - Stock options
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Risk-free interest rate 1.40% 2.40% 2.50%
Expected volatility of common stock 48.50% 54.80% 59.50%
Dividend yield 0.00% 0.00% 0.00%
Expected option term 5 years 3 months 18 days 5 years 4 months 24 days 4 years 8 months 12 days
XML 65 R50.htm IDEA: XBRL DOCUMENT v3.20.4
Share-Based Compensation - Summary of Activity Related to Stock Options (Details)
$ / shares in Units, shares in Thousands, $ in Millions
 12 Months Ended
Dec. 31, 2020
USD ($)
$ / shares
shares
Number of Stock Options  
Beginning Balance, Outstanding (in shares) | shares 6,100
Granted (in shares) | shares 1,300
Exercised (in shares) | shares (600)
Canceled (in shares) | shares 0
Ending Balance, Outstanding (in shares) | shares 6,800
Exercisable (in shares) | shares 4,700
Weighted Average Exercise Price  
Beginning Balance, Outstanding (in USD per share) | $ / shares $ 52.62
Granted (in USD per share) | $ / shares 103.44
Exercised (in USD per share) | $ / shares 43.90
Canceled (in USD per share) | $ / shares 0
Ending Balance, Outstanding (in USD per share) | $ / shares 62.98
Exercisable (in USD per share) | $ / shares $ 49.80
Weighted-Average Remaining Contractual Life and Aggregate Intrinsic Value  
Weighted-Average Remaining Contractual Term, Outstanding 6 years 4 months 24 days
Weighted-Average Remaining Contractual Term, Exercisable 5 years 6 months
Aggregate Intrinsic Value, Outstanding | $ $ 235.4
Aggregate Intrinsic Value, Exercisable | $ $ 218.2
XML 66 R51.htm IDEA: XBRL DOCUMENT v3.20.4
Share-Based Compensation - Summary and Changes in Restricted Stock Units Outstanding (Details) - USD ($)
$ / shares in Units, $ in Millions
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
RSUs      
Number of Units      
Beginning Balance, Unvested (in shares) 1,400,000    
Granted (in shares) 700,000    
Released (in shares) (500,000)    
Canceled (in shares) (100,000)    
Ending Balance, Unvested (in shares) 1,500,000 1,400,000  
Weighted-Average Grant Date Fair Value      
Beginning Balance, Unvested (in USD per share) $ 74.77    
Granted (in USD per share) 102.92    
Released (in USD per share) 67.86    
Canceled (in USD per share) 84.95    
Ending Balance, Unvested (in USD per share) $ 89.60 $ 74.77  
Weighted-Average Remaining Contractual Life and Aggregate Intrinsic Value      
Unvested, weighted average remaining contractual term (in years) 1 year 3 months 18 days    
Unvested, aggregate intrinsic value $ 147.5    
PRSUs      
Number of Units      
Beginning Balance, Unvested (in shares) 300,000    
Granted (in shares) 200,000    
Released (in shares) (100,000) 0 0
Canceled (in shares) (200,000)    
Ending Balance, Unvested (in shares) 200,000 300,000  
Weighted-Average Grant Date Fair Value      
Beginning Balance, Unvested (in USD per share) $ 59.62    
Granted (in USD per share) 102.90    
Released (in USD per share) 82.04    
Canceled (in USD per share) 45.67    
Ending Balance, Unvested (in USD per share) $ 102.90 $ 59.62  
Weighted-Average Remaining Contractual Life and Aggregate Intrinsic Value      
Unvested, weighted average remaining contractual term (in years) 2 years 2 months 12 days    
Unvested, aggregate intrinsic value $ 15.8    
XML 67 R52.htm IDEA: XBRL DOCUMENT v3.20.4
Income Taxes - Components of Income Tax Expense for Continuing Operations (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Current:      
Federal $ 0.0 $ 0.0 $ (0.1)
State 10.1 9.5 0.8
Total current taxes 10.1 9.5 0.7
Deferred:      
Federal (287.5) 0.0 0.0
State (23.2) 0.0 0.0
Total deferred taxes (310.7) 0.0 0.0
(Benefit from) provision for income taxes $ (300.6) $ 9.5 $ 0.7
XML 68 R53.htm IDEA: XBRL DOCUMENT v3.20.4
Income Taxes - Provision for Income Taxes on Earnings Subject to Income Taxes Differs from Statutory Federal Rate (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Income Tax Disclosure [Abstract]      
Federal income taxes, rate 21.00% 21.00% 21.00%
Federal income taxes at 21% for 2020, 2019, 2018 $ 22.4 $ 9.8 $ 4.6
State income tax, net of federal benefit 5.5 4.0 0.4
Non-deductible expenses 0.6 0.8 0.4
Branded prescription drug fee 4.9 3.7 0.0
Share-based compensation expense (6.7) (12.8) (9.8)
Officer compensation 3.7 3.1 0.9
Change in tax rate 3.3 (4.1) (0.2)
Expired tax attributes 1.1 1.2 13.9
Research credits (39.0) (10.4) (13.5)
Change in valuation allowance (296.3) 13.9 4.3
Other (0.1) 0.3 (0.3)
(Benefit from) provision for income taxes $ (300.6) $ 9.5 $ 0.7
XML 69 R54.htm IDEA: XBRL DOCUMENT v3.20.4
Income Taxes - Components of Deferred Tax Assets (Details) - USD ($)
$ in Millions
Dec. 31, 2020
Dec. 31, 2019
Deferred tax assets:    
Net operating losses $ 111.4 $ 181.3
Research and development credits 109.6 71.9
Capitalized research and development 24.7 28.0
Share-based compensation expense 29.8 22.9
Operating lease assets 25.2 23.3
Intangible assets 86.7 49.3
Other 23.9 18.5
Total deferred tax assets 411.3 395.2
Deferred tax liabilities:    
Convertible senior notes (13.8) (24.1)
Operating lease liabilities (19.9) (18.2)
Other (8.4) (6.9)
Total deferred tax liabilities (42.1) (49.2)
Net of deferred tax assets and liabilities 369.2 346.0
Valuation allowance (49.8) (346.0)
Net deferred tax assets $ 319.4 $ 0.0
XML 70 R55.htm IDEA: XBRL DOCUMENT v3.20.4
Income Taxes - Additional Information (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Income Taxes [Line Items]      
Deferred tax assets, valuation allowance $ 49.8 $ 346.0  
Realizable deferred tax assets 319.4    
Deferred tax assets, net valuation release 296.3    
Research and development tax credit carry forwards 109.6 71.9  
Increase related to current year tax positions 3.9 $ 9.5 $ 11.7
Unrecognized tax benefits that would affect effective tax rate 53.9    
Federal      
Income Taxes [Line Items]      
Operating loss carry forward, net 518.2    
Research and development tax credit carry forwards 92.1    
State and local jurisdiction      
Income Taxes [Line Items]      
Operating loss carry forward, net 340.8    
Research and development tax credit carry forwards $ 56.4    
XML 71 R56.htm IDEA: XBRL DOCUMENT v3.20.4
Income Taxes - Summary of Activity Related to Unrecognized Tax Benefits (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Income Tax Disclosure [Abstract]      
Balance at January 1 $ 63.9 $ 54.8 $ 37.4
(Decrease) related to prior year tax positions (5.7)    
Increase related to prior year tax positions   0.3 6.1
Increase related to current year tax positions 3.9 9.5 11.7
Settlements related to prior year tax positions (0.2) 0.0 0.0
Expiration of the statute of limitations for the assessment of taxes (1.1) (0.7) (0.4)
Balance at December 31 $ 60.8 $ 63.9 $ 54.8
XML 72 R57.htm IDEA: XBRL DOCUMENT v3.20.4
Leases - Additional Information (Details)
$ in Millions
 12 Months Ended
Dec. 31, 2020
USD ($)
renewalOption
Dec. 31, 2019
USD ($)
Leases [Line Items]    
Number of renewal options | renewalOption 2  
Renewal term 10 years  
Restricted cash $ 3.2 $ 3.2
Cost 10.1 8.1
Payments $ 8.6 $ 7.7
Weighted average remaining term 10 years 3 months 18 days 11 years 2 months 12 days
Weighted average discount rate 5.60% 5.80%
Letter of Credit    
Leases [Line Items]    
Restricted cash $ 3.2  
XML 73 R58.htm IDEA: XBRL DOCUMENT v3.20.4
Leases - Summary of Future Minimum Lease Payments Under Operating Lease Liabilities (Details) - USD ($)
$ in Millions
Dec. 31, 2020
Dec. 31, 2019
Leases [Abstract]    
Year ending December 31, 2021 $ 10.7  
Year ending December 31, 2022 12.4  
Year ending December 31, 2023 12.7  
Year ending December 31, 2024 13.1  
Year ending December 31, 2025 13.5  
Thereafter 77.5  
Total operating lease payments 139.9  
Less accreted interest 35.2  
Total operating lease liabilities 104.7  
Less current operating lease liabilities 10.3  
Noncurrent operating lease liabilities 94.4 $ 86.7
Non-cancelable future minimum lease payments for operating leases that have not yet commenced $ 19.7  
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List] us-gaap:OtherLiabilitiesCurrent  
XML 74 R59.htm IDEA: XBRL DOCUMENT v3.20.4
Retirement Plan - Additional Information (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Retirement Benefits [Abstract]      
Defined contribution plan, maximum employee contribution percentage 60.00%    
Defined contribution plan, employer contribution amount $ 6.7 $ 4.9 $ 1.8
XML 75 R60.htm IDEA: XBRL DOCUMENT v3.20.4
Summary of Quarterly Results of Operations (Details) - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
 3 Months Ended 12 Months Ended
Dec. 31, 2020
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Quarterly Financial Information Disclosure [Abstract]                      
Total revenues $ 247.9 $ 258.5 $ 302.4 $ 237.1 $ 244.1 $ 222.1 $ 183.5 $ 138.4 $ 1,045.9 $ 788.1 $ 451.2
Total operating expenses 176.1 302.8 225.8 178.2 195.3 132.0 149.1 239.4 882.9 715.8 414.4
Net income (loss) $ 347.9 $ (57.6) $ 79.6 $ 37.4 $ 34.0 $ 53.8 $ 51.3 $ (102.1) $ 407.3 $ 37.0 $ 21.1
Net income (loss) per share, basic (in USD per share) $ 3.72 $ (0.62) $ 0.86 $ 0.40 $ 0.37 $ 0.59 $ 0.56 $ (1.12) $ 4.38 $ 0.40 $ 0.23
Net income (loss) per share, diluted (in USD per share) $ 3.58 $ (0.62) $ 0.81 $ 0.39 $ 0.35 $ 0.56 $ 0.54 $ (1.12) $ 4.16 $ 0.39 $ 0.22
Weighted average common shares outstanding, basic (in shares) 93.5 93.3 93.0 92.6 92.2 91.9 91.4 91.1 93.1 91.6 90.2
Weighted average common shares outstanding, diluted (in shares) 97.2 93.3 98.2 97.0 97.2 96.1 94.8 91.1 97.8 95.7 95.4
XML 76 R61.htm IDEA: XBRL DOCUMENT v3.20.4
Summary of Quarterly Results of Operations - Additional Information (Details) - USD ($)
$ in Millions
 3 Months Ended 12 Months Ended
Sep. 30, 2020
Jun. 30, 2020
Dec. 31, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Acquired in-process research and development           $ 164.5 $ 154.3 $ 4.8
Idorsia | Collaborative Arrangement                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Acquired in-process research and development   $ 46.0            
Takeda | Collaborative Arrangement                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Acquired in-process research and development $ 118.5              
Voyager | Collaborative Arrangement                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Acquired in-process research and development       $ 5.0 $ 113.1      
Xenon | Collaborative Arrangement                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Acquired in-process research and development     $ 36.2          
EXCEL 77 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 79 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 80 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.4 html 281 434 1 false 68 0 false 9 false false R1.htm 0001001 - Document - Cover Page Sheet http://www.neurocrine.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1001002 - Statement - Consolidated Balance Sheets Sheet http://www.neurocrine.com/role/ConsolidatedBalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 1002003 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.neurocrine.com/role/ConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 1003004 - Statement - Consolidated Statements Income and Comprehensive Income Sheet http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome Consolidated Statements Income and Comprehensive Income Statements 4 false false R5.htm 1004005 - Statement - Consolidated Statements of Stockholders' Equity Sheet http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity Consolidated Statements of Stockholders' Equity Statements 5 false false R6.htm 1005006 - Statement - Consolidated Statements of Cash Flows Sheet http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows Consolidated Statements of Cash Flows Statements 6 false false R7.htm 2101101 - Disclosure - Organization and Summary of Significant Accounting Policies Sheet http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPolicies Organization and Summary of Significant Accounting Policies Notes 7 false false R8.htm 2104102 - Disclosure - License and Collaboration Agreements Sheet http://www.neurocrine.com/role/LicenseandCollaborationAgreements License and Collaboration Agreements Notes 8 false false R9.htm 2106103 - Disclosure - Debt Securities Sheet http://www.neurocrine.com/role/DebtSecurities Debt Securities Notes 9 false false R10.htm 2111104 - Disclosure - Fair Value Measurements Sheet http://www.neurocrine.com/role/FairValueMeasurements Fair Value Measurements Notes 10 false false R11.htm 2116105 - Disclosure - Convertible Senior Notes Notes http://www.neurocrine.com/role/ConvertibleSeniorNotes Convertible Senior Notes Notes 11 false false R12.htm 2120106 - Disclosure - Other Balance Sheet Details Sheet http://www.neurocrine.com/role/OtherBalanceSheetDetails Other Balance Sheet Details Notes 12 false false R13.htm 2126107 - Disclosure - Net Income Per Share Sheet http://www.neurocrine.com/role/NetIncomePerShare Net Income Per Share Notes 13 false false R14.htm 2130108 - Disclosure - Share-Based Compensation Sheet http://www.neurocrine.com/role/ShareBasedCompensation Share-Based Compensation Notes 14 false false R15.htm 2139109 - Disclosure - Income Taxes Sheet http://www.neurocrine.com/role/IncomeTaxes Income Taxes Notes 15 false false R16.htm 2146110 - Disclosure - Leases Sheet http://www.neurocrine.com/role/Leases Leases Notes 16 false false R17.htm 2150111 - Disclosure - Retirement Plan Sheet http://www.neurocrine.com/role/RetirementPlan Retirement Plan Notes 17 false false R18.htm 2152112 - Disclosure - Selected Quarterly Financial Data (Unaudited) Sheet http://www.neurocrine.com/role/SelectedQuarterlyFinancialDataUnaudited Selected Quarterly Financial Data (Unaudited) Notes 18 false false R19.htm 2202201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies) Sheet http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies Organization and Summary of Significant Accounting Policies (Policies) Policies http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPolicies 19 false false R20.htm 2307301 - Disclosure - Debt Securities (Tables) Sheet http://www.neurocrine.com/role/DebtSecuritiesTables Debt Securities (Tables) Tables http://www.neurocrine.com/role/DebtSecurities 20 false false R21.htm 2312302 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.neurocrine.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.neurocrine.com/role/FairValueMeasurements 21 false false R22.htm 2317303 - Disclosure - Convertible Senior Notes (Tables) Notes http://www.neurocrine.com/role/ConvertibleSeniorNotesTables Convertible Senior Notes (Tables) Tables http://www.neurocrine.com/role/ConvertibleSeniorNotes 22 false false R23.htm 2321304 - Disclosure - Other Balance Sheet Details (Tables) Sheet http://www.neurocrine.com/role/OtherBalanceSheetDetailsTables Other Balance Sheet Details (Tables) Tables http://www.neurocrine.com/role/OtherBalanceSheetDetails 23 false false R24.htm 2327305 - Disclosure - Net Income Per Share (Tables) Sheet http://www.neurocrine.com/role/NetIncomePerShareTables Net Income Per Share (Tables) Tables http://www.neurocrine.com/role/NetIncomePerShare 24 false false R25.htm 2331306 - Disclosure - Share-Based Compensation (Tables) Sheet http://www.neurocrine.com/role/ShareBasedCompensationTables Share-Based Compensation (Tables) Tables http://www.neurocrine.com/role/ShareBasedCompensation 25 false false R26.htm 2340307 - Disclosure - Income Taxes (Tables) Sheet http://www.neurocrine.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://www.neurocrine.com/role/IncomeTaxes 26 false false R27.htm 2347308 - Disclosure - Leases (Table) Sheet http://www.neurocrine.com/role/LeasesTable Leases (Table) Tables http://www.neurocrine.com/role/Leases 27 false false R28.htm 2353309 - Disclosure - Selected Quarterly Financial Data (Unaudited) (Tables) Sheet http://www.neurocrine.com/role/SelectedQuarterlyFinancialDataUnauditedTables Selected Quarterly Financial Data (Unaudited) (Tables) Tables http://www.neurocrine.com/role/SelectedQuarterlyFinancialDataUnaudited 28 false false R29.htm 2403401 - Disclosure - Organization and Summary of Significant Accounting Policies - Additional Information (Details) Sheet http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails Organization and Summary of Significant Accounting Policies - Additional Information (Details) Details 29 false false R30.htm 2405402 - Disclosure - License and Collaboration Agreements - Additional Information (Details) Sheet http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails License and Collaboration Agreements - Additional Information (Details) Details 30 false false R31.htm 2408403 - Disclosure - Debt Securities - Amortized Cost, Gross Unrealized Gain (Loss) Positions and Estimated Fair Value for Available-For-Sale Debt Securities (Details) Sheet http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainLossPositionsandEstimatedFairValueforAvailableForSaleDebtSecuritiesDetails Debt Securities - Amortized Cost, Gross Unrealized Gain (Loss) Positions and Estimated Fair Value for Available-For-Sale Debt Securities (Details) Details 31 false false R32.htm 2409404 - Disclosure - Debt Securities - Gross Unrealized Losses and Fair Value Available-For-Sale Debt securities in Unrealized Loss Position (Details) Sheet http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails Debt Securities - Gross Unrealized Losses and Fair Value Available-For-Sale Debt securities in Unrealized Loss Position (Details) Details 32 false false R33.htm 2410405 - Disclosure - Debt Securities - Additional Information (Details) Sheet http://www.neurocrine.com/role/DebtSecuritiesAdditionalInformationDetails Debt Securities - Additional Information (Details) Details 33 false false R34.htm 2413406 - Disclosure - Fair Value Measurements - Assets Measured at Fair Value on Recurring Basis (Details) Sheet http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails Fair Value Measurements - Assets Measured at Fair Value on Recurring Basis (Details) Details 34 false false R35.htm 2414407 - Disclosure - Fair Value Measurements - Reconciliation of Equity Securities Measured at Fair Value on Recurring Basis (Details) Sheet http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofEquitySecuritiesMeasuredatFairValueonRecurringBasisDetails Fair Value Measurements - Reconciliation of Equity Securities Measured at Fair Value on Recurring Basis (Details) Details 35 false false R36.htm 2415408 - Disclosure - Fair Value Measurements - Additional Information (Details) Sheet http://www.neurocrine.com/role/FairValueMeasurementsAdditionalInformationDetails Fair Value Measurements - Additional Information (Details) Details 36 false false R37.htm 2418409 - Disclosure - Convertible Senior Notes - Additional Information (Details) Notes http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails Convertible Senior Notes - Additional Information (Details) Details 37 false false R38.htm 2419410 - Disclosure - Convertible Senior Notes, Net of Discounts and Deferred Financing Costs (Details) Notes http://www.neurocrine.com/role/ConvertibleSeniorNotesNetofDiscountsandDeferredFinancingCostsDetails Convertible Senior Notes, Net of Discounts and Deferred Financing Costs (Details) Details 38 false false R39.htm 2422411 - Disclosure - Other Balance Sheet Details - Inventories (Details) Sheet http://www.neurocrine.com/role/OtherBalanceSheetDetailsInventoriesDetails Other Balance Sheet Details - Inventories (Details) Details 39 false false R40.htm 2423412 - Disclosure - Other Balance Sheet Details - Property and Equipment (Details) Sheet http://www.neurocrine.com/role/OtherBalanceSheetDetailsPropertyandEquipmentDetails Other Balance Sheet Details - Property and Equipment (Details) Details 40 false false R41.htm 2424413 - Disclosure - Other Balance Sheet Details - Accounts Payable and Accrued Liabilities (Details) Sheet http://www.neurocrine.com/role/OtherBalanceSheetDetailsAccountsPayableandAccruedLiabilitiesDetails Other Balance Sheet Details - Accounts Payable and Accrued Liabilities (Details) Details 41 false false R42.htm 2425414 - Disclosure - Other Balance Sheet Details - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details) Sheet http://www.neurocrine.com/role/OtherBalanceSheetDetailsReconciliationofCashCashEquivalentsandRestrictedCashDetails Other Balance Sheet Details - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details) Details 42 false false R43.htm 2428415 - Disclosure - Net Income Per Share - Schedule of Net Income (Loss) Per Share (Details) Sheet http://www.neurocrine.com/role/NetIncomePerShareScheduleofNetIncomeLossPerShareDetails Net Income Per Share - Schedule of Net Income (Loss) Per Share (Details) Details 43 false false R44.htm 2429416 - Disclosure - Net Income Per Share - Schedule of Anti-Dilutive Shares Excluded from Diluted Per Share Amounts (Details) Sheet http://www.neurocrine.com/role/NetIncomePerShareScheduleofAntiDilutiveSharesExcludedfromDilutedPerShareAmountsDetails Net Income Per Share - Schedule of Anti-Dilutive Shares Excluded from Diluted Per Share Amounts (Details) Details 44 false false R45.htm 2432417 - Disclosure - Share-Based Compensation - Additional Information (Details) Sheet http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails Share-Based Compensation - Additional Information (Details) Details 45 false false R46.htm 2433418 - Disclosure - Share-Based Compensation - Compensation Cost Related to Share-Based Compensation (Details) Sheet http://www.neurocrine.com/role/ShareBasedCompensationCompensationCostRelatedtoShareBasedCompensationDetails Share-Based Compensation - Compensation Cost Related to Share-Based Compensation (Details) Details 46 false false R47.htm 2434419 - Disclosure - Share-Based Compensation - Schedule of Share-based Compensation Expense by Award-type (Details) Sheet http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpensebyAwardtypeDetails Share-Based Compensation - Schedule of Share-based Compensation Expense by Award-type (Details) Details 47 false false R48.htm 2435420 - Disclosure - Share-Based Compensation - Schedule of Share-based Compensation Expense (Details) Sheet http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpenseDetails Share-Based Compensation - Schedule of Share-based Compensation Expense (Details) Details 48 false false R49.htm 2436421 - Disclosure - Share-Based Compensation - Weighted-Average Assumptions for Stock Option Grants using Black-Scholes Option-Pricing Model (Details) Sheet http://www.neurocrine.com/role/ShareBasedCompensationWeightedAverageAssumptionsforStockOptionGrantsusingBlackScholesOptionPricingModelDetails Share-Based Compensation - Weighted-Average Assumptions for Stock Option Grants using Black-Scholes Option-Pricing Model (Details) Details 49 false false R50.htm 2437422 - Disclosure - Share-Based Compensation - Summary of Activity Related to Stock Options (Details) Sheet http://www.neurocrine.com/role/ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails Share-Based Compensation - Summary of Activity Related to Stock Options (Details) Details 50 false false R51.htm 2438423 - Disclosure - Share-Based Compensation - Summary and Changes in Restricted Stock Units Outstanding (Details) Sheet http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails Share-Based Compensation - Summary and Changes in Restricted Stock Units Outstanding (Details) Details 51 false false R52.htm 2441424 - Disclosure - Income Taxes - Components of Income Tax Expense for Continuing Operations (Details) Sheet http://www.neurocrine.com/role/IncomeTaxesComponentsofIncomeTaxExpenseforContinuingOperationsDetails Income Taxes - Components of Income Tax Expense for Continuing Operations (Details) Details 52 false false R53.htm 2442425 - Disclosure - Income Taxes - Provision for Income Taxes on Earnings Subject to Income Taxes Differs from Statutory Federal Rate (Details) Sheet http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails Income Taxes - Provision for Income Taxes on Earnings Subject to Income Taxes Differs from Statutory Federal Rate (Details) Details 53 false false R54.htm 2443426 - Disclosure - Income Taxes - Components of Deferred Tax Assets (Details) Sheet http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails Income Taxes - Components of Deferred Tax Assets (Details) Details 54 false false R55.htm 2444427 - Disclosure - Income Taxes - Additional Information (Details) Sheet http://www.neurocrine.com/role/IncomeTaxesAdditionalInformationDetails Income Taxes - Additional Information (Details) Details 55 false false R56.htm 2445428 - Disclosure - Income Taxes - Summary of Activity Related to Unrecognized Tax Benefits (Details) Sheet http://www.neurocrine.com/role/IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails Income Taxes - Summary of Activity Related to Unrecognized Tax Benefits (Details) Details 56 false false R57.htm 2448429 - Disclosure - Leases - Additional Information (Details) Sheet http://www.neurocrine.com/role/LeasesAdditionalInformationDetails Leases - Additional Information (Details) Details 57 false false R58.htm 2449430 - Disclosure - Leases - Summary of Future Minimum Lease Payments Under Operating Lease Liabilities (Details) Sheet http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails Leases - Summary of Future Minimum Lease Payments Under Operating Lease Liabilities (Details) Details 58 false false R59.htm 2451431 - Disclosure - Retirement Plan - Additional Information (Details) Sheet http://www.neurocrine.com/role/RetirementPlanAdditionalInformationDetails Retirement Plan - Additional Information (Details) Details 59 false false R60.htm 2454432 - Disclosure - Summary of Quarterly Results of Operations (Details) Sheet http://www.neurocrine.com/role/SummaryofQuarterlyResultsofOperationsDetails Summary of Quarterly Results of Operations (Details) Details 60 false false R61.htm 2455433 - Disclosure - Summary of Quarterly Results of Operations - Additional Information (Details) Sheet http://www.neurocrine.com/role/SummaryofQuarterlyResultsofOperationsAdditionalInformationDetails Summary of Quarterly Results of Operations - Additional Information (Details) Details 61 false false All Reports Book All Reports nbix-20201231.htm nbix-20201231.xsd nbix-20201231_cal.xml nbix-20201231_def.xml nbix-20201231_lab.xml nbix-20201231_pre.xml nbix-20201231exhibit211.htm nbix-20201231exhibit231.htm nbix-20201231exhibit311.htm nbix-20201231exhibit312.htm nbix-20201231exhibit32.htm nbix-20201231_g1.jpg nbix-20201231_g2.jpg nbix-20201231_g3.jpg http://fasb.org/us-gaap/2020-01-31 http://xbrl.sec.gov/dei/2020-01-31 http://fasb.org/srt/2020-01-31 true true JSON 83 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "nbix-20201231.htm": { "axisCustom": 1, "axisStandard": 26, "contextCount": 281, "dts": { "calculationLink": { "local": [ "nbix-20201231_cal.xml" ] }, "definitionLink": { "local": [ "nbix-20201231_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "nbix-20201231.htm" ] }, "labelLink": { "local": [ "nbix-20201231_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "nbix-20201231_pre.xml" ] }, "referenceLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml", "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "nbix-20201231.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 564, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2020-01-31": 9, "http://xbrl.sec.gov/dei/2020-01-31": 4, "total": 13 }, "keyCustom": 39, "keyStandard": 395, "memberCustom": 25, "memberStandard": 40, "nsprefix": "nbix", "nsuri": "http://www.neurocrine.com/20201231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover Page", "role": "http://www.neurocrine.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2111104 - Disclosure - Fair Value Measurements", "role": "http://www.neurocrine.com/role/FairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2116105 - Disclosure - Convertible Senior Notes", "role": "http://www.neurocrine.com/role/ConvertibleSeniorNotes", "shortName": "Convertible Senior Notes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2120106 - Disclosure - Other Balance Sheet Details", "role": "http://www.neurocrine.com/role/OtherBalanceSheetDetails", "shortName": "Other Balance Sheet Details", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2126107 - Disclosure - Net Income Per Share", "role": "http://www.neurocrine.com/role/NetIncomePerShare", "shortName": "Net Income Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2130108 - Disclosure - Share-Based Compensation", "role": "http://www.neurocrine.com/role/ShareBasedCompensation", "shortName": "Share-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2139109 - Disclosure - Income Taxes", "role": "http://www.neurocrine.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2146110 - Disclosure - Leases", "role": "http://www.neurocrine.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2150111 - Disclosure - Retirement Plan", "role": "http://www.neurocrine.com/role/RetirementPlan", "shortName": "Retirement Plan", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:QuarterlyFinancialInformationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2152112 - Disclosure - Selected Quarterly Financial Data (Unaudited)", "role": "http://www.neurocrine.com/role/SelectedQuarterlyFinancialDataUnaudited", "shortName": "Selected Quarterly Financial Data (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:QuarterlyFinancialInformationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "nbix:BusinessDescriptionPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2202201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)", "role": "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies", "shortName": "Organization and Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "nbix:BusinessDescriptionPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "i04b7ec05369244eebe79a6452649afd7_I20201231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001002 - Statement - Consolidated Balance Sheets", "role": "http://www.neurocrine.com/role/ConsolidatedBalanceSheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "i04b7ec05369244eebe79a6452649afd7_I20201231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:MarketableSecuritiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2307301 - Disclosure - Debt Securities (Tables)", "role": "http://www.neurocrine.com/role/DebtSecuritiesTables", "shortName": "Debt Securities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2312302 - Disclosure - Fair Value Measurements (Tables)", "role": "http://www.neurocrine.com/role/FairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2317303 - Disclosure - Convertible Senior Notes (Tables)", "role": "http://www.neurocrine.com/role/ConvertibleSeniorNotesTables", "shortName": "Convertible Senior Notes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2321304 - Disclosure - Other Balance Sheet Details (Tables)", "role": "http://www.neurocrine.com/role/OtherBalanceSheetDetailsTables", "shortName": "Other Balance Sheet Details (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2327305 - Disclosure - Net Income Per Share (Tables)", "role": "http://www.neurocrine.com/role/NetIncomePerShareTables", "shortName": "Net Income Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2331306 - Disclosure - Share-Based Compensation (Tables)", "role": "http://www.neurocrine.com/role/ShareBasedCompensationTables", "shortName": "Share-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2340307 - Disclosure - Income Taxes (Tables)", "role": "http://www.neurocrine.com/role/IncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2347308 - Disclosure - Leases (Table)", "role": "http://www.neurocrine.com/role/LeasesTable", "shortName": "Leases (Table)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2353309 - Disclosure - Selected Quarterly Financial Data (Unaudited) (Tables)", "role": "http://www.neurocrine.com/role/SelectedQuarterlyFinancialDataUnauditedTables", "shortName": "Selected Quarterly Financial Data (Unaudited) (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "div", "nbix:BusinessDescriptionPolicyPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "nbix:NumberOfIrishSubsidiaries", "reportCount": 1, "unique": true, "unitRef": "subsidiary", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403401 - Disclosure - Organization and Summary of Significant Accounting Policies - Additional Information (Details)", "role": "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails", "shortName": "Organization and Summary of Significant Accounting Policies - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "nbix:BusinessDescriptionPolicyPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "nbix:NumberOfIrishSubsidiaries", "reportCount": 1, "unique": true, "unitRef": "subsidiary", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "i04b7ec05369244eebe79a6452649afd7_I20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002003 - Statement - Consolidated Balance Sheets (Parenthetical)", "role": "http://www.neurocrine.com/role/ConsolidatedBalanceSheetsParenthetical", "shortName": "Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "i04b7ec05369244eebe79a6452649afd7_I20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "i04b7ec05369244eebe79a6452649afd7_I20201231", "decimals": "-8", "first": true, "lang": "en-US", "name": "nbix:PotentialMilestonePayments", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405402 - Disclosure - License and Collaboration Agreements - Additional Information (Details)", "role": "http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails", "shortName": "License and Collaboration Agreements - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "i257e90a486974747899becd428e20bbc_I20200731", "decimals": "-5", "lang": "en-US", "name": "nbix:UpfrontPaymentsMade", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "idce3e91b366c406685df930cadf32f38_I20201231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408403 - Disclosure - Debt Securities - Amortized Cost, Gross Unrealized Gain (Loss) Positions and Estimated Fair Value for Available-For-Sale Debt Securities (Details)", "role": "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainLossPositionsandEstimatedFairValueforAvailableForSaleDebtSecuritiesDetails", "shortName": "Debt Securities - Amortized Cost, Gross Unrealized Gain (Loss) Positions and Estimated Fair Value for Available-For-Sale Debt Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "idce3e91b366c406685df930cadf32f38_I20201231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "i37972e19ce3448d8addd2bec549432ab_I20201231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409404 - Disclosure - Debt Securities - Gross Unrealized Losses and Fair Value Available-For-Sale Debt securities in Unrealized Loss Position (Details)", "role": "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails", "shortName": "Debt Securities - Gross Unrealized Losses and Fair Value Available-For-Sale Debt securities in Unrealized Loss Position (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "i37972e19ce3448d8addd2bec549432ab_I20201231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "i04b7ec05369244eebe79a6452649afd7_I20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "nbix:DebtSecuritiesAvailableForSalePositionNumberOfPositions", "reportCount": 1, "unique": true, "unitRef": "security", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410405 - Disclosure - Debt Securities - Additional Information (Details)", "role": "http://www.neurocrine.com/role/DebtSecuritiesAdditionalInformationDetails", "shortName": "Debt Securities - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "i04b7ec05369244eebe79a6452649afd7_I20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "nbix:DebtSecuritiesAvailableForSalePositionNumberOfPositions", "reportCount": 1, "unique": true, "unitRef": "security", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "ix:continuation", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "iad7d8c26c43040ac8423eb140604d3d1_I20201231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:Investments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413406 - Disclosure - Fair Value Measurements - Assets Measured at Fair Value on Recurring Basis (Details)", "role": "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails", "shortName": "Fair Value Measurements - Assets Measured at Fair Value on Recurring Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "ix:continuation", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "iad7d8c26c43040ac8423eb140604d3d1_I20201231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:Investments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "ie7ce5f1bbc51478e98b231f0247f59bf_I20191231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:EquitySecuritiesFvNiRestricted", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414407 - Disclosure - Fair Value Measurements - Reconciliation of Equity Securities Measured at Fair Value on Recurring Basis (Details)", "role": "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofEquitySecuritiesMeasuredatFairValueonRecurringBasisDetails", "shortName": "Fair Value Measurements - Reconciliation of Equity Securities Measured at Fair Value on Recurring Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "i05c117b96dea48f4ac63a4022bae19d6_I20171231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:EquitySecuritiesFvNiRestricted", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "i83c603ce0ef14a36b7c219ff93558f30_I20201231", "decimals": "3", "first": true, "lang": "en-US", "name": "us-gaap:EquitySecuritiesFvNiMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415408 - Disclosure - Fair Value Measurements - Additional Information (Details)", "role": "http://www.neurocrine.com/role/FairValueMeasurementsAdditionalInformationDetails", "shortName": "Fair Value Measurements - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "i83c603ce0ef14a36b7c219ff93558f30_I20201231", "decimals": "3", "first": true, "lang": "en-US", "name": "us-gaap:EquitySecuritiesFvNiMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "i04b7ec05369244eebe79a6452649afd7_I20201231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418409 - Disclosure - Convertible Senior Notes - Additional Information (Details)", "role": "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails", "shortName": "Convertible Senior Notes - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "i4275d4edccb744bf87c8dce992b293b1_I20170502", "decimals": "-5", "lang": "en-US", "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "i04b7ec05369244eebe79a6452649afd7_I20201231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419410 - Disclosure - Convertible Senior Notes, Net of Discounts and Deferred Financing Costs (Details)", "role": "http://www.neurocrine.com/role/ConvertibleSeniorNotesNetofDiscountsandDeferredFinancingCostsDetails", "shortName": "Convertible Senior Notes, Net of Discounts and Deferred Financing Costs (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "i04b7ec05369244eebe79a6452649afd7_I20201231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:DeferredFinanceCostsNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "i04b7ec05369244eebe79a6452649afd7_I20201231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2422411 - Disclosure - Other Balance Sheet Details - Inventories (Details)", "role": "http://www.neurocrine.com/role/OtherBalanceSheetDetailsInventoriesDetails", "shortName": "Other Balance Sheet Details - Inventories (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "i04b7ec05369244eebe79a6452649afd7_I20201231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003004 - Statement - Consolidated Statements Income and Comprehensive Income", "role": "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome", "shortName": "Consolidated Statements Income and Comprehensive Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231", "decimals": "-5", "lang": "en-US", "name": "nbix:CostOfSales", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "i04b7ec05369244eebe79a6452649afd7_I20201231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2423412 - Disclosure - Other Balance Sheet Details - Property and Equipment (Details)", "role": "http://www.neurocrine.com/role/OtherBalanceSheetDetailsPropertyandEquipmentDetails", "shortName": "Other Balance Sheet Details - Property and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "i04b7ec05369244eebe79a6452649afd7_I20201231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "i04b7ec05369244eebe79a6452649afd7_I20201231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2424413 - Disclosure - Other Balance Sheet Details - Accounts Payable and Accrued Liabilities (Details)", "role": "http://www.neurocrine.com/role/OtherBalanceSheetDetailsAccountsPayableandAccruedLiabilitiesDetails", "shortName": "Other Balance Sheet Details - Accounts Payable and Accrued Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "i04b7ec05369244eebe79a6452649afd7_I20201231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "i04b7ec05369244eebe79a6452649afd7_I20201231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2425414 - Disclosure - Other Balance Sheet Details - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)", "role": "http://www.neurocrine.com/role/OtherBalanceSheetDetailsReconciliationofCashCashEquivalentsandRestrictedCashDetails", "shortName": "Other Balance Sheet Details - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "nbix:SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "i04b7ec05369244eebe79a6452649afd7_I20201231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:RestrictedCashAndCashEquivalents", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "ie215d2c9f17d4c709f20026fb2fad01e_D20201001-20201231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2428415 - Disclosure - Net Income Per Share - Schedule of Net Income (Loss) Per Share (Details)", "role": "http://www.neurocrine.com/role/NetIncomePerShareScheduleofNetIncomeLossPerShareDetails", "shortName": "Net Income Per Share - Schedule of Net Income (Loss) Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "ib9f0bb09b01845ce9c7ec4ef22aa86a7_D20200101-20201231", "decimals": "-5", "lang": "en-US", "name": "nbix:IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "id1037f7d26e440b1a850a872e881c1ff_D20200101-20201231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2429416 - Disclosure - Net Income Per Share - Schedule of Anti-Dilutive Shares Excluded from Diluted Per Share Amounts (Details)", "role": "http://www.neurocrine.com/role/NetIncomePerShareScheduleofAntiDilutiveSharesExcludedfromDilutedPerShareAmountsDetails", "shortName": "Net Income Per Share - Schedule of Anti-Dilutive Shares Excluded from Diluted Per Share Amounts (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "id1037f7d26e440b1a850a872e881c1ff_D20200101-20201231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2432417 - Disclosure - Share-Based Compensation - Additional Information (Details)", "role": "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails", "shortName": "Share-Based Compensation - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2433418 - Disclosure - Share-Based Compensation - Compensation Cost Related to Share-Based Compensation (Details)", "role": "http://www.neurocrine.com/role/ShareBasedCompensationCompensationCostRelatedtoShareBasedCompensationDetails", "shortName": "Share-Based Compensation - Compensation Cost Related to Share-Based Compensation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "i965516f5121d4176b5ae292b90be804a_D20200101-20201231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2434419 - Disclosure - Share-Based Compensation - Schedule of Share-based Compensation Expense by Award-type (Details)", "role": "http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpensebyAwardtypeDetails", "shortName": "Share-Based Compensation - Schedule of Share-based Compensation Expense by Award-type (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "ib20438b56ac9433bb1bffb44583e9870_D20200101-20201231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "ibdaaf1063b5640c096eab926298a36b4_I20201231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2435420 - Disclosure - Share-Based Compensation - Schedule of Share-based Compensation Expense (Details)", "role": "http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpenseDetails", "shortName": "Share-Based Compensation - Schedule of Share-based Compensation Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "ib20438b56ac9433bb1bffb44583e9870_D20200101-20201231", "decimals": null, "lang": "en-US", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "ib20438b56ac9433bb1bffb44583e9870_D20200101-20201231", "decimals": "3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2436421 - Disclosure - Share-Based Compensation - Weighted-Average Assumptions for Stock Option Grants using Black-Scholes Option-Pricing Model (Details)", "role": "http://www.neurocrine.com/role/ShareBasedCompensationWeightedAverageAssumptionsforStockOptionGrantsusingBlackScholesOptionPricingModelDetails", "shortName": "Share-Based Compensation - Weighted-Average Assumptions for Stock Option Grants using Black-Scholes Option-Pricing Model (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "ib20438b56ac9433bb1bffb44583e9870_D20200101-20201231", "decimals": "3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "i3a23b0e35de74dc0b44113bd6d8a068e_I20171231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004005 - Statement - Consolidated Statements of Stockholders' Equity", "role": "http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity", "shortName": "Consolidated Statements of Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "i3a23b0e35de74dc0b44113bd6d8a068e_I20171231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "ie7ce5f1bbc51478e98b231f0247f59bf_I20191231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2437422 - Disclosure - Share-Based Compensation - Summary of Activity Related to Stock Options (Details)", "role": "http://www.neurocrine.com/role/ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails", "shortName": "Share-Based Compensation - Summary of Activity Related to Stock Options (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "ie7ce5f1bbc51478e98b231f0247f59bf_I20191231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "i9b9010f4078c43eb99d30b01f597843b_I20191231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2438423 - Disclosure - Share-Based Compensation - Summary and Changes in Restricted Stock Units Outstanding (Details)", "role": "http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails", "shortName": "Share-Based Compensation - Summary and Changes in Restricted Stock Units Outstanding (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "id346ae866f214a02b30d9c12a084f7ef_D20200101-20201231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2441424 - Disclosure - Income Taxes - Components of Income Tax Expense for Continuing Operations (Details)", "role": "http://www.neurocrine.com/role/IncomeTaxesComponentsofIncomeTaxExpenseforContinuingOperationsDetails", "shortName": "Income Taxes - Components of Income Tax Expense for Continuing Operations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2442425 - Disclosure - Income Taxes - Provision for Income Taxes on Earnings Subject to Income Taxes Differs from Statutory Federal Rate (Details)", "role": "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails", "shortName": "Income Taxes - Provision for Income Taxes on Earnings Subject to Income Taxes Differs from Statutory Federal Rate (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "i04b7ec05369244eebe79a6452649afd7_I20201231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2443426 - Disclosure - Income Taxes - Components of Deferred Tax Assets (Details)", "role": "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails", "shortName": "Income Taxes - Components of Deferred Tax Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "i04b7ec05369244eebe79a6452649afd7_I20201231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "i04b7ec05369244eebe79a6452649afd7_I20201231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DeferredTaxAssetsValuationAllowance", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2444427 - Disclosure - Income Taxes - Additional Information (Details)", "role": "http://www.neurocrine.com/role/IncomeTaxesAdditionalInformationDetails", "shortName": "Income Taxes - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "i04b7ec05369244eebe79a6452649afd7_I20201231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:DeferredTaxAssetsNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "ie7ce5f1bbc51478e98b231f0247f59bf_I20191231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2445428 - Disclosure - Income Taxes - Summary of Activity Related to Unrecognized Tax Benefits (Details)", "role": "http://www.neurocrine.com/role/IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails", "shortName": "Income Taxes - Summary of Activity Related to Unrecognized Tax Benefits (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "ie84e64d4ffbf45999357185cd064c9c1_I20171231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "i04b7ec05369244eebe79a6452649afd7_I20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "nbix:NumberOfRenewalOptions", "reportCount": 1, "unique": true, "unitRef": "renewaloption", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2448429 - Disclosure - Leases - Additional Information (Details)", "role": "http://www.neurocrine.com/role/LeasesAdditionalInformationDetails", "shortName": "Leases - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "i04b7ec05369244eebe79a6452649afd7_I20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "nbix:NumberOfRenewalOptions", "reportCount": 1, "unique": true, "unitRef": "renewaloption", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "i04b7ec05369244eebe79a6452649afd7_I20201231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2449430 - Disclosure - Leases - Summary of Future Minimum Lease Payments Under Operating Lease Liabilities (Details)", "role": "http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails", "shortName": "Leases - Summary of Future Minimum Lease Payments Under Operating Lease Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "i04b7ec05369244eebe79a6452649afd7_I20201231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2451431 - Disclosure - Retirement Plan - Additional Information (Details)", "role": "http://www.neurocrine.com/role/RetirementPlanAdditionalInformationDetails", "shortName": "Retirement Plan - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005006 - Statement - Consolidated Statements of Cash Flows", "role": "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "ie215d2c9f17d4c709f20026fb2fad01e_D20201001-20201231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2454432 - Disclosure - Summary of Quarterly Results of Operations (Details)", "role": "http://www.neurocrine.com/role/SummaryofQuarterlyResultsofOperationsDetails", "shortName": "Summary of Quarterly Results of Operations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "ie215d2c9f17d4c709f20026fb2fad01e_D20201001-20201231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:OperatingExpenses", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2455433 - Disclosure - Summary of Quarterly Results of Operations - Additional Information (Details)", "role": "http://www.neurocrine.com/role/SummaryofQuarterlyResultsofOperationsAdditionalInformationDetails", "shortName": "Summary of Quarterly Results of Operations - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R7": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101101 - Disclosure - Organization and Summary of Significant Accounting Policies", "role": "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPolicies", "shortName": "Organization and Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2104102 - Disclosure - License and Collaboration Agreements", "role": "http://www.neurocrine.com/role/LicenseandCollaborationAgreements", "shortName": "License and Collaboration Agreements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2106103 - Disclosure - Debt Securities", "role": "http://www.neurocrine.com/role/DebtSecurities", "shortName": "Debt Securities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nbix-20201231.htm", "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 68, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r604", "r605", "r606" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report", "terseLabel": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r607" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r602" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]", "terseLabel": "Documents Incorporated by Reference" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/CoverPage" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r608" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "verboseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r608" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r608" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r609" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float", "terseLabel": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/CoverPage" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r608" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r608" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r608" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r608" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer", "terseLabel": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r604", "r605", "r606" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag", "terseLabel": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r601" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r603" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "nbix_A2020EquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2020 Equity Incentive Plan", "label": "2020 Equity Incentive Plan [Member]", "terseLabel": "2020 Plan" } } }, "localname": "A2020EquityIncentivePlanMember", "nsuri": "http://www.neurocrine.com/20201231", "presentation": [ "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "nbix_A225ConvertibleSeniorNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2.25% Convertible Senior Notes.", "label": "2.25% Convertible Senior Notes [Member]", "terseLabel": "2.25% Convertible Senior Notes" } } }, "localname": "A225ConvertibleSeniorNotesMember", "nsuri": "http://www.neurocrine.com/20201231", "presentation": [ "http://www.neurocrine.com/role/NetIncomePerShareScheduleofNetIncomeLossPerShareDetails" ], "xbrltype": "domainItemType" }, "nbix_AbbvieIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information related to AbbVie Inc., an entity with which Neurocrine has a collaboration agreement.", "label": "Abbvie Inc [Member]", "terseLabel": "AbbVie" } } }, "localname": "AbbvieIncMember", "nsuri": "http://www.neurocrine.com/20201231", "presentation": [ "http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "nbix_AccruedBrandedPrescriptionDrugFee": { "auth_ref": [], "calculation": { "http://www.neurocrine.com/role/OtherBalanceSheetDetailsAccountsPayableandAccruedLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued Branded Prescription Drug Fee", "label": "Accrued Branded Prescription Drug Fee", "terseLabel": "Accrued Branded Prescription Drug Fee" } } }, "localname": "AccruedBrandedPrescriptionDrugFee", "nsuri": "http://www.neurocrine.com/20201231", "presentation": [ "http://www.neurocrine.com/role/OtherBalanceSheetDetailsAccountsPayableandAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "nbix_AccruedResearchAndDevelopmentExpenseCurrent": { "auth_ref": [], "calculation": { "http://www.neurocrine.com/role/OtherBalanceSheetDetailsAccountsPayableandAccruedLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued research and development expense current.", "label": "Accrued Research And Development Expense Current", "terseLabel": "Accrued development costs" } } }, "localname": "AccruedResearchAndDevelopmentExpenseCurrent", "nsuri": "http://www.neurocrine.com/20201231", "presentation": [ "http://www.neurocrine.com/role/OtherBalanceSheetDetailsAccountsPayableandAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "nbix_BIALMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information related to BIAL, an entity with which Neurocrine has a license agreement.", "label": "B I A L [Member]", "terseLabel": "B I A L" } } }, "localname": "BIALMember", "nsuri": "http://www.neurocrine.com/20201231", "presentation": [ "http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "nbix_BusinessDescriptionPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business Description Policy [Text Block]", "label": "Business Description Policy [Policy Text Block]", "terseLabel": "Business Activities" } } }, "localname": "BusinessDescriptionPolicyPolicyTextBlock", "nsuri": "http://www.neurocrine.com/20201231", "presentation": [ "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "nbix_CarryingAmountOfLiabilityComponentAtSettlement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount of the liability component at settlement.", "label": "Carrying Amount Of Liability Component At Settlement", "terseLabel": "Carrying amount of the liability component at settlement" } } }, "localname": "CarryingAmountOfLiabilityComponentAtSettlement", "nsuri": "http://www.neurocrine.com/20201231", "presentation": [ "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "nbix_CarryingAmountOfLiabilityComponentUponIssuance": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying amount of the liability component upon issuance.", "label": "Carrying Amount Of Liability Component Upon Issuance", "terseLabel": "Carrying amount of the liability component upon issuance" } } }, "localname": "CarryingAmountOfLiabilityComponentUponIssuance", "nsuri": "http://www.neurocrine.com/20201231", "presentation": [ "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "nbix_CashAndMoneyMarketFundMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Currency on hand as well as demand deposits with banks or financial institutions, and funds that invest in short-term money-market instruments, for example, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Cash And Money Market Fund [Member]", "terseLabel": "Cash and money market funds" } } }, "localname": "CashAndMoneyMarketFundMember", "nsuri": "http://www.neurocrine.com/20201231", "presentation": [ "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "nbix_CollaborationRevenueMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaboration revenue.", "label": "Collaboration Revenue [Member]", "terseLabel": "Collaboration revenue" } } }, "localname": "CollaborationRevenueMember", "nsuri": "http://www.neurocrine.com/20201231", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome" ], "xbrltype": "domainItemType" }, "nbix_ConversionPeriodOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Conversion Period One", "label": "Conversion Period One [Member]", "terseLabel": "Conversion Period One" } } }, "localname": "ConversionPeriodOneMember", "nsuri": "http://www.neurocrine.com/20201231", "presentation": [ "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "nbix_ConversionPeriodTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Conversion Period Two", "label": "Conversion Period Two [Member]", "terseLabel": "Conversion Period Two" } } }, "localname": "ConversionPeriodTwoMember", "nsuri": "http://www.neurocrine.com/20201231", "presentation": [ "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "nbix_CostOfSales": { "auth_ref": [], "calculation": { "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of costs relating to expenses directly or indirectly attributed to the goods or services sold, which may include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, unallocated production overheads and abnormal amounts of production costs of inventories.", "label": "Cost Of Sales", "terseLabel": "Cost of sales" } } }, "localname": "CostOfSales", "nsuri": "http://www.neurocrine.com/20201231", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "nbix_DebtConversionObservationPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The duration of time during which the weighted-average share price is used to calculate the excess conversion value due upon conversion of a convertible note, in the format of PnYnMnD.", "label": "Debt Conversion Observation Period", "terseLabel": "Conversion observation period" } } }, "localname": "DebtConversionObservationPeriod", "nsuri": "http://www.neurocrine.com/20201231", "presentation": [ "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "nbix_DebtInstrumentConversionAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Conversion", "label": "Debt Instrument, Conversion [Axis]", "terseLabel": "Debt Instrument, Conversion [Axis]" } } }, "localname": "DebtInstrumentConversionAxis", "nsuri": "http://www.neurocrine.com/20201231", "presentation": [ "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "nbix_DebtInstrumentConversionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Conversion", "label": "Debt Instrument, Conversion [Domain]", "terseLabel": "Debt Instrument, Conversion [Domain]" } } }, "localname": "DebtInstrumentConversionDomain", "nsuri": "http://www.neurocrine.com/20201231", "presentation": [ "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "nbix_DebtInstrumentConvertibleConversionPremium": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The percentage of excess of the price paid for the convertible note over the closing stock price on the closing date of the convertible note.", "label": "Debt Instrument Convertible Conversion Premium", "terseLabel": "Conversion premium" } } }, "localname": "DebtInstrumentConvertibleConversionPremium", "nsuri": "http://www.neurocrine.com/20201231", "presentation": [ "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt securities available for sale position number of positions.", "label": "Debt Securities Available For Sale Position Number Of Positions", "terseLabel": "Debt securities available for sale position number of positions" } } }, "localname": "DebtSecuritiesAvailableForSalePositionNumberOfPositions", "nsuri": "http://www.neurocrine.com/20201231", "presentation": [ "http://www.neurocrine.com/role/DebtSecuritiesAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "nbix_DeferredTaxAssetsCapitalizedResearchAndDevelopment": { "auth_ref": [], "calculation": { "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails": { "order": 7.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from research and development costs capitalized.", "label": "Deferred Tax Assets Capitalized Research And Development", "terseLabel": "Capitalized research and development" } } }, "localname": "DeferredTaxAssetsCapitalizedResearchAndDevelopment", "nsuri": "http://www.neurocrine.com/20201231", "presentation": [ "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "nbix_DeferredTaxAssetsLiabilitiesGross": { "auth_ref": [], "calculation": { "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred tax assts (liabilities) gross.", "label": "Deferred Tax Assets Liabilities Gross", "totalLabel": "Net of deferred tax assets and liabilities" } } }, "localname": "DeferredTaxAssetsLiabilitiesGross", "nsuri": "http://www.neurocrine.com/20201231", "presentation": [ "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "nbix_DeferredTaxAssetsOperatingLeasesAssets": { "auth_ref": [], "calculation": { "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred tax assets operating leases assets.", "label": "Deferred Tax Assets Operating Leases Assets", "terseLabel": "Operating lease assets" } } }, "localname": "DeferredTaxAssetsOperatingLeasesAssets", "nsuri": "http://www.neurocrine.com/20201231", "presentation": [ "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "nbix_DeferredTaxLiabilitiesConvertibleSeniorNotes": { "auth_ref": [], "calculation": { "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred tax liabilities convertible senior notes.", "label": "Deferred Tax Liabilities Convertible Senior Notes", "negatedTerseLabel": "Convertible senior notes" } } }, "localname": "DeferredTaxLiabilitiesConvertibleSeniorNotes", "nsuri": "http://www.neurocrine.com/20201231", "presentation": [ "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "nbix_DeferredTaxLiabilitiesOperatingLeasesLiabilities": { "auth_ref": [], "calculation": { "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred tax liabilities operating leases liabilities.", "label": "Deferred Tax Liabilities Operating Leases Liabilities", "negatedTerseLabel": "Operating lease liabilities" } } }, "localname": "DeferredTaxLiabilitiesOperatingLeasesLiabilities", "nsuri": "http://www.neurocrine.com/20201231", "presentation": [ "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "nbix_DevelopmentProductCandidatesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Development Product Candidates", "label": "Development Product Candidates [Member]", "terseLabel": "Development Product Candidates" } } }, "localname": "DevelopmentProductCandidatesMember", "nsuri": "http://www.neurocrine.com/20201231", "presentation": [ "http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "nbix_EventsOfDefaultPercentageOfPrincipalAndAccruedAndUnpaidInterestDueAndPayableUponDefault": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Events of default percentage of principal and accrued and unpaid interest due and payable upon default.", "label": "Events Of Default Percentage Of Principal And Accrued And Unpaid Interest Due And Payable Upon Default", "terseLabel": "Events of default percentage of principal and accrued and unpaid interest due and payable upon default" } } }, "localname": "EventsOfDefaultPercentageOfPrincipalAndAccruedAndUnpaidInterestDueAndPayableUponDefault", "nsuri": "http://www.neurocrine.com/20201231", "presentation": [ "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "nbix_FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of the liability component immediately before extinguishment.", "label": "Fair Value Of Liability Component Immediately Before Extinguishment", "terseLabel": "Fair value of the liability component immediately before extinguishment" } } }, "localname": "FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment", "nsuri": "http://www.neurocrine.com/20201231", "presentation": [ "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "nbix_IdorsiaPharmaceuticalsLtdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Idorsia Pharmaceuticals Ltd", "label": "Idorsia Pharmaceuticals Ltd [Member]", "terseLabel": "Idorsia" } } }, "localname": "IdorsiaPharmaceuticalsLtdMember", "nsuri": "http://www.neurocrine.com/20201231", "presentation": [ "http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails", "http://www.neurocrine.com/role/SummaryofQuarterlyResultsofOperationsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "nbix_IncomeTaxReconciliationExpirationOfTaxCredits": { "auth_ref": [], "calculation": { "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails": { "order": 8.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Income tax reconciliation, expiration of tax credits.", "label": "Income Tax Reconciliation Expiration Of Tax Credits", "terseLabel": "Expired tax attributes" } } }, "localname": "IncomeTaxReconciliationExpirationOfTaxCredits", "nsuri": "http://www.neurocrine.com/20201231", "presentation": [ "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails" ], "xbrltype": "monetaryItemType" }, "nbix_IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee": { "auth_ref": [], "calculation": { "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails": { "order": 4.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Income tax reconciliation nondeductible expense branded prescription drug fee.", "label": "Income Tax Reconciliation Nondeductible Expense Branded Prescription Drug Fee", "terseLabel": "Branded prescription drug fee" } } }, "localname": "IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee", "nsuri": "http://www.neurocrine.com/20201231", "presentation": [ "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails" ], "xbrltype": "monetaryItemType" }, "nbix_IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost": { "auth_ref": [], "calculation": { "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails": { "order": 6.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Income tax reconciliation nondeductible expense officer compensation cost.", "label": "Income Tax Reconciliation Nondeductible Expense Officer Compensation Cost", "terseLabel": "Officer compensation" } } }, "localname": "IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost", "nsuri": "http://www.neurocrine.com/20201231", "presentation": [ "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails" ], "xbrltype": "monetaryItemType" }, "nbix_IncomeTaxesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Income Taxes [Line Items]", "label": "Income Taxes [Line Items]", "terseLabel": "Income Taxes [Line Items]" } } }, "localname": "IncomeTaxesLineItems", "nsuri": "http://www.neurocrine.com/20201231", "presentation": [ "http://www.neurocrine.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "nbix_IncomeTaxesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Income Taxes [Table]", "label": "Income Taxes [Table]", "terseLabel": "Income Taxes [Table]" } } }, "localname": "IncomeTaxesTable", "nsuri": "http://www.neurocrine.com/20201231", "presentation": [ "http://www.neurocrine.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities": { "auth_ref": [], "calculation": { "http://www.neurocrine.com/role/NetIncomePerShareScheduleofNetIncomeLossPerShareDetails": { "order": 3.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the treasury stock method.", "label": "Incremental Common Shares Attributable To Dilutive Effect Of Conversion Of Debt Securities", "terseLabel": "2024 Notes (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities", "nsuri": "http://www.neurocrine.com/20201231", "presentation": [ "http://www.neurocrine.com/role/NetIncomePerShareScheduleofNetIncomeLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "nbix_InvestmentIncomeAndOtherNet": { "auth_ref": [], "calculation": { "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome": { "order": 4.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Investment income and other net.", "label": "Investment Income And Other Net", "terseLabel": "Investment income and other, net" } } }, "localname": "InvestmentIncomeAndOtherNet", "nsuri": "http://www.neurocrine.com/20201231", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "nbix_LargestThreeCustomersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Largest Three Customers", "label": "Largest Three Customers [Member]", "terseLabel": "Largest three customers" } } }, "localname": "LargestThreeCustomersMember", "nsuri": "http://www.neurocrine.com/20201231", "presentation": [ "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "nbix_LargestTwoCustomersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Largest Two Customers", "label": "Largest Two Customers [Member]", "terseLabel": "Largest two customers" } } }, "localname": "LargestTwoCustomersMember", "nsuri": "http://www.neurocrine.com/20201231", "presentation": [ "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "nbix_LongTermInvestmentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Investments which are intended be sold or mature more than one year from the balance sheet date or operating cycle, if longer.", "label": "Long Term Investments [Member]", "terseLabel": "Long-term investments" } } }, "localname": "LongTermInvestmentsMember", "nsuri": "http://www.neurocrine.com/20201231", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainLossPositionsandEstimatedFairValueforAvailableForSaleDebtSecuritiesDetails" ], "xbrltype": "domainItemType" }, "nbix_MilestonePayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments made for milestones under a collaboration agreement.", "label": "Milestone Payment", "terseLabel": "Milestone payments" } } }, "localname": "MilestonePayment", "nsuri": "http://www.neurocrine.com/20201231", "presentation": [ "http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The minimum percentage of the product of the common stock trading price multiplied by the conversion rate during the measurement period as compared to the principal note amount that triggers a conversion option on the notes, if it falls below this percentage.", "label": "Minimum Percentage Of Trading Price To Last Reported Sale Price", "terseLabel": "Minimum percentage of common stock price trigger" } } }, "localname": "MinimumPercentageOfTradingPriceToLastReportedSalePrice", "nsuri": "http://www.neurocrine.com/20201231", "presentation": [ "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "nbix_MitsubishiTanabePharmaCorporationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information related to the Mitsubishi Tanabe Pharma Corporation.", "label": "Mitsubishi Tanabe Pharma Corporation [Member]", "terseLabel": "Mitsubishi Tanabe" } } }, "localname": "MitsubishiTanabePharmaCorporationMember", "nsuri": "http://www.neurocrine.com/20201231", "presentation": [ "http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "nbix_NBI827104Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "NBI-827104", "label": "NBI-827104 [Member]", "terseLabel": "NBI-827104" } } }, "localname": "NBI827104Member", "nsuri": "http://www.neurocrine.com/20201231", "presentation": [ "http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommenced": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Non cancelable future minimum lease payments for operating leases not yet commenced.", "label": "Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced", "terseLabel": "Non-cancelable future minimum lease payments for operating leases that have not yet commenced" } } }, "localname": "NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommenced", "nsuri": "http://www.neurocrine.com/20201231", "presentation": [ "http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "nbix_NumberOfIrishSubsidiaries": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Irish Subsidiaries", "label": "Number Of Irish Subsidiaries", "terseLabel": "Number of wholly owned Irish subsidiaries" } } }, "localname": "NumberOfIrishSubsidiaries", "nsuri": "http://www.neurocrine.com/20201231", "presentation": [ "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "nbix_NumberOfRenewalOptions": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of renewal options under the terms of the lease.", "label": "Number Of Renewal Options", "terseLabel": "Number of renewal options" } } }, "localname": "NumberOfRenewalOptions", "nsuri": "http://www.neurocrine.com/20201231", "presentation": [ "http://www.neurocrine.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Organization and summary of significant accounting policies.", "label": "Organization And Summary Of Significant Accounting Policies [Line Items]", "terseLabel": "Organization And Summary Of Significant Accounting Policies [Line Items]" } } }, "localname": "OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems", "nsuri": "http://www.neurocrine.com/20201231", "presentation": [ "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Organization And Summary Of Significant Accounting Policies [Table]", "label": "Organization And Summary Of Significant Accounting Policies [Table]", "terseLabel": "Organization And Summary Of Significant Accounting Policies [Table]" } } }, "localname": "OrganizationAndSummaryOfSignificantAccountingPoliciesTable", "nsuri": "http://www.neurocrine.com/20201231", "presentation": [ "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "nbix_OtherBalanceSheetDetailsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other balance sheet details.", "label": "Other Balance Sheet Details [Abstract]", "terseLabel": "Other Balance Sheet Details [Abstract]" } } }, "localname": "OtherBalanceSheetDetailsAbstract", "nsuri": "http://www.neurocrine.com/20201231", "xbrltype": "stringItemType" }, "nbix_PatentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Term of the patent, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Patent term", "terseLabel": "Patent term" } } }, "localname": "PatentTerm", "nsuri": "http://www.neurocrine.com/20201231", "presentation": [ "http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "nbix_PerformanceBasedRestrictedStockUnitMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted stock units which are awarded to employees after certain performance targets are met.", "label": "Performance Based Restricted Stock Unit [Member]", "terseLabel": "PRSUs" } } }, "localname": "PerformanceBasedRestrictedStockUnitMember", "nsuri": "http://www.neurocrine.com/20201231", "presentation": [ "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails", "http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpensebyAwardtypeDetails", "http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails" ], "xbrltype": "domainItemType" }, "nbix_PotentialCommercialMilestonePayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Potential payments for commercial milestones under a collaboration agreement.", "label": "Potential Commercial Milestone Payments", "terseLabel": "Potential commercial milestone payments" } } }, "localname": "PotentialCommercialMilestonePayments", "nsuri": "http://www.neurocrine.com/20201231", "presentation": [ "http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "nbix_PotentialMilestonePaymentReceipts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Potential later stage milestone payments and royalties.", "label": "Potential Milestone Payment Receipts", "terseLabel": "Potential milestone payment receipts" } } }, "localname": "PotentialMilestonePaymentReceipts", "nsuri": "http://www.neurocrine.com/20201231", "presentation": [ "http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "nbix_PotentialMilestonePayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of potential milestone payments to be paid under a license agreement.", "label": "Potential Milestone Payments", "terseLabel": "Potential milestone payments" } } }, "localname": "PotentialMilestonePayments", "nsuri": "http://www.neurocrine.com/20201231", "presentation": [ "http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "nbix_PrincipalAmountOnConversionRate": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Principal amount on conversion rate.", "label": "Principal Amount On Conversion Rate", "terseLabel": "Principal amount on conversion rate" } } }, "localname": "PrincipalAmountOnConversionRate", "nsuri": "http://www.neurocrine.com/20201231", "presentation": [ "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "nbix_ResearchAndDevelopmentExpenseExcludingResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff": { "auth_ref": [], "calculation": { "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding the write-off for research and development assets that were acquired in a transaction other than a business combination during the period. Excludes software research and development, which has a separate concept.", "label": "Research And Development Expense Excluding Research And Development Asset Acquired Other Than Through Business Combination Written Off", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseExcludingResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff", "nsuri": "http://www.neurocrine.com/20201231", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "nbix_ResearchCollaborationTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Research Collaboration Term", "label": "Research Collaboration Term", "terseLabel": "Research collaboration term" } } }, "localname": "ResearchCollaborationTerm", "nsuri": "http://www.neurocrine.com/20201231", "presentation": [ "http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "nbix_RestrictedCashMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted cash.", "label": "Restricted Cash [Member]", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashMember", "nsuri": "http://www.neurocrine.com/20201231", "presentation": [ "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "nbix_RevenueRelatedReservesForDiscountsAndAllowances": { "auth_ref": [], "calculation": { "http://www.neurocrine.com/role/OtherBalanceSheetDetailsAccountsPayableandAccruedLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Revenue-related reserves for discounts and allowances.", "label": "Revenue Related Reserves For Discounts And Allowances", "terseLabel": "Revenue-related reserves for discounts and allowances" } } }, "localname": "RevenueRelatedReservesForDiscountsAndAllowances", "nsuri": "http://www.neurocrine.com/20201231", "presentation": [ "http://www.neurocrine.com/role/OtherBalanceSheetDetailsAccountsPayableandAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "nbix_ScientificEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Scientific equipment.", "label": "Scientific Equipment [Member]", "terseLabel": "Scientific equipment" } } }, "localname": "ScientificEquipmentMember", "nsuri": "http://www.neurocrine.com/20201231", "presentation": [ "http://www.neurocrine.com/role/OtherBalanceSheetDetailsPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information related to the 2.25% Convertible Senior Notes Due in May 2024.", "label": "Senior Convertible Notes Two Point Two Five Percent Due In May Two Thousand Twenty Four [Member]", "terseLabel": "2.25% Convertible senior notes due 2024" } } }, "localname": "SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember", "nsuri": "http://www.neurocrine.com/20201231", "presentation": [ "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails", "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award, purchase period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Purchase Period", "terseLabel": "Share based compensation arrangement by share based payment award purchase period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod", "nsuri": "http://www.neurocrine.com/20201231", "presentation": [ "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "nbix_StockOptionsRestrictedStockAndConvertibleSeniorNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock options, restricted stock and convertible senior notes.", "label": "Stock Options Restricted Stock And Convertible Senior Notes [Member]", "terseLabel": "Stock options restricted stock and convertible senior notes" } } }, "localname": "StockOptionsRestrictedStockAndConvertibleSeniorNotesMember", "nsuri": "http://www.neurocrine.com/20201231", "presentation": [ "http://www.neurocrine.com/role/NetIncomePerShareScheduleofAntiDilutiveSharesExcludedfromDilutedPerShareAmountsDetails" ], "xbrltype": "domainItemType" }, "nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of reconciliation of cash cash equivalents and restricted cash.", "label": "Summary Of Reconciliation Of Cash Cash Equivalents And Restricted Cash [Table Text Block]", "terseLabel": "Reconciliation of Cash, Cash Equivalents and Restricted Cash" } } }, "localname": "SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock", "nsuri": "http://www.neurocrine.com/20201231", "presentation": [ "http://www.neurocrine.com/role/OtherBalanceSheetDetailsTables" ], "xbrltype": "textBlockItemType" }, "nbix_TakedaPharmaceuticalCompanyLimitedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Takeda Pharmaceutical Company Limited", "label": "Takeda Pharmaceutical Company Limited [Member]", "terseLabel": "Takeda" } } }, "localname": "TakedaPharmaceuticalCompanyLimitedMember", "nsuri": "http://www.neurocrine.com/20201231", "presentation": [ "http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails", "http://www.neurocrine.com/role/SummaryofQuarterlyResultsofOperationsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "nbix_TotalEquitySecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Total equity securities.", "label": "Total Equity Securities [Member]", "terseLabel": "Total equity securities" } } }, "localname": "TotalEquitySecuritiesMember", "nsuri": "http://www.neurocrine.com/20201231", "presentation": [ "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "nbix_TradingDaysDuringObservationPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading days during observation period.", "label": "Trading Days During Observation Period", "terseLabel": "Trading days during observation period" } } }, "localname": "TradingDaysDuringObservationPeriod", "nsuri": "http://www.neurocrine.com/20201231", "presentation": [ "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "nbix_TwoThousandAndElevenPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Thousand and Eleven Plan [Member].", "label": "Two Thousand And Eleven Plan [Member]", "terseLabel": "2011 Plan" } } }, "localname": "TwoThousandAndElevenPlanMember", "nsuri": "http://www.neurocrine.com/20201231", "presentation": [ "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "nbix_UpfrontPaymentsMade": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Upfront payments made under a collaboration agreement.", "label": "Upfront Payments Made", "terseLabel": "Upfront payments made" } } }, "localname": "UpfrontPaymentsMade", "nsuri": "http://www.neurocrine.com/20201231", "presentation": [ "http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "nbix_UpfrontPaymentsReceived": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Upfront payments received under a collaboration agreement.", "label": "Upfront Payments Received", "terseLabel": "Upfront payments received" } } }, "localname": "UpfrontPaymentsReceived", "nsuri": "http://www.neurocrine.com/20201231", "presentation": [ "http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "nbix_VoyagerTherapeuticsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Voyager therapeutics.", "label": "Voyager Therapeutics [Member]", "terseLabel": "Voyager" } } }, "localname": "VoyagerTherapeuticsMember", "nsuri": "http://www.neurocrine.com/20201231", "presentation": [ "http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails", "http://www.neurocrine.com/role/SummaryofQuarterlyResultsofOperationsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "nbix_XenonPharmaceuticalsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Xenon Pharmaceuticals Inc", "label": "Xenon Pharmaceuticals Inc [Member]", "terseLabel": "Xenon" } } }, "localname": "XenonPharmaceuticalsIncMember", "nsuri": "http://www.neurocrine.com/20201231", "presentation": [ "http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails", "http://www.neurocrine.com/role/SummaryofQuarterlyResultsofOperationsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": { "auth_ref": [ "r113", "r120", "r219", "r357", "r358", "r359", "r401", "r402" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]", "terseLabel": "Cumulative-effect adjustment to equity due to adoption of ASU 2016-02" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAxis": { "auth_ref": [ "r113", "r120", "r219", "r357", "r358", "r359", "r401", "r402" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption [Axis]", "terseLabel": "Cumulative Effect, Period of Adoption [Axis]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "stringItemType" }, "srt_CumulativeEffectPeriodOfAdoptionDomain": { "auth_ref": [ "r113", "r120", "r219", "r357", "r358", "r359", "r401", "r402" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption [Domain]", "terseLabel": "Cumulative Effect, Period of Adoption [Domain]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r183", "r287", "r291", "r563" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]", "terseLabel": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r314", "r315", "r479", "r480", "r481", "r482", "r483", "r484", "r504", "r561", "r564" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r314", "r315", "r479", "r480", "r481", "r482", "r483", "r484", "r504", "r561", "r564" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails", "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r183", "r287", "r291", "r563" ], "lang": { "en-us": { "role": { "label": "Customer [Domain]", "terseLabel": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r181", "r287", "r290", "r505", "r560", "r562" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome", "http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r181", "r287", "r290", "r505", "r560", "r562" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome", "http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r294", "r314", "r315", "r479", "r480", "r481", "r482", "r483", "r484", "r504", "r561", "r564" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails", "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r294", "r314", "r315", "r479", "r480", "r481", "r482", "r483", "r484", "r504", "r561", "r564" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails", "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_WeightedAverageMember": { "auth_ref": [ "r479", "r481", "r484" ], "lang": { "en-us": { "role": { "label": "Weighted Average [Member]", "terseLabel": "Weighted average" } } }, "localname": "WeightedAverageMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdateExtensibleList": { "auth_ref": [ "r114", "r115", "r116", "r117", "r216", "r217", "r218", "r219", "r220", "r221", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r401", "r402", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576" ], "lang": { "en-us": { "role": { "documentation": "Indicates amendment to accounting standards.", "label": "Accounting Standards Update [Extensible List]", "terseLabel": "Accounting Standards Update [Extensible List]" } } }, "localname": "AccountingStandardsUpdateExtensibleList", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "extensibleListItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r44" ], "calculation": { "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.neurocrine.com/role/OtherBalanceSheetDetailsAccountsPayableandAccruedLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts Payable and Accrued Liabilities, Current", "terseLabel": "Accounts payable and accrued liabilities", "totalLabel": "Total accounts payable and accrued liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedBalanceSheets", "http://www.neurocrine.com/role/OtherBalanceSheetDetailsAccountsPayableandAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": { "auth_ref": [], "calculation": { "http://www.neurocrine.com/role/OtherBalanceSheetDetailsAccountsPayableandAccruedLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.", "label": "Accounts Payable and Other Accrued Liabilities, Current", "terseLabel": "Accounts payable and other accrued liabilities" } } }, "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/OtherBalanceSheetDetailsAccountsPayableandAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r4", "r25", "r184", "r185" ], "calculation": { "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r42", "r254" ], "calculation": { "http://www.neurocrine.com/role/OtherBalanceSheetDetailsPropertyandEquipmentDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/OtherBalanceSheetDetailsPropertyandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r28", "r61", "r62", "r63", "r549", "r572", "r576" ], "calculation": { "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r60", "r63", "r64", "r110", "r111", "r112", "r423", "r567", "r568" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r26" ], "calculation": { "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r110", "r111", "r112", "r357", "r358", "r359" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of subsequent adjustments to additional paid in capital for convertible financial instruments where a component of equity and a component of debt are recognized.", "label": "Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Subsequent Adjustments", "negatedTerseLabel": "Equity component of repurchased convertible senior notes, net", "verboseLabel": "Equity component of repurchased convertible senior notes" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity", "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r317", "r319", "r363", "r364" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Share-based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Reconciliation of net income to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "auth_ref": [ "r366" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for advertising cost.", "label": "Advertising Cost [Policy Text Block]", "terseLabel": "Advertising Expense" } } }, "localname": "AdvertisingCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_AdvertisingExpense": { "auth_ref": [ "r367" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.", "label": "Advertising Expense", "terseLabel": "Advertising expense" } } }, "localname": "AdvertisingExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r319", "r349", "r362" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Total share-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ShareBasedCompensationCompensationCostRelatedtoShareBasedCompensationDetails", "http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpensebyAwardtypeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r80", "r95", "r450" ], "calculation": { "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization of Debt Discount (Premium)", "terseLabel": "Amortization of debt discount" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCosts": { "auth_ref": [ "r77", "r95", "r452" ], "calculation": { "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt issuance costs.", "label": "Amortization of Debt Issuance Costs", "terseLabel": "Amortization of debt issuance costs" } } }, "localname": "AmortizationOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r136" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "verboseLabel": "Anti-dilutive shares excluded from diluted per share amounts (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/NetIncomePerShareScheduleofAntiDilutiveSharesExcludedfromDilutedPerShareAmountsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r136" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/NetIncomePerShareScheduleofAntiDilutiveSharesExcludedfromDilutedPerShareAmountsDetails", "http://www.neurocrine.com/role/NetIncomePerShareScheduleofNetIncomeLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/NetIncomePerShareScheduleofAntiDilutiveSharesExcludedfromDilutedPerShareAmountsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r136" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/NetIncomePerShareScheduleofAntiDilutiveSharesExcludedfromDilutedPerShareAmountsDetails", "http://www.neurocrine.com/role/NetIncomePerShareScheduleofNetIncomeLossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails", "http://www.neurocrine.com/role/SummaryofQuarterlyResultsofOperationsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r106", "r164", "r173", "r179", "r215", "r420", "r424", "r441", "r523", "r546" ], "calculation": { "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r6", "r7", "r57", "r106", "r215", "r420", "r424", "r441" ], "calculation": { "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r426" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "terseLabel": "Fair value of assets on recurring basis" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r197" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Unrealized Gain" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainLossPositionsandEstimatedFairValueforAvailableForSaleDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r198" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax", "negatedLabel": "Unrealized Loss" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainLossPositionsandEstimatedFairValueforAvailableForSaleDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r194", "r228" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Amortized Cost", "terseLabel": "Amortized Cost", "verboseLabel": "Amortized cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainLossPositionsandEstimatedFairValueforAvailableForSaleDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r192", "r195", "r228", "r528" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale", "verboseLabel": "Fair Value" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainLossPositionsandEstimatedFairValueforAvailableForSaleDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableforsaleSecuritiesMember": { "auth_ref": [ "r210" ], "lang": { "en-us": { "role": { "documentation": "Investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available-for-sale Securities [Member]", "terseLabel": "Total debt securities available-for-sale" } } }, "localname": "AvailableforsaleSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r320", "r351" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails", "http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpenseDetails", "http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpensebyAwardtypeDetails", "http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails", "http://www.neurocrine.com/role/ShareBasedCompensationWeightedAverageAssumptionsforStockOptionGrantsusingBlackScholesOptionPricingModelDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combinations [Abstract]", "terseLabel": "Business Combinations [Abstract]" } } }, "localname": "BusinessCombinationsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationsPolicy": { "auth_ref": [ "r104", "r414" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.", "label": "Business Combinations Policy [Policy Text Block]", "terseLabel": "Asset Acquisitions" } } }, "localname": "BusinessCombinationsPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock": { "auth_ref": [ "r109", "r158" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the business description and accounting policies concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity.", "label": "Business Description and Accounting Policies [Text Block]", "terseLabel": "Organization and Summary of Significant Accounting Policies" } } }, "localname": "BusinessDescriptionAndAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r100", "r101", "r102" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Non-cash capital expenditures" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r2", "r38", "r97" ], "calculation": { "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.neurocrine.com/role/OtherBalanceSheetDetailsReconciliationofCashCashEquivalentsandRestrictedCashDetails": { "order": 1.0, "parentTag": "us-gaap_RestrictedCashAndCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedBalanceSheets", "http://www.neurocrine.com/role/OtherBalanceSheetDetailsReconciliationofCashCashEquivalentsandRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainLossPositionsandEstimatedFairValueforAvailableForSaleDebtSecuritiesDetails", "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r12", "r98", "r104" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r90", "r97", "r103" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents and restricted cash at end of period", "periodStartLabel": "Cash and cash equivalents and restricted cash at beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r90", "r442" ], "calculation": { "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Change in cash and cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsMember": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Equivalents [Member]", "terseLabel": "Cash equivalents" } } }, "localname": "CashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CertificatesOfDepositMember": { "auth_ref": [ "r540" ], "lang": { "en-us": { "role": { "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.", "label": "Certificates of Deposit [Member]", "terseLabel": "Certificates of deposit" } } }, "localname": "CertificatesOfDepositMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "auth_ref": [ "r416", "r417", "r419" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.", "label": "Collaborative Arrangement Disclosure [Text Block]", "terseLabel": "License and Collaboration Agreements" } } }, "localname": "CollaborativeArrangementDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/LicenseandCollaborationAgreements" ], "xbrltype": "textBlockItemType" }, "us-gaap_CollaborativeArrangementMember": { "auth_ref": [ "r418" ], "lang": { "en-us": { "role": { "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.", "label": "Collaborative Arrangement [Member]", "terseLabel": "Collaborative Arrangement" } } }, "localname": "CollaborativeArrangementMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails", "http://www.neurocrine.com/role/SummaryofQuarterlyResultsofOperationsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails", "http://www.neurocrine.com/role/SummaryofQuarterlyResultsofOperationsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CollateralAxis": { "auth_ref": [ "r227" ], "lang": { "en-us": { "role": { "documentation": "Information by category of collateral or no collateral, from lender's perspective.", "label": "Collateral Held [Axis]", "terseLabel": "Collateral Held [Axis]" } } }, "localname": "CollateralAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofEquitySecuritiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CollateralDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Category of collateral or no collateral, from lender's perspective.", "label": "Collateral Held [Domain]", "terseLabel": "Collateral Held [Domain]" } } }, "localname": "CollateralDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofEquitySecuritiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r262" ], "lang": { "en-us": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial paper" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainLossPositionsandEstimatedFairValueforAvailableForSaleDebtSecuritiesDetails", "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r258", "r259", "r260", "r261" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/LicenseandCollaborationAgreements" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r110", "r111" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity", "http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in USD per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r24", "r269" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r24" ], "calculation": { "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.001 par value; 220.0 shares authorized; issued and outstanding shares were 93.5 million and 92.3 million at December\u00a031, 2020 and 2019, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Retirement Benefits [Abstract]", "terseLabel": "Retirement Benefits [Abstract]" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r66", "r68", "r69", "r74", "r531", "r555" ], "calculation": { "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive income" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]", "terseLabel": "Computer equipment" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/OtherBalanceSheetDetailsPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r153", "r154", "r183", "r439", "r440" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Type" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r153", "r154", "r183", "r439", "r440", "r578" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r153", "r154", "r183", "r439", "r440", "r578" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r148", "r542" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentration of Credit Risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r153", "r154", "r183", "r439", "r440" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Concentration risk, percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r153", "r154", "r183", "r439", "r440" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r104", "r422" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r276", "r277", "r288" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract with Customer, Liability", "terseLabel": "Contract with customer, liability" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r289" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "Contract with Customer, Liability, Revenue Recognized", "terseLabel": "Deferred revenue recognized" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebt": { "auth_ref": [ "r20", "r526", "r547" ], "calculation": { "http://www.neurocrine.com/role/ConvertibleSeniorNotesNetofDiscountsandDeferredFinancingCostsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.", "label": "Convertible Debt", "totalLabel": "Net carrying amount" } } }, "localname": "ConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConvertibleSeniorNotesNetofDiscountsandDeferredFinancingCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtCurrent": { "auth_ref": [ "r17" ], "calculation": { "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Convertible Debt, Current", "terseLabel": "Convertible senior notes" } } }, "localname": "ConvertibleDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtNoncurrent": { "auth_ref": [ "r51" ], "calculation": { "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.", "label": "Convertible Debt, Noncurrent", "terseLabel": "Convertible senior notes" } } }, "localname": "ConvertibleDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r295", "r310", "r577" ], "lang": { "en-us": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate debt securities" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainLossPositionsandEstimatedFairValueforAvailableForSaleDebtSecuritiesDetails", "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails", "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfSalesPolicyTextBlock": { "auth_ref": [ "r293" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.", "label": "Cost of Goods and Service [Policy Text Block]", "terseLabel": "Cost of Sales" } } }, "localname": "CostOfSalesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Federal, State and Local, Tax Expense (Benefit) [Abstract]", "terseLabel": "Current:" } } }, "localname": "CurrentFederalStateAndLocalTaxExpenseBenefitAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/IncomeTaxesComponentsofIncomeTaxExpenseforContinuingOperationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "auth_ref": [ "r107", "r397", "r405" ], "calculation": { "http://www.neurocrine.com/role/IncomeTaxesComponentsofIncomeTaxExpenseforContinuingOperationsDetails": { "order": 1.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Federal Tax Expense (Benefit)", "terseLabel": "Federal" } } }, "localname": "CurrentFederalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/IncomeTaxesComponentsofIncomeTaxExpenseforContinuingOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "auth_ref": [ "r107", "r397", "r405", "r407" ], "calculation": { "http://www.neurocrine.com/role/IncomeTaxesComponentsofIncomeTaxExpenseforContinuingOperationsDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.", "label": "Current Income Tax Expense (Benefit)", "totalLabel": "Total current taxes" } } }, "localname": "CurrentIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/IncomeTaxesComponentsofIncomeTaxExpenseforContinuingOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "auth_ref": [ "r107", "r397", "r405" ], "calculation": { "http://www.neurocrine.com/role/IncomeTaxesComponentsofIncomeTaxExpenseforContinuingOperationsDetails": { "order": 2.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current State and Local Tax Expense (Benefit)", "terseLabel": "State" } } }, "localname": "CurrentStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/IncomeTaxesComponentsofIncomeTaxExpenseforContinuingOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r151", "r183" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer Concentration Risk" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "auth_ref": [ "r100", "r102" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.", "label": "Debt Conversion, Converted Instrument, Shares Issued", "terseLabel": "Shares issued to settle notes at initial conversion rate (in shares)" } } }, "localname": "DebtConversionConvertedInstrumentSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails", "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]", "terseLabel": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r268" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Convertible Senior Notes" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConvertibleSeniorNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r17", "r19", "r20", "r524", "r526", "r544" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails", "http://www.neurocrine.com/role/NetIncomePerShareScheduleofNetIncomeLossPerShareDetails", "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent": { "auth_ref": [ "r263" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.", "label": "Debt Instrument, Convertible, Carrying Amount of Equity Component", "terseLabel": "Carrying amount of the equity component upon issuance" } } }, "localname": "DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "auth_ref": [ "r265" ], "lang": { "en-us": { "role": { "documentation": "The price per share of the conversion feature embedded in the debt instrument.", "label": "Debt Instrument, Convertible, Conversion Price", "terseLabel": "Conversion price (in USD per share)" } } }, "localname": "DebtInstrumentConvertibleConversionPrice1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_DebtInstrumentConvertibleConversionRatio1": { "auth_ref": [ "r50", "r270", "r271", "r273" ], "lang": { "en-us": { "role": { "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.", "label": "Debt Instrument, Convertible, Conversion Ratio", "terseLabel": "Conversion ratio" } } }, "localname": "DebtInstrumentConvertibleConversionRatio1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails" ], "xbrltype": "pureItemType" }, "us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1": { "auth_ref": [ "r264" ], "lang": { "en-us": { "role": { "documentation": "Remaining amortization period for discount on the liability component of convertible debt which may be settled in cash upon conversion, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument, Convertible, Remaining Discount Amortization Period", "terseLabel": "Remaining discount amortization period" } } }, "localname": "DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.", "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days", "terseLabel": "Threshold consecutive common stock trading days" } } }, "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.", "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger", "terseLabel": "Threshold percentage of common stock price trigger" } } }, "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.", "label": "Debt Instrument, Convertible, Threshold Trading Days", "terseLabel": "Threshold common stock trading days" } } }, "localname": "DebtInstrumentConvertibleThresholdTradingDays", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r451", "r453" ], "calculation": { "http://www.neurocrine.com/role/ConvertibleSeniorNotesNetofDiscountsandDeferredFinancingCostsDetails": { "order": 1.0, "parentTag": "us-gaap_ConvertibleDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Principal amount", "verboseLabel": "Principal" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails", "http://www.neurocrine.com/role/ConvertibleSeniorNotesNetofDiscountsandDeferredFinancingCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFairValue": { "auth_ref": [ "r438" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.", "label": "Debt Instrument, Fair Value Disclosure", "terseLabel": "Fair value" } } }, "localname": "DebtInstrumentFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateDuringPeriod": { "auth_ref": [ "r49", "r451" ], "lang": { "en-us": { "role": { "documentation": "The average effective interest rate during the reporting period.", "label": "Debt Instrument, Interest Rate During Period", "terseLabel": "Assumed borrowing rate" } } }, "localname": "DebtInstrumentInterestRateDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r49" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Stated interest rate percentage" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentMeasurementInput": { "auth_ref": [ "r431" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt.", "label": "Debt Instrument, Measurement Input", "terseLabel": "Discount rate" } } }, "localname": "DebtInstrumentMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails" ], "xbrltype": "decimalItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r51" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails", "http://www.neurocrine.com/role/NetIncomePerShareScheduleofNetIncomeLossPerShareDetails", "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of principal amount of debt redeemed.", "label": "Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed", "terseLabel": "Redemption rate" } } }, "localname": "DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentRepurchasedFaceAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of the original debt instrument that was repurchased.", "label": "Debt Instrument, Repurchased Face Amount", "terseLabel": "Aggregate principal amount repurchased" } } }, "localname": "DebtInstrumentRepurchasedFaceAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r51", "r108", "r270", "r272", "r273", "r274", "r450", "r451", "r453", "r541" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument, Term", "terseLabel": "Term" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r450", "r453" ], "calculation": { "http://www.neurocrine.com/role/ConvertibleSeniorNotesNetofDiscountsandDeferredFinancingCostsDetails": { "order": 3.0, "parentTag": "us-gaap_ConvertibleDebt", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Debt Instrument, Unamortized Discount", "negatedLabel": "Debt discount, net" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConvertibleSeniorNotesNetofDiscountsandDeferredFinancingCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff": { "auth_ref": [ "r229" ], "lang": { "en-us": { "role": { "documentation": "Period when accrued interest on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), is considered uncollectible and written off, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Debt Securities, Available-for-Sale, Accrued Interest, Threshold Period, Writeoff", "terseLabel": "Accrued interest receivables write-off threshold period" } } }, "localname": "DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff": { "auth_ref": [ "r230" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of writeoff of accrued interest on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized by reversing interest income.", "label": "Debt Securities, Available-for-Sale, Accrued Interest Writeoff", "terseLabel": "Accrued interest receivables write-off" } } }, "localname": "DebtSecuritiesAvailableForSaleAccruedInterestWriteoff", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": { "auth_ref": [ "r196", "r228", "r237", "r238" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Allowance for Credit Loss", "terseLabel": "Allowance for Credit Losses" } } }, "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainLossPositionsandEstimatedFairValueforAvailableForSaleDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": { "auth_ref": [ "r208", "r235", "r240" ], "calculation": { "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails": { "order": 2.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer", "terseLabel": "12 Months or Longer, Fair Value" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": { "auth_ref": [ "r208", "r235" ], "calculation": { "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails": { "order": 2.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss", "negatedLabel": "12 Months or Longer, Unrealized Losses" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": { "auth_ref": [ "r208", "r235", "r240" ], "calculation": { "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails": { "order": 1.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months", "terseLabel": "Less Than 12 Months, Fair Value" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": { "auth_ref": [ "r208", "r235" ], "calculation": { "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails": { "order": 1.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss", "negatedLabel": "Less Than 12 Months, Unrealized Losses" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": { "auth_ref": [ "r204", "r231", "r240" ], "calculation": { "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.", "label": "Debt Securities, Available-for-sale, Unrealized Loss Position", "totalLabel": "Total Fair Value" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": { "auth_ref": [ "r205", "r232" ], "calculation": { "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss", "negatedTotalLabel": "Total Unrealized Losses" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": { "auth_ref": [ "r203", "r234", "r240" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table Text Block]", "terseLabel": "Gross unrealized losses and fair value available-for-sale investments in unrealized loss position" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/DebtSecuritiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": { "auth_ref": [ "r206", "r233" ], "lang": { "en-us": { "role": { "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions", "terseLabel": "Number of debt securities available-for-sale in an unrealized loss position" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/DebtSecuritiesAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "auth_ref": [ "r107", "r398", "r405" ], "calculation": { "http://www.neurocrine.com/role/IncomeTaxesComponentsofIncomeTaxExpenseforContinuingOperationsDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Federal Income Tax Expense (Benefit)", "terseLabel": "Federal" } } }, "localname": "DeferredFederalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/IncomeTaxesComponentsofIncomeTaxExpenseforContinuingOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]", "terseLabel": "Deferred:" } } }, "localname": "DeferredFederalStateAndLocalTaxExpenseBenefitAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/IncomeTaxesComponentsofIncomeTaxExpenseforContinuingOperationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredFinanceCostsGross": { "auth_ref": [ "r452" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Gross", "terseLabel": "Transaction cost related to issuance of convertible senior note" } } }, "localname": "DeferredFinanceCostsGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFinanceCostsNet": { "auth_ref": [ "r43", "r452" ], "calculation": { "http://www.neurocrine.com/role/ConvertibleSeniorNotesNetofDiscountsandDeferredFinancingCostsDetails": { "order": 2.0, "parentTag": "us-gaap_ConvertibleDebt", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Net", "negatedLabel": "Deferred financing costs" } } }, "localname": "DeferredFinanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConvertibleSeniorNotesNetofDiscountsandDeferredFinancingCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxAssetsNet": { "auth_ref": [ "r373", "r374" ], "calculation": { "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.", "label": "Deferred Income Tax Assets, Net", "terseLabel": "Deferred tax assets" } } }, "localname": "DeferredIncomeTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r95", "r107", "r398", "r405", "r406", "r407" ], "calculation": { "http://www.neurocrine.com/role/IncomeTaxesComponentsofIncomeTaxExpenseforContinuingOperationsDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "totalLabel": "Total deferred taxes" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/IncomeTaxesComponentsofIncomeTaxExpenseforContinuingOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilities": { "auth_ref": [ "r21", "r22", "r388", "r525", "r543" ], "calculation": { "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails": { "order": 1.0, "parentTag": "nbix_DeferredTaxAssetsLiabilitiesGross", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.", "label": "Deferred Tax Liabilities, Gross", "negatedTotalLabel": "Total deferred tax liabilities" } } }, "localname": "DeferredIncomeTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxesAndTaxCredits": { "auth_ref": [ "r96" ], "calculation": { "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) and income tax credits.", "label": "Deferred Income Taxes and Tax Credits", "terseLabel": "Deferred income taxes (including benefit from valuation allowance release)" } } }, "localname": "DeferredIncomeTaxesAndTaxCredits", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "auth_ref": [ "r107", "r398", "r405" ], "calculation": { "http://www.neurocrine.com/role/IncomeTaxesComponentsofIncomeTaxExpenseforContinuingOperationsDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred State and Local Income Tax Expense (Benefit)", "terseLabel": "State" } } }, "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/IncomeTaxesComponentsofIncomeTaxExpenseforContinuingOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": { "auth_ref": [], "calculation": { "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.", "label": "Deferred Tax Assets, Goodwill and Intangible Assets", "terseLabel": "Intangible assets" } } }, "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r389" ], "calculation": { "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails": { "order": 2.0, "parentTag": "nbix_DeferredTaxAssetsLiabilitiesGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Gross", "totalLabel": "Total deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGrossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Gross [Abstract]", "terseLabel": "Deferred tax assets:" } } }, "localname": "DeferredTaxAssetsGrossAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r391" ], "calculation": { "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "Deferred Tax Assets, Net", "totalLabel": "Net deferred tax assets" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r391" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Net of Valuation Allowance", "terseLabel": "Realizable deferred tax assets" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r395", "r396" ], "calculation": { "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails": { "order": 5.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Deferred Tax Assets, Operating Loss Carryforwards", "terseLabel": "Net operating losses" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOther": { "auth_ref": [ "r395", "r396" ], "calculation": { "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.", "label": "Deferred Tax Assets, Other", "terseLabel": "Other" } } }, "localname": "DeferredTaxAssetsOther", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": { "auth_ref": [ "r394", "r395", "r396" ], "calculation": { "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails": { "order": 6.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.", "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research", "terseLabel": "Research and development credits", "verboseLabel": "Research and development tax credit carry forwards" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/IncomeTaxesAdditionalInformationDetails", "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": { "auth_ref": [ "r395", "r396" ], "calculation": { "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits", "terseLabel": "Share-based compensation expense" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r390" ], "calculation": { "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedTerseLabel": "Valuation allowance", "terseLabel": "Deferred tax assets, valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/IncomeTaxesAdditionalInformationDetails", "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Tax Liabilities, Gross [Abstract]", "terseLabel": "Deferred tax liabilities:" } } }, "localname": "DeferredTaxLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxLiabilitiesOther": { "auth_ref": [ "r395", "r396" ], "calculation": { "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.", "label": "Deferred Tax Liabilities, Other", "negatedTerseLabel": "Other" } } }, "localname": "DeferredTaxLiabilitiesOther", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanCostRecognized": { "auth_ref": [ "r313" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost for defined contribution plan.", "label": "Defined Contribution Plan, Cost", "terseLabel": "Defined contribution plan, employer contribution amount" } } }, "localname": "DefinedContributionPlanCostRecognized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/RetirementPlanAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.", "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent", "terseLabel": "Defined contribution plan, maximum employee contribution percentage" } } }, "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/RetirementPlanAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r95", "r252" ], "calculation": { "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows", "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r365" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "Share-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ShareBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Abstract]", "terseLabel": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r75", "r118", "r119", "r120", "r121", "r122", "r126", "r128", "r133", "r134", "r135", "r139", "r140", "r532", "r556" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Net income (loss) per share, basic (in USD per share)", "verboseLabel": "Basic (in USD per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome", "http://www.neurocrine.com/role/NetIncomePerShareScheduleofNetIncomeLossPerShareDetails", "http://www.neurocrine.com/role/SummaryofQuarterlyResultsofOperationsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAndDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic and Diluted [Abstract]", "terseLabel": "Net income per share:" } } }, "localname": "EarningsPerShareBasicAndDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/NetIncomePerShareScheduleofNetIncomeLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r75", "r118", "r119", "r120", "r121", "r122", "r128", "r133", "r134", "r135", "r139", "r140", "r532", "r556" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Net income (loss) per share, diluted (in USD per share)", "verboseLabel": "Diluted (in USD per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome", "http://www.neurocrine.com/role/NetIncomePerShareScheduleofNetIncomeLossPerShareDetails", "http://www.neurocrine.com/role/SummaryofQuarterlyResultsofOperationsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r104", "r136", "r137" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Net Income Per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r136", "r137", "r138", "r141" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Income Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/NetIncomePerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r376", "r408" ], "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "terseLabel": "Federal income taxes, rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r47" ], "calculation": { "http://www.neurocrine.com/role/OtherBalanceSheetDetailsAccountsPayableandAccruedLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued employee related costs" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/OtherBalanceSheetDetailsAccountsPayableandAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ShareBasedCompensationCompensationCostRelatedtoShareBasedCompensationDetails", "http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpenseDetails", "http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpensebyAwardtypeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r350" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized Expense", "verboseLabel": "Unrecognized expense" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails", "http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r350" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Weighted-Average Recognition Period" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpenseDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.", "label": "Employee Stock [Member]", "terseLabel": "ESPP" } } }, "localname": "EmployeeStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails", "http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpensebyAwardtypeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r347" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "terseLabel": "Stock options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/NetIncomePerShareScheduleofNetIncomeLossPerShareDetails", "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails", "http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpenseDetails", "http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpensebyAwardtypeDetails", "http://www.neurocrine.com/role/ShareBasedCompensationWeightedAverageAssumptionsforStockOptionGrantsusingBlackScholesOptionPricingModelDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r110", "r111", "r112", "r115", "r123", "r125", "r145", "r219", "r269", "r275", "r357", "r358", "r359", "r401", "r402", "r443", "r444", "r445", "r446", "r447", "r448", "r567", "r568", "r569" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity", "http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesFvNiMeasurementInput": { "auth_ref": [ "r431" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Measurement Input", "terseLabel": "Equity securities, FV-NI, measurement input" } } }, "localname": "EquitySecuritiesFvNiMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "decimalItemType" }, "us-gaap_EquitySecuritiesFvNiRestricted": { "auth_ref": [ "r487" ], "calculation": { "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of restricted investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Restricted", "periodEndLabel": "Equity securities, ending balance", "periodStartLabel": "Equity securities, beginning balance", "terseLabel": "Equity securities", "verboseLabel": "Equity securities fair value amount" } } }, "localname": "EquitySecuritiesFvNiRestricted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedBalanceSheets", "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofEquitySecuritiesMeasuredatFairValueonRecurringBasisDetails", "http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": { "auth_ref": [ "r214", "r557" ], "calculation": { "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 }, "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)", "negatedLabel": "Change in fair value of equity securities", "terseLabel": "Unrealized loss on restricted equity securities", "verboseLabel": "Unrealized loss included in earnings" } } }, "localname": "EquitySecuritiesFvNiUnrealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome", "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows", "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofEquitySecuritiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesMember": { "auth_ref": [ "r13", "r18", "r212", "r545", "r593", "r594", "r595" ], "lang": { "en-us": { "role": { "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.", "label": "Equity Securities [Member]", "terseLabel": "Equity securities\u2013biotechnology industry" } } }, "localname": "EquitySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails", "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofEquitySecuritiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": { "auth_ref": [ "r213" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity security without readily determinable fair value.", "label": "Equity Securities without Readily Determinable Fair Value, Amount", "terseLabel": "Investment in equity securities without readily determinable fair value" } } }, "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails", "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofEquitySecuritiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r426", "r427", "r428", "r434" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails", "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofEquitySecuritiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]", "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "auth_ref": [ "r429" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]", "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r426", "r427" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]", "terseLabel": "Investments measured at fair value on recurring basis" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r432", "r434" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Reconciliation of equity securities measured at fair value on recurring basis using significant unobservable inputs" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r295", "r297", "r298", "r299", "r300", "r301", "r302", "r310", "r427", "r476", "r477", "r478" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails", "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofEquitySecuritiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r426", "r427", "r430", "r431", "r435" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails", "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofEquitySecuritiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r433" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r295", "r297", "r302", "r310", "r427", "r476" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r295", "r297", "r302", "r310", "r427", "r477" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r295", "r297", "r298", "r299", "r300", "r301", "r302", "r310", "r427", "r478" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails", "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofEquitySecuritiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails", "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofEquitySecuritiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r295", "r297", "r298", "r299", "r300", "r301", "r302", "r310", "r476", "r477", "r478" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails", "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofEquitySecuritiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r433", "r435" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Fair value measurements recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails", "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofEquitySecuritiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r104", "r436", "r437" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r201", "r202", "r222", "r223", "r224", "r225", "r226", "r234", "r236", "r239", "r240", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainLossPositionsandEstimatedFairValueforAvailableForSaleDebtSecuritiesDetails", "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails", "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts": { "auth_ref": [ "r186" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for charging off uncollectible financing receivables, including, but not limited to, factors and methodologies used in estimating the allowance for credit loss.", "label": "Financing Receivable, Allowance for Credit Losses, Policy for Uncollectible Amounts [Policy Text Block]", "terseLabel": "Allowance for Credit Losses" } } }, "localname": "FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r245", "r247", "r249", "r250", "r506", "r507" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r245", "r248" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]", "terseLabel": "Furniture and fixtures" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/OtherBalanceSheetDetailsPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r95", "r266", "r267" ], "calculation": { "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 }, "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain (Loss) on Extinguishment of Debt", "negatedTerseLabel": "Loss on extinguishment of convertible senior notes", "terseLabel": "Loss on extinguishment of convertible senior notes" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome", "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows", "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r104", "r251", "r257" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "terseLabel": "Impairment of Long-Lived Assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r72", "r164", "r172", "r175", "r178", "r180", "r520", "r529", "r534", "r558" ], "calculation": { "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Income before (benefit from) provision for income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r256" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ShareBasedCompensationCompensationCostRelatedtoShareBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ShareBasedCompensationCompensationCostRelatedtoShareBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r378" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]", "terseLabel": "Income Tax Authority" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]", "terseLabel": "Income Tax Authority" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r377", "r386", "r393", "r403", "r409", "r411", "r412", "r413" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r107", "r124", "r125", "r163", "r375", "r404", "r410", "r559" ], "calculation": { "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 }, "http://www.neurocrine.com/role/IncomeTaxesComponentsofIncomeTaxExpenseforContinuingOperationsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "(Benefit from) provision for income taxes", "totalLabel": "(Benefit from) provision for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome", "http://www.neurocrine.com/role/IncomeTaxesComponentsofIncomeTaxExpenseforContinuingOperationsDetails", "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r70", "r104", "r371", "r372", "r386", "r387", "r392", "r399", "r598" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r376" ], "calculation": { "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails": { "order": 10.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount", "terseLabel": "Change in valuation allowance" } } }, "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": { "auth_ref": [ "r370", "r376" ], "calculation": { "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails": { "order": 7.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.", "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount", "terseLabel": "Change in tax rate" } } }, "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r376" ], "calculation": { "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount", "terseLabel": "Federal income taxes at 21% for 2020, 2019, 2018" } } }, "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther": { "auth_ref": [ "r376" ], "calculation": { "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails": { "order": 3.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount", "terseLabel": "Non-deductible expenses" } } }, "localname": "IncomeTaxReconciliationNondeductibleExpenseOther", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": { "auth_ref": [ "r376" ], "calculation": { "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails": { "order": 5.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount", "terseLabel": "Share-based compensation expense" } } }, "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationOtherAdjustments": { "auth_ref": [ "r376" ], "calculation": { "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails": { "order": 11.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.", "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount", "terseLabel": "Other" } } }, "localname": "IncomeTaxReconciliationOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r376" ], "calculation": { "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount", "terseLabel": "State income tax, net of federal benefit" } } }, "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": { "auth_ref": [ "r376" ], "calculation": { "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails": { "order": 9.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount", "negatedLabel": "Research credits" } } }, "localname": "IncomeTaxReconciliationTaxCreditsResearch", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaid": { "auth_ref": [ "r92", "r99" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.", "label": "Income Taxes Paid", "terseLabel": "Cash paid for income taxes" } } }, "localname": "IncomeTaxesPaid", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r94" ], "calculation": { "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable and accrued liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r94" ], "calculation": { "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r94" ], "calculation": { "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet": { "auth_ref": [], "calculation": { "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in current operating assets after deduction of current operating liabilities classified as other.", "label": "Increase (Decrease) in Other Current Assets and Liabilities, Net", "negatedLabel": "Other assets and liabilities, net" } } }, "localname": "IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r129", "r130", "r131", "r135" ], "calculation": { "http://www.neurocrine.com/role/NetIncomePerShareScheduleofNetIncomeLossPerShareDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements", "terseLabel": "Effect of dilutive securities (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/NetIncomePerShareScheduleofNetIncomeLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r71", "r162", "r449", "r452", "r533" ], "calculation": { "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r89", "r91", "r99" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestReceivableCurrent": { "auth_ref": [ "r56" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.", "label": "Interest Receivable, Current", "terseLabel": "Accrued interest receivables" } } }, "localname": "InterestReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InternalRevenueServiceIRSMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity.", "label": "Internal Revenue Service (IRS) [Member]", "terseLabel": "Federal" } } }, "localname": "InternalRevenueServiceIRSMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r32", "r243" ], "calculation": { "http://www.neurocrine.com/role/OtherBalanceSheetDetailsInventoriesDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Inventory, Finished Goods, Net of Reserves", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/OtherBalanceSheetDetailsInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r3", "r54" ], "calculation": { "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.neurocrine.com/role/OtherBalanceSheetDetailsInventoriesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventories", "totalLabel": "Total inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedBalanceSheets", "http://www.neurocrine.com/role/OtherBalanceSheetDetailsInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r11", "r55", "r104", "r142", "r241", "r242", "r244" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "terseLabel": "Inventory" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "auth_ref": [ "r34", "r243" ], "calculation": { "http://www.neurocrine.com/role/OtherBalanceSheetDetailsInventoriesDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.", "label": "Inventory, Raw Materials, Net of Reserves", "terseLabel": "Raw materials" } } }, "localname": "InventoryRawMaterialsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/OtherBalanceSheetDetailsInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "auth_ref": [ "r33", "r243" ], "calculation": { "http://www.neurocrine.com/role/OtherBalanceSheetDetailsInventoriesDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.", "label": "Inventory, Work in Process, Net of Reserves", "terseLabel": "Work in process" } } }, "localname": "InventoryWorkInProcessNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/OtherBalanceSheetDetailsInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentOwnedBalanceShares": { "auth_ref": [ "r579", "r583" ], "lang": { "en-us": { "role": { "documentation": "Balance held at close of period in number of shares.", "label": "Investment Owned, Balance, Shares", "terseLabel": "Equity securities number of shares (in shares)" } } }, "localname": "InvestmentOwnedBalanceShares", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r580", "r581", "r582", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595" ], "lang": { "en-us": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]", "terseLabel": "Investment Type" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainLossPositionsandEstimatedFairValueforAvailableForSaleDebtSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r580", "r581", "r582", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595" ], "lang": { "en-us": { "role": { "documentation": "Asset obtained to generate income or appreciate in value.", "label": "Investments [Domain]", "terseLabel": "Investments" } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainLossPositionsandEstimatedFairValueforAvailableForSaleDebtSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Investments": { "auth_ref": [ "r553" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments.", "label": "Investments", "verboseLabel": "Fair value" } } }, "localname": "Investments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]", "terseLabel": "Investments, Debt and Equity Securities [Abstract]" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "auth_ref": [ "r212", "r521", "r539", "r596" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for investments in certain debt and equity securities.", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "terseLabel": "Debt Securities" } } }, "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/DebtSecurities" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r253" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Tenant improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/OtherBalanceSheetDetailsPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]", "terseLabel": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Leases [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r459" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]", "terseLabel": "Leases [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r465" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Summary of minimum lease payments for operating lease liabilities" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/LeasesTable" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r465" ], "calculation": { "http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total operating lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r465" ], "calculation": { "http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r465" ], "calculation": { "http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "Year ending December 31, 2021" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r465" ], "calculation": { "http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five", "terseLabel": "Year ending December 31, 2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r465" ], "calculation": { "http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "Year ending December 31, 2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r465" ], "calculation": { "http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "Year ending December 31, 2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r465" ], "calculation": { "http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "Year ending December 31, 2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r465" ], "calculation": { "http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails_1": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "verboseLabel": "Less accreted interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "auth_ref": [ "r458" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Renewal Term", "terseLabel": "Renewal term" } } }, "localname": "LesseeOperatingLeaseRenewalTerm", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r467" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_LetterOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).", "label": "Letter of Credit [Member]", "terseLabel": "Letter of Credit" } } }, "localname": "LetterOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r45", "r106", "r174", "r215", "r421", "r424", "r425", "r441" ], "calculation": { "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r31", "r106", "r215", "r441", "r527", "r551" ], "calculation": { "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Stockholders\u2019 Equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r48", "r106", "r215", "r421", "r424", "r425", "r441" ], "calculation": { "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_MarketableSecuritiesCurrent": { "auth_ref": [ "r5", "r46" ], "calculation": { "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security, classified as current.", "label": "Marketable Securities, Current", "terseLabel": "Debt securities available-for-sale (amortized cost $612.4 million at December\u00a031, 2020 and $557.3 million at December\u00a031, 2019)" } } }, "localname": "MarketableSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesNoncurrent": { "auth_ref": [ "r39" ], "calculation": { "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security, classified as noncurrent.", "label": "Marketable Securities, Noncurrent", "terseLabel": "Debt securities available-for-sale (amortized cost $226.7 million at December\u00a031, 2020 and $299.3 million at December\u00a031, 2019)" } } }, "localname": "MarketableSecuritiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesPolicy": { "auth_ref": [ "r538" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment classified as marketable security.", "label": "Marketable Securities, Policy [Policy Text Block]", "terseLabel": "Debt Securities" } } }, "localname": "MarketableSecuritiesPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_MarketableSecuritiesUnrealizedGainLoss": { "auth_ref": [ "r76" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment in marketable security.", "label": "Marketable Securities, Unrealized Gain (Loss)", "terseLabel": "Unrealized gain (loss) on debt securities available-for sale" } } }, "localname": "MarketableSecuritiesUnrealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember": { "auth_ref": [ "r429" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using amount by which value of business ownership interest is reduced to reflect lack of ability to convert business interest into cash quickly.", "label": "Measurement Input, Discount for Lack of Marketability [Member]", "terseLabel": "Measurement input, discount for lack of marketability" } } }, "localname": "MeasurementInputDiscountForLackOfMarketabilityMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputDiscountRateMember": { "auth_ref": [ "r429" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate to determine present value of future cash flows.", "label": "Measurement Input, Discount Rate [Member]", "terseLabel": "Discount rate" } } }, "localname": "MeasurementInputDiscountRateMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r429" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]", "terseLabel": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails", "http://www.neurocrine.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Domain]", "terseLabel": "Measurement Input Type [Domain]" } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails", "http://www.neurocrine.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r90" ], "calculation": { "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash (used in) provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash Flows from Financing Activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r90" ], "calculation": { "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by (used in) investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash Flows from Investing Activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r90", "r93", "r96" ], "calculation": { "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash Flows from Operating Activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r65", "r67", "r73", "r96", "r106", "r114", "r118", "r119", "r120", "r121", "r124", "r125", "r132", "r164", "r172", "r175", "r178", "r180", "r215", "r441", "r530", "r554" ], "calculation": { "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net income (loss)", "totalLabel": "Net income", "verboseLabel": "Net income" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome", "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows", "http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity", "http://www.neurocrine.com/role/NetIncomePerShareScheduleofNetIncomeLossPerShareDetails", "http://www.neurocrine.com/role/SummaryofQuarterlyResultsofOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Adopted and Issued Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r79" ], "calculation": { "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other expense, net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other (expense) income:" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome" ], "xbrltype": "stringItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r159" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [ "r159" ], "lang": { "en-us": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Number of Reportable Segments", "terseLabel": "Number of reportable segments" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses", "verboseLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome", "http://www.neurocrine.com/role/SummaryofQuarterlyResultsofOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r164", "r172", "r175", "r178", "r180" ], "calculation": { "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Operating income" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r460", "r466" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r455" ], "calculation": { "http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails_1": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "totalLabel": "Total operating lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r455" ], "calculation": { "http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "verboseLabel": "Less current operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r456" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.", "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]", "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]" } } }, "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails" ], "xbrltype": "extensibleListItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r455" ], "calculation": { "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Noncurrent operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedBalanceSheets", "http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r457", "r461" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Payments" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r454" ], "calculation": { "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r464", "r466" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted average discount rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r463", "r466" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted average remaining term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r394" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Operating Loss Carryforwards", "terseLabel": "Operating loss carry forward, net" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r56" ], "calculation": { "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r43" ], "calculation": { "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other long-term assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r59", "r61" ], "calculation": { "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax", "terseLabel": "Unrealized gain (loss) on debt securities available-for-sale" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r9", "r10", "r47" ], "calculation": { "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Other current liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r52" ], "calculation": { "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherOperatingActivitiesCashFlowStatement": { "auth_ref": [], "calculation": { "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).", "label": "Other Operating Activities, Cash Flow Statement", "terseLabel": "Other" } } }, "localname": "OtherOperatingActivitiesCashFlowStatement", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PatentsMember": { "auth_ref": [ "r415" ], "lang": { "en-us": { "role": { "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.", "label": "Patents [Member]", "terseLabel": "Patents" } } }, "localname": "PatentsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "auth_ref": [ "r81", "r83", "r193" ], "calculation": { "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Payments to Acquire Debt Securities, Available-for-sale", "negatedLabel": "Purchases of debt securities available-for-sale" } } }, "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r84" ], "calculation": { "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireRestrictedInvestments": { "auth_ref": [ "r85" ], "calculation": { "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to acquire investments (not to include restricted cash) that are pledged or subject to withdrawal restrictions.", "label": "Payments to Acquire Restricted Investments", "negatedLabel": "Purchases of equity securities", "terseLabel": "Purchases" } } }, "localname": "PaymentsToAcquireRestrictedInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows", "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofEquitySecuritiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "auth_ref": [ "r294", "r296", "r302", "r303", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r316" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for retirement benefits.", "label": "Retirement Benefits [Text Block]", "terseLabel": "Retirement Plan" } } }, "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/RetirementPlan" ], "xbrltype": "textBlockItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r320", "r351" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in USD per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r23" ], "calculation": { "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock, $0.001 par value; 5.0 shares authorized; no shares issued and outstanding at December\u00a031, 2020 and 2019" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.", "label": "Prepaid Expense and Other Assets", "terseLabel": "Incremental funding provided" } } }, "localname": "PrepaidExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.", "label": "Reclassification, Comparability Adjustment [Policy Text Block]", "terseLabel": "Reclassifications" } } }, "localname": "PriorPeriodReclassificationAdjustmentDescription", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ProceedsFromConvertibleDebt": { "auth_ref": [ "r87" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Proceeds from Convertible Debt", "verboseLabel": "Proceeds from issuance" } } }, "localname": "ProceedsFromConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r86" ], "calculation": { "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Issuances of common stock under benefit plans" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": { "auth_ref": [ "r81", "r82", "r193" ], "calculation": { "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-sale", "terseLabel": "Sales and maturities of debt securities available-for-sale" } } }, "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r86", "r352" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Cash received from stock option exercises" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductMember": { "auth_ref": [ "r290" ], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Product [Member]", "terseLabel": "Product sales, net" } } }, "localname": "ProductMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]", "terseLabel": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r42", "r255" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Property, Plant and Equipment, Type" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/OtherBalanceSheetDetailsPropertyandEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r41", "r253" ], "calculation": { "http://www.neurocrine.com/role/OtherBalanceSheetDetailsPropertyandEquipmentDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property and equipment" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/OtherBalanceSheetDetailsPropertyandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/OtherBalanceSheetDetailsPropertyandEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r14", "r15", "r255", "r552" ], "calculation": { "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.neurocrine.com/role/OtherBalanceSheetDetailsPropertyandEquipmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "totalLabel": "Total property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedBalanceSheets", "http://www.neurocrine.com/role/OtherBalanceSheetDetailsPropertyandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r40", "r104", "r255", "r599", "r600" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r14", "r255" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/OtherBalanceSheetDetailsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r14", "r253" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Property, Plant and Equipment, Type" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/OtherBalanceSheetDetailsPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Property, plant and equipment, useful life" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_QuarterlyFinancialInformationDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Quarterly Financial Information Disclosure [Abstract]", "terseLabel": "Quarterly Financial Information Disclosure [Abstract]" } } }, "localname": "QuarterlyFinancialInformationDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_QuarterlyFinancialInformationTextBlock": { "auth_ref": [ "r144" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.", "label": "Quarterly Financial Information [Text Block]", "terseLabel": "Selected Quarterly Financial Data (Unaudited)" } } }, "localname": "QuarterlyFinancialInformationTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/SelectedQuarterlyFinancialDataUnaudited" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReceivablesPolicyTextBlock": { "auth_ref": [ "r104", "r187", "r189", "r190", "r191" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.", "label": "Receivable [Policy Text Block]", "terseLabel": "Accounts Receivable" } } }, "localname": "ReceivablesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r304", "r468", "r469" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails", "http://www.neurocrine.com/role/SummaryofQuarterlyResultsofOperationsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r304", "r468", "r470", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]", "terseLabel": "Related Party" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails", "http://www.neurocrine.com/role/SummaryofQuarterlyResultsofOperationsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RepaymentsOfConvertibleDebt": { "auth_ref": [ "r88" ], "calculation": { "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Repayments of Convertible Debt", "negatedTerseLabel": "Partial repurchase of convertible senior notes" } } }, "localname": "RepaymentsOfConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfDebt": { "auth_ref": [ "r88" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.", "label": "Repayments of Debt", "terseLabel": "Aggregate repurchase price paid in cash" } } }, "localname": "RepaymentsOfDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff": { "auth_ref": [ "r246" ], "calculation": { "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.", "label": "Research and Development Asset Acquired Other than Through Business Combination, Written-off", "terseLabel": "Acquired in-process research and development" } } }, "localname": "ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome", "http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails", "http://www.neurocrine.com/role/SummaryofQuarterlyResultsofOperationsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and development expense" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ShareBasedCompensationCompensationCostRelatedtoShareBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r104", "r368" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and Development Expenses" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedCashAndCashEquivalents": { "auth_ref": [ "r12", "r97", "r103", "r522", "r548" ], "calculation": { "http://www.neurocrine.com/role/OtherBalanceSheetDetailsReconciliationofCashCashEquivalentsandRestrictedCashDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash and Cash Equivalents", "totalLabel": "Total cash, cash equivalents and restricted cash" } } }, "localname": "RestrictedCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/OtherBalanceSheetDetailsReconciliationofCashCashEquivalentsandRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainLossPositionsandEstimatedFairValueforAvailableForSaleDebtSecuritiesDetails", "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": { "auth_ref": [ "r8", "r16", "r97", "r103", "r597" ], "calculation": { "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.neurocrine.com/role/OtherBalanceSheetDetailsReconciliationofCashCashEquivalentsandRestrictedCashDetails": { "order": 2.0, "parentTag": "us-gaap_RestrictedCashAndCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash and Cash Equivalents, Noncurrent", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashAndCashEquivalentsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedBalanceSheets", "http://www.neurocrine.com/role/LeasesAdditionalInformationDetails", "http://www.neurocrine.com/role/OtherBalanceSheetDetailsReconciliationofCashCashEquivalentsandRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r136" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "verboseLabel": "Restricted stock units" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/NetIncomePerShareScheduleofNetIncomeLossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "RSUs" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails", "http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpenseDetails", "http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpensebyAwardtypeDetails", "http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r27", "r275", "r360", "r550", "r571", "r576" ], "calculation": { "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r110", "r111", "r112", "r115", "r123", "r125", "r219", "r357", "r358", "r359", "r401", "r402", "r567", "r569" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r160", "r161", "r171", "r176", "r177", "r181", "r182", "r183", "r286", "r287", "r505" ], "calculation": { "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Revenues", "verboseLabel": "Total revenues" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome", "http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails", "http://www.neurocrine.com/role/SummaryofQuarterlyResultsofOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r105", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r292" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenues:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome" ], "xbrltype": "stringItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r462", "r466" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Right-of-use assets acquired through operating leases" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RoyaltyMember": { "auth_ref": [ "r290" ], "lang": { "en-us": { "role": { "documentation": "Money for usage-based right to asset.", "label": "Royalty [Member]", "terseLabel": "Royalty" } } }, "localname": "RoyaltyMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SalesRevenueProductLineMember": { "auth_ref": [ "r152" ], "lang": { "en-us": { "role": { "documentation": "Revenue from specified product or service, when it serves as benchmark in concentration of risk calculation. Includes, but is not limited to, revenue from contract with customer and other sources.", "label": "Revenue, Product and Service Benchmark [Member]", "terseLabel": "Revenue, Product and Service Benchmark" } } }, "localname": "SalesRevenueProductLineMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.", "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]", "terseLabel": "Accounts Payable and Accrued Liabilities" } } }, "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/OtherBalanceSheetDetailsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r136" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/NetIncomePerShareScheduleofAntiDilutiveSharesExcludedfromDilutedPerShareAmountsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Securities, Available-for-sale [Line Items]", "terseLabel": "Debt Securities, Available-for-sale [Line Items]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainLossPositionsandEstimatedFairValueforAvailableForSaleDebtSecuritiesDetails", "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.", "label": "Schedule of Available-for-sale Securities Reconciliation [Table Text Block]", "terseLabel": "Amortized cost, gross unrealized gain (loss) positions and estimated fair value for available-for-sale debt securities" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/DebtSecuritiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": { "auth_ref": [ "r199", "r200", "r207", "r208", "r209", "r211", "r536", "r537" ], "lang": { "en-us": { "role": { "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.", "label": "Schedule of Available-for-sale Securities [Table]", "terseLabel": "Schedule of Available-for-sale Securities [Table]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainLossPositionsandEstimatedFairValueforAvailableForSaleDebtSecuritiesDetails", "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r418" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails", "http://www.neurocrine.com/role/SummaryofQuarterlyResultsofOperationsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r399" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "terseLabel": "Components of income tax expense for continuing operations" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r51", "r108", "r270", "r272", "r273", "r274", "r450", "r451", "r453", "r541" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule of Long-term Debt Instruments [Table Text Block]", "terseLabel": "Convertible senior notes net of discounts and deferred financing costs" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConvertibleSeniorNotesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r391" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "terseLabel": "Components of deferred tax assets" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r135" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of net income (loss) per share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/NetIncomePerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r376" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Provision for income taxes on earnings subject to income taxes differs from statutory federal rate" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r319", "r348", "r362" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ShareBasedCompensationCompensationCostRelatedtoShareBasedCompensationDetails", "http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpenseDetails", "http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpensebyAwardtypeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r319", "r348", "r362" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Compensation cost related to share based compensation" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r11", "r35", "r36", "r37" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Inventories" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/OtherBalanceSheetDetailsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r42", "r255" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/OtherBalanceSheetDetailsPropertyandEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock": { "auth_ref": [ "r143" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.", "label": "Quarterly Financial Information [Table Text Block]", "terseLabel": "Summary of Quarterly Results of Operations" } } }, "localname": "ScheduleOfQuarterlyFinancialInformationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/SelectedQuarterlyFinancialDataUnauditedTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r320", "r351" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails", "http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails", "http://www.neurocrine.com/role/ShareBasedCompensationWeightedAverageAssumptionsforStockOptionGrantsusingBlackScholesOptionPricingModelDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "auth_ref": [ "r326" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.", "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "Summary and changes in restricted stock units outstanding" } } }, "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r326", "r336", "r339" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Summary and changes in stock options outstanding" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r342" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Weighted-average assumptions for stock option grants using black-scholes option-pricing model" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": { "auth_ref": [ "r385", "r400" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the change in unrecognized tax benefits.", "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]", "terseLabel": "Activity related to unrecognized tax benefits" } } }, "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r104", "r165", "r166", "r167", "r168", "r169", "r170", "r182" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment Reporting, Policy [Policy Text Block]", "terseLabel": "Industry Segment and Geographic Information" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r78" ], "calculation": { "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]", "terseLabel": "Selling, general and administrative expense" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ShareBasedCompensationCompensationCostRelatedtoShareBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r94" ], "calculation": { "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Share-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": { "auth_ref": [ "r321" ], "lang": { "en-us": { "role": { "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period", "terseLabel": "Share-based compensation arrangement by share-based payment award, award requisite service period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r321" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]", "terseLabel": "Weighted-Average Remaining Contractual Life and Aggregate Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r331" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Canceled (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r335" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Canceled (in USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r333" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "verboseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r333" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "verboseLabel": "Granted (in USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r332" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Ending Balance, Unvested (in shares)", "periodStartLabel": "Beginning Balance, Unvested (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Number of Units" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r332" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Ending Balance, Unvested (in USD per share)", "periodStartLabel": "Beginning Balance, Unvested (in USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted-Average Grant Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": { "auth_ref": [ "r340" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms", "terseLabel": "Unvested, weighted average remaining contractual term (in years)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r334" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedTerseLabel": "Released (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": { "auth_ref": [ "r338" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value", "verboseLabel": "Total fair value of PRSUs vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r334" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Released (in USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r345" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ShareBasedCompensationWeightedAverageAssumptionsforStockOptionGrantsusingBlackScholesOptionPricingModelDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r344" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Expected volatility of common stock" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ShareBasedCompensationWeightedAverageAssumptionsforStockOptionGrantsusingBlackScholesOptionPricingModelDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r346" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ShareBasedCompensationWeightedAverageAssumptionsforStockOptionGrantsusingBlackScholesOptionPricingModelDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails", "http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails", "http://www.neurocrine.com/role/ShareBasedCompensationWeightedAverageAssumptionsforStockOptionGrantsusingBlackScholesOptionPricingModelDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r323" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "terseLabel": "Number of common stock authorized for issuance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]", "terseLabel": "Weighted-Average Remaining Contractual Life and Aggregate Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r329" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Exercisable (in USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r338" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Stock options exercised in period intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r331" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Canceled (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "verboseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r337" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-average fair values of stock options granted (in USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r328", "r351" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Ending Balance, Outstanding (in shares)", "periodStartLabel": "Beginning Balance, Outstanding (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Number of Stock Options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r327" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Ending Balance, Outstanding (in USD per share)", "periodStartLabel": "Beginning Balance, Outstanding (in USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "auth_ref": [ "r341" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "auth_ref": [ "r341" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number", "terseLabel": "Exercisable (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r339" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r318", "r324" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails", "http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpenseDetails", "http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpensebyAwardtypeDetails", "http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails", "http://www.neurocrine.com/role/ShareBasedCompensationWeightedAverageAssumptionsforStockOptionGrantsusingBlackScholesOptionPricingModelDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Exercised (in USD per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Canceled (in USD per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Granted (in USD per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r104", "r320", "r325" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-based Payment Arrangement [Policy Text Block]", "terseLabel": "Share-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "terseLabel": "Share price (in USD per share)", "verboseLabel": "Market price of common stock (in USD per share)" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails", "http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested", "terseLabel": "Unvested, aggregate intrinsic value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested", "terseLabel": "Total intrinsic value vested in period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r322" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period", "terseLabel": "Contractual term of stock options" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r343", "r361" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected option term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ShareBasedCompensationWeightedAverageAssumptionsforStockOptionGrantsusingBlackScholesOptionPricingModelDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r341" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted-Average Remaining Contractual Term, Exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r340" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted-Average Remaining Contractual Term, Outstanding" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchase price of common stock expressed as a percentage of its fair value.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent", "terseLabel": "Discounted purchase price percentage of common stock authorized for issuance" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermInvestmentsMember": { "auth_ref": [ "r592", "r593", "r594", "r595" ], "lang": { "en-us": { "role": { "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.", "label": "Short-term Investments [Member]", "terseLabel": "Short-term investments" } } }, "localname": "ShortTermInvestmentsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainLossPositionsandEstimatedFairValueforAvailableForSaleDebtSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StateAndLocalJurisdictionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.", "label": "State and Local Jurisdiction [Member]", "terseLabel": "State and local jurisdiction" } } }, "localname": "StateAndLocalJurisdictionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r53", "r110", "r111", "r112", "r115", "r123", "r125", "r145", "r219", "r269", "r275", "r357", "r358", "r359", "r401", "r402", "r443", "r444", "r445", "r446", "r447", "r448", "r567", "r568", "r569" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity", "http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome", "http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r110", "r111", "r112", "r145", "r505" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome", "http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r23", "r24", "r269", "r275" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Issuance of common stock for employee stock purchase plan (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r23", "r24", "r269", "r275" ], "lang": { "en-us": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture", "terseLabel": "Issuance of common stock for vested restricted stock units (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r23", "r24", "r269", "r275", "r330" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedLabel": "Exercised (in shares)", "terseLabel": "Issuance of common stock for stock option exercises (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity", "http://www.neurocrine.com/role/ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "auth_ref": [ "r23", "r24", "r269", "r275" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.", "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "terseLabel": "Issuance of common stock for employee stockpurchase plan" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r53", "r269", "r275" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Issuance of common stock for stock option exercises" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r24", "r29", "r30", "r106", "r188", "r215", "r441" ], "calculation": { "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedBalanceSheets", "http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r471", "r472" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/LicenseandCollaborationAgreements" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Different names of stock transactions and the different attributes of each transaction.", "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]", "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]" } } }, "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/NetIncomePerShareScheduleofNetIncomeLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Subsidiary, Sale of Stock [Line Items]", "terseLabel": "Subsidiary, Sale of Stock [Line Items]" } } }, "localname": "SubsidiarySaleOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/NetIncomePerShareScheduleofNetIncomeLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "auth_ref": [ "r58" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.", "label": "Supplemental Balance Sheet Disclosures [Text Block]", "terseLabel": "Other Balance Sheet Details" } } }, "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/OtherBalanceSheetDetails" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental Disclosure:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r201", "r202", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainLossPositionsandEstimatedFairValueforAvailableForSaleDebtSecuritiesDetails", "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails", "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r418" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails", "http://www.neurocrine.com/role/SummaryofQuarterlyResultsofOperationsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember": { "auth_ref": [ "r295", "r535" ], "lang": { "en-us": { "role": { "documentation": "Debentures, bonds and other debt securities issued by US government sponsored entities (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB). Excludes debt issued by the Government National Mortgage Association (GNMA or Ginnie Mae).", "label": "US Government-sponsored Enterprises Debt Securities [Member]", "terseLabel": "Securities of government-sponsored entities" } } }, "localname": "USGovernmentSponsoredEnterprisesDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainLossPositionsandEstimatedFairValueforAvailableForSaleDebtSecuritiesDetails", "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails", "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r369", "r379" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "periodEndLabel": "Balance at December 31", "periodStartLabel": "Balance at January 1" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r380" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions", "negatedTerseLabel": "(Decrease) related to prior year tax positions" } } }, "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": { "auth_ref": [ "r382" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.", "label": "Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities", "negatedTerseLabel": "Settlements related to prior year tax positions" } } }, "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "auth_ref": [ "r381" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.", "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions", "terseLabel": "Increase related to current year tax positions" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/IncomeTaxesAdditionalInformationDetails", "http://www.neurocrine.com/role/IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r380" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions", "terseLabel": "Increase related to prior year tax positions" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": { "auth_ref": [ "r383" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.", "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations", "negatedLabel": "Expiration of the statute of limitations for the assessment of taxes" } } }, "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": { "auth_ref": [ "r384" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.", "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate", "terseLabel": "Unrecognized tax benefits that would affect effective tax rate" } } }, "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r146", "r147", "r149", "r150", "r155", "r156", "r157" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "auth_ref": [ "r391" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.", "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount", "negatedTerseLabel": "Deferred tax assets, net valuation release" } } }, "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]", "terseLabel": "Effect of dilutive securities:" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/NetIncomePerShareScheduleofNetIncomeLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r127", "r135" ], "calculation": { "http://www.neurocrine.com/role/NetIncomePerShareScheduleofNetIncomeLossPerShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted average common shares outstanding, diluted (in shares)", "totalLabel": "Diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome", "http://www.neurocrine.com/role/NetIncomePerShareScheduleofNetIncomeLossPerShareDetails", "http://www.neurocrine.com/role/SummaryofQuarterlyResultsofOperationsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Weighted-average common shares outstanding:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/NetIncomePerShareScheduleofNetIncomeLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r126", "r135" ], "calculation": { "http://www.neurocrine.com/role/NetIncomePerShareScheduleofNetIncomeLossPerShareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average common shares outstanding, basic (in shares)", "verboseLabel": "Basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome", "http://www.neurocrine.com/role/NetIncomePerShareScheduleofNetIncomeLossPerShareDetails", "http://www.neurocrine.com/role/SummaryofQuarterlyResultsofOperationsDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 9 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r109": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21728-107793" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1707-109256" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(12))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1757-109256" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1500-109256" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258" }, "r141": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e543-108305" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=121640914&loc=d3e1280-108306" }, "r144": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "270", "URI": "http://asc.fasb.org/topic&trid=2126967" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r158": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a,b)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=SL6953423-111524" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5033-111524" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aaa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27337-111563" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27340-111563" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "8B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL6284393-111563" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)-(d)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27357-111563" }, "r212": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=120269885&loc=SL75117539-209714" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=120269885&loc=SL75117546-209714" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121647567&loc=SL82921835-210448" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "3C", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL120267859-210455" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "3D", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL120267862-210455" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(3)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922890-210455" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(i)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r244": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r261": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031898-161870" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031898-161870" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12317-112629" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12355-112629" }, "r268": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r292": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r293": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "705", "URI": "http://asc.fasb.org/topic&trid=2122478" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(l)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(o)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(p)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(q)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r316": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "http://asc.fasb.org/topic&trid=2235017" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907" }, "r365": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(a)", "Topic": "720", "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(b)", "Topic": "720", "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=SL37586934-109318" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32059-109318" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(4)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "217", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121610041&loc=d3e36027-109320" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r413": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)-(d)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5504-128473" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r419": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "808", "URI": "http://asc.fasb.org/topic&trid=5833765" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13279-108611" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13433-108611" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918631-209977" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.2)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971" }, "r467": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r472": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL6224234-111729" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953" }, "r521": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "940", "URI": "http://asc.fasb.org/subtopic&trid=2176304" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62586-112803" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62652-112803" }, "r539": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/subtopic&trid=2209399" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "405", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(15)(b)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(b))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(h))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(d))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121641442&loc=d3e19393-158473" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(c)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841" }, "r58": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "210", "URI": "http://asc.fasb.org/topic&trid=2122208" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r596": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "946", "URI": "http://asc.fasb.org/subtopic&trid=2324412" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "740", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r601": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r602": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r603": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r604": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r605": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r606": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r607": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r608": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r609": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(7)(c))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(8))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3151-108585" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6904-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586" } }, "version": "2.1" } ZIP 84 0000914475-21-000020-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000914475-21-000020-xbrl.zip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

60J,JMUUFVN7N^@>/PBN]84[_WU]_X?@Q'"60V]_ ?):[9PY6#KE1CM4*D TY)S M%JSQS!LG4RPBDW_6@@R;P7MJ'&F@E :[2<4QKD!P_&[PZ[E MYI+VE""7O2HV0:@GV<6P*&1F 0H(GH(Q;:)B[T7VU C3K2HZW%QFYT97U^OS MD9,7-'.H?\=)KP@>E+>)"2E"-7TY\^ =*QRTJ"$\46UVWGO'2YZ*MCL59@,O MP H"A9!2**F3<[S&J6%S"HI=,A%>FQRD[,6T5.A1+>B;^!E7CD_%W>2 M_<&40"Z\H^%@_ ++<+0(L?@$WW!,Z]<(Z/W] 8R^SPQO&EV-U"9QG\W&-[>@ M>LIG@"+(8]9(WI1RDD$QF:$0PD8E389&T9'-QO3HW9R'HN\&R]LEY,74>H$# MTL^DQYU04D7%4M21:12.15V01;!!II(LF"96SAH\3X1"^\FYP4I&&^RUDQS/ M32*^04U:J*503&*@G&?&>6Z=U=JT";^]@>+1JWIWF39(^9R942OB_JX\K_\[ M/*LWG!<.V+O!M6HYH_Z8?O2*OAU\?H^C_C#3X-Z5&F #,7E4F?9T2/4^*&OF M(Q3FG,TUD+0DW<1Y;C6@1T^[!Z'I-IFJRT.ZA&9)5@F%9%P&R[10F46O"LO% M2N#!",UC"Q+>@>G1\Z@K>3?(2/T51@/BY_@B0[86\$H]&8/5BO H52ML!"Y9 M--*1OTC.@<5Y_M[QV?_$6G0;\\E7+3W M_=!2PK_UTD0GD"65) U=%!:0 TM.VZ*U@LQ7U^%^*D4Q]M']'K(\=E&,\6C2 M>S\:YFF:O!M]Q-'7?IJG;LM4LL-0_?M @_ .6>#>,!DPZ +6E[")14+/OT8& M^FZ9".L /)!"&%OIS=7(C4%M4OMA&X;?1'+;( M13>*NJWUCJ1\. H(KD,1@N58J[E);: MN54M=5>Q=EUPXN7PC#X:SN_O%AFF%Z47LA?9RLRBKKFJ.D4&'( 8C='SJ(4N MFU6<6/^.QZS++L5WW#(3PS(KP'1[5->8N73&Y:5N'\T2^4D MN,TFY5QDT*AYR*!=1+"J2$PE%%Q33F+E>SHO(\%-3CYPQ3*@9UKDQ"+2(IF3 M2&!D#EDWJ2W7?1F)VTYLB#%D5([95"+3)'$6R7VEN4(N$P?RG6*;+*4'>7RP MC:9O5S/:1[8-*DGL M[OVDV\!.O'G9KV(*Y-L:1B9O386IQ96<+DSD['/]@T.;D, '%T"QCY9WEVF# M@/#?8/0G3NJAQM5M^8JP=5NX=-Y*AK$DII7.S'L:>>:!UVI-,H4F87N;P7OT ME&B@A0;91B?YOZ>+DFN?AB>F M21>HU@-[]/Q\4)IO$"9ZDM)P6L->/W^LAA:,\OB/+]4O^+6Z%.,^3>.6ZW&1$PH41^Y8TH$S M;7PD[S/1" "#R>BQB$8=3K?&^NB)UUH_#6)9[X9[7F'FF;%H8Y4TR- -2'6PNY)J;.4)9#CFVOE>B\9!().LT,'K6E:M#'X=T+[5+G5H8Y: M!/?>O@52(AMR$9!H7JN(9')]HS*1"2\Y"J=CJ]O#NV_8.KE/ IJO*))@M04$ M29NV"? $):0(1L?BP#5)S;WO/FGO8-JB'0B(GAFM)-,!"@M2R%G?"^F4PN14 MFX$]D&#:_6;NSK(\=C#MK2$L'1>,YTV1/"IG@F)*V1I64AMFTG;&7*PU)K,' MX=OVE5B%ZH&$VVZE[77$V5OJS2IY76):1"UM JIEU[F5J([3:*Y#[:VLU]6% MZ _&"TQ>VT@J\]HXVAG)BXJ1 \T*(8,"0$AM,D$/QX=[FLD=F@[;2+P!#:YU MT5T$'YI(=A^0N8!M$ M5ZVY7EB RT75*W[)$) S'36R(+AA(6>'R1CG3!/[\4Y43X$'W8F]P1IPDM+T M?'I68U37E<"X (HJI "<@:A5P\AE)1%XQ6S*7,=8HO--DO4V1O@DN-)$'4U: M8$QHK)@O0<#6=6^53[$2D6%$9FI; Y MUB/YLLDQRT;979L >L2N9A.9=[@D;()O,1$V0=AUVN=FT Z? ]J]2K?@RQ[Z MZ#A!=$.D*2!PA<"*LD!F$JVC@%XP!TD$Z5!QLXGU\> 9&$QA\"2MI(;'WU*G143V!;<83,86RAWF\UI'\VL M]8,/E./X$L:GK\^&?XUO MHOM?'JH4TS&M=@7TIDM"YI$X7*/$N=10CD=289 M@U3!>.[XVD3&E:/85N[O1I]AL&C>#H/\<7I^#J/OP_*Q_WG0+_T$@\E5V.Y[ M@I'ZN),N=GM1)_KI8(Q+.M/6)QF$4Q R?:U (TU7K9/6.A>PO;U'>Q ]'ER? M#T"O&^F7EY3)O7>*_$:MK >I2-6T>4,0(5NWFWZ/IN>K([ W@S('S:7S1)'/)*I5Y*30GF-W 6,WNC:&5!'Q&)VX\B=;F/.B$M.K\8R7UMI6J6\08,E+'<;6E-58C\<>Q7- MN"C/]F;4'Y_6H/U^[L.('M\+2MC W9G1K M7W$X@_/0VKY16*,;$3>X>[D =MD"\.,\ZJ.6.+#T\W^I&_\?8RS3L[?]@CWKC'("$Z.%M0JE MFHS:>Y:C+"Y$(UQNDFJS ;;GPZZN%=4@,?X5?AEAZL\SJI&&J"0B+DH =H?_TD66OT /J/H&5KL M?"W]R6WV\XXAP4)B$+.$FA:68I/.+'>!>CXTZ4PU#7+63_*L\D=M-W;1SC6 M$%+:PK#>]L^RGX,*6)LY:TC2&).;N&VWH3P?BNRIAA;YYRM+=IR,1C#X/+NP M??']ZE?>P_?ZT1$ FC(> M>=(E,BC5R"3Y,##2,V6CQV0%D!Q;'4)L#O/I<_ ZFO2+VO763//0[@:UGB6 M3?+I% :+NCF_UZ&/:>CS.XV>Y2H45:HW)&M@NN,T4O",2Q]5DB'8U.3<]6 C M?#XHY!TZ;B#*\MHW/A)L'Y#$8M9S*UF4P MR4'J9!QULS^0:HY=>:/&/G^HDVH6>5\T#R+&:H] 8CK6)"_%@<8 (MI,]DK8 MY/QWHW#SR[<>.JWIH.H=[BOFCC,09B 6(>R;P.@ZD^G:^P^?KK2C!I9UN(?X M&FJ3VRB"YH9)HB33IABB99*T\(%%7F+(?I/.$P]#BW>D$'6KQ&VDUK'R?B-) MG4_/%T"DS&"<5"PEP9EV0$ L&I:\C";E8!+?I&S%1NJ[\>;#IO'L+/MA%X+K M,"AR!@2^70-B%6@;DB?[40>FI0PLB)!8\-F[XLFM+YTU@[SQYD>HP9T%UZ2$ MS-)5R8OO+W"03LD@^'.VSL0 VG#D+$A.#!/"L>A58:!,*#K%Z$NCBC)W WL. MAE,3)34(7KR-[P+=(C%Q$WPM*Y;=!_ XQN]G.E )P=9@)9QBF)1V, X MS[9VM*OWM=&R9'C4(&2QKDE8SG$XS 6RVYZO(\?>RKA$';*-8C")6=JWQ-,M:U.<9HVW5#O M4KBWX%TVH4G?TX/S8WOKI#D]MI%]"UI,QY/A>:WSMP3Q8D\LNGB=-%.Z5JL' M)/<^>,>2 F]$H055-;F6O0?7 [!+=M7A,C*1:\-WH=(7+TT AC=SC>Y!*%UPQW!#(%&H J&> RC'R M_X)*44'7BC\68;?30HGW ]59&%_5HO;(RY4P8>"%(UI&E5G=, M3U9:!E>4:V*HK,!RA#92':MLN7G GO)N8)?4.,JK0+&YA>[0B "2A2P$T[I8 M%KS*+&A/"=+9$]%-,B5O8FHSH<+3WP#7"T-CW7 CF-N[*NX M.WFPI]0;[!EK\6'0/F6MF0?GF([)LAB"9$E*7C!%+*J)'W-8-MQC21R*#-L( MNT,2S#- <- ?CJZU+O]].*$5\*_A^R$)CO[[NO\5%YF6KZ;X9O ;?*=//YT. MIV,8Y$]_T>??7P^GHXO8%6U43!*93$#;JE*)!6LT,[226N&MC\O][M8E\G0+ M[/#F1S?J'CX07;5H?%.CVR^/$CT(5#X4!A+)%!,06.#.L&1B\-QD#FV:'-U M\9QLE-W%WZ#\PKW9$>,[7-DV#>90 MBFYQ5M-B;&BX\RD$%JU1Y$@F9$'&PJPB%U62%>+4<7*]'PQY[['B'CAWM]%O MU\8?V0JS8L*#-(?\ ='1U3MLKIO.P\7_FPS2Q67=O!\G&;?H+!26N(Y, M.U>8M](P)W@R/DKKP707,[[\^N=@P'4@^ XK)U4T\^/5&Y@6]-\$5-<)66O1 M'#X]:U\U#5O)N./$G_7@P$074\PL)F.9SC8PR*2O["T1/\:LXB;U'A^BXN_( MZ#J(WK<1;=>6PUL8?:Z%;/\:7HYRL1O1RV4,3K)C%KW%>#:N=IQ;ZVW_51+I,& [-TS8L-P'F9U\IGPSTO(WP"T M60^8^Q_:24^7+;$O]6A15A:KO98B:DUVN8\"HM*"9S1:%]_;:A2=R[WKOCS[ MO? P^MJYWT[00@)7B0>?M84 6)SQ.26T,04N[]=E@]XZ5_&1EV_\BM<]27(3 M?A\.TIH?7PM4N%;XPX&Q!F5DUD;)=(F\ULJE/Q""$: "EDT\JQT"DKL;Q'[' M%4/2_*0/9[_USVBA'0YPX82/>UD6G3T)0P1TM+XJR0"$9:KH8+(S2NO-ZL>M M?\0"RV^0L<=E]L4AX?$2:P=+26,4JL8& M2X/&&5'$1BQ8\?#GJOY]Y=S@G/W]"+] /R]*O)(T9A6Q3L9C)$X6R,4D0!J9 M)1/:&V0>1&2N@"H0R91KTZKB+E#/D#N=ZZK##/<9KS\@V02C='K#*/B$H_,> MYS8YZ02QNR2F%1$;;*J-R2SY!E"B=&:C563M*YXA'SJ4>8?Y@CT$(B;S&!2.0M61# M82$YSHJ$[#S8J$.;8.Q=$3]#&AY6RPWB?&<7E.]'Y//VC/=0^VBR&(NOQ<2 MIDRH19FE318Q%VP2^GT%X1D3:$<]- BM>C.K#EM'^>ZO >87<%;OE.<5E7O! M9Y<]N6Q>S!936YCW*;+H,M<\.Q';M$>Z"]0S9DUGNFK0&F=Y27S]]??^55!" MCVO'DPIDO"-73,L4"*ET-)Q^/GTQ'9-@QF,R#B/MO554M1,=F8SO2ND5 M&A"JZ!AP%:JH0DWS*\PD@]H4*+Q-_'#7 WG&C#TJ)SIL_C/S998=EUZ$$'F. MFF6PF6D3# ,E-'-!Q.205O"PV1WJ\I.?(6/VEW"7G7"N^#NKH?6:Y/5R6*M6 MI$GU&R[N@G_]ELZFN3_X7!E-_^1/\*T7DBP^"<6DK^Z"RY(%Q0WCQ20K9 Y% M-=DV=\#Z#'EV*,VVZ(FS"NC;/L3^&9D%BP%]P#3\/.C_+]D#1JKD2T*F7&V5 M#H0Y&EHK,4G#@W625LLVMXO;P'S&'&RHSQ9-N6=1!D^:M M51*B![M9NY@U+WB&;.A,WBM(L//!^]U!"#-X7R;C'G!"Y(UA2LH*SQ86K U, M>. Z1RF]=?M%@%R\ZKD2HUL=K*#(SH??OE\O;KN'#YS&>K]-VDND*[^^<(IU/,TUK3IP/1S--OO"9/405@ M-F1-A!6<>4,>8RZF.(RB<-ODT*C[H;3N7/9@6/E V'#L+F=7GND9S=#\'D:3 M[]='].+[]9_,,E# >AX=!V9";10<9:(-W&7&:70\:N$MY!9DWQSBH;/W'@J7 M;ITV--%I@TB\ZW@NTBBX6O#4&50J/F1/W5"(X'B6V$7S7J8*?X$_,\/X41N>0<#KIIUE\ MUQ<8?'_;/^\3TD6.%'I>0HJ!!1?)OE0E$,C@&9"7:8+01N3-/+A-WWAXFWY? MU0Q;R[7K*/TW>3@:]Y=0CM].+K"I$B4W7#'K::^MRJ[E**74_O_\+!<+"$[,T@711$#9"=S:[4Z"7"@-Z([VN?<7CUFDWDNLZTOW%FY.W%S""!>\!F8::Y0S<,I^\9 :U M%,Z)O&E&]]4S'[?&=I1-AQ'FBZ"&R7@:^^/3_B<8T,_FZ\++X>C+(EWBHE* MC#(Z(1D*6NBUS+2I@T&6C(@E"XZWPNW61I-L],+'K=P64NTP>'N&\23&KWV\ M6OBM,L770'(3DZ[5ZH$!EMH:FO[//<]2;K9U+CWX<6MR'RDU"*ZN1;_>E6LG M0?,VWI!-H?V9Z>0,TR(KPD-N*8_"2G+@2G2;%+W9VL]=B>;'H5I'FNK0NKJL M37A+&+!Z_ NV;P*WY>':EGB/<_+6@::72^4>0$T-3N"VA9V+]C(YR4()M/L) MK5G02C#'E495\[NCD^J;;33I%7BZE5Z@0Z4$HHGQ1(FVM"S MKI6K@F 2A$C6.REEDX8!=\,ZO*W35*NW@K8Z4TF+)GD3,OHJG'DB2CV:' YF M8IF5PS,YJD@J=:DF,SF3670V,0$F!/*00_!-K@+N1/7#5.I88-Q,:[K$ M=%$#[L#LB'^]KA'9@.VTB\B9ER?CX<7._)5ONQ21<]9Y85XD MSHK+W!OOO95-=II;2 YOC'2@H5LFQS[B;6!EO*Y"Q+V+,R\O M].+[O+SG&8SG9/>:#*KB(Y.>;"'-?69@8ZS5R[+5Q4+13?R;+3#^L$"::K5! M/9@[H%X!O=ZK9 .X+2V5+?$>QX9IIO_->=:9\AIL9!<.T>^^BA4FT;G;6HL3B+^[\\I?!2*TC A"RZEH@0 M#(0 IJ2.!7($E$W2]6Z@.+S]U%1GRX42=Q9XQSU=WH^&>9HF[T8?1F($:0^:%9%'0M\%)5V:WXK:SKBZK #QSNZ@3O71X87T-3QW_ M%X M,0TV =5UTY>U: [?]&5_1=W6>D=2[KCMRWIPW!?G JU_M%]FIJ.NV>H&J1+O)N/^['KUJ.Q9GB]R;X72U/GT_&)K<(5K@,A"CC7TAD/M-ZT8;12YT$AJ MD[&NU'?CS8?=97>6_; +P:VUDCOND_<*X^2JC.[-MV_6@&WI"9UT5+L+U7*+ M-(Z0A":11J43(@1.AHZ2(EH0T6-O/;[]9#7;8CN0V.(Y#>2V"N&2]*RUJ0 D M!QRTDHFDQX/61I-IKT7DO?NP[B?#D_/A:%(K^KT#\L00\864MD6Z.&OZMJQZU;9C)^B?,1T; MJ+=%IM*.@ZB;V]4@' !-L1*8RZK4,AB>^1PL4]9I(\BU,+))@ZU.T/_@:)?J M;9"KN01Z:4@G9V?#OVJS'OK^Y0AS?U+!]PQDB8# O)GYL\XPFF6:J:BL1419 M3)-,X%W /F4&-E=>@TR7]3*Y.9J>D,$E;C-3H09TAYR8YYP3-X0R1_RNQ4Y6O[">XD^@:6_DU$+\GH^SP<]?_W>A&>31"VS)"X'^)QDB+V M5>:=W.A,$\?A3"1/0'B+K*"N77=EJ$VAD4$,VE@1B@ON*7'EGJ2&PU-E&P4T MH,C'T^%HUJ7@"NI%*):0W*:8#!,HD>E8F]?H7%A62!MT".#:[#7K(1W>'NY: M@;>:'7 MC(X[E&2+=&\8UW:A]3\UV?DKV4\7J>U9!BLSIV4NB43(4F8^T;!-"@:B-U"4 M:C'OUT-ZVK9F1ZIH<')WU?5X-<;5GUYD8FV O6T_@]W!'\=.[8H(M[L#'U:+ M37HB[#&&J(+CGK92P"28+A@9&6V%.&,<&@FR;!03^ 08>(_U^Q )N(WR&I5% MH0VC#V?O@7:.B]H=/GFAG&8R%]J\N?/D$V3.A$ZQA**U\K;)%KD*S3'JTAY* MH2NJJ.RGC3:55&!0,;T9D%BFES4.:6@!$ED:(D@R&D':6F$7R43@UGLM,)4F M5UAK\#QM(ZH+)32XBIKE310<7>73] >?WY45:,?5^1BO_M%%XNH&8VEI474Y MF*.51]F?)L%/,.S(-M)&UV!J1)C9I M47HGJL/;:L=3^"W;K2MM-;#A_OCXC^%7' WJ8#]^&0[&PQ'F7P<3''T9]PS)EYSW:Y=VIKF4ZT( M^<.:IW"9GK J>'!\^=?[@YM_]R+5H;.-_&2#YJO M7&8:-=)FR2.+$3G+ MCNBBHHK&-3%MNAW&0X]NW(:9VX7--E5X ^NHV]%<"UN?10O+X+GQ6M9QU4H2 M/C$?,FWPKA078@I<\8?/YJ51_2#W(>C0P*G<;W 7@WHWJC?_];3;!2=TD8Q; M24-"*QB-R#*E5/%6V^"6VT4^!'(O#^,'FYLH_.#)-MN.9GEN"I*RDKRP:*#> MM-0ZK4DY%J1*A1?D$!\!FW\LU4>@0X/+E;L'MWI(O1RC*-(D%B &IK/*+*(! M%J5,/$G)L33)!-\%[/-E9@?*:Y +M OFY3E3I,K)H&/%D &O9[G"062&)@1O ME4EHFX0.=(#]!QV[4VV'-:6WOVA7U0RQ')A0+C$-GMQ),KMG_6=,2 5"F[8& MCSQ3;1]^M5'.0\E46W=3:8N-W-5JKEA[?2(HY@LD!MF5F@8<^'(K[F<> K.5 M\C<,@=E&"0\]EF"3L?P(@=DE!&8KEK0,*MA%Q0^=MMG'(M!FIBW4'';IR&XM MGE@6,,NHE?--G(Z'3]<=0V >#%NWT6P#ENYTM^U#1+P2-> M6I>#,E:!U2(!*"F#+L[)C(YG6#[]>M)W(*T'<]KIU,-Z@/'6+6 MR40K5=+:@8U.&.FU<-KY$+5?+=G]RT2O?.RB.>'\DPR3RU\:#C[4F4./^#RK M2KK'\M+-B]OI;#\9+"]*7 7K$V2(4H/,WJ/Q*@B3A,]>\M7:W1K"GN=6E_%R ML_?2?ORV#[%_MM@&YRC>7;UZWB1E= /)U?F@D;K>2P26P-28T41.B:PGP<*Y M*"T$U:;99Z>CZ*[FS+CG0@H\J<2$3[JF^B46DA:L&%.L-MIFWZ22P#4,1^A] M>C1.K:\^LYTJ6M12GLGB4C2O^N-Z/$V2Z#E9#,CH6 C.T;"\)M>E BNDK&RU MIM6B!4?6(GK.C.E&30W..;H0T?R$79A88C*9\2)T%0^R8)&&5)S5V>MHH,F: MU-D(#G4W]G!8>1SE/YB[M8O1O_A^^>7_[>.(D)U^?UL[*LY.1),E4\M:S5+0 M]>8(X[R]GM'19A#!V=3D;&4S>,>Z>3L2==81N#L5MEQCKQODM_$NSITV =OR M)FXKM$>Z:FN@]G7,:J:SHQ-->%% &\&L=,!TC(HLCRQ9P)A06LL!FMR=/0"" MW7#+=#*>24!% MLP=CB7R>+-E%%0=:2]1%1WH9C1,<6!2I^L*8F2]&,B6E=P!)R-RD7GXC1 M?IYTW3$N\L&P=1O-'KPTF'(JH2*_(T:09%NZ&ME$+/%1%U4".!1-"C<]Y3BT MK12^51S:-MIZ**7!0LB"_!0R=4LM&N6K-(S/S/"L('HN2XX_0FR/3KSFNFVP MM%VF$)7A:'PCA6B!KW 3,3GRG(LGS[GHZCESQ;AQB605K+)-PKOO _:,>=:I MSAKX(K5*]^3[+51"!G2J5A8-M?51KLV-'3AF"Z:L QH5FKBQJ^$\8_YTH)\. MZR_,.MM\&D[@; TN;7D4M66GL+R>\)K$?,J%!8,)2I1)E:6[Z#5=@NYXR3-D M0Z=R;U >X8[V$0I%D4";I./UU"8ZPV(ASDJ(4)2QQH4V%O>#ZRGT,,[$.E)5 M@Z(N>_66V 3[CYY#+8C093VE;Q+(V9N0;&59WO>6Q]1/:1EG#%I)ND4>[*(&T>3?NG3KU57XQ5^J56I+GMLT:BX M*"SG6I@/,3#05I.+@3)X!!EMF]X7ZS$])[ITI)D.#WIF"]Y-@2P I:B*(&ZTI:QZ^C-0>C>2;>!(K>Z5EX4%84IF8+&6"TB* M11L]<[G(!*HXY$UBEYY$Y\)]UH2]M='@P.9: /&U**[7(_R?*0[2]YD17KQQ MAG8TQI'7=HV<".Q-9.!2H6_(#,]-2OYN@.UY'^%TK;R6_%H%<'$0N@G$0^>1 M+&$\>O9(-_K=(+2_"^4<*&%D&6J&DHHDAXVVUUJM)AM:G&UD.J+6"GGDIFWH M]J'YLWERR-'HLXU.#I5G=+DJ7V[J*=L AH9OR4K+)(V8A&0N8/%:QQ1CDYN) M3< ]C*CNO;2Z23[1/BI9>_;2<>&I=<"'@T0;_ZR$TK##F9#B&U*S33 M2FY+)6B,*P!!@P8.F@RJD&*.,2A%_WH492T;NP)W_)H';R\3\(4$Z;B.+%M= M:NE\R4!$PY*Q-AAIP>>V:90/H3C-LBY??_V]?^42]HQT*<=<&*A<,R5-/?15 M4.N+>AND0]NF7/7=L!Y[09)MF'=?X,L>"FMP2O\>OL_#/88GB8".\ K:]=H[ MVCE(6I-OEVI'JYP]\\DX)H0"86L*5&D2#+H9O.=,KP8*;&#'KIH$5QTI_D$B MG[6?\,88*"HSKS$PS6MZ'222"_@ ,4'4T"3N\1S(F58IL&!* M[0["970*259M"_ \S\)2^\S+XRC_ 1:66GM"9+/P/JI2W7SR]8,1+"BI6,E" MYL(5V-3D(OE9G/YO19H=3O^W4=Z13FTW@?CC]+\+_>YP?+N+_J_E59W.?W?1B5-.IBMLX>*FG@)E^AN=@F-\#3TH99!G2D1)(] ME+16WWM(N$E1B258EK2-QAA]K4/E/)>(!<7CU?A]B1L-%;Z- M8 ]PX'I1DHZ':&KY\NZ2JC%XE$6G,)9'][%UBH+1AT@@CG"_6I[;NQA,OMMW1R4A7*FP0G;U= M^<1-P/XHMMVYVO;-N$H&$6@6QJ1%<@[RY$79CR-1902Y&P2=KJ M R!8-\6V#\>O;51UX *Y43B"(!3ST9(0G'+TE91,F5SO$+WCC7,&'E^!W*VT MN46!W&U4<=18RJY[>6[_DH:-]7;M[,FM5<;ZXKW5V@D>8\D)LI.HG4YI71.] MNUYW_.OR^O=GD#YA.AWT_V>*UZYSG0PZ&)K=R=8"EI%\26]T8#+*DG7Q".+! MMF>Z:V M@C.NZ7PV\WN%?"1IBF4&.4WV9&FR:YKV!;@7D*LG?K (H&5PCS/^ MIS.N;A(2M)<^6SK#W0IP[N)I!<8;VN9BC.3B&2%8M#4)CB,FS:6,V+:(?H-! M/:8(FF;,?C"L.7:<.08"G; &)+/&Y&KE91:L"*R>:P%F;L5R MGOU*OM-#KW&=OEOF^8VW/N:3H&XX,-Q7%QVZ3I<@+LHW;@!CBU.=S:EQC()C M>VA@68=[B*^A-H.V7H&6#%VAS5J3&Q=16Y:=$CK$H/U&E14>AA;7'(9TK\1M MI-:Q\GXC29U/SR]*,9B2(A1@JDA:2X ,+C!%,,ZQF!PM>6*;1()LI+X;;SZ< M8;R7[(=="*Y#(W4&!+Y= ^*+4=&J62V=6E*5&P8>,BM1%S#)5$"=:?#ZFQ^A M!G<67,=S\)_8_WPZP7SR%4=P.:QZDYA$ELQQ [5#'&VMQ#9]]M8! M^F$G#QMH[D",NBQ+<#^REG>DZZ$=YT*T&Q5NP(L]Y-_@7NH.A,H*8<%Q9D5V M3&-*M8>,8]QG1UN=!.!-NDT=FAGWW&0>FAC;B/T A'C5'Z?A=#!Y/1R]A?3G MNS*O_3I?=K\O-DX:*==(4LB6DSR*\+*$+&UJ<@^^"]C#GZQWI>Q[ M.-2YI@YUP?ER./A::X#&VNEET!^.?A].<*=;S#5/ZN2J1".3DZ\)S MO8XV&6/QELO,2S3<)15Z]^/M1I8S"Z=#B2Z>UU"NJQ O21=4%,)PU&"XSIQL M=!T@I>BY NFE6B/=V]B[D7'7-_([O*6A/G:^DS?2E !!2.Z,CB8 5TDZ3)[3 M9IED6:.EAI?RM4O958>9JUL<* YS)N(6T%H=Z?<@C*Y DH,U*N";)NVOP M[+N1WWSL:TAXE.;]>%X\@$F^'%"?^3WY'[3#^ S]K)U.JELF0V!AI_( M^85:7E=E8[7EPF?3Y(YY=@?$/'Y-GQ-;-;*1!8 \M)*EV<-#DUR06] ]/3H$=70F]PGG1SN-? ?2(-CT^'9_G3 M"')_\/D5?!_WK Z>[#%@SL8*-F1RD$&QE#TDH''(O,FY])[KR3THGP9GVBFF M03+'_6#ILS&FZ:3_%:_A%CWC7!' '8L(I=8[Q1KVBTSP$FP)ANC?Y$AJ9\3/ MA5U=**Q!1?7[@5_MM>_*Q\DP_?E^U$\TAO[GSS6YWB9?? [,8E),<^UJ]X*Z M^GJ=>"#7WAS 5-X:]W-A77?*N\T]LU?O& (R2/TO<#9W MX-YO#K@7.U\WH^ M"05*%.9+[9<5A&+1&!).2B"ES(BX61N9>U[TN)G0N2AOJ]GNI>9%:,=U'BZ6 MOSD3AV^!#'O\,AR16?\1SG#V<:_>+!,#:<-U,C+MZZVU"36@( =0(20I-]/^ M;N]_ J0X@.!O<\7MUP'Z:E]\-:W7T>_B&$=?9P=;-([^,/=X( M>UASN7#OF M8.U%7*JWQXOP)(\HELLRK6L$?>^[G@ '.A;H;7W[O?1=QWNU5-W&)JT640K# M3*FI^W[>TCHPF1PF<,+0HK:1LN]YT1/0=)>BO*WFT,S*O+%3]8>B9Q,9)04M M*R+%>OLF63!:,NNXDI%C-O$ 1\QW('S<9&FKD!7G:QV?SJY$.MNY1"]&+13Q MG)E8;XJYH:5,6\%2HL4,/4].-8D!VQCALZ'.#@I909V]SV9O+HH+I+40^P7X MCZ= ?M*;\7B*6?30D^,M0V U'Y9I[4V-/B],0#0J1J 7-,D4W0[FTR%1(]6L M8-)^74XW(CR>]Z?G/1 Y.A")Y>02TQ8B65.6=ETM)-12["G[C2V6S=[YN/G0 M4L KB+#WP>R,EG-/*4(064G#BD+#M$+'0B2OFLL8G0C:)-&D5ML5A,>M^CU% MND*['1^&?L",YU\F%_O9=4]ZZ<2E_B:>8^[1?J=*-H%AW>=T48$D0A:3-JJV M]E:%!-'>!-D>^--@TD'5MX)_^QV(OH31Z'L-R9\?XI6+P/WO+X?G7X8#POX' M_:?NB#"@N6*U3$I%S62UQK5R-4*1 U-:%C"J\.AAHZUFN_<^;J:T%O0*4NQ\ M?'I_+,3\3&?AX2MI4PXAL<0K8WF0C)Y5,W,(=O!@K&VR'6T&[W'3IJ$J5C!F MYT/4^SVT)>9_.L5YV9!+YO=,BD$'\MDB]SR))Q*+-[!&11JLRBM<9S98O2!UB.*I2G M2(^M1;Q"Z^T.=3]@%5.]>%CD6Q!UZ2?_>^U 6O1X-&1VU6MG54L1>:X)N-;$ M631!V*22/&S@P":HGR*76BIN18!=!P?"!4&=F_*]?:VG" M=^75/ -TM7\WR"P_>:[%(-_L5S>L[XD+PF MUT_[4'N0(P-M.$O96A#<.\3-'*M& !\WJ1Z,ZE;PL>/@WP_X93I*IS"FJ7.5 M[&"%"Z%PQ;P3M&L;26AMK<=@ZL)JR5[#)ET=-\#VN)G52@DKB++W,3*A6C0* MKI,@3GH*R'PWM'36ZU2FLTPL"AF9L#*BRZJ01%JP8AG(TZ# 7N)=H>^=#Y9G MJ]UE38Y51TUOSL\Q]V&"9]]?8!F.\-=O$S+ IOWQZ?G,M+4T;E5UE8;7!GN2"5WSYZ"6 M3<.L67$"I%?1J=BD.OK=L!XW:1J(?@4S]CX/1W+S/)?R=S,OF(D\F\DFY/"(Y\L_X.$-'X['(]Q_&YPF'91)*AM MP#Y TF;9AV M0'\4CPR"*[13&S3@4L3E-:)-$8<%GJ=!ARZ$O2)?MN,HX7FY0A=!*U$<0^!$ M3(F:!14M@QQY]F"X/42QAH/6\3_ S=/6HCUVU?S5XYC5IPL>K8\RT]+%:WTZ MJ6I!2\4D1,>#AJ#2 2+&CUDO=&_EWDF6K87^ZKN#MYL*?4#\D*Z4,0QB4F7=:+#K1.(),!??32<< FC5@/RX9["GH> MB@S;"+M#$LP\;STW5_#]T,2'/WW=?_K1=#HJ]H)[S?X3I]^.AU. MQS#(G_ZBS[^_'DY'B[*1*:KD2I#,&*5HBY6>@9>!(8TJ&P,)\V8N:J4%"$+S,<:.)@,?16 YIQ*46OP0>4F!:,>6A7SKJV2 M3@1^V.+CFR#[47Q\6Q5N7F-Z%_D?MOAX+*$&&M.$JG_HNBW';!QSY'P[9[.W M\6 M#QYB\?%&Q-A&[ RS-$+&;/*RTO_ ]+XFHW^> K?1II=*_I: MZOLL[O[=X&)CX:)8:VO&!R^<:2$+JWXU(X^6$\0$-F^V?J]]Q>&VZ4H,+/"2.$"*AOTR]I' 4@>-2,N_*P%* M\D)G-&#(^0,MC-52>Y'7=-#871;;; M(5V2/R<9!^^*E>"U0/!9A.# !G*H=+:AMPGFKF2Z>R>?>Y[85+Z;=/,!B,+D MD&M 7B9B*Y_J@;7B@2NR=]9*>?]^/NN>_&90,WF&HS[NLU)M\?2F.KAO-$OZ M<,YX89R,%H460?GBC?59TVJ$)O+U^KA[7%WIYOUH2([SY#NM:S4@]$O=@QLH MZ:[7--76QN-;WBQ4=F"2S;PHG9,)Q@A3;,P>K2+O;:W:[GKAWDU$9D]^3^^< MG%Q[_-NK")X8%6%4K%9L)A\GEIJ,8%BHB9:!^"9TDQC_^Z%UT$%E]1OF.:;> M9".M4@RAEGY#,MACT(7Q$D&CC4FZ)E7Y[H9U^)/,CCFRHJ5*5UIH<&-ZDM+T M?'I66_^\PB\C3/U%MS-:N&9B'^0;J>KK!M-+3OCDK62*JT3CJ#43: 1,2BN1 M6V-S:%+>I*L!/#G>'46S;?I K09&3D:O\!0C>;,T9WRMU,%)0+4CKG+:YJ2, MCJG)C!'*1O4H5@ VS'NCILPXE-%ZD==7/(G>S:W?DF$%M&)VV \3AA2IWK M=U/^[*F<(_'(":3_\<1R$00U<\< >&19@I(\BJRA/"G^W!/,]!#HLXU.&M#F M+<(8:^NR-^=?1L.OLZUQO+C>,3IH)6M57BL=00-@P7O#4!$UJQMV! MZ0&9T;OJ<-A& 5U?G'Y,?4+2+_UT.>(%*F6=4K5)E4^B,&U]9A&U8]8%,$8) MB6XI;'I=Z/VZ5SP=+7#AVZ%'P#O_GU=$22G8YJO;?7_6_UJ_$ELEA-;<=B]+7O=^;, M6V*J%)!,]#EXV22[=SVDI\>*CL2_-ORQXTB+=1,]UJI=7]5& M'[N,QM?6WXTCTO@*9QW,]]&'VOK987 MO=BO[C*$2IP+$QFF:,CMDLCJ1*V52HWT66/637+Y[H:UK_5^0YZ]++T"0>:G M\456UU*P&,"QE"3Y%=R%4D*+,=Y <7@;O4/-+YOGN\NW08C&/['_^93VXI.O M.(+/^/NTBH6&.^OC^&XZ&4]HRZZ%YR+MVI F/<&CS:@20^>!/(A8R)#S1'(X>SD\/Q\.YIA/)N3; MQNFD.A.?AK//7M0F!N_GA>U/1B,8?)[?S?0X.+0J 2NN3B(G#(T@<.:35+RV M2"[8Y%IL?^@/9"ULQ9;A457==4KJ1O!GHNQ_Q5]+P719>KI>?L_+Q7[$-!W- M#OQZ(OL04J[MX56-HY&UJK[0S!B'F9RXHDRXSW]M >QYD/+H*FVPEJZQ/=9) MLB=S,MRB8SCK7R5T9L"E(.L#A#R$$CLLQ'$!]U<8U8YY ME^=%,[OV9) 7>"]%4HJCN8&U,Z=S!#.03H-9JEBRF9!G/(,D5X^!YDQ25E6@.3XLFNMN$'UL)OH$O MN@QJ,>">5J6(Q#T3#LCDB]'5F@:&4,I$_UC-;9.*M&OP/ ]&["+\%GDCEVOD MN]&\J\MO.#D=YII!/)X@7ELY7WR__9FLLF61Y=JHC@7FC:FN/ MH"2J5%1N?,FP_R .E7_2<',ZFDX?2G[*R6!"0YK[%%>^PZ_?TMDT8WY-NIA' MH\TN_]^56]/_^^H'S(L^NB*QV)J183W37B.+8!R#>A\2>,X:VN1WMAO3T?)A MCL;3Y131!\*7!GO^:F372F9O@J]EHLU] (^39?-@&+$14_=4YS%HQ\D.%EI$ MEE,U>QP0XBP*.%:2"WRFM)!J*/WFMA@A,'Z&'\P][>7SL-CD'6=I39!->S M[N&UE>(V;=NTB]2;KR+7\'FNZ7\^L.(%,IV5)'NJ +/6!2T".H #-'Y\>#V\ MFI!A&V%W'9%P(J597=KUHM&3#\'HJ)@+GG9.88',:T&&C]/)ZQC1JZ7XK#4A M!O>]Z0%UV=I*(<-6TEQK/':<\W='.'^UJRYB%^;7QA<^6Y7FXH3_XJ_-^V'O MDP;8"$GK3(O.I+24B*$%N;0"I>?&:^X"L2X:KL&JX)/U<%=*[2$DH9+R3& D,]8Y MPV+-,B:7!YQSV9B8'Z 4Y^@?BB?9F+T=']?OH/D&!Q57Q<#V',[<'5-:98': ML$3>.OG;RC)/U"/'#+0*N?CLFYQP=#N,0UV^/@@:'Y$!S^&BUCCM:I\&ED2L MS3^,8D$GQY0M5AN H%23&?$4+VJ/R-0#7M5NPYACW)EM@N_'5>W1&+'MY=DN MZCP&[8H-4B0;64@YU%!KSGP,@F4AK=#/*=)T*A*!F$"2QK5>^1I&>^1#+:A8A>15&DV;#I_JLHRD\FW:[G*VM>5(G9V.;H%PNA&6*4Z!EKN6,0A;D1X#, MUM(J(*6SIG<_WFYDN7NAG3N?UU"N&Y3)4^^^+[[>3:OV"4KPX,N)51&268A)1I MCX?$:J0$[?%6ZV1#(.^GR3G-WM#W/O#:%<'- @\GT\GI<-3_7\P])83,M9:# MU35JQ=#>!,YK)AWXJ&0D[C0Q3#L?R1%2XP[+Y%M'7T?E0HO3W(HGWC^@N#R@ M7[]]Z8_FC8=FG69[: AL29)9"5B334.ME$RRE5$ :FV+;E)JH;,1/$\R'USW M#4X"=I;C[(__)'>"7-WY4$1/DA.K5 T!-4[5.%#.H#H.(1ERUP/^ZV>H%]AS#^C'BM36WE2/G]_P75.%^>4F5 MQQYO.>6=<6S/;O+$:@ -F5F:G)"4=YU?GP9)VQ(E2CSD 0]IR56CD47YG+Y\ M +K1M^F&Q1=75W.\HN/D]NJIAAFQ[942W&%F:C5JQ47#0DB>!>F+T0%E<.UV MW=/S^^2 ?PFXNKN<;&]5H#C_,DYXOQ)^FZVKE]:>RF)UQ-S\_.5LL?QMMOQO M7-;1$%?3U:52Y!G(>:&-05A3[3'#8K&.'!KNHA0B"&S34:L51T]N29P'-NZ" MW@UFIC^ZUM>+^I8M]L,Y449$HTQA22.=G-)'!MQ&.CZYL1&\T^J\KMR/8O?) M+9<+0-7=M>0'L\?>7<_3)_KANSGM+;5MZ:K!:34YB5ZVJ&V/-")J824;::M-V/I::Z)X=%Q%_>AOQ*$1T6\V"7C34:O"=GS1 Z5 M\.2=%U48"!N8I\,1T&()J4DM4F\W M)]#T(RGMK13=1:1]9YQ__.?LXZ?9=1WB6:<63_ +3BMYFUSF(I.5=7: #BK5 MR!KM6+15L<1S"BY %FIK\]^15?[P>P:8UWR$"F9MY-=CMM6FB01IX9N_6\09I$6Z*H3;4UT(F4-)E'I#-60(IB0>>PW>IK9T..A]YSN:KM47XMJI%6 MM@7]\FHW\EES&8QAJ('<(L<]@PC .!A'/)I49).2M%#I%D>PAL6.K^R+M50$TSS:K?I ME(BW)'B $&(;=_9RP/M88>=Y8[>+?EMWVMU8"MX)60MR6 :GZPQ/RT(V2 A1 M #Z!,JE]C]VAK+'AE?Q01]X#--2@*&)WDV#P7#C)-7/A/$[ONC-HSGS> #M96@[UGJT[Y#]+,XOV'/[ZU#"SDKP07&1HRJW5"P7RV M9. 6I[UU0A7=)$?C0:J>X=2CUGKT(U8.\#N,>2K]1F:32/@4F MO%U9 8+\)HA,2!F435H2I7O=)>S]RB<,G(:ZZ3%-?C%?CMY7T:S,1!6E-08* M@5>NIC1)!C8FAEP:F\ F)^(>FP\]],;&0W_;WG1NO?5IWD<<+O@6VM^ +Q[W\(S2PK<,CQ->C@;%-CI8Z<*LD*RK7\7X&R%PFFM!JA2E8 M)\L^I;?GH<4=[F[_2NPBM9Z5]U>2U.?KS]^"$JGD()QG,5CR=K H%B$C$Y9. M8\V3RGOE)NZEOEMO/MVA?93L9WT(KDS^7^^]"\Z![V_8 M'Z*2WF'T'TC)":HW7DQ6#QK7EGH_ MY TP"7I M--Z)O/:OPJ9]S/N1W;?I4BI+$3Q#C+4QL)XE@DM#U(W3&9*;[K<#R-'*.+D M:%&Q!$P\, ?U,I:'S,!*7^M:G?,9BH,FM/U,N.E;%&OX8W'=_->Z&K_AU%62LM/9^ M<7@X"0WO#GN2R];U(1@/ JSP 93.)7KN+/EZTD'Q(@?<<7UX.#'G=8.8B7M9 MTYTX;9NT[( SC\77!0+1UD9DNLG=PV7>($H-S@@5& H)3/M2Q^@YI)VJ!%>D MMQS#\PWB:=!XX UB%Q5>S UBH1=)%2WCJHYW!$/\<#KF!%GLW%J,#MLTVG^^ M0>P'O,/#XEQN$&^7)A2GA3#%,J]#G?T3(WFB4%BD8[OF57F-Z@G4Q T&B@?K MX[HHYU)*B_;AZ;D^KGM]7">LG*+&Z!!%7PJ(97'()7B6=7!DXR3-?,'(A G* M"9U FC;SD2\&O)WJX\X.NUWTV[H^[E;Q#'J15)(D&NF(L%0""Y$7ECQB!NZ5 M"DW\HY^]U*F3POJBK387J \4S0AM58 D6*8_3.<0&7A.;EMP1AL4V;2Q M_)Y"J=,Q<.I/:WVWP=F_G*84YP")MB1JY" 2^H,)FAFMDA+)>U.V*C*?2YT. M!DY#W31HNG%?93$77H/7CHF':"A MG152YQ3<&2JBS^:;']7?$R,'VF+!P.@T M);M,1<^B(.9U]F!09B\X7-2RN)?-Y[5RII!JCN]3D4V\\B&!X6YQF*A8#)<5.8QMHLV4B2*3>6%>0B&Y]5 M5DUZ#_W$H=A.H'@P%-M%.9<2Q=J'I^=0;/=0;">LG"*<=8BB+P7$QD.QUG&F M8HY,1V%92#$S8CD9.I>\#\^AV/U#L6>'W2[Z/6DH5D?O>+T-#;98IF7(E3#- MA$($+6R)=I_V(L^AV&,4OG/D[CJ\^U0N%+SB'*WRQ6%Q_7@]2++/YC;7R%Y+T MELBF!@H-;DU^]TD,P*E;(T M2:32)'9\/.F##>W]/BKU!@S>CQ?_>#W'.I(;Y[3MO8K"?=( M/G3P5M%62GM? BZB;E.?VYJS,SS;^D5Z;Z-XFV"E1=E/GPS6^'0]]?\VF]!C M)N/EUQ6+(A<1"@*ST9,"HLXLBI1J;R3NH^!&Y?,:5[T_;\\+8F"\#''=<@B+ MK\9?QID,DA6#*6NOI NL]H0D!=C$0LR%F6!546AU#.=U]N[+V?-R&!0K#=(. M[T]$VF/N]D,,?L3Y9S$R22N,)C")EC@S6K,H@V<*LR\&0_;YO*:R/\K2TX3_ M\.CHL;?\W;C:X;8X!H0W,G^)4]F.P M/(C&SS.D[I+1T2K/0G:^+CZRP(*@Q2=11;#!9-FF(>UYA=1/"H0'P^A=%'(I M$'H.HW+S>) M9EX.>#N%T<\.NUWT>](PNLO&FQ(CL[9.'G?/\/\ZZR\2,OQEWHE]WW^Q ^N%OV7@75Z;F%HEU' (IB'(8<:W9-" ]CY !B!H\[ MEY*<2Q"8]S[50GS#/&AD45G/E>(U.^2L[KZ'CSO_^K_7M V\F9*"KU?'VN_+ M3SC_2)K?; ;?*U_>SR:3U[-Y_4OI5=0#.SBFX_2BCZQ2X-]-U,=$HR0^ MLP,&L79/B3FY@HJ#:M(.X%0,/B^G09;3$2AK%1UOPN??5OKXSB=Z:7PRFH%0 MA6EA+8L%#:/_?)(ZQ)#;]%$^$8//JVF0U70$REK$W)OQ25HH.+[):E(0$\K( MLM>*U1Y-S)-"F$'@P2H!R=K+6E!W>'Q>4X.LJ>.P=G=9Z?-=5MNV+8F\Y(2< M>5E/8ZCE0LHC"TDIE4 $UZ8?W4 ^U%FJ8JMB964OO8(E?L^XNKF").G%8"ZL M6&>9]B1:KW5B/'%,(=L$<&%FQ4%RN*"=\F(ND9KA\**%[,Y[F86P+Y@N_6'A>$%[1Y[FB6P+Y$N_WKN>X>%P*(I9DI-(, MI91,JSIC,5O-G!6<=CE?)/#+6LY=V']>R^>YEIM!^#)O%!^7@31"9"43T\'Z M.I=;,X@RLZ MN!BUR="D1ND;6=P.35>%$+V"J@7T3Z?4C+49#. MV9@DBS$2;D5 %@.=1ZY.4H\QE 3GU0GB.'XO:*\]]WO%_G!U4:[*C0S>K4WA M/59 T,]?SJ8K(5S#I%9.+T9DW!D)GA:!])J$46ACU":PC!C1*0-<-YD3<592 MN*"E=TKLGVR]M@9NJRO$^+@P8G<%7EW-\8H.\#?$\7BZ&*?5*?[]O!_Q%%*2 MWC+KL) M@X$%S@VST0'46YAL2K,E.PC+S^MS[_5Y_I!L<:3V5H0/T;OL,#&I M?21G@>O:2$JS%(K/"H)RL8V[_P3[;QQE.PZB\?/LOR$Y;1&!#D$1HV(ZQ<*" MTH'IP@/*J%,638I[?[+^&YV \&#_C2X*N9C6!7OP]-Q_HWO_C4Y8.4D/@P,4 M?2D@YFA#"2DSK,W)M;"9@>"1EKA(202CT3V/L=B__\;98;>+?AM@]N%.]@!D M>7/AF"J>9)0X9U%DS[R1)7%0*?LF*5M/8?Y )\5WFC_016L]EK1V'#>>I0'A MR(K.J(E_5T,\N&K^J814P=F0M\(;SZ/@#P9.0]V<:H+%FRE]BQ_A7WA0)XZ; M_[R7+AH[Z=D>E1V<"=R+A$)I189Y+*0W2VXC9&EE'NV@[ CYK)R#8Z6T>4C? MLKJ/MNV>(484%[0-0H+VY%FC2?7J-)N8O9-B]""51\BM+M+9M"[+6?G^X\U, M3Z]^)V]OM92/Z1/4SXO[UD]?,MC2:;'%1*,AFEAH@^)1 8 N M IU))K@XZET:1^#@W7SV95R-2WK;C1_/IK_"O%[L+SY*(;UWCID^>+%8X++![K/S%2WWF?WXVE*SK5VEC.$H M,SEP,H2<(>IBC.(E>@>[=I1].#Q"7S]B)6^F*VNK_J4?/3WXZ+[ULS\?6WI1 M(CO4,G/4I!=.5J3$X$+,407/I1KM^Y(CO) ;K_AQ=\^3"S*JD]W+X;COZNE@::J8!ND&&U=I>O5VMEB\ MA/G\:UEGBR]&20C+D7-F1%T$:@52!-DSJ-P\C]2:'6IY+N0LL>%-X'8K8^WQVX.39#_VJ]+CA7,N"8G?F7AQO?PTFX^77U<)(C8GZ8,P M#%!J AW2?F:#(- )+V2!H'(3!^I^F>]B[F!7WV7JDUP?1^Z6N8, M[B)LF+R_/I3W*!Z.D/PID8$"/0ATK/"B:!$XHL\HP;1'S %<\KK)[>MI$?%( M,MTI =%%X$V L,3Y%";O\0M.K_$#SK^,$[YY_V&3(V-CB4:+Q&(A)UXKVEA! MV\24(O:YDNB4:(.'!^DZ?9)3/PJ\@XK^I-]B;,.2#-07T_R6?G/R']?S\2*/ M4Q7SACP3L[*F)*:3YD2>!A:RT,REFOECM8RZ3>W^PW3]).#H4_H#I*_M'H"U MPU'J)WQ\\&O[#BWWP_]VTI@/IHBD?;))"^=CX;4E<4HZ>96X&?4LB:[Z?[NZ M5#E$A9M_V8L6[J/B3OI,KJ*4BJ2H493@O!,)BY+<<%JLH[OT'":+M?=[L$!N M.,_]2.4>>K93&Y0,W.A0=/!TY)!9XU,(2NHH@0B4HQV4'2:?OC-)]GAJC](\ M/'\D)\'1V"BEUB*8J $@B^Q"REJ%/-KC^<<=[F]QL4!85+HB[/S=BV-R; M)&$,X2NGP,7+930 MM 3L)2P^D5E=_U?[*WR!24V9_&TV3>OPSPAST="3B/5-,TOJ8)X.5LL1QD3;7V"& =RS#5/AGE=B$ 9"-XZ!\V; M7)#<)>7G L61HFZ057*;HDT9VV+$P?B8I&46K2$FB2!OG&Y27+B M_>3\S" X2.0-$D-N4[6K+];JPWKRB9$/,7E90TE(!YX&GQD8(E\3L;$H+@>UNQ,RXZVJM\.%^=H& M-^M4;!*:S.XF,[B[$OJ$8'6LFGI,\'A8%NN0MW#DOH;(62H06+T38Q%#9!Z3 M=]*B3+I)4NP#-)VJ359[5^AXD9]+$LDZ2?,UI/'D6RPT:>US-<2U6(E'DBU6 M'+"2R>IF?&75*&ZF_5FY)GO0J[@>M\FZ)-9&L?FEJFD-Q'U##I(\X\H-3#RS+?XG)9[WW7M&T"T-%PGH0R#(JJQ3Z1OO/5?$Z&YU7+/FB2V7X?,:>W,8]7 MTQVKX4@9[[Q9[SG(OPY-?0\OO[ZNXR[^2H_^?/WYEJ/^QY2HN&TOOQU#K (; MXS'Q_IXIZ#$@V$8J6\%#DQPO.BL0/N@8@R]@"WC'0P&CK!FUDT]7K+S'Y7B^ MLD9K?Z=#=+WUA%YT]1!56[(.3H2BO$BV<*U\[1B5HP(#4D!P5HUVTW>@,9'QPH-X&V.L*Z=:EH\#QJ'3V&:QC!Y!4OX8PK7N0X+/T0Q^SZZ%ZT62B#S!,%+[PIM/\4& M*8VSAAR;HHQ",3J HT;Z.+Q'6+<7G%(W>_06*Q(YDJVA'0@-449:01%K!H_- M12K<5T/']QW[?@9]?].ZXFXQ*[VT%^OT_'ZT=#!'6TI*M(U%'WF1!NK*&*$@-W422I91:AYM;1'^DRE%QP M/Q4W3 )[.9O03V?U15_P9L?.%]-D%O7]3V79%VX4K/W^=C\@6GOY!B914T-(H'IH4Y/3-R .^E#8OB>_93A,M"@+^3[9H0<1KR_,(P9EP$=& M&R-GVB;)@B?Q%G*^,D85,V\\W:4O5DX5OSH;= ^,AG.)D6V**][1,?[U)D>_ M?+WYR;J.4'GD=/JS)$NI$]D% _"26<]YH;7K0LAMMO1]21Q^9LPP6+JS<3?1 M:9/LUA_T?*LTWH.BE@&ZNR0-$YYKI<0'L'*$!DZ##2-- >XR4]QD6A0<6R$%)*K;?@08,V T'B2Z"[Q$*ZX87>39?C.'=)R 7,N'U2?(1_ M8-XBK3:%ANG7M^//]4+OV^0+4WAT7C..*C&M S*PWC/E=8DB@HO;F8,[5+WO M&R];YTWDVO?R_MOL*UQ5)Q+G\.>*R,6&*A\5D2(%X[)8IKDV+ (G$R@EX7-0 M*@6QE[9WON*RU=N/Y'HL-UE1]5\XG4VWMIDWT_2M^-]R6QP LT9+0AHO+%IE MR!RJ#2- 9*[+7CI]\#67K=?^)-B@FJ1./?J]W'!=5N:&,KYX*^EYMD+[$E3#2K1[@H#[N=_@_9]R&WI#7:D=QA7L0=- M;X^?/8&:&KB,G0:@ MZJ"=%DG#.W;I#76Z9*LDD)LD"YW#PJDZH9ZH$V@M%MJV8Y/ZR8?).KWETU2K MVRG&_:FD:]+IYL?U2X0%_ON__3]02P,$% @ <()%4J'?R8;LK $ F X" M !0 !N8FEX+3(P,C Q,C,Q7VI->(KV#U*" ]%Y"[R6A!@C)Y3O//7-G M?G//F7+.>>;>,[^5_?EC/VOOM=[W76]=60EA@C /W%!54E$"B(B(@/C+#T"8 M!IX"),3$?UV7C?3RND)^Y0HIZ14*,K*KY-FOTS R,= QT=+1T_TU"!')Y3ND5ZY=N7*-CHJ2BN[?W0@_@9OD MQ.U7ATF([@'$-XE(;A(1.@ 0 !!=(?J'!OS?C8CXDL:K9.37*"@O'ZBZ 1 3 MD9 0DY+\1?5EK_=E/T!Z\PKM75&%J[>TWY+=_:Q0,C$S,+%S_FL#0[/WYA\L M+*VLG9Q=7-WT=G%[+[U^^AX9'1L?&)R:F%Q:7EE=6U]8U-S/[!X='Q"?;T["^^B 2 MHO_6_E_YNGG)%S$I*0DIV5]\$1&[_?7 3=(K=T6OTBIHD[UUO'5/S)><[DET M9EGK-8X'+]'T[SX.4C!PBB]P8?YB[1\X^[ MR4T #%SH9(7P G_'?PR(*Q>Q(CR-!""@9ZV?$Z_?D?J!%X<4*B.+#6!>)\OQ M&H41@/.[!*#/F@"4)Y; =UB ,^(0WHR_X_]G:(9?1!& U2KXY(NQEN-P;R(( M&-\-/S!LVI3..6"K8O;\:X4O)X#QIXU_QIDW(_\Y[)2D0V MM-"H>"P6Z7C+V7+Z7IWE8OXB.$@@M3:,G8,29REQZKV2U-Z(,4^-KXRG?7B- MR>I!6]DZE?%XE>Z@<]UNI& V>7.Q)P4:Q.)>#[IN>>+9M)5X^V.AIIBR)TW' M^*JL1:=[A].9:Q\\S$PTTO,5"B=:/:!WXN><:3D03\@1_>G;V:)+]N;L/_6'X!7P"!;W79B$"[?A?8LJ02^+-AC4O%#>+GGO#$W1%M16L?9SIM1>#O^,\#_0$!V XB M !)%^-\?J@A )72=XI0 '#\E $FC!,#\@2$!F!(G.KQ"I_WX?PBQEWJ2'/E7 MTU4>@WA_G?2/53J#;T*P/NN:Y@Z#DB[]O^G[/\@"OT9^PY-$_FD:UDP5O[A2"MI5BA3POJH.B_9VX\[TN>&;S81VVCE=ZV]$^Z>3O_NGVM!VQ>(U^\6C: M77B^)[?Q&0$H@M%DKIVNML">3WSXYCZ6=1J?#%;R^9)='%R<]_%'-T=MGA[- MI]*I\U;IZ]L?=\RIES:? .KV>D'[ 89V<2HZWJP0!VU%.N9_5:Y_Q_\^_(LP M??:W'A_P)E*DT_K70-;?0G=H]AW;MM&V*%!L?/?L8@_GSK(,1>%YW%]@8Y\> MW%$?KZYS1S\RQW-=$.$$?AJ\L-$-))\/P1$ L?9&^;O'\?D7$)[.8CT&?ORA M,SQOSG+3!O)3NAG5*%@*G&U;GZHVEPT>FQK.3JB<<"F!?)DD]DN.OB=Y[W06 M9]O\Z!ZL/;PS3P#X3YO)_-I6F=,8C.JZH'VJ!" >N0Z3X6(T9+-+7U4PL?=U MJMX;%KB QB!>8;D6'LEJEU@=4WPO&>T6N[]#NX_K)#K?O_9 ?N_,O[GDY52HTYVP?H!BYLE&?PSQ<4J5%LFZK #3.QB7O"] MVKI!_1?2LK(!:;HT'-1_@G8CVR7FU[Z]<)6\PF_@ C?3_UZ<=.@IPS-KW4(R M^PLMAES4E: ;-VJ G5=4U6+#\P7>_[HN@!_RQ?4YU+=;U:]F"OULJ GQH#9X MYT(B7]L'2UZRY>CXJ,[5V97I5F1T*[6/0Q12>(P3"#[]NB1(?B)QVB=_K;^P M4^U6RJ^>&J'Q):Y3CA-CLJL#8=XY+!N24^"TO&GPI)LTK,B1Z%96RHJ<0(>/ MA#O,JIF;)842_Z5 )(GFNW\0R#0(([%ZF1W1W'3_H.L-UJ\/%L%56 BGJ^?= M:[H-,_V!]'TVAB"M MX^$54(LF .+2^PTJ4M4[+K9VGJ\^AGW0#]8=U@G\,SW=U-A8ZO"C[>06IW98 M0U2A7)]WT[DD[A'DVCI?D2FO6D]WA^OFS$W&ES[%\,=RT#;\%9C$#S7?Q18F M$Z,-PRN-S<9"S@N*O6FAFV3YI45+C$$PVZ6]8#U/I-]NWJCX-0;.'W7#=J)4 M%;Q$_F\6-+93TCKT-Z1Z/[:UJJ9XK.2&>LDW!_4[7KWWJ$0_KJT\CS3Y*ZK= MY?C6(*1H_'U_"6^^H%F:#*MSG:/0[ZXL [HW#]Z\C^P*+=KR8CJ9Z:>OAWOJ M4X -C^+S\3XK;BN&L8.O1;$'[3%]R[EU;X;66!7;UD['1AAOFBAQ!CZ+HU$* M]Z?IU1%VMM;!+HX7C M35"&RXW0Z"CI.' '6=75PW7=(F:-%%;MV9RLHVV75WINP2Y;8,KUFJ323 Y% M'U=P2>1;W\5LE_#C$5B*)5L=9ZE[@J.Z7UNZ.IV ZXQ<F*+G MDA>].* %DTBW:QN-'YOGCZY6;GW!%F!H18!UKR5B$XTE 5M&2%'Z6X7QSSFF M5>XZ[:C4)D'WA$X"$'A&XT>?KCGZ>@[,E]9\])TCA")$FD4XYMSE^5<6V M)"@OSO?T;#S#.BE\M<);8G:Y7--1@,'"1X4[T2+/!-);9M3*.20Z14\7F^1_ M!A**@S6'Z%H[]13!Q^;JTZ T[1Z<]G,VP?"6I",1?U3%:$N81"VNVV#[S=U2 MX=NP#+BS9ZQI\CQD\N35V/>(-2.J7 ,7T9JSU6.D/7(?D>4L1X%L3[+1D_:N MGYY6ND_OF?[1*]VS1#.EW_V/$ OO:.?"8DF #\] MFVM;U0R?GG^58U&ZJ^4M>1.KW_=VOV$IS4R[M@?B!A= #1N!>"!R!5]Z%J(6 M8@KZ?M<5#]M6"1@[+:WW(]JZ6ZSLR7R,4.91[$>_#GLX,-8R,J-I&R;I=L<7M M)F)"=%MDPT4Y8OPIS3 M>4]].)MHEP(M]9EQ6R%CS>PX%2PQO$I<74/]N7)0PO['[B+\C$7&"2C5VU\] M1B+IX7.M]7:HP'4_&C,-9,+3T HN86,SW8*F)E_X&0]M[.\G>52-\LK:;Q9F^N'#RM?[]&7G0I-D/\,_BTH3]JD8? MR-I$C2+L5Y'/:%)Z(,Y\D4KL1+.FMJ8BYK6M64N>1 ,ZO8LE+Z*1 MT:K(>DK'2O)E#*G%]R+?+W3LCV71W@(A6# F]C7F)!*FF(5JA;)5I[?T6+X* ME(JU_*,IJ^6HU?[AM>?KWZ_,+5NYM+FK]&OZ39'ZF'&\"DU(R]8O I#C""G; MP\48@+>Y)/'^;*XM;/#E*&P1OC']3)_^G)T _.**Q;?IP-=%!T<.>>&_'ACA MFY$$0$6: (2"KQRFASI.L)Y_*=X5["%-ND']:HE?X4S?(L.R>HYU4-"YZ'X/ MU(*B]899;)725J:N]FQXCXN"L[8F0H]R@$%+ RQ- [IUV[/'4K5R3['NH\#V\/B3"_HE L#< M8DEI'SCNN'YFFW=Y^;:A*635^9'Q5JPTEI>Q[GE/V1_.- MP)_Q+A"[Q,JY26F43::=W@/K N0/LR1AU[=2;HQ?,F^_6&%QB/_S4;LE3V>3 M16"E!SREUM5,,G*W"C,>./-XAEF/X_JW?NWTN!;5,Y$V'\%A6=M,(^LS]9]U MY2FPDK ;SW7_(NMV8H1*V.\EEK@8A_BAT$9(GT]N)_U*"R->S@I.L1+1OEV^ M*=W;S1DQZ:-+H0)4>$6Y,TNLH''*V,DEY2/F:#MB>LT+QAE!YWR MR-IK>W7IO\2&2]M;::CRG;G(9V4UOX)'IM^29YU])FN6<3IF,R&,_A8*KU^Z MU^R'[N^PY>ALIK2GW1@2K];NV%=A!WLP*_;<9:\T[KG?[9CHS*%GI4KK^C)T M57_'J0 1 X>FAQ .IS XA[IQF4,V!,ZE,#$?XTW[$O_H<0^XW@MD-OLD)F;U MH+_S#?_\B(E2ZI"GQ\Y)6LNE>S4>L:8R^:(7LKTDO95'PB4$P)L!%. 51_G.:5.7=[7VVP@J37-Y=GR^+80WUYWG,CVK M-@_3@G7$E"<@D M)^>$!RJXP!,X)E+P],=78$5H"%[#K1-R?$( LJ]XZZHS8UQ4U!B5J-8+VE . MEO::2YXCR,C M6O:58;H$P%3S0B#D(A*^'',9M=[RM1PR;55AMP@ 9U GY&B9 S5(B9.\"J" MZ<>TR9="B$C7RKSL[+,_.P==<*Z!;>U/B;#Z^.9< C# T'32!M[G7T<=K='@ M/PG\;/GO=_*Y,+R]' 9/AM,%/UAA4S.L1(-WM-T*W-.XS^_6"<:*+=]YW_'1 MRQ>YL@,QMO(<#:RS3I#V7I:,DKI>_F3!EVS#N*8C\K,I.S;S0T&1T=>&<-5. M#QK:O&JORZC/Z'TNBAUNK1%R6@#=9-9]71O9>[\.^2)L?K!L?;0@WO$*B_Q4 MRX\2#7[V_486(_$SD"HVMIW%(K0RL7+6\(],CXH21?;%KO%:PB,1HKY'\GESS9 *[ H&M* ^\G!.?.A[4_G"BPKN6(1WS;A2N%P_/]<>EE9KRH,=?7'+G M6KWMEC[^(O7U!04XP6_B;V'ABP$ABD73-YUNW&/M]C$PZ[V>3DXX:74LA- MS8_>ZK 6**9B$=+FE5^",\_YY6T>U?S^5R!8A8QTL3D:+1(AWA]LRN;_>B@' M9<_SNQOE*ZSF78K W!URZ)-?5HA]KC0NH<;V7&O8 M=D_$IN+8(U>]2_8(:=^? UVFL3Y%+D*0D)M;S0\36M, _]Z&+U/,=G%/1=]& M33NU!B[ZYZNC9;IEU_C+F_PNG?#*?WHT^3\%_ZNBXC]%=JV?3#YGX'N# M>]&JTO>[S3E(06W?LWQW"N7%,!:!1P1@,G)1>JM>3!8/JOO(PQ M!'("9'@&7MCK0E'"GE5\*3XBW['_O:K&FG"-/PW;/\>^V""GHU(Q+LA=/B*4 MU5B9Z-KX@-?\[2&"% /?=LNRUJ=QRK!V6M]&WIO37NVB]F+/\'&1L?'Y="!8 M(Y=#_J%ON(3>WC)N).$D ;ZY9;;.4!^@[YATOV5.4-04@GEZ'(A&M6_Q+=;4 M1^J-.3QS==UE$O!LH/8_0O 1@$ 5#*R].[WKA@3B24..K#<-_0R6\?@%&AEH M9]8PFIL J7O";);H^H2F/K*IOP#'MVEVG89F/KVJX]WL^^;>=Z,71E(BOG"J MH\@OA?-!& ]5:(KOY7K,B\ M+SJRDTJ_$S7E-P_Q0*W/F3[<>^.Y5N591;Z]*&A^W94_]85LZ=<[S5;06OT> M>(4(+EZ$U=N< Q6'7%Y0-I!?K;H@R[#U7H747<)(0)0=W-GLN[$I5_\_F], MY7WL=5N6\LI")7YY6YD*LR4$+@9$#Q^/)0"JBRUFJ%/.DC,!OV M#;:_]:PTF.=<1_\>+I?SO"7$E/L@8GRG4/@D:<>&M3@ RA+SV/L.7=0;/"4!F M^^4]Q2+^(8P=S%CL7.28'RZS+=:8'.9U8@>8(:KL]E^1BV MS61>7<=_=;G^02S ./U:P&>$U*/J!I-U]\#(GCM'46?W6TD=P(8G,C+GMJJS/%6U$:N,1/'**??OG'27BBQ:7"98L)>? M'^80^6N%NR+A]K[W(GX2 '@Q].5'2?$?96>?.;4+ MUKUN1S[(8^Y"C!9RQH9J:+MNIIU=VERKG--2==/"A;89= M!;>OD0F66U$.3M/T:P2@+"YU1IYR+"^.S9:[$<+A]C3@-!B'7#$X$]GV%SK. M2/ 1Q(C7QP_'1Z 4H6SCV$9F5-UK M2D(4UR_8.NJ2\XA/5<^:?Y;6&]9/6W:1&Q&+ ;^ZK$I"Q?>VA>1 OVH2RU_8 M7#M-.=%C>G2;IG>\;F)3KSZG7M/"B7Y$F$0PJO:-PEZT,;P#X9]V&YMMUS(5 MWR6P/FZC/T8 ! OE:$Z"RBX$.J>/U3'R7V0008V7TG@'#^ZA!.4_462)WOXH M^R>%BZ5%+S]&77R%T:Y@%W'Y'EKS'7:V% M7Q3J5($O5['Y)5""I&C\S>JBF M)C\W]O=/FT"(7(3:V'.@TX-+.6>J=4SNM:<%Q%'O@\5QA52@8X7:$0G2.HS% MEY61)^F)0B<,CAM-IZ X;\K+%:;9P#,.[E0V"4\*"=J.VSC>F?>,W5193J+L M7/S![*,O6T&F.Q:GPCV;%%+S_JQB><]?_FX%U@JSU*%GRO'6BFNXSR;A ;IP M]?%O%3D2HO$9_?'!_MN#01&*T31WO_J!I0_L0U# (4W(1Z&9[3.[XD(ZT^E\ MKD_K;/!0]B9HC^VE4P4S;%S:Z;&/U,-C$M_;MOP8_+I43J$TIDJL](Y#YVC' M.4MC@8I4=6IE/71?SFAQO*N/=:$ZCI\3@]HJ+YV&DALY,<@23ZRW]&<@:"^B M=X5+F[G=DZ#S/1Y<#8VM@>1._/'=.WV>B/;TR?3V.?(1LU'[M03(:-2>2NE7 M\B7[O2MK/#-)3>CI^2)W,J3T2;!&KC !J.P-^K5_O#W+C:];#7^2)LG3:E[; M2,U@IY.BWSQL_.><:Y +Y=JODQ7"'_G'[S_[6Z__D_"_Z+C1/T$Q ;@!%<5Z M/6L:656*$7B=I/=J\_%AJ5DGF+Y85J8$;C;]>@XJG91[:KMM-O..J;_7)[U7 M[T/94@D8":;$JV8HD\K(!9W-,X] MTM]\A#PL43UH(<;&(-O@9,[AFMH)OZL#9][[QJB\ TCJQ'M X7HO(0:*^>M3 M:9'VGH]KZAN#R:>ED'!/H0E].?:095DKS#UDZTFU*\B\;N1()O-;\?:X4]P1 M.!H7KC7H(V9EV-5DEA4J,VVBL3#W2&B7@V) +&PAT"OB\\L*MD&4KKJ1MCI( MI:DEVF"IRG?-W/0[?_P=']UN]]#%T8C04I7O!E;C4[,X@7K+2Q;O'?.,9*WXQKY;FF>M#;ETFKBNFL[S3) M#:;%)ZD^6?4F-*],G)Z7C]R\;N5$^YN^/BQLL;%G8:SD;1:,='C/1092;?", M2X1Z8+IEZ#8U#9NCB6Y0AQ"_G,[3(8ZJI%$7 =VTP6I?]IGW/&1^HNJE;743 MPZ:*8>83O 3 Y<@7ZU4N+Y GE MJ*BJ&%)L&D_ABECJ?W8QA_IFVX]@XU7=MITX]A3X5(UM_?Y\(;'**!DZ+949 M;3O$O- 1^\CX4W:3I JVT\*E9-(J*3XZ?]T)1J<&)D8Z &*7?53^UP=UCW8<761S-B;#!SPT8<-6V51 M4[ M,YE+R+>LD51IGMX9#*"-M&%9AUD1@'L^-03 5 >^?C6N:L2<%V>U.F-B.[SZ M4"^?,VV+PQJ_K1+F(GOS)=:MZ&LU[46J" =MU-.VY0";B* [R_I7 M%KEJ*H:X&H9=*/T]' 5=:^(#\)I)HVY +7YW."GMS#Q6 MOXB=ZK-D?A^V8A31D@8U6M@+.BQQ6N2)Y!C9%MKC5/LQ6+S.],E@7PE.,]1 M<]L=JCH (UI4&BZ^4VXEF/(H@'CWYY)$GHY\D%P.5FFZ"TYZ2*G6 M()\YH':?$XL/"%RL?Q+7;T>FV8MW1C$9=H*0*'*-X"+!ZEVV3^<3M&;@5(9R M03!H\8"))_$[?^Y2.)*-;!G.;Q&*F*_#7BS(N'\WX/(CH[WR:$KY(]$)$AS\ M_4JZ'[QQ7-91 #9$ *S$]N0YYHT'/%//@OWXHXK<( MP(::+@%@7M^O:4N_#CTVNY!1#&&-DR\(F*&I=H"3O!+?.WU(WC(+O^"S'L4\ MS!8G %2R? L-#^^=&(4PR9NJ=@#"*(WT0$L"<%^\^>8>YD,5PGUJ42S=SM'J M0\GHW1<6H)=DB[FI&"P!Z.0Q(P"000+ H2M/U8NG'V]4F/=*9$[J@E1./3AR M-V+&6_L46Z.0!."4;AN^=09>MO+.O(AU0K(SEX_M.)L\UQI12K?_KE$3UDND MWR7U2-89(8DM6>IC[$P*"L@8VC5<5)9X]L%>T#?,MY4C#0I?$D^WKD&F /+P9Q*,2"G;XA7T^QM(.K)S=0HD2\"I$IG"=/0S3Y)-%7,K M>N0.C0=G,%MFV4PB&_4H,^Y+@40 Y?E3RPZ TJHO1@;#Q9TN[H@?J%GOI4]K MIZ!Q"@ /#%?YIT^Q*B*EAI/!7[^ZG%+B_K@M;(?.K_5:&^Z%[<$;1JUHNB(PV*=G#Z!9ZTW M\#>QDNU3->T7PJM+*A5UM6\65=COOX[:&3E;HD-I9_I"^?>PG)/YA^/>[T-_1C#_$.JWZY*"X_ MNE(_EB3/ M,:$CEL7]F8.LR=6^WS6?_XO)=LU!=W :W$AIJ]GZ*?73[>#6JIPW5GFWZIT=DQSS2'GWJZTH ,. <%J[(H/P&RAH?K4<%?(6CG\C[QK!ZO/B;&C MD>L! 6@#'Y_W,"WY6<*XV'[O/"9R.2#GI&[BFQ#VE$U23TE["[7\%?MA&V$2 MQ)>>N?&Z'O19(QFA6?CB> ZJ-)!E.!T>;^:/52AQHD4I?:TR(=G^%NZ:I/&9;J6Q']/Y77BVO M,!:]-VZOM!55%/X-1RS_CG\C_GD :O[T-Z=K'H,>:RO2 ?\.$/UT3UZ0MIZ[ MY^VF.B9 1E$W'J'FLI3);]/<)U:<, M/WF%/S3@'-=7.@WTT:O2\)_3EK*/X%FF6Y*> 5^GUC7IPS:&%F9:Y%2T-P1]N 923IBX3NX7RZ%8H1)#,),Y,(2 MG-2A^8:Y$Z5".9/<*/0?N/3!'E;I$$6#@Z)+D[_')V;Z&>SFQ&B**;T#K;H> M_03E>()#\*Q6:<(C62/"/(U5C2%@/O.J9(N>E"6F(^[OZ,CV5-;66$U'\]LQ M5'0\V))^6..283(39DQ.)_9K+RQ,+R' MAV5CCGGPB/5AO-'IT9VVXUVS@[XHA3/OI=.DK?6"!K;H51;-UBM#A^J:RGA4 M8[IF@WKTX_6'K0=!W<,.]ZZ#RH8#*P%$H#FR(T-/5FG^6E[ M-DN1W)D^KII>]D?9*]%!,+?2P!#A-F2J"0QDHM.VICIRU--S_CU%T]YGGLSW M$W"%>2/2LT2RE7,D/*>K"#&W:1A>B>EA&RF4?_4"OZ,O^SY*9=-!8#@_K[>M M^])'T,+N5F(8@TNK6G8$DH44!I_13J/?F"-[J3VZE]B/S%I;KG.@Q^H<2R#6 M"2QS)?P>[Q;G;2<:':YJYKC1O5Q]^][C.!P=2$7669-4E5ORL5KRHVS%ACG< M=<6WFT G8)#H^N>WN+;AA T7XR_=?[OEM/S:[FS[U3LW>Y M,W6\HG1U3G.ISY.-KK2M>UX<%"!D46JXF=35Y(;H_U!;K19 499N3/P1WE8/ MHG6W\_ZXIUX;I 7E+G.-T_E-*_#()#.8\R.1#;S):$3;E4%J4OXVTLF)MW;$ M/+[+8&ICY]E;IP?<;=--,CM'>YI56'@U4KNF822GP:L$?"[*M=_FH;7P:=[% M_MN!B3>=24"$]4'K?9.+RJJ.3R:46C]YE[IMPKRAK*UX4&TYYE'JRR/GSSCX51AB:M6M091"?-<2AMQ;961;J73/\]>XQVO*R!(K8ZI%>3,XU4 M\<9.UFZ.T]G5#RH?1%W[*:O_B !0;BTD7-!!KA& ^?UQ A#QB@ PR3-NM##) M@S:;F49&2.O5!]3#OG&;OE0XE/-6X&CRD<$.MYXE?(+I%JRS5')3GE]+8GYU MTKHI%[SL;0G6F!:9/K2R6 M^J_/FF@L2F7XOZYQB_[R4U?KE#.MK4$5)UX3G1EMPI1=\+L\Y88W],CM6!V[ MW,*,9YU.WO!WCU73K1ZA2T]Z0M;S$#S%!I_J>V'-(ZP' S$ZL"[,"(I^LX[X M+F)E8HVH&,Z>'IOMM\L*$3#;O__OW4/YKXC_\)G,PDW#U-)(,XF=HS;#J;:& M[_%/ [0?)VOKFQ<*K.TQ^0S_J:%56&B2E_RB<64%#9:LS^ ?<$)^"[=!C" !.I(6- RX$0#. M>0*PY QO.\>@+LC@^QHT>$G=(P\F>+&[YDK"3$OO.7'(94Z-9T1%$(!U&0(0 MXP#'U(,7O+%[>/^64QXR L":O;E/)56 M"U?JGY)TLM9]0$8#D%A+.+ M+.H&C\GR[/?L0E:]?15A\$MCV4/"#R]'_24%QLZ"T,VXR]$54+A8?P(0/GCD M07:&_(PW\.[!]?_@1402@'].[]]P(X^X0P!>H]-[1.K@B<=7_E7Y/!]=!FVQ MWSHU/Q$YD/^9U0S^6W+_AINS1O\+LS:X8/,*WF*"3O^R\/@;>O^6'?VHOXO_ M[^+_MXJ?$G. ?./GTGO.J@S&AORM- ]$@N!6?:Y=NB;O?D_K^,M6/OWUU8># MW^<;R/"DY2IV21DSEG@\R[W4J_LSGI'5/#BMMZGA8&!^/NGWJQ6J?J-KB6_+ M$/%?J[8//US0:1ND96@KPGZ=6[NW+UJTL]%H8-S\7" \BD$7K"^K]NEQN4)? MDWG*_@QO!!SEQLU&&@GTK"4MW?7+DV#6?+;BC)A^=K*QZBVIZ*.!V!G$>.$# MR2_7@AG<=NDDJ?K^\9Y_A@6L3@""C5((0/]O.*SE]-:13[,D ?#[!",B )\3 MVK/:PQ,HUN3&ADWU@2:A[19RHMCN]W?8_U0CUN2&&(&2S/%N-H1W/<5 MF&S>G\R#D)#C)"PW ;B"OS=C..DO&7AT\[B/?T5CQ?+U,O?NBJ<7VFL\T=)P M="U((E1(1S-U!U&\8K 01TU1GN)_IB=V /:*N+M:!Z_I*?Q8UX6)BZW8<-ZK M&$28YNS18W6TT> O56R4>KXE593,2D;&SA M@Q>CO/I1+0]MFW(_>W:^Q!8!8'?V D]QS.,3,4'M:/ZM>ANHU:*,E,?;2J+5 MI5(RXWG8]_0%1'S)N7[J%SN&&%D'P5!G MDW?]'=**:7EYO34/]1T%!WX'W8T+5"BJ0H]OFV%B"( N>BX/_>M(<_M".R/& MEGA?H99COD(Q\K&/C:?]<>ESXXM\>2$LQ*1Y2$).RPAE\'N@A]4H_Z[OV:O1 M/C[M/)983=/9_M6:GU*;B0$P*I9HC=2D5=M'BCM<[R] %IEG/(HPRGGP-&57 M?!KO<,XX0N]<^8!XINT>A2K[-5)G#L0"Q'VC/JZZ+&\:8O"[8FI&J;SSWJ$Y MQYVQ;[=_![[MVZZ)5()U>;>[S[%_9>#OT_Q09>@\*J0FKJWHF?<[X!]^O*C? M@T)K1X;+"V(ISZ5FL'FM-5MY4+X"(Z,O::)W)K:?7F']^1 .CTVT'H5Y%3$"2J M(C(01N,VKVX@7GC"WE\IG9Y(F"D(&Y UAT7J!D'0 M;7\8M7X8Z3YW5VFG>SOX:=F;E^3D7D@W.C)4/)W=':*&80CP8L_.WG3=<+%R MN7GZ/KQ+X5@^8Y_\SKZ Z2<*@1#LZ*( 2#'<6!\JG)5[XS8B/_:%5H6B"K- M5Y;:Z_.Y-P%OU6JQ-$#89MDS/M']K@M>5QF(?@QJ.M2S"+3G&I&5S#'1F,Y+ M&^)[;V,FV'T-G%@B#? BTN#6_=/^"VO;Z;G?#2]ZDQ A=N\.;&7E\A9*V53N M*"_CRG(55B(TJ RW\"7 M*HG.'17ALI(0M-;>%/>F:P*>(;Z,81L6+:B:'=%N#G6WP%.8G#]SM]OX8 _J M+PIXM%\EX[[R=+B4CGVNJ0^ *]#IMZ:C-2#3J"Y(E7U(H\*"/9/EE#&CIU[R M18:$D(RSC\7>2[E CBAYO%-#C>KYGTNIH/L7:W!T%4MK 7@^]Y[G/S#&HA-6 M9Z,[.8T?^JZ]'G+393X&*%9:%C9 E> +J@'X/*T6V5X)/9:> - H7V1>>GV[ MRQ@!Q#1 @BY7[+5F>!IC4PU^SE\18YJ6OG4W:6:Z%W?IIG1Y0">_,FAF* 3: M"8 Y:&JX#525X&MDA,9XL;T<"#X28ED)2H7>97,_[_:ZCW-P1SAD$(?@WET4 MM0I^]^U*F(>9Y)+%\.>]AY!0('[@. M1E^[U(FQ$!P% 0CZ[C- XE%2Y=G;X\249M7'%]>GC"V:!S_?%[Y_G[\%1S>\5!,& MMTB?) J&!$_"?IA"0^S6;(K*87/"\@2*V]-:F>3792T5P$^N8.08 A) MRWPAA&$;+^RNW>BR*.!U:8UR^T\+G]G&W+\#RU:I_?C0#G5)!6(ZV2MX=V/1$@G+:S5_ .G&3ZP$.#=;GP2)G_'4IX(WX&?:SDG.QXKN!K^]CR1 M\P#!/;NBN,\WG5IR\)#.+$;@UGQ_QR]Y7G6-M2# MTB:.'HE2;^>?;;W:Z'6WZLE=([V& M=+/3L=_1<5/T)J+[%61MW \VI@186^>8*]'P0/$=]M\]ZL,+5<%7_9^7,>BE MO>7Z;IEQ?AKL!$S0*]IQSTO.SEXY&C9[>,?ZWKR6YK9MOC_C)O:\34 ZV+#%EOP<%N MM+N1NEN02ODR++$U$7F" LZOB[S3S/#YU5(F-]Y5)-6HNUBW*XX@2[@WQWN_ MAG%%X]I+A6OL"E?J4VZ(CGAW@83:WUAZ6X"*=LZ,BO"-_<2E_*7W\LK;=V;V MY:#'&=@JQ$SC"?BF[--;%7;W?I_NZ,CWW-0B^\&4[]PR9;38'.W [;\H\N6] MP]-W6SKQ"^X$X(/26ZQ9TL4[=.3V"7KZ9_67J^'SJ0PH2V2J4):ZZ-+MGCL6 MM?HC_+UIB\O(5=.\3#9K<#7:;>65'"IA MA0"0PK40+97CJS >=#J>0G-Q]NJF@#W[Q@_W9 TI&@\SEFE3GB);IG ",-L& M;X+ <.+8[ 5$:#.C/P3=G,.>_9;G]SRL_,G%4C0-?_O ^R$#UG-Q5!6M\IBC)[M<=J.+I'DVY3[IOSX@TJ'6Z BIL9_@D!& MT'HK:+C\"\7\C9P?"0X6T=M+A35FV\K28ST_$N,8(23?&WS"G7%? OFK&?(J M.JPCIU@$P.UG1Y$ASFPR!L,\1B4R6C41FW/FZYCZ0)W3FX;TZ#[Q[?X,U"LZ M7:^MWM#.,^I(AR J>GP>Z?6\@: WSY\J^6,T6WWX MZ]2\;UUVECFL4=('YI'N=GB2OM,T')[\,S-3.O?YH.NX;D1;D3Y109%>36_L M<(]FLFJN [-G4(8[*Z^CO(V"*8;LITD<@U92%BJ:=>K/9?"!BT\E=]IUAK; MJ7GOVH5;K;^0?%4^5KS4,+PGM%?"N<)3'?=>Z4PLALJXX ^(UC*.M^>#85:( M@)A?B !KA[PX^C+5UF4U&7>>I3;RKMR]&LJ"O^FKS[,+YX,JNV MB"8<15VETO'05![=M(P$GML73\LX_9R7CH_AZ.#MS%,\/7+TJ/0>-?>GJQ3;2H_?/1B/A615G1I= M:C06XQHPWQ)^=JFTP2XEX"=EMM3N>FLZ]1%S]U8MR;7^//Y%H2&-AA[JX%E( M%MPNZ"(OZY+YX[^V__1S4@<2Q@B &Y5@]7-AXJQC^8.Q-6_%EX-')> .0_/F MG!S(U*:G2]MNX.X?\R2^JXYQ+IPWHSS91W^;PIRQMGESFE 7#&5;];B6C*+@ M+:A>-Z8^1:P\H?N.'[F<*$2.Q2G66M0.F;M"7V3AJ*A@YFU;:& T9S"CZ&;A MR-)'U4'-_DC[$__O=C_R.WY2=T:.+K5!P=O;-F?2V-346-'*PIY57:)CEU8J M6D&P%_D)((UQ!_39+###"]69'E=*$!TB%#.S&EMT6D]+C&2ZMQT*"T&<,8\! MESYCJS_6&'VNWZ*SJ9UT+Q]<>:GR\W:,-05#R)*+9CB(IE(MUCX?N]?^D)&D M6-^PL]$.?-7!NLL?8]0JSUM[P[)9=$#"X]<4QX^1^=0OAVUE)=YQ:I"XZ8$( M][EQZ4+>PK/ 3-OO$\9S<_UL):F5MN+#O:TOQ;74'MP: *[UO3=X%W**@=N8 M2';<4ITC1Y.%P]QRV^^&5]D*J E8+M^,BEAFX$BCB)BK*VU?L-]A6X"$&,XB M@Q;]7Z%1(24#OR2#<$\_V(K07Q5K5;D;)!?A^(NX@<]A]^''P=?R&>-LY5Q>>@># M[GFQE-OC7AE8?S6,1NS5@JQ-/<_F1/D]_OTVYS3FAV5Z4YO*4F\46N?]!%;L MIV_AZ=UP7*; N07N'AA]60^U.7Z'VY]>IH#G%A.R-:CC1AQ>J5] WJ*GYH-[ MI[?$/!BK2 6Z,LN;4ODG -_$S'G'7M.]OL<=-:%6CF%\*!0*7"&[8.DL2H6 MA_;A KK=DV;4^#N^D:^%JD)%'#XAO BIS?\MA\R;7V(QF'OV].XAMMQ#[\3# MY7J]7F'$,Q92SCZY@UZ<(')QZOD/8Q>:]$ZIV<>&#)"C6C6'B,^)H64?N+ZE MQ'@F;6:RUG##W&Z^R]%(X57$&;9$?=56= /]L_](N9/>&ZT59Y+Y\>-CIML'IB#3UJ6]R1/\#?@U%!0^30!L MST42SB/+3KUJE M.&MO#[/HU1H=@)&B-T,7^(.EZ:T.7RH,>#XGZV4KRX8Y< MIM/GYES*@LJ'LJ,%^>M%1]'V:($WFOK.9@M$B(/&@K332R M;7W"NL[$5FC_3$2N;\ZI.D//E@C*-W^OT^OO2(HQ+D9]%7^->#^,DLE6W M; OY9^[$7K?-%CSO4J-:T'OX-N8:T^TT]<*DR:+;NF*3_*HES 5%^QO>>*\T M?=-?"RW^GL)EZ$![>G47GWH_@UEC\NQH4J,LL2M,?"DP?]FSP](*I&&0;S.U MH562F+M&OTF+J$?0CB,W 1 1E$7&19?W_EQX_+/U/(-73A%Q+(J]57AI=PO? M57(A*L3&%C"OSSE1:^?%!I[I#:/U*3G:E4EZK.*BUD;.DXXGX7R!DKHZJS+59-W7F/C;O[[QU$,& MXNSG02#L%YB*3I6-QK]AU##U_A[^!@MA0S/WE MI$@\\$F_4E]%(+Z\H"ME4R_)+ZS.9&^EJF;F]$_(678'_CK6S67!",($L4PW M&QX:DTGG[GO!_+RS6YFVXPQ^"?X C6V/PNJ%]3&X'E[P$8I M9DBJ/1\6YQRMK?Q&NYP<^6*9EM^[.J&LX=?[0G[Y,=DA_9!QW1-+6+^BET5; MNM]#0U1PU?&8VIR5H?IR$LPZKX=1K.!NJ*WM;SI;*38U:I^7U&N!LFKS(L%S M_/7H5K1KLA54)/'8:,MY?V[)S(YIDJ720_'#2H/MHSZ=_'J!B;6=Z&A].0+;,VG.A" XH1.N:IE)8_[O9"%]8U50@(]FIF &EB[O.W.IU! M]#Z@3C3*N'QHJ='K)*;/CC,QZH[@^VB'HEC? -/O![$HDF%YMO7C%BH?<1/L MV\J]FHL*VM?6"@XLN,5^OZ(-BFC3G%+K9/$N1CZ-?5)=.R)L MLQ@O9U)]^H,W,:+S]$%D=/W]\[5(@^/P/JZRH?*S5VAZ_E'7_!R[>J.\_F;4 MEX-9&W>E<:5&#/UW^3L-24AE6[QW9RW7.'FG W&-WI0T>TNX]UWH/ $@,\*) MHO$-11L/K=@"PILS'RA>MSP1OK-P.TIR]P.(#_S EDS6OW6]'OD9YXU):'?< MD+]=73'4<8OS^&!*R<_BIFJ[LW7OY^M\9,Q_G%*$096K&MU!K2[-OF_>5B?I*7V2_2-E\-L MT"_T(725ZC2/ATN*TX[_W.&H^O2[9P6\CH&3K&-\G M\7,Y0;(6^/X6RDI[>JL3PUT$XW1C***B_3H8:.L:*A-/82\C,,G:DD6I2==:2?ILB7Z'L(;D3KJ?\BTC*9'+V M%Y*'9EXO- ,*H:V".E?BAX<8NE2$AO6JPU-\]@49C,MWF3D+ M=66OFYFF6(V$[>[8NAT8RK#;+VZ9L/1WZ#M@?7:A.W==/1@9@2";K/AN_B96 MAW5I'XE(T[I%>^(-_)V+C%ST#'^27KJ DNID1SZ]WNC[-X52I/,'$9069)E[ MLBZ."Z#/0U;Q$#1B841\\E&"5LRL\?.ZY/^+O?>.:NKKUH6W@@)2(KT(1"D* M@B"])RH"(@)B 0$A*BI"1$ ZA 1!0&D1$% 4(J+2B725$GJ1IK30(0&D2T() M@;0OOW/'^+[[ON>,[]QQQ[C_W3\R1K*S]YYKS3G7G,^SUUISSPM=*KZ/X#)R MC %<-MVCI/!W8+^%188-X>6]V7EAV.,CN)S5433C-0;AK+W; & MVU?C*XNLS7OIW?#\D5NC"=*"V>%+V-=T>3+F.BDOMD2[*$2#OX&1^P2Y58%: M&W+@R%590B;:0EOTS?IVJQOR\*+OB+8"H\$UYX>TO:Y-/:FD+3GQ$.^VJ/ A MPYO6SI6<5GF__^;GC?D\\8?54(D&8_H)'/44^=1UTL)XQ81*2'40IZ\VG\W( M/@5"K-O'V>,>;T3(SUFT.*K[3Z"TVJ3DJGK3?V_9O.EYQ0(:(SI9P*,C]"\/ ME-IN'6V8+CCV3:(F;;IG*W%IB*.)*\!?HH6HY:IG[D8ZW M3>)D2GS*4J6R]<\D".1N%7;#S) =*+''VEYN=E1?XH@P5:6MF^(A_YJ>OJNJ M^RG*1,_G>\?5V*H03/O&\_W8)LR+'YA8=5-CNYJW<-\$'H+;ICY=?S_J5N>N MS]Z[=#<'-:R H\)GKO!3,N\V?4-UEOIS(""8,W((>O )4\)S\!3]).18PB05 MN7)-KTLH(<1Q-0)R/6DB7&6^WM3VVX#WW\?8$_"P6@\IR9Q7=Y.'"*]ID=PE MWK'3^D/,8U3<%;)8LD;,?OO=T_MG96[&^EA(8-DP!0[B7&Z D$9>DFN;SZ+7 M2GS%9.Z-0Y#=@8>G>HSN1^;EG; ECP@-R^J J>=[(:7;+41GWW6IVF][RG0K M6E=IGC!-F?XHGF"+AK05"^H]#VBC"11XJVL\?\+YW'_/K[\P11E7Z=#T%L*' ML/CQM8;_Y+,09L;G27>?1Q+S:F%IM 8J5WUP93A\#1?M\ LY!#[X! GV3"D@ M8V/DM[:=WX)ZM8^[=?<9 2*S_MQ^(]^*+,8M4K'G'_X.4=,UZ(42;'X5US7T MVM("EM7_XN3_8/A6';)E1AY764,>UM17I+G'W%PI_G04OH).'+?.:-^(,*GHE^'!IOHE3AWY80Z+ M6F(!_9U::V><3;6:5(9S2S(FHJ@Y6TX=M"Y9#^]=L_ LF@3=E69=F7UX:)$Q M?Z[WBU9VT3 1;%O'19M.V^KH $5KTA7)"R-9LLO^\>CM+,,Y Q"O[&&VEO+P MDANW9V)VWN$$5G6=LI[W'EHH+M*^IOZ0"YI1$[JG=*]PGCH=V"#^L+84]P=M MI-MT-SA/>>'+WR_?/] @F'E\(=1>J11*L&VULGW9P%<^XO7S4T^MVEVN-Y\Y M_H!M32<=[L(J[$KXS/2'OVQ(JN3N@01CBZ)+3HNF?19_6/>+S>K+^D3)ZG31 M+>85YA:S10RV+XBM+B+"J"J+]+>,14:,*FY;_APX%5>F3L_"-X-IDH]QVX^P M2YNX]]#1#*;-*@'$2*B&[6L[;(>< [^9(3GW[PDU2*%&+\RQ +,X^JLF _W9 M@'_V@%'/+-)?POBA:R=\6<#'-D04FPV/4Z]_0#RF$HJIZJW510&?/;-EZU]^ M.T8,SWV<'V:8??X#*(@%1%HQQTR;0F>I.L151N;) N6,C\]S4>QH@&MI':B;^F)O/R7 M9!;SZC&$$VC*X';9+:)=071S49VQ*X(QE MB,'W"@9P\\KN+, EE05<$#G N$!59UYD\#+KCK. W_#;I]9-R.W]E "J/!$F M/<6]D-G.GQZXJ?O;I)LLY#[) D[__6?KIQPRF@6X'D4M56'[0=0S&0FE_BP@ M1O8 :5)8TWG%Z35>3X/B*Z36QXB7 N@8,@M !\S$R6H.UUTGNESPNNX\? H> M_^[MFY1;VQPF(GR (0#(J/S%C'$Q>:#%]/ND=70"1-XS2%:4M$-4'0GU*@15 M3YYH$J#%R%_3:M=["A+=?(GI-EH@H#:S? M98S=WB^\FR6=5+ZC\WY&^5'@Z=#\0 M6_[H P@-=6/[RJE)<+EXVX90,/H2^7;FWV>%R] [22,4H,;.ECQ'0MR T>/,VA&VIT;9\%K!\)6U?@W:$!309,8_2D8SW_NJ2P:7= MU]\YUW[[EN10C0M^56A9Y9/[K!';A_KW*VD/V$UD?TW5(-4PPJ=12X/G_GF^ MR!G#P(S=XHV @) M!!F_5>UM+A_#>>F3;)TT?L-L8;WAG8?.\"39:>+"Y_E,=^X7N04/C0_\A9./ M,8^4T6Y2@R@1U+2<8'BS.$_^DJNP\_/4&VB&RW#/9XX7_?[G)0[4IC]I%#J0 MP6X)FOQ/M3,H/%'O4J2]"]3UZ_>JVD04^KZ7PGV&I!ERQ8'H31?O+0A=:8P.>_GJHSEH-^+>Z+8H[<$YBV,KCS8K2N_%WDU5!\!ZXFB)ZU MT:9.XZUA1J3MR[,O^L[(@1Q#Z# RO"K1(L&#EK]VSA>Z7/)2/S5VW!X1A38] M)YO, @1B&1CVH8IQ?^SVR7 MDMV__KQZ&+O& FA&5 N*)^GQM 3IOM[5Y:>358-GIEJN3$Q@3]6(XA'G2)"W M9)6FT/[HJL_)VR5.4R5/["6/&)BOQDA'V2-4B+W@#BG^+S4?/,]ZCEL/;$1N MCM58'-\Y7+7$0413_:%K#!9P;AW.CB$I+" 13%I"C=&8S\;Q3'ZV4TC17/-7 M,Q=B8_SA4\XW:V-:K,NC2]742J7ES*02*C1,@(,14!.D,:K)!/< .[9(2,+. M>0N/K]J-CGZ1JW%QLM5=4]W6V/+WMX#R3V5CV>?BL3%:O]-M/+?,TT M;_F56.8%ES+I.]F.WSFF&^(8#=#'B1:44NJ'.=MTN#>P5$I:&E%(_D.!%W % M(7Q 4[<%:E_2;)D\5K2C+*!9)6\"X4ZNBM&)_X:FRX^'-]\9;YT\]H6+.GI? M+?2@C>9Y .R(;,%41./7FD@@2]*7@L":T/D^_#@ZW4_ZNF6DF^FD^E0_0M@E M8YV'9A1L2LDD66.C$7#^H7WK*GIH MS#YU?-^Y=RRHJAB>4X\.7M?:5_5UKY M?ZFTNAG*,^H& 3O63X@IF;,5OOVXNO)"-27?XEV0 5CA$L]\ZAY?)D#_S:B# M/H".U5"N4!]+==L.JR."BE7,YOT'G,XY2>D),X+^@=Z.B?#LI-ZIUR3T$S:-+. MMP$7US7@BGSA1,YJ5=A^=M@18/]48[9P5".2A\0>>B5Y*7\F++Y&V29YG /) MM4E]>-@A><*O[\"DY MPL0:I2.K1!:K(J.(]I^+IU,#L,&I-\)>:M"O]ROKRTZ\XQC'W8+.5H!E)EJ@ M_/[@&,. ]N[^H[V4J?,.V+%[CPM3)_S?(7.L$7[L,5?SST0Q;SPE<[!*I1ME M9$KZA!K/<,Y0>M!URZZAA)V @ ^@=\@SB#-X)"_]_'#=,>(EL1G'04DQ_^MI MW>:E9\-(S;BGT-FW+ ,)00C>\:-'6H@2!SAO8?XPCN_KW:T HG]. MY.3][$+_#1*Z+0O"I_B+V3(L&>I]X%/-8]#5DYR8BZ*$&=)E6[0I07W]!)PP M=6&^+8=:?_C=\8=[UQ8-GI4-*G[]ONT),.XQ-0PW#-G[B_;IEZ=S).N8>$H0U<4MWRS,F[3; MM.5D]OVHJA/2=G!:;W6ZIBE]M"0CE:31OLH"#F)S58A8ZFF^0?66_D.M1;28 MX?ONWN9'7^5NGMES*$B_?E/C=2Z;CZ?GG52ST3Z)=R/ GD,X4"]9@'"=%N'F MPXO#ZKF1CL(;"HX]"2;-AZ'1R'$/*>LO49\=EW^$_W :'6M.IY#,SY:UQXG> M" , [$_0J)S2)T:!\J MC/T,?R)B9X9(7DM,T4G_CV**?,6:W":)2"WF( O@NTLU);>T,F4J$CJ^J#:O MM(5Q*]K)Y5- MD>W^\51*0CDCBWZX9E7$@2DW)/EA8$U10>4KAS\V*?"XO/Y\NEWR>W0F"YA- M][.FH%_:'7BCN]QCF_MP'M3COHE5_"=;!P]X"R-_B^\[OLT>/%\9^5.)!3S7 M.OZV4_9[*B<+*#C#F5E8Z[O:&]^C"!MQ7VH")BLL/DZ6 M"ZYP7[G7P X9D8%TT( V*N8WX@*N+&;5=?A/VN/2D^=ZX=['WI#>THK[DJP$ M+HT;!M"D:C47^7L.N>>G0Z3;$(RJ>=!6^=X:-?5/.GU5NU M&$Z5-3UZNYYG^U!:6G:6!-_.I9QAE#RD$MQ]"6@1;0UJB^WSRQF"$?'Y%\Y* M4I(XXRY-&C:S(V$J5'=B/-!7]"10)+;N!E)+BF^Q&P)8 M2V,!E1WKN41T?.;"WPQ"[X75KN&@,_3$"P[ MDWCW2UG/LH"Q#ON8\8>1X9XK,DJ&.^.T3\G(1&F;O-%,*HAB035]0,Z;"TS. M6#P\+$PGZ6Q$I% MVB7"L99MYC_'>>EQ<\LM"M+[NKGRBQ;E"?8YE MRP*/P- 1C*];OE-+^ .?&(.2O_)"%G+9.:])%B-8QOT,/5+ESA!LS'-&-F^A M9JV#YD%]1]"M??")BK'[@:\35U&]UN&_KCJB\C[D55GWW;".SN.^4;""=+WJ M_;2L^JE/7;YP7ZEND=_OBW+YBC@FCY['=O2/XPG\>4VPQ/'VV"_R;)^3@XV: MMZ9*:[K/=\U'!P1(+A[1ZD4^0S9!M#'MT KD2YF>$IWV1.-QN\#5*NY'^*6R MSCB3U_8A(U*)E\]V7+7_,[.(QW^_)561L!";3U%FCH&K8'0E$X$)\U\7]62U MAN7509EZBJ^-L=G=]"N73MP@72XSX.#:$F_-5B7KM?8?Y9V"7QLR-BN^K=L* MC_7XI) M*/YU^Z;$MN@4>8F:NIMC7]9G$<"TIVHS+1 M#<6VH;14BC(U;!8*M3$1N7?N-(YP=*1G9_+.RL@(VG-:3O'3]E-+!H[<" M5&U" 9/3E]-MHQ)=;3RZ=^@I!N[]2:6$WD>Y6R.VD5#!>Q4T9RI7&P\? PJCR^P">BID!@T,;II7N1.I&9B\9!Y.Q"FP@+M0J7ZVPX^;MGPM[I7) M_EJ^G*%DJ.]_1H(%X K J[!"B"Y9*!C:%,JL/]X3ZHKQ133NFQTS8 &_X(M: MCX6:B=^5SR@6L@#YP29\0/Z6K3_"F>:)')?"QE2M]@/!!VEK>KJXVN& ?-#& M-1O2!=1S+%GO:K!$TRE""=2"?*K5Q-/[ZYAGP\GA1:_-\&SE)W\53M7>$3LU M.5@9+V-%U$LJ+LX,_#:\LVYY0JN[*V3Q-7_O:CH"OR[>O!'= *::SM+4!:B! M[496SOX'+2^@=?]<00QTSK2V,ET. P<;LJL\#40EKN?Q]K( !]1'XTS_E8?" M3U/++>9BRDAP(E?LFNON#9+>2^T)?2:C[4^RKPA\Y^&Y0]YT<49NG3=)RSXR MG.-FNHNJY8\Y\Q]/*:E)<^ZD,N;F+,-"E&8">P\EV6&?C4,C TJ$V\?Y7XO,UH^Q;K[ON]HK"#JFJAI<8 M/ ['DZ*(Z:GD# (EC5@OO5Y3A]ZM7GM*V1)0>%D_M/OW;*C4WN)_7@K0#YW- M:-#&K+OJDEZ75SB+Q-ZHB3>6/WCO-0MH?!;+W,.:LB/_.U37X5^HM0L1A$Z.6ZPC.6!;-*BN]Z MW#;G/O1"YMD#R5W141;0HD%W9 $?@XA0NG@74W0-1[*&[JGO8QCQN^!]R#3. M5F6JIR+NVVGF3PUK1UFD. >?&21P+<1AK8+ L&K&5;";LEURKSU<[UI5Q?WL MD84CEL="DGQ^ADH+[N'G\]I!>RJNNBS@Z\(N\[4)S%Z#/I&T[0'MR_RR9+T-=9:O#0X6,9WL\/0W+3KZC3SM8P&4A MW+T&?537/\OPV3>(9:9:PI)P[#O.EP2?8K:D0_>OIE$^?Z!KDCNCRM.WS(CN;\("#,'XN/Y3X?,'=_> M2^,NG%:@>A$W#E^H"(YJ'A^)YCW*F9F>I?/C_?;"D,,:.H:IAS @GWD/RJ7B M6W8U-!.3+?(OEN;*\#V(4I=Y(3K@*?;#(K'RV+KAPZIA[8E.)YXY>T>[WWA. MV=R<$MA1^^Q'5&9W>;#65-;970 ,C\:X*)/7$2M21X(R;& =2TF=# M1^S$?4W+.W\#<]OGYT\2]91G^9(C#?87*4L-WV!1NH97@LYX>)3"1PQ=UCHG M B=JM71MO]CYK;?Y"+()NP:=E^^E7'!%J^>*J0J'=Y,,"QC&#T E&\269R0; MI%>F189\9\WEB?/M?]0U9N&#-#U/E"1P]L34(Y)DY(XQ6;H:A3 MZ1(&\N\SUXRO^V(M2%P4!/4EUF6/":DB'_KDZ^GZ<*_T\5_9:V5&V)F9(VVU MQ@Q2R)ELK"4;@;5B.58-A_%Q$#YGQ$5\@+7^(_RTTH#Q.3EKFU]R'QR]OD!5 M1.V^1Y;:P*\3,M9H1-31U6S!C+;00WD1="X";T;#;X2X=Y%E0<^3[B>.[EEO MG]U4*"_,UC0'3IEH8FW.QFJYKE?]0$RO6BMD[83C2Q+2# R,3F%3!YWWV0F! M+W2Q%3?6T8@2K?+2NC%2J:(SM+9C%'[9N3O,R%>'/80^VT\OC.MJ-G9'=-J> MN''_7NT45\L^++KRC7:]N'7%@':G7HA]X%&%HQW?XW6'K@+=0C9<"JE.(@X_ M+Y=8MEVX]L-9MOGYOQ_Q-OB1+16=>CN9D./=9"5SE;'K:E77;8 MQS=KF2K6#9B=UG[:WN8H<:> BU.*1FEP9WQH$._]Y%D1G&$3B\SRGRA-X]I_ M:[F IJF&]!= /O[(O]S7LR=[HOERE1(^$J?&Q)! XA_C5+[1M__G76@4T!B* M:;%NRFQ*02V-%N+:^P^O[M>TKC]TAGWM/HJGE0%2G/*E4 MO1%I/ 21617V-'RL.]BORO^DV[^XN[*\VGQ$>L$"Y;0!)>3_4PGV' /,I'>S M@ XXEZ3RUL5]0_T$Q2M\/E7S@]<:XEC R&+69+!X:W7@9C\TMNK6\9=670KI MUPH_/DNQ5&GDJ _GH;$A0F=4/FK4QI8A*AJ274$S#\ZX_7NC$UV<=KGU*Z QIVBY&':#?'VF06=KR&/4ZR,KJMY6*^-A%7..OEVRX2 MN/-9J<^WPK0)WS3K:U?$4W/,:$H(P0Z'*64YJ D40U QM"-1AUM[9MRB6?AV MUT+[B-S1T5.+KR;E!$P<7R.-\?U,0;+93"3=S*-XS(*OQGZ"HMB<$OM44SKB M_%)'_6WR(EH']"*SU3#I,W^E<-O!B<+QHM/K?+VIW]$&;C,#A5>?9NW?ZN!/ MB@%SK3'',S/2T]D 8@#J>49V!V'[Q?/+% NHF.[UBFY<0/S:U#!=\FE,V%F4 M;.KX$!QD4?\+Y0ZO/7-A:EUMT+(A,,9&TG2O]+M,DH1/B(P ?XAL+%LQM6:# M R/F%<.Z=U3QO[4NB0" :G'M#_#4$X3MWT%%X MP>#:V406$+OV^>+0BVX(ZH$6=W6RY-/PJ-;4U?#U?M+&CK4HF!ES8.8=N MI9KNH;E;=6IR(BZ!0P7+;.KD'& _NH,6A:?78&2,!3]?H/TMOE>7'O[I:,-] M+L_WTC'-[IP"DK:AF^P!%\5V[5[%3^,(L%Y)C>9@>"7!:@99.5A4'2QJKZ)1$+B]SZA(O MS?FJC<:E&:@GT*.,0[<+4: &)4\^*XLL1@W _VL M[JYF(>S^]NK^CK39C*J;>YXS= OR@FJ4?_YDSERM8JK>56KQ' MCU,W' <1-T.(,I!5&O1:;;KC_;/YRK1VU>ZJ\B/S)(%0CB$.EX6.=0-B5\E" MXAG_HJ" TQ46G-&ODG=CEKD[5SOE1PO2]O[-R6;IDK4%AA@T[ ML-9H@=5L.3SN$0C41?32T"ZYP'VRYI;;RV1',0/FW>_O?!2^3@H(Z!?C_M5& M; 3+YB4HPDDV=V:[N/^TA]?F>/\+G,CL&C>TS(W>N[1^]/\U M<>L ;SZFS%#X!G';2O .YD%4UZU?N'4<\T5*[C!2$^[4\2RUN<)I5"W[E>D3 MA20]H?47!==3J/V=6AW8RW_H\L1XW"%JW*!C>9+DDY*:-:MH18'Y^P9 U&]T MJ/SA7,5)#?T5'5]_%8M'2C/S?_N#J;&E3E0_2@SI\\[J7F#1O3+CYQ'"/1YS M?*VO#D8VIHYRL!UEW3)GJH/(?\IQ[$>[,ZS<^ZI-E^@4J4-"$M1A8.0\4-?? MD^_#'L1L]9ZEHKPNYGEH9FH'UV>^*2CN* M$<(L((YCEC%=48PDCEC>'Q*%K+ZA?%1JN?/D*49=WPB?#>]A"DW3+Y"8;U%A MA'K%'7Y%?$_PWU=OWL:<#XY94&,!)ZX)&\P>M9GT0VI3RXBV,G_15^LW'SLS M;WL=2 (3C!-2Z/G>;]Y+SXF"GS4HP5D R*4]PR?10]X[I8^@U[I>F3!WO&#Y M9W)6T?MG<08R[U8ZTR%1!>:"KW./>!05N6Y@78S1'XR%R5R7J'/>X9]6D%(! MEV[\G'YR\MGY8S=>GOVL8(21 B6_,N]]#.D(=FCU!UB^.FA/R/'Q(,SN.8M M@F6NIUB.2ZA9+DINW$;FT*X$_]@I#5\[.%6Y#G[HDS[:;["0\N0G'7+@[NW.M_F*FWB#?\\VU# M)?O,2PI\\Z"ZP,[#MJZ ;//[#^.61>^WM8[<6!E^[_E3>L#[_J##^N0DXR-3 MYM$T>& MH/=TGXRAI5I#K['NTDV%GOM%A[@\Y[J-3V_A3N5!0"Y<"75!Q=2M MJ\XEKJM]F[O<=\UXI4_;7+H)CNCJ.LZ7^NPV \[]K;UG4^O(MJ_$RQLYLK=P M*P0S$?O8]_\?$'+Q;H'%!N&.[LQ713NI2+R %Q7[2NVCZD(/4+O*UZ5U0G,/W3MIW9G3 "["VT)FB-!;" M(S,=%FV9)M7]('BY=E(9MMO[:4C W ?O.J.G%IX,W5(K8EY+EA:QXYD.C&_E M=PR;B/*\^=?).@B-NOF#]@,39]?YN_R' M4''>\:0/^#'O"DHC(\ORZDGJN]DW05[27>&>7,=]4R[) +0F"[+#3R24!,DC MS;0;8F-V@A/T]A'MI^8.=-ST76N,-$GTAW(P55? AYCR'DC%\BF%JPW=M7>" MLP\3!@?UE\*.\@M!B_T2I"M4SQ@_/&@U<7UWN0%M[<:4+ %W;>L_%NV4YY3: M-Z5 J;EYMU:<\EJ@8GI9[$ K?FHLKM-\(NSCV22MP2 .QFQL63X*OO'\!RIV M9P(,IEY19?*1G1CEXL\1KZZT^)WDFN(RBEA/,7+HU_BG8QH.UU_]]#E?+!O- MQB*^-M<_#V2R@)H<;1; <\&*M!8$DV@06X%R(4]X(J6&1# G=IW[DTX]QR1W M#"$_#$*DJ'-V5+\Y?O56P]M?C&J5+T8$!OPM-HK45%GF_0P;WZ($.W>2]5HQ MA]I>"J)&8,X'1H,4^$@04@?9H:MZCY.C":LG&OSIMX&]QI\WE]\8(QRJ\_[> M0%ODM;%[[=#K#RE@Y-6)?Z'66/YN.!M\[:R_5X"]R66157@ FBA3$0F2^!E% MOU!W&%\5YKV62I9K-DJ\3L#&W;(BP$1.1%^,?:%F>Z0[^_!? ^9F3BD'T;VE MB 5$9^L/(4R0W^%!/=?F#MY"3_FN6>Q@TWL^YH&]96OWH-13R:E#V0>+-Z^8 MUG[!6N.J;//ZP+R;%9 H*BI ?%V29 _CFOY1DX#0 6=][I5';#4?U@TC1YN$ M*F,QD-XS64/I6_)FVE?L?L<<^:I_'.V$(?0GJC/!U"(;O/_RD=M.G1*EP0%, M14BKPW?D;UG05[RJ/_;E]+$$&;#3575YV[V[ODESU3[G=V&A>X_]D?71 0YD MY8U%6?1"Q6;9XB [*=YN([B^5JDFC.OHO0Y7)%OT+>72M.D.4 '$G71\^?IO MG9."M_]"5;WHFD@N;#5\X^:=G]P&7*_,D X3*"=:%,6%RD:&/+'1AZ/SK6OM M!W[):8H+6N(J"?*)\>NR6ZC*1M\*W8$5[F'>4Z-?;2F^NSM29+GO MG['$M/CVVTQTGT ]Y]"*(SGT[VG1^FE\CJ@E\X9Q[$O4+!:SZ;Z+H4B4LX!? MB0#2AMF*VPR"<:/6'K"/_/Z(R_W)]&$!]V![1MCG4(KF&&KI-^SW H!T0S5Y M0^SHQ>6, ,@=8-3*1[4^D_!'69;G(DT5]/X[( !#O!<.8TQ/13 M>DCC5B?;OY75Q9R(VM)+JP6GI%(=-DQ06KB*O+80)!?=A^2>Y#9YW6)(R+$Y MH>S9LZ0[7 6)DZ!09@H;)O6J=+A*#AJ?SYDVR_]C!7))+GCY_ M]7 ]8H9V"SDER\MX%6 K,$HMNHBO\@CX]B7S\&_BLV%.,PZN+44;&W*">P[V MD\JF!9.7W0-Y=#-FGSP$W=97XE@'C]E2F"3HNA]QW:UE6NP7XOQGE^5 J'>Z MRSTE(5U;C>N>>T^_]]T*D&C4V5Y'ZK& )B'4_(]@&K.MC 5\MG-8BP90FF!9 MZ/PW!)NLGT9 %<+$^G\$7/\Y_%;>:_ M\:_TL>TLX+]0R69!X\,R-(=5X M88K$_.8=R?4RC>0U/Y>9-12-.WB.4C4$F;GS:RG[2-7W3?6=B5@N./_GW+BS M0<;O;LD^LP@479DAW<"-KC)%8EL#J5&$,#%TD^O)K$_9^AF[@>(]EOYS?W,W MN__>$@"PNBP@,IR)KX&6X]I&8_*TT;,N(2EXQYHN.5E4T-- M1;><%@*67]T;2GUY^*V.^<$W+M986A.J:IE]C$Z1:U!(/K!!,NJ3O MEDJY6*4:UT%SW73?8??0W$Y#D< VXB;335$!!!I>?,>H= 6\N! MQ6=ON7U*TA3_=7^G#7F-V8.KZ'^!8[N#4R"L\TA M#5$%V@>K)\U6OKN3&H.[E4K\Q M?M?4Q U,*QU/O!>CR)W\H;GP602P!I1>)Z@W]X/HHM2@C\%:+6+Q[KG+5[G= MKAY>/E;4N5A;(=2ZG[FZ]!_%48U:74\,(D[EP%:=VM8,GZ3=Y9B<,;N*K.S<3US MEP503[NO=T(4X>)@'F-!I&V,]G)9\8PSKAOED_?B/%M173MW3%2ZH;/OH66/ M<97]K5#J)829EQP"0J+_Q'MUBN,Y^*I7P@W%MCE#?W$-@4F7P:.Q--F^B3E8 MXC8==EN9G #<$B(G@%$NKY8!6<[NK@EBE08O3_$D6*YIKRSV4$7P1WBC ^X1_UBP9\5@@9& M9L<\"N<.>7U4O(Z^'FD[@KN*FWV#$MCV'NNF6+XCJB=XGT% $-:G*"6]S ]$ MT<@>F73"&W)5[ 87(P#;B8E@XTUOIC[B#@D;^9@C9+R-[F-YNG3CI-Q8BNE: MT7?T ,X1.EL@!4HHA?!250C0%O#AE?W25Y=-9BC6N5TR]?4_.".EL5AC\-\C MP+;W.&8NJ%$=/0,@W&;#-1L=6 ML[CL(S<'_$2GWG,^!YU-AV;K4CF@M3Z_,/30&]#H<$M'B"JI 3/GS>?YXW ):%Q[ZO*X ME?,+VNN XZ_"!-]'C4; BWB=5W8(#A4:);;C@Z^-,$G@BM@D(A5.[F_*EON> M=J>B"G?K[\,GR4U*&I<[EE(TZ"J4Y%N:D0+GYP5A+W#B#:*KT,.(\ (JS#DZ M)YD_IDP!6V<-AG*'=2!2XS,V YC MI17T[ 2$#*1)Y4J-G*1&@: FNH6-_EJC%IL_8/!ZN5L69BC76KN==LMR-C' MY%N&,=J&R"*>/D>0B$D6ML;?*IVR0ITVU@-EG@_&:&D-_, M[I?+-!5*):-2&Q83*LH"8NID"DP+@P<(4L*^CXB7*GM(?3WZFDD^6>@S"<#, M.R87R;Z*K-4N%11;:>2.&]Y1KON&A]15E*U]>/#2!#C9,"?7]!.MJU8=-PZK ML0^6C ZX-G2WB%D)/0^=?2M[])T5%4;T%KQ\1 U;H"IX$+)Y#A,<]B2M@\Z) M[T!5S??JK2O/4?Q2=(1P$68NXB3T5GPWBDAC$6":2'5G?LLX!FVA)T)U8'^ MN8VQ_E9E#Q FY%-E:*5EDJ\@Y*XL\>0KI@2V=V.L: Z@@LE1YF1CW&ET^EZ%X05;G5 M$W>LSG 6L4Y8>@:U>I> TG)E U/.CF1TD[K@%Z0=4?*2[)_Q&6BGPPMVEK5! MS5<%>S/;J"Q@^PNQOH+)D\@"%!Q:,92SEBS@T\@.Y1MF3ZAE82^;7WUW#]'? MCXGC54 )&SM52/?\J!_U8^+?[S$\/T$.DQ5[-'I!L3N.]Y)-/[U\H&Q_39/[ M1 BG0SYRS/4 AMV"=6'BJ"Q8#7_]FV%5T8'-.K^4-8L!6PUD(7QU8_0=Y2NI MKXRT>XFD%Z?C'"[<:G@1[NZAN/U1'WO'57Y\O3% POKY_*S@^UI%XBA'Q]Y^E["J"Z)"8TZ\GO1YF$ .OMZCJ*+<9 MS=#1/[%CV3H9E.=4_V)-:(W7,;)0 3@?.VY(=V6\81,:0H/,/Y.U>!9@?H21 M@S5]"4VT'=PQ*,<1NH=4YF%4Y:]@4LZV)WSODB6NX.G687BZR 3SDB[[+FYG<,R4*8=G M;(_01,W7KIJA98 W^,T/\R(OE)IAH:"" ?T/ M.,8Z7.!,_J+VQ*;QN'(=7\D?!'MDQ!U'N6'B MQV%-J,1JP_;O\N=S79TM\UQNGT[?O/FS_#M'"L?'1>FY4]EI^UT$S+'@L/9 MCX /\$QDQ9,Y%<7H@2M0\H O0R7^A;+UO?K/E1Z>WNE]D.[T__,;CY[=5#W!.535/*'Q(?DXL=28KZJ\(1#1;GS^/;Q?8>HI):A%OS[AR5%>]E)LI\\K]NHSD'^FQEX MFBBYA7GIG])Z:S VX\F\3 ^@0EF (KP)2I%F,YB!Y]B"3NA4$ @YI'P,[LOM+N]')ITQP/?ZO3X3KF>_+BI+2A^8)YW =%V(S6)VA8\=JWC M_,]209BO3G&545'''W-AVV2>=XNB<(4E>R(UG"P7S#AL7/XNA/\Y6 MUC;D^,GQGE;5N_.GU(_)\CQ.?N47889,=)B=3J.@UZV@Y0>?T.S7#JUP32RYLFMXIOM1A=Y)_H;[G#2^2-Q;V2MH_?^+ G(G M>J!?S[I@IA$X%L!73\3N_U?O_U?O_W]Z MYUJK)V;OQR1Q,0+_Z2E^2.0:9?!_:#W[$ $WYB7_]@$^ &4@,C\QFG.@H722 M:4K&/OZ%@.8%NUDGM5A5)O6-0)+;#3'7;!5HV7#SN+[KKVO<"Z(;[Y)038D8 M9(Z9R T9PC_%MVX$]'IVMX2:_"W*GU0LB7YO;;QUR4=0Y'ZJ0Q'!EJKDWK%Q MQHT*_SA);U7=KTM.[?"/A::"\V4K![YO(Z IP_T51X)/.YTJQCPJF=D+&=V[ M3HF@5D';L7%.N)>?$DSA\MRJQ",'K/P[K^R7+22%51L>N(V+,I8OH&ZU2;G' M;@?S]WW.M_EJ"GZ<.I3=R)<2!L"Y'4;!![3?V8[5S/85D-&N-?9DL<_';E$] M^^YVJ7%O:2R%DI#$FA(AZ-<*/FOC6+5H/FEUDQ.731;*7>-#(%WE>>MWB>MZ M!-PS.I2DU>(77VLM*A3NM)PTI]C5O2[9-^WX)B)XDLMS[VI@D51I21#6,R,T M*<=GUP'_M'*P_T2W45FWQJX"O@39C3O$MKHOXF*2$7F>ZF9I6^.)MVU6M>J\ M$'JP%4SE=AO_FI[;?"VGQ?%VWHNL/6^#[N(O.ZD[WA?K!==0'%[W&&^07"LX MD9T'\JWC]),=%[XFEZ4],2U?3/L9LZ]>(+I9X6(9$J#8VOO#\79M-= MG.*C M+[J,J^)J3R:'$875LF@8/@]>BHG:5+"=% DF$W\'"3B\6W)ZT%=5X#3JV(P7 M=Q!2M;L8I?CF_0'7)^IP>>E4+OLTP[?I!DY589>M]N0:)% 312C=?G=&!E(( M\W(:8KEQ:X+J9V:'*G 1KKKID':%HGJ>SB%53[N < *+-9R8='6*R#1Y15., MG+W?GKGR_HA!SL$X)^Y=1L-^[SABJ?;:KO?M/\]O_H_DP&X3KD%<#/UUY@"FV/%"\G_57/>"MWS=EA;/G MNYI4BP;+W:E%XA0_TG!&"^:P)TH,8<&]6?(LRKSFE9]VAWQP?\.-\&/C=4&M ML@KU9-0+;%66^76=A?DOCA*T;8Y1/E!S@[.P>O[=!^I[(3>=!V10)/5.(IO> M\3IF1C(/2TZQ@%"LV3+_S&X]9PVV!'JFQ?MQKTJO32'6GN M4XP<&->)4\)_+$PXL&?7[*@W4@8=%\VH!<7VN3!AF!PRY+A[-V^LXP.NC2%J M7>X$;W7#S@PY@#(^A&!'EW]* *5"ZUC U[8,YG/X>B$)/.%'\1O&>4(C MA:GR9L.JV_%CZA]JQ?6:>L+<%)(W(Y_Z+9\#OX#^I\W&9R '4$WR]"!2[)Q[ MI#$\? XF,#WVR+!2ZOD(917Z5LZ<$%=ZE>]]D,Y^QG^Q"WFOF\F]RP)./<90 M#M4R+^ NHF8_0,NP+Z!P!E=SH)1 [9GA)(_YT*'CU]":CA@6=H)X#!5:PN$WS*C)H\ MRX U,^7*T':_ YS=JWY4I^;F\DG+M@9P/N7F?*H2& -SA!<#G)1]ASC_W:WM+/O[BO?<=G,1?&MW\#@ M.R_F'8Z?Z7##["V> Y<@>5E ,O0""\!R0[>=AFU?, \,()6#A5U(Z;5'A^N MR8YG 5ZOV/0P20IP46'RH@A=CYN&D&(KNKLG>%2\BSZ](H:'D#)LZ< M@E4GH*HM7AIKH;P)]J3ZTFA.DH5T!LXCI&[DPJU7<>+'N*1W5EW'V)20TY;Z MHT(_MCV;)[ABLS)U6D7P[Z'O'8O.V>(L(%*>ND(D6+Q@G@@.;>>C]WYN,>D^ ML"8C+UN_Q %ER6=!@!YN>HAFGXW#W5?ZHCW%0>$BHM>B0_)5Q\XH".//$ MD!>R+2 L4$PIP7F8E,RW;F#7Y0:S82OW!'F.:17;"J5)5($9RBFXQ[C9-/#F M0X@8VVZU_0PI^ +T!89DOO%"5HOZC(@Z>GX.PW_^<$FA"ZQ#)-[WNY#CVV%G MP;GC9_N,\#.8LHY&%UL*G K*I0K?&BK1<5Y5SDO[6VS*_2XL'7@"D+<_".P2 M-YKK>><<6DK\FK(5JL4-[8N>_,*!M;WHFLIK/WTL!G!9H''Y6==:F@'=:80. MPI[0[S[>K!C3/^4"D/ M31:0LY*A=.7IN8[=5UV58AWF7%RI5VN M>ZK\\ZLVR3.Y&[ EPI1PG*# MO)&O"H1TSXV[F4"JUL&5%G0A6 =,LD$ON*5]1%:;M!.=7H5XDE/]W9'>.528 MH'LT85XVIFZ5*9U*%F?&LD,Q&Q7I0>E/(DPJHTCGAJ\ M&"'W__#VGE%-=^&^8!05!24B17I40!0$1 21%M$7$!$B*!V)@((0Z2U ( K2 MFX" TJ+T'GHG 4)'I/<20N^$%@()R>4]=\U:<^>/+N;53G+RG'K^(I'S?S/YO&-("XRHR:FLYR3 9Z#6RW[&6NM'0,BPI_Z>V9AUH0?[,V!FHNV\K MMBJA:7L<1$"3W@A<'#D L]L*:17 SC[_\K/]^:!B\.@O_B.16!,0<0$5C-T' MDZ&THYK_*+N/B_&]10?TG6H7)&5I^50\]C%6(7$;ROS(OI Y((4.X 1*< @ MZ/XMN/^IEFTU.X4P%@WR*2H\HP,"3L5R$NK?"OB/1>8D3X"TT^3%V"/)TP#? M6-]N:'EE%.4-0@[)];%6;R;Z8Y6SL4_J3AS*V5)$K.TQFOTTT;-H_6:"9""1 M:::W^8^X#)C#%//C^!M8J8"7^;DE"/_N:> &,^O?B_O0,1C)>@3\ >I?"E

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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�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̡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�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�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�:!(*,>"T=:!]24D'^G.;ROO'R1FWENUX -I+_-V! MZ%\X_?*5;.RK[_33+W2MUW#W^I?U=N<3YV-RHL:FF&O=O\MU8+HA.ZM#+%*) MD(]@FYXG=-Q:LN,!;V"5]0[)6AE51XW4%M(/N$CUPG-!LE#5=;[B^]-U^N[B]7% G^GXW=^<7[O5OCG MC'3[^)OX% _I QZ8@D%?DMO(I=&KL_$H+&<@9;*@M'"UBBI!CH$I^I4NO%$6 MX6@U,M05G6-G^8Z.PWWTE4%$X*$BL.4:AL_;$ M]N@()$+'SC*.@\!=-71""'Q5Z#MOF%2Z:%-,@I*")$.?"KA(AEZSR"UW5EM_ MM#?>9ZD=._%X="SNKZL3 N1$HD$9+8>@4UTA40KXZ!CDHB-7RB9LTZBZ+8%C M)Q>/#KN=--+!PM8G^?KG+%]E23&__3/17[V:J&U=U-P8 ='+#"J*#,%H!11[ MV8(B&!:.#[M-U&Z%07?J&!Q$5UU,#-[ X"2[1*&3<2!++N36KG<(2@/:!YFD M\.+-D&-JY&$DU("B;EE$%P6;GQ!AP%YT!,9 PA MZ"R/B9[7.Y1&<7:Z*-I'_#U;H3L578[)S)R/$$JHBYM8!B>KR%P*/D67LSA" M2J_XGI\3DEINA\E M60?<27(8'*I8FHQ_&8J![7!\"N\6HZCTKU(3,WE0F#9&5>?.UM\-<2HPN)(/@65TWHRB.=;DP**$8;3$RLK$M9+,OP2/W%S="W<-; MZBCJ[/=6NF\_AI[1L\.G-[&'1Y_9LPMJM=,I94_.%#DQH(2II;Y20TJ%%YX= M6M%F^L3Q;.4;.CTSS*_GL]5B&B_J-U:U_![^K#?[J]GL(IS=_>7R R[>$K#F M/_"F(MIJALPE!X);2>?,D9B\I&.N#=7:+/?Q9J#LQ#(1M986K,90I[=)")@]R(P6<]!)R28=05M1-VZ%YLC8 M/$!1_5[EG_ ,:Q_P_W<1%O1E9S]NXNHW817^.0L7=!EBWN<>W_:C![K$]^)D MH!O\Y^^\ZSK\C$Z5I3>\EII'M*"8UA!UYA!B(D>487&NR3OTCG0>:O&>_+I; MIUA[EPS3$5@]/THF1>YQ#&"E23Q8%$$TJ0[>CKQQ[^.6R'IH]QJHZ^0-WWJB MT%YAS&Y?<%PC^!A7(YE"X:R.03C@P=4AE>3..1?J/MTLH^0%0YMJQ".;PD_I M*^:+,WQ?GCYE]T?Y!IU-EN37QE!S%+(NB.,D'!T$\ZF4P'.3QIV]J#TM0[D+ M[AX:RO;*[-AN7N?;;UB_7+BRG)>K%#L%:P=D?W;Z_*&LYMX\C60T;4C%)B'! M9B'J"YL%KSCA*?(D8Q(AJ"8E'$+9>UQ+!N8YEPZU S1&")CIIRF;R3C!XB4R6S)$QL,Z5^#UI/ MRV#N@KF?YTVU561?E5=O_ZQI"EQ.2B$FI"K O==U83)2''(2E*X9\9=]V ME,8U)>/F;8Z)M,.4T 6._L#5Y>JJW^;+Y<0:AT4G"J^4DB&MSF?AD1MCE JZB15ZE)IQNUN/B:3#E=$AHMY,SRY6F"=!,L8-2DC& M!U!*6W"^*.!*U'II9E.;1IH-](S;L3HFJO912 >X>C#4ZGJX\IJEY?N+U7(5 M9M4AO#PT%!QSQ4*J%:ETA&HF! /Y^_TL@WYN\'.C=BR H4N[N M329?MES=];JMT/_^)G4YI%K/ZL:L+R)L(9F97Y*93)*Q7#."NHJ".LH"+Y(3 M.ZJ7=6^J?B2#Y8PW73*'46< 4VH=8EYF9)B1;;H MCNQGW0NM$Z!S% -^\FVYL4]JO;_1C]S ^_!S7<=2;W">9/F>JPSY<"#W^=5W MG@\HHLN8G$$VBY26K)8*^=8M\7N7[7,?3U8K:&\>JM2?M"'?E3KP>8;_]?!0 M[?NAXH>+5B@P#N>+7&)1>TYRDA*]:IM"=,(%6F33;WQ1/M>>X#'$'DZB5,%@ M J[&55SFBO"7J//M8V%.MX^_[.IJ:6$B#2D2SU/.[2.* (83;2A-@MK&VE " M\-=WL2ZXM6%ZLM]=Q+(38W:HWZ6X2D";0 3-]68UC<2%9$@" ]Q:=-C*LSF% MA6_4+N$0__!9\W*P7'I;]^3H,Q=LB"F] 2=(TVJ(L M$<-%SRRZX[R1GO*0]N.I W>$_]/0=%AYBQ&[0AJM3<<,?L>P)TH^]@OM]GQQ MFX\N#4(%E:AKC"0TYA/?TD8"VA@BC$R..6C<_BOU!S!Y;8MU4VAC\E)$Q[7! M^=%M,=A?S>88[=WMA.H'*8P3V'7.".5)$TDEQO= <1WWGIE@A?"6O8J4@TW4 MS8Z-B<8X6JS-PJ_8=NW>='C6^D$2I:E.#0#12N8K>#01IX4BZ-,IR8 %NI]0 M/<##B\W4S7.-R<1XVIR ^SK#WUVD1W[_SAT3RB3#622!*YSH;.-1"*Z(L-PD M"";Z,O4*GNU-W85F8H'4^^TU >B>*@^>U]6N*9+N.K*?=3WH$I)$I:,$A)^<23N3Y1J7%8!0Q MB5K'A"/8%3E2^G*WZC)6E(BNF'DF#-L1B\?YOUI:EDDCA=/$IJA0K5(39W$! M:<"9* 37$8H\@3BF$'5CA(FMZM7HF,#(N$++8P=RT=WO\3XNN[O=XM7W<7WB M_VP6V*/=FR*S.;2S^:K;W,Q/-SU*V_<8I+M%NX/FYVJQ7L?V(J7K"(W5B7FB M@K%$@@ "D5O"O!=6&AI8FET,C$Q+FAT;>566V_:,!1^WZ]P,TU]:>+<@"Y-D=H0:9DZ6G%1M:?) MQ :L.G%D.Z3LU\^YL)5!I[UL4ELD0NQS^[YSCLT)3T:WT>SK70S6*F/@;GY] MDT3 ,"&\]R((1[,1^#3[<@-\RW; 3*!<4D5YCAB$\=@ QEJI(H"PJBJK\BPN M5G V@;4K'S+.);&PPL8PK'?TDR \?!>>F"88\;3,2*Y *@A2!(-2TGP%[C&1 M#\ T.ZV(%UM!5VL%7-MUP#T7#W2#6KFBBI'ASD\(VW4(FR#A@N/M,,1T RB^ M-.B2N)Z?^OUS3)!OIRYR7/^\Y^*>ZWDN&>!OC@8)M7IK(]66D4LCH[FY)G7\ MH.<7ZJ*B6*T#Q[8_&'MZBCPJ$S&ZRH,&K98NN>;6B5/.N C>V\WGHI:82Y11 MM@U.9S0C$HQ)!28\0_GIF=09-B41=-DJ2OJ=Z(@Z>+.L6C0#[8?1G.S0.6X- M*7Y?%=N6\ZSL3VY=W_)[_;]R"QO(+6Q-7Q8H MOS0\8V=0((SUZ0S;74/Y>"2DS3>G^/](LL_,%5TES(8U(*G@J] MK_\V3I;%KR=K(/:BZ(;\NRTVK0I$V$GH9K%(<#8?=L9^5F:A_^ %!+ P04 " !P@D52)OJ_^U$$ !G M$0 &P &YB:7@M,C R,#$R,S%E>&AI8FET,C,Q+FAT;=58W6_;-A!_WU_! M.EC: M:W/V39,=#:#E8LRXS$0]"G@9(HFPA-:B05Q_OK=Z3D-&GB-7[H.ON! M$'7'^_CQ[GRGT9OI[Y/%Y_D,K?2:H?D?'R\^35#+\;R;:.)YT\44_;+X[0)U M7#] "XFYHIH*CIGGS2Y;J+72NDP\;[/9N)O(%7+I+:X\(ZKC,2$4<7.=M\8C M\P96@O/Q3Z,WCH.F(JO6A&N428(UR5&E*%^BFYRH6^0X#==$E%M)ERN-0C\, MT(V0M_0.UW1--2/CG9R15^]'GE4R2D6^'8]R>H=H?M:B>=@=Y%GLX[A#.@4) ML)_&:='/BTZ:]<-^[\\ C/2 O3ZC]):1L]::U-7V0PR@G.^N"T)@TNU_1E )6D1N,/,._ M\^F99X\LS@ ](G^0R1/!E8D"4:!//"'@$SK\+WN]S ;T[%W*-KIT870KE MHBB*G*#?C>-!NWX>^$$_WCWW!T&OC3#/[3X,PK@/HDLB-:;< -5@&_I!@&9_ M551O(9),3-,[@N8,V!SXGJ:RPW)Z>0,$>=MMUU[NA M>@6,JB390RMA.@O!:'VLH!SSC&(&3CP@^9J,L:)(48!@@(X398]1TP]"AV^4 M:"D8$G=$/E)2VVPNXILZH.-A50XFVOZ&*O2!\PI$7%D1S6T'OO/K^V_)@M9( M6G.W!$MDVL0<30F4VQ1LBP(+E>\^N]R'3A[+)33SJ=!:K),N7%'S1HO2;E]H MX35.&=D)2(7,B70@/!@N%4EV#\.@ MQ'D.MY>$Y3T*GKK.2*&_-K[&K/42G :\("R_X[QC)294@RG9OV>5Q>;TI-,? M*KON0N$_3FYK!II)KC0Z/8GB(?H,<\L275S,OQK)'F[*LS'SPRO2-?S-3BE9 MBC:: -R0;YSB_TFU?+$P[DWVQR-[*>H/%HDD#)LJMW>(;VJ#_^4(3J'&5OKY MD;U_)T_6^A.$_1@R_@=02P,$% @ <()%4M>4?J<4" ZB4 !L !N M8FEX+3(P,C Q,C,Q97AH:6)I=#,Q,2YH=&WM6FUOVS@2_GZ_@IO@NBW@-SEV MTCAN@-1QML9VDT7J7G<_'6B)LHE0HI:D[/A^_3U#28F=.%MWBW9]P06($Y'# MX0SGX3-#6OT?SJ\&X]]_';*92Q3[]>/;]Z,!VZLWFY\.!LWF^?BC+%NJ<2;O42F]9F@^7O=3N9. M%C)RLU[0:OUS;TW.B5M7YTI.TYZW%KVQAF]E=ZB5-KW]EO\YH9YZS!.IEKT? MQS(1EEV*!;O6"4]_K%FL<-T*(^-"T,K_",R(R?WCHK#F"'J43$5E7= FDX:W M,SF1CAT$C:#?)/G*IT>>K5@<8O6$^>8F=S::/!A>CT<7H\'9>'1UR:XNV.#= M:'C!AK\-!Q_'HW\-T83>X36 >?WAX]GE>-VO'?1H?,4^# ?>G8-6FUP:OQNR M#V?7;\\NAQ_J5[^]'_[.S@9CZFFW6NTG'4JXF0)_3F?0G'U[3&UV9U1C/XNY M3-F@P7[2!OIJ;#"3(F;#6Q'F3LX%NXIC&0K#=(Q98@F[,H$*<'I0NZ10"H0:,O-DD02?B,P_8I. MB[8(-F%*Y?,PYB"!4!KD78@13F!)A.V_F,EPQFQ.'_?C%\*(4@DYD$BKD* I MUR^DF\%!FXG0&TAZ,YBF([@YQ["(39;%:A3+\%R0>/"_@T3!8IDBR(27^Z#6 M@#^(H]NL],LTI@1!Y2'^#U4>02> \QC/-6!/&K5D&<)/R"5$*W4/S1(5]H$% M0'_DR\\:2>0* L"C!FC\K-:;%7([8['2"UN!U8BIM ZUJV.<&@OS86QM!7.V M,N8IHY\+^CH[A[[Q6HQ>[+]N!TBRSJ#HC1@WPN,$<9<3)2B> M3 "C$R7MC,1)+ %9$F'2#[HOQ2L_-.A&Q5/Q**GN3 N@DGY&-+:"WP)(9,O6 M$\5K$\68B/Q\B&I(4,[_BIKJX'"'(,I?[1!$VQU:AW-A<;1 M'Q^^SR4:I1Z M0Y[;[8=0#IP(P**/)SN#X MN'%X]!C&6_/5(S1OSW1;@QH;82XCPBJW.N5$Z=P"YU1B$H"YB2HP =Z23Z22 M;DDY?M.TM+4\[CRDBEVQ)KI2HOK,<5LZE.4F Z2MKTG"4)O(&^"+U:E(46HH M(!L](J,M0R(HQ OT8FO)#.3]7/ ;[@Q^[WAX..B*!8$9GG4T3S/ 'G1SB#OCCF+F#YU.O G\K*(\P(;2)>&XP0E_&5"NN[CJ\*J M&;=W50=1H=\!(O(YPF^9DK^73,D;HHJ^$^TZ=R;K/Y$SF+QZC M:J?4[JF*"'05IO>L55'?%]0BCXK:._,X"ENGC;U+_[X!*I-$.B<\JC<,FV@4 M%]072=CG%;P$F,'&EM@>?ZFTKG:@^".7,-_OMCP-R8E7_S]Y?;.,?Z90K*%X ME :'7;IV.POJ&69M>].0 O!;R@-%\6;3\2^[/2WH-4E$85Y>QHN#BO%5<,& M6N,1!EIQQVI/XK(L5C$$ $--62MJ 8M"P.8)\(%5\LZ4V63CK=IS2O"[=S0Z M0P*/#0BCAJ@+SW/ C;^S+@%6*_*?3.=:S04EP91/RZMW4U*C2#*EEP*]BYDN M^)"OP1=P^Y(*P3Z)S<:.?W-X3E6ZYT5V(28&)<;RQ7YPV#KIUORW^9\S?Z*= MTTD/V>ADQ:%NA>'UK]N=/R^6"B;88,+4X:CBF16]ZI\39*9,\65/IMY5 M1+6*G6)J.@XHF_'TS=[!7B53(KC7SFY9L+XD!.J'3A5K6;RT\-W1X%^7>+'? M ;S])_O&.]]K[$D'U\,M+'OP]?:#%R?^8GQ*"/HMF,%)NF)CE7=?&#PH^?Y; M^$^7YON ]N_S^XD7'![[W_04LH'#5M\:RG3QSE2ON)6=BR??(RHIKW4_A$\ MG=P]'E(LS&E_0E:L(7;ULW@+RK^/=?I?4$L#!!0 ( '""15+)]\Z:P@< M %TF ; ;F)I>"TR,#(P,3(S,65X:&EB:70S,3(N:'1M[5IM;]LX$OY^ MOX*;XKHMX/>7).NX 5S'08WK)HO4B]Y^.E 291&11"U)V?']^GN&DAP[<5#G MBK9&T )U+'$XG.$\?&9&UO"7B^OQ[*\_)BRR2MATBPP]%:S.AX%<,!F\ M.Y*=T#OAGG_<:OG'O7ZW?>J?=-J;7R\*:$^B) M92HJZ]H=,FER%TE/6M9M-SK#)LE7/CWVC.LYG+,JPUPHW_# QVX*_:J1!+ MYUKY&KK8>ZF,+T7J"U-CT]1OU!B$K Q7S$;I@'"/JC3G1^T4>U&Y6IT+.(*$ZW(O8LE9@BM-9S/D/F[A;";((585+&&B3@2XU$#3&""BP)0 ++2/H1,SE] MW,]?"BU*)>1 (DV,C$[%P5+:" Z:3/C.0-*;P305P,T%I@7,6^W8C1>$R>Y/ M3/[$Y(%ALG=PF)Q%E-#FTE@T+-CJTT[[Y,PPA>#HJK*@X*FR&N%IP*:,:^$B MJ=#C>+%@(7 G (OEB8B<1)+ %P"+UT'TOBQ,CGF$:2UBHV3R9 =18#;AKWA MA@4BA-4!P6]RYT<\G0LV EIN\A@2[2ZOM_MOQ%LWM=T/BJOB4E*5BF:KTL\( M4BQ$$H[/=J'"V'0 MBR!@CFZ^C*8:,:'/<[/_%*(D3P 9Y4H%R:E<0P%H:B$-FOD:28G4Z:%Z^YY= M90IPX I"@$?,'=1*EKN'"S&K'^>.#R78$K88%2') %%[M, MD9*FW! _NI-I')D"O#921L @=/1N4L:!<3^/N8Y7#&XY(^YY%C,*UG8L6R8; M?/,$"6:X@9,=?!WA'A24O8.!\F^-XY/'2-Z;M1X!>G^^VQO7. L+&1!5#IP!KGR8BU1H'@/<&!$9G1H206E4 !BG2V:@\!<$8?]@(+QF MX\F"Q[FC+ JP"$-4='*!T!A3%8P[:HH]*+BX%(8>.3FVVM5B [F8#Q8EX&+4 M4[E]VI!]<@5?2PN,E%_W*4V95Y7T[DR*8E]@EL,?K?,R,!@<# ;7-%J$=0,E M942H4RH+.C>R$XK/($]*\LKWFT&5\*/H[1T*&ZC=/ M3 F!9M#: ^G2NHVZMX55$3?K\H,(T:%?!"Y3N/TH67R%5NY6Q&7' M]T"^]M5;]/50/Z@6K?]"6C3WJ#*H3DGMGJF(/S>1>D]:%?,]HRAY5."NS>,H MH?Q2C<4$A*8(W:7VJDW5-M6:;O=4.T%/R6$G%1R+E4 M[$I0]XP*<5Q#;G\R+GJ7XN'##G+C 28:L>:V)Z%9%JZ8 HRAOJP5U8!!*6#R M!!#!+CEGRIQR;\M&E_?"4OSA=4HC9/)0@S9J"+QP; ?HN(>*)<9J12*4Z4+% M"T'9,.7S\MFH+@E2)%FL5@*CRT@5K,BW$ S$/:=4,$_"LW'X/SY>4-'N"))= M"D^CW%B]?M4^;IWU:^ZU@3T]0%HZV_A9O+_]@W'UN[YU'62IP,,Q$[H.1V.> M&3&HOIPA164Q7PUDZLQUD\X6E-50$94:L4CU0D'OI''BLN+0:OP/*OWE<*/E MQIHVV#'8ZU=S=X]O3FXZ];J2J':Q7)K:@MAD/'UWU#VJ9$H0#SK9'6MO;PGA M^J%3Q5X6;T=\=S2X]S)>O^H!X>Z3?>/#[S0.I(7K_AZ6[?J%_,%K&O]GD$H< MNK(S(P@EW_\/+5I9+\6O=3N ?\Y/;QE&)CSH<>6;$%V\W/XL4K]PK8^?\ 4$L# M!!0 ( '""15+5N7RVD04 "$M : ;F)I>"TR,#(P,3(S,65X:&EB M:70S,BYH=&WM6NMOVD@0_WY_Q93HTE3"3PP-CT8B8"ZH*43@7-M/I\5>AU5M MKV^]A'!__]<<][_.9"W,91W!V?GPZ M[$%%,XR/M9YA]+T^G'@?3L'130L\09*,2<83$AF&.ZI 92YEVC*,Y7*I+VLZ M%Q>&-S&4*,>(.,^H'LB@5ID&?^XN8)A)\08FD 2PREES MQX!F7T#3UJMZ/%T)=C&78)NV!1^Y^,(N24&73$;TJ)33,8K?'2/?I#/CP>JH M$[!+8,&["O-MXC?,IC\CEN]8S48SI(229D#J=7/FV/Y?%BIIX/*")Y.KB+ZK MQ"S1YE3MWWIKI[*]9(&X8:G6)Z"XN(BX0FN0I\ E:M;E:?/8;N%+K] M\9GG]F$#SE:UUPDQXU+R^'GE1&GWIMG " +OQ(5I=W+<';E3;?SIU/T,W9ZG M*+9IVC\,D"4!@FO5&NGC%ZW[\0T3\'F24%^U%5@R.0XMX+P7V!PN"8\)R29)7_ MLMIO(.0B%[^B1 !%\ 'TJ4_C&17[>U;#;->LJNHU)I ,0A8A_5JE*?47 KL? M8B=) .Z5/R?)!<4F%<"HJJ;VA1H2F50W2J\IY-5_ E MX4LTTP7=WZL?MG\D %,2!-CSM8B&LE5W;H6D9AT^64P>6&]*(#]_^YMV:>@U M1]G!0X^LDR%<1-$*DR9.(Q6+U_$IZ-\+)J@Z#67*5;="X("\ 8Q^JWX08.B5 M3OX:T]?QO/:TU:PYZ--F6T7[_\2O]C/T*V822T*5_7D%Q&(H";(&>#=W4>EU MP@2Z/14T4PZN*C*)(D VU 9+)1)2]'A6S;E"EI#$5_=18)"?V?.JA:L641$? M/*4BWS.[55ST[_7V6X2]<9:LYXZ59!;1DF'&14"%AA:.2)K15OFE'; LCN76S.'9+@?]!*7]-UG.2(8.[-*>NF_7:5K*I M6UMIWQ+;T.M-^\&E6GK3<1YPL3HJPS#X5VE5BD9UB'< MLM,KL&X>DE14W^/ XD'II^=;'BL#.A,+(E9%!:SGC=VZ]6BT-LA#87T*F,>K MFZWWP2 5:?Y$J JG/2*H)PO+_3WG;3O+K_#([2B7V&(2H?O?H=FMP^@]J?(8 M]>%AL=M/&EU/5P5&)*:_=!U8'S7RH5:*:O*(!5#J]V+#=1V M [7=0&TW4-L-U/[S0,VV'GY(U="=VHL:J&TG[P9J+_N(N!NH[09J#S-0N^]$ MNINJ/0M$NZG:+S15^V8>[C+P.;MN-UI[,:[:,FGY@=':YLNV*2]>-6X)&A$U MJMOZ^NWZZ"TR M,#(P,3(S,2YH=&U02P$"% ,4 " !P@D52:Y9.EW83 EQ $0 M @ %2>0, ;F)I>"TR,#(P,3(S,2YX"TR,#(P,3(S,5]C M86PN>&UL4$L! A0#% @ <()%4K8!'1:>:0 J)\$ !4 M ( !3;4# &YB:7@M,C R,#$R,S%?9&5F+GAM;%!+ 0(4 Q0 ( '""15*A MW\F&[*P! )@. @ 4 " 1X?! !N8FEX+3(P,C Q,C,Q7VL &I: 0 4 " 5Y4" !N8FEX+3(P,C Q,C,Q7V$_ M"0!N8FEX+3(P,C Q,C,Q7VQA8BYX;6Q02P$"% ,4 " !P@D52ZG]%2QRA M #,> < %0 @ $ 40H ;F)I>"TR,#(P,3(S,5]P&UL M4$L! A0#% @ <()%4JR[5!'9 @ $ P !L ( !3_(* M &YB:7@M,C R,#$R,S%E>&AI8FET,C$Q+FAT;5!+ 0(4 Q0 ( '""15(F M^K_[400 &<1 ; " 6'U"@!N8FEX+3(P,C Q,C,Q97AH M:6)I=#(S,2YH=&U02P$"% ,4 " !P@D52UY1^IQ0( #J)0 &P M @ 'K^0H ;F)I>"TR,#(P,3(S,65X:&EB:70S,3$N:'1M4$L! A0# M% @ <()%4LGWSIK"!P 728 !L ( !. (+ &YB:7@M M,C R,#$R,S%E>&AI8FET,S$R+FAT;5!+ 0(4 Q0 ( '""15+5N7RVD04 M "$M : " 3,*"P!N8FEX+3(P,C Q,C,Q97AH:6)I=#,R :+FAT;5!+!08 #@ . +P# #\#PL ! end